0001232524-24-00008610-Q Jazz Pharmaceuticals plc 20241107202411070732060732070732070 0001232524-24-000086 10-Q 87 20240930 20241107 20241107 Jazz Pharmaceuticals plc 0001232524 2834 981032470 L2 1231 10-Q 34 001-33500 241433195 FIFTH FLOOR, WATERLOO EXCHANGE WATERLOO ROAD DUBLIN L2 4 353-1-634-7800 FIFTH FLOOR, WATERLOO EXCHANGE WATERLOO ROAD DUBLIN L2 4 JAZZ PHARMACEUTICALS INC 20030513 10-Q 1 jazz-20240930.htm 10-Q jazz-20240930Jazz Pharmaceuticals plcfalse2024Q3000123252412/31http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent000.0065339xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesjazz:segmentxbrli:pureutr:Rateiso4217:EURjazz:customerjazz:litigationCasejazz:patent00012
01-012024-09-300001232524201-10-310001232524201-09-300001232524201-12-310001232524jazz:ProductAndServicesProductSalesNetOfDeductionsMember2024-07-012024-09-300001232524jazz:ProductAndServicesProductSalesNetOfDeductionsMember2023-07-012023-09-300001232524jazz:ProductAndServicesProductSalesNetOfDeductionsMember2024-01-012024-09-300001232524jazz:ProductAndServicesProductSalesNetOfDeductionsMember2023-01-012023-09-300001232524jazz:ProductAndServicesRoyaltiesAndContractRevenueMember2024-07-012024-09-300001232524jazz:ProductAndServicesRoyaltiesAndContractRevenueMember2023-07-012023-09-300001232524jazz:ProductAndServicesRoyaltiesAndContractRevenueMember2024-01-012024-09-300001232524jazz:ProductAndServicesRoyaltiesAndContractRevenueMember2023-01-012023-09-300001232524us-gaap:CommonStockMember2023-12-310001232524jazz:EuroDeferredSharesMember2023-12-310001232524jazz:CapitalRedemptionReserveMember2023-12-310001232524us-gaap:AdditionalPaidInCapitalMember2023-12-310001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001232524us-gaap:RetainedEarningsMember2023-12-310001232524us-gaap:CommonStockMember2024-01-012024-03-310001232524us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001232524us-gaap:CommonStockMember2024-01-012024-03-310001232524jazz:PerformanceBasedRestrictedStockUnitsRSUsMemberus-gaap:CommonStockMember2024-01-012024-03-310001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001232524us-gaap:RetainedEarningsMember2024-01-012024-03-310001232524us-gaap:CommonStockMember2024-03-310001232524jazz:EuroDeferredSharesMember2024-03-310001232524jazz:CapitalRedemptionReserveMember2024-03-310001232524us-gaap:AdditionalPaidInCapitalMember2024-03-310001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001232524us-gaap:RetainedEarningsMember2024-03-310001232524us-gaap:CommonStockMember2024-04-012024-06-300001232524us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001232524us-gaap:RetainedEarningsMember2024-04-012024-06-300001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001232524us-gaap:CommonStockMember2024-06-300001232524jazz:EuroDeferredSharesMember2024-06-300001232524jazz:CapitalRedemptionReserveMember2024-06-300001232524us-gaap:AdditionalPaidInCapitalMember2024-06-300001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001232524us-gaap:RetainedEarningsMember2024-06-300001232524us-gaap:CommonStockMember2024-07-012024-09-300001232524us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001232524us-gaap:RetainedEarningsMember2024-07-012024-09-300001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001232524us-gaap:CommonStockMember2024-09-300001232524jazz:EuroDeferredSharesMember2024-09-300001232524jazz:CapitalRedemptionReserveMember2024-09-300001232524us-gaap:AdditionalPaidInCapitalMember2024-09-300001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001232524us-gaap:RetainedEarningsMember2024-09-300001232524us-gaap:CommonStockMember2022-12-310001232524jazz:EuroDeferredSharesMember2022-12-310001232524jazz:CapitalRedemptionReserveMember2022-12-310001232524us-gaap:AdditionalPaidInCapitalMember2022-12-310001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001232524us-gaap:RetainedEarningsMember2022-12-310001232524us-gaap:CommonStockMember2023-01-012023-03-310001232524us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001232524us-gaap:RetainedEarningsMember2023-01-012023-03-310001232524us-gaap:CommonStockMember2023-03-310001232524jazz:EuroDeferredSharesMember2023-03-310001232524jazz:CapitalRedemptionReserveMember2023-03-310001232524us-gaap:AdditionalPaidInCapitalMember2023-03-310001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001232524us-gaap:RetainedEarningsMember2023-03-310001232524us-gaap:CommonStockMember2023-04-012023-06-300001232524us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001232524us-gaap:CapitalRedemptionReserveMember2023-04-012023-06-300001232524us-gaap:RetainedEarningsMember2023-04-012023-06-300001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001232524us-gaap:CommonStockMember2023-06-300001232524jazz:EuroDeferredSharesMember2023-06-300001232524jazz:CapitalRedemptionReserveMember2023-06-300001232524us-gaap:AdditionalPaidInCapitalMember2023-06-300001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001232524us-gaap:RetainedEarningsMember2023-06-300001232524us-gaap:CommonStockMember2023-07-012023-09-300001232524us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001232524us-gaap:RetainedEarningsMember2023-07-012023-09-300001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001232524us-gaap:CommonStockMember2023-09-300001232524jazz:EuroDeferredSharesMember2023-09-300001232524jazz:CapitalRedemptionReserveMember2023-09-300001232524us-gaap:AdditionalPaidInCapitalMember2023-09-300001232524us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001232524us-gaap:RetainedEarningsMember2023-09-300001232524us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-09-300001232524us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001232524jazz:FiveCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300001232524jazz:ExpressScriptsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300001232524jazz:ASDSpecialtyHealthcareLLCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300001232524jazz:McKessonCorporationMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300001232524jazz:FiveCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001232524jazz:ExpressScriptsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001232524jazz:ASDSpecialtyHealthcareLLCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001232524jazz:McKessonCorporationMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001232524us-gaap:CashMember2024-09-300001232524us-gaap:BankTimeDepositsMember2024-09-300001232524us-gaap:MoneyMarketFundsMember2024-09-300001232524us-gaap:CashMember2023-12-310001232524us-gaap:BankTimeDepositsMember2023-12-310001232524us-gaap:MoneyMarketFundsMember2023-12-310001232524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001232524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001232524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001232524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001232524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2024-09-300001232524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2024-09-300001232524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2023-12-310001232524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2023-12-310001232524us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeForwardMember2024-09-300001232524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMember2024-09-300001232524us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMember2024-09-300001232524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMember2023-12-310001232524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeForwardMember2023-12-310001232524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2024-09-300001232524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2024-09-300001232524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2023-12-310001232524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2023-12-310001232524us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMember2023-12-310001232524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001232524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001232524us-gaap:FairValueMeasurementsRecurringMember2024-09-300001232524us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001232524us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001232524jazz:ExchangeableSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-09-300001232524jazz:ExchangeableSeniorNotesDue2030Memberus-gaap:ConvertibleDebtMember2024-09-300001232524us-gaap:FairValueInputsLevel2Memberjazz:ExchangeableSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-09-300001232524us-gaap:FairValueInputsLevel2Memberjazz:ExchangeableSeniorNotesDue2030Memberus-gaap:ConvertibleDebtMember2024-09-300001232524jazz:ExchangeableSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2024-09-300001232524jazz:SeniorNotesDue2029Memberjazz:JazzSecuritiesDesignatedActivityCompanyMemberjazz:SeniorSecuredDebtMember2024-09-300001232524jazz:TwoThousandTwentyOneCreditAgreementDollarTermLoanMemberjazz:TermLoanMember2024-01-012024-09-300001232524us-gaap:FairValueInputsLevel2Memberjazz:SeniorNotesDue2029Memberjazz:JazzSecuritiesDesignatedActivityCompanyMemberjazz:SeniorSecuredDebtMember2024-09-300001232524us-gaap:FairValueInputsLevel2Memberjazz:TwoThousandTwentyOneCreditAgreementDollarTermLoanMemberjazz:TermLoanMember2024-09-300001232524us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-12-310001232524us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-07-012024-09-300001232524us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-07-012023-09-300001232524us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-01-012024-09-300001232524us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-01-012023-09-300001232524jazz:TermLoanMember2024-09-300001232524us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300001232524us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2023-07-012023-09-300001232524us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300001232524us-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2023-01-012023-09-300001232524us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMember2024-09-300001232524us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMember2023-12-310001232524us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMember2024-09-300001232524us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMember2023-12-310001232524us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccruedLiabilitiesMember2024-09-300001232524us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccruedLiabilitiesMember2023-12-310001232524us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-09-300001232524us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001232524us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:AccruedLiabilitiesMember2024-09-300001232524us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:AccruedLiabilitiesMember2023-12-310001232524srt:ProFormaMember2024-09-300001232524srt:ProFormaMember2023-12-310001232524jazz:GWPharmaceuticalsPlcMember2024-09-300001232524jazz:GWPharmaceuticalsPlcMember2023-12-310001232524us-gaap:DevelopedTechnologyRightsMember2024-01-012024-09-300001232524us-gaap:DevelopedTechnologyRightsMember2024-09-300001232524us-gaap:DevelopedTechnologyRightsMember2023-12-310001232524jazz:ManufacturingContractsMember2024-09-300001232524jazz:ManufacturingContractsMember2023-12-310001232524us-gaap:TrademarksMember2024-09-300001232524us-gaap:TrademarksMember2023-12-310001232524jazz:ManufacturingContractsMember2024-01-012024-09-300001232524us-gaap:TrademarksMember2024-01-012024-09-300001232524us-gaap:MachineryAndEquipmentMember2024-09-300001232524us-gaap:MachineryAndEquipmentMember2023-12-310001232524us-gaap:LeaseholdImprovementsMember2024-09-300001232524us-gaap:LeaseholdImprovementsMember2023-12-310001232524us-gaap:LandAndBuildingMember2024-09-300001232524us-gaap:LandAndBuildingMember2023-12-310001232524us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-09-300001232524us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-310001232524us-gaap:ConstructionInProgressMember2024-09-300001232524us-gaap:ConstructionInProgressMember2023-12-310001232524us-gaap:ComputerEquipmentMember2024-09-300001232524us-gaap:ComputerEquipmentMember2023-12-310001232524us-gaap:FurnitureAndFixturesMember2024-09-300001232524us-gaap:FurnitureAndFixturesMember2023-12-310001232524jazz:ExchangeableSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2023-12-310001232524jazz:ExchangeableSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2023-12-310001232524jazz:SeniorNotesDue2029Memberus-gaap:ConvertibleDebtMember2024-09-300001232524jazz:SeniorNotesDue2029Memberus-gaap:ConvertibleDebtMember2023-12-310001232524jazz:TermLoanMember2023-12-310001232524jazz:TwoThousandTwentyOneCreditAgreementDollarTermLoanMemberus-gaap:LineOfCreditMember2021-05-052021-05-050001232524jazz:TwoThousandTwentyOneCreditAgreementDollarTermLoanMemberus-gaap:LineOfCreditMember2021-05-050001232524jazz:TwoThousandTwentyOneCreditAgreementEuroTermLoanMemberus-gaap:LineOfCreditMember2021-05-052021-05-050001232524jazz:TwoThousandTwentyOneCreditAgreementEuroTermLoanMemberus-gaap:LineOfCreditMember2021-05-050001232524jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-05-052021-05-050001232524jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-05-050001232524jazz:TrancheB1DollarTermLoanMemberus-gaap:LineOfCreditMember2024-01-310001232524jazz:TrancheB2DollarTermLoanMemberus-gaap:LineOfCreditMember2024-07-310001232524us-gaap:LineOfCreditMember2024-07-310001232524jazz:TrancheB2DollarTermLoanMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-012024-07-

310001232524jazz:TrancheB2DollarTermLoanMemberus-gaap:LineOfCreditMemberus-gaap:PrimeRateMember2024-07-012024-07-310001232524jazz:TrancheB2DollarTermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-012024-07-310001232524jazz:TrancheB2DollarTermLoanMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2024-07-012024-07-310001232524jazz:TrancheB2DollarTermLoanMemberus-gaap:LineOfCreditMember2024-09-300001232524jazz:TwoThousandTwentyOneCreditAgreementDollarTermLoanMemberus-gaap:LineOfCreditMember2024-09-300001232524jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMember2024-07-012024-07-310001232524jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2024-07-012024-07-310001232524jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:PrimeRateMembersrt:MaximumMember2024-07-012024-07-310001232524jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:PrimeRateMembersrt:MinimumMember2024-07-012024-07-310001232524jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MaximumMember2024-07-012024-07-3100012325 24jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MinimumMember2024-07-012024-07-310001232524jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-09-300001232524jazz:ExchangeableSeniorNotesDue2030Memberjazz:JazzSecuritiesDesignatedActivityCompanyMemberus-gaap:ConvertibleDebtMember2024-09-012024-09-300001232524jazz:ExchangeableSeniorNotesDue2030Memberus-gaap:ConvertibleDebtMember2024-09-012024-09-300001232524jazz:JazzInvestmentsILimitedMember2024-09-300001232524jazz:ExchangeableSeniorNotesDue2030Memberus-gaap:ConvertibleDebtMember2024-07-012024-09-300001232524jazz:ExchangeableSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2023-07-012023-09-300001232524jazz:ExchangeableSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-07-012024-09-300001232524jazz:ExchangeableSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2023-01-012023-09-300001232524jazz:ExchangeableSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-01-012024-09-300001232524jazz:ExchangeableSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2024-08-152024-08-15001232524jazz:ExchangeableSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2024-07-012024-09-300001232524jazz:ExchangeableSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2023-07-012023-09-300001232524jazz:ExchangeableSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2024-01-012024-09-300001232524jazz:ExchangeableSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2023-01-012023-09-300001232524jazz:TeamstersAndGEHALawsuitsMember2020-06-182020-06-230001232524jazz:AvadelPharmaceuticalsPlcLawsuitMember2021-05-130001232524jazz:AvadelPharmaceuticalsPlcLawsuitMember2023-02-242023-02-240001232524jazz:AvadelPharmaceuticalsPlcLawsuitMember2022-06-070001232524jazz:AvadelPharmaceuticalsPlcLawsuitMember2024-08-272024-08-270001232524jazz:AvadelPharmaceuticalsPlcLawsuitMember2022-07-212022-07-210001232524jazz:LupinLawsuitMember2021-06-300001232524jazz:LupinLawsuitMember2021-07-310001232524jazz:LupinLawsuitMember2021-07-012021-07-310001232524jazz:LupinLawsuitMemberjazz:XywavMember2021-06-012021-06-300001232524jazz:LupinLawsuitMember2022-06-222022-06-220001232524jazz:TevaLawsuitMember2023-03-310001232524jazz:TevaLawsuitMember2023-03-012023-03-310001232524jazz:EpidiolexPatentLitigationMember2023-03-012023-03-310001232524jazz:EpidiolexPatentLitigationMember2024-09-300001232524jazz:EpidiolexPatentLitigationMember2023-12-152023-12-15001232524jazz:EpidiolexPatentLitigationMember2024-07-032024-07-030001232524jazz:OrdinarySharesMemberjazz:July2024ShareRepurchaseProgramMember2024-07-310001232524jazz:OrdinarySharesMemberjazz:November2016ShareRepurchaseProgramMember2024-07-310001232524jazz:OrdinarySharesMemberjazz:July2024ShareRepurchaseProgramMember2024-07-012024-09-300001232524jazz:OrdinarySharesMemberjazz:November2016ShareRepurchaseProgramAndJuly2024ShareRepurchaseProgramMember2024-01-012024-09-300001232524jazz:OrdinarySharesMemberjazz:November2016ShareRepurchaseProgramMember2023-01-012023-09-300001232524jazz:OrdinarySharesMemberjazz:July2024ShareRepurchaseProgramMember2024-09-300001232524us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-31001232524us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001232524us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-09-300001232524us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300001232524us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-09-300001232524us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300001232524jazz:ExchangeableSeniorNotesDue2024Memberus-gaap:ConvertibleDebtMember2024-08-31001232524jazz:ExchangeableSeniorNotesDue2026Memberus-gaap:ConvertibleDebtMember2024-07-310001232524us-gaap:EquityUnitPurchaseAgreementsMember2024-07-012024-09-300001232524us-gaap:EquityUnitPurchaseAgreementsMember2023-07-012023-09-300001232524us-gaap:EquityUnitPurchaseAgreementsMember2024-01-012024-09-300001232524us-gaap:EquityUnitPurchaseAgreementsMember2023-01-012023-09-300001232524jazz:XywavMember2024-07-012024-09-300001232524jazz:XywavMember2023-07-012023-09-300001232524jazz:XywavMember2024-01-012024-09-300001232524jazz:XywavMember2023-01-012023-09-300001232524jazz:XyremMember2024-07-012024-09-300001232524jazz:XyremMember2023-07-012023-09-300001232524jazz:XyremMember2024-01-012024-09-300001232524jazz:XyremMember2023-01-012023-09-300001232524jazz:EpidiolexEpidyolexMember2024-07-012024-09-300001232524jazz:EpidiolexEpidyolexMember2023-07-012023-09-300001232524jazz:EpidiolexEpidyolexMember2024-01-012024-09-300001232524jazz:EpidiolexEpidyolexMember2023-01-012023-09-300001232524jazz:SativexMember2024-07-012024-09-300001232524jazz:SativexMember2023-07-012023-09-300001232524jazz:SativexMember2024-01-012024-09-300001232524jazz:SativexMember2023-01-012023-09-300001232524jazz:TotalNeuroscienceMember2024-07-012024-09-300001232524jazz:TotalNeuroscienceMember2023-07-012023-09-300001232524jazz:TotalNeuroscienceMember2024-01-012024-09-300001232524jazz:TotalNeuroscienceMember2023-01-012023-09-300001232524jazz:RylazeEnrylazeMember2024-07-012024-09-300001232524jazz:RylazeEnrylazeMember2023-07-012023-09-300001232524jazz:RylazeEnrylazeMember2024-01-012024-09-300001232524jazz:RylazeEnrylazeMember2023-01-012023-09-300001232524jazz:ZepzelcaMember2024-07-012024-09-300001232524jazz:ZepzelcaMember2023-07-012023-09-300001232524jazz:ZepzelcaMember2024-01-012024-09-300001232524jazz:ZepzelcaMember2023-01-012023-09-300001232524jazz:DefitelioDefibrotideMember2024-07-012024-09-300001232524jazz:DefitelioDefibrotideMember2023-07-012023-09-300001232524jazz:DefitelioDefibrotideMember2024-01-012024-09-300001232524jazz:DefitelioDefibrotideMember2023-01-012023-09-300001232524jazz:VyxeosMember2024-07-012024-09-300001232524jazz:VyxeosMember2023-07-012023-09-300001232524jazz:VyxeosMember2024-01-012024-09-300001232524jazz:VyxeosMember2023-01-012023-09-300001232524jazz:TotalOncologyMember2024-07-012024-09-300001232524jazz:TotalOncologyMember2023-07-012023-09-300001232524jazz:TotalOncologyMember2024-01-012024-09-300001232524jazz:TotalOncologyMember2023-01-012023-09-300001232524jazz:OtherProductsMember2024-07-012024-09-300001232524jazz:OtherProductsMember2023-07-012023-09-300001232524jazz:OtherProductsMember2024-01-012024-09-300001232524jazz:OtherProductsMember2023-01-012023-09-300001232524jazz:HighSodiumAGOxybateProductRoyaltyRevenueMember2024-07-012024-09-300001232524jazz:HighSodiumAGOxybateProductRoyaltyRevenueMember2023-07-012023-09-300001232524jazz:HighSodiumAGOxybateProductRoyaltyRevenueMember2024-01-012024-09-300001232524jazz:HighSodiumAGOxybateProductRoyaltyRevenueMember2023-01-012023-09-300001232524jazz:OtherRoyaltyAndContractRevenuesMember2024-07-012024-09-300001232524jazz:OtherRoyaltyAndContractRevenuesMember2023-07-012023-09-300001232524jazz:OtherRoyaltyAndContractRevenuesMember2024-01-012024-09-300001232524jazz:OtherRoyaltyAndContractRevenuesMember2023-01-012023-09-300001232524country:US2024-07-012024-09-300001232524country:US2023-07-012023-09-300001232524country:US2024-01-012024-09-300001232524country:US2023-01-012023-09-300001232524srt:EuropeMember2024-07-012024-09-300001232524srt:EuropeMember2023-07-012023-09-300001232524srt:EuropeMember2024-01-012024-09-300001232524srt:EuropeMember2023-01-012023-09-300001232524jazz:OtherCountriesMember2024-07-012024-09-300001232524jazz:OtherCountriesMember2023-07-012023-09-300001232524jazz:OtherCountriesMember2024-01-012024-09-300001232524jazz:OtherCountriesMember2023-01-012023-09-300001232524jazz:ExpressScriptsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-300001232524jazz:ExpressScriptsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300001232524jazz:ExpressScriptsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-300001232524jazz:ExpressScriptsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-300001232524jazz:McKessonCorporationMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-300001232524jazz:McKessonCorporationMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300001232524jazz:McKessonCorporationMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-300001232524jazz:McKessonCorporationMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-300001232524jazz:ASDSpecialtyHealthcareLLCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-300001232524jazz:ASDSpecialtyHealthcareLLCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300001232524jazz:ASDSpecialtyHealthcareLLCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-300001232524jazz:ASDSpecialtyHealthcareLLCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-300001232524srt:MinimumMember2024-01-012024-09-300001232524srt:MaximumMember2024-01-012024-09-300001232524us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001232524us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001232524us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001232524us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001232524us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001232524us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001232524us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001232524us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001232524us-gaap:CostOfSalesMember2024-07-012024-09-300001232524us-gaap:CostOfSalesMember2023-07-012023-09-300001232524us-gaap:CostOfSalesMember2024-01-012024-09-300001232524us-gaap:CostOfSalesMember2023-01-012023-09-300001232524us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001232524us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001232524us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001232524us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001232524jazz:PerformanceBasedRestrictedStockUnitsRSUsMembersrt:MinimumMember2024-01-012024-09-300001232524jazz:PerformanceBasedRestrictedStockUnitsRSUsMembersrt:MaximumMember2024-01-012024-09-300001232524jazz:PerformanceBasedRestrictedStockUnitsRSUsMember2024-07-012024-09-300001232524jazz:PerformanceBasedRestrictedStockUnitsRSUsMember2023-07-012023-09-300001232524jazz:PerformanceBasedRestrictedStockUnitsRSUsMember2024-01-012024-09-300001232524jazz:PerformanceBasedRestrictedStockUnitsRSUsMember2023-01-012023-09-300001232524us-gaap:RestrictedStockUnitsRSUMember2024-09-300001232524jazz:PerformanceBasedRestrictedStockUnitsRSUsMember2024-09-300001232524us-gaap:EmployeeStockMember2024-09-300001232524us-gaap:EmployeeStockOptionMember2024-09-300001232524us-gaap:EmployeeStockMember2024-01-012024-09-300001232524us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001232524us-gaap:ForeignCountryMemberus-gaap:LuxembourgInlandRevenueMember2024-01-012024-09-30

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549Â FORM 10-Q (Mark One)â˜’Quarterly report pursuant to SectionÂ 13 or 15(d) of the Securities Exchange Act of 1934For the quarterly period ended SeptemberÂ 30, 2024 orâ˜Transition report pursuant to SectionÂ 13 or 15(d) of the Securities Exchange Act of 1934For the transition period from Â Â Â

receivable, net of allowances723,639Â 705,794Â Inventories539,302Â 597,039Â Prepaid expenses155,132Â 185,476Â Other current assets354,215Â 320,809Â Total current assets4,390,423Â 3,435,428Â Property, plant and equipment, net176,422Â 169,646Â Operating lease assets77,164Â 65,340Â Intangible assets, net5,144,217Â 5,418,039Â Goodwill1,804,646Â 1,753,130Â Deferred tax assets, net583,218Â 477,834Â Deferred financing costs4,395Â 6,478Â Other non-current assets75,231Â 67,464Â Total assets$12,255,716Â $11,393,359Â LIABILITIES AND SHAREHOLDERSâ€™ EQUITYCurrent liabilities:Accounts payable$85,425Â $102,750Â Accrued liabilities858,578Â 793,914Â Current portion of long-term debt31,000Â 604,954Â Income taxes payable54,974Â 35,074Â Total current liabilities1,029,977Â 1,536,692Â Long-term debt, less current portion6,080,802Â 5,107,988Â Operating lease liabilities, less current portion71,115Â 59,225Â Deferred tax liabilities, net791,784Â 847,706Â Other non-current liabilities110,971Â 104,751Â Commitments and contingencies (Note 9)Shareholdersâ€™ equity:Ordinary shares6Â 6Â Non-voting euro deferred shares55Â 55Â Capital redemption reserve473Â 473Â Additional paid-in capital3,837,698Â 3,699,954Â Accumulated other comprehensive loss(603,397)(842,147)Retained earnings936,232Â 878,656Â Total shareholdersâ€™ equity4,171,067Â 3,736,997Â Total liabilities and shareholdersâ€™ equity$12,255,716Â $11,393,359Â The accompanying notes are an integral part of these condensed consolidated financial statements.3Table of ContentsJAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED STATEMENTS OF INCOME(In thousands, except per share amounts)(Unaudited)Â Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Â 202420232024202323Revenues:Product sales, net$989,707Â $938,398Â $2,795,953Â $2,769,604Â Royalties and contract revenues65,262Â 33,742Â 184,824Â 52,665Â Total revenues1,054,969Â 972,140Â 2,980,777Â 2,822,269Â Operating expenses:Cost of product sales (excluding amortization of acquired developed technologies)111,611Â 102,153Â 317,000Â 328,334Â Selling, general and administrative325,772Â 308,310Â 1,016,007Â 947,071Â Research and development199,919Â 234,402Â 643,500Â 633,050Â Intangible asset amortization157,457Â 154,883Â 468,410Â 456,731Â Acquired in-process research and developmentâ€”Â â€”Â 10,000Â 1,000Â Total operating expenses794,759Â 799,748Â 2,454,917Â 2,366,186Â Income from operations260,210Â 172,392Â 525,860Â 456,083Â Interest expense, net(58,702)(71,497)(186,841)(219,114)Foreign exchange loss(701)(1,377)(1,887)(566)Income before income tax benefit and equity in loss (gain) of investees200,807Â 99,518Â 337,132Â 236,403Â Income tax benefit(14,533)(47,176)(33,517)(86,823)Equity in loss (gain) of investees285Â (126)1,644Â 2,548Â Net income$215,055Â $146,820Â $369,005Â $320,678Â Net income per ordinary share:Basic$3.50Â $2.33Â $5.93Â $5.05Â Diluted$3.42Â $2.14Â $5.63Â $4.67Â Weighted-average ordinary shares used in per share calculations - basic61,414Â 63,114Â 62,275Â 63,532Â Weighted-average ordinary shares used in per share calculations - diluted63,174Â 71,293Â 67,511Â 72,866Â The accompanying notes are an integral part of these condensed consolidated financial statements.4Table of ContentsJAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)(In thousands)(Unaudited)Â Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Â 2024202320242023Net income$215,055Â $146,820Â $369,005Â $320,678Â Other comprehensive income (loss):Foreign currency translation adjustments291,367Â (170,826)241,218Â 82,952Â Unrealized gain (loss) on cash flow hedging activities, net of income tax (benefit) expense of $(1,727), $1,176, $522 and $3,063 respectively(5,197)3,539Â 1,572Â 9,218Â Gain on cash flow hedging activities reclassified from accumulated other comprehensive loss to interest expense, net of income tax expense of $445, $428, $1,342 and $684 respectively(1,340)(1,289)(4,040)(2,060)Other comprehensive income (loss)284,830Â (168,576)238,750Â 90,110Â Total comprehensive income (loss)$499,885Â $(21,756)$607,755Â $410,788Â The accompanying notes are an integral part of these condensed consolidated financial statements.5Table of ContentsJAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERSâ€™ EQUITY(In thousands)(Unaudited)Â Ordinary SharesNon-voting Euro DeferredCapitalRedemptionReserveAdditionalPaid-inCapitalAccumulatedOtherComprehensiveLossRetainedEarningsTotal EquitySharesAmountSharesAmountBalance at DecemberÂ 31, 202362,255Â $6Â 4,000Â $55Â $473Â $3,699,954Â $(842,147)$878,656Â $3,736,997Â Issuance of ordinary shares in conjunction with exercise of share options7Â â€”Â â€”Â â€”Â â€”Â 494Â â€”Â â€”Â 494Â Issuance of ordinary shares in conjunction with vesting of restricted stock units686Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Issuance of ordinary shares in conjunction with vesting of performance-based restricted stock units80Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Shares withheld for payment of employee's withholding tax liabilityâ€”Â â€”Â â€”Â â€”Â â€”Â (49,296)â€”Â â€”Â (49,296)Share-based compensationâ€”Â â€”Â â€”Â â€”Â â€”Â 63,131Â â€”Â â€”Â 63,131Â Other comprehensive lossâ€”Â â€”Â â€”Â â€”Â â€”Â (40,247)â€”Â (40,247)Net lossâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â (14,618)(14,618)Balance at March 31, 202463,028Â $6Â 4,000Â $55Â $473Â $3,714,283Â $(882,394)$864,038Â $3,696,461Â Issuance of ordinary shares in conjunction with exercise of share options4Â â€”Â â€”Â â€”Â â€”Â 54Â â€”Â â€”Â 54Â Issuance of ordinary shares under employee stock purchase plan122Â â€”Â â€”Â â€”Â â€”Â 10,886Â â€”Â â€”Â 10,886Â Issuance of ordinary shares in conjunction with vesting of restricted stock units49Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Shares withheld for payment of employee's withholding tax liabilityâ€”Â â€”Â â€”Â â€”Â â€”Â (2,847)â€”Â â€”Â (2,847)Share-based compensationâ€”Â â€”Â â€”Â â€”Â 56,738Â â€”Â â€”Â 56,738Â Shares repurchased(1,458)â€”Â â€”Â â€”Â â€”Â â€”Â (161,428)(161,428)Other comprehensive lossâ€”Â â€”Â â€”Â â€”Â â€”Â (5,833)â€”Â (5,833)Net incomeâ€”Â â€”Â â€”Â â€”Â 168,568Â 168,568Â Balance at June 30, 202461,745Â $6Â 4,000Â $55Â $473Â $3,779,114Â $(888,227)$871,178Â $3,762,599Â Issuance of ordinary shares in conjunction with exercise of share options1Â â€”Â â€”Â â€”Â â€”Â 17Â â€”Â â€”Â 17Â Issuance of ordinary shares in conjunction with vesting of restricted stock units69Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Shares withheld for payment of employee's withholding tax liabilityâ€”Â â€”Â â€”Â â€”Â â€”Â (1,605)â€”Â â€”Â (1,605)Share-based compensationâ€”Â â€”Â â€”Â â€”Â 60,172Â â€”Â â€”Â 60,172Â Shares repurchased(1,372)â€”Â â€”Â â€”Â â€”Â â€”Â (150,001)(150,001)Other comprehensive incomeâ€”Â â€”Â â€”Â â€”Â â€”Â 284,830Â â€”Â 284,830Â Net incomeâ€”Â â€”Â â€”Â â€”Â 215,055Â 215,055Â Balance at September 30, 202460,443Â $6Â 4,000Â $55Â $473Â $3,837,698Â $(603,397)$936,232Â $4,171,067Â 6Table of ContentsJAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERSâ€™ EQUITY(In thousands)(Unaudited)Â Ordinary SharesNon-voting Euro DeferredCapitalRedemptionReserveAdditionalPaid-inCapitalAccumulatedOtherComprehensiveLossRetainedEarningsTotal EquitySharesAmountSharesAmountBalance at DecemberÂ 31, 202263,214Â $6Â 4,000Â $55Â $472Â $3,477,124Â $(1,125,509)$733,586Â $3,085,734Â Issuance of ordinary shares in conjunction with exercise of share options188Â â€”Â â€”Â â€”Â â€”Â 21,228Â â€”Â â€”Â 21,228Â Issuance of ordinary shares in conjunction with vesting of restricted stock units585Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Shares withheld for payment of employee's withholding tax liabilityâ€”Â â€”Â â€”Â â€”Â â€”Â (43,266)â€”Â â€”Â (43,266)Share-based compensationâ€”Â â€”Â â€”Â â€”Â 56,646Â â€”Â â€”Â 56,646Â Other comprehensive incomeâ€”Â â€”Â â€”Â â€”Â 145,279Â â€”Â 145,279Â Net incomeâ€”Â â€”Â â€”Â â€”Â 69,420Â 69,420Â Balance at March 31, 202363,987Â $6Â 4,000Â $55Â $472Â $3,511,732Â $(980,230)$803,006Â $3,335,041Â Issuance of ordinary shares in conjunction with exercise of share options28Â â€”Â â€”Â â€”Â â€”Â 2,003Â â€”Â â€”Â 2,003Â Issuance of ordinary shares under employee stock purchase plan81Â â€”Â â€”Â â€”Â â€”Â 8,863Â â€”Â â€”Â 8,863Â Issuance of ordinary shares in conjunction with vesting of restricted stock units58Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Shares withheld for payment of employee's withholding tax liabilityâ€”Â â€”Â â€”Â â€”Â â€”Â (4,188)â€”Â â€”Â (4,188)Share-based compensationâ€”Â â€”Â â€”Â â€”Â 61,705Â â€”Â â€”Â 61,705Â Shares repurchased(756)â€”Â â€”Â â€”Â 1Â â€”Â â€”Â (95,595)(95,594)Other comprehensive incomeâ€”Â â€”Â â€”Â â€”Â 113,407Â â€”Â 113,407Â Net incomeâ€”Â â€”Â â€”Â 104,438Â 104,438Â Balance at June 30, 202363,398Â $6Â 4,000Â $55Â $473Â $3,580,115Â $(866,823)$811,849Â $3,525,675Â Issuance of ordinary shares in conjunction with exercise of share options50Â â€”Â â€”Â â€”Â â€”Â 5,512Â â€”Â â€”Â 5,512Â Issuance of ordinary shares in conjunction with vesting of restricted stock units59Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Shares withheld for payment of employee's withholding tax liabilityâ€”Â â€”Â â€”Â â€”Â â€”Â (1,884)â€”Â â€”Â (1,884)Share-based compensationâ€”Â â€”Â â€”Â â€”Â 56,197Â â€”Â â€”Â 56,197Â Shares repurchased(562)â€”Â â€”Â â€”Â â€”Â â€”Â (74,371)(74,371)Other comprehensive lossâ€”Â â€”Â â€”Â â€”Â (168,576)â€”Â (168,576)Net incomeâ€”Â â€”Â â€”Â 146,820Â 146,820Â Balance at September 30, 202362,945Â $6Â 4,000Â $55Â $473Â $3,639,940Â $(1,035,399)$884,298Â $3,489,373Â The accompanying notes are an integral part of these condensed consolidated financial statements.7Table of ContentsJAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Â Â Nine Months EndedSeptember 30,Â 20242023Operating activitiesNet income$369,005Â $320,678Â Adjustments to reconcile net income to net cash provided by operating activities:Intangible asset amortization468,410Â 456,731Â Share-based compensation177,855Â 173,900Â Acquisition accounting inventory fair value step-up adjustment97,220Â 119,094Â Depreciation23,240Â 22,764Â Non-cash interest expense18,877Â 16,255Â Provision for losses on accounts receivable and inventory15,866Â 7,732Â Acquired in-process research and development10,000Â 1,000Â Deferred tax benefit(205,972)(224,317)Other non-cash transactions19,615Â 54,262Â Changes in assets and liabilities:Accounts receivable(21,979)23,581Â Inventories(26,877)(12,016)Prepaid expenses and other current assets708Â (37,327)Operating lease assets10,697Â 14,423Â Other non-current assets(9,544)(20,881)Accounts payable(16,938)17,705Â Accrued liabilities56,428Â (76,261)Income taxes payable20,098Â 61,159Â Deferred revenueâ€”Â (459)Operating lease liabilities, less current portion(9,701)(13,855)Other non-current liabilities320Â 20,500Â Net cash provided by operating activities997,328Â 924,668Â Investing activitiesAcquisition of investments(835,125)(270,000)Purchases of property, plant and equipment(24,783)(13,860)Acquired in-process research and development(10,000)(1,000)Proceeds from maturity of investments555,000Â 20,000Â Net cash used in investing activities(314,908)(264,860)Financing activitiesNet proceeds from issuance of exchangeable senior notes, due 2030980,767Â â€”Â Proceeds from employee equity incentive and purchase plans11,451Â 37,606Â Repayments of long-term debt(23,250)(23,250)Payment of employee withholding taxes related to share-based awards(53,748)(49,338)Share repurchases(311,429)(169,966)Repayment of exchangeable senior notes, due 2024(575,000)â€”Â Net cash provided by (used in) financing activities28,791Â (204,948)Effect of exchange rates on cash and cash equivalents614Â (652)Net increase in cash and cash equivalents711,825Â 454,208Â Cash and cash equivalents, at beginning of period1,506,310Â 881,482Â Cash and cash equivalents, at end of period$2,218,135Â $1,335,690Â The accompanying notes are an integral part of these condensed consolidated financial statements.8Table of ContentsJAZZ PHARMACEUTICALS PLCNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)1. The Company and Summary of Significant Accounting PoliciesJazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases - often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience.Our lead marketed products, listed below, are approved in countries around the world to improve patient care.Neuroscienceâ€¢XywavÂ® (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product approved by the U.S. Food and Drug Administration, or FDA, in JulyÂ 2020, and launched in the U.S. in NovemberÂ 2020 for the treatment of cataplexy or excessive daytime sleepiness, or EDS, in patients seven years of age and older with narcolepsy, and also approved by FDA in AugustÂ 2021 for the treatment of idiopathic hypersomnia, or IH, in adults and launched in the U.S. in NovemberÂ 2021. Xywav contains 92% less sodium than XyremÂ®. Xywav is also approved in Canada for the treatment of cataplexy in patients with narcolepsy.â€¢EpidiolexÂ® (cannabidiol) oral solution, a product approved by FDA and launched in the U.S. in 2018 by GW Pharmaceuticals plc, or GW, and currently indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, or LGS, Dravet syndrome, or DS, or tuberous sclerosis complex, or TSC, in patients one year of age or older; in the EU and Great Britain (where it is marketed as EpidyolexÂ®) and other markets, it is approved for adjunctive treatment of seizures associated with LGS or DS, in conjunction with clobazam (EU and Great Britain only), in patients 2 years of age and older and for adjunctive treatment of seizures associated with TSC in patients 2 years of age and older.Oncologyâ€¢RylazeÂ® (asparaginase erwinia chrysanthemi (recombinant)-rywn), a product approved by FDA in JuneÂ 2021 and launched in the U.S. in JulyÂ 2021 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who have developed hypersensitivity to E. coli-derived asparaginase. In SeptemberÂ 2023, the European Commission granted marketing authorization under the trade name Enrylaze. This therapy is also approved in Great Britain, Canada and Switzerland.â€¢ZepzelcaÂ® (lurbinectedin), a product approved by FDA in JuneÂ 2020 under FDA's accelerated approval pathway and launched in the U.S. in JulyÂ 2020 for the treatment of adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based chemotherapy; in Canada, Zepzelca received conditional approval in SeptemberÂ 2021 for the treatment of adults with Stage III or metastatic SCLC, who have progressed on or after platinum-containing therapy.Throughout this Quarterly Report on FormÂ 10-Q, unless otherwise indicated or the context otherwise requires, all references to â€œJazz Pharmaceuticals,â€ â€œthe registrant,â€ â€œthe Company,â€ â€œwe,â€ â€œus,â€ and â€œourâ€ refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries. Throughout this Quarterly Report on FormÂ 10-Q, all references to â€œordinary sharesâ€ refer to Jazz Pharmaceuticals plcâ€™s ordinary shares.Basis of PresentationThese unaudited condensed consolidated financial statements have been prepared following the requirements of the U.S. Securities and Exchange Commission for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or U.S. GAAP, can be condensed or omitted. The information included in this Quarterly Report on FormÂ 10â‘Q should be read in conjunction with our annual audited consolidated financial statements and accompanying notes included in our Annual Report on FormÂ 10â‘K for the year ended DecemberÂ 31,Â 2023. In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the 9Table of Contentsthree and nine months ended SeptemberÂ 30,Â 2024, are not necessarily indicative of the results to be expected for the year ending DecemberÂ 31,Â 2024, for any other interim period or for any future period.Our significant accounting policies have not changed substantially from those previously described in our Annual Report on FormÂ 10â‘K for the year ended DecemberÂ 31,Â 2023. These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our subsidiaries, and intercompany transactions and balances have been eliminated.Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker, or CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the identification, development and commercialization of meaningful pharmaceutical products that address unmet medical needs.Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.Adoption of New Accounting StandardsIn NovemberÂ 2023, the Financial Accounting Standards Board, or FASB, issued ASU 2023-07, â€œSegment Reporting (Topic 280) - Improvements to Reportable Segment Disclosuresâ€, which requires enhanced disclosures about significant segment expenses. The amendments are effective retrospectively to all prior periods presented in the financial statements, for fiscal years beginning after DecemberÂ 15,Â 2023. The new guidance is not expected to have a material impact on our financial statement disclosures.Significant Risks and UncertaintiesWe expect that our business will continue to meaningfully depend on oxybate revenues; however, there is no guarantee that oxybate revenues will remain at current levels. In this regard, our ability to maintain oxybate revenues and realize the anticipated benefits from our investment in Xywav are subject to a number of risks and uncertainties including, without limitation, those related to the commercialization of Xywav for the treatment of IH in adults and adoption in that indication; competition from the introduction of two authorized generic, or AG, versions of high-sodium oxybate and a branded fixed-dose, high-sodium oxybate, Avadelâ€™s Lumryz, for treatment of cataplexy and/or EDS in narcolepsy in the U.S. market, as well as potential future competition from additional AG versions of high-sodium oxybate and from generic versions of high-sodium oxybate and from other competitors; increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party payors, including our ability to maintain adequate coverage and reimbursement for Xywav; increased rebates required to maintain access to our products; challenges to our intellectual property around Xywav and/or Xyrem, including from pending

antitrust and intellectual property litigation; and continued acceptance of Xywav and Xyrem by physicians and patients. A significant decline in oxybate revenues could cause us to reduce our operating expenses or seek to raise additional funds and would have a material adverse effect on our business, financial condition, results of operations and growth prospects, including on our ability to acquire, in-license or develop new products to grow our business.In addition to risks related specifically to Xywav and Xyrem, we are subject to other challenges and risks related to successfully commercializing a portfolio of oncology products and other neuroscience products, and other risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: ongoing clinical research activity and related outcomes; obtaining regulatory approval of our late-stage product candidates, such as zanidatamab; effectively commercializing our approved products such as Epidiolex, Rylaze and Zepzelca; obtaining and maintaining adequate coverage and reimbursement for our products; contracting and rebates to pharmacy benefit managers and similar organizations that reduce our net revenue; increasing scrutiny of pharmaceutical product pricing and resulting changes in healthcare laws and policy; market acceptance; regulatory concerns with controlled substances generally and the potential for abuse; future legislation; action by the U.S. Federal Government authorizing the sale, distribution, use, and insurance reimbursement of non-FDA approved cannabinoid products; delays or problems in the supply of our products; loss of single source suppliers or failure to comply with manufacturing regulations; delays or problems with third parties that are part of our manufacturing and supply chain; identifying, acquiring or in-licensing additional products or product candidates; our ability to realize the anticipated benefits of acquired or in-licensed products or product candidates, such as Epidiolex and zanidatamab, at the expected levels, with the expected costs and within the expected timeframe; pharmaceutical product 10Table of Contentsdevelopment and the inherent uncertainty of clinical success; the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements; and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt obligations.Concentrations of RiskFinancial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of SeptemberÂ 30,Â 2024, we had foreign exchange forward contracts with notional amounts totaling $292.7Â million. As of SeptemberÂ 30,Â 2024, the outstanding foreign exchange forward contracts had a net asset fair value of $8.4Â million. As of SeptemberÂ 30,Â 2024, we had interest rate swap contracts with notional amounts totaling $500.0Â million with a liability fair value of $3.0 million. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant.We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and, as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, allowances on receivables were not material. As of SeptemberÂ 30,Â 2024, five customers accounted for 81% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliates, or ESSDS, which accounted for 41% of gross accounts receivable, ASD Specialty Healthcare LLC, or ASD, which accounted for 14% of gross accounts receivable and McKesson Corporation and affiliates, or McKesson, which accounted for 14% of gross accounts receivable. As of DecemberÂ 31,Â 2023, five customers accounted for 79% of gross accounts receivable, including ESSDS, which accounted for 41% of gross accounts receivable, ASD, which accounted for 13% of gross accounts receivable and McKesson, which accounted for 11% of gross accounts receivable. We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to our oxybate products, the API is manufactured for us by a single source supplier and the finished products are manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based supplier.Recent Accounting PronouncementsIn DecemberÂ 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740) - Improvements to Income Tax Disclosuresâ€, which requires enhanced tax disclosures providing greater disaggregation of information in the Company's effective tax rate reconciliation and disaggregates income taxes paid by jurisdiction. The amendments are effective on a prospective basis, with the option to apply it retrospectively, for fiscal years beginning after DecemberÂ 15,Â 2024. We are currently evaluating the impact of adopting this new accounting guidance.2. Cash and Available-for-Sale Securities Cash, cash equivalents and investments consisted of the following (in thousands):Â September 30, 2024AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesEstimatedFair ValueCash andCashEquivalentsInvestmentsCash$797,583Â $â€”Â $â€”Â $797,583Â $797,583Â $â€”Â $â€”Â Time deposits650,000Â â€”Â â€”Â 650,000Â 250,000Â 400,000Â Money market funds1,170,552Â â€”Â â€”Â 1,170,552Â 1,170,552Â â€”Â Totals$2,618,135Â $â€”Â $â€”Â $2,618,135Â $2,218,135Â $400,000Â 11Table of ContentsDecember 31, 2023AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesEstimatedFair ValueCash and CashEquivalentsInvestmentsCash$437,724Â $â€”Â $â€”Â $â€”Â $437,724Â $437,724Â $â€”Â $â€”Â Time deposits420,000Â â€”Â â€”Â 420,000Â 300,000Â 120,000Â Money market funds768,586Â â€”Â â€”Â 768,586Â 768,586Â â€”Â Totals$1,626,310Â $â€”Â $â€”Â $1,626,310Â $1,506,310Â $120,000Â Cash equivalents and investments are considered available-for-sale securities. We use the specific-identification method for calculating realized gains and losses on securities sold and include them in interest expense, net in the condensed consolidated statements of income. Our investment balances represent time deposits with original maturities of greater than three months and less than one year. Interest income from available-for-sale securities was $26.0 million and $74.6Â million in the three and nine months ended SeptemberÂ 30,Â 2024, respectively, and $19.2 million and $44.4 million in the three and nine months ended SeptemberÂ 30,Â 2023, respectively.3. Fair Value Measurement The following table summarizes, by major security type, our available-for-sale securities and derivative contracts as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands):Â September 30, 2024December 31, 2023QuotedPrices inActiveMarketsÂ forIdenticalAssets(Level 1)SignificantOtherObservableInputs(Level 2)TotalEstimatedFairÂ ValueQuotedPrices inActiveMarketsÂ forIdenticalAssets(Level 1)SignificantOtherObservableInputs(Level 2)TotalEstimatedFairÂ ValueAssets:Available-for-sale securities:Money market funds$1,170,552Â $â€”Â $1,170,552Â $768,586Â $â€”Â $768,586Â Time depositsâ€”Â 650,000Â 650,000Â â€”Â 420,000Â 420,000Â Foreign exchange forward contractsâ€”Â 8,364Â 8,364Â â€”Â 18,035Â 18,035Â Interest rate contractsâ€”Â 13Â 13Â â€”Â 3,784Â 3,784Â Totals$1,170,552Â $658,377Â $1,828,929Â $768,586Â $441,819Â $1,210,405Â Liabilities:Interest rate contracts$â€”Â $2,976Â $2,976Â $â€”Â $3,410Â $3,410Â Foreign exchange forward contractsâ€”Â â€”Â â€”Â â€”Â 681Â 681Â Totals$â€”Â $2,976Â $2,976Â $â€”Â $4,091Â $4,091Â As of SeptemberÂ 30,Â 2024, our available-for-sale securities included money market funds and time deposits and their carrying values were approximately equal to their fair values. Money market funds were measured using quoted prices in active markets, which represent Level 1 inputs and time deposits were measured at fair value using Level 2 inputs. Level 2 inputs are obtained from various third party data providers and represent quoted prices for similar assets in active markets, or these inputs were derived from observable market data, or if not directly observable, were derived from or corroborated by other observable market data.Our derivative assets and liabilities include interest rate and foreign exchange derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterpartiesâ€™ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the fair value hierarchy.There were no transfers between the different levels of the fair value hierarchy in 2024 or 2023.As of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, the carrying amount of investments measured using the measurement alternative for equity investments without a readily determinable fair value was $4.3Â million and $4.7Â million, respectively. The carrying amount, which is recorded within other non-current assets, is based on the latest observable transaction price.12Table of ContentsAs of SeptemberÂ 30,Â 2024, the estimated fair values of the 2.000% exchangeable senior notes due 2026, or 2026 Notes, and the 3.125% exchangeable senior notes due 2030, or 2030 Notes, were approximately $1.0Â billion and $1.0Â billion, respectively. The 2030 Notes together with the 2026 Notes and the 1.50% exchangeable senior notes due 2024, or 2024 Notes, that were repaid upon maturity on August 15, 2024, are collectively known as the Exchangeable Senior Notes. As of SeptemberÂ 30,Â 2024, the estimated fair values of the 4.375% senior secured notes, due 2029, or the Secured Notes, and the seven-year U.S. dollar term loan B facility were approximately $1.4Â billion and $2.7Â billion, respectively. The fair values of each of these debt facilities was estimated using quoted market prices obtained from brokers (Level 2).4. Derivative Instruments and Hedging Activities We are exposed to certain risks arising from operating internationally, including fluctuations in foreign exchange rates primarily related to the translation of sterling and euro denominated net monetary liabilities, including intercompany balances, held by subsidiaries with a U.S. dollar functional currency and fluctuations in interest rates on our outstanding term loan borrowings. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.We enter into foreign exchange forward contracts, with durations of up to 12 months, designed to limit the exposure to fluctuations in foreign exchange rates related to the translation of certain non-U.S. dollar denominated liabilities, including intercompany balances. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, the notional amount of foreign exchange contracts where hedge accounting is not applied was $292.7Â million and $511.7Â million, respectively.The foreign exchange loss in our condensed consolidated statements of income included the following gains (losses) associated with foreign exchange contracts not designated as hedging instruments (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Foreign Exchange Forward Contracts:20242023202420232023Gain (loss) recognized in foreign exchange loss$14,396Â $(13,549)$9,485Â $(8,921)To achieve a desired mix of floating and fixed interest rates on our variable rate debt, we entered into interest rate swap agreements in AprilÂ 2023, which are effective until AprilÂ 2026. These agreements hedge contractual term loan interest rates. As of SeptemberÂ 30,Â 2024, the interest rate swap agreements had a notional amount of $500.0 million. As a result of these agreements, the interest rate on a portion of our term loan borrowings is fixed at 3.9086%, plus the borrowing spread, until AprilÂ 30,Â 2026.The impact on accumulated other comprehensive loss and earnings from derivative instruments that qualified as cash flow hedges for the three and nine months ended SeptemberÂ 30,Â 2024 was as follows (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Interest Rate Contracts:20242023202420232023Gain (loss) recognized in accumulated other comprehensive loss, net of tax$(5,197)$3,539Â $1,572Â $9,218Â Gain reclassified from accumulated other comprehensive loss to interest expense, net of tax(1,340)(1,289)(4,040)(2,060)Assuming no change in the U.S dollar Secured Overnight Financing Rate, or Term SOFR, based interest rates from market rates as of SeptemberÂ 30,Â 2024, $0.5 million of loss, net of tax, recognized in accumulated other comprehensive loss will be reclassified to earnings over the next 12 months.The cash flow effects of our derivative contracts for the nine months ended SeptemberÂ 30,Â 2024 and 2023 are included within net cash provided by operating activities in the condensed consolidated statements of cash flows.13Table of ContentsThe following tables summarize the fair value of outstanding derivatives (in thousands):ClassificationSeptember 30,2024December 31,2023AssetsDerivatives designated as hedging instruments:Interest rate contractsOther current assets$13Â $3,784Â Derivatives not designated as hedging instruments:Foreign exchange forward contractsOther current assets8,364Â 18,035Â Total fair value of derivative asset instruments$8,377Â $21,819Â LiabilitiesDerivatives designated as hedging instruments:Interest rate contractsAccrued liabilities$572Â $â€”Â Interest rate contractsOther non-current liabilities2,404Â 3,410Â Derivatives not designated as hedging instruments:Foreign exchange forward contractsAccrued liabilitiesâ€”Â 681Â Total fair value of derivative liability instruments$2,976Â $4,091Â Although we do not offset derivative assets and liabilities within our condensed consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following table summarizes the potential effect on our condensed consolidated balance sheets of offsetting our interest rate and foreign exchange forward contracts subject to such provisions (in thousands):September 30, 2024Gross Amounts of Recognized Assets/ LiabilitiesGross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets/ Liabilities Presented in the Consolidated Balance SheetGross Amounts Not Offset in the Consolidated Balance SheetDescriptionDerivative Financial InstrumentsCash Collateral Received (Pledged)Net AmountDerivative assets$8,377Â $â€”Â $8,377Â $(1,830)$â€”Â $6,547Â Derivative liabilities(2,976)â€”Â (2,976)1,830Â â€”Â (1,146)December 31, 2023Gross Amounts of Recognized Assets/ LiabilitiesGross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets/ Liabilities Presented in the Consolidated Balance SheetGross Amounts Not Offset in the Consolidated Balance SheetDescriptionDerivative Financial InstrumentsCash Collateral Received (Pledged)Net AmountDerivative assets$21,819Â $â€”Â $21,819Â $(4,091)$â€”Â $17,728Â Derivative liabilities(4,091)â€”Â (4,091)4,091Â â€”Â â€”Â 5. Inventories Inventories consisted of the following (in thousands):Â September 30,2024December 31,2023Raw materials$24,819Â $25,595Â Work in process366,602Â 431,732Â Finished goods147,881Â 139,712Â Total inventories$539,302Â $597,039Â As of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, inventories included $243.4Â million and $328.0Â million, respectively, related to the purchase accounting inventory fair value step-up on inventory acquired as part of our acquisition of GW.14Table of Contents6. Goodwill and Intangible Assets The gross carrying amount of goodwill was as follows (in thousands):Balance at December 31, 2023$1,753,130Â Foreign exchange51,516Â Balance at September 30, 2024$1,804,646Â The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):Â Â September 30, 2024December 31, 2023Â RemainingWeighted-AverageÂ UsefulLife(In years)GrossCarryingAmountAccumulatedAmortizationNet BookValueGrossCarryingAmountAccumulatedAmortizationNet BookValueAcquired developed technologies8.0$8,064,193Â $(2,919,976)$5,144,217Â $7,785,495Â $(2,367,456)$5,418,039Â Manufacturing contractsâ€”11,984Â (11,984)â€”Â 11,828Â (11,828)â€”Â Trademarksâ€”2,889Â (2,889)â€”Â 2,886Â (2,886)â€”Â Total finite-lived intangible assets$8,079,066Â $(2,934,849)$5,144,217Â $7,800,209Â $(2,382,170)$5,418,039Â The increase in the gross carrying amount of intangible assets as of SeptemberÂ 30,Â 2024, compared to DecemberÂ 31,Â 2023, relates to the positive impact of foreign currency translation adjustments due to the strengthening of sterling against the U.S. dollar.The assumptions and estimates used to determine future cash flows and remaining useful lives of our intangible and other long-lived assets are complex and subjective. They can be affected by various factors, including external factors, such as industry and economic trends, and internal factors such as changes in our business strategy and our forecasts for specific product lines.Based on finite-lived intangible assets recorded as of SeptemberÂ 30,Â 2024, and assuming the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands):Â Year Ending December 31,Estimated Amortization Expense2024 (remainder)$162,109Â 2025648,436Â 2026648,436Â 2027648,436Â 2028647,104Â Thereafter2,389,696Â Total$5,144,217Â 15Table of Contents7. Certain Balance Sheet Items Property, plant and equipment consisted of the following (in thousands):September 30,2024December 31,2023Manufacturing equipment and machinery$91,560Â $82,897Â Leasehold improvements71,950Â 67,722Â Land and buildings70,762Â 70,912Â Computer software41,847Â 38,134Â Construction-in-progress30,645Â 18,661Â Computer equipment17,530Â 15,398Â Furniture and fixtures8,942Â 9,273Â Subtotal333,236Â 302,997Â Less accumulated depreciation and amortization(156,814)(133,351)Property, plant and equipment, net$176,422Â $169,646Â Accrued liabilities consisted of the following (in thousands):September 30,2024December 31,2023Rebates and other sales deductions$405,134Â $325,711Â Employee compensation and benefits125,497Â 121,209Â Accrued royalties40,923Â 30,706Â Clinical trial accruals37,620Â 44,757Â Consulting and professional services32,844Â 19,538Â Sales return reserve24,545Â 20,435Â Selling and marketing accruals24,539Â 14,743Â Accrued interest22,445Â 36,443Â Current portion of lease liabilities19,103Â 19,447Â Inventory-related accruals14,015Â 13,977Â Accrued collaboration expenses12,805Â 10,158Â Accrued construction-in-progress9,040Â 5,141Â Accrued facilities expenses5,439Â 55,455Â Derivative instrument liabilities572Â 681Â Other84,057Â 75,513Â Total accrued liabilities$858,578Â $793,914Â 16Table of Contents8. Debt The following table summarizes the carrying amount of our indebtedness

(in thousands):September 30,2024December 31,20232024 Notes$â€”Â $575,000Â Unamortized - debt issuance costsâ€”Â (1,046)2024 Notes, netâ€”Â 573,954Â 2026 Notes 1,000,000Â 1,000,000Â Unamortized - debt issuance costs(4,456)(6,400)2026 Notes, net995,544Â 993,600Â 2030 Notes1,000,000Â â€”Â Unamortized - debt issuance costs(19,081)â€”Â 2030 Notes, net980,919Â â€”Â Secured Notes 1,482,824Â 1,480,214Â Term Loan 2,652,515Â 2,665,174Â Total debt6,111,802Â 5,712,942Â Less current portion31,000Â 604,954Â Total long-term debt$6,080,802Â $5,107,988Â Credit Agreement On MayÂ 5,Â 2021, the Company, Jazz Financing Lux S.Ã .r.l., or Jazz Lux, and certain of our other subsidiaries, as borrowers, or, collectively with the Company and Jazz Lux, the â€œBorrowersâ€, entered into the Credit Agreement by and among the Borrowers, the lenders and issuing banks from time to time party thereto, Bank of America, N.A., as administrative agent and U.S. Bank Trust Company, National Association, as collateral trustee, or the Credit Agreement. The Credit Agreement initially provided for (i) a seven-year $3.1Â billion term loan B facility, or the Dollar Term Loan, which was drawn by Jazz Lux on the closing date thereof in U.S. dollars (ii) a seven-year â‚¬625.0 million term loan B facility, or the Euro Term Loan, which was drawn by Jazz Lux on the closing date thereof in Euros and (iii) a five-year $500.0Â million revolving credit facility, or the Revolving Credit Facility.In January 2024, Jazz Lux entered into an amendment, or the Repricing Amendment No.1, to the Credit Agreement. Upon entry into the Repricing Amendment No.1, certain existing lenders converted a portion of the outstanding Dollar Term Loan into a new tranche of U.S. dollar term loans, or the Tranche B-1 Dollar Term Loans, and Jazz Lux borrowed $201.9Â million aggregate principal amount of additional Tranche B-1 Dollar Term Loans, the proceeds of which were used to repay the portion of the outstanding Dollar Term Loan that was not converted. In JulyÂ 2024, Jazz Lux entered into an amendment, or the Repricing Amendment No. 2, to the Credit Agreement, or the Amended Credit Agreement. Upon entry into the Amended Credit Agreement, certain existing lenders converted a portion of the outstanding Tranche B-1 Dollar Term Loans into a new tranche of U.S. dollar term loans, or the Tranche B-2 Dollar Term Loans, and Jazz Lux borrowed $289.6Â million aggregate principal amount of additional Tranche B-2 Dollar Term Loans, the proceeds of which were used to repay the portion of the outstanding Tranche B-1 Dollar Term Loans that were not converted.The Tranche B-2 Dollar Term Loans are a separate class of term loans under the Amended Credit Agreement with the same material terms (including with respect to maturity, prepayment, security, covenants and events of default) as the previously outstanding Tranche B-1 Dollar Term Loans and the initial Dollar Term Loan incurred on May 5, 2021, with the interest rate amended as described below and the credit spread adjustment removed. The principal amount of Tranche B-1 Dollar Term Loans outstanding immediately prior to the Repricing Amendment No. 2 and the outstanding principal amount of Tranche B-2 Dollar Term Loans immediately following the Repricing Amendment No.2, each totaled $2.7Â billion. The Tranche B-2 Dollar Term Loans bear interest at a rate equal to either (a) Term SOFR, or (b) the prime lending rate, in each case, plus an applicable margin. The applicable margin for the Tranche B-2 Dollar Term Loans is 2.25% (in the case of 17Table of ContentsTerm SOFR borrowings) and 1.25% (in the case of borrowings at the prime lending rate), a decrease of 75 basis points from the applicable margin on the Tranche B-1 Dollar Term Loans. The Tranche B-2 Dollar Term Loans are subject to a Term SOFR floor of 0.50%. As of SeptemberÂ 30,Â 2024, the interest rate and effective interest rate on the Tranche B-2 Dollar Term Loans were 7.10% and 8.27%, respectively. The Tranche B-2 Dollar Term Loans will amortize in quarterly installments equal to 0.286294791% of the initial aggregate principal amount thereof, with the remaining balance payable on MayÂ 5,Â 2028.The applicable margin for the Revolving Credit Facility ranges from 3.25% to 2.75% (in the case of Term SOFR borrowings) and 2.25% to 1.75% (in the case of borrowings at the prime lending rate), depending on our first lien secured net leverage ratio level, any loans under the Revolving Credit Facility are not subject to a Term SOFR floor. The Revolving Credit Facility has a commitment fee payable on the undrawn amount ranging from 0.50% to 0.40% per annum based upon our first lien secured net leverage ratio. As of SeptemberÂ 30,Â 2024, we had an undrawn Revolving Credit Facility totaling $500.0Â million.2030 NotesIn September 2024, Jazz Investments I Limited, or Jazz Investments, our wholly owned subsidiary, completed a private placement of $1.0 billion principal amount of the 2030 Notes. Interest on the 2030 Notes is payable semi-annually in cash in arrears on March 15 and September 15 of each year, beginning on March 15, 2025, at a rate of 3.125%Â per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2030 Notes. The 2030 Notes mature on SeptemberÂ 15, 2030, unless earlier exchanged, redeemed or repurchased.The holders of the 2030 Notes have the ability to require us to repurchase all or a portion of their 2030 Notes for cash at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date in the event we undergo a fundamental change (as defined in the indenture related to the 2030 Notes), such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from any of The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or The Nasdaq Capital Market (or any of their respective successors). Additionally, the terms and covenants in the indenture related to the 2030 Notes include certain events of default after which the 2030 Notes may be due and payable immediately. Prior to September 15, 2030, we may redeem the 2030 Notes, in whole but not in part, in connection with certain tax-related events. We also may redeem the 2030 Notes on or after September 20, 2027 and prior to June 15, 2030, in whole or in part (subject to the partial redemption limitation described in the indenture related to the 2030 Notes), if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.The 2030 Notes are exchangeable at an initial exchange rate of 6.5339 ordinary shares per $1,000 principal amount of 2030 Notes, which is equivalent to an initial exchange price of approximately $153.05 per ordinary share. Upon exchange of the 2030 Notes, we will pay cash up to the aggregate principal amount of the 2030 Notes to be exchanged and pay or deliver, as the case may be, cash, ordinary shares or a combination of cash and ordinary shares, at our election, in respect of the remainder, if any, of our exchange obligation in excess of the aggregate principal amount of the 2030 Notes being exchanged. The exchange rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes (as defined in the indenture related to the 2030 Notes) that occur prior to the maturity date or upon our issuance of a notice of redemption, we will, in certain circumstances, increase the exchange rate for a holder who elects to exchange its 2030 Notes in connection with that make-whole fundamental change or exchange its 2030 Notes called (or deemed called) for redemption during the related redemption period. Prior to June 15, 2030, the 2030 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.Exchangeable Senior NotesThe Exchangeable Senior Notes were issued by Jazz Investments, or the Issuer, a 100%-owned finance subsidiary of Jazz Pharmaceuticals plc. The Exchangeable Senior Notes are senior unsecured obligations of the Issuer and are fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc. No subsidiary of Jazz Pharmaceuticals plc guaranteed the Exchangeable Senior Notes. Subject to certain local law restrictions on payment of dividends, among other things, and potential negative tax consequences, we are not aware of any significant restrictions on the ability of Jazz Pharmaceuticals plc to obtain funds from the Issuer or Jazz Pharmaceuticals plcâ€™s other subsidiaries by dividend or loan, or any 18Table of Contentslegal or economic restrictions on the ability of the Issuer or Jazz Pharmaceuticals plcâ€™s other subsidiaries to transfer funds to Jazz Pharmaceuticals plc in the form of cash dividends, loans or advances. There is no assurance that in the future such restrictions will not be adopted.The 2030 Notes are accounted for as a single liability measured at its amortized cost. The total liability is reflected net of issuance costs of $19.2Â million which will be amortized over the term of the 2030 Notes. The effective interest rate of the 2030 Notes is 3.46%. During the three months ended September 30, 2024 we recognized interest expense of $2.3Â million, of which $2.2Â million related to the contractual coupon rate and $0.1Â million related to the amortization of debt issuance costs. The total liability of the 2026 Notes is reflected net of issuance costs of $15.3Â million which will be amortized over the term of the 2026 Notes. The effective interest rate of the 2026 Notes is 2.26%. During the three months ended SeptemberÂ 30,Â 2024 and 2023, we recognized interest expense of $5.7Â million, of which $5.0Â million related to the contractual coupon rate and $0.7Â million related to the amortization of debt issuance costs, respectively. During the nine months ended SeptemberÂ 30,Â 2024 and 2023, we recognized interest expense of $16.8Â million, of which $15.0Â million related to the contractual coupon rate and $1.8Â million related to the amortization of debt issuance costs, respectively.On AugustÂ 15, 2024, the maturity date for the 2024 Notes, we repaid the $575.0Â million aggregate principal amount, plus accrued and unpaid interest thereon. During the three months ended SeptemberÂ 30,Â 2024, we recognized interest expense of $1.3Â million, of which $1.0Â million related to the contractual coupon rate and $0.3Â million related to the amortization of debt issuance costs. During the three months ended SeptemberÂ 30,Â 2023, we recognized interest expense of $2.5Â million, of which $2.1Â million related to the contractual coupon rate and $0.4Â million related to the amortization of debt issuance costs. During the nine months ended SeptemberÂ 30,Â 2024, we recognized interest expense of $6.4Â million, of which $5.3Â million related to the contractual coupon rate and $1.1Â million related to the amortization of debt issuance costs. During the nine months ended SeptemberÂ 30,Â 2023, we recognized interest expense of $7.6Â million, of which $6.4Â million related to the contractual coupon rate and $1.2Â million related to the amortization of debt issuance costs, respectively.MaturitiesScheduled maturities with respect to our long-term debt principal balances outstanding as of SeptemberÂ 30,Â 2024 were as follows (in thousands): Year Ending December 31,Scheduled Long-Term Debt Maturities2024 (remainder)$7,750Â 202531,000Â 20261,031,000Â 202731,000Â 20282,598,500Â Thereafter2,500,000Â Total$6,199,250Â 9. Commitments and Contingencies IndemnificationIn the normal course of business, we enter into agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. Our exposure under these agreements is unknown because it involves future claims that may be made but have not yet been made against us. To date, we have not paid any claims or been required to defend any action related to these indemnification obligations.We have agreed to indemnify our executive officers, directors and certain other employees for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we did not recognize any liabilities relating to these obligations as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023. No assurances can be given that the covering insurers will not attempt to dispute 19Table of Contentsthe validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.Legal Proceedings We are involved in legal proceedings, including the following matters:Xyrem Antitrust LitigationFrom JuneÂ 2020 to MayÂ 2022, a number of lawsuits were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the patent litigation settlement agreements we entered with generic drug manufacturers who had filed Abbreviated New Drug Applications, or ANDA, violate state and federal antitrust and consumer protection laws, as follows:On JuneÂ 17,Â 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by Blue Cross and Blue Shield Association, or BCBS, against Jazz Pharmaceuticals plc, Jazz Pharmaceuticals, Inc., and Jazz Pharmaceuticals Ireland Limited, or, collectively, the Company Defendants (hereinafter referred to as the BCBS Lawsuit). The BCBS Lawsuit also names Roxane Laboratories, Inc., Hikma Pharmaceuticals USA Inc., Eurohealth (USA), Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., and Lupin Inc., or, collectively, the BCBS Defendants.On JuneÂ 18 and JuneÂ 23,Â 2020, respectively, two additional class action lawsuits were filed against the Company Defendants and the BCBS Defendants: one by the New York State Teamsters Council Health and Hospital Fund in the United States District Court for the Northern District of California, and another by the Government Employees Health Association Inc. in the United States District Court for the Northern District of Illinois (hereinafter referred to as the GEHA Lawsuit).On JuneÂ 18,Â 2020, a class action lawsuit was filed in the United States District Court for the Northern District of California by the City of Providence, Rhode Island, on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc, and Roxane Laboratories, Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals USA Inc., and Hikma Pharmaceuticals plc, or, collectively, the City of Providence Defendants.On JuneÂ 30,Â 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by UFCW Local 1500 Welfare Fund on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals Ireland Ltd., Jazz Pharmaceuticals, Inc., Roxane Laboratories, Inc., Hikma Pharmaceuticals plc, Eurohealth (USA), Inc. and West-Ward Pharmaceuticals Corp., or collectively the UFCW Defendants (hereinafter referred to as the UFCW Lawsuit).On JulyÂ 13,Â 2020, the plaintiffs in the BCBS Lawsuit and the GEHA Lawsuit dismissed their complaints in the United States District Court for the Northern District of Illinois and refiled their respective lawsuits in the United States District Court for the Northern District of California. On JulyÂ 14,Â 2020, the plaintiffs in the UFCW Lawsuit dismissed their complaint in the United States District Court for the Northern District of Illinois and on JulyÂ 15,Â 2020, refiled their lawsuit in the United States District Court for the Northern District of California.On JulyÂ 31,Â 2020, a class action lawsuit was filed in the United States District Court for the Southern District of New York by the A.F. of L.-A.G.C. Building Trades Welfare Plan on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc (hereinafter referred to as the AFL Plan Lawsuit). The AFL Plan Lawsuit also names Roxane Laboratories Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc.On AugustÂ 14,Â 2020, an additional class action lawsuit was filed in the United States District Court for the Southern District of New York by the Self-Insured Schools of California on behalf of itself and all others similarly situated, against the Company Defendants, as well as Hikma Pharmaceuticals plc, Eurohealth (USA) Inc., Hikma Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Roxane Laboratories, Inc., Amneal Pharmaceuticals LLC, Endo International, plc, Endo Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., Lupin Inc., Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Holdings USA, Inc., Sun Pharmaceutical Industries, Inc., Ranbaxy Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Watson Laboratories, Inc., Wockhardt Ltd., Morton Grove Pharmaceuticals, Inc., Wockhardt USA LLC, Mallinckrodt plc, and Mallinckrodt LLC (hereinafter referred to as the Self-Insured Schools Lawsuit).On SeptemberÂ 16,Â 2020, an additional class action lawsuit was filed in the United States District Court for the Northern District of California, by Ruth Hollman on behalf of herself and all others similarly situated, against the same defendants named in the Self-Insured Schools Lawsuit.In DecemberÂ 2020, the above cases were centralized and transferred to the United States District Court for the Northern District of California, where the multidistrict litigation will proceed for the purpose of discovery and pre-trial proceedings. On MarchÂ 18,Â 2021, United Healthcare Services, Inc. filed a lawsuit in the United States District Court for the District of Minnesota against the Company Defendants, Hikma Pharmaceuticals plc, Roxane Laboratories, Inc., Hikma Pharmaceuticals 20Table of ContentsUSA Inc., Eurohealth (USA) Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., and Lupin Pharmaceuticals, Inc., raising similar allegations, or the UHS Lawsuit. On MarchÂ 24,Â 2021, the U.S. Judicial Panel on Multidistrict Litigation conditionally transferred the UHS Lawsuit to the United States District Court for the Northern District of California, where it was consolidated for discovery and pre-trial proceedings with the other cases.On AugustÂ 13,Â 2021, the United States District Court for the Northern District of California granted in part and denied in part the Company Defendants' motion to dismiss the complaints in the cases referenced above.On OctoberÂ 8,Â 2021, Humana Inc. filed a lawsuit in the United States District Court for the Northern District of California against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On OctoberÂ 8,Â 2021, Molina Healthcare Inc. filed a lawsuit in the United States District Court for the Northern District of California against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On FebruaryÂ 17,Â 2022, Health Care Service Corporation filed a lawsuit in the United States District Court for the Northern District of California against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations.On AprilÂ 19,Â 2023, the Court held a hearing on class certification in the consolidated multi-district litigation referenced above. On MayÂ 12,Â 2023, the Court granted the plaintiffsâ€™ motion and preliminarily certified classes of Xyrem purchasers seeking monetary and injunctive relief. The Court excluded Xywav purchasers from the classes. On AprilÂ 26,Â 2024, we, Hikma, and the plaintiffs filed motions for summary judgment. The Court held oral argument on these motions on JulyÂ 19,Â 2024. On August 26, 2024, the Court issued a decision granting in part and denying in part the partiesâ€™ motions for summary judgment. On JuneÂ 13,Â 2024, we filed a motion to decertify the class. On June 28,Â 2024, the plaintiffs filed a motion to amend the definition of the certified class. The Court held oral argument on these motions on AugustÂ 22,Â 2024. On October 18, 2024, the Court issued a decision denying our motion to decertify the class and

granting the plaintiffsâ€™ motion to amend the class definition. On November 1, 2024, we filed a petition with the United States Court of Appeals for the Ninth Circuit seeking leave to appeal the Courtâ€™s decision amending the class definition. The Ninth Circuit has not yet ruled on the petition. Trial in this matter has been rescheduled for May 19,Â 2025. On JanuaryÂ 13,Â 2023, Amneal Pharmaceuticals LLC, Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, notified the Court that they had reached a settlement-in-principle with the class action plaintiffs. On AprilÂ 19,Â 2023, the Court held a hearing on a motion for preliminary approval of this proposed settlement. On MayÂ 12,Â 2023, the Court granted the motion for preliminary approval of the proposed settlement. On JanuaryÂ 11,Â 2024, the Court held a hearing on the motion for final approval of the proposed settlement. The Court deferred ruling and scheduled a further hearing for final approval of the proposed settlement on AprilÂ 17,Â 2024. During February and MarchÂ 2024, the parties notified the Court of settlements between certain non-class action plaintiffs and each of Amneal and Lupin, and the Court dismissed those plaintiffsâ€™ claims against the applicable parties. On AprilÂ 17,Â 2024, the Court issued an order granting the motion for final approval of the settlement between the class action plaintiffs, Amneal, and Lupin. On DecemberÂ 11,Â 2023, Blue Cross and Blue Shield of Florida, Inc. and Health Options, Inc. filed a lawsuit in the United States District Court for the Middle District of Florida against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., and Eurohealth (USA), Inc., raising similar allegations. On JanuaryÂ 23,Â 2024, the Blue Cross Florida case was transferred to the United States District Court for the Northern District of California and consolidated with the above referenced multidistrict litigation for pretrial purposes.On MayÂ 9,Â 2022, Aetna Inc., or Aetna, filed a lawsuit in the Superior Court of California for the County of Alameda against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On DecemberÂ 27,Â 2022, the Court granted in part and denied in part our motion to dismiss Aetnaâ€™s complaint. As a result of that ruling, the generic defendants have been dismissed from the case, and certain of Aetnaâ€™s claims against Jazz have been dismissed. On JanuaryÂ 27,Â 2023, Aetna filed an amended complaint against Jazz. On MarchÂ 22,Â 2023, we filed motions to dismiss and to strike portions of the amended complaint. On JuneÂ 26,Â 2023, the Court granted our motions, and granted Aetna leave to further amend its complaint. On NovemberÂ 17,Â 2023, Aetna filed its second amended complaint. On FebruaryÂ 2,Â 2024, we filed our answer to the second amended complaint and Hikma filed a motion to quash service. The Court scheduled a hearing on Hikmaâ€™s motion for December 4, 2024. The Court has not set a further schedule in this case.21Table of ContentsThe plaintiffs in certain of these lawsuits are seeking to represent a class of direct purchasers of Xyrem, and the plaintiffs in the remaining lawsuits are seeking to represent a class of indirect purchasers of Xyrem. Each of the lawsuits generally alleges violations of U.S. federal and state antitrust, consumer protection, and unfair competition laws in connection with the Company Defendantsâ€™ conduct related to Xyrem, including actions leading up to, and entering into, patent litigation settlement agreements with each of the other named defendants. Each of the lawsuits seeks monetary damages, exemplary damages, equitable relief against the alleged unlawful conduct, including disgorgement of profits and restitution, and injunctive relief. It is possible that additional lawsuits will be filed against the Company Defendants making similar or related allegations. If the plaintiffs were to be successful in their claims, they may be entitled to injunctive relief or we may be required to pay significant monetary damages, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.Patent Infringement LitigationAvadel LitigationOn MayÂ 13,Â 2021, we filed a patent infringement suit against Avadel Pharmaceuticals plc, or Avadel, and several of its corporate affiliates in the United States District Court for the District of Delaware. The suit alleges that Avadelâ€™s Lumryz will infringe five of our patents related to controlled release formulations of oxybate and the safe and effective distribution of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe these patents, and an award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product will not infringe our patents. Avadel filed a motion for partial judgment on the pleadings on its counterclaim that one of our patents should be delisted from FDA's Orange Book, or the Orange Book. On NovemberÂ 18,Â 2022, the Court issued an order that we delist the patent from the Orange Book. On NovemberÂ 22,Â 2022, we filed a notice of appeal to the United States Court of Appeals for the Federal Circuit. The Federal Circuit temporarily stayed the District Courtâ€™s delisting order. On FebruaryÂ 24,Â 2023, the Federal Circuit affirmed the District Courtâ€™s delisting order, lifted the temporary stay, and gave Jazz 14 days to request that FDA delist the patent from the Orange Book. Jazz complied with the Federal Circuitâ€™s order and requested delisting on FebruaryÂ 28,Â 2023. On MarchÂ 3,Â 2023, we and Avadel stipulated to the dismissal without prejudice of the claims and counterclaims related to infringement and validity of the delisted patent in both this suit and a later-filed suit described below related to the same patent.On AugustÂ 4,Â 2021, we filed an additional patent infringement suit against Avadel in the United States District Court for the District of Delaware. The second suit alleges that Avadelâ€™s Lumryz will infringe a newly-issued patent related to sustained-release formulations of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe this patent, and an award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product will not infringe our patents. On NovemberÂ 10,Â 2021, we filed an additional patent infringement suit against Avadel in the United States District Court for the District of Delaware. The third suit alleges that Avadelâ€™s Lumryz will infringe a newly-issued patent related to sustained-release formulations of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe this patent, and an award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product will not infringe our patents.On AprilÂ 14,Â 2022, Avadel sued us in the United States District Court for the District of Delaware. Avadelâ€™s suit alleges that we misappropriated trade secrets related to Avadelâ€™s once-nightly sodium oxybate development program and breached certain contracts between the parties. Avadel seeks monetary damages, an injunction preventing us from using Avadelâ€™s confidential information, and an order directing the United States Patent and Trademark Office to modify the inventorship of one of our oxybate patents. On JulyÂ 8,Â 2022, we filed a motion for judgment on the pleadings, which the Court denied on JulyÂ 18,Â 2023. The denial is not a ruling that Jazz misappropriated Avadelâ€˜s trade secrets or breached any contract. The case will go forward in discovery and the Court instructed the parties to submit a proposed scheduling order.On JuneÂ 7,Â 2022, we received notice from Avadel that it had filed a "paragraph IV certification" regarding one patent listed in the Orange Book for Xyrem. A paragraph IV certification is a certification by a generic applicant that alleges that patents covering the branded product are invalid, unenforceable, and/or will not be infringed by the manufacture, use or sale of the generic product. On JulyÂ 15,Â 2022, we filed an additional lawsuit against Avadel asserting infringement of that patent. The suit alleges that the filing of Avadelâ€™s application for approval of FT218 is an act of infringement, and that Avadelâ€™s product would infringe the patent if launched. The suit seeks an injunction to prevent Avadel from launching a product that would infringe the patent, and an award of damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patent is invalid, that its product would not infringe, and that by listing the patent in the Orange Book, we engaged in unlawful monopolization in violation of the Sherman Act. On DecemberÂ 9,Â 2022, we filed a motion to dismiss Avadelâ€™s counterclaims. On JuneÂ 29,Â 2023, we filed a motion seeking leave to supplement our motion to 22Table of Contentsdismiss, as well as a motion to stay discovery pending resolution of the motion to dismiss. As noted above, on MarchÂ 3,Â 2023, we and Avadel stipulated to the dismissal without prejudice of the claims and counterclaims related to infringement and validity of the delisted patent.On NovemberÂ 1,Â 2023, the Court held a claim construction hearing relating to disputed terms in the asserted patents. On DecemberÂ 15,Â 2023, the Court issued a written opinion and order resolving the partiesâ€™ remaining claim construction disputes. On NovemberÂ 20,Â 2023, we and Avadel each filed motions for summary judgment. On FebruaryÂ 14,Â 2024, the Court issued a written opinion and order denying both partiesâ€™ motions for summary judgment.Trial regarding our patent infringement claims against Avadel began on FebruaryÂ 26,Â 2024, and concluded on MarchÂ 4,Â 2024, with the jury finding both of our asserted patents valid, and awarding us damages for infringement for Avadelâ€™s past sales of Lumryz. On AprilÂ 12,Â 2024, we filed a motion for a permanent injunction and ongoing royalties. On AugustÂ 27,Â 2024, the Court granted our motion for an injunction in part, and requested additional briefing about ongoing royalties. The issued injunction prevents Avadel from seeking FDA approval or marketing Lumryz for the treatment of idiopathic hypersomnia or other indications not already a part of Lumryzâ€™s product labeling as of March 4, 2024, and enjoins Avadel from infringing in any way Claim 24 of our â€™782 patent by making, using or selling Lumryz through and including the FebruaryÂ 2036 expiration date of the â€™782 patent, subject to certain exclusions including, among other things (i) for the treatment of narcolepsy, (ii) for the treatment of patients who have been prescribed Lumryz as of the effective date of the injunction conditioned on the payment of an amount to be determined and (iii) in clinical trials and studies ongoing as of the effective date of the injunction. The Court also granted our motion for an ongoing royalty for any future sale of Lumryz to patients with narcolepsy at a rate to be determined based upon further briefing by the parties on the appropriate ongoing rate above 3.5%. Avadel is appealing this injunction to the United States Court of Appeals for the Federal Circuit. The Federal Circuit has said the appeal will be placed on its February 2025 oral argument calendar. Avadel filed a motion with the district court for a stay of the injunction pending appeal, which the district court denied. Avadel also filed a motion to stay the injunction pending appeal with the Federal Circuit, which the Federal Circuit granted to the limited extent that the injunction enjoins initiating new clinical trials or studies and denied in all other respects. The Court scheduled a trial regarding Avadelâ€™s counterclaims for unlawful monopolization for NovemberÂ 3,Â 2025 and a trial regarding Avadelâ€™s trade secret misappropriation claims for DecemberÂ 15,Â 2025. On MarchÂ 13,Â 2024 and MarchÂ 19,Â 2024, we filed motions to stay Avadelâ€™s unlawful monopolization counterclaim and trade secret claims, respectively, pending resolution of post-trial motions and potential appeals in the patent infringement suit. On MayÂ 24,Â 2024, the Court denied the motion to stay the unlawful monopolization counterclaim and the previously-filed motion to dismiss the same. On JuneÂ 7,Â 2024, we filed a motion for reargument or, in the alternative, to certify the decision for interlocutory appeal. That motion remains pending and no hearing date has been set. The Court stayed Avadelâ€™s trade secret misappropriation claims pending appeal of the injunction in the related patent matter. We filed a further motion to stay the unlawful monopolization counterclaims, which remains pending.On JulyÂ 21,Â 2022, Avadel filed a lawsuit against FDA in the United States District Court for the District of Columbia, challenging FDAâ€™s determination that Avadel was required to file a paragraph IV certification regarding one of our Orange Book listed patents. Avadel filed a motion for preliminary injunction or, in the alternative, summary judgment, seeking relief including a declaration that FDAâ€™s decision requiring patent certification was unlawful, an order setting aside that decision, an injunction prohibiting FDA from requiring such certification as a precondition to approval of its application for FT218, and an order requiring FDA to take final action on Avadelâ€™s application for approval of FT218 within 14 days of the Courtâ€™s ruling. On JulyÂ 27,Â 2022, we filed a motion to intervene in that case, which the Court granted. The Court held a hearing on the partiesâ€™ respective motions for summary judgment on OctoberÂ 7,Â 2022. On NovemberÂ 3,Â 2022, the Court granted our and FDAâ€™s motions for summary judgment and denied Avadelâ€™s motion.Xywav Patent LitigationIn JuneÂ 2021, we received notice from Lupin Inc., or Lupin, that it has filed with FDA an ANDA, for a generic version of Xywav. The notice from Lupin included a paragraph IV certification with respect to ten of our patents listed in FDAâ€™s Orange Book for Xywav on the date of our receipt of the notice. The asserted patents relate generally to the composition and method of use of Xywav, and methods of treatment when Xywav is administered concomitantly with certain other medications.In JulyÂ 2021, we filed a patent infringement suit against Lupin in the United States District Court for the District of New Jersey. The complaint alleges that by filing its ANDA, Lupin has infringed ten of our Orange Book listed patents. We are seeking a permanent injunction to prevent Lupin from introducing a generic version of Xywav that would infringe our patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on Lupin's ANDA. In JuneÂ 2021, FDA recognized seven years of Orphan Drug Exclusivity for Xywav through JulyÂ 21,Â 2027. On OctoberÂ 4,Â 2021, Lupin filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product, if approved, will not infringe our patents.23Table of ContentsIn AprilÂ 2022, we received notice from Lupin that it had filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Xywav. On MayÂ 11,Â 2022, we filed an additional lawsuit against Lupin in the United States District Court for the District of New Jersey alleging that by filing its ANDA, Lupin infringed the newly-issued patent related to a method of treatment when Xywav is administered concomitantly with certain other medications. The suit seeks a permanent injunction to prevent Lupin from introducing a generic version of Xywav that would infringe our patent. On JuneÂ 22,Â 2022, the Court consolidated the two lawsuits we filed against Lupin. In NovemberÂ 2022, we received notice from Lupin that it had filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Xywav. On JanuaryÂ 19,Â 2023, we filed an additional lawsuit against Lupin in the United States District Court for the District of New Jersey alleging that by filing its ANDA, Lupin infringed the newly-issued patent referenced in its NovemberÂ 2022 paragraph IV certification, as well as another patent that issued in JanuaryÂ 2023. The suit seeks a permanent injunction to prevent Lupin from introducing a generic version of Xywav that would infringe the two patents in suit. On FebruaryÂ 15,Â 2023, the Court consolidated the new lawsuit with the two suits we previously filed against Lupin. No trial date has been set in the consolidated case against Lupin.In FebruaryÂ 2023, we received notice from Teva Pharmaceuticals, Inc., or Teva, that it had filed with FDA an ANDA for a generic version of Xywav. The notice from Teva included a paragraph IV certification with respect to thirteen of our patents listed in FDAâ€™s Orange Book for Xywav on the date of the receipt of the notice. The asserted patents relate generally to the composition and method of use of Xywav, and methods of treatment when Xywav is administered concomitantly with certain other medications. In MarchÂ 2023, we filed a patent infringement suit against Teva in the United States District Court for the District of New Jersey. The complaint alleges that by filing its ANDA, Teva has infringed thirteen of our Orange Book listed patents. We are seeking a permanent injunction to prevent Teva from introducing a generic version of Xywav that would infringe our patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on Tevaâ€™s ANDA. On MayÂ 23,Â 2023, Teva filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product, if approved, will not infringe our patents.On DecemberÂ 15,Â 2023, based on a stipulation between all parties, the Court consolidated the Lupin lawsuits and the Teva lawsuit for all purposes. No trial date has been set in the consolidated case.In July 2024, we received notices from Lupin and Teva that they had each filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Xywav. On August 27, 2024, we filed an additional lawsuit in the United States District Court for the District of New Jersey against each of Lupin and Teva, alleging that, by filing its ANDA, each party infringed the newly-issued patent related to a method of treatment using Xywav. The suits seek orders that the effective date of FDA approval of each defendantâ€™s application shall be a date no earlier than the expiration of the newly-issued patent.Epidiolex Patent LitigationIn November and DecemberÂ 2022, we received notices from: Teva Pharmaceuticals, Inc.; Padagis US LLC; Apotex Inc.; API Pharma Tech LLC and InvaGen Pharmaceuticals, Inc.; Lupin Limited; Taro Pharmaceutical Industries Ltd.; Zenara Pharma Private Limited and Biophore Pharma, Inc.; MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc.; Alkem Laboratories Ltd.; and Ascent Pharmaceuticals, Inc. (hereinafter referred to as the â€œEpidiolex ANDA Filersâ€), that they have each filed with FDA an ANDA for a generic version of Epidiolex (cannabidiol) oral solution. As of the date of this filing, we are not aware of other ANDA filers. The notices from the Epidiolex ANDA Filers each included a â€œparagraph IV certificationâ€ with respect to certain of our patents listed in FDAâ€™s Orange Book for Epidiolex on the date of the receipt of the notice. The listed patents relate generally to the composition and method of use of Epidiolex, and methods of treatment using Epidiolex. A paragraph IV certification is a certification by a generic applicant that alleges that patents covering the branded product are invalid, unenforceable, and/or will not be infringed by the manufacture, use or sale of the generic product.On JanuaryÂ 3,Â 2023, we filed a patent infringement suit against the Epidiolex ANDA Filers in the United States District Court for the District of New Jersey. The complaint alleges that by filing their ANDAs, the Epidiolex ANDA Filers have infringed certain of our Orange Book listed patents, and seeks an order that the effective date of FDA approval of the ANDAs shall be a date no earlier than the expiration of the last to expire of the asserted patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on the Epidiolex ANDA Filersâ€™ ANDAs.From MarchÂ 2023 through MayÂ 2023, we received the Epidiolex ANDA Filersâ€™ answers to the complaint. The answers include defenses and counterclaims asserting that the Epidiolex ANDA Filersâ€™ products, if launched, would not infringe our patents, that our patents are invalid and, in one instance, counterclaims related to allegations of inequitable conduct and improper listing of patents in the Orange Book. On MayÂ 25,Â 2023, we filed a motion to dismiss certain of the counterclaims. On JanuaryÂ 11,Â 2024, the Court issued an order granting in part and denying in part our motion to dismiss. On SeptemberÂ 20,Â 2024, the Court held a claim construction hearing relating to disputed terms in the asserted patents. The Court has not yet issued a decision on the claim construction disputes. 24Table of ContentsThe Court in the Epidiolex Patent Litigation scheduled trial for SeptemberÂ 2025.In June and JulyÂ 2023, we received notice from certain of the Epidiolex ANDA Filers that they had each filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Epidiolex. On JulyÂ 21,Â 2023, we filed an additional lawsuit against all of the Epidiolex ANDA Filers in the United States District Court for the District of New Jersey alleging that, by filing its ANDA, each Epidiolex ANDA Filer infringed the newly-issued patent related to a method of treatment using Epidiolex. The suit seeks an order that the

effective date of FDA approval of each Epidiolex ANDA Filerâ€™s application shall be a date no earlier than the expiration of the newly-issued patent.On OctoberÂ 24,Â 2023, we entered into a settlement agreement with Padagis US LLC, or Padagis, that resolved our patent litigation with Padagis related to Epidiolex. Under the settlement agreement, we granted Padagis a license to manufacture, market, and sell its generic version of Epidiolex on a date that depends on the occurrence of certain other events. The specific terms of the Padagis settlement agreement are confidential.On NovemberÂ 20,Â 2023, we entered into a settlement agreement with Teva Pharmaceuticals, Inc., or Teva, that resolved our patent litigation with Teva related to Epidiolex. Under the settlement agreement, we granted Teva a license to manufacture, market and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the Teva settlement agreement are confidential.On DecemberÂ 4,Â 2023, we entered into a settlement agreement with Alkem Laboratories Ltd., or Alkem, that resolved our patent litigation with Alkem related to Epidiolex. Under the settlement agreement, we granted Alkem a license to manufacture, market, and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the Alkem settlement are confidential.On JuneÂ 7,Â 2024, we entered into a settlement agreement with MSN Laboratories Private, Ltd. and MSN Pharmaceuticals, Inc., or together MSN, that resolved our patent litigation with MSN related to Epidiolex. Under the settlement agreement, we granted MSN a license to manufacture, market, and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the MSN settlement are confidential.On September 4, 2024, we entered into a settlement agreement with Lupin, Ltd., that resolved our patent litigation with Lupin related to Epidiolex. Under the settlement agreement, we granted Lupin a license to manufacture, market, and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the Lupin settlement are confidential.On November 1, 2024, we entered into a settlement agreement with InvaGen Pharmaceuticals, Inc., Cipla Ltd., Cipla USA, Inc., and API Pharma Tech LLC (collectively â€œInvaGenâ€) that resolved our patent litigation with InvaGen related to Epidiolex. Under the settlement agreement, we granted InvaGen a license to manufacture, market, and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the InvaGen settlement are confidential.The settlements with Padagis, Teva, Alkem, MSN, Lupin and InvaGen do not resolve the litigation against the other four Epidiolex ANDA Filers, which is ongoing. We cannot predict the specific timing or outcome of events in these matters with respect to the remaining defendants or the impact of developments involving any specific parties or patents on other ongoing proceedings with any specific Epidiolex ANDA Filer.In September and OctoberÂ 2023, we received notice from certain of the Epidiolex ANDA Filers that they had each filed a paragraph IV certification regarding one or more newly-issued patents listed in the Orange Book for Epidiolex. On DecemberÂ 15,Â 2023, we filed an additional lawsuit against seven of the original Epidiolex ANDA Filers with whom we have not previously settled. We filed this lawsuit in the United States District Court for the District of New Jersey alleging that, by filing its ANDA, each Epidiolex ANDA Filer infringed the newly-issued patents related to methods of treatment using Epidiolex. The suit seeks an order that the effective date of FDA approval of each Epidiolex ANDA Filerâ€™s application shall be a date no earlier than the expiration of the newly-issued patents.In March and AprilÂ 2024, we received notice from certain of the Epidiolex ANDA Filers that they had each filed a paragraph IV certification regarding one or more newly-issued patents listed in the Orange Book for Epidiolex. On JulyÂ 3,Â 2024, we filed an additional lawsuit against six of the original Epidiolex ANDA Filers with whom we had not previously settled. We filed this lawsuit in the United States District Court for the District of New Jersey alleging that, by filing its ANDA, each Epidiolex ANDA Filer infringed the newly-issued patents related to methods of treatment using Epidiolex. The suit seeks an order that the effective date of FDA approval of each Epidiolex ANDA Filerâ€™s application shall be a date no earlier than the expiration of the newly-issued patents.Epidiolex also has orphan drug exclusivity, or ODE, for the treatment of seizures associated with LGS or DS in patients 2 years of age and older through SeptemberÂ 28,Â 2025, and for the treatment of seizures associated with LGS or DS in patients between 1 and 2 years of age and for the treatment of seizures associated with TSC through JulyÂ 31,Â 2027.25Table of ContentsThe Company vigorously enforces its intellectual property rights but cannot predict the outcome of these matters.Zepzelca Patent LitigationIn July and August 2024, we received notices from Sandoz Inc., InvaGen Pharmaceuticals, Inc., CIPLA USA, Inc. CIPLA (EU) Limited, CIPLA Limited, Zydus Lifesciences Global FZE, Zydus Pharmaceuticals (USA) Inc., Zydus Lifesciences Limited, RK Pharma, Inc., Apicore US LLC, Archis Pharma LLC, Vgyaan Pharmaceuticals LLC, MSN Pharmaceuticals Inc., and MSN Laboratories PVT. LTD. (hereinafter referred to as the â€œZepzelca ANDA Filersâ€), that they have each filed with FDA an ANDA for a generic version of Zepzelca (lurbinectedin). As of the date of this filing, we are not aware of other ANDA filers. The notices from the Zepzelca ANDA Filers each included a paragraph IV certification with respect to a patent listed in the Orange Book for Zepzelca on the date of the receipt of the notice. The listed patent relates to the drug substance, drug product and approved use of Zepzelca. Jazz is the exclusive licensee to this Zepzelca patent pursuant to an agreement with Pharma Mar, S.A, or PharmaMar. A paragraph IV certification is a certification by a generic applicant that alleges that the patent covering the branded product is invalid, unenforceable, and/or will not be infringed by the manufacture, use or sale of the generic product.On September 11, 2024, we and PharmaMar filed a patent infringement suit against the Zepzelca ANDA Filers in the United States District Court for the District of New Jersey. The complaint alleges that by filing their ANDAs, the Zepzelca ANDA Filers have infringed the Orange Book listed patent for Zepzelca, and seeks an order that the effective date of FDA approval of the ANDAs shall be a date no earlier than the expiration of the asserted patent. On September 12, 2024, we and PharmaMar filed a patent infringement suit against RK Pharma, Inc., Apicore US LLC, Archis Pharma LLC, Vgyaan Pharmaceuticals LLC (collectively â€œRK Pharmaâ€), in the United States District Court for the District of Delaware. The complaint alleges that by filing its ANDA, RK Pharma has infringed the Orange Book listed patent for Zepzelca, and seeks an order that the effective date of FDA approval of RK Pharmaâ€™s ANDA shall be no earlier than the expiration of the asserted patent. MSP LitigationOn AprilÂ 3,Â 2023, MSP Recovery Claims, Series LLC, or MSP, filed a class action lawsuit on behalf itself and others similarly situated against Jazz Pharmaceuticals plc, Jazz Pharmaceuticals, Inc., and Jazz Pharmaceuticals Ireland Limited, (collectively, the Company Defendants), Express Scripts, Inc., Express Scripts Holding Company, Express Scripts Specialty Distribution Services, Inc., Curascript, Inc. d/b/a Curascript, S.D., Priority Healthcare Distribution, Inc. d/b/a Curascript SD and Curascript Specialty Distribution SD, Caring Voice Coalition, and Adira Foundation (collectively with the Company Defendants, referred to as the Defendants) in the United States District Court for the Northern District of California. The MSP complaint alleges that the Defendants conspired to increase the price and quantity dispensed of Xyrem and Prialt, in violation of the Racketeer Influenced and Corrupt Organizations Act and several state laws. The allegations relate generally to the conduct at issue in the investigation conducted by the United States Department of Justice from 2016-2019, involving the Companyâ€™s contributions to certain charitable foundations. MSP seeks monetary damages, restitution, disgorgement, and a declaration that the conduct alleged is unlawful. On JulyÂ 25,Â 2023, we and certain other defendants filed motions to dismiss MSP's complaint, which the Court granted on DecemberÂ 12,Â 2023. On JanuaryÂ 5,Â 2024, the MSP filed an amended complaint. On FebruaryÂ 20,Â 2024, we filed a motion to dismiss MSPâ€™s amended complaint. The Court scheduled a hearing on the motion for JuneÂ 13,Â 2024. On JuneÂ 21,Â 2024, the Court cancelled the hearing. On July 22, 2024, the Court granted the motion. The Court set a deadline of August 12, 2024, to file a second amended complaint. On August 12, 2024, MSP voluntarily dismissed its complaint.FDA LitigationOn JuneÂ 22,Â 2023, we filed a complaint in the United States District Court for the District of Columbia seeking a declaration that FDAâ€™s approval on MayÂ 1,Â 2023, of the New Drug Application, or NDA, for Avadel's Lumryz was unlawful. In the complaint, we alleged that FDA acted outside its authority under the Orphan Drug Act, when, despite ODE protecting Jazzâ€™s low-sodium oxybate product Xywav, FDA approved the Lumryz NDA and granted Lumryz ODE based on FDAâ€™s finding that Lumryz makes a major contribution to patient care and is therefore clinically superior to Xywav and Xyrem. Jazz further alleged that, in doing so, FDA failed to follow its own regulations, failed to follow established agency policy without providing a reasoned explanation for the departure, reversed prior decisions by its own staff and experts without a reasoned explanation, and disregarded the relevant scientific literature and data. The complaint, filed pursuant to the Administrative Procedure Act, asked the Court to vacate and set aside FDAâ€™s approval of the Lumryz NDA and sought a declaration that FDAâ€™s approval of the Lumryz NDA was arbitrary, capricious, an abuse of discretion and otherwise not in accordance with law and that approval of the Lumryz NDA was in excess of FDAâ€™s statutory authority and was made without observance of procedure required by law.On SeptemberÂ 15,Â 2023, we filed a motion for summary judgment. On OctoberÂ 20,Â 2023, Avadel and FDA filed cross motions for summary judgment. Oral argument on these motions was held on MayÂ 10,Â 2024 and on October 30, 2024, the 26Table of ContentsDistrict Court issued an order denying Jazzâ€™s motion for summary judgment and granting Avadelâ€™s and the FDAâ€™s cross-motions for summary judgment. Jazz respectfully disagrees with the Courtâ€™s decision and is evaluating potential options for appeal.Qui tam matterIn July 2022, we received a subpoena from the U.S. Attorneyâ€™s Office, or USAO, for the District of Massachusetts requesting documents related to Xyrem and U.S. Patent No. 8,772,306 (â€œMethod of Administration of Gamma Hydroxybutyrate with Monocarboxylate Transportersâ€), product labeling changes for Xyrem, communications with FDA and the USPTO, pricing of Xyrem, and other related documents. On July 18, 2024, the United States District Court for the District of Massachusetts unsealed a qui tam whistleblower lawsuit underlying the USAOâ€™s subpoena, captioned 1:21-cv-10891-PBS and originally filed under seal on May 27, 2021. The public docket in this matter indicates that on MayÂ 24 and JuneÂ 7,Â 2024, respectively, the United States and a number of states named in the whistleblower complaint declined to intervene in this matter. As such, private whistleblower litigation will proceed in the United States District Court for the District of Massachusetts. The Court set a deadline of September 1, 2024, for the plaintiff to file an amended complaint, and DecemberÂ 1,Â 2024, for Jazz to file a motion to dismiss the amended complaint. The plaintiff filed the amended complaint on SeptemberÂ 1,Â 2024. From time to time, we are involved in legal proceedings arising in the ordinary course of business. We believe there is no other litigation pending that could have, individually or in the aggregate, a material adverse effect on our results of operations or financial condition.10. Shareholdersâ€™ EquityShare Repurchase ProgramIn July 2024, our board of directors authorized a share repurchase program to repurchase ordinary shares having an aggregate purchase price of $500.0Â million, exclusive of any brokerage commissions, or the New Repurchase Program. Under the New Repurchase Program, which has no expiration date, we may repurchase ordinary shares from time to time by any methods and/or structures permitted by applicable law. The timing and amount of repurchases will depend on a variety of factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under the Amended Credit Agreement and the indenture for our Secured Notes, corporate and regulatory requirements and market conditions. The New Repurchase Program may be modified, suspended or discontinued at any time without our prior notice. The New Repurchase Program replaces and supersedes the share repurchase program authorized by our board of directors in November 2016, which, as of the date of it being superseded by the New Repurchase Program, had authorized the repurchase of ordinary shares having an aggregate purchase price of up to $1.5Â billion, exclusive of any brokerage commissions, or the Old Repurchase Program, and, together with the New Repurchase Program, the â€œrepurchase programsâ€. During the three months ended September 30, 2024, we spent a total of $150.0Â million to repurchase 1.4Â million of our ordinary shares, all under the New Repurchase Program, at a purchase price, including commissions, of $109.32 per share. The repurchases during the three months ended September 30, 2024, were effected in privately negotiated transactions with or through one of the initial purchasers of the 2030 Notes concurrently with the pricing of the offering of the 2030 Notes. During the nine months ended September 30, 2024, we spent a total of $311.4Â million to purchase 2.8Â million of our ordinary shares under the repurchase programs at an average total purchase price, including commissions, of $110.06 per share. During the nine months ended September 30, 2023, we spent a total of $170.0Â million to purchase 1.3Â million of our ordinary shares under the Old Repurchase Program at an average total purchase price, including commissions, of $128.89 per share. All ordinary shares repurchased were cancelled. As of September 30, 2024, the remaining amount authorized for repurchases under the New Repurchase Program was $350.0Â million, exclusive of any brokerage commissions.27Table of ContentsAccumulated Other Comprehensive LossThe components of accumulated other comprehensive loss as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023 were as follows (in thousands):Â Net UnrealizedGain From Hedging ActivitiesForeignCurrencyTranslationAdjustmentsTotalAccumulatedOtherComprehensiveLossBalance at December 31, 2023$235Â $(842,382)$(842,147)Other comprehensive income before reclassifications1,572Â 241,218Â 242,790Â Amounts reclassified from accumulated other comprehensive loss(4,040)â€”Â (4,040)Other comprehensive income (loss), net(2,468)241,218Â 238,750Â Balance at September 30, 2024$(2,233)$(601,164)$(603,397)During the nine months ended SeptemberÂ 30,Â 2024, other comprehensive income (loss) primarily reflects foreign currency translation adjustments, primarily due to the strengthening of the sterling against the U.S. dollar.11. Net Income per Ordinary ShareBasic net income per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net income per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding.Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023Numerator:Net income$215,055Â $146,820Â $369,005Â $320,678Â Effect of interest on assumed conversions of Exchangeable Senior Notes, net of tax1,028Â 5,912Â 10,761Â 19,951Â Net income for dilutive net income per ordinary share$216,083Â $152,732Â $379,766Â $340,629Â Denominator:Weighted-average ordinary shares used in per share calculations - basic61,414Â 63,114Â 62,275Â 63,532Â Dilutive effect of Exchangeable Senior Notes1,325Â 7,560Â 4,721Â 8,549Â Dilutive effect of employee equity incentive and purchase plans435Â 619Â 515Â 785Â Weighted-average ordinary shares used in per share calculations - diluted63,174Â 71,293Â 67,511Â 72,866Â Net income per ordinary share:Basic$3.50Â $2.33Â $5.93Â $5.05Â Diluted$3.42Â $2.14Â $5.63Â $4.67Â Potentially dilutive ordinary shares from our employee equity incentive and purchase plans are determined by applying the treasury stock method to the assumed vesting of outstanding restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs, the assumed exercise of share options and the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP. Potentially dilutive ordinary shares from the Exchangeable Senior Notes are determined by applying the if-converted method to the assumed issuance of ordinary shares upon exchange of the Exchangeable Senior Notes. In AugustÂ 2023, we made an irrevocable election to fix the settlement method for exchanges of the 2024 Notes to a combination of cash and ordinary shares of the Company with a specified cash amount per $1,000 principal amount of the 2024 Notes of $1,000. As a result, the assumed issuance of ordinary shares upon exchange of the 2024 Notes has only been included in the calculation of diluted net income per ordinary share in the three and nine months ended SeptemberÂ 30,Â 2023 up to the date the irrevocable election was made.28Table of ContentsIn JulyÂ 2024, we made an irrevocable election to fix the settlement method for exchanges of the 2026 Notes to a combination of cash and ordinary shares of the Company with a specified cash amount per $1,000 principal amount of the 2026 Notes of $1,000. As a result, the assumed issuance of ordinary shares upon exchange of the 2026 Notes has only been included in the calculation of diluted net income per ordinary share in the three and nine months ended SeptemberÂ 30,Â 2024, up to the date the irrevocable election was made.For the 2030 Notes, we are required to settle the principal amount in cash and have the option to settle the conversion feature for the amount above the conversion price, or the conversion spread, in cash, ordinary shares or a combination of cash and ordinary shares. The conversion spread will have a dilutive impact on diluted net income per ordinary share when the average market price of our ordinary shares for a given period exceeds the conversion price of the 2030 Notes. For the three and nine months ended SeptemberÂ 30,Â 2024, the 2030 Notes have been excluded from the computation of diluted net income per ordinary share, as the effect would be anti-dilutive since the conversion price of the 2030 Notes exceeded the average market price of our ordinary shares for the three and nine months ended SeptemberÂ 30,Â 2024. The following table represents the weighted-average ordinary shares that were excluded from the calculation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Â 2024202320242023Employee equity incentive and purchase plans4,465Â 2,501Â 4,701Â 3,091Â  12. Revenues The following table presents a summary of total revenues (in thousands):Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023Xywav$388,466Â $331,633Â $1,072,238Â $935,958Â Xyrem58,114Â 125,110Â 184,526Â 463,009Â Epidiolex/Epidyolex251,558Â 213,711Â 697,376Â 604,846Â Sativex4,58 Neuroscience702,724Â 675,081Â 1,967,844Â 2,018,344Â Rylaze/Enrylaze98,780Â 104,859Â 309,359Â 292,479Â Zepzelca85,843Â 77,994Â 241,990Â 215,523Â Defitelio/defibrotide 65,818Â 47,730Â 158,915Â 132,917Â Vyxeos34,313Â 29,827Â 109,348Â 100,583Â Total Oncology284,754Â 260,410Â 819,612Â 741,502Â Other2,229Â 2,907Â 8,497Â 9,758Â Product sales, net989,707Â 938,398Â 2,795,953Â 2,769,604Â High-sodium oxybate AG royalty revenue58,157Â 28,921Â 162,268Â 36,531Â Other royalty and contract revenues7,105Â 4,821Â 22,556Â 16,134Â Total revenues$1,054,969Â $972,140Â $2,980,777Â $2,822,269Â The following table presents a summary of total revenues attributed to geographic sources (in thousands):Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023United States$953,669Â $884,579Â $2,686,486Â $2,579,401Â Europe77,318Â 68,971Â 230,821Â 194,198Â All other23,982Â 18,590Â 63,470Â 48,670Â Total revenues$1,054,969Â $972,140Â $2,980,777Â $2,822,269Â 29Table of ContentsThe following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023ESSDS42Â %47Â %42Â %49Â %McKesson13Â %12Â %12Â %11Â %ASD10Â %9Â %9Â %7Â %Financing and paymentOur payment terms vary by the type and location of

our customer but payment is generally required in a term ranging from 30 to 65 days.13. Share-Based Compensation Share-based compensation expense related to RSUs, PRSUs, grants under our ESPP and share options was as follows (in thousands):Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023Selling, general and administrative$37,101Â $35,268Â $112,451Â $113,155Â Research and development18,927Â 16,635Â 55,030Â 49,346Â Cost of product sales3,732Â 4,212Â 10,374Â 11,399Â Total share-based compensation expense, pre-tax59,760Â 56,115Â 177,855Â 173,900Â Income tax benefit from share-based compensation expense(12,190)(9,792)(25,218)(29,533)Total share-based compensation expense, net of tax$47,570Â $46,323Â $152,637Â $144,367Â Restricted Stock UnitsThe table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023RSUs granted (in thousands)102Â 91Â 2,112Â 1,728Â Grant date fair value$110.55Â $134.33Â $118.31Â $145.05Â The fair value of RSUs is determined on the date of grant based on the market price of our ordinary shares on that date. The fair value of RSUs is expensed ratably over the vesting period, generally over four years.Performance-Based Restricted Stock UnitsThe Compensation & Management Development Committee of our board of directors and, in the case of our Chief Executive Officer, the independent members of our board of directors, approved awards of PRSUs to certain employees of the Company, subject to vesting on the achievement of certain commercial and pipeline performance criteria to be assessed over a performance period from the date of the grant to DecemberÂ 31,Â 2024, DecemberÂ 31,Â 2025 and DecemberÂ 31,Â 2026, respectively. The number of shares that will be awarded is determined based on the Companyâ€™s achievement with respect to the performance criteria. For PRSUs granted prior to 2024, the amount of shares awarded will be subject to adjustment based on the application of a relative total shareholder return, or TSR, modifier. For PRSUs granted in 2024, the relative TSR represents one of the performance metrics. In both cases, the number of shares that may be earned ranges between 0% and 200% of the target number of PRSUs granted.30Table of ContentsThe table below shows the number of PRSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of PRSUs granted:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023PRSUs granted (in thousands)58Â 13Â 371Â 270Â Grant date fair value$107.07Â $142.65Â $130.58Â $157.01Â For the PRSUs granted that are subject to a market condition, the grant date fair value for such PRSUs was based on a Monte Carlo simulation model. For PRSUs granted without a market condition, the fair value is determined based on the market price of our ordinary shares on the date of grant. The Company evaluated the performance targets in the context of its current long-range financial plan and its product candidate development pipeline and recognized expense based on the probable number of awards that will ultimately vest.As of SeptemberÂ 30,Â 2024, compensation cost not yet recognized related to unvested RSUs, PRSUs, ESPP and share options was $347.2Â million, $37.3Â million, $9.2Â million and $0.1Â million, respectively, which is expected to be recognized over a weighted-average period of 2.6 years, 1.4 years, 1.1 years and 0.3 years, respectively.14. Income Taxes Our income tax benefit was $14.5Â million and $33.5Â million for the three and nine months ended SeptemberÂ 30,Â 2024, respectively, compared to $47.2Â million and $86.8Â million for the same periods in 2023, relating to tax arising on income or losses in Ireland, the U.K., the U.S. and certain other foreign jurisdictions and tax deficiencies from share based compensation, offset by deductions on subsidiary equity, foreign derived intangible income benefits and tax credits. The decrease in the income tax benefit for the three and nine months ended September 30, 2024 compared to the same periods in 2023 resulted primarily from changes in the mix of pre-tax income and losses across tax jurisdictions.Our net deferred tax liability is primarily related to acquired intangible assets, and is net of deferred tax assets related to U.S. federal and state tax credits, U.S. federal and state and foreign net operating loss carryforwards and other temporary differences. We maintain a valuation allowance against certain deferred tax assets. Each reporting period, we evaluate the need for a valuation allowance on our deferred tax assets by jurisdiction and adjust our estimates as more information becomes available.We are required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. As a result, we have recorded an unrecognized tax benefit for certain tax benefits which we judge may not be sustained upon examination. We file income tax returns in multiple tax jurisdictions, the most significant of which are Ireland, the U.K. and the U.S. (both at the federal level and in various state jurisdictions). For Ireland, we are no longer subject to income tax examinations by taxing authorities for the years prior to 2019. For the U.K., we are no longer subject to income tax examinations by taxing authorities for the years prior to 2016. The U.S. jurisdictions generally have statute of limitations three to four years from the later of the return due date or the date when the return was filed. However, in the U.S. (at the federal level and in most states), carryforwards that were generated in 2019 and earlier may still be adjusted upon examination by the taxing authorities. One of our subsidiaries is currently under examination by the Luxembourg taxing authorities for the years ended DecemberÂ 31,Â 2017, 2018 and 2019. In OctoberÂ 2022 and in JanuaryÂ 2023, we received tax assessment notices from the Luxembourg taxing authorities for all years under examination relating to certain transfer pricing and other adjustments. The notices propose additional Luxembourg income tax of approximately $25.0Â million, translated at the foreign exchange rate as SeptemberÂ 30, 2024. We disagree with the proposed assessments and are contesting them vigorously. The Government of Ireland, the jurisdiction in which Jazz Pharmaceuticals Plc is incorporated, transposed the Global Minimum Tax Pillar Two rules into domestic legislation as part of the Finance (No. 2) Act 2023 (the "Finance Act"). The Finance Act closely follows the EU Minimum Tax Directive and certain OECD Guidance released to date. The Company is within the scope of these rules, which took effect from January 1, 2024. Under the new legislation, we are liable to pay a top-up tax for the difference between the Pillar Two effective tax rate per jurisdiction and the 15% minimum rate. The rules on how to calculate the 15% effective tax rate are detailed and highly complex and specific adjustments envisaged in the Pillar Two legislation can give rise to different effective tax rates compared to those calculated for accounting purposes. We will account for it as a current tax when it is incurred. We expect to be subject to the top-up tax in relation to our operations in Ireland, where the trading statutory tax rate is 12.5%, though the impact in 2024 is not significant. The proportion of our profit before tax which is subject to the top-up tax and our exposure to Pillar Two income taxes in future years will depend on factors such as future revenues, costs and foreign currency exchange rates. We will continue to monitor changes in law and guidance in relation to Pillar Two.31Table of ContentsItem 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsThe following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and the notes to condensed consolidated financial statements included elsewhere in this Quarterly Report on FormÂ 10â€‘Q. This discussion contains forward-looking statements that involve risks and uncertainties. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that could impact our business. In particular, we encourage you to review the risks and uncertainties described in â€œRisk Factorsâ€ in Part I, Item 1A of our Annual Report on FormÂ 10-K for the year ended DecemberÂ 31,Â 2023, as supplemented by the risks and uncertainties described in "Risk Factors" Item 1A. Risk Factors in Part II of this Quarterly Report on FormÂ 10-Q. These risks and uncertainties could cause actual results to differ materially from those projected in forward-looking statements contained in this report or implied by past results and trends. Forward-looking statements are statements that attempt to forecast or anticipate future developments in our business, financial condition or results of operations. See the â€œCautionary Note Regarding Forward-Looking Statementsâ€ that appears at the end of this discussion. These statements, like all statements in this report, speak only as of the date of this Quarterly Report on FormÂ 10â€‘Q (unless another date is indicated), and we undertake no obligation to update or revise these statements in light of future developments.OverviewJazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases - often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Our strategy for growth is rooted in executing commercial launches and ongoing commercialization initiatives, advancing robust research and development, or R&D, programs and delivering impactful clinical results, effectively deploying capital to strengthen the prospects of achieving our short- and long-term goals through strategic corporate development, and delivering strong financial performance. We focus on patient populations with high unmet needs. We identify and develop differentiated therapies for these patients that we expect will be long-lived assets and that we can support with an efficient commercialization model. In addition, we leverage our efficient, scalable operating model and integrated capabilities across our global infrastructure to effectively reach patients around the world. Our strategy to deliver sustainable growth and enhanced value continues to be focused on:â€¢Strong commercial execution to drive diversified revenue growth and address unmet medical needs of our patients across our product portfolio, which focuses on neuroscience and oncology medicines;â€¢Expanding and advancing our pipeline to achieve a valuable portfolio of durable, highly differentiated products; â€¢Continuing to build a flexible, efficient and productive development engine for targeted therapeutic areas to identify and progress early-, mid- and late-stage assets; â€¢Identifying and acquiring novel product candidates and approved therapies to complement our existing pipeline and commercial portfolio;â€¢Investing in an efficient, scalable operating model and differentiated capabilities to enable growth; and â€¢Unlocking further value through indication expansion and entry into global markets.32Table of ContentsIn 2024, consistent with our strategy, we are continuing to focus on research and development activities within our neuroscience and oncology therapeutic areas. Our lead marketed products, listed below, are approved in countries around the world to improve patient care.ProductIndicationsInitial Approval DateMarketsNEUROSCIENCEXywavÂ® (calcium, magnesium, potassium, and sodium oxybates)Treatment of cataplexy or excessive daytime sleepiness, or EDS, in patients seven years of age and older with narcolepsy.July 2020U.S.Treatment of idiopathic hypersomnia, or IH, in adults.August 2021U.S.Treatment of cataplexy in patients with narcolepsy.May 2023CanadaEpidiolexÂ® (cannabidiol)Treatment of seizures associated with Lennox-Gastaut syndrome, or LGS, Dravet syndrome, or DS, or tuberous sclerosis complex, or TSC, in patients 1 year of age and older.June 2018U.S.EpidyolexÂ® (cannabidiol)For adjunctive therapy of seizures associated with LGS or DS, in conjunction with clobazam, for patients 2 years of age and older.1September 2019EU, Great Britain, EEA2, Israel, Switzerland, Australia and New ZealandFor adjunctive therapy of seizures associated with TSC for patients 2 years of age and older.April 2021EU, Great Britain, Israel and SwitzerlandEpidiolexÂ® (cannabidiol)For adjunctive therapy of seizures associated with LGS, DS or TSC for patients 2 years of age and older.November 2023CanadaONCOLOGYRylazeÂ® (asparaginase erwinia chrysanthemi (recombinant)-rywn)A component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia, or ALL, and lymphoblastic lymphoma, or LBL, in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.June 2021U.S.RylazeÂ® (crisantaspase recombinant)A component of a multi-agent chemotherapeutic regimen for the treatment of ALL and LBL, in adults and pediatric patients 1 year or older who have developed hypersensitivity toE. coli-derived asparaginase.September 2022CanadaEnrylazeÂ® (recombinant crisantaspase)A component of a multi-agent chemotherapeutic regimen for the treatment of ALL and LBL in adult and pediatric patients (1 month and older) who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.September 2023EU, Great BritainZepzelcaÂ® (lurbinectedin)Treatment of adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based chemotherapy.June 2020U.S. (licensed from Pharma Mar S.A., or PharmaMar)3Treatment of adults with Stage III or metastatic SCLC who have progressed on or after platinum-containing therapy.September 2021Canada (licensed from PharmaMar)41 The clobazam restriction limited to EU and Great Britain2 European Economic Area3 Accelerated approval received from U.S. Food and Drug Administration, or FDA4 Conditional approval received from Health Canada33Table of ContentsNeuroscienceWe are the global leader in the development and commercialization of oxybate therapy for patients with sleep disorders. Xyrem was approved by FDA in 2002 for treatment of cataplexy and in 2005 for treatment of EDS in narcolepsy. In 2020, we received FDA approval for Xywav for the treatment of cataplexy or EDS, in patients seven years of age and older with narcolepsy. In AugustÂ 2021, Xywav became the first and only therapy approved by FDA for the treatment of IH in adults. Xywav is an oxybate therapy that contains 92% less sodium than Xyrem. Xywav has become a standard of care for patients with narcolepsy and IH.Since there is no cure for narcolepsy and long-term disease management is needed, we believe that Xywav represents an important therapeutic option for patients with this sleep disorder. Our commercial efforts are focused on educating patients and physicians about the lifelong impact of high sodium intake, and how the use of Xywav enables them to address what is a modifiable risk factor for cardiovascular morbidity. We view the adoption of Xywav in narcolepsy as a positive indication that physicians and patients appreciate the benefits of a low-sodium oxybate option.In JuneÂ 2021, FDA recognized seven years of Orphan Drug Exclusivity, or ODE, for Xywav in narcolepsy. ODE extends through January 2028. Nevertheless, Lumryz, a fixed-dose, high-sodium oxybate, was approved by FDA on MayÂ 1,Â 2023, for the treatment of cataplexy or EDS in adults with narcolepsy. FDA continues to recognize seven years of ODE for Xywav in narcolepsy. In connection with granting ODE, FDA stated that "Xywav is clinically superior to Xyrem by means of greater safety because Xywav provides a greatly reduced chronic sodium burden compared to Xyrem.â€ FDA's summary also stated that "the differences in the sodium content of the two products at the recommended doses will be clinically meaningful in reducing cardiovascular morbidity in a substantial proportion of patients for whom the drug is indicated." FDA has also recognized that the difference in sodium content between Xywav and Lumryz is likely to be clinically meaningful in all patients with narcolepsy and that Xywav is safer than Lumryz in all such patients. Lumryz has the same sodium content as Xyrem. Xywav is the only approved oxybate therapy that does not carry a warning and precaution related to high sodium intake.On AugustÂ 12,Â 2021, FDA approved Xywav for the treatment of IH in adults. Xywav remains the first and only FDA-approved therapy to treat IH. We initiated the U.S. commercial launch of Xywav for the treatment of IH in adults in NovemberÂ 2021. In JanuaryÂ 2022, FDA recognized seven years of ODE for Xywav in IH that extends through AugustÂ 2028. IH is a debilitating neurologic sleep disorder characterized by chronic EDS (the inability to stay awake and alert during the day resulting in the irrepressible need to sleep or unplanned lapses into sleep or drowsiness), severe sleep inertia, and prolonged and non-restorative nighttime sleep. An estimated 37,000 people in the U.S. have been diagnosed with IH and are actively seeking healthcare.We have agreements in place for Xywav with all three major pharmacy benefit managers, or PBMs, in the U.S. To date, we have entered into agreements with various entities and have achieved benefit coverage for Xywav in both narcolepsy and IH indications for approximately 90% of commercial lives.We have seen strong adoption of Xywav in narcolepsy since its launch in NovemberÂ 2020, and increasing adoption in IH since its launch in NovemberÂ 2021. Exiting the third quarter of 2024, there were approximately 13,625 patients taking Xywav, including approximately 10,075 patients with narcolepsy and approximately 3,550 patients with IH. We acquired Epidiolex (Epidyolex outside the U.S.) in MayÂ 2021 as part of the acquisition of GW Pharmaceuticals plc, or GW, which we refer to as the GW Acquisition, which expanded our growing neuroscience business with a global, high-growth childhood-onset epilepsy franchise. Epidiolex was approved in the U.S. in JuneÂ 2018 for the treatment of seizures associated with two rare and severe forms of epilepsy, LGS and DS, in patients two years of age and older, and subsequently approved in JulyÂ 2020 for the treatment of seizures associated with TSC in patients one year of age and older. FDA also approved the expansion of all existing indications, LGS and DS, to patients one year of age and older. The rolling European launch of Epidyolex is also underway following European Commission, or EC, approval in SeptemberÂ 2019 for use as adjunctive therapy of seizures associated with LGS or DS, in conjunction with clobazam, for patients two years of age and older. The clobazam restriction is limited to the EU and Great Britain. Epidyolex is now launched in all five key European markets: United Kingdom, Germany, Italy, Spain and France. Epidyolex was also approved for adjunctive therapy of seizures associated with TSC for patients 2 years of age and older in the EU in AprilÂ 2021 and Great Britain in AugustÂ 2021, and is approved or under review for this indication in other markets. Outside the U.S. and Europe, Epidiolex/Epidyolex is approved in Israel, Canada, Australia, New Zealand and Taiwan.OncologyRylaze was approved by FDA in JuneÂ 2021 under the Real-Time Oncology Review program, and was launched in the U.S. in JulyÂ 2021 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with ALL or LBL in pediatric and adult patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase. Rylaze is the only recombinant erwinia asparaginase manufactured product approved in the U.S. that maintains a clinically meaningful level of asparaginase activity throughout the entire course of treatment. We developed Rylaze to address the needs 34Table of Contentsof patients and health care providers for an innovative, high-quality erwinia asparaginase with reliable supply. The initial approved recommended dosage of Rylaze was for an intramuscular, or IM, administration of 25 mg/m2 every 48 hours. In NovemberÂ 2022, FDA approved a supplemental Biologics License Application, or sBLA, for a Monday/Wednesday/Friday 25/25/50 mg/m2 IM dosing schedule. In SeptemberÂ 2023, the EC granted marketing authorization for JZP458 under the trade name Enrylaze. This product has also been approved in Great Britain, Canada and Switzerland.We acquired U.S. development and commercialization rights to Zepzelca in early 2020, and launched six months thereafter, with an indication for treatment of patients with SCLC with disease progression on or after platinum-based chemotherapy. Our education and promotional efforts are focused on SCLC-treating physicians. We are continuing to raise awareness of Zepzelca across academic and community cancer centers. In collaboration with F. Hoffmann-La Roche Ltd, or Roche, we have an ongoing Phase 3 pivotal clinical trial in maintenance treatment for extensive-stage SCLC of Zepzelca in combination with TecentriqÂ® (atezolizumab) following induction therapy with carboplatin, etoposide and Tecentriq. In October 2024, we announced positive top-line results from the trial showing a statistically significant and clinically meaningful benefit for Zepzelca and atezolizumab

in combination in the first-line maintenance setting. We plan to submit a supplemental New Drug Application, or sNDA, in the first half of 2025 to support this combination in the first-line maintenance setting. Defitelio is the first and only approved treatment for patients with VOD, severe VOD, or sVOD, or VOD with renal or pulmonary dysfunction following HSCT by regulatory authorities in the U.S., Europe, Japan and other markets. There was a significant decline in the number of patients receiving HSCT due to the effects of the COVID-19 pandemic. Moving forward, while HSCT procedures are gradually returning to pre-pandemic numbers, we expect changes in chemotherapy regimens and the increasing use of cell therapies to potentially lower the incidence of sVOD; additionally, there has been a reduction ofprophylactic use of Defitelio in Europe.Vyxeos is a treatment for adults with newly-diagnosed t-AML, or AML-MRC. In March 2021, FDA approved a revised label to include a new indication to treat newly-diagnosed t-AML, or AML-MRC, in pediatric patients aged one year and older. We continue to expand into new markets internationally as the product receives approvals and reimbursement in relevant markets. In the U.S., with ongoing trends towards lower-intensity treatments and away from intensive chemotherapy regimens for AML, we have seen increasing competition from other therapeutic options.Research and Development ProgressOur research and development activities encompass all stages of development and currently include clinical testing of new product candidates and activities related to clinical improvements of, or additional indications or new clinical data for, our existing marketed products. We also have active preclinical programs for novel therapies, including neuroscience and precision medicines in oncology. We are increasingly leveraging our growing internal research and development function, and we have also entered into collaborations with third parties for the research and development of innovative early-stage product candidates and have supported additional investigator-sponsored trials that are anticipated to generate additional data related to our products. We also seek out investment opportunities in support of the development of early- and mid-stage technologies in our therapeutic areas and adjacencies. We have a number of licensing and collaboration agreements with third parties, including biotechnology companies, academic institutions and research-based companies and institutions, related to preclinical and clinical research and development activities in hematology and in precision oncology, as well as in neuroscience. Within our oncology R&D program, in OctoberÂ 2022, we announced an exclusive licensing and collaboration agreement with Zymeworks Inc., or Zymeworks, providing us the right to acquire development and commercialization rights to Zymeworks' zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia/Pacific territories previously licensed by Zymeworks. In DecemberÂ 2022, we exercised the option to continue with the exclusive development and commercialization rights to zanidatamab. Under the terms of the agreement, Zymeworks received an upfront payment of $50.0 million, and following the exercise of our option to continue the collaboration, a second, one-time payment of $325 million. Zymeworks is also eligible to receive regulatory and commercial milestone payments of up to $1.4Â billion, for total potential payments of $1.76 billion. Pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on our net sales. Zanidatamab is a bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding. Zanidatamab is currently being evaluated in multiple clinical trials as a treatment for patients with HER2-expressing cancers. Following positive data from a pivotal Phase 2 clinical trial evaluating zanidatamab monotherapy in patients with previously treated advanced or metastatic HER2-amplified biliary tract cancer, or BTC, we completed a BLA submission in second-line BTC in MarchÂ 2024. In MayÂ 2024, FDA granted Priority Review of the BLA and set a target action date of NovemberÂ 29,Â 2024. The European Medicines Agency, or EMA, has validated our Marketing Authorization Application, or MAA, for zanidatamab in second-line BTC; we anticipate a response to our MAA in 2025. In addition, we have an ongoing Phase 3 randomized clinical trial evaluating zanidatamab in combination with chemotherapy plus or minus tislelizumab as a first-line treatment for HER2-expressing gastroesophageal adenocarcinoma, or GEA, and an ongoing Phase 2 trial examining zanidatamab in combination with chemotherapy in first-line patients with HER2-expressing metastatic GEA. In July 2024, we announced the initiation of the Phase 3 EmpowHER-BC-303 to evaluate 35Table of Contentszanidatamab plus chemotherapy or trastuzumab plus chemotherapy in patients with HER2-positive breast cancer whose disease has progressed on previous trastuzumab deruxtecan, or T-DXd, treatment. There are also multiple ongoing clinical trials exploring zanidatamab in breast cancer and other HER2-expressing tumor types. Our development plan for Zepzelca continues to progress. We are collaborating with Roche on a pivotal Phase 3 clinical trial evaluating Zepzelca in combination with Tecentriq in first-line extensive-stage SCLC. In October 2024, we announced positive top-line results from the trial showing a statistically significant and clinically meaningful benefit for Zepzelca and atezolizumab in combination in the first-line maintenance setting. We plan to submit an sNDA in the first half of 2025 to support this combination in the first-line maintenance setting. In DecemberÂ 2021, our licensor PharmaMar initiated a confirmatory trial in second-line SCLC. This ongoing three-arm trial is comparing Zepzelca as either monotherapy or in combination with irinotecan to investigator's choice of irinotecan or topotecan. Data from either the first-line trial of Zepzelca in combination with Tecentriq or the PharmaMar trial could serve to confirm clinical benefit of Zepzelca and secure full approval in the U.S.In addition, we have an ongoing Phase 4 observational study to collect real world safety and outcome data in adult Zepzelca monotherapy patients with SCLC who progress on or after prior platinum-containing chemotherapy. Preliminary findings from this study presented at the 2024 World Conference on Lung Cancer demonstrated Zepzelca provided clinical benefit when administered as second-line SCLC therapy. The safety and tolerability profile observed in this study was consistent with prior findings, with no new safety signals reported. In JuneÂ 2022, we announced the FDA had cleared our Investigational New Drug application for JZP815 and, in OctoberÂ 2022, we enrolled the first patient in a Phase 1 trial. JZP815 is an investigational stage pan-RAF kinase inhibitor that targets specific components of the mitogen-activated protein kinase pathway that, when activated by oncogenic mutations, can be a frequent driver of human cancer.In AprilÂ 2022, we announced that we had entered into a licensing and collaboration agreement with Werewolf Therapeutics, Inc., or Werewolf, to acquire exclusive global development and commercialization rights to Werewolf's investigational WTX-613, now referred to as JZP898. Under the terms of the agreement, we made an upfront payment of $15.0Â million to Werewolf, and Werewolf is eligible to receive development, regulatory and commercial milestone payments of up to $1.26 billion. If approved, Werewolf is eligible to receive a tiered, mid-single-digit percentage royalty on net sales of JZP898. This transaction underscores our commitment to enhancing our pipeline to deliver novel oncology therapies to patients, and also provides us with an opportunity to expand into immuno-oncology. JZP898 is a differentiated, conditionally-activated interferon alpha, or IFNÎ±, INDUKINEâ„¢ molecule. We initiated a Phase 1 clinical trial of JZP898 in late 2023.Our neuroscience R&D efforts include an ongoing Phase 3 trial of Epidyolex for LGS, DS and TSC in Japan. In AugustÂ 2024, we announced top-line results from the trial. The trial did not meet the primary efficacy endpoint of a pre-specified percentage change in indication-associated seizure frequency during the treatment period (up to 16 weeks) compared to baseline in Japanese pediatric patients; however, numeric improvements were observed in the primary and several secondary endpoints. No new safety signals were observed in the trial. We are continuing to collect data in Japanese patients and plan to engage with regulatory authorities in Japan regarding a potential new drug application. In DecemberÂ 2021, we initiated a Phase 2 clinical trial for suvecaltamide (JZP385), for essential tremor, or ET. Additionally, in NovemberÂ 2022, we initiated a Phase 2 trial of suvecaltamide in patients with Parkinson's disease tremor. In JuneÂ 2024, we announced the ET trial did not achieve statistical significance on the primary and key secondary endpoint for the 30 mg dose. We are continuing to evaluate data from this trial and await results from the ongoing Parkinson's disease tremor trial to determine next steps, if any, for the suvecaltamide program. We are also pursuing early-stage activities related to the development of JZP324, an extended-release low sodium, oxybate formulation that we believe could provide a clinically meaningful option for narcolepsy patients.In MayÂ 2022, we announced that we had entered into a licensing agreement with Sumitomo Pharma Co., Ltd, or Sumitomo, to acquire exclusive development and commercialization rights in the United States, Europe and other territories for JZP441, also known as DSP-0187, a potent, highly selective oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy, IH and other sleep disorders. Under the terms of the agreement, we made an upfront payment of $50Â million to Sumitomo, and Sumitomo is eligible to receive development, regulatory and commercial milestone payments of up to $1.09 billion. If approved, Sumitomo is eligible to receive a tiered, low double-digit royalty on our net sales of JZP441. In NovemberÂ 2023, we announced that we achieved initial proof-of-concept in our Phase 1 clinical trial program in healthy volunteers as demonstrated by the Maintenance of Wakefulness Test (MWT). At that time, we also noted the program was being paused as we analyze safety findings related to visual disturbances and cardiovascular effects; no liver toxicity signals were observed. Following additional review of the trial findings and input from FDA, we plan to initiate a small Phase 1b trial of JZP441 in narcolepsy Type 1 patients in 2025. We expect data from this trial will further our understanding of JZP441 and orexin-2 receptor agonism, providing learnings that could inform future development efforts. 36Table of ContentsBelow is a summary of our key ongoing and planned development projects related to our products and pipeline and their corresponding current stages of development:Product CandidatesDescriptionONCOLOGYRegulatory ReviewZanidatamabPreviously treated, advanced HER2-expressing BTC (ongoing trial) (pivotal trial)Phase 3ZanidatamabFirst-line HER2-positive GEA (ongoing trial)ZanidatamabFirst-line HER2-positive BTC (ongoing trial)ZanidatamabPreviously treated HER2-positive breast cancer in patients whose disease has progressed on previous T-DXd treatment (EMPOWHER-BC-303) (ongoing trial)ZepzelcaFirst-line extensive-stage SCLC in combination with Tecentriq (collaboration with Roche) (ongoing trial)Confirmatory second-line trial (PharmaMar study) (ongoing trial)VyxeosAML or high-risk Myelodysplastic Syndrome, or MDS (AML18) (cooperative group studies) (ongoing trial) Newly diagnosed adults with standard- and high-risk AML (AML Study Group cooperative group study) (ongoing trial) Newly diagnosed pediatric patients with AML (Childrenâ€™s Oncology Group cooperative group study) (ongoing trial)Phase 2ZanidatamabHER2-expressing GEA, BTC or colorectal cancer in combination with standard first-line chemotherapy (ongoing trial)ZanidatamabBasket trial including HER2-positive solid tumors (DiscovHER-Pan-206) (ongoing trial)VyxeosHigh-risk MDS (European Myelodysplastic Syndromes) (cooperative group study) (ongoing trial)Newly diagnosed untreated patients with intermediate- and high-risk AML (cooperative group study) (ongoing trial)Vyxeos + other approved therapiesRelapsed/refractory, or R/R AML or hypomethylating agent failure MDS (MD Anderson collaboration study) (ongoing trial) De novo or R/R AML (MD Anderson collaboration study) (ongoing trial)Phase 2aZanidatamabPreviously treated HER2+ HR+ breast cancer in combination with palbociclib (ongoing trial)Phase 1b/2ZanidatamabFirst-line breast cancer and GEA (BeiGene trial) (ongoing trial)ZanidatamabHER2-expressing breast cancer in combination with ALX148 (ongoing trial)Phase 1JZP815Raf and Ras mutant tumors (acquired from Redx Pharma plc, or Redx) (ongoing trial)ZanidatamabPreviously treated metastatic HER2-expressing cancers in combination with select antineoplastic therapies (cooperative group study) (ongoing trial)JZP341 (long-acting Erwinia asparaginase)Solid tumors (licensed from Ligand Pharmaceuticals Incorporated) (ongoing trial)JZP898Conditionally-activated IFNÎ± INDUKINEâ„¢ molecule in solid tumors (ongoing trial)VyxeosLow intensity dosing for higher risk MDS (MD Anderson collaboration study) (ongoing trial)PreclinicalKRAS inhibitor targetsG12D selective and pan-KRAS molecules (acquired from Redx)Undisclosed targetsOncologyCombiPlexÂ®Hematology/oncology exploratory activities37Table of ContentsProduct CandidatesDescriptionNEUROSCIENCEPhase 3EpidyolexLGS, TSC and DS (ongoing trial in Japan)Phase 2Suvecaltamide (JZP385)Parkinson's disease tremor (ongoing trial)Phase 1JZP324Oxybate extended-release formulation (planned trial)JZP441*Potent, highly selective oral orexin-2 receptor agonist (paused)PreclinicalUndisclosed targetsSleepEpilepsyOther Neuroscience*Also known as DSP-0187Challenges, Risks and Trends Related to Our BusinessOur operating plan assumes that Xywav, with 92% lower sodium compared to high-sodium oxybates (depending on the dose) absence of a sodium warning and dosing titration option, will remain the treatment of choice for patients who can benefit from oxybate treatment. In JuneÂ 2021, FDA recognized seven years of ODE for Xywav in narcolepsy through JulyÂ 21,Â 2027, stating that Xywav is clinically superior to Xyrem by means of greater safety due to reduced chronic sodium burden. While we expect that our business will continue to meaningfully depend on oxybate revenues, there is no guarantee that oxybate revenues will remain at current levels. Our ability to successfully commercialize Xywav depends on, among other things, our ability to maintain adequate payor coverage and reimbursement for Xywav and acceptance of Xywav by physicians and patients, including of Xywav for the treatment of IH in adults. In an effort to support strong adoption of Xywav and patient success, we are focused on facilitating payor coverage for Xywav and providing robust patient copay and savings programs.Xywav and Xyrem face competition from a branded product for treatment of cataplexy and/or EDS in narcolepsy. Avadelâ€™s Lumryz was launched in the U.S. market in JuneÂ 2023. On JuneÂ 22,Â 2023, we filed a complaint in the United States District Court for the District of Columbia seeking a declaration that FDAâ€™s approval of the New Drug Application, or NDA, for Avadel's Lumryz was unlawful. In the complaint, we alleged that FDA acted outside its authority under the Orphan Drug Act, when, despite ODE protecting Xywav, FDA approved the Lumryz NDA and granted Lumryz ODE based on FDAâ€™s finding that Lumryz makes a major contribution to patient care and is therefore clinically superior to Xywav and Xyrem. On September 15, 2023, we filed a motion for summary judgment. On October 20, 2023, Avadel and FDA filed cross motions for summary judgment. Oral argument on these motions was held on May 10, 2024, and on October 30, 2024, the District Court issued an order denying Jazzâ€™s motion for summary judgment and granting Avadelâ€™s and the FDAâ€™s cross-motions for summary judgment. Jazz respectfully disagrees with the Courtâ€™s decision and is evaluating potential options for appeal. We cannot at this time predict the timing or ultimate outcome of this litigation or the impact of this litigation on our business. In addition, in January 2023, our oxybate products began to face competition from an authorized generic, or AG, version of high-sodium oxybate pursuant to a settlement agreement we entered into with an abbreviated new drug application, or ANDA, filer. In JulyÂ 2023, a volume-limited ANDA filer launched an AG version of high-sodium oxybate. These AG products have negatively impacted and are expected to continue to negatively impact Xyrem and Xywav sales for patients with narcolepsy. Specifically, a wholly owned subsidiary of Hikma Pharmaceuticals PLC, or Hikma, launched its AG version of sodium oxybate in JanuaryÂ 2023 and Amneal Pharmaceuticals LLC, or Amneal, launched its AG version of sodium oxybate in JulyÂ 2023. Hikma has elected to continue to sell the Hikma AG product, with royalties to be paid to us, for a total of up to four years beginning in JanuaryÂ 2024, which election may be terminated by Hikma in accordance with the notice provisions in the agreements between the parties. We have the right to receive a meaningful royalty from Hikma on net sales of the Hikma AG product; the royalty rate was fixed for the second half of 2023. There was a substantial increase in the royalty rate beginning in JanuaryÂ 2024, which will remain fixed for the duration of the agreement's term. We are also paid for supply of the Hikma AG product and reimbursed by Hikma for a portion of the services costs associated with the operation of the Xywav and Xyrem risk evaluation and mitigation strategy, or REMS, and distribution of the Hikma AG product. We also granted Hikma a license to launch its own generic sodium oxybate product but, if it elects to launch its own generic product, Hikma will no longer have the right to sell the Hikma AG product. In addition, Hikma would need to set up its own REMS (or join an existing REMS operated by another company), which must be open to any other company seeking to commercialize a sodium oxybate product. In our settlements with Amneal, Lupin Inc., or Lupin, and Par Pharmaceutical, Inc., or Par, we granted each party the right to 38Table of Contentssell a limited volume of an AG product in the U.S. beginning on JulyÂ 1,Â 2023 and ending on DecemberÂ 31,Â 2025, with royalties to be paid to us. Amneal launched its AG version of high-sodium oxybate in JulyÂ 2023. At this time, Amneal has rights to sell a low-single-digit percentage of historical Xyrem sales over each 6-month sales period. At this time, Lupin and Par have elected not to launch an AG product. AG products will be distributed through the same REMS as Xywav and Xyrem. We also granted each of Amneal, Lupin and Par a license to launch its own generic sodium oxybate product under its ANDA on or after DecemberÂ 31,Â 2025, or earlier under certain circumstances, including the circumstance where Hikma elects to launch its own generic product. If Amneal, Lupin or Par elects to launch its own generic product under such circumstance, it will no longer have the right to sell an AG product. In addition, any company commercializing a generic version of high-sodium oxybate would need to establish its own REMS, or join an existing REMS operated by another company. In the future, we expect our oxybate products to continue to face competition from generic versions of high-sodium oxybate pursuant to settlement agreements we entered into with multiple ANDA filers. In addition, we received notices in JuneÂ 2021 and FebruaryÂ 2023, that Lupin and Teva, respectively, filed ANDAs for generic versions of Xywav. On OctoberÂ 13,Â 2023, Lupin announced that it has received tentative approval for its application to market a generic version of Xywav. Generic competition can decrease the net prices at which branded products, such as Xywav and Xyrem are sold, as can competition from other branded products. In addition, we have increasingly experienced pressure from third party payors to agree to discounts, rebates or restrictive pricing terms, and we cannot guaranteeÂ we will be able to agree to commercially reasonable terms with PBMs, or similar organizations and other third party payors, or that we will be able to ensure patient access and acceptance on formularies. Entering into agreements with PBMs or similar organizations and payors to ensure patient access has and may continue to result in decreased net prices for some of our products. Moreover, generic or AG high-sodium oxybate products or branded high-sodium oxybate entrants in narcolepsy, such as Avadelâ€™s Lumryz, have had and may continue to have the effect of changing payor or formulary coverage of Xywav or Xyrem in favor of other products, and indirectly adversely affect sales of Xywav and Xyrem.Our financial condition, results of operations and growth prospects are also dependent on our ability to maintain or increase sales of Epidiolex/Epidyolex in the U.S. and Europe, which is subject to many risks and there is no guarantee that we will be able to continue to successfully commercialize Epidiolex/Epidyolex for its approved indications. The commercial success of Epidiolex/Epidyolex depends on the extent to which patients and physicians accept and adopt Epidiolex/Epidyolex as a treatment for seizures associated with LGS, DS and TSC, and we do not know whether our or othersâ€™ estimates in this regard will be accurate. Physicians may not prescribe Epidiolex and patients may be unwilling to use Epidiolex/Epidyolex if coverage is not provided or reimbursement is inadequate to cover a significant portion of the cost. Additionally,

any negative development for Epidiolex/Epidyolex in the market, in clinical development for additional indications, or in regulatory processes in other jurisdictions, may adversely impact the commercial results and potential of Epidiolex/Epidyolex. Moreover, we expect that Epidiolex will face competition from generic products in the future. For example, in November and DecemberÂ 2022, we received notices from ten ANDA filers that they have each filed with FDA an ANDA for a generic version of Epidiolex. In addition, there are non-FDA approved cannabidiol preparations being made available from companies through the state-enabled medical marijuana industry, which might attempt to compete with Epidiolex. Thus, significant uncertainty remains regarding the commercial potential of Epidiolex/Epidyolex. In addition to our neuroscience products and product candidates, we are commercializing a portfolio of oncology products, including Rylaze, Zepzelca, Defitelio and Vyxeos. An inability to effectively commercialize Rylaze, Zepzelca, Defitelio and Vyxeos and to maximize their potential where possible through successful research and development activities could have a material adverse effect on our business, financial condition, results of operations and growth prospects. A key aspect of our growth strategy is our continued investment in our evolving and expanding R&D activities. If we are not successful in the clinical development of our product candidates, if we are unable to obtain regulatory approval for our product candidates in a timely manner, or at all, or if sales of an approved product do not reach the levels we expect, our anticipated revenue from our product candidates would be negatively affected, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In addition to continued investment in our R&D pipeline, we intend to continue to grow our business by acquiring or in-licensing, and developing, including with collaboration partners, additional products and product candidates that we believe are highly differentiated and have significant commercial potential. Failure toÂ identify and acquire, in-license or develop additional products or product candidates, successfully manage the risks associated with integrating any products or product candidates into our portfolio or the risks arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing, such as the GW Acquisition, could have a material adverse effect on our business, results of operations and financial condition. The success of the GW Acquisition will depend, in part, on our ability to realize the anticipated benefits from the combination of our and GWâ€™s historical businesses. Nonetheless, Epidiolex and the other products and technologies acquired may not be successful or continue to grow at the same rate as if our companies operated independently or they may require significantly greater resources and investments than originally anticipated. For example, in the third quarter of 2022, we 39Table of Contentsrecorded a $133.6 million asset impairment charge as a result of the decision to discontinue the nabiximols program. As a result, the anticipated benefits of the GW Acquisition may not be realized at the expected level, within the expected timeframe or at all or may take longer to realize or cost more than expected, which could materially and adversely affect our business, financial condition, results of operations and growth prospects. Our industry has been, and is expected to continue to be, subject to healthcare cost containment and drug pricing scrutiny by regulatory agencies in the U.S. and internationally. If new healthcare policies or reforms intended to curb healthcare costs are adopted or if we experience negative publicity with respect to pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for our products may be affected, our commercial opportunity may be limited and/or our revenues from sales of our products may be negatively impacted. For example, the Inflation Reduction Act of 2022 among other things, requires the U.S. Department of Health and Human Services Secretary to negotiate, with respect to Medicare units and subject to a specified cap, the price of a set number of certain high Medicare spend drugs and biologicals per year starting in 2026, penalizes manufacturers of certain Medicare Parts B and D drugs for price increases above inflation, and makes several changes to the Medicare Part D benefit, including a limit on annual out-of-pocket costs, and a change in manufacturer liability under the program, that could negatively affect our business and financial condition. In addition, under the Medicaid Drug Rebate Program, rebates owed by manufacturers are no longer subject to a cap on the rebate amount, which could adversely affect our rebate liability. We are also subject to increasing pricing pressure and restrictions on reimbursement imposed by payors. If we fail to obtain and maintain adequate formulary positions and institutional access for our current products and future approved products, we will not be able to achieve a return on our investment and our business, financial condition, results of operations and growth prospects would be materially adversely affected. While certain preparations of cannabis remain Schedule I controlled substances, if such products are approved by FDA for medical use in the U.S. they are rescheduled to Schedules II-V, since approval by FDA satisfies the â€œaccepted medical useâ€ requirement; or such products may be removed from control under the Controlled Substances Act entirely. If any of our product candidates receive FDA approval, the Department of Health and Human Services and the U.S. Drug Enforcement Administration will make a scheduling determination. U.S. or foreign regulatory agencies may request additional information regarding the abuse potential of our products which may require us to generate more clinical or other data than we currently anticipate to establish whether or to what extent the substance has an abuse potential, which could increase the cost, delay the approval and/or delay the launch of that product. Finally, business practices by pharmaceutical companies, including product formulation improvements, patent litigation settlements, and REMS programs, have increasingly drawn public scrutiny from legislators and regulatory agencies, with allegations that such programs are used as a means of improperly blocking or delaying competition. Government investigations with respect to our business practices, including as they relate to the Xywav and Xyrem REMS, the launch of Xywav, our Xyrem patent litigation settlement agreements or otherwise, could cause us to incur significant monetary charges to resolve these matters and could distract us from the operation of our business and execution of our strategy. In addition, from JuneÂ 2020 to MayÂ 2022, a number of lawsuits were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the patent litigation settlement agreements we entered with certain generic companies violate state and federal antitrust and consumer protection laws. For additional information on these lawsuits and other legal matters, see Note 9, Commitments and Contingenciesâ€”Legal Proceedings of the Notes to Condensed Consolidated Financial Statements, included in Part I, Item 1 of this Quarterly Report on FormÂ 10â€‘Q. It is possible that additional lawsuits will be filed against us making similar or related allegations. We cannot predict the outcome of these or potential additional lawsuits; however, if the plaintiffs were to be successful in their claims against us, they may be entitled to injunctive relief or we may be required to pay significant monetary damages. Moreover, we are, and expect to continue to be, the subject of various claims, legal proceedings, and government investigations apart from those set forth above that have arisen in the ordinary course of business that have not yet been fully resolved and that could adversely affect our business and the execution of our strategy. Any of the foregoing risks and uncertainties could have a material adverse effect on our business, financial condition, results of operations and growth prospects. These risks and uncertainties are discussed in greater detail, along with other risks and uncertainties, in â€œRisk Factorsâ€ in Part I, Item 1A of our Annual Report on Form 10-K for the year ended DecemberÂ 31,Â 2023, as supplemented by the risks and uncertainties described in "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q.40Table of ContentsResults of OperationsThe following table presents our revenues and expenses (in thousands, except percentages):Â Â Three Months EndedSeptember 30,Increase/Nine Months EndedSeptember 30,Increase/Â 20242023(Decrease)20242023(Decrease)Product sales, net$989,707Â $938,398Â 5Â %$2,795,953Â $2,769,604Â 1Â %Royalties and contract revenues65,262Â 33,742Â 93Â %184,824Â 52,665Â N/A(1)Cost of product sales (excluding amortization of acquired developed technologies)111,611Â 102,153Â 9Â %317,000Â 328,334Â (3)%Selling, general and administrative325,772Â 308,310Â 6Â %1,016,007Â 947,071Â 7Â %Research and development199,919Â 234,402Â (15)%643,500Â 633,050Â 2Â %Intangible asset amortization157,457Â 154,883Â 2Â %468,410Â 456,731Â 3Â %Acquired in-process research and developmentâ€”Â â€”Â â€”Â 10,000Â 1,000Â N/A(1)Interest expense, net58,702Â 71,497Â (18)%186,841Â 219,114Â (15)%Foreign exchange loss701Â 1,377Â (49)%1,887Â 566Â 233Â %Income tax benefit(14,533)(47,176)(69)%(33,517)(86,823)(61)%Equity in loss (gain) of investees285Â (126)N/A(1)1,644Â 2,548Â (35)%_____(1)Comparison to prior period not meaningful.RevenuesThe following table presents our net product sales, royalties and contract revenues, and total revenues (in thousands, except percentages):Â Three Months EndedSeptember 30,Increase/Nine Months EndedSeptember 30,Increase/Â 20242023(Decrease)20242023(Decrease)Xywav$388,466Â $331,633Â 17Â %$1,072,238Â $935,958Â 15Â %Xyrem58,114Â 125,110Â (54)%184,526Â 463,009Â (60)%Epidiolex/Epidyolex251,55 Neuroscience702,724Â 675,081Â 4Â %1,967,844Â 2,018,344Â (3)%Rylaze/Enrylaze98,780Â 104,859Â (6)%309,359Â 292,479Â 6Â %Zepzelca85,843Â 77,994Â 10Â %241,990Â 215,523Â 12Â %De 65,818Â 47,730Â 38Â %158,915Â 132,917Â 20Â %Vyxeos34,313Â 29,827Â 15Â %109,348Â 100,583Â 9Â %Total Oncology284,754Â 260,410Â 9Â %819,612Â 741,502Â 11Â %Other2,229Â 2,907Â (23)%8,497Â 9,758Â (13)%Product sales, net989,707Â 938,398Â 5Â %2,795,953Â 2,769,604Â 1Â %High-sodium oxybate AG royalty revenue58,157Â 28,921Â 101Â %162,268Â 36,531Â N/A(1)Other royalty and contract revenues7,105Â 4,821Â 47Â %22,556Â 16,134Â 40Â %Total revenues$1,054,969Â $972,140Â 9Â %$2,980,777Â $2,822,269Â 6Â %_____(1)Comparison to prior period not meaningful.Product Sales, NetXywav product sales increased in the three and nine months ended SeptemberÂ 30,Â 2024, compared to the same periods in 2023, primarily due to increased sales volumes of 17% and 15% in the respective periods and, to a lesser extent, a higher selling price, offset by higher gross to net deductions. We continue to see Xywav adoption in patients with narcolepsy driven by educational initiatives around efficacy and the benefit of lowering sodium intake. In addition, Xywav product sales were positively impacted by adoption in IH; Xywav is the only oxybate therapy approved to treat IH and we see continued growth of new prescribers. Exiting the quarter, there were 10,075 patients taking Xywav for narcolepsy and 3,550 taking Xywav for IH, an increase of approximately 6% and 39%, respectively, compared to the same period in 2023. Xyrem product sales decreased 41Table of Contentsin the three and nine months ended SeptemberÂ 30,Â 2024, compared to the same periods in 2023, primarily due to decreased sales volumes of 53% and 59% in the respective periods, due to high-sodium oxybate competition, the adoption of Xywav by existing Xyrem patients and higher gross to net deductions, partially offset by a higher selling price. Epidiolex/Epidyolex product sales increased in the three and nine months ended SeptemberÂ 30,Â 2024, compared to the same periods in 2023, primarily due to increased sales volumes of 13% and 12% in the respective periods, due to increased demand and geographic expansion and a higher average selling price.Rylaze/Enrylaze product sales decreased in the three months ended SeptemberÂ 30,Â 2024, compared to the same period in 2023, primarily due to decreased sales volumes of 2%, partially offset by a higher average selling price. Rylaze/Enrylaze product sales increased in the nine months ended SeptemberÂ 30,Â 2024, compared to the same period in 2023, due to a higher average selling price and increased sales volumes of 6%, partially offset by higher gross to net deductions. Rylaze sales volumes in the three and nine months ended SeptemberÂ 30,Â 2024, have been affected by a recent update to the Childrenâ€™s Oncology Group, or COG, pediatric treatment protocols for ALL which impact the timing of asparaginase administration. While this will have a temporary negative impact on Rylaze revenue in the third and fourth quarters of 2024, we do not expect it will affect ongoing demand and we anticipate our revenue will normalize by early 2025. We expect that Rylaze demand will continue to be driven by widespread utilization in pediatric asparaginase-based oncology protocols in the U.S. and the opportunity for future growth in the adolescent and young adult market. Zepzelca product sales increased in the three and nine months ended SeptemberÂ 30,Â 2024, compared to the same periods in 2023, due to increased sales volumes and a higher average selling price, offset by higher gross to net deductions. Defitelio/defibrotide product sales increased in the three months ended SeptemberÂ 30,Â 2024, compared to the same period in 2023, primarily due to increased sales volumes. Defitelio/defibrotide product sales increased in the nine months ended SeptemberÂ 30,Â 2024, compared to the same period in 2023, primarily due to increased sales volumes and, to a lesser extent, a higher average selling price. Vyxeos product sales increased in the three and nine months ended SeptemberÂ 30,Â 2024, compared to the same periods in 2023, primarily due to an increase in sales volumes, partially offset by a lower average selling price due to regional mix.We expect total product sales will increase in 2024 over 2023, primarily due to our key growth drivers; Xywav, through continued growth in the IH market, Epidiolex through growth in current markets and expansion into new markets and Rylaze through demand, offset by the impact of the update to the COG treatment protocol on the timing of Rylaze administration, which we expect to be primarily limited to the third and fourth quarters of 2024 and to normalize by early 2025, and a decrease in sales of Xyrem due to the impact of high-sodium oxybate competition and continued Xywav adoption.Royalties and Contract RevenuesRoyalties and contract revenues increased in the three and nine months ended SeptemberÂ 30,Â 2024, compared to the same periods in 2023, primarily due to royalty revenue received from Hikma Pharmaceuticals plc on net sales of their high sodium oxybate AG. We expect royalties and contract revenues to increase in 2024 compared to 2023, primarily due to increased royalty revenues arising from net sales of high-sodium oxybate AG, primarily due to higher royalty rates in 2024.Cost of Product Sales Cost of product sales increased in the three months ended SeptemberÂ 30,Â 2024, compared to the same period in 2023, primarily due to higher product sales, net and an increase in the acquisition accounting inventory fair value step-up expense, or fair value step-up expense. Cost of product sales decreased in the nine months ended SeptemberÂ 30,Â 2024, compared to the same period in 2023, primarily due to a reduction in the fair value step-up expense, partially offset by changes in product mix. Gross margin as a percentage of net product sales was 88.7% for both the three and nine months ended SeptemberÂ 30,Â 2024, compared to 89.1% and 88.1% for the same periods in 2023. Cost of product sales for 2024 is expected to be in line with 2023.42Table of ContentsSelling, General and Administrative Expenses Selling, general and administrative expenses for the three months ended SeptemberÂ 30,Â 2024, increased compared to the same period in 2023, primarily due to increased compensation-related expenses of $15.3 million, primarily driven by higher headcount in support of our key growth drivers. Selling, general and administrative expenses for the nine months ended SeptemberÂ 30,Â 2024, increased compared to the same period in 2023, primarily due to increased compensation-related expenses of $36.7 million, primarily driven by higher headcount in support of our key growth drivers, increased marketing investment in our priority programs of $18.5Â million, increased litigation costs of $16.9 million, offset by costs related to program terminations of $23.5 million incurred in the nine months ended SeptemberÂ 30,Â 2023.For 2024, we expect selling, general and administrative expenses in 2024 to increase compared to 2023, primarily due to continued investment in our key growth drivers, such as Xywav in IH, Epidiolex and Rylaze along with increased employee expenses.Research and Development Expenses Research and development expenses consist primarily of costs related to clinical studies and outside services, personnel expenses and other research and development costs. Clinical study and outside services costs relate primarily to services performed by clinical research organizations, materials and supplies, and other third party fees. Personnel expenses relate primarily to salaries, benefits and share-based compensation. Other research and development expenses primarily include overhead allocations consisting of various support and facilities-related costs. We do not track fully-burdened research and development expenses on a project-by-project basis. We manage our research and development expenses by identifying the research and development activities that we anticipate will be performed during a given period and then prioritizing efforts based on our assessment of which development activities are important to our business and have a reasonable probability of success, and by dynamically allocating resources accordingly. We also continually review our development pipeline projects and the status of their development and, as necessary, reallocate resources among our development pipeline projects that we believe will best support the future growth of our business. The following table provides a breakout of our research and development expenses by major categories of expense (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023Clinical studies and outside services$108,362Â $140,036Â $373,946Â $366,659Â Personnel expenses71,081Â 65,945Â 212,382Â 192,435Â Milestone expenseâ€”Â 5,000Â â€”Â 5,500Â Other 20,476Â 23,421Â 57,172Â 68,456Â Total$199,919Â $234,402Â $643,500Â $633,050Â Research and development expenses decreased by $34.5Â million in the three months ended SeptemberÂ 30,Â 2024, compared to the same period in 2023. Clinical studies and outside services costs decreased in the three months ended SeptemberÂ 30,Â 2024, compared to the same period in 2023, primarily due to the inclusion of costs related to JZP150 (post-traumatic stress disorder, or PTSD) in the three months ended September 30, 2023 and lower costs related to zanidatamab. Research and development expenses increased by $10.5Â million in the nine months ended SeptemberÂ 30,Â 2024, compared to the same period in 2023. Clinical studies and outside services costs increased in the nine months ended SeptemberÂ 30,Â 2024, compared to the same period in 2023, primarily due to higher costs related to zanidatamab programs, offset by the inclusion of costs related to JZP150 (PTSD) incurred in the nine months ended September 30, 2023. Personnel expenses increased in the three and nine months ended SeptemberÂ 30,Â 2024, compared to the same periods in 2023, primarily driven by increased compensation costs in support of our development programs.For 2024, we expect that our research and development expenses will continue to increase compared to 2023, as we prepare for anticipated data read-outs from clinical trials, initiate and undertake additional clinical trials and related development work primarily relating to zanidatamab.Intangible Asset Amortization Intangible asset amortization increased in the three and nine months ended SeptemberÂ 30,Â 2024, compared to the same periods in 2023, primarily due to the impact of foreign currency translation adjustments. Intangible asset amortization for 2024 is expected to be in line with 2023.43Table of ContentsAcquired In-Process Research and DevelopmentAcquired in-process research and development, or IPR&D, expense in the nine months ended SeptemberÂ 30,Â 2024, related to the upfront payment ofÂ $10.0Â million made in connection with our asset purchase and collaboration agreement with Redx to acquire global rights to the Kirsten rat sarcoma virus, or KRAS, Inhibitor Program.Interest Expense, NetInterest expense, net decreased by $12.8Â million and $32.3Â million in the three and nine months ended SeptemberÂ 30,Â 2024, compared to the same periods in 2023, primarily due to higher interest income on investments driven by our increased deposits and higher interest rates and lower interest expense on the seven-year

$2.7Â billion term loan B facility, or the Tranche B-2 Dollar Term Loans. We expect interest expense, net to decrease in 2024 compared to 2023, primarily due to higher interest income on investments driven by our increased deposits and higher interest rates and lower interest expense following the repricing of the Tranche B-2 Dollar Term Loans. For further information on this, please refer to Liquidity and Capital Resources.Foreign Exchange LossThe foreign exchange loss is primarily related to the translation of sterling and euro-denominated net monetary liabilities, primarily intercompany balances, held by subsidiaries with a U.S. dollar functional currency and related foreign exchange forward contracts not designated as hedging instruments.Income Tax BenefitOur income tax benefit was $14.5Â million and $33.5Â million for the three and nine months ended SeptemberÂ 30,Â 2024, respectively, compared to $47.2Â million and $86.8Â million for the same periods in 2023, relating to tax arising on income or losses in Ireland, the U.K., the U.S. and certain other foreign jurisdictions and tax deficiencies from share based compensation, offset by deductions on subsidiary equity, foreign derived intangible income benefits and tax credits. The decrease in the income tax benefit for the three and nine months ended September 30, 2024 compared to the same periods in 2023 resulted primarily from changes in the mix of pre-tax income and losses across tax jurisdictions.Liquidity and Capital Resources As of SeptemberÂ 30,Â 2024, we had cash, cash equivalents and investments of $2.6Â billion, borrowing availability under our five-year $500.0Â million revolving credit facility, or the Revolving Credit Facility, of $500.0Â million and long-term debt principal balance of $6.2Â billion. Our long-term debt included $2.7Â billion aggregate principal amount of the Tranche B-2 Dollar Term Loan, $1.5Â billion in aggregate principal amount of 4.375% senior secured notes, due 2029, or the Secured Notes, $1.0Â billion principal amount on our 2.000% exchangeable senior notes due 2026, or 2026 Notes, and $1.0Â billion principal amount on our 3.125% exchangeable senior notes due 2030, or 2030 Notes. We generated cash flows from operations of $997.3Â millionÂ during the nine months ended SeptemberÂ 30,Â 2024, and we expect to continue to generate positive cash flows from operations which will enable us to operate our business and de-lever our balance sheet over time.Since the closing of the acquisition of GW in MayÂ 2021, we have fully repaid our seven-year â‚¬625.0 million ($753.0Â million) term loan B facility, or the Euro Term Loan, made voluntary and mandatory repayments of $300.0Â million and $100.8Â million, respectively, relating to our Tranche B-2 Dollar Term Loans (formally our seven-year $3.1Â billion term loan B facility, or Dollar Term Loan). In August 2024, we repaid the $575.0 million aggregate principal amount of our 1.50% exchangeable senior notes due 2024, or the 2024 Notes.We have a significant amount of debt outstanding on a consolidated basis. For a more detailed description of our debt arrangements, including information relating to our scheduled maturities with respect to our long-term debt, see Note 8, Debt, of the Notes to Condensed Consolidated Financial Statements, included in Part I, Item 1 of this Quarterly Report on FormÂ 10â€‘Q. This substantial level of debt could have important consequences to our business, including, but not limited to the factors set forth in â€œRisk Factorsâ€ of our Annual Report on Form 10-K for the year ended DecemberÂ 31,Â 2023, under the heading â€œWe have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial position, and our business would be adversely affected if we are unable to service our debt obligations.â€We believe that our existing cash, cash equivalents and investments balances, cash we expect to generate from operations and funds available under our Revolving Credit Facility will be sufficient to fund our operations and to meet our existing obligations for the foreseeable future. The adequacy of our cash resources depends on many assumptions, including primarily our assumptions with respect to product sales and expenses, as well as the other factors set forth in "Risk Factors" under the heading "Risks Related to our Lead Products and Product Candidatesâ€ in Part I, Item 1A of our Annual Report on Form 10-K for the year ended DecemberÂ 31,Â 2023, as supplemented by the risks described in â€œRisk Factors" under the heading â€œDelays or 44Table of Contentsproblems in the supply of our products for sale or for use in clinical trials, loss of our single source suppliers or failure to comply with manufacturing regulations could materially and adversely affect our business, financial condition, results of operations and growth prospectsâ€ in Part II, Item 1A of this Quarterly Report on Form 10-Q, as well as those factors set forth in â€œRisk Factors" under the heading and â€œTo continue to grow our business, we will need to commit substantial resources, which could result in future losses or otherwise limit our opportunities or affect our ability to operate and grow our businessâ€ in Part I, Item 1A of our Annual Report on Form 10-K for the year ended DecemberÂ 31,Â 2023.Our assumptions may prove to be wrong or other factors may adversely affect our business, and as a result we could exhaust or significantly decrease our available cash resources, and we may not be able to generate sufficient cash to service our debt obligations which could, among other things, force us to raise additional funds and/or force us to reduce our expenses, either of which could have a material adverse effect on our business. To continue to grow our business over the longer term, we plan to commit substantial resources to product acquisition and in-licensing, product development, clinical trials of product candidates and expansion of our commercial, development, manufacturing and other operations. In this regard, we have evaluated and expect to continue to evaluate a wide array of strategic transactions as part of our strategy to acquire or in-license and develop additional products and product candidates. Acquisition opportunities that we pursue could materially affect our liquidity and capital resources and may require us to incur additional indebtedness, seek equity capital or both. We regularly evaluate the performance of our products and product candidates to ensure fit within our portfolio and support efficient allocation of capital. In addition, we may pursue new operations or continue the expansion of our existing operations. Accordingly, we expect to continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to expand our operations or for general corporate purposes. Raising additional capital could be accomplished through one or more public or private debt or equity financings, collaborations or partnering arrangements. However, our ability to raise additional capital may be adversely impacted by worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the U.S. and worldwide resulting from the effects of inflationary pressures, potential future bank failures, or otherwise. Accordingly, we could experience an inability to access additional capital or our liquidity could otherwise be impacted, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make other important, opportunistic investments. In addition, under Irish law we must have authority from our shareholders to issue any ordinary shares, including ordinary shares that are part of our authorized but unissued share capital, and we currently have such authorization. Moreover, as a matter of Irish law, when an Irish public limited company issues ordinary shares to new shareholders for cash, the company must first offer those shares on the same or more favorable terms to existing shareholders on a pro rata basis, unless this statutory pre-emption obligation is dis-applied, or opted-out of, by approval of its shareholders. At our annual general meeting of shareholders in JulyÂ 2024, our shareholders voted to approve our proposal to dis-apply the statutory pre-emption obligation. This current pre-emption opt-out authority is due to expire in JanuaryÂ 2026. If we are unable to obtain further pre-emption authorities from our shareholders in the future, or otherwise continue to be limited by the terms of new pre-emption authorities approved by our shareholders in the future, our ability to use our unissued share capital to fund in-licensing, acquisition or other business opportunities, or to otherwise raise capital, including at the time we are required to make repurchases of the 2026 Notes, the 2030 Notes and/or the Secured Notes, are required to repay outstanding amounts under the Amended Credit Agreement (as defined below), or pay cash upon exchange of the 2026 Notes or the 2030 Notes, could likewise be adversely affected. In any event, an inability to borrow or raise additional capital in a timely manner and on attractive terms could prevent us from expanding our business or taking advantage of acquisition opportunities and could otherwise have a material adverse effect on our business and growth prospects. In addition, if we use a substantial amount of our funds to acquire or in-license products or product candidates, we may not have sufficient additional funds to conduct all of our operations in the manner we would otherwise choose. Furthermore, any equity financing would be dilutive to our shareholders, and could require the consent of the lenders under the Amended Credit Agreement that provides for (i) the Tranche B-2 Dollar Term Loans, (ii) the Euro Term Loan (iii) the Revolving Credit Facility, and the indenture for the Secured Notes for certain financings.45Table of ContentsIn July 2024, our board of directors authorized a share repurchase program to repurchase ordinary shares having an aggregate purchase price of $500.0Â million, exclusive of any brokerage commissions, or the New Repurchase Program. Under the New Repurchase Program, which has no expiration date, we may repurchase ordinary shares from time to time by any methods and/or structures permitted by applicable law. The timing and amount of repurchases will depend on a variety of factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under the Amended Credit Agreement and the indenture for our Secured Notes, corporate and regulatory requirements and market conditions. The New Repurchase Program may be modified, suspended or discontinued at any time without our prior notice. The New Repurchase Program replaces and supersedes the share repurchase program authorized by our board of directors in November 2016, which, as of the date of it being superseded by the New Repurchase Program, had authorized the repurchase of ordinary shares having an aggregate purchase price of up to $1.5Â billion, exclusive of any brokerage commissions, or the Old Repurchase Program, and, together with the New Repurchase Program, the â€œrepurchase programsâ€. During the three months ended September 30, 2024, we spent a total of $150.0Â million to repurchase 1.4Â million of our ordinary shares, all under the New Repurchase Program, at a purchase price, including commissions, of $109.32 per share. The repurchases during the three months ended September 30, 2024 were effected in privately negotiated transactions with or through one of the initial purchasers of the 2030 Notes concurrently with the pricing of the offering of the 2030 Notes. During the nine months ended September 30, 2024, we spent a total of $311.4Â million to purchase 2.8Â million of our ordinary shares under the share repurchase programs at an average total purchase price, including commissions, of $110.06 per share. During the nine months ended September 30, 2023, we spent a total of $170.0Â million to purchase 1.3Â million of our ordinary shares under the Old Repurchase Program at an average total purchase price, including commissions, of $128.89 per share. All ordinary shares repurchased were cancelled. As of September 30, 2024, the remaining amount authorized for repurchases under the New Repurchase Program was $350.0Â million, exclusive of any brokerage commissions.The following table presents a summary of our cash flows for the periods indicated (in thousands): Â Nine Months EndedSeptember 30,Â 20242023Net cash provided by operating activities$997,328Â $924,668Â Net cash used in investing activities(314,908)(264,860)Net cash provided by (used in) financing activities28,791Â (204,948)Effect of exchange rates on cash and cash equivalents614Â (652)Net increase in cash and cash equivalents$711,825Â $454,208Â Operating activitiesNet cash provided by operating activities increased by $72.7Â million in the nine months ended SeptemberÂ 30,Â 2024, compared to the same period in 2023, primarily due to cash received from increased sales of our products and the timing of payment of accrued expenses. Investing activitiesNet cash used in investing activities increased by $50.0Â million in the nine months ended SeptemberÂ 30,Â 2024, compared to the same period in 2023, primarily due to the following:â€¢$30.1Â million net increase in the acquisition of investments, driven by time deposits;â€¢$10.9Â million increase in purchases of property, plant and equipment; andâ€¢ $10.0Â million upfront payment to Redx related to our asset purchase and collaboration agreement in the nine months ended SeptemberÂ 30,Â 2024.Financing activitiesNet cash provided by (used in) financing activities increased by $233.7Â million in the nine months ended SeptemberÂ 30,Â 2024, compared to the same period in 2023, primarily due to:â€¢An increase of $405.8Â million in debt financing due to net proceeds from issuance of the 2030 Notes of $980.8Â million, offset by the repayment of the 2024 Notes of $575.0Â million; partially offset byâ€¢An increase of $141.5Â million in share repurchases; andâ€¢A decrease of $26.2Â million in proceeds from employee equity incentive and purchase plans.46Table of ContentsDebtThe summary of our outstanding indebtedness and scheduled maturities with respect to our long-term debt principal balances is included in Note 8, Debt, of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on FormÂ 10-Q. In January and JulyÂ 2024, we entered into amendments to the Credit Agreement, as described below. In JulyÂ 2024, we made an irrevocable election to fix the settlement method for exchanges of the 2026 Notes and, as a result, an exchanging noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of the 2026 Notes exchanged and (ii) any combination of cash and/or our ordinary shares, for any exchange consideration in excess of $1,000 per $1,000 principal amount of the 2026 Notes. In August 2024, we repaid the $575.0 million aggregate principal amount of the 2024 Notes at maturity, plus accrued and unpaid interest thereon. In September 2024, Jazz Investments I Limited, our wholly owned subsidiary, or Jazz Investments, completed a private offering of an aggregate $1.0 billion principal amount of the 2030 Notes. During the nine months ended SeptemberÂ 30,Â 2024, there were no other changes to our financing arrangements, as set forth in Note 12, Debt, of the Notes to Consolidated Financial Statements included in our Annual Report on FormÂ 10-K for the year ended DecemberÂ 31,Â 2023.Credit Agreement On MayÂ 5,Â 2021, the Company, Jazz Financing Lux S.Ã .r.l., or Jazz Lux, and certain of our other subsidiaries, as borrowers, or, collectively with the Company and Jazz Lux, the â€œBorrowersâ€, entered into the Credit Agreement by and among the Borrowers, the lenders and issuing banks from time to time party thereto, Bank of America, N.A., as administrative agent and U.S. Bank Trust Company, National Association, as collateral trustee, or the Credit Agreement. The Credit Agreement initially provided for (i) the Dollar Term Loan which was drawn by Jazz Lux on the closing date thereof in U.S. dollars (ii) the Euro Term Loan which was drawn by Jazz Lux on the closing date thereof in Euros and (iii) the Revolving Credit Facility.In January 2024, Jazz Lux entered into an amendment, or the Repricing Amendment No.1, to the Credit Agreement. Upon entry into the Repricing Amendment No.1, certain existing lenders converted a portion of the outstanding Dollar Term Loan into a new tranche of U.S. dollar term loans, or the Tranche B-1 Dollar Term Loans, and Jazz Lux borrowed $201.9Â million aggregate principal amount of additional Tranche B-1 Dollar Term Loans, the proceeds of which were used to repay the portion of the outstanding Dollar Term Loan that was not converted. In JulyÂ 2024, Jazz Lux entered into an amendment, or the Repricing Amendment No. 2, to the Credit Agreement, or the Amended Credit Agreement. Upon entry into the Amended Credit Agreement, certain existing lenders converted a portion of the outstanding Tranche B-1 Dollar Term Loans into a new tranche of U.S. dollar term loans, or the Tranche B-2 Dollar Term Loans, and Jazz Lux borrowed $289.6Â million aggregate principal amount of additional Tranche B-2 Dollar Term Loans, the proceeds of which were used to repay the portion of the outstanding Tranche B-1 Dollar Term Loans that were not converted.The Tranche B-2 Dollar Term Loans are a separate class of term loans under the Amended Credit Agreement with the same material terms (including with respect to maturity, prepayment, security, covenants and events of default) as the previously outstanding Tranche B-1 Dollar Term Loans and the initial Dollar Term Loan incurred on May 5, 2021, with the interest rate amended as described below and the credit spread adjustment removed. The principal amount of Tranche B-1 Dollar Term Loans outstanding immediately prior to the Repricing Amendment No. 2 and the outstanding principal amount of Tranche B-2 Dollar Term Loans immediately following the Repricing Amendment No.2, each totaled $2.7Â billion. The Tranche B-2 Dollar Term Loans bear interest at a rate equal to either (a) Term SOFR, or (b) the prime lending rate, in each case, plus an applicable margin. The applicable margin for the Tranche B-2 Dollar Term Loans is 2.25% (in the case of Term SOFR borrowings) and 1.25% (in the case of borrowings at the prime lending rate), a decrease of 75 basis points from the applicable margin on the Tranche B-1 Dollar Term Loans. The Tranche B-2 Dollar Term Loans are subject to a Term SOFR floor of 0.50%. As of SeptemberÂ 30,Â 2024, the interest rate and effective interest rate on the Tranche B-2 Dollar Term Loans were 7.10% and 8.27%, respectively. The Tranche B-2 Dollar Term Loans will amortize in quarterly installments equal to 0.286294791% of the initial aggregate principal amount thereof, with the remaining balance payable on MayÂ 5,Â 2028.The applicable margin for the Revolving Credit Facility ranges from 3.25% to 2.75% (in the case of Term SOFR borrowings) and 2.25% to 1.75% (in the case of borrowings at the prime lending rate), depending on our first lien secured net leverage ratio level, any loans under the Revolving Credit Facility are not subject to a Term SOFR floor. The Revolving Credit Facility has a commitment fee payable on the undrawn amount ranging from 0.50% to 0.40% per annum based upon our first lien secured net leverage ratio. As of SeptemberÂ 30,Â 2024, we had an undrawn Revolving Credit Facility totaling $500.0Â million. 2030 NotesIn September 2024, Jazz Investments completed a private placement of $1.0 billion principal amount of the 2030 Notes. 47Table of ContentsInterest on the 2030 Notes is payable semi-annually in cash in arrears on MarchÂ 15 and SeptemberÂ 15 of each year, beginning on MarchÂ 15,Â 2025, at a rate of 3.125% per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2030 Notes. The 2030 Notes mature on SeptemberÂ 15,Â 2030, unless earlier exchanged, redeemed or repurchased.The holders of the 2030 Notes have the ability to require us to repurchase all or a portion of their 2030 Notes for cash at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date in the event we undergo a fundamental change (as defined in the indenture related to the 2030 Notes), such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from any of The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or The Nasdaq Capital Market (or any of their respective successors). Additionally, the terms and covenants in the indenture related to the 2030 Notes include certain events of default after which the 2030 Notes may be due and payable immediately. Prior to September 15, 2030, we may redeem the 2030 Notes, in whole but not in part, in connection with certain tax-related events. We also may redeem the 2030 Notes on or after September 20, 2027 and prior to June 15, 2030, in whole or in part (subject to the partial redemption limitation described in the indenture related to the 2030 Notes), if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.The 2030 Notes are exchangeable at an initial exchange rate of 6.5339 ordinary shares per $1,000 principal amount of 2030 Notes, which is equivalent to an initial exchange price of approximately $153.05 per ordinary share. Upon exchange of the 2030 Notes, we

will pay cash up to the aggregate principal amount of the 2030 Notes to be exchanged and pay or deliver, as the case may be, cash, ordinary shares or a combination of cash and ordinary shares, at our election, in respect of the remainder, if any, of our exchange obligation in excess of the aggregate principal amount of the 2030 Notes being exchanged. The exchange rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes (as defined in the indenture related to the 2030 Notes) that occur prior to the maturity date or upon our issuance of a notice of redemption, we will, in certain circumstances, increase the exchange rate for a holder who elects to exchange its 2030 Notes in connection with that make-whole fundamental change or exchange its 2030Â Notes called (or deemed called) for redemption during the related redemption period. Prior to JuneÂ 15,Â 2030, the 2030Â Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.Contractual Obligations During the nine months ended SeptemberÂ 30,Â 2024, there were no material changes to our contractual obligations as set forth in Part II, Item 7 â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ in our Annual Report on FormÂ 10-K for the year ended DecemberÂ 31,Â 2023.Critical Accounting EstimatesTo understand our financial statements, it is important to understand our critical accounting estimates. The preparation of our financial statements in conformity with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in determining the amounts to be deducted from gross revenues and also with respect to the acquisition and valuation of intangibles and income taxes. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. For any given individual estimate or assumption we make, there may also be other estimates or assumptions that are reasonable. Although we believe our estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Our critical accounting policies and significant estimates are detailed in our Annual Report on FormÂ 10â€‘K for the year ended DecemberÂ 31,Â 2023. Our critical accounting policies and significant estimates have not changed substantially from those previously disclosed in our Annual Report on FormÂ 10â€‘K for the year ended DecemberÂ 31,Â 2023.48Table of ContentsCautionary Note Regarding Forward-Looking StatementsThis Quarterly Report on FormÂ 10â€‘Q contains forward-looking statements within the meaning of SectionÂ 27A of the Securities Act of 1933, as amended, and SectionÂ 21E of the Securities Exchange Act of 1934, as amended, which are subject to the â€œsafe harborâ€ created by those sections. Forward-looking statements are based on our managementâ€™s current plans, objectives, estimates, expectations and intentions and on information currently available to our management. In some cases, you can identify forward-looking statements by terms such as â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œcould,â€ â€œwould,â€ â€œexpect,â€ â€œplan,â€ â€œanticipate,â€ â€œbelieve,â€ â€œestimate,â€ â€œproject,â€ â€œpredict,â€ â€œpropose,â€ â€œintend,â€ â€œcontinue,â€ â€œpotential,â€ â€œpossible,â€ â€œforeseeable,â€ â€œlikely,â€ â€œunforeseenâ€ and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. These known and unknown risks, uncertainties and other factors include, without limitation:â€¢Our inability to maintain revenues from our oxybate franchise together with high-sodium oxybate AG royalty revenue would have a material adverse effect on our business, financial condition, results of operations and growth prospects.â€¢The introduction of new products in the U.S. market that compete with, or otherwise disrupt the market for, our oxybate products and product candidates has adversely affected and may continue to adversely affect sales of our oxybate products and product candidates.â€¢The distribution and sale of our oxybate products are subject to significant regulatory restrictions, including the requirements of a risk evaluation and mitigation strategy and safety reporting requirements, and these regulatory and safety requirements subject us to risks and uncertainties, any of which could negatively impact sales of Xywav and Xyrem.â€¢While we expect Xywav and Epidiolex/Epidyolex to remain our largest products, our success also depends on our ability to effectively commercialize our other existing products and potential future products. â€¢We face substantial competition from other companies, including companies with larger sales organizations and more experience working with large and diverse product portfolios, and competition from generic drugs.â€¢Adequate coverage and reimbursement from third party payors may not be available for our products and we may be unable to successfully contract for coverage from pharmacy benefit managers and other organizations; conversely, to secure coverage from these organizations, we may be required to pay rebates or other discounts or other restrictions to reimbursement, either of which could diminish our sales or adversely affect our ability to sell our products profitably. â€¢The pricing of pharmaceutical products has come under increasing scrutiny as part of a global trend toward healthcare cost containment and resulting changes in healthcare law and policy, including changes to Medicare, may impact our business in ways that we cannot currently predict, which could have a material adverse effect on our business and financial condition.â€¢In addition to access, coverage and reimbursement, the commercial success of our products depends upon their market acceptance by physicians, patients, third party payors and the medical community.â€¢Delays or problems in the supply of our products for sale or for use in clinical trials, loss of our single source suppliers or failure to comply with manufacturing regulations could materially and adversely affect our business, financial condition, results of operations and growth prospects.â€¢Our future success depends on our ability to successfully develop and obtain and maintain regulatory approvals for our late-stage product candidates and, if approved, to successfully launch and commercialize those product candidates.â€¢We may not be able to successfully identify and acquire or in-license additional products or product candidates to grow our business, and, even if we are able to do so, we may otherwise fail to realize the anticipated benefits of these transactions.â€¢Conducting clinical trials is costly and time-consuming, and the outcomes are uncertain. A failure to prove that our product candidates are safe and effective in clinical trials, or to generate data in clinical trials to support expansion of the therapeutic uses for our existing products, could materially and adversely affect our business, financial condition, results of operations and growth prospects.â€¢It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.â€¢We have incurred, and may in the future incur, substantial costs as a result of litigation or other proceedings relating to patents, other intellectual property rights and related matters, and we may be unable to protect our rights to, or commercialize, our products.49Table of Contentsâ€¢Significant disruptions of information technology systems or data security breaches could adversely affect our business.â€¢We are subject to significant ongoing regulatory obligations and oversight, which may subject us to civil or criminal proceedings, investigations, or penalties and may result in significant additional expense and limit our ability to commercialize our products. â€¢If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.â€¢We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial position, and our business would be adversely affected if we are unable to service our debt obligations.â€¢To continue to grow our business, we will need to commit substantial resources, which could result in future losses or otherwise limit our opportunities or affect our ability to operate and grow our business.Additional discussion of the risks, uncertainties and other factors described above, as well as other risks material to our business, can be found under â€œRisk Factorsâ€ in Part I, Item 1A of our Annual Report on Form 10-K for the year ended DecemberÂ 31,Â 2023, as supplemented by the risks and uncertainties described in "Risk Factors" Part II, Item 1A. in this Quarterly Report on Form 10-Q.Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our plans, objectives, estimates, expectations and intentions only as of the date of this filing. You should read this Quarterly Report on FormÂ 10â€‘Q completely and with the understanding that our actual future results and the timing of events may be materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as required by law, we undertake no obligation to update or supplement any forward-looking statements publicly, or to update or supplement the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.Item 3.Quantitative and Qualitative Disclosures About Market Risk Except as set forth below, during the nine months ended SeptemberÂ 30,Â 2024, there were no material changes to our market risk disclosures as set forth in Part II, Item 7A â€œQuantitative and Qualitative Disclosures About Market Riskâ€ in our Annual Report on FormÂ 10-K for the year ended DecemberÂ 31,Â 2023.Exchangeable Senior Notes 2030In September 2024, Jazz Investments I Limited, our wholly owned subsidiary, completed a private placement of $1.0Â billion aggregate principal amount of the 2030 Notes. The 2030 Notes have a fixed annual interest rate of 3.125% and we therefore do not have economic interest rate exposure on the 2030 Notes. However, the fair value of the 2030 Notes is exposed to interest rate risk. Generally, the fair value of the 2030 Notes will increase as interest rates fall and decrease as interest rates rise. The fair value of the 2030 Notes is also affected by volatility in our ordinary share price. As of September 30, 2024 the fair value of the 2030 Notes was estimated to be $1.0 billion.Item 4.Controls and ProceduresEvaluation of Disclosure Controls and Procedures. We have carried out an evaluation under the supervision and with the participation of management, including our principal executive officer and principal financial officer, of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report on FormÂ 10â€‘Q. Based on their evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of SeptemberÂ 30,Â 2024.Limitations on the Effectiveness of Controls.Â  A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.50Table of ContentsChanges in Internal Control over Financial Reporting.Â  During the quarter ended SeptemberÂ 30,Â 2024, there were no changes to our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.51Table of ContentsPART II â€“ OTHER INFORMATIONItem 1.Legal ProceedingsThe information required to be set forth under this Item 1 is incorporated by reference to Note 9, Commitments and Contingenciesâ€”Legal Proceedings of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on FormÂ 10â€‘Q.Item 1A.Risk FactorsBelow we are providing, in supplemental form, changes to our risk factors from those previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended DecemberÂ 31,Â 2023. Our risk factors disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended DecemberÂ 31,Â 2023, provide additional discussion regarding these supplemental risks and we encourage you to read and carefully consider all of the risk factors disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended DecemberÂ 31,Â 2023, together with the below, for a more complete understanding of the risks and uncertainties material to our business. Delays or problems in the supply of our products for sale or for use in clinical trials, loss of our single source suppliers or failure to comply with manufacturing regulations could materially and adversely affect our business, financial condition, results of operations and growth prospects.The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of process controls required to consistently produce the API and the finished product in sufficient quantities while meeting detailed product specifications on a repeated basis. We and our suppliers may encounter difficulties in production, including difficulties with the supply of manufacturing materials, production costs and yields, process controls, quality control and quality assurance, including testing of stability, impurities and impurity levels and other product specifications by validated test methods, and compliance with strictly enforced U.S., state and non-U.S. regulations. In addition, we and our suppliers are subject to FDAâ€™s current Good Manufacturing Practices, or cGMP, requirements, federal and state controlled substances obligations and equivalent rules and regulations prescribed by non-U.S. regulatory authorities. If we or any of our suppliers encounter manufacturing, quality or compliance difficulties with respect to any of our products, whether due to the ongoing military conflict in Ukraine and related sanctions imposed against Russia (including as a result of disruptions of global shipping, the transport of products, energy supply, cybersecurity incidents and banking systems as well as of our ability to control input costs) or otherwise, we may be unable to obtain or maintain regulatory approval or meet commercial demand for such products, which could adversely affect our business, financial condition, results of operations and growth prospects. In addition, we could be subject to enforcement action by regulatory authorities for our failure to comply with cGMP with respect to the products we manufacture in our facilities as well as for our failure to adequately oversee compliance with cGMP by any of our third party suppliers operating under contract. Moreover, failure to comply with applicable legal and regulatory requirements subjects us and our suppliers to possible regulatory action, including restrictions on supply or shutdown, which may adversely affect our or a supplierâ€™s ability to supply the ingredients or finished products we need. We have a manufacturing and development facility in Athlone, Ireland where we manufacture Xywav and Xyrem, a manufacturing plant in Villa Guardia, Italy where we produce the defibrotide drug substance and a manufacturing and development facility in the U.K. at Kent Science Park, where we produce Epidiolex/Epidyolex and have capability to develop product candidates. We currently do not have our own commercial manufacturing or packaging capability for our other products, their APIs or product candidates outside of those developed at Kent Science Park. As a result, our ability to develop and supply products in a timely and competitive manner depends primarily on third party suppliers being able to meet our ongoing commercial and clinical trial needs for API, other raw materials, packaging materials and finished products. In part due to the limited market size for our products and product candidates, we have a single source of supply for most of our marketed products, product candidates and their APIs. Single sourcing puts us at risk of interruption in supply in the event of manufacturing, quality or compliance difficulties. If one of our suppliers fails or refuses to supply us for any reason, it would take a significant amount of time and expense to implement and execute the necessary technology transfer to, and to qualify, a new supplier. FDA and similar international or national regulatory bodies must approve manufacturers of the active and inactive pharmaceutical ingredients and certain packaging materials used in our products. If there are delays in qualifying new suppliers or facilities or a new supplier is unable to meet FDAâ€™s or similar international regulatory bodyâ€™s requirements for approval, there could be a shortage of the affected products for the marketplace or for use in clinical studies, or both, which could negatively impact our anticipated revenues and could potentially cause us to breach contractual obligations with customers or to violate local laws requiring us to deliver the product to those in need. We are responsible for the manufacture and supply of Epidiolex/Epidyolex for commercial use and for use in clinical trials. The manufacturing of Epidiolex/Epidyolex necessitates compliance with Good Manufacturing Practice, or GMP, and 52Table of Contentsother regulatory requirements in jurisdictions internationally. Our ability to successfully manufacture Epidiolex/Epidyolex involves cultivation of botanical raw material from specific cannabinoid plants, extraction and purification processes, manufacture of finished products and labeling and packaging, which includes product information, tamper evidence and anti-counterfeit features, under tightly controlled processes and procedures. In addition, we must ensure chemical consistency among our batches, including clinical batches and, if approved, marketing batches. Demonstrating such consistency may require typical manufacturing controls as well as clinical data. We must also ensure that our batches conform to complex release specifications. We have a second site at which we can grow the specific cannabinoid plants that produce the CBD used in Epidiolex/Epidyolex and a second site at which we can crystallize the purified CBD from the liquid plant extract. If we are unable to manufacture Epidiolex/Epidyolex in accordance with regulatory specifications, including GMP, or if there are disruptions in our manufacturing process due to damage, loss or otherwise, or failure to pass regulatory inspections of our manufacturing facilities, we may not be able to meet current demand or supply sufficient product for use in clinical trials, and this may also harm our ability to commercialize Epidiolex/Epidyolex on a timely or cost-competitive basis, if at all. Our manufacturing program requires significant time and resources and may not be successful, may lead to delays, interruptions to supply or may prove to be more costly than anticipated. Vyxeos is manufactured by Simtra Biopharma Solutions, which is a sole source supplier from a single site location. Moreover, the proprietary technology that supports the manufacture of Vyxeos is not easily transferable. Consequently, engaging an alternate manufacturer may be difficult, costly and time-consuming. If we fail to obtain a sufficient supply of Vyxeos in accordance with applicable specifications on a timely basis, our sales of Vyxeos, our future maintenance and potential growth of the market for this product, our ability to conduct ongoing and future clinical trials of Vyxeos, and our business, financial condition, results of operations and growth prospects could be materially adversely affected. Rylaze drug substance is manufactured by AGC Biologics A/S at its facility in Copenhagen, Denmark and the drug product is manufactured and packaged by Patheon at its facility in Greenville, North Carolina. To successfully manufacture Rylaze, the manufacturer must have an adequate master and working cell bank. If we fail to obtain a sufficient supply of Rylaze in accordance with applicable specifications on a timely basis, our sales of Rylaze, our future maintenance and potential growth of the market for this product, our competitive advantage over competing products that have supply constraints, and our business, financial condition, results of operations and growth

prospects could be materially adversely affected. In addition, in order to conduct our ongoing and any future clinical trials of, complete marketing authorization submissions for, and potentially launch our other product candidates, we also need to have sufficient quantities of product manufactured. We currently rely on WuXi Biologics Co., Ltd., or WuXi, a company based in the People's Republic of China, or PRC, as the sole supplier of our product candidate, zanidatamab. Accordingly, there is a risk that supplies of our product candidate may be significantly delayed by, or may become unavailable as a result of, manufacturing, equipment, process, regulatory or business-related issues affecting that company. We may also face additional manufacturing and supply-chain risks due to the regulatory and political structure of the PRC, or as a result of the international relationship between the PRC and the U.S., including but not limited to potential sanctions imposed by the U.S. government on WuXi. Although to date there has been no impact on our ability to obtain supply of zanidatamab, there can be no assurance that operations would not be impacted in the future with a negative impact on supply of our product candidate.Moreover, to obtain approval from FDA or a similar international or national regulatory body of any product candidate, including zanidatamab, we or our suppliers for that product must obtain approval by the applicable regulatory body to manufacture and supply product, in some cases based on qualification data provided to the applicable body as part of our regulatory submission. Any delay in generating, or failure to generate, data required in connection with submission of the chemistry, manufacturing and controls portions of any regulatory submission could negatively impact our ability to meet our anticipated submission dates, and therefore our anticipated timing for obtaining FDA or similar international or national regulatory body approval, or our ability to obtain regulatory approval at all. In addition, any failure of us or a supplier to obtain approval by the applicable regulatory body to manufacture and supply product or any delay in receiving, or failure to receive, adequate supplies of a product on a timely basis or in accordance with applicable specifications could negatively impact our ability to successfully launch and commercialize products and generate sales of products at the levels we expect.53Table of ContentsItem 2.Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity SecuritiesIssuer Purchases of Equity Securities The following table summarizes purchases of our ordinary shares made by or on behalf of us or any of our â€œaffiliated purchasersâ€ as defined in Rule 10b-18(a)(3) under the Securities Exchange Act of 1934, as amended, during each fiscal month during the three-month period ended SeptemberÂ 30, 2024:Total Number of Shares Purchased (1)Average Price Paid per Share (2)Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (3)Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs (4)July 1 - July 31, 2024â€”Â $â€”Â â€”Â $500,000,000Â August 1 - August 31, 2024â€”Â $â€”Â â€”Â $500,000,000Â September 1 - September 30, 20241,372,119Â $109.32Â 1,372,119Â $349,999,951Â Total1,372,119Â $109.32Â 1,372,119Â 1.This table does not include ordinary shares that we withheld in order to satisfy tax withholding requirements in connection with the vesting and release of restricted stock units. All the ordinary shares reported in this column were purchased pursuant to our publicly announced share repurchase program.2.Average price paid per ordinary share includes brokerage commissions.3.On July 31, 2024, we announced that our board of directors had authorized the use of up to $500.0 million to repurchase our ordinary shares, or the New Repurchase Program. Under the New Repurchase Program, which has no expiration date, we may repurchase ordinary shares from time to time by any methods and/or structures permitted by applicable law. The timing and amount of repurchases will depend on a variety of factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under our outstanding credit agreement and the indenture for our Secured Notes, corporate and regulatory requirements and market conditions. The New Repurchase Program may be modified, suspended or discontinued at any time without our prior notice. The ordinary shares reported in the table above were purchased pursuant to the New Repurchase Program. The New Repurchase Program replaces and supersedes the share repurchase program authorized by our board of directors in November 2016, which, as of July 25, 2024, the date it was replaced and superseded by the New Repurchase Program, had authorized the repurchase of ordinary shares having an aggregate purchase price of up to $1.5 billion, exclusive of any brokerage commissions, or the Old Repurchase Program. On July 25, 2024, the amount remaining authorized for repurchase under the Old Repurchase Program was $47,475, exclusive of any brokerage commissions, which amount is included in the $500.0 million authorized for repurchase under the New Repurchase Program. 4.The dollar amount shown represents, as of the end of each period, the approximate dollar value of ordinary shares that may yet be purchased under the New Repurchase Program, exclusive of any brokerage commissions. 54Table of ContentsItem 6.ExhibitsExhibitNumberDescription of Document2.1â€¡Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals PLC (incorporated herein by reference to Exhibit 2.1 in Jazz Pharmaceuticals plcâ€™s Current Report on Form 8-K (File No. 001-33500), as filed with the SEC on February 4, 2021).3.1Amended and Restated Memorandum and Articles of Association of Jazz Pharmaceuticals plc, as amended on August 4, 2016 (incorporated herein by reference to Exhibit 3.1 in Jazz Pharmaceuticals plcâ€™s Quarterly Report on Form 10-Q (File No.Â 001-33500) for the period ended June 30, 2016, as filed with the SEC on August 9, 2016).10.1Indenture, dated as of September 6, 2024 among Jazz Pharmaceuticals Public Limited Company, Jazz Investments I Limited and U.S. Bank Trust Company, National Association (incorporated by reference to Exhibit 4.1 in Jazz Pharmaceuticals plcâ€™s Current Report on Form 8-K (File No. 001-033500), as filed with the SEC on September 6, 2024).10.2Form of 3.125% Exchangeable Senior Note due 2030 (incorporated by reference to Exhibit 4.2 in Jazz Pharmaceuticals plcâ€™s Current Report on Form 8-K (File No. 001-033500), as filed with the SEC on September 6, 2024).31.1Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.31.2Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.32.1*Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.101.INSXBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document101.SCHInline XBRL Taxonomy Extension Schema With Embedded Linkbase Document104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)_____â€¡Â Â Â Â Certain portions of this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K.*Â Â Â Â The certification attached as ExhibitÂ 32.1 accompanies this Quarterly Report on FormÂ 10â€’Q pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed â€œfiledâ€ by the Registrant for purposes of SectionÂ 18 of the Securities Exchange Act of 1934, as amended.55Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.Date: November 7, 2024 Â  JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY(Registrant)/s/ Bruce C. CozaddBruce C. CozaddChairmanÂ andÂ ChiefÂ ExecutiveÂ OfficerÂ andÂ Director(Principal Executive Officer)/s/ Philip L. JohnsonPhilip L. JohnsonExecutive Vice President and Chief Financial Officer(Principal Financial Officer)/s/ Patricia CarrPatricia CarrSenior Vice President, Chief Accounting Officer(Principal Accounting Officer)56 EX-31.1 2 jazzq32024ex311.htm CERTIFICATION OF CEO PURSUANT TO RULES 13A-14(A) AND 15D-14(A) DocumentExhibit 31.1 CERTIFICATION I, Bruce C. Cozadd, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Jazz PharmaceuticalsÂ public limited company;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;Â 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andÂ 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Â Date: November 7, 2024By:/s/Â Â Â Â BruceÂ C.Â CozaddBruceÂ C.Â CozaddChairman and ChiefÂ ExecutiveÂ Officer and Director EX-31.2 3 jazzq32024ex312.htm CERTIFICATION OF CFO PURSUANT TO RULES 13A-14(A) AND 15D-14(A) DocumentExhibit 31.2 CERTIFICATION I, Philip L. Johnson, certify that: Â 1.I have reviewed this Quarterly Report on Form 10-Q of Jazz Pharmaceuticals public limited company;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):Â a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Â Date: November 7, 2024By:/s/Â Â Â Â Philip L. JohnsonPhilip L. JohnsonExecutive Vice President and Chief Financial OfficerÂ Â Â Â Â Â Â Â Â Â  EX-32.1 4 jazzq32024ex321.htm CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350 DocumentExhibit 32.1 CERTIFICATION(1)Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), and SectionÂ 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. SectionÂ 1350), Bruce C. Cozadd, Chief Executive Officer of Jazz Pharmaceuticals public limited company (the â€œCompanyâ€), and Philip L. Johnson, Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: Â 1.The Companyâ€™s Quarterly Report on Form 10-Q for the period ended SeptemberÂ 30, 2024, to which this Certification is attached as Exhibit 32.1 (the â€œPeriodic Reportâ€), fully complies with the requirements of SectionÂ 13(a) or SectionÂ 15(d) of the Exchange Act; and2.The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: November 7, 2024 Â /s/Â Â Â Â Â Bruce C. CozaddBruce C. CozaddChairman and ChiefÂ ExecutiveÂ Officer and Director (Principal Executive Officer)/s/ Â Â Â Â Philip L. JohnsonPhilip L. JohnsonExecutive Vice President and Chief Financial Officer(Principal Accounting Officer)Â _____(1)This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Jazz Pharmaceuticals public limited company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the FormÂ 10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by SectionÂ 906 of the Sarbanes-Oxley Act of 2002 has been provided to Jazz Pharmaceuticals public limited company and will be retained by Jazz Pharmaceuticals public limited company and furnished to the Securities and Exchange Commission or its staff upon request. EX-101.SCH 5 jazz-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERSâ€™ EQUITY link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - The Company and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Cash and Available-for-Sale Securities link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Derivative Instruments and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Certain Balance Sheet Items link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Net Income per Ordinary Share link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Cash and Available-for-Sale Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Certain Balance Sheet Items (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Net Income per Ordinary Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - The Company and Summary of Significant Accounting Policies - Basis of Presentation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - The Company and Summary of Significant Accounting Policies - Concentrations of Risk (Narrative)

(Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Cash and Available-for-Sale Securities - Schedule of Cash, Cash Equivalents and Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Cash and Available-for-Sale Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Fair Value Measurement - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Foreign Exchange Gain (Loss) Associated with Foreign Exchange Contracts Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Impact on Accumulated Other Comprehensive [Loss] and Earnings from Derivative Instruments that Qualified as Cash Flow Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Fair Value of Outstanding Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Offsetting Assets and Offsetting Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Goodwill and Intangible Assets - Schedule of Gross Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Goodwill and Intangible Assets - Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Certain Balance Sheet Items - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Certain Balance Sheet Items - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Debt - Schedule of Carrying Amount of Indebtedness (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Debt - Schedule of Carrying Amount of Indebtedness (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Debt - Credit Agreement Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Debt - 2030 Notes Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Debt - Exchangeable Senior Notes Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Debt - Schedule of Maturities of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Shareholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Shareholders' Equity - Schedule of Components of Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Net Income per Ordinary Share - Schedule of Basic and Diluted Net Income Per Ordinary Share Computation (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Net Income per Ordinary Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Net Income per Ordinary Share - Schedule of Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Revenues - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Revenues - Schedule of Percentage of Total Revenues from Customers (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Revenues - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Share-Based Compensation - Schedule of Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Share-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Share-Based Compensation - Schedule of Performance-Based Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 jazz-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 jazz-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 jazz-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Derivative Financial Instruments Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Remaining amount authorized for repurchase of shares Share Repurchase Program, Remaining Authorized, Amount Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Schedule of Cash, Cash Equivalents and Investments Cash, Cash Equivalents and Investments [Table Text Block] Cover [Abstract] Cover [Abstract] Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Income Tax Authority [Domain] Income Tax Jurisdiction [Domain] Trading Symbol Trading Symbol Asset derivatives Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement Interest rate contracts Gross Amounts of Recognized Assets/ Liabilities Derivative Asset, Subject to Master Netting Arrangement, before Offset Schedule of Basic and Diluted Net Income Per Ordinary Share Computation Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Income tax benefit from share-based compensation expense Share-Based Payment Arrangement, Expense, Tax Benefit Rylaze/Enrylaze Rylaze/Enrylaze [Member] Rylaze/Enrylaze Derivative [Line Items] Derivative [Line Items] Xyrem Xyrem [Member] Xyrem [Member] Debt instrument, convertible, number of shares per principal amount basis (in shares) Debt Instrument, Convertible, Conversion Ratio Income tax (benefit) expense effect on cash flow hedging activities Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Accounts receivable Increase (Decrease) in Accounts Receivable Derivative [Table] Derivative [Table] Income Taxes [Table] Income Tax Contingency [Table] Clinical trial accruals Accrued Clinical Trial Liability, Current Accrued Clinical Trial Liability, Current Issuance of ordinary shares in conjunction with vesting of restricted stock units and performance-based restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Hedging Relationship [Domain] Hedging Relationship [Domain] Schedule of Fair Value of Outstanding Derivatives Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Fair Value Measurement Fair Value Disclosures [Text Block] Inventory-related accruals Accrued Inventory Related Liabilities, Current Accrued Inventory Related Liabilities, Current Total share-based compensation expense, net of tax Share-Based Payment Arrangement, Expense, after Tax FDA stay of approval period FDA Stay Of Approval Period FDA Stay Of Approval Period Gain (loss) recognized in foreign exchange loss Derivative, Gain (Loss) on Derivative, Net 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Thereafter Finite-Lived Intangible Asset, Expected Amortization, After Year Four Finite-Lived Intangible Asset, Expected Amortization, After Year Four Contractual coupon rate interest expense Interest Expense, Debt, Contractual Coupon Rate Interest Expense, Debt, Contractual Coupon Rate Operating lease liabilities, less current portion Operating Lease, Liability, Noncurrent Cash Flow Hedges Cash Flow Hedging [Member] Significant Risks and Uncertainties Significant Risks And Uncertainties [Policy Text Block] Describes risks and uncertainties related to the pharmaceutical industry. Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] United States UNITED STATES Other non-current assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Teamsters and GEHA Lawsuits Teamsters And GEHA Lawsuits [Member] Teamsters And GEHA Lawsuits [Member] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Schedule of Carrying Amount of Indebtedness Schedule of Long-Term Debt Instruments [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Money market funds Money Market Funds [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Net proceeds from issuance of exchangeable senior notes, due 2030 Proceeds from Convertible Debt Effect of interest on assumed conversions of Exchangeable Senior Notes, net of tax Interest on Convertible Debt, Net of Tax Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Income taxes payable Taxes Payable, Current Net income per ordinary share: Earnings Per Share Reconciliation [Abstract] Schedule of Components of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Prepaid expenses Prepaid Expense, Current Equity Components [Axis] Equity Components [Axis] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Other current assets Other Assets, Current Estimated Fair Value Available-for-sale securities Debt Securities, Available-for-Sale Epidiolex/Epidyolex Epidiolex/Epidyolex [Member] Epidiolex/Epidyolex Measurement Frequency [Axis] Measurement Frequency [Axis] Tranche B 2 Dollar Term Loan Tranche B 2 Dollar Term Loan [Member] Tranche B 2 Dollar Term Loan Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Use of Estimates Use of Estimates, Policy [Policy Text Block] Total operating expenses Costs and Expenses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Number of days requested for FDA to take action Plaintiff, Number Of Days Requested For FDA To Take Action Plaintiff, Number Of Days Requested For FDA To Take Action Additional paid-in capital Additional Paid in Capital, Common Stock Smaller Reporting Company Entity Small Business Acquired developed technologies Developed Technology Rights [Member] Geographical [Axis] Geographical [Axis] Inventory, step-up value Inventory, Step-Up Value Inventory, Step-Up Value Exchangeable Senior Notes Due 2026 2026 Notes Exchangeable Senior Notes Due 2026 [Member] Exchangeable Senior Notes Due 2026 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Repurchase Programs November 2016 Share Repurchase Program And July 2024 Share Repurchase Program [Member] November 2016 Share Repurchase Program And July 2024 Share Repurchase Program Shares repurchased Stock Repurchased During Period, Value Schedule of Subsidiary or Equity Method Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock [Table] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Issuance of ordinary shares under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Ordinary shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Cash and Available-for-Sale Securities Cash, Cash Equivalents, and Short-Term Investments [Text Block] Credit Facility [Domain] Credit Facility [Domain] Cash and cash equivalents, at beginning of period Cash and cash equivalents, at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Selling and marketing accruals Accrued Marketing Costs, Current Unrecognized compensation cost related to unvested RSU's, PRSUs, ESPP and share options Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets: Assets, Current [Abstract] Goodwill Goodwill, beginning of period Goodwill, end of period Goodwill Jazz Investments I Limited Jazz Investments I Limited [Member] Jazz Investments I Limited [Member] Payment of employee withholding taxes related to share-based awards Payment, Tax Withholding, Share-Based Payment Arrangement Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Total amount authorized for repurchase of shares under share repurchase program Share Repurchase Program, Authorized, Amount Inventories Inventory Disclosure [Text Block] Prime Rate Prime Rate [Member] Product and Service [Domain] Product and Service [Domain] Stock Option Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Foreign exchange forward contracts Foreign Exchange Forward [Member] Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Depreciation Depreciation Net asset (liability) fair value Derivative, Fair Value, Net Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Security Exchange Name Security Exchange Name Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Award Type [Axis] Award Type [Axis] Cost of product sales (excluding amortization of acquired developed technologies) Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment Total costs related to goods produced and sold during the reporting period excluding amortization of acquired developed technologies and intangible asset impairment presented separately. Accrued collaboration expenses Accrued Collaboration Costs, Current Accrued Collaboration Costs, Current Foreign exchange Goodwill, Foreign Currency Translation Gain (Loss) Net income per ordinary share: Net Income Loss Per Ordinary Share [Abstract] Net Income Loss Per Ordinary Share Work in process Inventory, Work in Process, Net of Reserves Convertible Debt Convertible Debt Convertible Debt [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Remaining Weighted-AverageÂ Useful Life (In years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life FDA recognition of orphan drug exclusivity, period FDA Recognition Of Orphan Drug Exclusivity, Period FDA Recognition Of Orphan Drug Exclusivity, Period Revolving Credit Facility Revolving Credit Facility [Member] Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Deferred financing costs Debt Issuance Costs, Noncurrent, Net Offsetting Liabilities [Line Items] Offsetting Liabilities [Line Items] Debt instrument, convertible, threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Income taxes payable Increase (Decrease) in Income Taxes Payable Entity [Domain] Entity [Domain] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Percentage of gross accounts receivable (as a percent) Percentage of total revenues (as a percent) Concentration Risk, Percentage Computer equipment Computer Equipment [Member] Derivative liability Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet Derivative Liability Secured Notes Senior Notes Due 2029 [Member] Senior Notes Due 2029 Issuance of ordinary shares in conjunction with exercise of share options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Debt Instrument [Line Items] Debt Instrument [Line Items] Research and development Research and Development Expense [Member] Europe Europe [Member] Less accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Cash Cash [Member] Xywav Xywav [Member] Xywav Weighted-average ordinary shares used in per share calculations - diluted (in shares) Weighted-average ordinary shares used in per share calculations - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Accrued liabilities Accrued Liabilities [Member] 2024 (remainder) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Decrease in basis spread on variable rate Debt Instrument, Decrease In Basis Spread On Variable Rate Debt Instrument, Decrease In Basis Spread On Variable Rate Total shareholdersâ€™ equity Beginning balance Ending balance Equity, Attributable to Parent Sales return reserve Sales Return Reserve, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales returns reserve. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Litigation Case [Axis] Litigation Case [Axis] Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Deferred tax benefit Deferred Income Tax Expense (Benefit) Schedule of Gross Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Computer software Software and Software Development Costs [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Selling, general and administrative Selling, General and Administrative Expense Entity Address, Country Entity Address, Country Repayment of exchangeable senior notes, due 2024 Repayments of convertible debt Repayments of Convertible Debt Other comprehensive income (loss) Other comprehensive (loss) income Other comprehensive income (loss), net Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Income Taxes [Line Items] Income Tax Contingency [Line Items] Recurring Fair Value, Recurring [Member] Accounts receivable, net of allowances Accounts Receivable, after Allowance for Credit Loss, Current Debt instrument, convertible, conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Cost of product sales Cost of Sales [Member] Percentage of ownership (as a percent) Subsidiary, Ownership Percentage, Parent Pro Forma Pro Forma [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total debt Long-Term Debt Tax expense effect on cash flow hedging activities reclassified Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Document Fiscal period Focus Document Fiscal Period Focus 2028 Long-Term Debt, Maturity, Year Four Dilutive effect of employee equity incentive and purchase plans (in shares) Incremental Common Shares Attributable

to Dilutive Effect of Share-Based Payment Arrangements Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two ASSETS Assets [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Document Type Document Type Line of credit facility, commitment fee percentage (as a percentage) Line of Credit Facility, Commitment Fee Percentage Effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Derivative Contract [Domain] Derivative Contract [Domain] Performance-Based Restricted Stock Units (PRSUs) Performance-Based Restricted Stock Units (RSUs) [Member] Performance-Based Restricted Stock Units (RSUs) Average price of shares repurchased (in dollars per share) Shares Acquired, Average Cost Per Share Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Schedule of Estimated Future Amortization Expenses Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Inventory, Current [Table] Inventory, Current [Table] Maximum Maximum [Member] Available-for-sale securities: Debt Securities, Available-for-Sale [Abstract] Intangible asset amortization Intangible asset amortization Amortization of Intangible Assets 2021 Credit Agreement, Euro Term Loan Two Thousand Twenty One Credit Agreement, Euro Term Loan [Member] Two Thousand Twenty One Credit Agreement, Euro Term Loan Furniture and fixtures Furniture and Fixtures [Member] Total Finite-Lived Intangible Assets, Net Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Gross Amounts Not Offset in the Consolidated Balance Sheet Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction [Abstract] Revenues: Revenues [Abstract] Leasehold improvements Leasehold Improvements [Member] Schedule of Offsetting Liabilities Offsetting Liabilities [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date All other Other Countries [Member] Other Countries [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Rebates and other sales deductions Accrued Rebates And Other Sales Deductions, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates and other sales deductions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Award Type [Domain] Award Type [Domain] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Non-voting euro deferred shares Nonvoting Euro Deferred Shares Shares issued to satisfy statutory minimum of Euro-denominated share capital required for a public limited company incorporated in Ireland. Country Region Country Region Schedule of Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Deferred tax assets, net Deferred Income Tax Assets, Net Other comprehensive income before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Additional Paid-in Capital Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Credit facility expiration period Line of Credit Facility, Expiration Period Redemption price, percentage Debt Instrument, Redemption Price, Percentage Zepzelca Zepzelca [Member] Zepzelca 2021 Credit Agreement, Revolving Credit Facility Two Thousand Twenty One Credit Agreement, Revolving Credit Facility [Member] Two Thousand Twenty One Credit Agreement, Revolving Credit Facility Adoption of New Accounting Standards and Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Debt Long-Term Debt [Text Block] Diluted (in dollars per share) Diluted (in dollars per share) Earnings Per Share, Diluted Number of patents, paragraph IV certification notice filed Number Of Patents, Paragraph IV Certification Notice Filed Number Of Patents, Paragraph IV Certification Notice Filed Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Acquired in-process research and development Payments To Acquire In Process Research And Development Other Than Through Business Combination Payments To Acquire In Process Research And Development Other Than Through Business Combination Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Entity Interactive Data Current Entity Interactive Data Current Deferred revenue Increase (Decrease) in Contract with Customer, Liability Employee compensation and benefits Accrued Employee Benefits, Current Summary Of Deferred Revenue [Table] Summary Of Deferred Revenue [Table] Summary Of Deferred Revenue [Table] Ownership [Axis] Ownership [Axis] Number of operating business segments Number of Operating Segments Foreign exchange loss Gain (Loss), Foreign Currency Transaction, before Tax Customer [Axis] Customer [Axis] Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Schedule of Percentage of Total Revenues from Customers Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Teva Lawsuit Teva Lawsuit [Member] Teva Lawsuit Derivative Financial Instruments Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Security Not Offset Liability derivatives Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement Repayments of long-term debt Repayments of Secured Debt Income tax benefit Income tax benefit Income Tax Expense (Benefit) Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Notional amount Derivative, Notional Amount Foreign exchange forward contracts Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet Derivative Asset Weighted-average period expected to be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Net income for dilutive net income per ordinary share Net Income (Loss) Available to Common Stockholders, Diluted Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Schedule of Foreign Exchange Gain (Loss) Associated with Foreign Exchange Contracts Not Designated as Hedging Instruments Derivative Instruments, Gain (Loss) [Table Text Block] ESSDS Express Scripts [Member] Express Scripts 1 [Member] Other non-current liabilities Increase (Decrease) in Other Noncurrent Liabilities Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Senior Secured Debt Senior Secured Debt [Member] Senior Secured Debt Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Income from operations Operating Income (Loss) Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Income Tax Authority [Axis] Income Tax Jurisdiction [Axis] Variable Rate [Domain] Variable Rate [Domain] Research and development Research and Development Expense (Excluding Acquired in Process Cost) Total liabilities and shareholdersâ€™ equity Liabilities and Equity Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Hedging Designation [Axis] Hedging Designation [Axis] Derivative instrument liabilities Derivative Liability, Current Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Interest income from available-for-sale securities Investment Income, Interest Interest expense, net Interest Income (Expense), Nonoperating Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Restricted Stock Units Activity and Performance-Based Restricted Stock Units Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] New Repurchase Program July 2024 Share Repurchase Program [Member] July 2024 Share Repurchase Program Schedule of Maturities of Long-Term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] The Company and Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Scenario [Domain] Scenario [Domain] Defitelio/defibrotide Defitelio/Defibrotide [Member] Defitelio/Defibrotide [Member] Shares withheld for payment of employee's withholding tax liability Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Accumulated Other Comprehensive Loss Total Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Net Unrealized Gain From Hedging Activities Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Inventories Total inventories Inventory, Net Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Other Other Products [Member] Other Products [Member] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Accrued facilities expenses Accrued Facilities Expenses, Current Accrued Facilities Expenses, Current Operating lease assets Increase (Decrease) In Operating Lease Assets Increase (Decrease) In Operating Lease Assets Operating expenses: Operating Expenses [Abstract] Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Financial Instruments [Domain] Financial Instruments [Domain] LIABILITIES AND SHAREHOLDERSâ€™ EQUITY Liabilities and Equity [Abstract] Proposed additional tax including interest and penalties Income Tax Examination, Estimate of Possible Loss Offsetting Assets [Line Items] Offsetting Assets [Line Items] Number of lawsuits filed Loss Contingency, New Claims Filed, Number Financing and Payment [Line Items] Summary Of Deferred Revenue [Line Items] [Line Items] for Summary Of Deferred Revenue [Table] Minimum Minimum [Member] Offsetting Liabilities [Table] Offsetting Liabilities [Table] Unamortized - debt issuance costs Unamortized Debt Issuance Expense Fair value of secured debt Notes Payable, Fair Value Disclosure Interest rate contracts Interest Rate Contract [Member] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Concentration Risk [Table] Concentration Risk [Table] Operating lease assets Operating Lease, Right-of-Use Asset Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Non-voting Euro Deferred Euro Deferred Shares [Member] Euro Deferred Shares [Member] Royalty rate for future sale (as a percent) Royalty Rate For Future Sale, Percentage Royalty Rate For Future Sale, Percentage Inventory [Line Items] Inventory [Line Items] Derivative Instrument [Axis] Derivative Instrument [Axis] Achievement target, percentage of awards granted Share-Based Compensation Arrangement By Share-Based Payment Award, Achievement Target, Percentage Of Awards Granted Share-Based Compensation Arrangement By Share-Based Payment Award, Achievement Target, Percentage Of Awards Granted Long term debt outstanding Total Long-Term Debt, Gross Fair value of lines of credit Lines of Credit, Fair Value Disclosure Totals Financial Liabilities Fair Value Disclosure Net Income per Ordinary Share Earnings Per Share [Text Block] Total Neuroscience Total Neuroscience [Member] Total Neuroscience Schedule of Impact on Accumulated Other Comprehensive [Loss] and Earnings from Derivative Instruments that Qualified as Cash Flow Hedges Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Issuance of ordinary shares under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of ordinary shares in conjunction with exercise of share options Stock Issued During Period, Value, Stock Options Exercised Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Unrealized gain (loss) on cash flow hedging activities, net of income tax (benefit) expense of $(1,727), $1,176, $522 and $3,063 respectively Gain (loss) recognized in accumulated other comprehensive loss, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Shareholdersâ€™ equity: Equity, Attributable to Parent [Abstract] Grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Investments Investments Investments Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Number of days provided to delist patent Number Of Days Provided To Delist Patent Number Of Days Provided To Delist Patent Term (in years) Debt Instrument, Term 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Provision for losses on accounts receivable and inventory Provision For Losses On Accounts Receivable And Inventory Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction off the carrying amount of inventory, generally attributable to obsolescence or market conditions. Acquisition accounting inventory fair value step-up adjustment Inventory Step-Up Value Adjustment The noncash expense recognized in the current period from the amortization of acquired inventory written up to fair value in purchase accounting Sativex Sativex [Member] Sativex Current portion of lease liabilities Operating And Finance Lease, Liability, Current Operating And Finance Lease, Liability, Current Variable Rate [Axis] Variable Rate [Axis] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Payment terms, range Revenue, Performance Obligation, Payment Terms Revenue, Performance Obligation, Payment Terms Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Other non-current assets Increase (Decrease) in Other Noncurrent Assets Proceeds from employee equity incentive and purchase plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised High-sodium oxybate AG royalty revenue High Sodium AG Oxybate Product Royalty Revenue [Member] High Sodium AG Oxybate Product Royalty Revenue Equity in loss (gain) of investees Income (Loss) from Equity Method Investments 2024 (remainder) Long-Term Debt, Maturity, Remainder of Fiscal Year Income before income tax benefit and equity in loss (gain) of investees Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Assets: Assets, Fair Value Disclosure [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Local Phone Number Local Phone Number Deferred tax liabilities, net Deferred Income Tax Liabilities, Net Net Amount Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Shares repurchased (in shares) Stock Repurchased During Period, Shares Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Gross Amounts of Recognized Assets/ Liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Accrued interest Interest Payable, Current Share Repurchase Program [Domain] Share Repurchase Program [Domain] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Irrevocable election for settlement method fix, maximum cash per $1,000 principal amount Debt Instrument, Irrevocable Election For Settlement Method Fix, Maximum Cash Per $1,000 Principal Amount Debt Instrument, Irrevocable Election For Settlement Method Fix, Maximum Cash Per $1,000 Principal Amount Ordinary Shares Common Stock [Member] Cash Collateral Received (Pledged) Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset Accrued construction-in-progress Accrued Construction-In-Progress, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for construction-in-progress. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Product sales, net Product sales, net Product And Services, Product Sales Net Of Deductions [Member] Product And Services, Product Sales Net Of Deductions [Member] Line of Credit Line of Credit [Member] Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Foreign Currency Translation Adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Subsidiary or Equity Method Investee [Line Items] Subsidiary or Equity Method Investee [Line Items] Shareholders' Equity Equity [Text Block] Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Current portion of long-term debt Less current portion Long-Term Debt, Current Maturities Land and buildings Land and Building [Member] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Employee equity incentive and purchase plans Equity Unit Purchase Agreements [Member] Numerator: Numerator [Abstract] Numerator [Abstract] Lupin Lawsuit Lupin Lawsuit [Member] Lupin Lawsuit Statement [Table] Statement [Table] Infringed patents suit, number of patents Infringed Patents Suit, Number Of Patents Infringed Patents Suit, Number Of Patents Interest expense, debt Interest Expense, Debt Measurement Frequency [Domain] Measurement Frequency [Domain] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Exchangeable Senior Notes Due 2030 2030 Notes Exchangeable Senior Notes Due 2030 [Member] Exchangeable Senior Notes Due 2030 Certain Balance Sheet Items [Abstract] Certain Balance Sheet Items [Abstract] Certain Balance Sheet Items [Abstract] Property, plant and equipment, gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Quoted Prices in Active MarketsÂ for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Accrued liabilities Increase (Decrease) in Accrued Liabilities Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Share repurchases Payments for Repurchase of Common Stock 2027 Long-Term Debt, Maturity, Year Three Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long-term debt, less current portion Total long-term debt Long-Term Debt, Excluding Current Maturities Five Customers Five Customers [Member] Five Customers Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity securities without readily determinable fair value Equity Securities without Readily

Determinable Fair Value, Amount Time deposits Bank Time Deposits [Member] Income Taxes Income Tax Disclosure [Text Block] Shares repurchased Stock Repurchased and Retired During Period, Value Earnings Per Share [Abstract] Earnings Per Share [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Retained earnings Retained Earnings (Accumulated Deficit) Exchangeable Senior Notes Due 2024 2024 Notes Exchangeable Senior Notes Due 2024 [Member] Exchangeable Senior Notes Due 2024 [Member] Shares repurchased (in shares) Stock Repurchased and Retired During Period, Shares Total Revenues Revenue from Contract with Customer Benchmark [Member] Loss, net of tax, to be reclassified to earnings over the next 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months 2021 Credit Agreement, Dollar Term Loan Two Thousand Twenty One Credit Agreement, Dollar Term Loan [Member] Two Thousand Twenty One Credit Agreement, Dollar Term Loan Inventories Increase (Decrease) in Inventories Capital Redemption Reserve Capital Redemption Reserve [Member] Capital Redemption Reserve [Member] 2026 Long-Term Debt, Maturity, Year Two Other non-current liabilities Other Noncurrent Liabilities [Member] Total Oncology Total Oncology [Member] Total Oncology Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Non-cash interest expense Noncash Interest Expense Noncash Interest Expense Tranche B 1 Dollar Term Loan Tranche B 1 Dollar Term Loan [Member] Tranche B 1 Dollar Term Loan Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag GW Pharmaceuticals plc GW Pharmaceuticals plc [Member] GW Pharmaceuticals plc Entity Registrant Name Entity Registrant Name Infringed patents suit, other party counterclaim, number of patents requested to be delisted Infringed Patents Suit, Other Party Counterclaim, Number Of Patents Requested To Be Delisted Infringed Patents Suit, Other Party Counterclaim, Number Of Patents Requested To Be Delisted Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Manufacturing equipment and machinery Machinery and Equipment [Member] Customer Concentration Risk Customer Concentration Risk [Member] Term Loan Term Loan [Member] Term Loan [Member] Debt issuance costs Debt Issuance Costs, Net Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Offsetting Assets [Table] Offsetting Assets [Table] Geographical [Domain] Geographical [Domain] Debt instrument, face amount Debt Instrument, Face Amount Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Share-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Basis of Presentation Consolidation, Policy [Policy Text Block] Epidiolex Patent Litigation Epidiolex Patent Litigation [Member] Epidiolex Patent Litigation Interest Rate Swap Interest Rate Swap [Member] Manufacturing contracts Manufacturing Contracts [Member] Manufacturing Contracts [Member] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Ordinary shares Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Cash and cash equivalents Cash and Cash Equivalents Cash and Cash Equivalents, at Carrying Value Vyxeos Vyxeos [Member] Vyxeos [Member] Gross Amounts Not Offset in the Consolidated Balance Sheet Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction [Abstract] Debt instrument, convertible, threshold trading days Debt Instrument, Convertible, Threshold Trading Days Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] Proceeds from maturity of investments Proceeds from Sale, Maturity and Collection of Investments Employee Stock Employee Stock [Member] Basic (in dollars per share) Earnings Per Share, Basic Capital redemption reserve Capital Redemption Reserve Capital redemption reserve created under Irish company law to preserve permanent capital in the company. Accounts payable Increase (Decrease) in Accounts Payable Property, plant and equipment, net Property, plant and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Ownership [Domain] Ownership [Domain] Acquired in-process research and development Acquired in-process research and development Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Trademarks Trademarks [Member] Derivative assets Derivative Asset [Abstract] Derivatives Designated as Hedging Instruments Designated as Hedging Instrument [Member] Ordinary Options Ordinary Shares [Member] Ordinary Shares [Member] Total current liabilities Liabilities, Current Share Repurchase Program [Axis] Share Repurchase Program [Axis] Total assets Assets Concentrations of Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One RSUs granted (in shares) PRSUs granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Luxembourg Inland Revenue Luxembourg Inland Revenue [Member] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Other non-current liabilities Other Liabilities, Noncurrent Commitments and contingencies (Note 9) Commitments and Contingencies Gross Amounts Offset in the Consolidated Balance Sheet Derivative Liability, Subject to Master Netting Arrangement, Asset Offset Accrued royalties Accrued Royalties, Current Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Debt instrument, convertible, threshold percentage of stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger 2025 Long-Term Debt, Maturity, Year One Share-Based Compensation Share-Based Payment Arrangement [Text Block] Net Amount Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Derivatives Not Designated as Hedging Instruments Not Designated as Hedging Instrument [Member] Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Denominator: Denominator [Abstract] Denominator [Abstract] Cash Collateral Received (Pledged) Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset Gross Amounts Offset in the Consolidated Balance Sheet Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Total share-based compensation expense, pre-tax Share-Based Payment Arrangement, Expense Old Repurchase Program November 2016 Share Repurchase Program [Member] November 2016 Share Repurchase Program [Member] Fair value of exchangeable senior notes Convertible Debt, Fair Value Disclosures Net income Net income Net (loss) income Net Income (Loss) Attributable to Parent Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Offsetting Assets Offsetting Assets [Table Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Foreign Tax Authority Foreign Tax Jurisdiction [Member] Entity File Number Entity File Number Thereafter Long-Term Debt, Maturity, After Year Four Long-Term Debt, Maturity, After Year Four Liabilities: Liabilities, Fair Value Disclosure [Abstract] Revenues Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Royalties and contract revenues Product And Services, Royalties And Contract Revenue [Member] Product And Services, Royalties And Contract Revenue [Member] Number of lawsuits ongoing Number Of Lawsuits Ongoing Number Of Lawsuits Ongoing Entity Address, Address Line Two Entity Address, Address Line Two Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Other Other Accrued Liabilities, Current Totals Assets, Fair Value Disclosure Other royalty and contract revenues Other Royalty And Contract Revenues [Member] Other Royalty And Contract Revenues Document Period End Date Document Period End Date Finished goods Inventory, Finished Goods, Net of Reserves Other non-cash transactions Other Noncash Income (Expense) Jazz Securities Designated Activity Company Jazz Securities Designated Activity Company [Member] Jazz Securities Designated Activity Company Avadel Pharmaceuticals plc Lawsuit Avadel Pharmaceuticals plc Lawsuit [Member] Avadel Pharmaceuticals plc Lawsuit McKesson McKesson Corporation [Member] McKesson Corporation [Member] Certain Balance Sheet Items Supplemental Balance Sheet Disclosures [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Other current assets Other Current Assets [Member] Gross Accounts Receivable Accounts Receivable [Member] Operating lease liabilities, less current portion Increase (Decrease) In Operating Lease Liabilities, Noncurrent Increase (Decrease) In Operating Lease Liabilities, Noncurrent Derivative liabilities Derivative Liability [Abstract] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Gain on cash flow hedging activities reclassified from accumulated other comprehensive loss to interest expense, net of income tax expense of $445, $428, $1,342 and $684 respectively Gain reclassified from accumulated other comprehensive loss to interest expense, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Litigation Case [Domain] Litigation Case [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Customer [Domain] Customer [Domain] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Amortization of debt issuance costs Amortization of Debt Issuance Costs Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Weighted-average ordinary shares used in per share calculations - basic (in shares) Weighted-average ordinary shares used in per share calculations - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Consulting and professional services Accrued Professional Fees, Current Debt instrument, quarterly amortization rate, percentage Debt Instrument, Quarterly Amortization Rate, Percentage Debt Instrument, Quarterly Amortization Rate, Percentage Acquisition of investments Payments to Acquire Investments Construction-in-progress Construction in Progress [Member] ASD Specialty Healthcare LLC ASD ASD Specialty Healthcare LLC [Member] ASD Specialty Healthcare LLC Entity Filer Category Entity Filer Category Amounts reclassified from accumulated other comprehensive loss Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Dilutive effect of exchangeable senior notes (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Loss Contingencies [Line Items] Loss Contingencies [Line Items] EX-101.PRE 9 jazz-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Oct. 31, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-33500 Â Entity Registrant Name Jazz Pharmaceuticals plc Â Entity Incorporation, State or Country Code L2 Â Entity Tax Identification Number 98-1032470 Â Entity Address, Address Line One Fifth Floor, Waterloo Exchange, Â Entity Address, Address Line Two Waterloo Road Â Entity Address, City or Town Dublin 4 Â Entity Address, Country IE Â Entity Address, Postal Zip Code D04 E5W7 Â Country Region 353 Â City Area Code 1 Â Local Phone Number 634-7800 Â Title of 12(b) Security Ordinary shares, nominal value $0.0001 per share Â Trading Symbol JAZZ Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Smaller Reporting Company false Â Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 60,454,592 Amendment Flag false Â Document Fiscal Year Focus 2024 Â Document Fiscal period Focus Q3 Â Entity Central Index Key 0001232524 Â Current Fiscal Year End Date --12-31 Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionRegion code of country + ReferencesNo definition available. + Details Name: dei_CountryRegion Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionISO 3166-1 alpha-2 country code. + ReferencesNo definition available. + Details Name: dei_EntityAddressCountry Namespace Prefix: dei_ Data Type: dei:countryCodeItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1:

http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â  Cash and cash equivalents $ 2,218,135 $ 1,506,310 Investments 400,000 120,000 Accounts receivable, net of allowances 723,639 705,794 Inventories 539,302 597,039 Prepaid expenses 155,132 185,476 Other current assets 354,215 320,809 Total current assets 4,390,423 3,435,428 Property, plant and equipment, net 176,422 169,646 Operating lease assets 77,164 65,340 Intangible assets, net 5,144,217 5,418,039 Goodwill 1,804,646 1,753,130 Deferred tax assets, net 583,218 477,834 Deferred financing costs 4,395 6,478 Other non-current assets 75,231 67,464 Total assets 12,255,716 11,393,359 Current liabilities: Â Â  Accounts payable 85,425 102,750 Accrued liabilities 858,578 793,914 Current portion of long-term debt 31,000 604,954 Income taxes payable 54,974 35,074 Total current liabilities 1,029,977 1,536,692 Long-term debt, less current portion 6,080,802 5,107,988 Operating lease liabilities, less current portion 71,115 59,225 Deferred tax liabilities, net 791,784 847,706 Other non-current liabilities 110,971 104,751 Commitments and contingencies (Note 9) Shareholdersâ€™ equity: Â Â  Ordinary shares 6 6 Non-voting euro deferred shares 55 55 Capital redemption reserve 473 473 Additional paid-in capital 3,837,698 3,699,954 Accumulated other comprehensive loss (603,397) (842,147) Retained earnings 936,232 878,656 Total shareholdersâ€™ equity 4,171,067 3,736,997 Total liabilities and shareholdersâ€™ equity $ 12,255,716 $ 11,393,359 X - DefinitionCapital redemption reserve created under Irish company law to preserve permanent capital in the company. + ReferencesNo definition available. + Details Name: jazz_CapitalRedemptionReserve Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionShares issued to satisfy statutory minimum of Euro-denominated share capital required for a public limited company incorporated in Ireland. + ReferencesNo definition available. + Details Name: jazz_NonvotingEuroDeferredShares Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX

210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DeferredFinanceCostsNoncurrentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(h)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_Investments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TaxesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues: Â Â Â Â Total revenues $ 1,054,969 $ 972,140 $ 2,980,777 $ 2,822,269 Operating expenses: Â Â Â Â Cost of product sales (excluding amortization of acquired developed technologies) 111,611 102,153 317,000 328,334 Selling, general and administrative 325,772 308,310 1,016,007 947,071 Research and development 199,919 234,402 643,500 633,050 Intangible asset amortization 157,457 154,883 468,410 456,731 Acquired in-process research and development 0 0 10,000 1,000 Total operating expenses 794,759 799,748 2,454,917 2,366,186 Income from operations 260,210 172,392 525,860 456,083 Interest expense, net (58,702) (71,497) (186,841) (219,114) Foreign exchange loss (701) (1,377) (1,887) (566) Income before income tax benefit and equity in loss (gain) of investees 200,807 99,518 337,132 236,403 Income tax benefit (14,533) (47,176) (33,517) (86,823) Equity in loss (gain) of investees 285 (126) 1,644 2,548 Net income $ 215,055 $ 146,820 $ 369,005 $ 320,678 Net income per ordinary share: Â Â Â Â Basic (in dollars per share) $ 3.50 $ 2.33 $ 5.93 $ 5.05 Diluted (in dollars per share) $ 3.42 $ 2.14 $ 5.63 $ 4.67 Weighted-average ordinary shares used in per share calculations - basic (in shares) 61,414 63,114 62,275 63,532 Weighted-average ordinary shares used in per share calculations - diluted (in shares) 63,174 71,293 67,511 72,866 Product sales, net Â Â Â Â Revenues: Â Â Â Â Total revenues $ 989,707 $ 938,398 $ 2,795,953 $ 2,769,604 Royalties and contract revenues Â Â Â Â Revenues: Â Â Â Â Total revenues $ 65,262 $ 33,742 $ 184,824 $ 52,665 X - DefinitionTotal costs related to goods produced and sold during the reporting period excluding amortization of acquired developed technologies and intangible asset impairment presented separately. + ReferencesNo definition available. + Details Name: jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNet Income Loss Per Ordinary Share + ReferencesNo definition available. + Details Name: jazz_NetIncomeLossPerOrdinaryShareAbstract Namespace Prefix: jazz_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=jazz_ProductAndServicesProductSalesNetOfDeductionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_ProductAndServicesRoyaltiesAndContractRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net income $ 215,055 $ 146,820 $ 369,005 $ 320,678 Other comprehensive income (loss): Â Â Â Â Foreign currency translation adjustments 291,367 (170,826) 241,218 82,952 Unrealized gain (loss) on cash flow hedging activities, net of income tax (benefit) expense of $(1,727), $1,176, $522 and $3,063 respectively (5,197) 3,539 1,572 9,218 Gain on cash flow hedging activities reclassified from accumulated other comprehensive loss to interest expense, net of income tax expense of $445, $428, $1,342 and $684 respectively (1,340) (1,289) (4,040) (2,060) Other comprehensive income (loss) 284,830 (168,576) 238,750 90,110 Total comprehensive income (loss) $ 499,885 $ (21,756) $ 607,755 $ 410,788 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15 + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Income tax (benefit) expense effect on cash flow hedging activities $ (1,727) $ 1,176 $ 522 $ 3,063 Tax expense effect on cash flow hedging activities reclassified $ 445 $ 428 $ 1,342 $ 684 X - DefinitionAmount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12 + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12 + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERSâ€™ EQUITY - USD ($) shares in Thousands, $ in Thousands Total Ordinary Shares Ordinary Shares Performance-Based Restricted Stock Units (PRSUs) Non-voting Euro Deferred Capital Redemption Reserve Additional Paid-in Capital Accumulated Other Comprehensive Loss Retained Earnings Beginning balance (in shares) at Dec. 31, 2022 Â 63,214 Â 4,000 Â Â Â Â Beginning balance at Dec. 31, 2022 $ 3,085,734 $ 6 Â $ 55 $ 472 $ 3,477,124 $ (1,125,509) $ 733,586 Increase (Decrease) in Shareholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Issuance of ordinary shares in conjunction with exercise of share options (in shares) Â 188 Â Â Â Â Â Â Issuance of ordinary shares in conjunction with exercise of share options 21,228 Â Â Â Â 21,228 Â Â Issuance of ordinary shares in conjunction with vesting of restricted stock units and performance-based restricted stock units (in shares) Â 585 Â Â Â Â Â Â Shares withheld for payment of employee's withholding tax liability (43,266) Â Â Â Â (43,266) Â Â Share-based compensation 56,646 Â Â Â Â 56,646 Â Â Other comprehensive (loss) income 145,279 Â Â Â Â Â 145,279 Â Net (loss) income 69,420 Â Â Â Â Â Â 69,420 Ending balance (in shares) at Mar. 31, 2023 Â 63,987 Â 4,000 Â Â Â Â Ending balance at Mar. 31, 2023 3,335,041 $ 6 Â $ 55 472 3,511,732 (980,230) 803,006 Beginning balance (in shares) at Dec. 31, 2022 Â 63,214 Â 4,000 Â Â Â Â Beginning balance at Dec. 31, 2022 3,085,734 $ 6 Â $ 55 472 3,477,124 (1,125,509) 733,586 Increase (Decrease) in Shareholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Other comprehensive (loss) income 90,110 Â Â Â Â Â Â Â Net (loss) income 320,678 Â Â Â Â Â Â Â Ending balance (in shares) at Sep. 30, 2023 Â 62,945 Â 4,000 Â Â Â Â Ending balance at Sep. 30, 2023 3,489,373 $ 6 Â $ 55 473 3,639,940 (1,035,399) 884,298 Beginning balance (in shares) at Mar. 31, 2023 Â 63,987 Â 4,000 Â Â Â Â Beginning balance at Mar. 31, 2023 3,335,041 $ 6 Â $ 55 472 3,511,732 (980,230) 803,006 Increase (Decrease) in Shareholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Issuance of ordinary shares in conjunction with exercise of share options (in shares) Â 28 Â Â Â Â Â Â Issuance of ordinary shares in conjunction with exercise of share options 2,003 Â Â Â Â 2,003 Â Â Issuance of ordinary shares under employee stock purchase plan (in shares) Â 81 Â Â Â Â Â Â Issuance of ordinary shares under employee stock purchase plan 8,863 Â Â Â Â 8,863 Â Â Issuance of ordinary shares in conjunction with vesting of restricted stock units and performance-based restricted stock units (in shares) Â 58 Â Â Â Â Â Â Shares withheld for payment of employee's withholding tax liability (4,188) Â Â Â Â (4,188) Â Â Share-based compensation 61,705 Â Â Â Â 61,705 Â Â Shares repurchased (in shares) Â (756) Â Â Â Â Â Â Shares repurchased (95,594) Â Â Â 1 Â Â (95,595) Other comprehensive (loss) income 113,407 Â Â Â Â Â 113,407 Â Net (loss) income 104,438 Â Â Â Â Â Â 104,438 Ending balance (in shares) at Jun. 30, 2023 Â 63,398 Â 4,000 Â Â Â Â Ending balance at Jun. 30, 2023 3,525,675 $ 6 Â $ 55 473 3,580,115 (866,823) 811,849 Increase (Decrease) in Shareholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Issuance of ordinary shares in conjunction with exercise of share options (in shares) Â 50 Â Â Â Â Â Â Issuance of ordinary shares in conjunction with exercise of share options 5,512 Â Â Â Â 5,512 Â Â Issuance of ordinary shares in conjunction with vesting of restricted stock units and performance-based restricted stock units (in shares) Â 59 Â Â Â Â Â Â Shares withheld for payment of employee's withholding tax liability (1,884) Â Â Â Â (1,884) Â Â Share-based compensation 56,197 Â Â Â Â 56,197 Â Â Shares repurchased (in shares) Â (562) Â Â Â Â Â Â Shares repurchased (74,371) Â Â Â Â Â Â (74,371) Other comprehensive (loss) income (168,576) Â Â Â Â Â (168,576) Â Net (loss) income 146,820 Â Â Â Â Â Â 146,820 Ending balance (in shares) at Sep. 30, 2023 Â 62,945 Â 4,000 Â Â Â Â Ending balance at Sep. 30, 2023 3,489,373 $ 6 Â $ 55 473 3,639,940 (1,035,399) 884,298 Beginning balance (in shares) at Dec. 31, 2023 Â 62,255 Â 4,000 Â Â Â Â Beginning balance at Dec. 31, 2023 3,736,997 $ 6 Â $ 55 473 3,699,954 (842,147) 878,656 Increase (Decrease) in Shareholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Issuance of ordinary shares in conjunction with exercise of share options (in shares) Â 7 Â Â Â Â Â Â Issuance of ordinary shares in conjunction with exercise of share options 494 Â Â Â Â 494 Â Â Issuance of ordinary shares in conjunction with vesting of restricted stock units and performance-based restricted stock units (in shares) Â 686 80 Â Â Â Â Â Â Shares withheld for payment of employee's withholding tax liability (49,296) Â Â Â Â

(49,296) Â Â Share-based compensation 63,131 Â Â Â Â 63,131 Â Â Other comprehensive (loss) income (40,247) Â Â Â Â Â (40,247) Â Net (loss) income (14,618) Â Â Â Â Â Â (14,618) Ending balance (in shares) at Mar. 31, 2024 Â 63,028 Â 4,000 Â Â Â Â Ending balance at Mar. 31, 2024 3,696,461 $ 6 Â $ 55 473 3,714,283 (882,394) 864,038 Beginning balance (in shares) at Dec. 31, 2023 Â 62,255 Â 4,000 Â Â Â Â Beginning balance at Dec. 31, 2023 3,736,997 $ 6 Â $ 55 473 3,699,954 (842,147) 878,656 Increase (Decrease) in Shareholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Other comprehensive (loss) income 238,750 Â Â Â Â Â Â Â Â Net (loss) income 369,005 Â Â Â Â Â Â Â Â Ending balance (in shares) at Sep. 30, 2024 Â 60,443 Â 4,000 Â Â Â Â Ending balance at Sep. 30, 2024 4,171,067 $ 6 Â $ 55 473 3,837,698 (603,397) 936,232 Beginning balance (in shares) at Mar. 31, 2024 Â 63,028 Â 4,000 Â Â Â Â Beginning balance at Mar. 31, 2024 3,696,461 $ 6 Â $ 55 473 3,714,283 (882,394) 864,038 Increase (Decrease) in Shareholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Issuance of ordinary shares in conjunction with exercise of share options (in shares) Â 4 Â Â Â Â Â Â Â Issuance of ordinary shares in conjunction with exercise of share options 54 Â Â Â Â Â 54 Â Â Issuance of ordinary shares under employee stock purchase plan (in shares) Â 122 Â Â Â Â Â Â Â Issuance of ordinary shares under employee stock purchase plan 10,886 Â Â Â Â 10,886 Â Â Issuance of ordinary shares in conjunction with vesting of restricted stock units and performance-based restricted stock units (in shares) Â 49 Â Â Â Â Â Â Â Shares withheld for payment of employee's withholding tax liability (2,847) Â Â Â Â (2,847) Â Â Share-based compensation 56,738 Â Â Â Â 56,738 Â Â Shares repurchased (in shares) Â (1,458) Â Â Â Â Â Â Â Shares repurchased (161,428) Â Â Â Â Â Â (161,428) Other comprehensive (loss) income (5,833) Â Â Â Â Â (5,833) Â Net (loss) income 168,568 Â Â Â Â Â Â 168,568 Ending balance (in shares) at Jun. 30, 2024 Â 61,745 Â 4,000 Â Â Â Â Ending balance at Jun. 30, 2024 3,762,599 $ 6 Â $ 55 473 3,779,114 (888,227) 871,178 Increase (Decrease) in Shareholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Issuance of ordinary shares in conjunction with exercise of share options (in shares) Â 1 Â Â Â Â Â Â Â Issuance of ordinary shares in conjunction with exercise of share options 17 Â Â Â Â 17 Â Â Issuance of ordinary shares in conjunction with vesting of restricted stock units and performance-based restricted stock units (in shares) Â 69 Â Â Â Â Â Â Â Shares withheld for payment of employee's withholding tax liability (1,605) Â Â Â Â (1,605) Â Â Share-based compensation 60,172 Â Â Â Â 60,172 Â Â Shares repurchased (in shares) Â (1,372) Â Â Â Â Â Â Â Shares repurchased (150,001) Â Â Â Â Â Â (150,001) Other comprehensive (loss) income 284,830 Â Â Â Â Â 284,830 Â Net (loss) income 215,055 Â Â Â Â Â Â 215,055 Ending balance (in shares) at Sep. 30, 2024 Â 60,443 Â 4,000 Â Â Â Â Ending balance at Sep. 30, 2024 $ 4,171,067 $ 6 Â $ 55 $ 473 $ 3,837,698 $ (603,397) $ 936,232 X - DefinitionAmount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-

gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares that have been repurchased and retired during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Operating activities Â Â  Net income $ 369,005 $ 320,678 Adjustments to reconcile net income to net cash provided by operating activities: Â Â  Intangible asset amortization 468,410 456,731 Share-based compensation 177,855 173,900 Acquisition accounting inventory fair value step-up adjustment 97,220 119,094 Depreciation 23,240 22,764 Non-cash interest expense 18,877 16,255 Provision for losses on accounts receivable and inventory 15,866 7,732 Acquired in-process research and development 10,000 1,000 Deferred tax benefit (205,972) (224,317) Other non-cash transactions 19,615 54,262 Changes in assets and liabilities: Â Â  Accounts receivable (21,979) 23,581 Inventories (26,877) (12,016) Prepaid expenses and other current assets 708 (37,327) Operating lease assets 10,697 14,423 Other non-current assets (9,544) (20,881) Accounts payable (16,938) 17,705 Accrued liabilities 56,428 (76,261) Income taxes payable 20,098 61,159 Deferred revenue 0 (459) Operating lease liabilities, less current portion (9,701) (13,855) Other non-current liabilities 320 20,500 Net cash provided by operating activities 997,328 924,668 Investing activities Â Â  Acquisition of investments (835,125) (270,000) Purchases of property, plant and equipment (24,783) (13,860) Acquired in-process research and development (10,000) (1,000) Proceeds from maturity of investments 555,000 20,000 Net cash used in investing activities (314,908) (264,860) Financing activities Â Â  Net proceeds from issuance of exchangeable senior notes, due 2030 980,767 0 Proceeds from employee equity incentive and purchase plans 11,451 37,606 Repayments of long-term debt (23,250) (23,250) Payment of employee withholding taxes related to share-based awards (53,748) (49,338) Share repurchases (311,429) (169,966) Repayment of exchangeable senior notes, due 2024 (575,000) 0 Net cash provided by (used in) financing activities 28,791 (204,948) Effect of exchange rates on cash and cash equivalents 614 (652) Net increase in cash and cash equivalents 711,825 454,208 Cash and cash equivalents, at beginning of period 1,506,310 881,482 Cash and cash equivalents, at end of period $ 2,218,135 $ 1,335,690 X - DefinitionIncrease (Decrease) In Operating Lease Assets + ReferencesNo definition available. + Details Name: jazz_IncreaseDecreaseInOperatingLeaseAssets Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (Decrease) In Operating Lease Liabilities, Noncurrent + ReferencesNo definition available. + Details Name: jazz_IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe noncash expense recognized in the current period from the amortization of acquired inventory written up to fair value in purchase accounting + ReferencesNo definition available. + Details Name: jazz_InventoryStepUpValueAdjustment Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash Interest Expense + ReferencesNo definition available. + Details Name: jazz_NoncashInterestExpense Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayments To Acquire In Process Research And Development Other Than Through Business Combination + ReferencesNo definition available. + Details Name: jazz_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction off the carrying amount of inventory, generally attributable to obsolescence or market conditions. + ReferencesNo definition available. + Details Name: jazz_ProvisionForLossesOnAccountsReceivableAndInventory Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -

Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent operating liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher

FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfSecuredDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3 The Company and Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â  The Company and Summary of Significant Accounting Policies The Company and Summary of Significant Accounting PoliciesJazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases - often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience.Our lead marketed products, listed below, are approved in countries around the world to improve patient care.Neuroscienceâ€¢XywavÂ® (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product approved by the U.S. Food and Drug Administration, or FDA, in JulyÂ 2020, and launched in the U.S. in NovemberÂ 2020 for the treatment of cataplexy or excessive daytime sleepiness, or EDS, in patients seven years of age and older with narcolepsy, and also approved by FDA in AugustÂ 2021 for the treatment of idiopathic hypersomnia, or IH, in adults and launched in the U.S. in NovemberÂ 2021. Xywav contains 92% less sodium than XyremÂ®. Xywav is also approved in Canada for the treatment of cataplexy in patients with narcolepsy.â€¢EpidiolexÂ® (cannabidiol) oral solution, a product approved by FDA and launched in the U.S. in 2018 by GW Pharmaceuticals plc, or GW, and currently indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, or LGS, Dravet syndrome, or DS, or tuberous sclerosis complex, or TSC, in patients one year of age or older; in the EU and Great Britain (where it is marketed as EpidyolexÂ®) and other markets, it is approved for adjunctive treatment of seizures associated with LGS or DS, in conjunction with clobazam (EU and Great Britain only), in patients 2 years of age and older and for adjunctive treatment of seizures associated with TSC in patients 2 years of age and older.Oncologyâ€¢RylazeÂ® (asparaginase erwinia chrysanthemi (recombinant)-rywn), a product approved by FDA in JuneÂ 2021 and launched in the U.S. in JulyÂ 2021 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who have developed hypersensitivity to E. coli-derived asparaginase. In SeptemberÂ 2023, the European Commission granted marketing authorization under the trade name Enrylaze. This therapy is also approved in Great Britain, Canada and Switzerland.â€¢ZepzelcaÂ® (lurbinectedin), a product approved by FDA in JuneÂ 2020 under FDA's accelerated approval pathway and launched in the U.S. in JulyÂ 2020 for the treatment of adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based chemotherapy; in Canada, Zepzelca received conditional approval in SeptemberÂ 2021 for the treatment of adults with Stage III or metastatic SCLC, who have progressed on or after platinum-containing therapy.Throughout this Quarterly Report on FormÂ 10-Q, unless otherwise indicated or the context otherwise requires, all references to â€œJazz Pharmaceuticals,â€ â€œthe registrant,â€ â€œthe Company,â€ â€œwe,â€ â€œus,â€ and â€œourâ€ refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries. Throughout this Quarterly Report on FormÂ 10-Q, all references to â€œordinary sharesâ€ refer to Jazz Pharmaceuticals plcâ€™s ordinary shares.Basis of PresentationThese unaudited condensed consolidated financial statements have been prepared following the requirements of the U.S. Securities and Exchange Commission for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or U.S. GAAP, can be condensed or omitted. The information included in this Quarterly Report on FormÂ 10â€‘Q should be read in conjunction with our annual audited consolidated financial statements and accompanying notes included in our Annual Report on FormÂ 10â€‘K for the year ended DecemberÂ 31,Â 2023. In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three and nine months ended SeptemberÂ 30,Â 2024, are not necessarily indicative of the results to be expected for the year ending DecemberÂ 31,Â 2024, for any other interim period or for any future period.Our significant accounting policies have not changed substantially from those previously described in our Annual Report on FormÂ 10â€‘K for the year ended DecemberÂ 31,Â 2023. These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our subsidiaries, and intercompany transactions and balances have been eliminated.Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker, or CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the identification, development and commercialization of meaningful pharmaceutical products that address unmet medical needs.Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.Adoption of New Accounting StandardsIn NovemberÂ 2023, the Financial Accounting Standards Board, or FASB, issued ASU 2023-07, â€œSegment Reporting (Topic 280) - Improvements to Reportable Segment Disclosuresâ€, which requires enhanced disclosures about significant segment expenses. The amendments are effective retrospectively to all prior periods presented in the financial statements, for fiscal years beginning after DecemberÂ 15,Â 2023. The new guidance is not expected to have a material impact on our financial statement disclosures.Significant Risks and UncertaintiesWe expect that our business will continue to meaningfully depend on oxybate revenues; however, there is no guarantee that oxybate revenues will remain at current levels. In this regard, our ability to maintain oxybate revenues and realize the anticipated benefits from our investment in Xywav are subject to a number of risks and uncertainties including, without limitation, those related to the commercialization of Xywav for the treatment of IH in adults and adoption in that indication; competition from the introduction of two authorized generic, or AG, versions of high-sodium oxybate and a branded fixed-dose, high-sodium oxybate, Avadelâ€™s Lumryz, for treatment of cataplexy and/or EDS in narcolepsy in the U.S. market, as well as potential future competition from additional AG versions of high-sodium oxybate and from generic versions of high-sodium oxybate and from other competitors; increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party payors, including our ability to maintain adequate coverage and reimbursement for Xywav; increased rebates required to maintain access to our products; challenges to our intellectual property around Xywav and/or Xyrem, including from pending antitrust and intellectual property litigation; and continued acceptance of Xywav and Xyrem by physicians and patients. A significant decline in oxybate revenues could cause us to reduce our operating expenses or seek to raise additional funds and would have a material adverse effect on our business, financial condition, results of operations and growth prospects, including on our ability to acquire, in-license or develop new products to grow our business.In addition to risks related specifically to Xywav and Xyrem, we are subject to other challenges and risks related to successfully commercializing a portfolio of oncology products and other neuroscience products, and other risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: ongoing clinical research activity and related outcomes; obtaining regulatory approval of our late-stage product candidates, such as zanidatamab; effectively commercializing our approved products such as Epidiolex, Rylaze and Zepzelca; obtaining and maintaining adequate coverage and reimbursement for our products; contracting and rebates to pharmacy benefit managers and similar organizations that reduce our net revenue; increasing scrutiny of pharmaceutical product pricing and resulting changes in healthcare laws and policy; market acceptance; regulatory concerns with controlled substances generally and the potential for abuse; future legislation; action by the U.S. Federal Government authorizing the sale, distribution, use, and insurance reimbursement of non-FDA approved cannabinoid products; delays or problems in the supply of our products; loss of single source suppliers or failure to comply with manufacturing regulations; delays or problems with third parties that are part of our manufacturing and supply chain; identifying, acquiring or in-licensing additional products or product candidates; our ability to realize the anticipated benefits of acquired or in-licensed products or product candidates, such as Epidiolex and zanidatamab, at the expected levels, with the expected costs and within the expected timeframe; pharmaceutical product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements; and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt obligations.Concentrations of RiskFinancial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of SeptemberÂ 30,Â 2024, we had foreign exchange forward contracts with notional amounts totaling $292.7Â million. As of SeptemberÂ 30,Â 2024, the outstanding foreign exchange forward contracts had a net asset fair value of $8.4Â million. As of SeptemberÂ 30,Â 2024, we had interest rate swap contracts with notional amounts totaling $500.0Â million with a liability fair value of $3.0 million. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant.We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and, as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, allowances on receivables were not material. As of SeptemberÂ 30,Â 2024, five customers accounted for 81% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliates, or ESSDS, which accounted for 41% of gross accounts receivable, ASD Specialty Healthcare LLC, or ASD, which accounted for 14% of gross accounts receivable and McKesson Corporation and affiliates, or McKesson, which accounted for 14% of gross accounts receivable. As of DecemberÂ 31,Â 2023, five customers accounted for 79% of gross accounts receivable, including ESSDS, which accounted for 41% of gross accounts receivable, ASD, which accounted for 13% of gross accounts receivable and McKesson, which accounted for 11% of gross accounts receivable. We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to our oxybate products, the API is manufactured for us by a single source supplier and the finished products are manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based supplier.Recent Accounting PronouncementsIn DecemberÂ 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740) - Improvements to Income Tax Disclosuresâ€, which requires enhanced tax disclosures providing greater disaggregation of information in the Company's effective tax rate reconciliation and disaggregates income taxes paid by jurisdiction. The amendments are effective on a prospective basis, with the option to apply it retrospectively, for fiscal years beginning after DecemberÂ 15,Â 2024. We are currently evaluating the impact of adopting this new accounting guidance. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Cash and Available-for-Sale Securities 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â  Cash and Available-for-Sale Securities Cash and Available-for-Sale Securities Cash, cash equivalents and investments consisted of the following (in thousands):Â September 30, 2024AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesEstimatedFair ValueCash andCashEquivalentsInvestmentsCash$797,583Â $â€”Â $â€”Â $797,583Â $797,583Â $â€”Â Time deposits650,000Â â€”Â â€”Â 650,000Â 250,000Â 400,000Â Money market funds1,170,552Â â€”Â â€”Â 1,170,552Â 1,170,552Â â€”Â Totals$2,618,135Â $â€”Â $â€”Â $2,618,135Â $2,218,135Â $400,000Â December 31, 2023AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesEstimatedFair ValueCash and CashEquivalentsInvestmentsCash$437,724Â $â€”Â $â€”Â $437,724Â $437,724Â $â€”Â Time deposits420,000Â â€”Â â€”Â 420,000Â 300,000Â 120,000Â Money market funds768,586Â â€”Â â€”Â 768,586Â 768,586Â â€”Â Totals$1,626,310Â $â€”Â $â€”Â $1,626,310Â $1,506,310Â $120,000Â Cash equivalents and investments are considered available-for-sale securities. We use the specific-identification method for calculating realized gains and losses on securities sold and include them in interest expense, net in the condensed consolidated statements of income. Our investment balances represent time deposits with original maturities of greater than three months and less than one year. Interest income from available-for-sale

securities was $26.0 million and $74.6Â million in the three and nine months ended SeptemberÂ 30,Â 2024, respectively, and $19.2 million and $44.4 million in the three and nine months ended SeptemberÂ 30,Â 2023, respectively. X - DefinitionThe entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent + Details Name: us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurement 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â  Fair Value Measurement Fair Value Measurement The following table summarizes, by major security type, our available-for-sale securities and derivative contracts as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands):Â September 30, 2024December 31, 2023QuotedPrices inActiveMarketsÂ forIdenticalAssets(Level 1)SignificantOtherObservableInputs(Level 2)TotalEstimatedFairÂ ValueQuotedPrices inActiveMarketsÂ forIdenticalAssets(Level 1)SignificantOtherObservableInputs(Level 2)TotalEstimatedFairÂ ValueAssets:Available-for-sale securities:Money market funds$1,170,552Â $â€”Â $1,170,552Â $768,586Â $â€”Â $768,586Â Time depositsâ€”Â 650,000Â 650,000Â â€”Â 420,000Â 420,000Â Foreign exchange forward contractsâ€”Â 8,364Â 8,364Â â€”Â 18,035Â 18,035Â Interest rate contractsâ€”Â 13Â 13Â â€”Â 3,784Â 3,784Â Totals$1,170,552Â $658,377Â $1,828,929Â $768,586Â $441,819Â $1,210,405Â Liabilities:Interest rate contracts$â€”Â $2,976Â $2,976Â $â€”Â $3,410Â $3,410Â Foreign exchange forward contractsâ€”Â â€”Â â€”Â â€”Â 681Â 681Â Totals$â€”Â $2,976Â $2,976Â $â€”Â $4,091Â $4,091Â As of SeptemberÂ 30,Â 2024, our available-for-sale securities included money market funds and time deposits and their carrying values were approximately equal to their fair values. Money market funds were measured using quoted prices in active markets, which represent Level 1 inputs and time deposits were measured at fair value using Level 2 inputs. Level 2 inputs are obtained from various third party data providers and represent quoted prices for similar assets in active markets, or these inputs were derived from observable market data, or if not directly observable, were derived from or corroborated by other observable market data.Our derivative assets and liabilities include interest rate and foreign exchange derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterpartiesâ€™ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the fair value hierarchy.There were no transfers between the different levels of the fair value hierarchy in 2024 or 2023.As of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, the carrying amount of investments measured using the measurement alternative for equity investments without a readily determinable fair value was $4.3Â million and $4.7Â million, respectively. The carrying amount, which is recorded within other non-current assets, is based on the latest observable transaction price.As of SeptemberÂ 30,Â 2024, the estimated fair values of the 2.000% exchangeable senior notes due 2026, or 2026 Notes, and the 3.125% exchangeable senior notes due 2030, or 2030 Notes, were approximately $1.0Â billion and $1.0Â billion, respectively. The 2030 Notes together with the 2026 Notes and the 1.50% exchangeable senior notes due 2024, or 2024 Notes, that were repaid upon maturity on August 15, 2024, are collectively known as the Exchangeable Senior Notes. As of SeptemberÂ 30,Â 2024, the estimated fair values of the 4.375% senior secured notes, due 2029, or the Secured Notes, and the seven-year U.S. dollar term loan B facility were approximately $1.4Â billion and $2.7Â billion, respectively. The fair values of each of these debt facilities was estimated using quoted market prices obtained from brokers (Level 2). X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative Instruments and Hedging Activities 9 Months Ended Sep. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â  Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities We are exposed to certain risks arising from operating internationally, including fluctuations in foreign exchange rates primarily related to the translation of sterling and euro denominated net monetary liabilities, including intercompany balances, held by subsidiaries with a U.S. dollar functional currency and fluctuations in interest rates on our outstanding term loan borrowings. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.We enter into foreign exchange forward contracts, with durations of up to 12 months, designed to limit the exposure to fluctuations in foreign exchange rates related to the translation of certain non-U.S. dollar denominated liabilities, including intercompany balances. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, the notional amount of foreign exchange contracts where hedge accounting is not applied was $292.7Â million and $511.7Â million, respectively.The foreign exchange loss in our condensed consolidated statements of income included the following gains (losses) associated with foreign exchange contracts not designated as hedging instruments (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Foreign Exchange Forward Contracts:20242023202420232023Gain (loss) recognized in foreign exchange loss$14,396Â $(13,549)$9,485Â $(8,921)To achieve a desired mix of floating and fixed interest rates on our variable rate debt, we entered into interest rate swap agreements in AprilÂ 2023, which are effective until AprilÂ 2026. These agreements hedge contractual term loan interest rates. As of SeptemberÂ 30,Â 2024, the interest rate swap agreements had a notional amount of $500.0 million. As a result of these agreements, the interest rate on a portion of our term loan borrowings is fixed at 3.9086%, plus the borrowing spread, until AprilÂ 30,Â 2026.The impact on accumulated other comprehensive loss and earnings from derivative instruments that qualified as cash flow hedges for the three and nine months ended SeptemberÂ 30,Â 2024 was as follows (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Interest Rate Contracts:20242023202420232023Gain (loss) recognized in accumulated other comprehensive loss, net of tax$(5,197)$3,539Â $1,572Â $9,218Â Gain reclassified from accumulated other comprehensive loss to interest expense, net of tax(1,340)(1,289)(4,040)(2,060)Assuming no change in the U.S dollar Secured Overnight Financing Rate, or Term SOFR, based interest rates from market rates as of SeptemberÂ 30,Â 2024, $0.5 million of loss, net of tax, recognized in accumulated other comprehensive loss will be reclassified to earnings over the next 12 months.The cash flow effects of our derivative contracts for the nine months ended SeptemberÂ 30,Â 2024 and 2023 are included within net cash provided by operating activities in the condensed consolidated statements of cash flows.The following tables summarize the fair value of outstanding derivatives (in thousands):ClassificationSeptember 30,2024December 31,2023AssetsDerivatives designated as hedging instruments:Interest rate contractsOther current assets$13Â $3,784Â Derivatives not designated as hedging instruments:Foreign exchange forward contractsOther current assets8,364Â 18,035Â Total fair value of derivative asset instruments$8,377Â $21,819Â LiabilitiesDerivatives designated as hedging instruments:Interest rate contractsAccrued liabilities$572Â $â€”Â Interest rate contractsOther non-current liabilities2,404Â 3,410Â Derivatives not designated as hedging instruments:Foreign exchange forward contractsAccrued liabilitiesâ€”Â 681Â Total fair value of derivative liability instruments$2,976Â $4,091Â Although we do not offset derivative assets and liabilities within our condensed consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following table summarizes the potential effect on our condensed consolidated balance sheets of offsetting our interest rate and foreign exchange forward contracts subject to such provisions (in thousands):September 30, 2024Gross Amounts of Recognized Assets/ LiabilitiesGross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets/ Liabilities Presented in the Consolidated Balance SheetGross Amounts Not Offset in the Consolidated Balance SheetDescriptionDerivative Financial InstrumentsCash Collateral Received (Pledged)Net AmountDerivative assets$8,377Â $â€”Â $8,377Â $(1,830)$â€”Â $6,547Â Derivative liabilities(2,976)â€”Â (2,976)1,830Â â€”Â (1,146)December 31, 2023Gross Amounts of Recognized Assets/ LiabilitiesGross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets/ Liabilities Presented in the Consolidated Balance SheetGross Amounts Not Offset in the Consolidated Balance SheetDescriptionDerivative Financial InstrumentsCash Collateral Received (Pledged)Net AmountDerivative assets$21,819Â $â€”Â $21,819Â $(4,091)$â€”Â $17,728Â Derivative liabilities(4,091)â€”Â (4,091)4,091Â â€”Â â€”Â  X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815/tableOfContent + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â  Inventories Inventories Inventories consisted of the following (in thousands):Â September 30,2024December 31,2023Raw materials$24,819Â $25,595Â Work in process366,602Â 431,732Â Finished goods147,881Â 139,712Â Total inventories$539,302Â $597,039Â As of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, inventories included $243.4Â million and $328.0Â million, respectively, related to the purchase accounting inventory fair value step-up on inventory acquired as part of our acquisition of GW. X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â  Goodwill and Intangible Assets Goodwill and Intangible Assets The gross carrying amount of goodwill was as follows (in thousands):Balance at December 31, 2023$1,753,130Â Foreign exchange51,516Â Balance at September 30, 2024$1,804,646Â The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):Â Â September 30, 2024December 31, 2023Â RemainingWeighted-AverageÂ UsefulLife(In years)GrossCarryingAmountAccumulatedAmortizationNet BookValueGrossCarryingAmountAccumulatedAmortizationNet BookValueAcquired developed technologies8.0$8,064,193Â $(2,919,976)$5,144,217Â $7,785,495Â $(2,367,456)$5,418,039Â Manufacturing contractsâ€”11,984Â (11,984)â€”Â 11,828Â (11,828)â€”Â Trademarksâ€”2,889Â (2,889)â€”Â 2,886Â (2,886)â€”Â Total finite-lived intangible assets$8,079,066Â $(2,934,849)$5,144,217Â $7,800,209Â $(2,382,170)$5,418,039Â The increase in the gross carrying amount of intangible assets as of SeptemberÂ 30,Â 2024, compared to DecemberÂ 31,Â 2023, relates to the positive impact of foreign currency translation adjustments due to the strengthening of sterling against the U.S. dollar.The assumptions and estimates used to determine future cash flows and remaining useful lives of our intangible and other long-lived assets are complex and subjective. They can be affected by various factors, including external factors, such as industry and economic trends, and internal factors such as changes in our business strategy and our forecasts for specific product lines.Based on finite-lived intangible assets recorded as of SeptemberÂ 30,Â 2024, and assuming the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands):Â Year Ending December 31,Estimated Amortization Expense2024 (remainder)$162,109Â 2025648,436Â 2026648,436Â 2027648,436Â 2028647,104Â Thereafter2,389,696Â Total$5,144,217Â  X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Certain Balance Sheet Items 9 Months Ended Sep. 30, 2024 Certain Balance

Sheet Items [Abstract] Â  Certain Balance Sheet Items Certain Balance Sheet Items Property, plant and equipment consisted of the following (in thousands):September 30,2024December 31,2023Manufacturing equipment and machinery$91,560Â $82,897Â Leasehold improvements71,950Â 67,722Â Land and buildings70,762Â 70,912Â Computer software41,847Â 38,134Â Construction-in-progress30,645Â 18,661Â Computer equipment17,530Â 15,398Â Furniture and fixtures8,942Â 9,273Â Subtotal333,236Â 302,997Â Less accumulated depreciation and amortization(156,814)(133,351)Property, plant and equipment, net$176,422Â $169,646Â Accrued liabilities consisted of the following (in thousands):September 30,2024December 31,2023Rebates and other sales deductions$405,134Â $325,711Â Employee compensation and benefits125,497Â 121,209Â Accrued royalties40,923Â 30,706Â Clinical trial accruals37,620Â 44,757Â Consulting and professional services32,844Â 19,538Â Sales return reserve24,545Â 20,435Â Selling and marketing accruals24,539Â 14,743Â Accrued interest22,445Â 36,443Â Current portion of lease liabilities19,103Â 19,447Â Inventory-related accruals14,015Â 13,977Â Accrued collaboration expenses12,805Â 10,158Â Accrued construction-in-progress9,040Â 5,141Â Accrued facilities expenses5,439Â 55,455Â Derivative instrument liabilities572Â 681Â Other84,057Â 75,513Â Total accrued liabilities$858,578Â $793,914Â  X - DefinitionCertain Balance Sheet Items [Abstract] + ReferencesNo definition available. + Details Name: jazz_CertainBalanceSheetItemsAbstract Namespace Prefix: jazz_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Debt 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â  Debt Debt The following table summarizes the carrying amount of our indebtedness (in thousands):September 30,2024December 31,20232024 Notes$â€”Â $575,000Â Unamortized - debt issuance costsâ€”Â (1,046)2024 Notes, netâ€”Â 573,954Â 2026 Notes 1,000,000Â 1,000,000Â Unamortized - debt issuance costs(4,456)(6,400)2026 Notes, net995,544Â 993,600Â 2030 Notes1,000,000Â â€”Â Unamortized - debt issuance costs(19,081)â€”Â 2030 Notes, net980,919Â â€”Â Secured Notes 1,482,824Â 1,480,214Â Term Loan 2,652,515Â 2,665,174Â Total debt6,111,802Â 5,712,942Â Less current portion31,000Â 604,954Â Total long-term debt$6,080,802Â $5,107,988Â Credit Agreement On MayÂ 5,Â 2021, the Company, Jazz Financing Lux S.Ã .r.l., or Jazz Lux, and certain of our other subsidiaries, as borrowers, or, collectively with the Company and Jazz Lux, the â€œBorrowersâ€, entered into the Credit Agreement by and among the Borrowers, the lenders and issuing banks from time to time party thereto, Bank of America, N.A., as administrative agent and U.S. Bank Trust Company, National Association, as collateral trustee, or the Credit Agreement. The Credit Agreement initially provided for (i) a seven-year $3.1Â billion term loan B facility, or the Dollar Term Loan, which was drawn by Jazz Lux on the closing date thereof in U.S. dollars (ii) a seven-year â‚¬625.0 million term loan B facility, or the Euro Term Loan, which was drawn by Jazz Lux on the closing date thereof in Euros and (iii) a five-year $500.0Â million revolving credit facility, or the Revolving Credit Facility.In January 2024, Jazz Lux entered into an amendment, or the Repricing Amendment No.1, to the Credit Agreement. Upon entry into the Repricing Amendment No.1, certain existing lenders converted a portion of the outstanding Dollar Term Loan into a new tranche of U.S. dollar term loans, or the Tranche B-1 Dollar Term Loans, and Jazz Lux borrowed $201.9Â million aggregate principal amount of additional Tranche B-1 Dollar Term Loans, the proceeds of which were used to repay the portion of the outstanding Dollar Term Loan that was not converted. In JulyÂ 2024, Jazz Lux entered into an amendment, or the Repricing Amendment No. 2, to the Credit Agreement, or the Amended Credit Agreement. Upon entry into the Amended Credit Agreement, certain existing lenders converted a portion of the outstanding Tranche B-1 Dollar Term Loans into a new tranche of U.S. dollar term loans, or the Tranche B-2 Dollar Term Loans, and Jazz Lux borrowed $289.6Â million aggregate principal amount of additional Tranche B-2 Dollar Term Loans, the proceeds of which were used to repay the portion of the outstanding Tranche B-1 Dollar Term Loans that were not converted.The Tranche B-2 Dollar Term Loans are a separate class of term loans under the Amended Credit Agreement with the same material terms (including with respect to maturity, prepayment, security, covenants and events of default) as the previously outstanding Tranche B-1 Dollar Term Loans and the initial Dollar Term Loan incurred on May 5, 2021, with the interest rate amended as described below and the credit spread adjustment removed. The principal amount of Tranche B-1 Dollar Term Loans outstanding immediately prior to the Repricing Amendment No. 2 and the outstanding principal amount of Tranche B-2 Dollar Term Loans immediately following the Repricing Amendment No.2, each totaled $2.7Â billion. The Tranche B-2 Dollar Term Loans bear interest at a rate equal to either (a) Term SOFR, or (b) the prime lending rate, in each case, plus an applicable margin. The applicable margin for the Tranche B-2 Dollar Term Loans is 2.25% (in the case of Term SOFR borrowings) and 1.25% (in the case of borrowings at the prime lending rate), a decrease of 75 basis points from the applicable margin on the Tranche B-1 Dollar Term Loans. The Tranche B-2 Dollar Term Loans are subject to a Term SOFR floor of 0.50%. As of SeptemberÂ 30,Â 2024, the interest rate and effective interest rate on the Tranche B-2 Dollar Term Loans were 7.10% and 8.27%, respectively. The Tranche B-2 Dollar Term Loans will amortize in quarterly installments equal to 0.286294791% of the initial aggregate principal amount thereof, with the remaining balance payable on MayÂ 5,Â 2028.The applicable margin for the Revolving Credit Facility ranges from 3.25% to 2.75% (in the case of Term SOFR borrowings) and 2.25% to 1.75% (in the case of borrowings at the prime lending rate), depending on our first lien secured net leverage ratio level, any loans under the Revolving Credit Facility are not subject to a Term SOFR floor. The Revolving Credit Facility has a commitment fee payable on the undrawn amount ranging from 0.50% to 0.40% per annum based upon our first lien secured net leverage ratio. As of SeptemberÂ 30,Â 2024, we had an undrawn Revolving Credit Facility totaling $500.0Â million.2030 NotesIn September 2024, Jazz Investments I Limited, or Jazz Investments, our wholly owned subsidiary, completed a private placement of $1.0 billion principal amount of the 2030 Notes. Interest on the 2030 Notes is payable semi-annually in cash in arrears on March 15 and September 15 of each year, beginning on March 15, 2025, at a rate of 3.125%Â per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2030 Notes. The 2030 Notes mature on SeptemberÂ 15, 2030, unless earlier exchanged, redeemed or repurchased.The holders of the 2030 Notes have the ability to require us to repurchase all or a portion of their 2030 Notes for cash at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date in the event we undergo a fundamental change (as defined in the indenture related to the 2030 Notes), such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from any of The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or The Nasdaq Capital Market (or any of their respective successors). Additionally, the terms and covenants in the indenture related to the 2030 Notes include certain events of default after which the 2030 Notes may be due and payable immediately. Prior to September 15, 2030, we may redeem the 2030 Notes, in whole but not in part, in connection with certain tax-related events. We also may redeem the 2030 Notes on or after September 20, 2027 and prior to June 15, 2030, in whole or in part (subject to the partial redemption limitation described in the indenture related to the 2030 Notes), if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.The 2030 Notes are exchangeable at an initial exchange rate of 6.5339 ordinary shares per $1,000 principal amount of 2030 Notes, which is equivalent to an initial exchange price of approximately $153.05 per ordinary share. Upon exchange of the 2030 Notes, we will pay cash up to the aggregate principal amount of the 2030 Notes to be exchanged and pay or deliver, as the case may be, cash, ordinary shares or a combination of cash and ordinary shares, at our election, in respect of the remainder, if any, of our exchange obligation in excess of the aggregate principal amount of the 2030 Notes being exchanged. The exchange rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes (as defined in the indenture related to the 2030 Notes) that occur prior to the maturity date or upon our issuance of a notice of redemption, we will, in certain circumstances, increase the exchange rate for a holder who elects to exchange its 2030 Notes in connection with that make-whole fundamental change or exchange its 2030 Notes called (or deemed called) for redemption during the related redemption period. Prior to June 15, 2030, the 2030 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.Exchangeable Senior NotesThe Exchangeable Senior Notes were issued by Jazz Investments, or the Issuer, a 100%-owned finance subsidiary of Jazz Pharmaceuticals plc. The Exchangeable Senior Notes are senior unsecured obligations of the Issuer and are fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc. No subsidiary of Jazz Pharmaceuticals plc guaranteed the Exchangeable Senior Notes. Subject to certain local law restrictions on payment of dividends, among other things, and potential negative tax consequences, we are not aware of any significant restrictions on the ability of Jazz Pharmaceuticals plc to obtain funds from the Issuer or Jazz Pharmaceuticals plcâ€™s other subsidiaries by dividend or loan, or any legal or economic restrictions on the ability of the Issuer or Jazz Pharmaceuticals plcâ€™s other subsidiaries to transfer funds to Jazz Pharmaceuticals plc in the form of cash dividends, loans or advances. There is no assurance that in the future such restrictions will not be adopted.The 2030 Notes are accounted for as a single liability measured at its amortized cost. The total liability is reflected net of issuance costs of $19.2Â million which will be amortized over the term of the 2030 Notes. The effective interest rate of the 2030 Notes is 3.46%. During the three months ended September 30, 2024 we recognized interest expense of $2.3Â million, of which $2.2Â million related to the contractual coupon rate and $0.1Â million related to the amortization of debt issuance costs. The total liability of the 2026 Notes is reflected net of issuance costs of $15.3Â million which will be amortized over the term of the 2026 Notes. The effective interest rate of the 2026 Notes is 2.26%. During the three months ended SeptemberÂ 30,Â 2024 and 2023, we recognized interest expense of $5.7Â million, of which $5.0Â million related to the contractual coupon rate and $0.7Â million related to the amortization of debt issuance costs, respectively. During the nine months ended SeptemberÂ 30,Â 2024 and 2023, we recognized interest expense of $16.8Â million, of which $15.0Â million related to the contractual coupon rate and $1.8Â million related to the amortization of debt issuance costs, respectively.On AugustÂ 15, 2024, the maturity date for the 2024 Notes, we repaid the $575.0Â million aggregate principal amount, plus accrued and unpaid interest thereon. During the three months ended SeptemberÂ 30,Â 2024, we recognized interest expense of $1.3Â million, of which $1.0Â million related to the contractual coupon rate and $0.3Â million related to the amortization of debt issuance costs. During the three months ended SeptemberÂ 30,Â 2023, we recognized interest expense of $2.5Â million, of which $2.1Â million related to the contractual coupon rate and $0.4Â million related to the amortization of debt issuance costs. During the nine months ended SeptemberÂ 30,Â 2024, we recognized interest expense of $6.4Â million, of which $5.3Â million related to the contractual coupon rate and $1.1Â million related to the amortization of debt issuance costs. During the nine months ended SeptemberÂ 30,Â 2023, we recognized interest expense of $7.6Â million, of which $6.4Â million related to the contractual coupon rate and $1.2Â million related to the amortization of debt issuance costs, respectively.MaturitiesScheduled maturities with respect to our long-term debt principal balances outstanding as of SeptemberÂ 30,Â 2024 were as follows (in thousands): Year Ending December 31,Scheduled Long-Term Debt Maturities2024 (remainder)$7,750Â 202531,000Â 20261,031,000Â 202731,000Â 20282,598,500Â Thereafter2,500,000Â Total$6,199,250Â  X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â  Commitments and Contingencies Commitments and Contingencies IndemnificationIn the normal course of business, we enter into agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. Our exposure under these agreements is unknown because it involves future claims that may be made but have not yet been made against us. To date, we have not paid any claims or been required to defend any action related to these indemnification obligations.We have agreed to indemnify our executive officers, directors and certain other employees for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we did not recognize any liabilities relating to these obligations as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.Legal Proceedings We are involved in legal proceedings, including the following matters:Xyrem Antitrust LitigationFrom JuneÂ 2020 to MayÂ 2022, a number of lawsuits were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the patent litigation settlement agreements we entered with generic drug manufacturers who had filed Abbreviated New Drug Applications, or ANDA, violate state and federal antitrust and consumer protection laws, as follows:On JuneÂ 17,Â 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by Blue Cross and Blue Shield Association, or BCBS, against Jazz Pharmaceuticals plc, Jazz Pharmaceuticals, Inc., and Jazz Pharmaceuticals Ireland Limited, or, collectively, the Company Defendants (hereinafter referred to as the BCBS Lawsuit). The BCBS Lawsuit also names Roxane Laboratories, Inc., Hikma Pharmaceuticals USA Inc., Eurohealth (USA), Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., and Lupin Inc., or, collectively, the BCBS Defendants.On JuneÂ 18 and JuneÂ 23,Â 2020, respectively, two additional class action lawsuits were filed against the Company Defendants and the BCBS Defendants: one by the New York State Teamsters Council Health and Hospital Fund in the United States District Court for the Northern District of California, and another by the Government Employees Health Association Inc. in the United States District Court for the Northern District of Illinois (hereinafter referred to as the GEHA Lawsuit).On JuneÂ 18,Â 2020, a class action lawsuit was filed in the United States District Court for the Northern District of California by the City of Providence, Rhode Island, on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc, and Roxane Laboratories, Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals USA Inc., and Hikma Pharmaceuticals plc, or, collectively, the City of Providence Defendants.On JuneÂ 30,Â 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by UFCW Local 1500 Welfare Fund on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals Ireland Ltd., Jazz Pharmaceuticals, Inc., Roxane Laboratories, Inc., Hikma Pharmaceuticals plc, Eurohealth (USA), Inc. and West-Ward Pharmaceuticals Corp., or collectively the UFCW Defendants (hereinafter referred to as the UFCW Lawsuit).On JulyÂ 13,Â 2020, the plaintiffs in the BCBS Lawsuit and the GEHA Lawsuit dismissed their complaints in the United States District Court for the Northern District of Illinois and refiled their respective lawsuits in the United States District Court for the Northern District of California. On JulyÂ 14,Â 2020, the plaintiffs in the UFCW Lawsuit dismissed their complaint in the United States District Court for the Northern District of Illinois and on JulyÂ 15,Â 2020, refiled their lawsuit in the United States District Court for the Northern District of California.On JulyÂ 31,Â 2020, a class action lawsuit was filed in the United States District Court for the Southern District of New York by the A.F. of L.-A.G.C. Building Trades Welfare Plan on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc (hereinafter referred to as the AFL Plan Lawsuit). The AFL Plan Lawsuit also names Roxane Laboratories Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc.On AugustÂ 14,Â 2020, an additional class action lawsuit was filed in the United States District Court for the Southern District of New York by the Self-Insured Schools of California on behalf of itself and all others similarly situated, against the Company Defendants, as well as Hikma Pharmaceuticals plc, Eurohealth (USA) Inc., Hikma Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Roxane Laboratories, Inc., Amneal Pharmaceuticals LLC, Endo International, plc, Endo Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., Lupin Inc., Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Holdings USA, Inc., Sun Pharmaceutical Industries, Inc., Ranbaxy Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Watson Laboratories, Inc., Wockhardt Ltd., Morton Grove Pharmaceuticals, Inc., Wockhardt USA LLC, Mallinckrodt plc, and Mallinckrodt LLC (hereinafter referred to as the Self-Insured Schools Lawsuit).On SeptemberÂ 16,Â 2020, an additional class action lawsuit was filed in the United States District Court for the Northern District of California, by Ruth Hollman on behalf of herself and all others similarly situated, against the same defendants named in the Self-Insured Schools Lawsuit.In DecemberÂ 2020, the above cases were centralized and transferred to the United States District Court for the Northern District of California, where the multidistrict

litigation will proceed for the purpose of discovery and pre-trial proceedings. On MarchÂ 18,Â 2021, United Healthcare Services, Inc. filed a lawsuit in the United States District Court for the District of Minnesota against the Company Defendants, Hikma Pharmaceuticals plc, Roxane Laboratories, Inc., Hikma Pharmaceuticals USA Inc., Eurohealth (USA) Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., and Lupin Pharmaceuticals, Inc., raising similar allegations, or the UHS Lawsuit. On MarchÂ 24,Â 2021, the U.S. Judicial Panel on Multidistrict Litigation conditionally transferred the UHS Lawsuit to the United States District Court for the Northern District of California, where it was consolidated for discovery and pre-trial proceedings with the other cases.On AugustÂ 13,Â 2021, the United States District Court for the Northern District of California granted in part and denied in part the Company Defendants' motion to dismiss the complaints in the cases referenced above.On OctoberÂ 8,Â 2021, Humana Inc. filed a lawsuit in the United States District Court for the Northern District of California against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On OctoberÂ 8,Â 2021, Molina Healthcare Inc. filed a lawsuit in the United States District Court for the Northern District of California against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On FebruaryÂ 17,Â 2022, Health Care Service Corporation filed a lawsuit in the United States District Court for the Northern District of California against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations.On AprilÂ 19,Â 2023, the Court held a hearing on class certification in the consolidated multi-district litigation referenced above. On MayÂ 12,Â 2023, the Court granted the plaintiffsâ€™ motion and preliminarily certified classes of Xyrem purchasers seeking monetary and injunctive relief. The Court excluded Xywav purchasers from the classes. On AprilÂ 26,Â 2024, we, Hikma, and the plaintiffs filed motions for summary judgment. The Court held oral argument on these motions on JulyÂ 19,Â 2024. On August 26, 2024, the Court issued a decision granting in part and denying in part the partiesâ€™ motions for summary judgment. On JuneÂ 13,Â 2024, we filed a motion to decertify the class. On June 28,Â 2024, the plaintiffs filed a motion to amend the definition of the certified class. The Court held oral argument on these motions on AugustÂ 22,Â 2024. On October 18, 2024, the Court issued a decision denying our motion to decertify the class and granting the plaintiffsâ€™ motion to amend the class definition. On November 1, 2024, we filed a petition with the United States Court of Appeals for the Ninth Circuit seeking leave to appeal the Courtâ€™s decision amending the class definition. The Ninth Circuit has not yet ruled on the petition. Trial in this matter has been rescheduled for May 19,Â 2025. On JanuaryÂ 13,Â 2023, Amneal Pharmaceuticals LLC, Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, notified the Court that they had reached a settlement-in-principle with the class action plaintiffs. On AprilÂ 19,Â 2023, the Court held a hearing on a motion for preliminary approval of this proposed settlement. On MayÂ 12,Â 2023, the Court granted the motion for preliminary approval of the proposed settlement. On JanuaryÂ 11,Â 2024, the Court held a hearing on the motion for final approval of the proposed settlement. The Court deferred ruling and scheduled a further hearing for final approval of the proposed settlement on AprilÂ 17,Â 2024. During February and MarchÂ 2024, the parties notified the Court of settlements between certain non-class action plaintiffs and each of Amneal and Lupin, and the Court dismissed those plaintiffsâ€™ claims against the applicable parties. On AprilÂ 17,Â 2024, the Court issued an order granting the motion for final approval of the settlement between the class action plaintiffs, Amneal, and Lupin. On DecemberÂ 11,Â 2023, Blue Cross and Blue Shield of Florida, Inc. and Health Options, Inc. filed a lawsuit in the United States District Court for the Middle District of Florida against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., and Eurohealth (USA), Inc., raising similar allegations. On JanuaryÂ 23,Â 2024, the Blue Cross Florida case was transferred to the United States District Court for the Northern District of California and consolidated with the above referenced multidistrict litigation for pretrial purposes.On MayÂ 9,Â 2022, Aetna Inc., or Aetna, filed a lawsuit in the Superior Court of California for the County of Alameda against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On DecemberÂ 27,Â 2022, the Court granted in part and denied in part our motion to dismiss Aetnaâ€™s complaint. As a result of that ruling, the generic defendants have been dismissed from the case, and certain of Aetnaâ€™s claims against Jazz have been dismissed. On JanuaryÂ 27,Â 2023, Aetna filed an amended complaint against Jazz. On MarchÂ 22,Â 2023, we filed motions to dismiss and to strike portions of the amended complaint. On JuneÂ 26,Â 2023, the Court granted our motions, and granted Aetna leave to further amend its complaint. On NovemberÂ 17,Â 2023, Aetna filed its second amended complaint. On FebruaryÂ 2,Â 2024, we filed our answer to the second amended complaint and Hikma filed a motion to quash service. The Court scheduled a hearing on Hikmaâ€™s motion for December 4, 2024. The Court has not set a further schedule in this case.The plaintiffs in certain of these lawsuits are seeking to represent a class of direct purchasers of Xyrem, and the plaintiffs in the remaining lawsuits are seeking to represent a class of indirect purchasers of Xyrem. Each of the lawsuits generally alleges violations of U.S. federal and state antitrust, consumer protection, and unfair competition laws in connection with the Company Defendantsâ€™ conduct related to Xyrem, including actions leading up to, and entering into, patent litigation settlement agreements with each of the other named defendants. Each of the lawsuits seeks monetary damages, exemplary damages, equitable relief against the alleged unlawful conduct, including disgorgement of profits and restitution, and injunctive relief. It is possible that additional lawsuits will be filed against the Company Defendants making similar or related allegations. If the plaintiffs were to be successful in their claims, they may be entitled to injunctive relief or we may be required to pay significant monetary damages, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.Patent Infringement LitigationAvadel LitigationOn MayÂ 13,Â 2021, we filed a patent infringement suit against Avadel Pharmaceuticals plc, or Avadel, and several of its corporate affiliates in the United States District Court for the District of Delaware. The suit alleges that Avadelâ€™s Lumryz will infringe five of our patents related to controlled release formulations of oxybate and the safe and effective distribution of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe these patents, and an award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product will not infringe our patents. Avadel filed a motion for partial judgment on the pleadings on its counterclaim that one of our patents should be delisted from FDA's Orange Book, or the Orange Book. On NovemberÂ 18,Â 2022, the Court issued an order that we delist the patent from the Orange Book. On NovemberÂ 22,Â 2022, we filed a notice of appeal to the United States Court of Appeals for the Federal Circuit. The Federal Circuit temporarily stayed the District Courtâ€™s delisting order. On FebruaryÂ 24,Â 2023, the Federal Circuit affirmed the District Courtâ€™s delisting order, lifted the temporary stay, and gave Jazz 14 days to request that FDA delist the patent from the Orange Book. Jazz complied with the Federal Circuitâ€™s order and requested delisting on FebruaryÂ 28,Â 2023. On MarchÂ 3,Â 2023, we and Avadel stipulated to the dismissal without prejudice of the claims and counterclaims related to infringement and validity of the delisted patent in both this suit and a later-filed suit described below related to the same patent.On AugustÂ 4,Â 2021, we filed an additional patent infringement suit against Avadel in the United States District Court for the District of Delaware. The second suit alleges that Avadelâ€™s Lumryz will infringe a newly-issued patent related to sustained-release formulations of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe this patent, and an award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product will not infringe our patents. On NovemberÂ 10,Â 2021, we filed an additional patent infringement suit against Avadel in the United States District Court for the District of Delaware. The third suit alleges that Avadelâ€™s Lumryz will infringe a newly-issued patent related to sustained-release formulations of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe this patent, and an award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product will not infringe our patents.On AprilÂ 14,Â 2022, Avadel sued us in the United States District Court for the District of Delaware. Avadelâ€™s suit alleges that we misappropriated trade secrets related to Avadelâ€™s once-nightly sodium oxybate development program and breached certain contracts between the parties. Avadel seeks monetary damages, an injunction preventing us from using Avadelâ€™s confidential information, and an order directing the United States Patent and Trademark Office to modify the inventorship of one of our oxybate patents. On JulyÂ 8,Â 2022, we filed a motion for judgment on the pleadings, which the Court denied on JulyÂ 18,Â 2023. The denial is not a ruling that Jazz misappropriated Avadelâ€˜s trade secrets or breached any contract. The case will go forward in discovery and the Court instructed the parties to submit a proposed scheduling order.On JuneÂ 7,Â 2022, we received notice from Avadel that it had filed a "paragraph IV certification" regarding one patent listed in the Orange Book for Xyrem. A paragraph IV certification is a certification by a generic applicant that alleges that patents covering the branded product are invalid, unenforceable, and/or will not be infringed by the manufacture, use or sale of the generic product. On JulyÂ 15,Â 2022, we filed an additional lawsuit against Avadel asserting infringement of that patent. The suit alleges that the filing of Avadelâ€™s application for approval of FT218 is an act of infringement, and that Avadelâ€™s product would infringe the patent if launched. The suit seeks an injunction to prevent Avadel from launching a product that would infringe the patent, and an award of damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patent is invalid, that its product would not infringe, and that by listing the patent in the Orange Book, we engaged in unlawful monopolization in violation of the Sherman Act. On DecemberÂ 9,Â 2022, we filed a motion to dismiss Avadelâ€™s counterclaims. On JuneÂ 29,Â 2023, we filed a motion seeking leave to supplement our motion to dismiss, as well as a motion to stay discovery pending resolution of the motion to dismiss. As noted above, on MarchÂ 3,Â 2023, we and Avadel stipulated to the dismissal without prejudice of the claims and counterclaims related to infringement and validity of the delisted patent.On NovemberÂ 1,Â 2023, the Court held a claim construction hearing relating to disputed terms in the asserted patents. On DecemberÂ 15,Â 2023, the Court issued a written opinion and order resolving the partiesâ€™ remaining claim construction disputes. On NovemberÂ 20,Â 2023, we and Avadel each filed motions for summary judgment. On FebruaryÂ 14,Â 2024, the Court issued a written opinion and order denying both partiesâ€™ motions for summary judgment.Trial regarding our patent infringement claims against Avadel began on FebruaryÂ 26,Â 2024, and concluded on MarchÂ 4,Â 2024, with the jury finding both of our asserted patents valid, and awarding us damages for infringement for Avadelâ€™s past sales of Lumryz. On AprilÂ 12,Â 2024, we filed a motion for a permanent injunction and ongoing royalties. On AugustÂ 27,Â 2024, the Court granted our motion for an injunction in part, and requested additional briefing about ongoing royalties. The issued injunction prevents Avadel from seeking FDA approval or marketing Lumryz for the treatment of idiopathic hypersomnia or other indications not already a part of Lumryzâ€™s product labeling as of March 4, 2024, and enjoins Avadel from infringing in any way Claim 24 of our â€™782 patent by making, using or selling Lumryz through and including the FebruaryÂ 2036 expiration date of the â€™782 patent, subject to certain exclusions including, among other things (i) for the treatment of narcolepsy, (ii) for the treatment of patients who have been prescribed Lumryz as of the effective date of the injunction conditioned on the payment of an amount to be determined and (iii) in clinical trials and studies ongoing as of the effective date of the injunction. The Court also granted our motion for an ongoing royalty for any future sale of Lumryz to patients with narcolepsy at a rate to be determined based upon further briefing by the parties on the appropriate ongoing rate above 3.5%. Avadel is appealing this injunction to the United States Court of Appeals for the Federal Circuit. The Federal Circuit has said the appeal will be placed on its February 2025 oral argument calendar. Avadel filed a motion with the district court for a stay of the injunction pending appeal, which the district court denied. Avadel also filed a motion to stay the injunction pending appeal with the Federal Circuit, which the Federal Circuit granted to the limited extent that the injunction enjoins initiating new clinical trials or studies and denied in all other respects. The Court scheduled a trial regarding Avadelâ€™s counterclaims for unlawful monopolization for NovemberÂ 3,Â 2025 and a trial regarding Avadelâ€™s trade secret misappropriation claims for DecemberÂ 15,Â 2025. On MarchÂ 13,Â 2024 and MarchÂ 19,Â 2024, we filed motions to stay Avadelâ€™s unlawful monopolization counterclaim and trade secret claims, respectively, pending resolution of post-trial motions and potential appeals in the patent infringement suit. On MayÂ 24,Â 2024, the Court denied the motion to stay the unlawful monopolization counterclaim and the previously-filed motion to dismiss the same. On JuneÂ 7,Â 2024, we filed a motion for reargument or, in the alternative, to certify the decision for interlocutory appeal. That motion remains pending and no hearing date has been set. The Court stayed Avadelâ€™s trade secret misappropriation claims pending appeal of the injunction in the related patent matter. We filed a further motion to stay the unlawful monopolization counterclaims, which remains pending.On JulyÂ 21,Â 2022, Avadel filed a lawsuit against FDA in the United States District Court for the District of Columbia, challenging FDAâ€™s determination that Avadel was required to file a paragraph IV certification regarding one of our Orange Book listed patents. Avadel filed a motion for preliminary injunction or, in the alternative, summary judgment, seeking relief including a declaration that FDAâ€™s decision requiring patent certification was unlawful, an order setting aside that decision, an injunction prohibiting FDA from requiring such certification as a precondition to approval of its application for FT218, and an order requiring FDA to take final action on Avadelâ€™s application for approval of FT218 within 14 days of the Courtâ€™s ruling. On JulyÂ 27,Â 2022, we filed a motion to intervene in that case, which the Court granted. The Court held a hearing on the partiesâ€™ respective motions for summary judgment on OctoberÂ 7,Â 2022. On NovemberÂ 3,Â 2022, the Court granted our and FDAâ€™s motions for summary judgment and denied Avadelâ€™s motion.Xywav Patent LitigationIn JuneÂ 2021, we received notice from Lupin Inc., or Lupin, that it has filed with FDA an ANDA, for a generic version of Xywav. The notice from Lupin included a paragraph IV certification with respect to ten of our patents listed in FDAâ€™s Orange Book for Xywav on the date of our receipt of the notice. The asserted patents relate generally to the composition and method of use of Xywav, and methods of treatment when Xywav is administered concomitantly with certain other medications.In JulyÂ 2021, we filed a patent infringement suit against Lupin in the United States District Court for the District of New Jersey. The complaint alleges that by filing its ANDA, Lupin has infringed ten of our Orange Book listed patents. We are seeking a permanent injunction to prevent Lupin from introducing a generic version of Xywav that would infringe our patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on Lupin's ANDA. In JuneÂ 2021, FDA recognized seven years of Orphan Drug Exclusivity for Xywav through JulyÂ 21,Â 2027. On OctoberÂ 4,Â 2021, Lupin filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product, if approved, will not infringe our patents.In AprilÂ 2022, we received notice from Lupin that it had filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Xywav. On MayÂ 11,Â 2022, we filed an additional lawsuit against Lupin in the United States District Court for the District of New Jersey alleging that by filing its ANDA, Lupin infringed the newly-issued patent related to a method of treatment when Xywav is administered concomitantly with certain other medications. The suit seeks a permanent injunction to prevent Lupin from introducing a generic version of Xywav that would infringe our patent. On JuneÂ 22,Â 2022, the Court consolidated the two lawsuits we filed against Lupin. In NovemberÂ 2022, we received notice from Lupin that it had filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Xywav. On JanuaryÂ 19,Â 2023, we filed an additional lawsuit against Lupin in the United States District Court for the District of New Jersey alleging that by filing its ANDA, Lupin infringed the newly-issued patent referenced in its NovemberÂ 2022 paragraph IV certification, as well as another patent that issued in JanuaryÂ 2023. The suit seeks a permanent injunction to prevent Lupin from introducing a generic version of Xywav that would infringe the two patents in suit. On FebruaryÂ 15,Â 2023, the Court consolidated the new lawsuit with the two suits we previously filed against Lupin. No trial date has been set in the consolidated case against Lupin.In FebruaryÂ 2023, we received notice from Teva Pharmaceuticals, Inc., or Teva, that it had filed with FDA an ANDA for a generic version of Xywav. The notice from Teva included a paragraph IV certification with respect to thirteen of our patents listed in FDAâ€™s Orange Book for Xywav on the date of the receipt of the notice. The asserted patents relate generally to the composition and method of use of Xywav, and methods of treatment when Xywav is administered concomitantly with certain other medications. In MarchÂ 2023, we filed a patent infringement suit against Teva in the United States District Court for the District of New Jersey. The complaint alleges that by filing its ANDA, Teva has infringed thirteen of our Orange Book listed patents. We are seeking a permanent injunction to prevent Teva from introducing a generic version of Xywav that would infringe our patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on Tevaâ€™s ANDA. On MayÂ 23,Â 2023, Teva filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product, if approved, will not infringe our patents.On DecemberÂ 15,Â 2023, based on a stipulation between all parties, the Court consolidated the Lupin lawsuits and the Teva lawsuit for all purposes. No trial date has been set in the consolidated case.In July 2024, we received notices from Lupin and Teva that they had each filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Xywav. On August 27, 2024, we filed an additional lawsuit in the United States District Court for the District of New Jersey against each of Lupin and Teva, alleging that, by filing its ANDA, each party infringed the newly-issued patent related to a method of treatment using Xywav. The suits seek orders that the effective date of FDA approval of each defendantâ€™s application shall be a date no earlier than the expiration of the newly-issued patent.Epidiolex Patent LitigationIn November and DecemberÂ 2022, we received notices from: Teva Pharmaceuticals, Inc.; Padagis US

LLC; Apotex Inc.; API Pharma Tech LLC and InvaGen Pharmaceuticals, Inc.; Lupin Limited; Taro Pharmaceutical Industries Ltd.; Zenara Pharma Private Limited and Biophore Pharma, Inc.; MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc.; Alkem Laboratories Ltd.; and Ascent Pharmaceuticals, Inc. (hereinafter referred to as the â€œEpidiolex ANDA Filersâ€), that they have each filed with FDA an ANDA for a generic version of Epidiolex (cannabidiol) oral solution. As of the date of this filing, we are not aware of other ANDA filers. The notices from the Epidiolex ANDA Filers each included a â€œparagraph IV certificationâ€ with respect to certain of our patents listed in FDAâ€™s Orange Book for Epidiolex on the date of the receipt of the notice. The listed patents relate generally to the composition and method of use of Epidiolex, and methods of treatment using Epidiolex. A paragraph IV certification is a certification by a generic applicant that alleges that patents covering the branded product are invalid, unenforceable, and/or will not be infringed by the manufacture, use or sale of the generic product.On JanuaryÂ 3,Â 2023, we filed a patent infringement suit against the Epidiolex ANDA Filers in the United States District Court for the District of New Jersey. The complaint alleges that by filing their ANDAs, the Epidiolex ANDA Filers have infringed certain of our Orange Book listed patents, and seeks an order that the effective date of FDA approval of the ANDAs shall be a date no earlier than the expiration of the last to expire of the asserted patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on the Epidiolex ANDA Filersâ€™ ANDAs.From MarchÂ 2023 through MayÂ 2023, we received the Epidiolex ANDA Filersâ€™ answers to the complaint. The answers include defenses and counterclaims asserting that the Epidiolex ANDA Filersâ€™ products, if launched, would not infringe our patents, that our patents are invalid and, in one instance, counterclaims related to allegations of inequitable conduct and improper listing of patents in the Orange Book. On MayÂ 25,Â 2023, we filed a motion to dismiss certain of the counterclaims. On JanuaryÂ 11,Â 2024, the Court issued an order granting in part and denying in part our motion to dismiss. On SeptemberÂ 20,Â 2024, the Court held a claim construction hearing relating to disputed terms in the asserted patents. The Court has not yet issued a decision on the claim construction disputes. The Court in the Epidiolex Patent Litigation scheduled trial for SeptemberÂ 2025.In June and JulyÂ 2023, we received notice from certain of the Epidiolex ANDA Filers that they had each filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Epidiolex. On JulyÂ 21,Â 2023, we filed an additional lawsuit against all of the Epidiolex ANDA Filers in the United States District Court for the District of New Jersey alleging that, by filing its ANDA, each Epidiolex ANDA Filer infringed the newly-issued patent related to a method of treatment using Epidiolex. The suit seeks an order that the effective date of FDA approval of each Epidiolex ANDA Filerâ€™s application shall be a date no earlier than the expiration of the newly-issued patent.On OctoberÂ 24,Â 2023, we entered into a settlement agreement with Padagis US LLC, or Padagis, that resolved our patent litigation with Padagis related to Epidiolex. Under the settlement agreement, we granted Padagis a license to manufacture, market, and sell its generic version of Epidiolex on a date that depends on the occurrence of certain other events. The specific terms of the Padagis settlement agreement are confidential.On NovemberÂ 20,Â 2023, we entered into a settlement agreement with Teva Pharmaceuticals, Inc., or Teva, that resolved our patent litigation with Teva related to Epidiolex. Under the settlement agreement, we granted Teva a license to manufacture, market and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the Teva settlement agreement are confidential.On DecemberÂ 4,Â 2023, we entered into a settlement agreement with Alkem Laboratories Ltd., or Alkem, that resolved our patent litigation with Alkem related to Epidiolex. Under the settlement agreement, we granted Alkem a license to manufacture, market, and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the Alkem settlement are confidential.On JuneÂ 7,Â 2024, we entered into a settlement agreement with MSN Laboratories Private, Ltd. and MSN Pharmaceuticals, Inc., or together MSN, that resolved our patent litigation with MSN related to Epidiolex. Under the settlement agreement, we granted MSN a license to manufacture, market, and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the MSN settlement are confidential.On September 4, 2024, we entered into a settlement agreement with Lupin, Ltd., that resolved our patent litigation with Lupin related to Epidiolex. Under the settlement agreement, we granted Lupin a license to manufacture, market, and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the Lupin settlement are confidential.On November 1, 2024, we entered into a settlement agreement with InvaGen Pharmaceuticals, Inc., Cipla Ltd., Cipla USA, Inc., and API Pharma Tech LLC (collectively â€œInvaGenâ€) that resolved our patent litigation with InvaGen related to Epidiolex. Under the settlement agreement, we granted InvaGen a license to manufacture, market, and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the InvaGen settlement are confidential.The settlements with Padagis, Teva, Alkem, MSN, Lupin and InvaGen do not resolve the litigation against the other four Epidiolex ANDA Filers, which is ongoing. We cannot predict the specific timing or outcome of events in these matters with respect to the remaining defendants or the impact of developments involving any specific parties or patents on other ongoing proceedings with any specific Epidiolex ANDA Filer.In September and OctoberÂ 2023, we received notice from certain of the Epidiolex ANDA Filers that they had each filed a paragraph IV certification regarding one or more newly-issued patents listed in the Orange Book for Epidiolex. On DecemberÂ 15,Â 2023, we filed an additional lawsuit against seven of the original Epidiolex ANDA Filers with whom we have not previously settled. We filed this lawsuit in the United States District Court for the District of New Jersey alleging that, by filing its ANDA, each Epidiolex ANDA Filer infringed the newly-issued patents related to methods of treatment using Epidiolex. The suit seeks an order that the effective date of FDA approval of each Epidiolex ANDA Filerâ€™s application shall be a date no earlier than the expiration of the newly-issued patents.In March and AprilÂ 2024, we received notice from certain of the Epidiolex ANDA Filers that they had each filed a paragraph IV certification regarding one or more newly-issued patents listed in the Orange Book for Epidiolex. On JulyÂ 3,Â 2024, we filed an additional lawsuit against six of the original Epidiolex ANDA Filers with whom we had not previously settled. We filed this lawsuit in the United States District Court for the District of New Jersey alleging that, by filing its ANDA, each Epidiolex ANDA Filer infringed the newly-issued patents related to methods of treatment using Epidiolex. The suit seeks an order that the effective date of FDA approval of each Epidiolex ANDA Filerâ€™s application shall be a date no earlier than the expiration of the newly-issued patents.Epidiolex also has orphan drug exclusivity, or ODE, for the treatment of seizures associated with LGS or DS in patients 2 years of age and older through SeptemberÂ 28,Â 2025, and for the treatment of seizures associated with LGS or DS in patients between 1 and 2 years of age and for the treatment of seizures associated with TSC through JulyÂ 31,Â 2027.The Company vigorously enforces its intellectual property rights but cannot predict the outcome of these matters.Zepzelca Patent LitigationIn July and August 2024, we received notices from Sandoz Inc., InvaGen Pharmaceuticals, Inc., CIPLA USA, Inc. CIPLA (EU) Limited, CIPLA Limited, Zydus Lifesciences Global FZE, Zydus Pharmaceuticals (USA) Inc., Zydus Lifesciences Limited, RK Pharma, Inc., Apicore US LLC, Archis Pharma LLC, Vgyaan Pharmaceuticals LLC, MSN Pharmaceuticals Inc., and MSN Laboratories PVT. LTD. (hereinafter referred to as the â€œZepzelca ANDA Filersâ€), that they have each filed with FDA an ANDA for a generic version of Zepzelca (lurbinectedin). As of the date of this filing, we are not aware of other ANDA filers. The notices from the Zepzelca ANDA Filers each included a paragraph IV certification with respect to a patent listed in the Orange Book for Zepzelca on the date of the receipt of the notice. The listed patent relates to the drug substance, drug product and approved use of Zepzelca. Jazz is the exclusive licensee to this Zepzelca patent pursuant to an agreement with Pharma Mar, S.A, or PharmaMar. A paragraph IV certification is a certification by a generic applicant that alleges that the patent covering the branded product is invalid, unenforceable, and/or will not be infringed by the manufacture, use or sale of the generic product.On September 11, 2024, we and PharmaMar filed a patent infringement suit against the Zepzelca ANDA Filers in the United States District Court for the District of New Jersey. The complaint alleges that by filing their ANDAs, the Zepzelca ANDA Filers have infringed the Orange Book listed patent for Zepzelca, and seeks an order that the effective date of FDA approval of the ANDAs shall be a date no earlier than the expiration of the asserted patent. On September 12, 2024, we and PharmaMar filed a patent infringement suit against RK Pharma, Inc., Apicore US LLC, Archis Pharma LLC, Vgyaan Pharmaceuticals LLC (collectively â€œRK Pharmaâ€), in the United States District Court for the District of Delaware. The complaint alleges that by filing its ANDA, RK Pharma has infringed the Orange Book listed patent for Zepzelca, and seeks an order that the effective date of FDA approval of RK Pharmaâ€™s ANDA shall be no earlier than the expiration of the asserted patent. MSP LitigationOn AprilÂ 3,Â 2023, MSP Recovery Claims, Series LLC, or MSP, filed a class action lawsuit on behalf itself and others similarly situated against Jazz Pharmaceuticals plc, Jazz Pharmaceuticals, Inc., and Jazz Pharmaceuticals Ireland Limited, (collectively, the Company Defendants), Express Scripts, Inc., Express Scripts Holding Company, Express Scripts Specialty Distribution Services, Inc., Curascript, Inc. d/b/a Curascript, S.D., Priority Healthcare Distribution, Inc. d/b/a Curascript SD and Curascript Specialty Distribution SD, Caring Voice Coalition, and Adira Foundation (collectively with the Company Defendants, referred to as the Defendants) in the United States District Court for the Northern District of California. The MSP complaint alleges that the Defendants conspired to increase the price and quantity dispensed of Xyrem and Prialt, in violation of the Racketeer Influenced and Corrupt Organizations Act and several state laws. The allegations relate generally to the conduct at issue in the investigation conducted by the United States Department of Justice from 2016-2019, involving the Companyâ€™s contributions to certain charitable foundations. MSP seeks monetary damages, restitution, disgorgement, and a declaration that the conduct alleged is unlawful. On JulyÂ 25,Â 2023, we and certain other defendants filed motions to dismiss MSP's complaint, which the Court granted on DecemberÂ 12,Â 2023. On JanuaryÂ 5,Â 2024, the MSP filed an amended complaint. On FebruaryÂ 20,Â 2024, we filed a motion to dismiss MSPâ€™s amended complaint. The Court scheduled a hearing on the motion for JuneÂ 13,Â 2024. On JuneÂ 21,Â 2024, the Court cancelled the hearing. On July 22, 2024, the Court granted the motion. The Court set a deadline of August 12, 2024, to file a second amended complaint. On August 12, 2024, MSP voluntarily dismissed its complaint.FDA LitigationOn JuneÂ 22,Â 2023, we filed a complaint in the United States District Court for the District of Columbia seeking a declaration that FDAâ€™s approval on MayÂ 1,Â 2023, of the New Drug Application, or NDA, for Avadel's Lumryz was unlawful. In the complaint, we alleged that FDA acted outside its authority under the Orphan Drug Act, when, despite ODE protecting Jazzâ€™s low-sodium oxybate product Xywav, FDA approved the Lumryz NDA and granted Lumryz ODE based on FDAâ€™s finding that Lumryz makes a major contribution to patient care and is therefore clinically superior to Xywav and Xyrem. Jazz further alleged that, in doing so, FDA failed to follow its own regulations, failed to follow established agency policy without providing a reasoned explanation for the departure, reversed prior decisions by its own staff and experts without a reasoned explanation, and disregarded the relevant scientific literature and data. The complaint, filed pursuant to the Administrative Procedure Act, asked the Court to vacate and set aside FDAâ€™s approval of the Lumryz NDA and sought a declaration that FDAâ€™s approval of the Lumryz NDA was arbitrary, capricious, an abuse of discretion and otherwise not in accordance with law and that approval of the Lumryz NDA was in excess of FDAâ€™s statutory authority and was made without observance of procedure required by law.On SeptemberÂ 15,Â 2023, we filed a motion for summary judgment. On OctoberÂ 20,Â 2023, Avadel and FDA filed cross motions for summary judgment. Oral argument on these motions was held on MayÂ 10,Â 2024 and on October 30, 2024, the District Court issued an order denying Jazzâ€™s motion for summary judgment and granting Avadelâ€™s and the FDAâ€™s cross-motions for summary judgment. Jazz respectfully disagrees with the Courtâ€™s decision and is evaluating potential options for appeal.Qui tam matterIn July 2022, we received a subpoena from the U.S. Attorneyâ€™s Office, or USAO, for the District of Massachusetts requesting documents related to Xyrem and U.S. Patent No. 8,772,306 (â€œMethod of Administration of Gamma Hydroxybutyrate with Monocarboxylate Transportersâ€), product labeling changes for Xyrem, communications with FDA and the USPTO, pricing of Xyrem, and other related documents. On July 18, 2024, the United States District Court for the District of Massachusetts unsealed a qui tam whistleblower lawsuit underlying the USAOâ€™s subpoena, captioned 1:21-cv-10891-PBS and originally filed under seal on May 27, 2021. The public docket in this matter indicates that on MayÂ 24 and JuneÂ 7,Â 2024, respectively, the United States and a number of states named in the whistleblower complaint declined to intervene in this matter. As such, private whistleblower litigation will proceed in the United States District Court for the District of Massachusetts. The Court set a deadline of September 1, 2024, for the plaintiff to file an amended complaint, and DecemberÂ 1,Â 2024, for Jazz to file a motion to dismiss the amended complaint. The plaintiff filed the amended complaint on SeptemberÂ 1,Â 2024. From time to time, we are involved in legal proceedings arising in the ordinary course of business. We believe there is no other litigation pending that could have, individually or in the aggregate, a material adverse effect on our results of operations or financial condition. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity 9 Months Ended Sep. 30, 2024 Stockholders' Equity Note [Abstract] Â  Shareholders' Equity Shareholdersâ€™ EquityShare Repurchase ProgramIn July 2024, our board of directors authorized a share repurchase program to repurchase ordinary shares having an aggregate purchase price of $500.0Â million, exclusive of any brokerage commissions, or the New Repurchase Program. Under the New Repurchase Program, which has no expiration date, we may repurchase ordinary shares from time to time by any methods and/or structures permitted by applicable law. The timing and amount of repurchases will depend on a variety of factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under the Amended Credit Agreement and the indenture for our Secured Notes, corporate and regulatory requirements and market conditions. The New Repurchase Program may be modified, suspended or discontinued at any time without our prior notice. The New Repurchase Program replaces and supersedes the share repurchase program authorized by our board of directors in November 2016, which, as of the date of it being superseded by the New Repurchase Program, had authorized the repurchase of ordinary shares having an aggregate purchase price of up to $1.5Â billion, exclusive of any brokerage commissions, or the Old Repurchase Program, and, together with the New Repurchase Program, the â€œrepurchase programsâ€. During the three months ended September 30, 2024, we spent a total of $150.0Â million to repurchase 1.4Â million of our ordinary shares, all under the New Repurchase Program, at a purchase price, including commissions, of $109.32 per share. The repurchases during the three months ended September 30, 2024, were effected in privately negotiated transactions with or through one of the initial purchasers of the 2030 Notes concurrently with the pricing of the offering of the 2030 Notes. During the nine months ended September 30, 2024, we spent a total of $311.4Â million to purchase 2.8Â million of our ordinary shares under the repurchase programs at an average total purchase price, including commissions, of $110.06 per share. During the nine months ended September 30, 2023, we spent a total of $170.0Â million to purchase 1.3Â million of our ordinary shares under the Old Repurchase Program at an average total purchase price, including commissions, of $128.89 per share. All ordinary shares repurchased were cancelled. As of September 30, 2024, the remaining amount authorized for repurchases under the New Repurchase Program was $350.0Â million, exclusive of any brokerage commissions.Accumulated Other Comprehensive LossThe components of accumulated other comprehensive loss as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023 were as follows (in thousands):Â Net UnrealizedGain From Hedging ActivitiesForeignCurrencyTranslationAdjustmentsTotalAccumulatedOtherComprehensiveLossBalance at December 31, 2023$235Â $(842,382)$(842,147)Other comprehensive income before reclassifications1,572Â 241,218Â 242,790Â Amounts reclassified from accumulated other comprehensive loss(4,040)â€”Â (4,040)Other comprehensive income (loss), net(2,468)241,218Â 238,750Â Balance at September 30, 2024$(2,233)$(601,164)$(603,397)During the nine months ended SeptemberÂ 30,Â 2024, other comprehensive income (loss) primarily reflects foreign currency translation adjustments, primarily due to the strengthening of the sterling against the U.S. dollar. X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235

-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income per Ordinary Share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â  Net Income per Ordinary Share Net Income per Ordinary ShareBasic net income per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net income per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding.Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023Numerator:Net income$215,055Â $146,820Â $369,005Â $320,678Â Effect of interest on assumed conversions of Exchangeable Senior Notes, net of tax1,028Â 5,912Â 10,761Â 19,951Â Net income for dilutive net income per ordinary share$216,083Â $152,732Â $379,766Â $340,629Â Denominator:Weighted-average ordinary shares used in per share calculations - basic61,414Â 63,114Â 62,275Â 63,532Â Dilutive effect of Exchangeable Senior Notes1,325Â 7,560Â 4,721Â 8,549Â Dilutive effect of employee equity incentive and purchase plans435Â 619Â 515Â 785Â Weighted-average ordinary shares used in per share calculations - diluted63,174Â 71,293Â 67,511Â 72,866Â Net income per ordinary share:Basic$3.50Â $2.33Â $5.93Â $5.05Â Diluted$3.42Â $2.14Â $5.63Â $4.67Â Potentially dilutive ordinary shares from our employee equity incentive and purchase plans are determined by applying the treasury stock method to the assumed vesting of outstanding restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs, the assumed exercise of share options and the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP. Potentially dilutive ordinary shares from the Exchangeable Senior Notes are determined by applying the if-converted method to the assumed issuance of ordinary shares upon exchange of the Exchangeable Senior Notes. In AugustÂ 2023, we made an irrevocable election to fix the settlement method for exchanges of the 2024 Notes to a combination of cash and ordinary shares of the Company with a specified cash amount per $1,000 principal amount of the 2024 Notes of $1,000. As a result, the assumed issuance of ordinary shares upon exchange of the 2024 Notes has only been included in the calculation of diluted net income per ordinary share in the three and nine months ended SeptemberÂ 30,Â 2023 up to the date the irrevocable election was made.In JulyÂ 2024, we made an irrevocable election to fix the settlement method for exchanges of the 2026 Notes to a combination of cash and ordinary shares of the Company with a specified cash amount per $1,000 principal amount of the 2026 Notes of $1,000. As a result, the assumed issuance of ordinary shares upon exchange of the 2026 Notes has only been included in the calculation of diluted net income per ordinary share in the three and nine months ended SeptemberÂ 30,Â 2024, up to the date the irrevocable election was made.For the 2030 Notes, we are required to settle the principal amount in cash and have the option to settle the conversion feature for the amount above the conversion price, or the conversion spread, in cash, ordinary shares or a combination of cash and ordinary shares. The conversion spread will have a dilutive impact on diluted net income per ordinary share when the average market price of our ordinary shares for a given period exceeds the conversion price of the 2030 Notes. For the three and nine months ended SeptemberÂ 30,Â 2024, the 2030 Notes have been excluded from the computation of diluted net income per ordinary share, as the effect would be anti-dilutive since the conversion price of the 2030 Notes exceeded the average market price of our ordinary shares for the three and nine months ended SeptemberÂ 30,Â 2024. The following table represents the weighted-average ordinary shares that were excluded from the calculation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Â 20242023202420232024Employee equity incentive and purchase plans4,465Â 2,501Â 4,701Â 3,091Â  X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â  Revenues Revenues The following table presents a summary of total revenues (in thousands):Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023Xywav$388,466Â $331,633Â $1,072,238Â $935,958Â Xyrem58,114Â 125,110Â 184,526Â 463,009Â Epidiolex/Epidyolex251,558Â 213,711Â 697,376Â 604,846Â Sativex4,58 Neuroscience702,724Â 675,081Â 1,967,844Â 2,018,344Â Rylaze/Enrylaze98,780Â 104,859Â 309,359Â 292,479Â Zepzelca85,843Â 77,994Â 241,990Â 215,523Â Defitelio/defibrotide 65,818Â 47,730Â 158,915Â 132,917Â Vyxeos34,313Â 29,827Â 109,348Â 100,583Â Total Oncology284,754Â 260,410Â 819,612Â 741,502Â Other2,229Â 2,907Â 8,497Â 9,758Â Product sales, net989,707Â 938,398Â 2,795,953Â 2,769,604Â High-sodium oxybate AG royalty revenue58,157Â 28,921Â 162,268Â 36,531Â Other royalty and contract revenues7,105Â 4,821Â 22,556Â 16,134Â Total revenues$1,054,969Â $972,140Â $2,980,777Â $2,822,269Â The following table presents a summary of total revenues attributed to geographic sources (in thousands):Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023United States$953,669Â $884,579Â $2,686,486Â $2,579,401Â Europe77,318Â 68,971Â 230,821Â 194,198Â All other23,982Â 18,590Â 63,470Â 48,670Â Total revenues$1,054,969Â $972,140Â $2,980,777Â $2,822,269Â The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023ESSDS42Â %47Â %42Â %49Â %McKesson13Â %12Â %12Â %11Â %ASD10Â %9Â %9Â %7Â %Financing and paymentOur payment terms vary by the type and location of our customer but payment is generally required in a term ranging from 30 to 65 days. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â  Share-Based Compensation Share-Based Compensation Share-based compensation expense related to RSUs, PRSUs, grants under our ESPP and share options was as follows (in thousands):Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023Selling, general and administrative$37,101Â $35,268Â $112,451Â $113,155Â Research and development18,927Â 16,635Â 55,030Â 49,346Â Cost of product sales3,732Â 4,212Â 10,374Â 11,399Â Total share-based compensation expense, pre-tax59,760Â 56,115Â 177,855Â 173,900Â Income tax benefit from share-based compensation expense(12,190)(9,792)(25,218)(29,533)Total share-based compensation expense, net of tax$47,570Â $46,323Â $152,637Â $144,367Â Restricted Stock UnitsThe table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023RSUs granted (in thousands)102Â 91Â 2,112Â 1,728Â Grant date fair value$110.55Â $134.33Â $118.31Â $145.05Â The fair value of RSUs is determined on the date of grant based on the market price of our ordinary shares on that date. The fair value of RSUs is expensed ratably over the vesting period, generally over four years.Performance-Based Restricted Stock UnitsThe Compensation & Management Development Committee of our board of directors and, in the case of our Chief Executive Officer, the independent members of our board of directors, approved awards of PRSUs to certain employees of the Company, subject to vesting on the achievement of certain commercial and pipeline performance criteria to be assessed over a performance period from the date of the grant to DecemberÂ 31,Â 2024, DecemberÂ 31,Â 2025 and DecemberÂ 31,Â 2026, respectively. The number of shares that will be awarded is determined based on the Companyâ€™s achievement with respect to the performance criteria. For PRSUs granted prior to 2024, the amount of shares awarded will be subject to adjustment based on the application of a relative total shareholder return, or TSR, modifier. For PRSUs granted in 2024, the relative TSR represents one of the performance metrics. In both cases, the number of shares that may be earned ranges between 0% and 200% of the target number of PRSUs granted.The table below shows the number of PRSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of PRSUs granted:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023PRSUs granted (in thousands)58Â 13Â 371Â 270Â Grant date fair value$107.07Â $142.65Â $130.58Â $157.01Â For the PRSUs granted that are subject to a market condition, the grant date fair value for such PRSUs was based on a Monte Carlo simulation model. For PRSUs granted without a market condition, the fair value is determined based on the market price of our ordinary shares on the date of grant. The Company evaluated the performance targets in the context of its current long-range financial plan and its product candidate development pipeline and recognized expense based on the probable number of awards that will ultimately vest.As of SeptemberÂ 30,Â 2024, compensation cost not yet recognized related to unvested RSUs, PRSUs, ESPP and share options was $347.2Â million, $37.3Â million, $9.2Â million and $0.1Â million, respectively, which is expected to be recognized over a weighted-average period of 2.6 years, 1.4 years, 1.1 years and 0.3 years, respectively. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â  Income Taxes Income Taxes Our income tax benefit was $14.5Â million and $33.5Â million for the three and nine months ended SeptemberÂ 30,Â 2024, respectively, compared to $47.2Â million and $86.8Â million for the same periods in 2023, relating to tax arising on income or losses in Ireland, the U.K., the U.S. and certain other foreign jurisdictions and tax deficiencies from share based compensation, offset by deductions on subsidiary equity, foreign derived intangible income benefits and tax credits. The decrease in the income tax benefit for the three and nine months ended September 30, 2024 compared to the same periods in 2023 resulted primarily from changes in the mix of pre-tax income and losses across tax jurisdictions.Our net deferred tax liability is primarily related to acquired intangible assets, and is net of deferred tax assets related to U.S. federal and state tax credits, U.S. federal and state and foreign net operating loss carryforwards and other temporary differences. We maintain a valuation allowance against certain deferred tax assets. Each reporting period, we evaluate the need for a valuation allowance on our deferred tax assets by jurisdiction and adjust our estimates as more information becomes available.We are required to recognize the financial statement effects of a tax position when it is more likely

than not, based on the technical merits, that the position will be sustained upon examination. As a result, we have recorded an unrecognized tax benefit for certain tax benefits which we judge may not be sustained upon examination. We file income tax returns in multiple tax jurisdictions, the most significant of which are Ireland, the U.K. and the U.S. (both at the federal level and in various state jurisdictions). For Ireland, we are no longer subject to income tax examinations by taxing authorities for the years prior to 2019. For the U.K., we are no longer subject to income tax examinations by taxing authorities for the years prior to 2016. The U.S. jurisdictions generally have statute of limitations three to four years from the later of the return due date or the date when the return was filed. However, in the U.S. (at the federal level and in most states), carryforwards that were generated in 2019 and earlier may still be adjusted upon examination by the taxing authorities. One of our subsidiaries is currently under examination by the Luxembourg taxing authorities for the years ended DecemberÂ 31,Â 2017, 2018 and 2019. In OctoberÂ 2022 and in JanuaryÂ 2023, we received tax assessment notices from the Luxembourg taxing authorities for all years under examination relating to certain transfer pricing and other adjustments. The notices propose additional Luxembourg income tax of approximately $25.0Â million, translated at the foreign exchange rate as SeptemberÂ 30, 2024. We disagree with the proposed assessments and are contesting them vigorously. The Government of Ireland, the jurisdiction in which Jazz Pharmaceuticals Plc is incorporated, transposed the Global Minimum Tax Pillar Two rules into domestic legislation as part of the Finance (No. 2) Act 2023 (the "Finance Act"). The Finance Act closely follows the EU Minimum Tax Directive and certain OECD Guidance released to date. The Company is within the scope of these rules, which took effect from January 1, 2024. Under the new legislation, we are liable to pay a top-up tax for the difference between the Pillar Two effective tax rate per jurisdiction and the 15% minimum rate. The rules on how to calculate the 15% effective tax rate are detailed and highly complex and specific adjustments envisaged in the Pillar Two legislation can give rise to different effective tax rates compared to those calculated for accounting purposes. We will account for it as a current tax when it is incurred. We expect to be subject to the top-up tax in relation to our operations in Ireland, where the trading statutory tax rate is 12.5%, though the impact in 2024 is not significant. The proportion of our profit before tax which is subject to the top-up tax and our exposure to Pillar Two income taxes in future years will depend on factors such as future revenues, costs and foreign currency exchange rates. We will continue to monitor changes in law and guidance in relation to Pillar Two. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3 The Company and Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â  Basis of Presentation Basis of PresentationThese unaudited condensed consolidated financial statements have been prepared following the requirements of the U.S. Securities and Exchange Commission for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or U.S. GAAP, can be condensed or omitted. The information included in this Quarterly Report on FormÂ 10â€‘Q should be read in conjunction with our annual audited consolidated financial statements and accompanying notes included in our Annual Report on FormÂ 10â€‘K for the year ended DecemberÂ 31,Â 2023. In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three and nine months ended SeptemberÂ 30,Â 2024, are not necessarily indicative of the results to be expected for the year ending DecemberÂ 31,Â 2024, for any other interim period or for any future period.Our significant accounting policies have not changed substantially from those previously described in our Annual Report on FormÂ 10â€‘K for the year ended DecemberÂ 31,Â 2023. These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our subsidiaries, and intercompany transactions and balances have been eliminated.Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker, or CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the identification, development and commercialization of meaningful pharmaceutical products that address unmet medical needs. Use of Estimates Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Adoption of New Accounting Standards and Recent Accounting Pronouncements Adoption of New Accounting StandardsIn NovemberÂ 2023, the Financial Accounting Standards Board, or FASB, issued ASU 2023-07, â€œSegment Reporting (Topic 280) - Improvements to Reportable Segment Disclosuresâ€, which requires enhanced disclosures about significant segment expenses. The amendments are effective retrospectively to all prior periods presented in the financial statements, for fiscal years beginning after DecemberÂ 15,Â 2023. The new guidance is not expected to have a material impact on our financial statement disclosures.Recent Accounting PronouncementsIn DecemberÂ 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740) - Improvements to Income Tax Disclosuresâ€, which requires enhanced tax disclosures providing greater disaggregation of information in the Company's effective tax rate reconciliation and disaggregates income taxes paid by jurisdiction. The amendments are effective on a prospective basis, with the option to apply it retrospectively, for fiscal years beginning after DecemberÂ 15,Â 2024. We are currently evaluating the impact of adopting this new accounting guidance. Significant Risks and Uncertainties Significant Risks and UncertaintiesWe expect that our business will continue to meaningfully depend on oxybate revenues; however, there is no guarantee that oxybate revenues will remain at current levels. In this regard, our ability to maintain oxybate revenues and realize the anticipated benefits from our investment in Xywav are subject to a number of risks and uncertainties including, without limitation, those related to the commercialization of Xywav for the treatment of IH in adults and adoption in that indication; competition from the introduction of two authorized generic, or AG, versions of high-sodium oxybate and a branded fixed-dose, high-sodium oxybate, Avadelâ€™s Lumryz, for treatment of cataplexy and/or EDS in narcolepsy in the U.S. market, as well as potential future competition from additional AG versions of high-sodium oxybate and from generic versions of high-sodium oxybate and from other competitors; increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party payors, including our ability to maintain adequate coverage and reimbursement for Xywav; increased rebates required to maintain access to our products; challenges to our intellectual property around Xywav and/or Xyrem, including from pending antitrust and intellectual property litigation; and continued acceptance of Xywav and Xyrem by physicians and patients. A significant decline in oxybate revenues could cause us to reduce our operating expenses or seek to raise additional funds and would have a material adverse effect on our business, financial condition, results of operations and growth prospects, including on our ability to acquire, in-license or develop new products to grow our business.In addition to risks related specifically to Xywav and Xyrem, we are subject to other challenges and risks related to successfully commercializing a portfolio of oncology products and other neuroscience products, and other risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: ongoing clinical research activity and related outcomes; obtaining regulatory approval of our late-stage product candidates, such as zanidatamab; effectively commercializing our approved products such as Epidiolex, Rylaze and Zepzelca; obtaining and maintaining adequate coverage and reimbursement for our products; contracting and rebates to pharmacy benefit managers and similar organizations that reduce our net revenue; increasing scrutiny of pharmaceutical product pricing and resulting changes in healthcare laws and policy; market acceptance; regulatory concerns with controlled substances generally and the potential for abuse; future legislation; action by the U.S. Federal Government authorizing the sale, distribution, use, and insurance reimbursement of non-FDA approved cannabinoid products; delays or problems in the supply of our products; loss of single source suppliers or failure to comply with manufacturing regulations; delays or problems with third parties that are part of our manufacturing and supply chain; identifying, acquiring or in-licensing additional products or product candidates; our ability to realize the anticipated benefits of acquired or in-licensed products or product candidates, such as Epidiolex and zanidatamab, at the expected levels, with the expected costs and within the expected timeframe; pharmaceutical product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements; and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt obligations. Concentrations of Risk Concentrations of RiskFinancial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant.We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding.We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to our oxybate products, the API is manufactured for us by a single source supplier and the finished products are manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based supplier. X - DefinitionDescribes risks and uncertainties related to the pharmaceutical industry. + ReferencesNo definition available. + Details Name: jazz_SignificantRisksAndUncertaintiesPolicyTextBlock Namespace Prefix: jazz_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Cash and Available-for-Sale Securities (Tables) 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â  Schedule of Cash, Cash Equivalents and Investments Cash, cash equivalents and investments consisted of the following (in thousands):Â September 30, 2024AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesEstimatedFair ValueCash

andCashEquivalentsInvestmentsCash$797,583Â $â€”Â $â€”Â $797,583Â $797,583Â $â€”Â Time deposits650,000Â â€”Â â€”Â 650,000Â 250,000Â 400,000Â Money market funds1,170,552Â â€”Â â€”Â 1,170,552Â 1,170,552Â â€”Â Totals$2,618,135Â $â€”Â $â€”Â $2,618,135Â $2,218,135Â $400,000Â December 31, 2023AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesEstimatedFair ValueCash and CashEquivalentsInvestmentsCash$437,724Â $â€”Â $â€”Â $437,724Â $437,724Â $â€”Â Time deposits420,000Â â€”Â â€”Â 420,000Â 300,000Â 120,000Â Money market funds768,586Â â€”Â â€”Â 768,586Â 768,586Â â€”Â Totals$1,626,310Â $â€”Â $â€”Â $1,626,310Â $1,506,310Â $120,000Â  X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash, cash equivalents, and investments. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurement (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â  Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table summarizes, by major security type, our available-for-sale securities and derivative contracts as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands):Â September 30, 2024December 31, 2023QuotedPrices inActiveMarketsÂ forIdenticalAssets(Level 1)SignificantOtherObservableInputs(Level 2)TotalEstimatedFairÂ ValueQuotedPrices inActiveMarketsÂ forIdenticalAssets(Level 1)SignificantOtherObservableInputs(Level 2)TotalEstimatedFairÂ ValueAssets:Available-for-sale securities:Money market funds$1,170,552Â $â€”Â $1,170,552Â $768,586Â $â€”Â $768,586Â Time depositsâ€”Â 650,000Â 650,000Â â€”Â 420,000Â 420,000Â Foreign exchange forward contractsâ€”Â 8,364Â 8,364Â â€”Â 18,035Â 18,035Â Interest rate contractsâ€”Â 13Â 13Â â€”Â 3,784Â 3,784Â Totals$1,170,552Â $658,377Â $1,828,929Â $768,586Â $441,819Â $1,210,405Â Liabilities:Interest rate contracts$â€”Â $2,976Â $2,976Â $â€”Â $3,410Â $3,410Â Foreign exchange forward contractsâ€”Â â€”Â â€”Â â€”Â 681Â 681Â Totals$â€”Â $2,976Â $2,976Â $â€”Â $4,091Â $4,091Â  X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative Instruments and Hedging Activities (Tables) 9 Months Ended Sep. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â  Schedule of Foreign Exchange Gain (Loss) Associated with Foreign Exchange Contracts Not Designated as Hedging Instruments The foreign exchange loss in our condensed consolidated statements of income included the following gains (losses) associated with foreign exchange contracts not designated as hedging instruments (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Foreign Exchange Forward Contracts:20242023202420242023Gain (loss) recognized in foreign exchange loss$14,396Â $(13,549)$9,485Â $(8,921) Schedule of Impact on Accumulated Other Comprehensive [Loss] and Earnings from Derivative Instruments that Qualified as Cash Flow Hedges The impact on accumulated other comprehensive loss and earnings from derivative instruments that qualified as cash flow hedges for the three and nine months ended SeptemberÂ 30,Â 2024 was as follows (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Interest Rate Contracts:20242023202420242023Gain (loss) recognized in accumulated other comprehensive loss, net of tax$(5,197)$3,539Â $1,572Â $9,218Â Gain reclassified from accumulated other comprehensive loss to interest expense, net of tax(1,340)(1,289)(4,040)(2,060) Schedule of Fair Value of Outstanding Derivatives The following tables summarize the fair value of outstanding derivatives (in thousands):ClassificationSeptember 30,2024December 31,2023AssetsDerivatives designated as hedging instruments:Interest rate contractsOther current assets$13Â $3,784Â Derivatives not designated as hedging instruments:Foreign exchange forward contractsOther current assets8,364Â 18,035Â Total fair value of derivative asset instruments$8,377Â $21,819Â LiabilitiesDerivatives designated as hedging instruments:Interest rate contractsAccrued liabilities$572Â $â€”Â Interest rate contractsOther non-current liabilities2,404Â 3,410Â Derivatives not designated as hedging instruments:Foreign exchange forward contractsAccrued liabilitiesâ€”Â 681Â Total fair value of derivative liability instruments$2,976Â $4,091Â  Schedule of Offsetting Assets The following table summarizes the potential effect on our condensed consolidated balance sheets of offsetting our interest rate and foreign exchange forward contracts subject to such provisions (in thousands):September 30, 2024Gross Amounts of Recognized Assets/ LiabilitiesGross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets/ Liabilities Presented in the Consolidated Balance SheetGross Amounts Not Offset in the Consolidated Balance SheetDescriptionDerivative Financial InstrumentsCash Collateral Received (Pledged)Net AmountDerivative assets$8,377Â $â€”Â $8,377Â $(1,830)$â€”Â $6,547Â Derivative liabilities(2,976)â€”Â (2,976)1,830Â â€”Â (1,146)December 31, 2023Gross Amounts of Recognized Assets/ LiabilitiesGross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets/ Liabilities Presented in the Consolidated Balance SheetGross Amounts Not Offset in the Consolidated Balance SheetDescriptionDerivative Financial InstrumentsCash Collateral Received (Pledged)Net AmountDerivative assets$21,819Â $â€”Â $21,819Â $(4,091)$â€”Â $17,728Â Derivative liabilities(4,091)â€”Â (4,091)4,091Â â€”Â â€”Â  Schedule of Offsetting Liabilities The following table summarizes the potential effect on our condensed consolidated balance sheets of offsetting our interest rate and foreign exchange forward contracts subject to such provisions (in thousands):September 30, 2024Gross Amounts of Recognized Assets/ LiabilitiesGross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets/ Liabilities Presented in the Consolidated Balance SheetGross Amounts Not Offset in the Consolidated Balance SheetDescriptionDerivative Financial InstrumentsCash Collateral Received (Pledged)Net AmountDerivative assets$8,377Â $â€”Â $8,377Â $(1,830)$â€”Â $6,547Â Derivative liabilities(2,976)â€”Â (2,976)1,830Â â€”Â (1,146)December 31, 2023Gross Amounts of Recognized Assets/ LiabilitiesGross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets/ Liabilities Presented in the Consolidated Balance SheetGross Amounts Not Offset in the Consolidated Balance SheetDescriptionDerivative Financial InstrumentsCash Collateral Received (Pledged)Net AmountDerivative assets$21,819Â $â€”Â $21,819Â $(4,091)$â€”Â $17,728Â Derivative liabilities(4,091)â€”Â (4,091)4,091Â â€”Â â€”Â  X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_OffsettingAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_OffsettingLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories (Tables) 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â  Schedule of Inventories Inventories consisted of the following (in thousands):Â September 30,2024December 31,2023Raw materials$24,819Â $25,595Â Work in process366,602Â 431,732Â Finished goods147,881Â 139,712Â Total inventories$539,302Â $597,039Â  X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets (Tables) 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â  Schedule of Gross Carrying Amount of Goodwill The gross carrying amount of goodwill was as follows (in thousands):Balance at December 31, 2023$1,753,130Â Foreign exchange51,516Â Balance at September 30, 2024$1,804,646Â  Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):Â Â September 30, 2024December 31, 2023Â RemainingWeighted-AverageÂ UsefulLife(In years)GrossCarryingAmountAccumulatedAmortizationNet BookValueGrossCarryingAmountAccumulatedAmortizationNet BookValueAcquired developed technologies8.0$8,064,193Â $(2,919,976)$5,144,217Â $7,785,495Â $(2,367,456)$5,418,039Â Manufacturing contractsâ€”11,984Â (11,984)â€”Â 11,828Â (11,828)â€”Â Trademarksâ€”2,889Â (2,889)â€”Â 2,886Â (2,886)â€”Â Total finite-lived intangible assets$8,079,066Â $(2,934,849)$5,144,217Â $7,800,209Â $(2,382,170)$5,418,039Â  Schedule of Estimated Future Amortization Expenses Based on finite-lived intangible assets recorded as of SeptemberÂ 30,Â 2024, and assuming the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands):Â Year Ending December 31,Estimated Amortization Expense2024 (remainder)$162,109Â 2025648,436Â 2026648,436Â 2027648,436Â 2028647,104Â Thereafter2,389,696Â Total$5,144,217Â  X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1AReference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2 + Details Name: us-gaap_ScheduleOfGoodwillTextBlock Namespace

Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Certain Balance Sheet Items (Tables) 9 Months Ended Sep. 30, 2024 Certain Balance Sheet Items [Abstract] Â  Schedule of Property, Plant and Equipment Property, plant and equipment consisted of the following (in thousands):September 30,2024December 31,2023Manufacturing equipment and machinery$91,560Â $82,897Â Leasehold improvements71,950Â 67,722Â Land and buildings70,762Â 70,912Â Computer software41,847Â 38,134Â Construction-in-progress30,645Â 18,661Â Computer equipment17,530Â 15,398Â Furniture and fixtures8,942Â 9,273Â Subtotal333,236Â 302,997Â Less accumulated depreciation and amortization(156,814)(133,351)Property, plant and equipment, net$176,422Â $169,646Â  Schedule of Accrued Liabilities Accrued liabilities consisted of the following (in thousands):September 30,2024December 31,2023Rebates and other sales deductions$405,134Â $325,711Â Employee compensation and benefits125,497Â 121,209Â Accrued royalties40,923Â 30,706Â Clinical trial accruals37,620Â 44,757Â Consulting and professional services32,844Â 19,538Â Sales return reserve24,545Â 20,435Â Selling and marketing accruals24,539Â 14,743Â Accrued interest22,445Â 36,443Â Current portion of lease liabilities19,103Â 19,447Â Inventory-related accruals14,015Â 13,977Â Accrued collaboration expenses12,805Â 10,158Â Accrued construction-in-progress9,040Â 5,141Â Accrued facilities expenses5,439Â 55,455Â Derivative instrument liabilities572Â 681Â Other84,057Â 75,513Â Total accrued liabilities$858,578Â $793,914Â  X - DefinitionCertain Balance Sheet Items [Abstract] + ReferencesNo definition available. + Details Name: jazz_CertainBalanceSheetItemsAbstract Namespace Prefix: jazz_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Debt (Tables) 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â  Schedule of Carrying Amount of Indebtedness The following table summarizes the carrying amount of our indebtedness (in thousands):September 30,2024December 31,20232024 Notes$â€”Â $575,000Â Unamortized - debt issuance costsâ€”Â (1,046)2024 Notes, netâ€”Â 573,954Â 2026 Notes 1,000,000Â 1,000,000Â Unamortized - debt issuance costs(4,456)(6,400)2026 Notes, net995,544Â 993,600Â 2030 Notes1,000,000Â â€”Â Unamortized - debt issuance costs(19,081)â€”Â 2030 Notes, net980,919Â â€”Â Secured Notes 1,482,824Â 1,480,214Â Term Loan 2,652,515Â 2,665,174Â Total debt6,111,802Â 5,712,942Â Less current portion31,000Â 604,954Â Total long-term debt$6,080,802Â $5,107,988Â  Schedule of Maturities of Long-Term Debt Scheduled maturities with respect to our long-term debt principal balances outstanding as of SeptemberÂ 30,Â 2024 were as follows (in thousands): Year Ending December 31,Scheduled Long-Term Debt Maturities2024 (remainder)$7,750Â 202531,000Â 20261,031,000Â 202731,000Â 20282,598,500Â Thereafter2,500,000Â Total$6,199,250Â  X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity (Tables) 9 Months Ended Sep. 30, 2024 Stockholders' Equity Note [Abstract] Â  Schedule of Components of Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023 were as follows (in thousands):Â Net UnrealizedGain From Hedging ActivitiesForeignCurrencyTranslationAdjustmentsTotalAccumulatedOtherComprehensiveLossBalance at December 31, 2023$235Â $(842,382)$(842,147)Other comprehensive income before reclassifications1,572Â 241,218Â 242,790Â Amounts reclassified from accumulated other comprehensive loss(4,040)â€”Â (4,040)Other comprehensive income (loss), net(2,468)241,218Â 238,750Â Balance at September 30, 2024$(2,233)$(601,164)$(603,397) X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income per Ordinary Share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â  Schedule of Basic and Diluted Net Income Per Ordinary Share Computation Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420234Numerator:Net income$215,055Â $146,820Â $369,005Â $320,678Â Effect of interest on assumed conversions of Exchangeable Senior Notes, net of tax1,028Â 5,912Â 10,761Â 19,951Â Net income for dilutive net income per ordinary share$216,083Â $152,732Â $379,766Â $340,629Â Denominator:Weighted-average ordinary shares used in per share calculations - basic61,414Â 63,114Â 62,275Â 63,532Â Dilutive effect of Exchangeable Senior Notes1,325Â 7,560Â 4,721Â 8,549Â Dilutive effect of employee equity incentive and purchase plans435Â 619Â 515Â 785Â Weighted-average ordinary shares used in per share calculations - diluted63,174Â 71,293Â 67,511Â 72,866Â Net income per ordinary share:Basic$3.50Â $2.33Â $5.93Â $5.05Â Diluted$3.42Â $2.14Â $5.63Â $4.67Â  Schedule of Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income Per Share The following table represents the weighted-average ordinary shares that were excluded from the calculation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Â 20242023202420234Employee equity incentive and purchase plans4,465Â 2,501Â 4,701Â 3,091Â  X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues (Tables) 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â  Schedule of Disaggregation of Revenue The following table presents a summary of total revenues (in thousands):Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420234Xywav$388,466Â $331,633Â $1,072,238Â $935,958Â Xyrem58,114Â 125,110Â 184,526Â 463,009Â Epidiolex/Epidyolex251,558Â 213,711Â 697,376Â 604,846Â Sativex4,58 Neuroscience702,724Â 675,081Â 1,967,844Â 2,018,344Â Rylaze/Enrylaze98,780Â 104,859Â 309,359Â 292,479Â Zepzelca85,843Â 77,994Â 241,990Â 215,523Â Defitelio/defibrotide 65,818Â 47,730Â 158,915Â 132,917Â Vyxeos34,313Â 29,827Â 109,348Â 100,583Â Total Oncology284,754Â 260,410Â 819,612Â 741,502Â Other2,229Â 2,907Â 8,497Â 9,758Â Product sales, net989,707Â 938,398Â 2,795,953Â 2,769,604Â High-sodium oxybate AG royalty revenue58,157Â 28,921Â 162,268Â 36,531Â Other royalty and contract revenues7,105Â 4,821Â 22,556Â 16,134Â Total revenues$1,054,969Â $972,140Â $2,980,777Â $2,822,269Â The following table presents a summary of total revenues attributed to geographic sources (in thousands):Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023United States$953,669Â $884,579Â $2,686,486Â $2,579,401Â Europe77,318Â 68,971Â 230,821Â 194,198Â All other23,982Â 18,590Â 63,470Â 48,670Â Total revenues$1,054,969Â $972,140Â $2,980,777Â $2,822,269Â  Schedule of Percentage of Total Revenues from Customers The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420232ESSDS42Â %47Â %42Â %49Â %McKesson13Â %12Â %12Â %11Â %ASD10Â %9Â %9Â %7Â % X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â  Schedule of Share-Based Compensation Expense Share-based compensation expense related to RSUs, PRSUs, grants under our ESPP and share options was as follows (in thousands):Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420232Selling, general and administrative$37,101Â $35,268Â $112,451Â $113,155Â Research and development18,927Â 16,635Â 55,030Â 49,346Â Cost of product sales3,732Â 4,212Â 10,374Â 11,399Â Total share-based compensation expense, pre-tax59,760Â 56,115Â 177,855Â 173,900Â Income tax benefit from share-based compensation expense(12,190)(9,792)(25,218)(29,533)Total share-based compensation expense, net of tax$47,570Â $46,323Â $152,637Â $144,367Â  Schedule of Restricted Stock Units Activity and Performance-Based Restricted Stock Units Activity The table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420232RSUs granted (in thousands)102Â 91Â 2,112Â 1,728Â Grant date fair value$110.55Â $134.33Â $118.31Â $145.05Â The table below shows the number of PRSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of PRSUs granted:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420232PRSUs granted (in thousands)58Â 13Â 371Â 270Â Grant date fair value$107.07Â $142.65Â $130.58Â $157.01Â  X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3 The Company and Summary of Significant Accounting Policies - Basis of Presentation (Narrative) (Details) 9 Months Ended Sep. 30, 2024 segment Accounting Policies [Abstract] Â  Number of operating business segments 1 X - ReferencesNo definition available. +

Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3 The Company and Summary of Significant Accounting Policies - Concentrations of Risk (Narrative) (Details) - USD ($) $ in Millions 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Customer Concentration Risk | Gross Accounts Receivable | Five Customers Â Â  Concentration Risk [Line Items] Â Â  Percentage of gross accounts receivable (as a percent) 81.00% 79.00% Customer Concentration Risk | Gross Accounts Receivable | ESSDS Â Â  Concentration Risk [Line Items] Â Â  Percentage of gross accounts receivable (as a percent) 41.00% 41.00% Customer Concentration Risk | Gross Accounts Receivable | ASD Specialty Healthcare LLC Â Â  Concentration Risk [Line Items] Â Â  Percentage of gross accounts receivable (as a percent) 14.00% 13.00% Customer Concentration Risk | Gross Accounts Receivable | McKesson Â Â  Concentration Risk [Line Items] Â Â  Percentage of gross accounts receivable (as a percent) 14.00% 11.00% Foreign exchange forward contracts | Derivatives Not Designated as Hedging Instruments Â Â  Concentration Risk [Line Items] Â Â  Notional amount $ 292.7 $ 511.7 Net asset (liability) fair value 8.4 Â  Interest Rate Swap | Derivatives Designated as Hedging Instruments Â Â  Concentration Risk [Line Items] Â Â  Notional amount 500.0 Â  Net asset (liability) fair value $ (3.0) Â  X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFair value of the assets less the liabilities of a derivative or group of derivatives. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeFairValueOfDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=jazz_FiveCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=jazz_ExpressScriptsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=jazz_ASDSpecialtyHealthcareLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=jazz_McKessonCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Cash and Available-for-Sale Securities - Schedule of Cash, Cash Equivalents and Investments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Securities, Available-for-sale [Line Items] Â Â  Amortized Cost $ 2,618,135 $ 1,626,310 Gross Unrealized Gains 0 0 Gross Unrealized Losses 0 0 Estimated Fair Value 2,618,135 1,626,310 Cash and Cash Equivalents 2,218,135 1,506,310 Investments 400,000 120,000 Cash Â Â  Debt Securities, Available-for-sale [Line Items] Â Â  Amortized Cost 797,583 437,724 Gross Unrealized Gains 0 0 Gross Unrealized Losses 0 0 Estimated Fair Value 797,583 437,724 Cash and Cash Equivalents 797,583 437,724 Investments 0 0 Time deposits Â Â  Debt Securities, Available-for-sale [Line Items] Â Â  Amortized Cost 650,000 420,000 Gross Unrealized Gains 0 0 Gross Unrealized Losses 0 0 Estimated Fair Value 650,000 420,000 Cash and Cash Equivalents 250,000 300,000 Investments 400,000 120,000 Money market funds Â Â  Debt Securities, Available-for-sale [Line Items] Â Â  Amortized Cost 1,170,552 768,586 Gross Unrealized Gains 0 0 Gross Unrealized Losses 0 0 Estimated Fair Value 1,170,552 768,586 Cash and Cash Equivalents 1,170,552 768,586 Investments $ 0 $ 0 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(h)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_Investments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CashMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Cash and Available-for-Sale Securities - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Investments, Debt and Equity Securities [Abstract] Â Â Â Â  Interest income from available-for-sale securities $ 26.0 $ 19.2 $ 74.6 $ 44.4 X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference

4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Available-for-sale securities: Â Â Available-for-sale securities $ 2,618,135 $ 1,626,310 Money market funds Â Â Available-for-sale securities: Â Â Available-for-sale securities 1,170,552 768,586 Time deposits Â Â Available-for-sale securities: Â Â Available-for-sale securities 650,000 420,000 Recurring Â Â Available-for-sale securities: Â Â Totals 1,828,929 1,210,405 Liabilities: Â Â Totals 2,976 4,091 Recurring | Money market funds Â Â Available-for-sale securities: Â Â Available-for-sale securities 1,170,552 768,586 Recurring | Time deposits Â Â Available-for-sale securities: Â Â Available-for-sale securities 650,000 420,000 Recurring | Foreign exchange forward contracts Â Â Available-for-sale securities: Â Â Foreign exchange forward contracts 8,364 18,035 Liabilities: Â Â Derivative liability 0 681 Recurring | Interest rate contracts Â Â Available-for-sale securities: Â Â Interest rate contracts 13 3,784 Liabilities: Â Â Derivative liability 2,976 3,410 Recurring | Quoted Prices in Active MarketsÂ for Identical Assets (Level 1) Â Â Available-for-sale securities: Â Â Totals 1,170,552 768,586 Liabilities: Â Â Totals 0 0 Recurring | Quoted Prices in Active MarketsÂ for Identical Assets (Level 1) | Money market funds Â Â Available-for-sale securities: Â Â Available-for-sale securities 1,170,552 768,586 Recurring | Quoted Prices in Active MarketsÂ for Identical Assets (Level 1) | Time deposits Â Â Available-for-sale securities: Â Â Available-for-sale securities 0 0 Recurring | Quoted Prices in Active MarketsÂ for Identical Assets (Level 1) | Foreign exchange forward contracts Â Â Available-for-sale securities: Â Â Foreign exchange forward contracts 0 0 Liabilities: Â Â Derivative liability 0 0 Recurring | Quoted Prices in Active MarketsÂ for Identical Assets (Level 1) | Interest rate contracts Â Â Available-for-sale securities: Â Â Interest rate contracts 0 0 Liabilities: Â Â Derivative liability 0 0 Recurring | Significant Other Observable Inputs (Level 2) Â Â Available-for-sale securities: Â Â Totals 658,377 441,819 Liabilities: Â Â Totals 2,976 4,091 Recurring | Significant Other Observable Inputs (Level 2) | Money market funds Â Â Available-for-sale securities: Â Â Available-for-sale securities 0 0 Recurring | Significant Other Observable Inputs (Level 2) | Time deposits Â Â Available-for-sale securities: Â Â Available-for-sale securities 650,000 420,000 Recurring | Significant Other Observable Inputs (Level 2) | Foreign exchange forward contracts Â Â Available-for-sale securities: Â Â Foreign exchange forward contracts 8,364 18,035 Liabilities: Â Â Derivative liability 0 681 Recurring | Significant Other Observable Inputs (Level 2) | Interest rate contracts Â Â Available-for-sale securities: Â Â Interest rate contracts 13 3,784 Liabilities: Â Â Derivative liability $ 2,976 $ 3,410 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AvailableForSaleSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 30: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section

50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E) (Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 28: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FinancialLiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_ForeignExchangeForwardMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurement - Narrative (Details) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Equity securities without readily determinable fair value $ 4.3 $ 4.7 Term Loan Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Interest rate (as a percent) 3.9086% Â Exchangeable Senior Notes Due 2026 | Convertible Debt Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Interest rate (as a percent) 2.00% Â Exchangeable Senior Notes Due 2030 | Convertible Debt Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Interest rate (as a percent) 3.125% Â Exchangeable Senior Notes Due 2024 | Convertible Debt Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Interest rate (as a percent) 1.50% Â Secured Notes | Senior Secured Debt | Jazz Securities Designated Activity Company Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Interest rate (as a percent) 4.375% Â 2021 Credit Agreement, Dollar Term Loan | Term Loan Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Term (in years) 7 years Â Significant Other Observable Inputs (Level 2) | Exchangeable Senior Notes Due 2026 | Convertible Debt Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Fair value of exchangeable senior notes $ 1,000.0 Â Significant Other Observable Inputs (Level 2) | Exchangeable Senior Notes Due 2030 | Convertible Debt Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Fair value of exchangeable senior notes 1,000.0 Â Significant Other Observable Inputs (Level 2) | Secured Notes | Senior Secured Debt | Jazz Securities Designated Activity Company Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Fair value of secured debt 1,400.0 Â Significant Other Observable Inputs (Level 2) | 2021 Credit Agreement, Dollar Term Loan | Term Loan Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Fair value of lines of credit $ 2,700.0 Â X - DefinitionFair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ConvertibleDebtFairValueDisclosures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LinesOfCreditFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of notes payable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=jazz_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_ExchangeableSeniorNotesDue2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_ExchangeableSeniorNotesDue2030Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_ExchangeableSeniorNotesDue2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_SeniorNotesDue2029Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=jazz_SeniorSecuredDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=jazz_JazzSecuritiesDesignatedActivityCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_TwoThousandTwentyOneCreditAgreementDollarTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative Instruments and Hedging Activities - Narrative (Details) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Derivative [Line Items] Â Â Loss, net of tax, to be reclassified to earnings over the next 12 months $ (0.5) Â Term Loan Â Â Derivative [Line Items] Â Â Interest rate (as a percent) 3.9086% Â Foreign exchange forward contracts | Derivatives Not Designated as Hedging Instruments Â Â Derivative [Line Items] Â Â Notional amount $ 292.7 $ 511.7 Interest Rate Swap | Derivatives Designated as Hedging Instruments Â Â Derivative [Line Items] Â Â Notional amount $ 500.0 Â X - DefinitionThe estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480870/815-30-50-1 + Details Name: us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=jazz_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative Instruments and Hedging Activities - Schedule of Foreign Exchange Gain (Loss) Associated with Foreign Exchange Contracts Not Designated as Hedging Instruments (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Derivatives Not Designated as

Hedging Instruments | Foreign exchange forward contracts Â Â Â Â  Derivative [Line Items] Â Â Â Â  Gain (loss) recognized in foreign exchange loss $ 14,396 $ (13,549) $ 9,485 $ (8,921) X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative Instruments and Hedging Activities - Schedule of Impact on Accumulated Other Comprehensive [Loss] and Earnings from Derivative Instruments that Qualified as Cash Flow Hedges (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â  Gain (loss) recognized in accumulated other comprehensive loss, net of tax $ (5,197) $ 3,539 $ 1,572 $ 9,218 Gain reclassified from accumulated other comprehensive loss to interest expense, net of tax (1,340) (1,289) (4,040) (2,060) Cash Flow Hedges | Interest rate contracts Â Â Â Â  Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â  Gain (loss) recognized in accumulated other comprehensive loss, net of tax (5,197) 3,539 1,572 9,218 Gain reclassified from accumulated other comprehensive loss to interest expense, net of tax $ (1,340) $ (1,289) $ (4,040) $ (2,060) X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E + Details Name: us-gaap_DerivativeInstrumentsGainLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15 + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative Instruments and Hedging Activities - Schedule of Fair Value of Outstanding Derivatives (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Derivatives, Fair Value [Line Items] Â Â  Asset derivatives $ 8,377 $ 21,819 Liability derivatives 2,976 4,091 Derivatives Designated as Hedging Instruments | Interest Rate Swap | Other current assets Â Â  Derivatives, Fair Value [Line Items] Â Â  Asset derivatives 13 3,784 Derivatives Designated as Hedging Instruments | Interest rate contracts | Accrued liabilities Â Â  Derivatives, Fair Value [Line Items] Â Â  Liability derivatives 572 0 Derivatives Designated as Hedging Instruments | Interest rate contracts | Other non-current liabilities Â Â  Derivatives, Fair Value [Line Items] Â Â  Liability derivatives 2,404 3,410 Derivatives Not Designated as Hedging Instruments | Foreign exchange forward contracts | Other current assets Â Â  Derivatives, Fair Value [Line Items] Â Â  Asset derivatives 8,364 18,035 Derivatives Not Designated as Hedging Instruments | Foreign exchange forward contracts | Accrued liabilities Â Â  Derivatives, Fair Value [Line Items] Â Â  Liability derivatives $ 0 $ 681 X - DefinitionFair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DerivativesFairValueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative Instruments and Hedging Activities - Schedule of Offsetting Assets and Offsetting Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Gross Amounts Not Offset in the Consolidated Balance Sheet Â Â  Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other non-current assets Other non-current assets Gross Amounts Not Offset in the Consolidated Balance Sheet Â Â  Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other non-current liabilities Other non-current liabilities Pro Forma Â Â  Derivative assets Â Â  Gross Amounts of Recognized Assets/ Liabilities $ 8,377 $ 21,819 Gross Amounts Offset in the Consolidated Balance Sheet 0 0 Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet 8,377 21,819 Gross Amounts Not Offset in the Consolidated Balance Sheet Â Â  Derivative Financial Instruments (1,830) (4,091) Cash Collateral Received (Pledged) 0 0 Net Amount 6,547 17,728 Derivative liabilities Â Â  Gross Amounts of Recognized Assets/ Liabilities (2,976) (4,091) Gross Amounts Offset in the Consolidated Balance Sheet 0 0 Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet (2,976) (4,091) Gross Amounts Not Offset in the Consolidated Balance Sheet Â Â  Derivative Financial Instruments 1,830 4,091 Cash Collateral Received (Pledged) 0 0 Net Amount $ (1,146) $ 0 X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeAssetFairValueAmountOffsetAgainstCollateralAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 8 -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B + Details Name: us-gaap_DerivativeAssetFairValueGrossLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes derivative asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -

Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 30: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 13 -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-13Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8 + Details Name: us-gaap_DerivativeCollateralObligationToReturnCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to return securities collateral under master netting arrangements that have not been offset against derivative assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 13 -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-13Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeCollateralObligationToReturnSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 13 -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-13Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8 + Details Name: us-gaap_DerivativeCollateralRightToReclaimCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of right to receive securities collateral under master netting arrangements that have not been offset against derivative liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 13 -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-13Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeCollateralRightToReclaimSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 13 -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8 + Details Name: us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 13 -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8 + Details Name: us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 28: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeLiabilityFairValueAmountOffsetAgainstCollateralAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of asset associated with financial liability or contract with one or more underlyings, notional amount

or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 8 -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20 + Details Name: us-gaap_DerivativeLiabilityFairValueGrossAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes derivative liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - Details Name: srt_StatementScenarioAxis=srt_ProFormaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â  Raw materials $ 24,819 $ 25,595 Work in process 366,602 431,732 Finished goods 147,881 139,712 Total inventories $ 539,302 $ 597,039 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories - Narrative (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 GW Pharmaceuticals plc Â Â  Inventory [Line Items] Â Â  Inventory, step-up value $ 243.4 $ 328.0 X - DefinitionInventory, Step-Up Value + ReferencesNo definition available. + Details Name: jazz_InventoryStepUpValue Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_InventoryLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=jazz_GWPharmaceuticalsPlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets - Schedule of Gross Carrying Amount of Goodwill (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Goodwill [Roll Forward] Â  Goodwill, beginning of period $ 1,753,130 Foreign exchange 51,516 Goodwill, end of period $ 1,804,646 X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillForeignCurrencyTranslationGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_GoodwillRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets - Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Finite-Lived Intangible Assets [Line Items] Â Â  Gross Carrying Amount $ 8,079,066 $ 7,800,209 Accumulated Amortization (2,934,849) (2,382,170) Total $ 5,144,217 5,418,039 Acquired developed technologies Â Â  Finite-Lived Intangible Assets [Line Items] Â Â  Remaining Weighted- AverageÂ Useful Life (In years) 8 years Â Gross Carrying Amount $ 8,064,193 7,785,495 Accumulated Amortization (2,919,976) (2,367,456) Total $ 5,144,217 5,418,039 Manufacturing contracts Â Â  Finite-Lived Intangible Assets [Line Items] Â Â  Remaining Weighted- AverageÂ Useful Life (In years) 0 years Â Gross Carrying Amount $ 11,984 11,828 Accumulated Amortization (11,984) (11,828) Total $ 0 0 Trademarks Â Â  Finite-Lived Intangible Assets [Line Items] Â Â  Remaining Weighted- AverageÂ Useful Life (In years) 0 years Â Gross Carrying Amount $ 2,889 2,886 Accumulated Amortization (2,889) (2,886) Total $ 0 $ 0 X - DefinitionWeighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jazz_ManufacturingContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expenses (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Goodwill and Intangible Assets Disclosure [Abstract] Â Â  2024 (remainder) $ 162,109 Â  2025 648,436 Â  2026 648,436 Â  2027 648,436 Â  2028 647,104 Â  Thereafter 2,389,696 Â  Total $ 5,144,217 $ 5,418,039 X - DefinitionFinite-Lived Intangible Asset, Expected Amortization, After Year Four + ReferencesNo definition available. + Details Name: jazz_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -

Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Certain Balance Sheet Items - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â Â  Property, plant and equipment, gross $ 333,236 $ 302,997 Less accumulated depreciation and amortization (156,814) (133,351) Property, plant and equipment, net 176,422 169,646 Manufacturing equipment and machinery Â Â  Property, Plant and Equipment [Line Items] Â Â  Property, plant and equipment, gross 91,560 82,897 Leasehold improvements Â Â  Property, Plant and Equipment [Line Items] Â Â  Property, plant and equipment, gross 71,950 67,722 Land and buildings Â Â  Property, Plant and Equipment [Line Items] Â Â  Property, plant and equipment, gross 70,762 70,912 Computer software Â Â  Property, Plant and Equipment [Line Items] Â Â  Property, plant and equipment, gross 41,847 38,134 Construction-in-progress Â Â  Property, Plant and Equipment [Line Items] Â Â  Property, plant and equipment, gross 30,645 18,661 Computer equipment Â Â  Property, Plant and Equipment [Line Items] Â Â  Property, plant and equipment, gross 17,530 15,398 Furniture and fixtures Â Â  Property, Plant and Equipment [Line Items] Â Â  Property, plant and equipment, gross $ 8,942 $ 9,273 X - DefinitionAmount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Certain Balance Sheet Items - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Certain Balance Sheet Items [Abstract] Â Â  Rebates and other sales deductions $ 405,134 $ 325,711 Employee compensation and benefits 125,497 121,209 Accrued royalties 40,923 30,706 Clinical trial accruals 37,620 44,757 Consulting and professional services 32,844 19,538 Sales return reserve 24,545 20,435 Selling and marketing accruals 24,539 14,743 Accrued interest 22,445 36,443 Current portion of lease liabilities 19,103 19,447 Inventory-related accruals 14,015 13,977 Accrued collaboration expenses 12,805 10,158 Accrued construction-in-progress 9,040 5,141 Accrued facilities expenses 5,439 55,455 Derivative instrument liabilities 572 681 Other 84,057 75,513 Total accrued liabilities $ 858,578 $ 793,914 X - DefinitionAccrued Clinical Trial Liability, Current + ReferencesNo definition available. + Details Name: jazz_AccruedClinicalTrialLiabilityCurrent Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued Collaboration Costs, Current + ReferencesNo definition available. + Details Name: jazz_AccruedCollaborationCostsCurrent Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for construction-in-progress. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: jazz_AccruedConstructionInProgressCurrent Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued Facilities Expenses, Current + ReferencesNo definition available. + Details Name: jazz_AccruedFacilitiesExpensesCurrent Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued Inventory Related Liabilities, Current + ReferencesNo definition available. + Details Name: jazz_AccruedInventoryRelatedLiabilitiesCurrent Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for rebates and other sales deductions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: jazz_AccruedRebatesAndOtherSalesDeductionsCurrent Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCertain Balance Sheet Items [Abstract] + ReferencesNo definition available. + Details Name: jazz_CertainBalanceSheetItemsAbstract Namespace Prefix: jazz_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOperating And Finance Lease, Liability, Current + ReferencesNo definition available. + Details Name: jazz_OperatingAndFinanceLeaseLiabilityCurrent Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for sales returns reserve. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: jazz_SalesReturnReserveCurrent Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedEmployeeBenefitsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: us-gaap_AccruedMarketingCostsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Schedule of Carrying Amount of Indebtedness (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Long term debt outstanding $ 6,199,250 Â Total debt 6,111,802 $ 5,712,942 Less current portion 31,000 604,954 Total long-term debt 6,080,802 5,107,988 Convertible Debt | 2024 Notes Â Â Debt Instrument [Line Items] Â Â Long term debt outstanding 0 575,000 Unamortized - debt issuance costs 0 (1,046) Total debt 0 573,954 Convertible Debt | 2026 Notes Â Â Debt Instrument [Line Items] Â Â Long term debt outstanding 1,000,000 1,000,000 Unamortized - debt issuance costs (4,456) (6,400) Total debt 995,544 993,600 Convertible Debt | 2030 Notes Â Â Debt Instrument [Line Items] Â Â Long term debt outstanding 1,000,000 0 Unamortized - debt issuance costs (19,081) 0 Total debt 980,919 0 Convertible Debt | Secured Notes Â Â Debt Instrument [Line Items] Â Â Total debt 1,482,824 1,480,214 Term Loan Â Â Debt Instrument [Line Items] Â Â Total debt $ 2,652,515 $ 2,665,174 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset. + ReferencesNo definition available. + Details Name: us-gaap_UnamortizedDebtIssuanceExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_ExchangeableSeniorNotesDue2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_ExchangeableSeniorNotesDue2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_ExchangeableSeniorNotesDue2030Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_SeniorNotesDue2029Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=jazz_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Credit Agreement Narrative (Details) â,¬ in Millions 1 Months Ended May 05, 2021 USD ($) Jul. 31, 2024 USD ($) Rate Sep. 30, 2024 USD ($) Rate Jan. 31, 2024 USD ($) May 05, 2021 EUR (â,¬) Line of Credit Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Remaining borrowing capacity Â $ 2,700,000,000 Â Â Â 2021 Credit Agreement, Dollar Term Loan | Line of Credit Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Credit facility expiration period 7 years Â Â Â Â Line of credit facility, maximum borrowing capacity $ 3,100,000,000 Â Â Â Â Debt instrument, quarterly amortization rate, percentage Â Â 0.28629% Â Â 2021 Credit Agreement, Euro Term Loan | Line of Credit Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Credit facility expiration period 7 years Â Â Â Â Line of credit facility, maximum borrowing capacity | â,¬ Â Â Â Â Â â,¬ 625.0 2021 Credit Agreement, Revolving Credit Facility | Line of Credit Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Credit facility expiration period 5 years Â Â Â Â Line of credit facility, maximum borrowing capacity $ 500,000,000 Â Â Â Â 2021 Credit Agreement, Revolving Credit Facility | Line of Credit | Revolving Credit Facility Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Line of credit facility, maximum borrowing capacity Â Â $ 500,000,000 Â Â 2021 Credit Agreement, Revolving Credit Facility | Line of Credit | Minimum | Revolving Credit Facility Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Line of credit facility, commitment fee percentage (as a percentage) Â 0.40% Â Â Â 2021 Credit Agreement, Revolving Credit Facility | Line of Credit | Maximum | Revolving Credit Facility Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Line of credit facility, commitment fee percentage (as a percentage) Â 0.50% Â Â Â 2021 Credit Agreement, Revolving Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR) | Minimum | Revolving Credit Facility Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Basis spread on variable rate Â 2.75% Â Â Â 2021 Credit Agreement, Revolving Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR) | Maximum | Revolving Credit Facility Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Basis spread on variable rate Â 3.25% Â Â Â 2021 Credit Agreement, Revolving Credit Facility | Line of Credit | Prime Rate | Minimum | Revolving Credit Facility Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Basis spread on variable rate Â 1.75% Â Â Â 2021 Credit Agreement, Revolving Credit Facility | Line of Credit | Prime Rate | Maximum | Revolving Credit Facility Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Basis spread on variable rate Â 2.25% Â Â Â Tranche B 1 Dollar Term Loan | Line of Credit Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument, face amount Â Â Â $ 201,900,000 Â Tranche B 2 Dollar Term Loan | Secured Overnight Financing Rate (SOFR) Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Decrease in basis spread on variable rate | Rate Â 0.75% Â Â Â Tranche B 2 Dollar Term Loan | Line of Credit Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt instrument, face amount Â $ 289,600,000 Â Â Â Interest rate (as a percent) | Rate Â Â 7.10% Â Â Effective interest rate (as a percent) | Rate Â Â 8.27% Â Â Tranche B 2 Dollar Term Loan | Line of Credit | Secured Overnight Financing Rate (SOFR) Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Basis spread on variable rate | Rate Â 2.25% Â Â Â Tranche B 2 Dollar Term Loan | Line of Credit | Secured Overnight Financing Rate (SOFR) | Minimum Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Basis spread on variable rate Â 0.50% Â Â Â Tranche B 2 Dollar Term Loan | Line of Credit | Prime Rate Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Basis spread on variable rate | Rate Â 1.25% Â Â Â X - DefinitionDebt Instrument, Decrease In Basis Spread On Variable Rate + ReferencesNo definition available. + Details Name: jazz_DebtInstrumentDecreaseInBasisSpreadOnVariableRate Namespace Prefix: jazz_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument, Quarterly Amortization Rate, Percentage + ReferencesNo definition available. + Details Name: jazz_DebtInstrumentQuarterlyAmortizationRatePercentage Namespace Prefix: jazz_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_TwoThousandTwentyOneCreditAgreementDollarTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_TwoThousandTwentyOneCreditAgreementEuroTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_PrimeRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_TrancheB1DollarTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_TrancheB2DollarTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - 2030 Notes Narrative (Details) - Exchangeable Senior Notes Due 2030 - Convertible Debt 1 Months Ended 3 Months Ended Sep. 30, 2024 USD ($) customer $ / shares Rate Sep. 30, 2024 USD ($) $ / shares Debt Instrument [Line Items] Â  Â  Debt instrument, face amount | $ $ 1,000,000,000.0 $ 1,000,000,000.0 Interest rate (as a percent) 3.125% 3.125% Debt instrument, convertible, threshold percentage of stock price trigger | Rate 130.00% Â  Debt instrument, convertible, threshold trading days | customer 20 Â  Debt instrument, convertible, threshold consecutive trading days | customer 30 Â  Debt instrument, convertible, number of shares per principal amount basis (in shares) Â  0.0065339 Debt instrument, convertible, conversion price (in dollars per share) | $ / shares $ 153.05 $ 153.05 Jazz Securities Designated Activity Company Â  Â  Debt Instrument [Line Items] Â  Â  Redemption price, percentage | Rate 100.00% Â  X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionRatio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionThreshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionMinimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThreshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdTradingDays Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage price of original principal amount of debt at which debt can be redeemed by the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentRedemptionPricePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=jazz_ExchangeableSeniorNotesDue2030Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=jazz_JazzSecuritiesDesignatedActivityCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Exchangeable Senior Notes Narrative (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Aug. 15, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Debt Instrument [Line Items] Â Â Â Â Â Repayments of convertible debt Â Â Â $ 575,000 $ 0 Exchangeable Senior Notes Due 2030 | Convertible Debt Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt issuance costs Â $ 19,200 Â $ 19,200 Â Effective interest rate (as a percent) Â 3.46% Â 3.46% Â Interest expense, debt Â $ 2,300 Â Â Â Contractual coupon rate interest expense Â 2,200 Â Â Â Amortization of debt issuance costs Â 100 Â Â Â 2026 Notes | Convertible Debt Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Debt issuance costs Â $ 15,300 Â $ 15,300 Â Effective interest rate (as a percent) Â 2.26% Â 2.26% Â Interest expense, debt Â $ 5,700 $ 5,700 $ 16,800 16,800 Contractual coupon rate interest expense Â 5,000 5,000 15,000 15,000 Amortization of debt issuance costs Â 700 700 1,800 1,800 2024 Notes | Convertible Debt Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Interest expense, debt Â 1,300 2,500 6,400 7,600 Contractual coupon rate interest expense Â 1,000 2,100 5,300 6,400 Amortization of debt issuance costs Â $ 300 $ 400 $ 1,100 $ 1,200 Repayments of convertible debt $ 575,000 Â Â Â Â Jazz Investments I Limited Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Percentage of ownership (as a percent) Â 100.00% Â 100.00% Â X - DefinitionInterest Expense, Debt, Contractual Coupon Rate + ReferencesNo definition available. + Details Name: jazz_InterestExpenseDebtContractualCouponRate Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe parent entity's interest in net assets of the subsidiary, expressed as a percentage. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestOwnershipPercentageByParent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=jazz_ExchangeableSeniorNotesDue2030Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_ExchangeableSeniorNotesDue2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_ExchangeableSeniorNotesDue2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=jazz_JazzInvestmentsILimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Schedule of

Maturities of Long-Term Debt (Details) $ in Thousands Sep. 30, 2024 USD ($) Debt Disclosure [Abstract] Â 2024 (remainder) $ 7,750 2025 31,000 2026 1,031,000 2027 31,000 2028 2,598,500 Thereafter 2,500,000 Total $ 6,199,250 X - DefinitionLong-Term Debt, Maturity, After Year Four + ReferencesNo definition available. + Details Name: jazz_LongTermDebtMaturityAfterYearFour Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Details) 1 Months Ended Aug. 27, 2024 Jul. 03, 2024 litigationCase Dec. 15, 2023 litigationCase Feb. 24, 2023 Jul. 21, 2022 Jun. 22, 2022 litigationCase Jun. 23, 2020 litigationCase Mar. 31, 2023 patent Jul. 31, 2021 patent Jun. 30, 2021 patent Sep. 30, 2024 litigationCase Jun. 07, 2022 patent May 13, 2021 patent Teamsters and GEHA Lawsuits Â Â Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Number of lawsuits filed | litigationCase Â Â Â Â Â Â 2 Â Â Â Â Â Â Â Avadel Pharmaceuticals plc Lawsuit Â Â Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Infringed patents suit, number of patents Â Â Â Â Â Â Â Â Â Â Â Â Â 5 Infringed patents suit, other party counterclaim, number of patents requested to be delisted Â Â Â Â Â Â Â Â Â Â Â Â Â 1 Number of days provided to delist patent Â Â Â 14 days Â Â Â Â Â Â Â Â Â Number of patents, paragraph IV certification notice filed Â Â Â Â Â Â Â Â Â Â 1 Â Royalty rate for future sale (as a percent) 3.50% Â Â Â Â Â Â Â Â Â Â Â Number of days requested for FDA to take action Â Â Â Â 14 days Â Â Â Â Â Â Â Â Â Â Lupin Lawsuit Â Â Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Number of lawsuits filed | litigationCase Â Â Â Â Â Â 2 Â Â Â Â Â Â Â Â Â Infringed patents suit, number of patents Â Â Â Â Â Â Â Â 10 Â Â Â Â Number of patents, paragraph IV certification notice filed Â Â Â Â Â Â Â Â 10 Â Â Â FDA stay of approval period Â Â Â Â Â Â Â 30 months Â Â Â Â Lupin Lawsuit | Xywav Â Â Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â FDA recognition of orphan drug exclusivity, period Â Â Â Â Â Â Â Â Â Â 7 years Â Â Â Teva Lawsuit Â Â Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Infringed patents suit, number of patents Â Â Â Â Â Â Â 13 Â Â Â Â Â FDA stay of approval period Â Â Â Â Â Â Â 30 months Â Â Â Â Epidiolex Patent Litigation Â Â Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Number of lawsuits filed | litigationCase Â 6 7 Â Â Â Â Â Â Â Â Â FDA stay of approval period Â Â Â Â Â Â Â 30 months Â Â Â Â Number of lawsuits ongoing | litigationCase Â Â Â Â Â Â Â Â Â Â Â 4 Â Â X - DefinitionFDA Recognition Of Orphan Drug Exclusivity, Period + ReferencesNo definition available. + Details Name: jazz_FDARecognitionOfOrphanDrugExclusivityPeriod Namespace Prefix: jazz_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFDA Stay Of Approval Period + ReferencesNo definition available. + Details Name: jazz_FDAStayOfApprovalPeriod Namespace Prefix: jazz_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionInfringed Patents Suit, Number Of Patents + ReferencesNo definition available. + Details Name: jazz_InfringedPatentsSuitNumberOfPatents Namespace Prefix: jazz_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionInfringed Patents Suit, Other Party Counterclaim, Number Of Patents Requested To Be Delisted + ReferencesNo definition available. + Details Name: jazz_InfringedPatentsSuitOtherPartyCounterclaimNumberOfPatentsRequestedToBeDelisted Namespace Prefix: jazz_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber Of Days Provided To Delist Patent + ReferencesNo definition available. + Details Name: jazz_NumberOfDaysProvidedToDelistPatent Namespace Prefix: jazz_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber Of Lawsuits Ongoing + ReferencesNo definition available. + Details Name: jazz_NumberOfLawsuitsOngoing Namespace Prefix: jazz_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber Of Patents, Paragraph IV Certification Notice Filed + ReferencesNo definition available. + Details Name: jazz_NumberOfPatentsParagraphIVCertificationNoticeFiled Namespace Prefix: jazz_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionPlaintiff, Number Of Days Requested For FDA To Take Action + ReferencesNo definition available. + Details Name: jazz_PlaintiffNumberOfDaysRequestedForFDAToTakeAction Namespace Prefix: jazz_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRoyalty Rate For Future Sale, Percentage + ReferencesNo definition available. + Details Name: jazz_RoyaltyRateForFutureSalePercentage Namespace Prefix: jazz_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe total number of new claims filed pertaining to a loss contingency during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyNewClaimsFiledNumber Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: srt_LitigationCaseAxis=jazz_TeamstersAndGEHALawsuitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=jazz_AvadelPharmaceuticalsPlcLawsuitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=jazz_LupinLawsuitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_XywavMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=jazz_TevaLawsuitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=jazz_EpidiolexPatentLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity - Narrative (Details) - Ordinary Options - USD ($) $ / shares in Units, shares in Millions, $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Jul. 31, 2024 Repurchase Programs Â Â Â Â Subsidiary or Equity Method Investee [Line Items] Â Â Â Â Â Shares repurchased Â $ 311.4 Â Â Â Shares repurchased (in shares) Â 2.8 Â Â Â Average price of shares repurchased (in dollars per share) Â $ 110.06 Â Â Â New Repurchase Program Â Â Â Â Â Subsidiary or Equity Method Investee [Line Items] Â Â Â Â Total amount authorized for repurchase of shares under share repurchase program Â Â Â $ 500.0 Shares repurchased $ 150.0 Â Â Â Shares repurchased (in shares) 1.4 Â Â Â Average price of shares repurchased (in dollars per share) $ 109.32 Â Â Â Remaining amount authorized for repurchase of shares $ 350.0 $ 350.0 Â Â Old Repurchase Program Â Â Â Â Subsidiary or Equity Method Investee [Line Items] Â Â Â Â Total amount authorized for repurchase of shares under share repurchase program Â Â Â $ 1,500.0 Shares repurchased Â Â $ 170.0 Â Shares repurchased (in shares) Â Â 1.3 Â Average price of shares repurchased (in dollars per share) Â Â $ 128.89 Â X - DefinitionAmount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4 + Details Name: srt_StockRepurchaseProgramAuthorizedAmount1 Namespace Prefix: srt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesNo definition available. + Details Name: us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTotal cost of shares repurchased divided by the total number of shares repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockAcquiredAverageCostPerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=jazz_OrdinarySharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ShareRepurchaseProgramAxis=jazz_November2016ShareRepurchaseProgramAndJuly2024ShareRepurchaseProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ShareRepurchaseProgramAxis=jazz_July2024ShareRepurchaseProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ShareRepurchaseProgramAxis=jazz_November2016ShareRepurchaseProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity - Schedule of Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward] Â Â Â Â Â Â Â Â Beginning balance $ 3,762,599 $ 3,696,461 $ 3,736,997 $ 3,525,675 $ 3,335,041 $ 3,085,734 $ 3,736,997 $ 3,085,734 Other comprehensive income before reclassifications Â Â Â Â Â Â 242,790 Â Amounts reclassified from accumulated other comprehensive loss Â Â Â Â Â Â (4,040) Â Other comprehensive income (loss), net 284,830 (5,833) (40,247) (168,576) 113,407 145,279 238,750 90,110 Ending balance 4,171,067 3,762,599 3,696,461 3,489,373 3,525,675 3,335,041 4,171,067 3,489,373 Total Accumulated Other Comprehensive Loss Â Â Â Â Â Â Â Â Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward] Â Â Â Â Â Â Â Â Beginning balance (888,227) (882,394) (842,147) (866,823) (980,230) (1,125,509) (842,147) (1,125,509) Other comprehensive income (loss), net 284,830 (5,833) (40,247) (168,576) 113,407 145,279 Â Â Ending balance (603,397) $ (888,227) (882,394) $ (1,035,399) $ (866,823) $ (980,230) (603,397) $ (1,035,399) Net Unrealized Gain From Hedging Activities Â Â Â Â Â Â Â Â Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward] Â Â Â Â Â Â Â Â Beginning balance Â Â 235 Â Â Â 235 Â Other comprehensive income before reclassifications Â Â Â Â Â Â 1,572 Â Amounts reclassified from accumulated other comprehensive loss Â Â Â Â Â Â (4,040) Â Other comprehensive income (loss), net Â Â Â Â Â Â (2,468) Â Ending balance (2,233) Â Â Â Â Â (2,233) Â Foreign Currency Translation Adjustments Â Â Â Â Â Â Â Â Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward] Â Â Â Â Â Â Â Â Beginning balance Â Â $ (842,382) Â Â Â (842,382) Â Other comprehensive income before reclassifications Â Â Â Â Â Â 241,218 Â Amounts reclassified from accumulated other comprehensive loss Â Â Â Â Â Â 0 Â Other comprehensive income (loss), net Â Â Â Â Â Â 241,218 Â Ending balance $ (601,164) Â Â Â Â Â $ (601,164) Â X - DefinitionAmount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15 + Details Name: us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15 + Details Name: us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income per Ordinary Share - Schedule of Basic and Diluted Net Income Per Ordinary Share Computation (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator: Â Â Â Â Â Â Â Â Net income $ 215,055 $ 168,568 $ (14,618) $ 146,820 $ 104,438 $ 69,420 $ 369,005 $ 320,678 Effect of interest on assumed conversions of Exchangeable Senior Notes, net of tax 1,028 Â Â 5,912 Â Â 10,761 19,951 Net income for dilutive net income per ordinary share $ 216,083 Â Â $ 152,732 Â Â $ 379,766 $ 340,629 Denominator: Â Â Â Â Â Â Â Â Weighted-average ordinary shares used in per share calculations - basic (in shares) 61,414 Â Â 63,114 Â Â 62,275 63,532 Dilutive effect of exchangeable senior notes (in shares) 1,325 Â Â 7,560 Â Â 4,721 8,549 Dilutive effect of employee equity incentive and purchase plans (in shares) 435 Â Â 619 Â Â 515 785 Weighted-average ordinary shares used in per share calculations - diluted (in shares) 63,174 Â Â 71,293 Â Â 67,511 72,866 Net income per ordinary share: Â Â Â Â Â Â Â Â Basic (in dollars per share) $ 3.50 Â Â $ 2.33 Â Â $ 5.93 $ 5.05 Diluted (in dollars per share) $ 3.42 Â Â $ 2.14 Â Â $ 5.63 $ 4.67 X - DefinitionDenominator [Abstract] + ReferencesNo definition available. + Details Name: jazz_DenominatorAbstract Namespace Prefix: jazz_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumerator [Abstract] + ReferencesNo definition available. + Details Name: jazz_NumeratorAbstract Namespace Prefix: jazz_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareReconciliationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_InterestOnConvertibleDebtNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income per Ordinary Share - Narrative (Details) - Convertible Debt - USD ($) $ in Thousands Aug. 31, 2024 Jul. 31, 2024 2024 Notes Â Â  Debt Instrument [Line Items] Â Â  Irrevocable election for settlement method fix, maximum cash per $1,000 principal amount $ 1 Â  2026 Notes Â Â  Debt Instrument [Line Items] Â Â  Irrevocable election for settlement method fix, maximum cash per $1,000 principal amount Â  $ 1 X - DefinitionDebt Instrument, Irrevocable Election For Settlement Method Fix, Maximum Cash Per $1,000 Principal Amount + ReferencesNo definition available. + Details Name: jazz_DebtInstrumentIrrevocableElectionForSettlementMethodFixMaximumCashPer1000PrincipalAmount Namespace Prefix: jazz_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=jazz_ExchangeableSeniorNotesDue2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=jazz_ExchangeableSeniorNotesDue2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income per Ordinary Share - Schedule of Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income Per Share (Details) - shares shares in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Employee equity incentive and purchase plans Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Ordinary shares (in shares) 4,465 2,501 4,701 3,091 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues $ 1,054,969 $ 972,140 $ 2,980,777 $ 2,822,269 United States Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 953,669 884,579 2,686,486 2,579,401 Europe Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 77,318 68,971 230,821 194,198 All other Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 23,982 18,590 63,470 48,670 Product sales, net Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 989,707 938,398 2,795,953 2,769,604 Total Neuroscience Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 702,724 675,081 1,967,844 2,018,344 Xywav Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 388,466 331,633 1,072,238 935,958 Xyrem Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 58,114 125,110 184,526 463,009 Epidiolex/Epidyolex Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 251,558 213,711 697,376 604,846 Sativex Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 4,586 4,627 13,704 14,531 Total Oncology Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 284,754 260,410 819,612 741,502 Rylaze/Enrylaze Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 98,780 104,859 309,359 292,479 Zepzelca Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 85,843 77,994 241,990 215,523 Defitelio/defibrotide Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 65,818 47,730 158,915 132,917 Vyxeos Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 34,313 29,827 109,348 100,583 Other Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 2,229 2,907 8,497 9,758 High-sodium oxybate AG royalty revenue Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 58,157 28,921 162,268 36,531 Other royalty and contract revenues Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues $ 7,105 $ 4,821 $ 22,556 $ 16,134 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_EuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=jazz_OtherCountriesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_ProductAndServicesProductSalesNetOfDeductionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_TotalNeuroscienceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_XywavMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_XyremMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_EpidiolexEpidyolexMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_SativexMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_TotalOncologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_RylazeEnrylazeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_ZepzelcaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_DefitelioDefibrotideMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_VyxeosMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_OtherProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_HighSodiumAGOxybateProductRoyaltyRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=jazz_OtherRoyaltyAndContractRevenuesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues - Schedule of Percentage of Total Revenues from Customers (Details) - Total Revenues - Customer Concentration Risk 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 ESSDS Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Percentage of total revenues (as a percent) 42.00% 47.00% 42.00% 49.00% McKesson Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Percentage of total revenues (as a percent) 13.00% 12.00% 12.00% 11.00% ASD Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Percentage of

total revenues (as a percent) 10.00% 9.00% 9.00% 7.00% X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: srt_MajorCustomersAxis=jazz_ExpressScriptsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=jazz_McKessonCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=jazz_ASDSpecialtyHealthcareLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues - Narrative (Details) 9 Months Ended Sep. 30, 2024 Minimum Â  Financing and Payment [Line Items] Â  Payment terms, range 30 days Maximum Â  Financing and Payment [Line Items] Â  Payment terms, range 65 days X - DefinitionRevenue, Performance Obligation, Payment Terms + ReferencesNo definition available. + Details Name: jazz_RevenuePerformanceObligationPaymentTerms Namespace Prefix: jazz_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition[Line Items] for Summary Of Deferred Revenue [Table] + ReferencesNo definition available. + Details Name: jazz_SummaryOfDeferredRevenueLineItems Namespace Prefix: jazz_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Â Â Â Â Total share-based compensation expense, pre-tax $ 59,760 $ 56,115 $ 177,855 $ 173,900 Income tax benefit from share-based compensation expense (12,190) (9,792) (25,218) (29,533) Total share-based compensation expense, net of tax 47,570 46,323 152,637 144,367 Selling, general and administrative Â Â Â Â Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Â Â Â Â Total share-based compensation expense, pre-tax 37,101 35,268 112,451 113,155 Research and development Â Â Â Â Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Â Â Â Â Total share-based compensation expense, pre-tax 18,927 16,635 55,030 49,346 Cost of product sales Â Â Â Â Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Â Â Â Â Total share-based compensation expense, pre-tax $ 3,732 $ 4,212 $ 10,374 $ 11,399 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after tax, of expense for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of tax benefit for recognition of expense of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares shares in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â RSUs granted (in shares) 102 91 2,112 1,728 Grant date fair value (in dollars per share) $ 110.55 $ 134.33 $ 118.31 $ 145.05 X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R68.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation - Narrative (Details) $ in Millions 9 Months Ended Sep. 30, 2024 USD ($) Restricted Stock Units (RSUs) Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Vesting period 4 years Unrecognized compensation cost related to unvested RSU's, PRSUs, ESPP and share options $ 347.2 Weighted-average period expected to be recognized 2 years 7 months 6 days Performance-Based Restricted Stock Units (PRSUs) Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Unrecognized compensation cost related to unvested RSU's, PRSUs, ESPP and share options $ 37.3 Weighted-average period expected to be recognized 1 year 4 months 24 days Performance-Based Restricted Stock Units (PRSUs) | Minimum Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Achievement target, percentage of awards granted 0.00% Performance-Based Restricted Stock Units (PRSUs) | Maximum Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Achievement target, percentage of awards granted 200.00% Employee Stock Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Unrecognized compensation cost related to unvested RSU's, PRSUs, ESPP and share options $ 9.2 Weighted-average period expected to be recognized 1 year 1 month 6 days Stock Option Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Unrecognized compensation cost related to unvested RSU's, PRSUs, ESPP and share options $ 0.1 Weighted-average period expected to be recognized 3 months 18 days X - DefinitionShare-Based Compensation Arrangement By Share-Based Payment Award, Achievement Target, Percentage Of Awards Granted + ReferencesNo definition available. + Details Name: jazz_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementTargetPercentageOfAwardsGranted Namespace Prefix: jazz_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name

Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=jazz_PerformanceBasedRestrictedStockUnitsRSUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R69.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation - Schedule of Performance-Based Restricted Stock Units Activity (Details) - Performance-Based Restricted Stock Units (PRSUs) - $ / shares shares in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â PRSUs granted (in shares) 58 13 371 270 Grant date fair value (in dollars per share) $ 107.07 $ 142.65 $ 130.58 $ 157.01 X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=jazz_PerformanceBasedRestrictedStockUnitsRSUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R70.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Taxes [Line Items] Â Â Â Â Income tax benefit $ 14,533 $ 47,176 $ 33,517 $ 86,823 Foreign Tax Authority | Luxembourg Inland Revenue Â Â Â Â Income Taxes [Line Items] Â Â Â Â Proposed additional tax including interest and penalties Â Â $ 25,000 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxContingencyLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEstimated amount of loss resulting from an adverse tax position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 + Details Name: us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 - Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_LuxembourgInlandRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 81 Financial_Report.xlsx IDEA: XBRL DOCUMENT r649 Financial_Report.xlsx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zR__PZ[;/B M GI%RJ5$Y3L*X>C^?&#:T&< ALO6"';,J=\!ZXC!F9K&;UBEA;%V6? EB8P@! M3#Y/KWPK+@K<4&=NXH@+ @#K<]X&I+Z/0[^#/FGHDQ],@%1L.%J68O,:!%'8 MR1-S##ZT **M4_X)%=Q>YM08P847!GHGF]EP 7:C0&=NP4$J8>+KU"U @B.,.]8[W$A3W*]-M8XE[- M]5KJ3WP)Y*'EU6>*O<"5@B\S57<\#AU1?:_VQ55$T(<5RXJ/E43*BCW4"N]H M#)XY-QPGU-?NF04711XV^H()HS3 E.B!LMR6^J[3-34:_8C[!>2M$1PK:U.- M76#7HU1G; <&Y 0Y\G;8%1ZEG=D,+#J8/Z:+=Rs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·W-H965T&ULK5=M7B9/KATX_$"P;>H! <28Z3_OJN@' V*+ZT]1= TNXC M[;/+KG:X8?R;2"F5Z*7(2S$R4BE7YZ8IDI06L3AC*UK"RH+Q(I8PY$M3K#B- MYY52D9L6QIY9Q%EIC(?5W!T?#]E:YEE)[S@2ZZ* (^>LES=EF9!#C;>(^6Z92 M39CCX2I>TAF5CZL[#B.S19EG!2U%QDK$Z6)D7)#SB&"E4$E\S>A&;'TC9

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

4_'X1OO/7Z[^?:\=!YF MW4*E]6Y30YO50&D"2I-0FD+13*UK6R3C;9%O-,LF(S+Q:157MF_"M\Y[4(;Z M)E!: Z6)@>=70J,J%,W4JK9-
,MXV\9EGD[D9]#R)$MM"YB-ZZP]JGD!I#90F MAIU>"0VJ4#13?MH[R;[!!VHRUVXX3\/83J.,^-C>0H1:)E!: Z4)*$T.["V%
MBFHJ49LF&>#;,QEE#:1Y9"^\YF-Y*P]JJ$!I#90FH#0)I:G3?6\]3YL]V==\ M5>;AOOLIJ4FHTY,13D\2.IM20X/61%#"Z8'&%%":A-(4BF8(,M=.3^[[59F3
M(LQ)#R3O+P]K9,Q/VSQ\ZWRU101T;!ZB]:[-0QUB$:5Q:6\I2A0\+\LXL1,\ MBBA8YFEX;"N'7-L\^5=^5.:D;<<'\!U4W%Y(_XJ,QI'1)?
7"'MX_ST1V7X!GK+:\!'98C6$^,*<8BD?4P4I.UC MHB!G'^?:<,B?\J,R.73%!)0VAM)J**V!T@24)J$TA:*9>14F'$Q_;6*Y)60VD-E":@- FE*13-
U*OV'7+>=QB4PLC=+'=_NPF= MG8/Y6-[ZA+H(4%H#I0DH34)I"D4S]:F]AMQK0R]FHCS]C@G][DM.9-MW^^C9
M#XU0^X$(2KV30&T%*$U":0I%,P6IW8?<:^7&(!$22QVB(@ISYX6D./U" G44 MB(#N"PG1>O>%Q"V4E$F1V[LO2J+@>1XFB?
URIHB"59+'#SZ;:7:@3MKG?-+> MZ^NY='|"]]+*W1PQE3V%!JV)H-2@ DW40VD22E,HFJE)G<[/?==N#-*AFP(_MDD"M3H\KT.0\$= =5X@$OCNN$(=
()U");W_0"52W()= +70&O B?,-%10#=[ M@M+&4%H-I350FH#2))2F4#13[MHO*'B_X,GFR?/M\+X2B R_-11" ]906@.E M"2A-
0FD*13/EK:V'XHF6@9"2)G9'LJ?)\^WS'K*A/@:4UD!I8L"YE="("D4S ME:H-EN+Q*SJ^_L.Y?'#OT9?XH$9L[U %#5E#:0V4)J T":4I%,U4M?91"MY'
MP7\YMW!-EB@L[346([Y=WN,NU&.!TAHH30P[O1(:5*%HIDBU>5+PYLGWO4") M;[SWT$U\Z,3>+Q@:L8;2&BA-0&D22E,HFGE1:,>F&+ Z!+^2J2
^31*7SOQ] MOG'>PS?4R8'2&BA-##N]$AI4H6BF4K654_!6CL\ZIL*U([*\<+Z>QD?TEA_4 M[('2&BA-
##N]$AI4H6BF_+015?!&E/]^P3S0^XY.+D[(;.,)&K2&TAHH34!I M$DI3*)JI56U0%;Q!-6S#X((P8:)\9]?8PR3TFRQ06@VE-5":@-(DE*8&=+XA
MOE([:R6_MN11%9360&D"2I-0FCK=]Z;RM!M5\F[4\._L MDA-%>+KO/5N);X?WE>":+I$]%$(]%RBM@=($E":A-(6BF?+6GDO)>R[?=+9227P$
MP[9=^/9Y#]E0VP5*:Z T,>#<2FA$A:*92M6>2\E[+M^W94@)PAMF9>4P9,[JW;YQGF/W5"["$IKH#0Q M[/1*:%"%HIE*U3Y0.<
'&FB9E\2V8&%4Q+;\H%X0E%9#:0V4)H:=7@D-JE T M0WZ5=H(JW@GRM\QYH.\=O2)\BBBQS_D8&K2&TAHH34!I$DI3*)JI5>T65;Q; M-
,PRKZCOM&=A&-IK./EHOL,DE%9#:0V4)J T":6I 9UOBD\;1A5O&#W*,J]< MCR4NTS*QMR'B8WM+$>H306D-E":@-
#FPMQ0JJJE$[115O%,TR#2O7)LC[B\$ MVX49\;&\E0=UD:"T!DH34)J$TM3IOC>5IRVNBO44OG;K()[N_>28$D_K[M9! MT*
U$90PS:$Q!90FH32%HIF"U"94Q9M0C]@ZZ$!\:$W36P<1!6W3G&^=M[;< M@(YI3K7>,NL@HB"Y==#%YKIMM^/)=G+Y[&;RL?UMLOXX7VV" M1?
NAKQC^M%M(LY_O+[_9=O=/#_KG]G>=]MMM]S_>-U.9NUZ5Z#__P]=M_WR MRT7/O^O6O^]C7/X_4$L#!!0 ( \9UG;1+>D5P@ # D 8 >&PO
M=V]R:W-H965T&ULK9IK;^,V%H;_"N$M%BTP'HL7W;))@-P& M#=!)@O&T_4S+=,RM+*H2[23[ZY>D%T3I]$\U>[
M9DR"YTU9M6>3M93UR6S6%FNVH>UG4;-*_634Y/S7W'IKS4[&5):_80P/:[69#FY=+5HJGLPF3"WAR16+=P%C\P=E3>_ =:%<60ORE M+VZ79Y-
(*V(E*Z3N@JJ/';MB9:E[4CK^[CJ=],_4#0^_O_;^Q3BOG%G0EEV) M\D^^E.NS238!2[:BVU)^$T^_LLXA([ 096O^@J?.-IJ 8MM*L>D:*P4;7NT_ MZ7,W$
<-5#_N!JAK@,8-B*F7'KFDIZ?MJ()!H:]6;_F+&QK16 MWO!*3^-<-NJ_7+63YU?W=]]_N[V^^*XNYM_5Q]>;N^]S#H$T 1(@X]5^]OC@-R M<#^RV/2'/?
W=UZRADE>/^U#EDC/G*.U[(>Y>]"H^:6M:L+.)6J8M:W9L[0 M 8<9BI(TZ\V.I,6]M#@X%Q?+_ZJEI+*/;($4*OT4HBIXR4#5:];W]55!VS6H M&
['C*BK!X@4(QSR>N#R,/W(B/ZBSH]%*^M%*@A-Y6TE:/?*%&A_:MFI,Z$8T MDO^/ZL3K\GS?77PP:23)"(Q&<^LPBY,40_?B>0$K
MRANPH^66@5:R>KJM >T#U^5.9NG,4X3&PVY;09A'.7%[D_?>Y$%OKIF*O(}[ MASJWGHHP(F-
M#BN4)AYI,!J@%H53D:BF9B'S2C*U0"1@SSHPG)FIZ^MH@+(L M34=2768).HB=8ZT' (9!K0\ZUYBJ2!5EH!1JQ;5@")%69RO&=]0LQVHYQ(O3
M%VB+C+,D&?MBFZ4I1AY7T. *>CO"&Z8U3E4*+5BKU;>,-L7::%^RG2H<:U\\ M=]T?
J8^B:!PT'C./^H'7,$A'%=$KUFCUDCZ#!:O8BKM58NOQ4Q3%:NF-=;H, M$<$P]4@=2 O#J+V7:]: ZC7*94-5TC-UL;L0(_:
Y0DM"862DX7O/3C%'XH3S^JM^,A&(@*PTB]L!>STV<;D5,$ M\S0?SY1MAW"<>4@*!Y3",$MON]SB*56A#<8I2ARITF$'4003C[Z!H#",T(>&
MU90O7[/Y/I"$60S%5JW=2G81YE1O@S"-LK%TVVB*56KT+=D!ES#,RV$[4#)5 MJX1TVE"$49);@^PP(T1O75Q"T3A.QJ@B-Z"8M%LV5&^<\JTH18G
M!%DJ;;-IFJ#$-Y0#_5"8?K?=+H@^L_!PVE!#491;.FVS!,(X]\@"&+$6^<&NV=W M*K=!E>7<&>$ B#B/Q8:LV,-3LRU8ZSE1T
MR9=/H"ZIIJ,J09ARR+NKP2[ZD33#(_TN.[6@$Y_\@9+X+4K^LVT9=A'4L2_S MV7GT#P3%88(^:,ULV8)5(S9@0^6VX?+E':&#'4R-
8X=PVPX%XN;@!#C,U#XW M;5LS^IW>=YP).W:.&)+<*E==AB@A_J 90(M),#-]X16MBG=(#?+ZA\^O/ZBW M8Z<'?N,PO_6$U4?
1QMMVJ\:!Z6ACSX79R9JCF)957&A,2LWVY98!%.'(.4(V MJ/,L2I-Q0>^P\\WBP'(<9OGQTF&;NA0OC)E\I5805XY5^F M:YOA$))X7)DXS'":1)
[='QY0C\.H_Z8V?R_[0WPU&Z6H']>2-1N5OA;NO.7: MKF(46\O_3;MCP0/=\1O;U;U<$SNO0__$Y7HMRJ5>6?MBNV$EE?K828#VX"R;
M/M'&_;L:=NQ18YP2*SDX[$B.L:=JP0/ <1C@YLA=Z7Z-&+=*!XZQ"A?[2KG!9P\72Z87C(#F.$FS]U.

T[.#=R\VK'DT MKZ2H?;X^E]J_N]#?[5][N3 O>XSN7*3J_W+*T,W^W=IOM)&S4X+2K9274:? M4Z6MV;^>LK^0HC9O>"R$E&)COJX97;)&&ZC_KX3*
<]V%?D#_DM#Y_P%02P,$ M% @ #QG663M93.M%@ .#\ !@ !X;"]W;W)KS-UF[M!XB$),0D MP0!DJ^5?/^?>"X"DK&ZW,[-5J5A-@Z))?
JJN3\]/3;TYJ;9NCIT_XV1O_ M](GKN\HVYHU7H:]K[7?/3.6VWQV=':4';^UZT]&#DZ=/6KTV"].];]]X_'62
M=REM;9I@7:.\67UW='GV[;,'MQX7_)P^NV/YC(S]>T7^&JP/]76UG[]>,C5?2A7SAGNN4@IO*%[O33)]YME:?5V(T^,*O\-HBS#2EET7E\:_%>]_3=QJCG
MKFYULU.Z*=5"E*/<2BWLNK$K6^BF4Y=%X?JFL\U:O7&5+:P)3TXZG$^[G!3Q MK&=RUOD-9SU6/[FFVP3ULBE-.7W_!'1GXL\3\
<_.;]UP8=JYNG\Z4^>GYP]N MV>]^%L9]WN_^#?L=X%+][^4R=![@^;]##,M^#P[O1P;U;6AU8;X[@L4$XZ_, MT=.__NGLF].+6ZA]D*E]<-
ON_V'5_7^=I?ZN/WY4;S8:)E28OL/"*JBV*I0- M2JMUY9:Z4DOKVLD25<33MAL7C&I[W]*_>*=SRC:-N]*=H<_031/(.:D.-%8P
M\4!4M;JSIND"4XMOK%MK4P;=C/^"S('T.C-R6'07V$\Q&ET5Y/DYNJ? MO4]R/%XY.".00CL$Z!6+CTL/JN%8V]8[76RPWY:.;,&<@6AP H%>>WQ%KT4)
MT^9*EU=T7BTJ*KP+T!J.\VX)GXG:W^^J=Y^???*C_WFWU%:S]X8,+]14@7=B^GH&>-13)'UO7 MZ2 ?6:RNQ&?EKG=+@#+<
W)@!\%5/<^_EBKKYW3O3SPO=K M=5DB6EAR7?3VC&#X_8M+ I#Z>U_MR&6>RKF5[AO$>F8^;X;//^.$>@E,T%(& M%WV; 2*@Z33,X7I'VYOKPH
="*?4NPZ16\!(N U_LL7"SX_VV8PA)\=(,(V MBR2 "7(5H"M&U ];@S>*K@)]^")MKSLUX0;4'IVF%);PL/H;@/SV^Q:P-35 MC=5,UNL?F"I=
(I"'.TOD;"X*!EZ:#LE/4(_/_P+( G9(UKW MZM=#GIVE^NI7T5C1>P^"*Z(^N=N#; 9C/_:>S"X$5UA>R$S^:. !KH]?Z=#I MOE-AUY3>U89/^?
$5(/7"PXGN?4%0HU-ZJ(M\="@J? B0/0462(>_?K=X/D4D M/!?C,<$1:QB-%TD"+]\S5Z^(D0,E+K&BZ>\=^MVWNW8IT=HE0/'N/VV"?'*?X&,1#TK%F1
$X M(@"M:O@1>PRF*#R (#>._=ZLJ:8Y; *ZZ)'45+NZW;AE!;SCA;5(%C0"6#*@=:4AX##FO+O#&K*K20!B:$9J\0Y4M$%W=IN1S'O
MY1PL5E8=XQU[Q<@>5#!7KQN%1+S+GO'^3"P%(;$U<('(&VL;N(I;(UGCA(;! M3QD"+'KCO/W(44HAW)HD%UT:^#=$D9>-9P#,U;L-Y7\LS=U!-
SK!]2QY54Y8 M <*/QE?X/+C*_S'M1U,5.D&KZCU0@WH1(KP[9DXCV7C\-TIF"I2R,ZH?]@STAU5V*SIZV,J=,LQ>G<70YB:9<$!SH5A2,#GE)9T"&XS
MVW8/&3?$Y@A>IG#1D3=X_?HU$37B+S*1 )L88%P?H#\&Y2$_WA%Z$ G6&X<8 MTA&0?
NFUQTN0^EM#J3#M1)6^.CL]_F4&I7(P9_ZWEFJ/'+\B$W2(N>Y&2[SY MO;>>\G32ACQ%MO_:FOV MG_3#Y@2^^!2I=GK*1!)]-]9I])[M*'
V2!QLR2((_3(@I="">"ZHO%.V-PD'1 M J>"NC* #A/N3",M/'MX 6U--YBK9YIB/D#VAFJ1IA,_@W(6VNH;C5*JB^B% MSY-/ Y,K"B$(8LB8\&*L5AA_2P,?
CIH>?I!C=E5)226:8Q#(:IRYN@27QJ.>)*J2DZ1ZV/<5H0VFSI%\ MY5S7N"X>((G&P(1MI(E'!R$Y[;CT:>A1!4U%LMG#,;D(8+ <^HI\6LL.;:CO
M6Q1XA6WY>!#-;[RZO'PS(]<#^8QD2O%&:">DF D=4L\F;W@[=$C+IX\O?H%R M75]1 :>H#WDPY:%B$GEO3^YH4/)G5,L51A$[#\2DR'),(^U[*?O>1-
_LI?C M3-)0LTN]@*-D-WC_C-M5]SENTB+J.; ?IH*_@?1LO)$\L[$I%0I1 M.T.42MW$632.+A-HAQ*&LMYHV.D4."? T5RWG#U\@@"B;A\".(,SZ687+349
M?DM])3:,]/VJ[Y4QR^DN1%&;;>Q6::V&Z.!Z!A_NZ+P9RPQF 5]MB9WAJEB.)Q8)I%V$*LJ9W([4+-CD) MO=25YB@TF(^AUEVCV5^1J > !;/FI 6&)-
Y9)*7)B8TA26PT&M/\0D[OD_7_PDU- G$!N$5FP#E:ZL MU)LD -G,7,/R(E"!$JJK4K>Q1'6*6-+0^10%MB8>;:2G!BGT@;LVB5]*O&RQ M49)]YS.+V%J:-
/:HY$<\@\2AT937DV]#*0#>5CVL=]KI38VY&)/*DA([1#ED M?]+YQ)K&F!)V_3ZPX;V$KZFI1\:&+MXN'W0#G$@W%':HIF'=Y(B5L[:1_R7- MD/"5R4=Q<
BAKZ5[&ZE=K6#PT1-$0.@ZHQ7KC70<]=)6'/IG6'AEFC[N2!X# M)A&AZDW%)H$\'35[X$(ZE@E?8CR'X]A<_33PM^2&-:5U X>0'R)PAW*,1$Z4
M>>EHLFTU$^Z7,!)S)1"6.!R0^R\K,ZKA"NN+OB:G4]#IET77LQF(QRPXAI=V MM>)N"+F^?<^422A!U^7B_>\Q_'IPUE*3Q?1_-
]F2_[J'<)WH@A>$K96( Z/I8FS1+'2<+4E M=5@. 6=?CT( K'BKUCV02Z"',Z'PE$-FY](P)(&!FNUPU5SA3<)_IF4LHOED
M$O76A@]B".^;F!USXOUK"M)BO[1O]G9;2R6T(X#T/%L:?!;'1LA9RDWIT&=# MOE ;M\5GSWCSD35PJKG=8>)1>V_)<:@3*'''|
[%1JBKRIB&FAQQHU@)0RFC9 MB^S$.]E&NG?[^XHC(><;PR<80J:N9>;1F!59/5L9;6F;*R-Y&>E<.M2$',31 MWUA,P(E"24W:A.WY+-=^(M<\EY).
X&5!V Q1,1J);JW%/8.Q0FAX&"?X/4/ M>ZTNG9R"C05-RL]<<\%=.=-)FAA]"@=CB3;QM&[K<@L*A'')8Z6!??EJIF@H MQ^X.2S=VO3F>SFCB/&T)-9?
LBZ]->5R"T]FAU3-U>:5+4^5B]<>^]KN/8DXW M=/RQ\8E,3HC'H=T_:1Y)-VU&"<"6&D#XMW64A)"MQ-3Q$VD@SJ9^S>6K.S'* MKT4)W?
T%26W3\Y8*UA(O4T) M0GPOQ-;+W@=Q!W 8+G )2Y"S'B>@FMSA_SNWF1-4#O/3%0P)'[U)F> MGD+Z8IB.6?&&IW9#&3W9M:
:@A[1N2GAN2I&J\HPK_$[RA8KNK+22V8$SPP* MXR0R6J=@@B=+8Y98W&TL-LCH.T\SL90"?[HK)23K:"V2MXGK*V/!SVXZFZ1F M G F-0C:S2Y
+SHFT:DMB3@]B5%(9'F,>\A-2?PO-+71>^8?4NOIQ$G*G<(; M*3\8\X$7:FJVC1"\@G2$DBWONA](="GC=0F'*: DQS\;A9;;',#'&)_LBE6A9]1*]!O[:L;7]/9
GL1G3H8& MU'@P/YK"#PODY,1'LH0N+G*&<%C]KE >!-5>^.R;\':VI&@R8"8FN$N11%',^.* >> M(,I%W#)UOI$Y]/C6@8/IZ\IG2-[N:.]]PJ'!E=V4H[
M)M\,G4<5[U(F%&N^>%,F0%,537_]&IQ_U*-*;^2<&M,E-Y8C '<"@_D--S_ M.ESCYH G5)%_81T/\6Z#Q*W;T*T2Z&@;O2O%P-
U%C/,CYWPQ5C&8!J":.$=A M$3C8=V[\4(]CU-*-%UM&B0+UFF!TV#7F#!6-(*H4("1GFEPX,27MIEZ1;AHQ
MC)A+I5YXT!4<7TF3#+OLQ01ZRH\D*B'F# X8\9, M=KHQ!E[$-ET.F&3A'J8S^!BIVI,O/)QP>;HB'"XBK&@MLZD)? 6W"4;V/!XC
M740_$(*55=,D>*Q23KPA:CNHN(5EH:#-0R*Q;M=2!.^;.)"BBPSBD1(T1PUC M"B_TN93NY!)KEE7,'9&?/"?7TW0I1<+
[5'Z/&B^P=*2CL2]"9I#=#I">$A-) M HM/]H)_!;@Y&@C;$:X?>QON#*2[$NXVCTE=< M;!RRAD!A[NU7T=NN1MR-9Q\=TWP,
[A#SCHRF\AQ#I>BT=Y:?.CY.&5K?4 M\Y=N4YJYI58G;)[8]D. S\$!PK\0[3Q77/R..\>%CM#: %%/RO/8F MM7/8&O3U,;*]NIVHEN3,='"A982EVF
60,\Y"ZJ8:;95KK@(F@*T*1"3NF) M,=UE*<7*8U ZQYA=*Z&>Y>/SE5W8.Q=X!)01+)(WN,J7<.+%_!2O5A,HVJX7 MTC:NRM7@83S%0#7 (?
8NS#5W^>FFD2^'25N<)BB^D,]42WXA#2R'.+=N8J>G MF PCA(\\KL!QBI'#CZ/#BQDR]2EZQ(6*+R5W,GKGTWMICP^(IX*LRDG?R!+&
M!DERA3PJ[H!0%L!GCGKA\?)UU!7*B=)QZXZ.&YTE]X]!(P?&*[G#P]5]?)_G MV'1C_,"T;4O#B3*+R*39.!YLM2\'TXT7'UVZ:Q*;[9WK@$,<]N?SQ^?SAPIY
M'$J3YK8C>?@Z\FMW.)M(U)S_<6=?1I5 2L]R__.C^8.['!QYG2HZ;'7[!5Q^ M?7HZ/TV'Q3"2QPR[?<+N#VNE$\M]<.-S:N*&>7,D0#)0#S'P?;9&1U)&'FRI
MFP\#*.)$0&8AA"!)X^#D>-H_:OF..@39L/DJUZA$'5MW[E7F0:!<.XH1,Q>L MHTR/$T^Y80^_2'TG_I;=!P6_:%&'-I34G,Q:(B+]:@-^CZ[XAA&VG-I-W?4-
XX,#25(RD^V<$*&R!W29)?*$3)XU .[_7?&"?50QLZHOC*C3 MI#KGZ='!N_&4.:OSDS,W+K2H5JD#_9Q_?D2= J9]BW1A(R4Y77,5L<:?!)!4 MJ-
E"#E:4G/I@$QU K(VK4>/G-HN,YF)\RE<&ASOX,ANI]2XE)UAV!183T.,8 MOJ.)[3JE!:*/-G6)F]RF2V+1L9BD;(XNBZPX?XP]9"A)?S Q&6%E'U3TR'7,
MU0]Y;E;MHH"'\?LP1BLGK;&(!ZI'S)#$'<8C]S4..A.Y[[_<.<;5FXK-1\W M2=-NU!Z)]QI2<^PV3[7BK"G"("3R8IAX=/87>F_-/]XX0/FX*_;RFEN\:E%X
MULLB(_O%&,H+&!N*"R#Y=5/,\\TSO5I!VY*!4#=\L:";S@*-*4T//DO3Y>+% MZ/0?AG+[1[I@2'W_Q8O#>Y\]N'UO)O>GXA_@T]&MUYS)"0JG/*1U?
^RHI+,# MFK]590\??X'*_DTIW\#9_2\VRUUD;@39L@UJ?.9T]CC#M.ZF2I^VJEW(Y<[0F?RTE!W] MBDQ^1OIIJW!-]BSY-('HS6N*/A26@?LV]5VILQW[%,-
QY)"P7GX[D+H!D=>> M!A^(0X>9R'7LBG[JLQE7Y(3HR6Y+>'_:JP_I;@^^$A]*OY_I-A7J!]@=Q=-& MG#I6TSJ*(?%"<#IXKMX:2M@G/_CS\.U]_E'7ZV9
YV@6?[EX]NF$_7&>L,/L M@5OU3E]#Z'&X_O#!P>'ZL/2+ANHH=":#=;F+0PRL:00':O&M7JJI[)JFA-,+ MBVIT ?=O831BIZTE::?Q
#_ARWZAK$N>B'5^/IW2@V[\ \ >F^ ]RMC;\J,=0DBF3&FZHQ(G]*LYF M^3%E!&8[OJ66+@',#_T,]F3T:V;XL#7_9CM(3B _;,Y/_"+^77T,-R^4WY
M3TA@Z:=9E5GAU=/YPZ^/I F3_NAD/.B#_ M6/[IOP!02P,$% @ #QG6?'AD7XC! APH !@ !X;"]W;W)KM M=77G^RI;0T&5)RHH4;,4LJ
:IW+EJTH"S:U1P?TH"%*_H*QTIF,K>Y;3L:@U M9R4\2Z+JHJ!R=P]<;"=.Z'2"KVRUUD;@3\<57<$<]._5L\29WZ/DK(!2,5$2 M"JUH26.9EM*.-
TP>$&=_IF3CF0.62U9)J! M&OL:?1D+/VMQ[QO&GEDD=8:)N%IQ\UT[N#R,F?LX72$@_/7^>2 MT/A(SOLP!76G*IK!Q,&*42 WX$P_O O3X..5")
(^@N0:^ANV[O_ )6:92S*S M&#!K&U1C+JTAV^>69 (+6&G(B5@2O0:R%!QO E:NR$^L1(FH%=JHG^\0O-)0
M+$#V^TQFA9"=_8W6OTBA5/O_I#3#@D1IS_5@.QOA>S*\';J#48RC#^]&41A] M/!KMM:?KON&U@Z5="<40+AT$;A $O;;[=O*H_29!\\6##SNL4?

F"=^JRQMA( MZ(;#P!T,HA.0O>9TS3>A*5?(*W+3<.2&\>!"+(?ZR(WZ<>KCO.:Q*=SVLGCUOV870QK\-TA%N7GD!T\G_K^XR&;AJE M;AP&%Z(XU(?
N(.C'+9>'_SKV5$)S]'.0F$]Z5$K*E)+J2\DCWX'4"FQYJ HR MMF39#5J6VHRH?;X*P%+)L7HDUAS/:HYBK"%\B+G=QQ4^P T-CEN)]8DV>Q=$
M"9ZW)#->Y]97@1/\:62H-(%7?.@5N*3$]-K*M!'D1IC;6 1GN3T=2N.GB1.+ M&A%% 1[YK98'*<"WDM,R0]
<2[.6'(GVT_UNFUT1(MF(EY;BONN.*F"N,"WDA M"6J82 !2-.^)C1#PL%H5'@FR RH]/*AM' T=LI2BN)YVLJ5X%*+4"_!AY=SV M" C^?
IAX:2]I$]%0,.H2;\N."YBW[FG?9,PQ)- M V\X<(ALVIYFHD5E6XV%T-BXV.$:.T609@'JET+H;F(<]+WG]!]02P,$% M @ #QG6>.BSB&F!@ I1$ !D
!X;"]W;W)K&ULI5AM<]LV$OXKM:6<8B:2H%SNV9^PFG7:F:7-QVOMPTP\0"4FH28 ! M0"NZ7W_/ B1%.9*3WLTD!@E@%\^^/+N@KG;:/-
BM$(Y]JDIEKT=;Y^K+R<3F M6U%Q.]:U4%A9:U-QAU>SF=C:"%YXH:JC9-1-O)>;K:.)R2R$KH:S4BAFQ
MOA[=)I=W&>WW&_Z08F<'SXPL66G]0"_%]>CF ")4N2..-' ,C^('49:D"# ^ MMCI'_9$D.'SNM/_H;86=L#NTF<5WHMZS*9QQ-(XS9[1-^T-
MG7I]TR\;^EK:O-1DJV7_OEU99Y ;?YZR.:C,3JLDOES:FN?B>@1"6&$>Q>CF MVV^2>?SJ&,$RLR9Y';P^Q&I4! M)QLR NR4X7@OE',G-
IK,*5ACO95D\T%*X7A)M_NV7=285$W%L+V^\M3&#_# MQ_[9: ?5]W*CY%KFG)RJ'2_/+]Q:*YR]9+?/^>^2F"3(^^8!17G= !)[P9(H
M6<31;);B^=MOEFF2OGHRNY@OH]ER?K3>S7U (450:FTE M&MSV=Q%,=Q/W;S M61K>NQ'U#]5-,?$IWW*UH<0Q.VZ*06P[T64TG6?
MWVXN64;Q=-8-/RN'Z%C' M#.)S0D,RI7_=VS1:++/VKW?B4U_,9SALL?"SRW097:071[[(,LPG%WX]3>(H MBV?L%\E7LFR]?
0[/T(UI=+&8#\;#RC3*DK@?_X:CSHWS9>+_]\9^#8HLBB^2 M?KP]P[.O(:]4>=F@@K/J\R0D9KFC1/(S6P%&Y=R8/7',4\L&!O*Z-OJ31.\4
MY9Z)CPTXX'0K<2"B'9]*^6/B!P)_#,RJC@W>_ MB$=1L@1;Z\:=LN"Y\A+.#"K25L7XR3OCD-#E]U.QAZ11W)
MU_76KP3"2\HU4QKO$K73(3*'K=$I18BN-D:O-#&DH,Z@<;8Y<*8_88L&S2 MU@BRN3P0K\LTC$/^T:[U4Q8=E-G0%/B7@O8YM-9/MD%^<-
L3DPZ%.X] V$ 4 MO5,LQP$2L](^D-0.MT<:.<#1<=S?+$$VVI_KAK10P&&?)^?BU5 #DN<.%\B" M^M8P>)%O3%_V&%F=EUA$5X&6G42&J3X?
@>)PCZT" 0U7=DV)N!)N M)X0* .0: EOJ^ Q(@WJ"UU3AAK(1?@2\;<$7DBD>B$@A'NT3XV!93M$]44V MGN*.79;^A] MC"/:O!HD!2LI
=TP@7VT>/B(\37BO+.#6R'O:VXQK+%=--,Q.OH_>FZ%>Y]0 M4A,\',T*> .ZYE$;VSG[57M.M,6>3<=).ONR!L+D-4SC3L.)IO B&<=L-?3Y
M8.*4SP_ZT$HVPON5G!R,Z^'V:)/Q[&O,S3ISLP[LX?:)2LTELK &1, .MV$\ MWS8;?*"Q9-8YWQ,4=^H.,7M05$2X]4C>##'B"BLUJMT=CLZI#NW/!#$[
M#F(*XCP3Q"=V" [6!'LL%<*5ZXZCLD?4/+C@Z"+0UO:V M+V8CE'W_HT!X<;KV'^(K[?!9[Q^W*$O"T :LKS6,:E_H@/Z7F9O_ E!+ P04 M " /&=9I%Z": ,)
#K&@ &0 'AL+W=O<>RFSWMY;BJO MLT*]M\)5>2[MPRNES?9B$ ^:A0_9)O6T,+H\+^5&W2K_2_G>XF[4X+-2>6\R6MB:)!G1?B5]
[4?.@3S\1,$DYI@PGH'0:SEC?3R M\MR:K;"T&]SH@DUE:BB7%1246V_Q- .=O[Q1-KN3Y!GQIG#>5G"X=T(6*_&3 M6FVR8B.NR'&9SY0['WF(,)14K-
_%=A/GF"_$#^;PJ=._%"LU*I//X*JK;Z3 M1M]7DV<9WJIR**;C2$S&D]DS_*:M_5/F-_TK[!"T-E^H51H9ZZ4B;H8H)*X_Z_A_19]ON5 M_W-N_$T)"1>J^]
(XM1+>B$19#P01-G.?0(8?(EE;DPO@CP5GW&:%5[:05,U2 MZX<("XFN5KQ35XFO^)'#L@!:H1X+B$A266R4 L(+FT&Z,GT _!$8X5E^U0)
M1+)PFNF%60L'09KXD@&JL@:%7AB4'],4P,KR M> !L:%DDM"%5>B66#\# I>=QW92!,]SH8TLQ-)89!+6W) BD,L"$]$O6NSH4
M2.N@#!B[4B79.H.UFRI;*4H"A[W65)N4/5:!"IY:M8$'URNM:8U4V*U#QTY" M(.R5A[_^ &<$B0->JT([1%E92@JXBLS=*CA$%,:SN(XLIB4=*QV$((!L;D//
M)BKR#OG(?)X06-A*NQ()\(G*&!(Y#JO*UNZ%)55)"1)/*-Q L0@J.' )>:.S M///LB\9[M/K"3'P^_YIR*$SQ73D[N!\Z)#30*)0T(="'; DW*S-
D&F03+*=!=9YGUVJ%L]O&HT!JL?B"E:GU% MF$?:I$1F<3@ _E[E2\2TZ0#,ZD8E]6K,J].(?0KS0@7)G(PF!I\%HXV^V*8H MI-J2I]VTA1\.)HO)\!3-
6&N>*Z#!P7$<[Y8B1)=RDYRH'X;B8ZH^ETSV4WY0 ML4 +1):@$%?.Z&S%$48->Q7<#]T18I.K.M+D5.:J-9=T[=C#X-4CA,N9)&,N MG-
7/&$[FA4CQ=A8UHC=C?]A1L$VE8.Y[N@,-EFE>LU=O 5&]%=>UU)_:*2^ MKHONNI%^%J)(0>M<_4BYS[8#P*:90F9+MMB"9Y[=*<#")
M>@ZLK0U.%!F ,?$L.4FJO HH;,"&RC '?4HGCKLZL[C_2UNP%CR./(&//H5J MOR,.H6FBBA+I4LJK;8A5:%F,]5PZQ+F@B@FM!1E$%;,G2
0YTM6E_I6%^*9Q M^P=R^U=7WTM<%O%X1 D@[ZGXCJ-X<4KEB+J<+JA4H^/3"9?G))X'89"B@5C!
M=>SE%P6G6VKH%82@/>F'<32=C8_H=S()!S.HC'?3Z+Q"7ZO'(ZBE#8%!M M)^Q<1:-8TW)O,6-09;^[P^Q)1SSQ&@VX2(B.O!D)A/4C)>WMN]
M;!,FST^J69%/U^3!>'C<=A=L>NS5Z"NB@BZ V6RI^JZ& ]OD-K OM$UU[W@HEHUEV:FUB0A@J*W728?;$?G^U*FI%TY_QW(0/XT.!I#B#>J+HIE^#I?
-83]*+F M?]8V\]>GY_URY]'T9";B>32>']/_>C20OC<[^<,D/4P](/K34_Q.XF@>+\0_ M=R/O7^6NJR2Q57^:AKR 4-
]^,Y_$D^^_X&J:T1NSNUPFT6P\@\MG\?AOD#T\9NHJ? M&7%[ S]0CK:^Z1[SQ2W/(SSE[WQX58^W/'_O9I4:)1B "#J@E-?A7$G0V3V?
M<+_F0TK%QS90,$A3P3N94Y@KTJ.4%@ZJ2@@"5.H'GD^RHCVIT?Y6@X89AA=, MF4%J_8:0! 1P[C+@77M!:(=!8<8ICF]5^- ^O\"NK\5;I/^+-
;E1+K%9R9'N MO""KYP>$LONJ[)J:TC7-' @,GL$Y"KM7XO"]IOEQ==2QK,NNA?@&+!L(V*U@ M )I/QT>]9R=3Y Y,IN^#.+"Q@:OD6T MJ^V7G*OP
6.W/7P&^EG:#;W*T&H-TO'P]'@@;/BT$FZ*2ESQM)X;W*^3"H M4Y8VX/G: "KK&Q+0?M^Z_"]02P,$% @ #QG69+$$3?S @ 4P8 !D M
!X;"]W;W)K&ULC57;;MLP#/T5PBN&#?#B:VY= M$J"7=>M#@:+=UH=A#XK-Q$)ER97DIOW[47+BID O>XE)2N?H4"*9V4;I6U,A
M6GBHA33SH+*V.8PB4U18,S-0#4I:62E=,TNN7D>FTC%3K155'/ M4O(:I>%*@L;5/#A*#H]SM]]O^,UQ8_9L<)DLE;IUSGDY#V(G" 46UC$P^MSC
M"0KAB$C&W98SZ(]TP'U[QW[FJMW=05[E*;-L M,=-J ]KM)C9G^%0]FL1QZ1[EVFI:Y82SBW-YC](JS=',(DN$+AP56_!Q!TY? M 4_A0DE;&?@F2RR?
XR,2TJM)=VJ.TS<)K[$90!:'D,9I_@9?UF>7>;[LG>P> MX92;0BC3:H0_1TMC-97#WY;OX6^WN/\=]@V+<+11UD+):@5F KA)42U(I0$'F$L*/!8(>9.ED
M$.]"(0T;TZ ?%^+1>8*YZ[/*7U_3ZJ*B.4 #I5'MM.XB>5]G*\8UW#/1(M"= M-
U_:!NB0IW56W+5<$QLST#!M74*JU5W<<#^I*/3]9O!2/45[C5ZC7OMQYIZ8 M='0]WT?[B7G4#8JG[=VXO6!ZS:4!@2N"QH/Q, #=C;#.L:KQ8V.I+
TA;U8T M]5&[#;2^4LKN"'= _S^R^ =02P,$% @ #QG69WC$1@W!0 % P !D M !X;"]W;W)K&ULG5=M;]LV$/XK!W_C<*^G+ MK3;?;(7HX*Z1REZ-
*N?:B\G$YA4VPHYUBXIV2FT:X6AJ-A/;&A2%5VKD) [# M=-*(6HV6EW[MHUE>ZL[)6N%' [9K&F'NKU']J[=4H&NT6/M6;RO'"9'G9B@W> MH/O2?
C0TF^Q1BKI!96NMP&!Y-5I%%]<)RWN!/VOQL.H*\LTXW@S(Q:&K5?\7=X(<#A2Q\1B$> M%&+/NS_(LWPCG%A>&KT%P]*$Q@-
OJM^6$VM1KB;"R%IV]G#@Z@R4G^81WW>/%S^ MX(-6KK+P5A58/-:?$+<]P7A' M\#H^"7B#[1BF80!Q&";_I3!L.;VN92V\X@_+-:6V6,.WY!5P+*52.
M(!R\P1R;-1J81C[64_@%HF ^FP;1- 2J0*HO!7B75T0$818%LR@]!*!$<0/" MD"T>(0N3(%W2Y_E:;Z"B_L>] VZ%[-"R$;HS4#_8+7J[MVCPE$E':#PU[1-R
MOV0.[SRE59YW32>%PP+^(";7S.3$UBK_WM6&5@J\I;[:TLAA7BDM]:8F]MDX M)..S($R3(%JP*_B8!$M@L4\/:?9+(B2)(BC.8WGP3R;!'ZUF<^77Z/JQ_
M-J(@%]#%LU^*@RQ;, 'ZG#]:3?O5]$!=.R&A) \Z_%525R^.!,K;/U^0#]+! M_FD29,GBJ?U9& 9QN!CLS^(@FH>/[>?DJ55.MY[E 07\1/(_I2)\/CW-C(!<
MV;2" ^GTTS0)Z-;CP%O>Y2-;;6N^Q* FK=P?5@Z%D7?&H,KO@2*C+&GY*Z_X M2C<(7:'$H>AP!T-=#=6&1CX#"<0Z--(;L:&TM,Y+?1G?C*&@+!=F[!U
QG1- MR\!]R:!U=>/I=;:WH$ "HDL*H>PL8?9I3QIE)X%C=[362%@3 M"0-2]\T0XITS&9?<)O'.R]EN_17]W>YIWM.A"M:$49:T3'KK>RIJ4U.) N>P M-
C;@8,JN8"9X1YP5I]-NSW9YQ2&K54'>,_>]L93TNJES8-\5),6+Q/B1[EZU M;U(,X2U;=Y:<0MG"]XG#30_).QP^M;VW]R%VU8Y7L$L'JA'CZO_ZY&0-
97'HJ+MD*D[UUK]1&'Y8 M,-E'U?)VK[TZ/.)M?T3?A<_Z["-KN;:CE,J<:IZV9I F69!,4YZDAY/YX22C MR9QT$LXRZ@0EQ1ZX7RR"=)$./>FPM1R[Z"<'+
[4&S<:_1RE?N'?TC[;]ZO[) MN^I?>@_B_7OY@S ;*E:06))J.)[/1F#Z-V@_<;KU[[ZU=O2*],.*GNUH6(#V M2ZW=;L('['\(+/\'4$L#!!0 ( \9UGANM-REP0 -()
9 >&PO M=V:R]W:GW[DN_ MT]K3?5.W_46T\[X[6RSZ:J<;U;^QG6ZQL[&N41Y3MUWTG=-J/2HU]4+$<;9H ME&FCY?FX=N.6YW;PM6GUC:-
^:!KE'JYT;?<7$8^."Y_-=N?#PF)YWJFMOM7^ MC^[&8;:84=:FT6UO;$M.;RZB2WYV)8/*/"GT?O^R9@"DY6U7\+DP_HBBH-# MNM:5#P@*GSM]K>LZ
,&-KP?,:#89%)^.C^CO1^[@LE*]OK;U7V;M=Q=1$=%: M;]10^\]V_ZL^\$D#7F7K?ORG_22;E!%50^]M>
[LGER0!EH8C%1';3AGVI"46^^P:Z#GE]?:>:2.KE2M MVDK3[5@)'[QN^O.%AX$@MJ@.8%<3F/@.6$F?;.MW/;UKUWK]K?X"CLW>B:-W
M5^(DX*WNWE 2,Q*QD"?PDIEM,N(E/\Z6_KY<]=ZA2OYYCOB$*Y_'#9USUG>J MTA<16J/7[DY'RY]_XEG\RPFOY>RU/(7^HSDZ"?:\JZ?
BMGG+.RC2F+&>Y$/0QH(3?:C#U&@8@$+,\$^%3#:PTXZM&;C;D/XYX*5DI!)1-Y0K?#RENO:DJ2A(DD@PG!RI$I[*FJ M&IJA5B'<:XWT549-
9UM@V%CGS;_3PDN>9JS@\A5&0$I2_NIT(AFUR/@+>)PQ MB:!AE)5@E]%E5;D!!FNC5J8VWL#E_R?KG_4*5/K1$0L4)$#5F./LF(+=PPT9 MIV,27E
B4I9S3N^:KK8/6L.+!G=3_QB"E6[UQJ .$0EHL8%9R(N9P[./JAZ M9""1>I$$G_(XHVMTB:D0=N\,_E405S42G+-,Q"0ER]-\K ,<]H%EL(8RV" K M,
Z5T$BF G""RI22>(G,%W0[$G(:F0YWV-AN)"1+438B9C))$:"Z/D+B7ORB M)P-'%X)P4A*'"S*9B9@6A:9[3T(P":P$6! MQG H00-
[RE*4\H=_'QE+/E#/.D[1@:5Y@E)>@RR4]=VXOGMRS MC7;;\341NF%H_73ESJOS@^5RNJ&PO=V]R:W-H965T;16$R M6>'6W%V5*Z-
DPI.R]"H*@O%5)G5^]OHE/_M@7K\LZBK5N?I@1%EGF30/-RHM MUJ_.PK/FP1_Z;EG1@ZO7+U?R3MVJZL_5!X.[JY9*HC.5E[K(A5&+5V?7X4\W M0QK/
_ZIU;KL70N29%X4G^CFU^3564 ,J53%%5&0^'>OWJ@T)4)@X[.C>=8N M21/[UPWU7UAVR#*7I7I3I/_22;5\=38]$XE:R#JM_BC6?U=.GA'1BXNTY+]B
M;<=&DS,1UV559&XR.,AT;O_++TX/O0G3X,"$R$V(F&^[$'/Y5E;R]4M3K(6A MT:!&%RPJSP9S.B>CW%8&;S7F5:_?
JGGU\JH");J_BMVL&SLK.C!K)GXK\FI9 MBI_S1"6;\Z_ 0*M6OA@$GHB":'B$WJ 5:\#T!D?$$F]U&:=%
M61LE_G,]+RL#%_CO/F$MK>%^6A06/Y4K&:M79_#[4IE[=?;ZQQ_"H'#7!TUGZ>6.B/2R4618I@T_F=J.0\52[B]%^J%!5>Q]*8!WHKLZ+.
M*U$L1%$;H6'+>:627)6EN- YQA9U*?.DO/Q)P$"5RN;*L)7>JMC=A-9DXGU1 M@?JY^/&':11&+W UFHR\( C$GSF6,1563\1S04L(79:US&-
P4I15V[J\04OAMYPA(4NQMXP""Y[!.V" ML]G(&PV'^#_PQJ 8!8-@9\&&JQ.6"V=>, TOVRD=/;?>-/!FX:Q]?ZMB.&W2 M+CF<1MX4.J&KP(O"H?
BH3";>%3(7D3<>1=XH'-'5>.2%$[PM*IE:5L9>&(;> M-(C$R)N$D3<;1N(=&1@K& 7CKXAWP.. )1/C8,@ZMB32(K][7M%:3.P=V;(EO)_,$3_Y!_
M_25^T3DT1$[XKOXB;OT??XBBX0O?^*GOB<+807CE"3B@B)6ID& :3RU CQ++ MO-2)AF.3'F4IYH5!\"E3$@4/RD\9^^]5^@!4K99]-IALMPB]
(>U'P8N;A@K? MAR\\ 8D4F4/G56%I;,L[M_3@"!1S&''3L4*WJ4)LF9('D7.0W'.9?RK%PA29 MJ)#F!-&F_RMIJ@>:9515>.(&PTCNZTP9'4M/O/>O?
197)L@'FF"-9!1(H>"$ M5OC3O_7MO(\&&:33_'M)IH9=K\NRB#7?,2E2E820>%71%*78"/MD]1EA=C0 M3BHM4VAZ98I[C:P %#* D4LA1:GN5?
[\04DCS@=^*.8Z3B)1U#3#&G"U@3Z>N41#T6#+J MODCOB4AL#;##UQ_M"&>B7]P(7_R:@Z6\1NG%".MU#&XX..25,&E"9NV17<'[ MB.QU\P[HY%-
H[P\)7_RY L.XPG)MX!PFTT2X^@*/I@%-R,1%?H]WX$ZV6 6] M$374F&4%O='P;6]QL@!>UW!I0 V-7_3]H+-
OV8KYT8V\>1[N4"R]#BI_C2=.:/O\67]B[VO7SIN)JL8Q'1+<_Z^)@ZA,0D0F0D/Y(V3F7) MC'9Z%349]*@;=$F^A).B2\)L32D-1+BBC=.:Q>!Q*)M7* ]
(=HRL#:/HBM5@ M?:JD*HR?Q@4RAE+K;,,BX AK@DT1<71)""BEKT^F>-,[/.E_L*]3NCPRL I)1$/ M%=6\'(3^I*E13G'>.67JU@:( 6D-
H3[7Y'V%4)H+U@MY::?=_O[+'XP3%_-+ MYSA4^1%F$7,TV:/*@+F*98F[55J7C+ZK58HRD+HZM'1WVC&X\YBKKT=A",6H MB/QH],SU>XI78Q4W?#IL
E_E)1LHW#N^&T4*V"_3)5 /+@GG" @ MV*241!%2:9HQ=K6>&?C1=!S-AI-9^*P!_ :(CB0?5[WV( C @?QK^YJ4>U_@ M*!MP [6FC[GKP?H5NLSOE/.1 ?
L@^$>D/LEYHV9BN'?BB5ZE" M&U@[U2JW60,@0GU]BE1AT)?1/%WP;4J9_V$GI1T66[IT>LQIK5(/TUA2MX@L MEF7:POQ";=B'.
OW+@X"Y.VB12KFP/"NLL0%RLP+?.\SG@_-!'UZBEJ.!98 M:P5>$*YAIW#0C%:TXO-'LGO[]:@I.V6Z=6UOZ(TL1D/8\0[#;VHI-MWZ+WV
M6+#ULJ#6MECG$*G=="^#*(%NEI671M]SM*0RMO4(I#P/P5K3[^[+9:3[CF.J MPAUV.+OTI"&@=$8K5::?DPVXY887PX.7]%^B4J >EZ/.
('V$(W;\3@UX@&4Y MM5"+Z2%]P=*Y\^9F$EL$?[MLADGHW2E\R/XTE5N&IO*.M8GKC-)V3-LQ:XKL M!] &,GRNM;%%)I68O:K5:J'DS0S".M127-?
2]DR'$)7\PC@#&]B8,PC I.9= M_;(CK_.VI ,-5\65NVJTP=)3*U=_' =])7D\Q(,CIK1=!G'AUP8-1KPD($H( MG!.J.Q-B"&5C#<51.%CZQ"SU'SL6AH/?
*YODYHTC-T*@&'>EN",F8%XBO]V[ M:-.G2-C)]F=C+1 Z5 +2_IWEM4^0"J!>91(&08O[A[PSYT4P>-ZGE#0U21R; MFOP?
3E;G*ZF3+OW1_M6\KDAIMO*VJ?,XA[P]XG"92VWR)4;*NV*_>!=;:9X4[;MBDY7NK!-F.H:]NUF M2L@%EG
=:K4=J8PH26T+K@8,>P6_+SXTK<:^8':H9"-WBSI7W 3TBGV6 MT&XLOX$_Y.Y+(A<]C0! I^>-N%887_R+
K#"V7A6D8%!>]ZH!#&0^IA*/%LQ4SG5*2LT[;=85/BA9MX0"M.?6)!$B4 M#-$Q.5"AM+#IZ%QXS!7* 4E5 $T,!QW@-%CJYN-1SET/U]&,:NVT**! 3.SV
MZ0.:^?52<4^%06ZS@2H.]6G0>SJ C9K"CF])=-N$CAO M[TW8;&A5K)*FKTQY:P*;6[_V9(MFGHZ_&XQPM)LI,@ MR9*-K3C@2(*\[1-:,S9EPM@?#0:S'=
C_SBW7YGVR=6/1*M(S8T*BJJ4LH#= M?=Q9U&J/JH85M/Y%9]9 Y^%HX >C/4[9;"U^Z;!^&PA@0>ZDJ%SAQ%JOFH@X
MOB.W%>760&W)T("6K6!2.*3QFJTC[D LOGF\IK>C/ZX#4'#.\;2I!6S:SY/M
MP5RX4>9ICC]X6_51U[,EQ(7FJLMK\E6GG'FJ[^QJO+M*F:&9_B15S!4%2ZL* MZV.;G@-S]YN<;E,**Y=%III<01[,YJ' AW[M2/?!B6O'PR' )6M3@7J][:$&
MSC/Y23VW^+I;:91?6VK8K=$B1D^TN1?6[#PZ"#%=+]5^0R;7W@LDK9_:_+2_ M#H=A['9+M:-O5I\|\"]2*'+#!ZB_A\.7"UGP< M9(UJB]PZCJU_'$O-
6\N#V]GG#1).[[:%@E?RQUT$AT[;KX%VSZ$N-1^Y<)T* MDA76$73*JE).:?EH U/\ML2DD6[53GIQ0I/@7?X+>]#D>_1GO'#OG;8EKB_ MTA

2CO/5<]L9+_BCONIUR"0@T_@ 6,K0%R,/P\)(!FGL/\(*;]79!W7>["=T M@-3BD&7%?H WY(#4$MO8;RW&;?)=+5',5\INIV',1U9(VL*P?
MKK!"S@DS)ZCF&@CM--=$GVO5]NK-+I-E'N.>Y"-&NF)1,K?X!W\IY"4NV8*I"+3 M\6/,?SL[A.;4)R[PPLI)&'1()RYQT(G*-H?W;&GW!DF8Y)Y1G
.%PQ(V0L%0 MUH;#C*&W(59S"N*.=D/XFC=*.#)U6@+.FNM%5ADS" M@4+KTKY->_")#CI9LI4].-3.T;1%LZ#,XG8#Z=##YODHWB:;^5'[V=/5T0ZE
MNU70<)JV"=VW><9%Q:%M^)V:!*P-_.'XF2_>=MFE6AH%-+7'&^V'M-V=2@H9 MH&^!^/A+]0IL]66E<@OKYY$_: 3RNF^N>!SUCG-L% R\Y8"T0XT
C$&IJ/VX M^0^B M@7>*W4;^9)_=1AO'<)YBM\DWV&W[$U!/]!Q5P_>5/!S[TWVBAU\K>]C1^PZR M_YZ+Z_J.#K2Y[6GW)6ZSAFX^)/4/D;+LW ?
0F_/1I"_0X3;FE(Z:/X3E3_?) MTPRR'T+"KW;%P3=!R!-E/,WI(G^T'R8/PMTC,@Z_EXRG!-A)(HX[GC81Y: Y M'HFJ;\L$3Q/Q-"M.ND-+?1"AZWQB(@'D^17
,=O%B"H4+MMNZJL>[A]'(@W M^3=//G?0X#YO;YYUD0>^:-IV2I9NHV'W6/V_Z>C(S^Z@7O]0?,+S"1;N+UO4=JG[2]YKNT/6+KA M]F= O_%Y@!)5_
)3D3U'9\+8G];8FZI8\<]9YD55%1E?+I6$_#0 [Q<%0-_= MT +M[YM>_Q]02P,$% @ #QG69-<]>K('P !X8 !D !X;"]W;W)K M&UL[3UI.KBI;M6%.R
MK8JQN[0>P&R01-1L,T"V:^?7[#@"-OJ@CLF>RDP^)178#>'CW!?#Y1ILK MNY2R3#ZO\L*^V%N6Y?KIP8%-EW(E[%BO90%/YMJL1 D?S>+
KHT4&0U:Y0>3 MP\/O#E9"%7LOG]-W%^;ETY[_X42V6)7YQ M\/+Y6BSDI2Q_6E\8^'009LG42A96Z2(Q'AVC D\.! 1,W8$)P\T($Y6M1BI?/C=XD!M^&V?
/VBJ-!N!4 M@42Y+ T\53"N?'FJ5RM5 I9+FX@B2TYU4:IB(8M42?O\H(0E\,6#U$WWBJ>; M#$SW??(>)EC:Y$V1R:PY_@! "_!-
/'RO)CLGO)3K<7)\.$HFAY.3'?,=A_T> MTWS']]EO\EK9-->V,C+YG^G,E@:8YG_[L,"+G/0O@H+TU*Y%*E_L@:18::[E MWLN__,?1=X?/=FSA)&SA9-?L=R?
9SNGZ@=V-IC,@[JI0!% M@\)OQ\G'RB3R\YI9J(+U#&(&L!%M65EX*I*F/=:Y]>PL7E5 MXN T%VKE\+,26W@5_H&]SJHR68IKQ':9;$%KSZ0L^)%8
!)MF50 R">=9+ S MPGQX?2U4!HC;^LEA>S3:R%\K90 -0!O0:++@MP0K3B-SPA$\Y+VT\:AGN5HP ME<;)SVX]VC -
\J\#.@D[,JU0$P,R809I@#LR6#PMM6&JPG?$#1I6@_=7ZUQO M)2(&P 7AM([XJ;:(S"*M#((. X"-"J?LB9Y^(GE->(?A.J6WBU3:F#%$=BV
ML^&OE2[D%H%.]34L[F>@M49@N6:_P +TW#W)%^F9D(")DJ2Y9Z YLU1'6T MR 0B\$0%4I/"PCI7),"!JVBDHXOC6L0M/I*%F.4 AD6(@#Z$$ %S&
9B3CSB MML1[M,1AXV1JP<8C.A%ZL5[#JD&BYHQ:,/@C>KQ1.6BD!:H)?,C[14 ,KBMP M)AD-0>AZR&
D81OE'5F$]\5\PFQ$6]^RQD"'@G723.8*$$:KSH4RH'_R2CHX M=G,Z8AYERJH%OU"4L/$TU099*M_2_!G(&[Z$Z(/7?I.$,Z]?D!(D7(0J+UWQ M&H)P
C:PE*L9[,(;0MK8:YFZ;X_HV^-DG'Q@E!&Y;0) (6LM0-H*ICENE)#) M^I#P;(D&!*J,F,4R*1\('_ARR%WAO@ M%S>[<$K7*2F/8
8!I3'9+%4*4@L^%O/OEJ4;Z6U+P<(4XPZP(P'!%ARP6Y%L MG)S+!ZYJ.9@&ASK+#7H^\S!.YW-C+QFD_H! M//+7.&#*/%.RU '+3#^\GHZ2:Z71KB1
VI*USEQF9,)%0"/K^0)U@$&*E$Z] M(ZY&2'\F!1#@8\$X/GI,LG"(N 4K!ZI U$, O>!"6 >L8J_EIP)U9W*)8) '
M6,)62_!X*E.2S<&7/@#B08T4]7,@R!EJ+@UZ8+9-7J'>.#6H>Q!H^GBY5!*4 M^]2Y&:2=8+Y7IZ\N1T$._B9^^RVY6
IPG5()AC$5.:C1/!WU/AF!KY6.60WV MCCQ#A0(/S]DDX((C0"%Y+"")J)=P/^#?K5$5O29K+Y#HW\#^I"K$'-TT"(VD M<=9(6!J"8"?GC,5OV=;%7P&
[69T48@5(_%%_%D"+O)M&W%^3]^NIFQIQ'E>GSJ.ZX#@(;/XH^7&I(10XLZ@%1DT# FPD M\SDC'0P^H=V" [-2N3#Y%OZ"H(:4QLW*"2?
9(>8_2UON_RQ,UAE]JLTZR#,, MM;=4#,2)PTI@0,UU$-0KI,ZM^NI&XZ>WIS\GYQIVD1P].CP$K.5S]$9(T+X$ MZ8)U(+6WR\#<6843%?JU-X%](T<
TF(",IH107>P48S0II3"5$=!\9(7E&-D MI.9SZZG9M&-.?<82C][P2D'H28\40KKB:>P#<@2N#)LB/N-E:CM1&X('U",1 MADYV8RA&[#
R'A@7V@/WJ+:;,7:\='X1C+B@ZJ%UPB4$1IWU@S5V>GTZ?CO& M[_'^]/Q#^/3%)-M)$P!_][!3MSD ]S:K=AAMG;QQ)LBT_ :\'DAF&0C!R@^^$*111Q5
M7%;MMS#)7B&%@15XKIYWWNFF^,B$" ?P0!1\KFJ[9N1ZF\AYQ:4+TNKT]>%*KB M /8N!(VQLA/2C+5_
%0'6F*BSL6E*81K!G;Q&T:GZ#\94=B:%@^'G@V2FUY= M57FI,O]:E-*B9*;+WH6)*7?&12D80YG*K2LAR7V8HIGP([YX+TRZ] $>. -N M
QR*IFA\+Z6Y5JG"]^M]@ MF2A%F^K""SL&'C'S-E?\$LSL= FF.76N,LJ=XA2WX%/.SN):G$(AB6SX(\<-
MM#Q$ZF&!!5A6'VMA.%R"R%I%7_6SZU^3E29L-.V?XX<$HYYR0"@R,_8]T5IOW'=B.NX[GF6%4E+/""$6(G[,:?8 7> M,^)NTM<9V+R2Y4ML
(1@T*DT52>-(N*NX$*5W/V-\3P07CAL0]"A"N7[16C6)J?< \,>GY,(QIX4'3VY M#9(]/K'M9>?N"?N!)#MEHK%M'EQOGF#\ ++'868/$=:R5'7C4E?Y\E8
A]/U M6J+J"NH7P '-KDR*BMM+6"ZQ!0MAHM=K;#BH;8T,@MIOKPOXI\X:(("A]\Q4 MKDN!<./V (/(424UI:QKDJ!QKML,6XLS&HK;(%W$$O.
(^4T4;,".O8+:I;_O MJZ5A#\R(-:OX1HDMM308*1!.H$[=);&OBGU0,D6JUKFLB=7($-0\AK0 &)$2
5.P\UIN!KV&ZMV&^UAAQ<(I#GJ"MLW2VU%@3.0@&_ MS5*U9LA\7@?XC?KUL DL\)!(YA7Y(&'9.RU$.H5I]-BKE-<5S1-<*4X]4:!9 MJT#6P'U\!
(O5\R/7EQMD?-^L5NAB?X!C:"7D.Y)UYOK M[45W2";\[-'FOLBQO9F[5)..5G@UK\ MWH=#4UFZE &WH^''T1 O7%9K:12\%D0[ MIO#KMFN--@FF-R]
<^PIX?9ZD1R M"$R[]FE'6JGEKKD4$E$ON#4AF81-R*WN4%$Z^\'KAJ;&.C%.C>ODH]2JM0XT M0
)&S0;U>7OUIKJEPFK/G$W1>QR<'&)+QX;.,4,_.537XWGCW&5LD_JGBGJ,ND'-KY6PR\1R]B1V M3F)')/)[:)[ &9&=#&)PXKV-* 1ROC58S>,\
M(%P@3.M.^$!\39H%3 VW$'L^IJQ_W4.8SBHZYI#??SJUOW:")B, M<,;E *[S95'#6R]>D52V3LID8B466"V2G_'L3?.K7V$$^8ZP:*\>) MG,]1Y# ;
TJQ/IV'KGM!M;)0"1LYTTF2A8?^R."N%Q*(Y&V.IP MTANP,X?E%#FL]ZW3O@8FV8"N8TWL.IU8,1%?,AS!!)Q7*[/]C3G3[PWV3 ?A MB!Z\;QOK#CP8:;
I$J4#](6ELX[@_]9:3W_>SOP!"B[VS_D#$QOG9U=Y5OD\ MG!L2PX>0*Y0)>6)(>"P-.@I^N;2>-\,'#!3]IR* ML?X<$)YU0C9".RP+0'-
Y&PB#D)/\UL/1J;#QB)1M0!N9%PR^@3-]EC9D MT9Q9H%PG\VP-/Z^/??PMGK%+?XX0E@-R>\?U[>OI7VWR$;PR@.R5UE>ACAY] MUW+!GG2]\W8.@
GN%XNP6+O+@_,[=W72D'E,HJ2T*Y^Q[ LM![.@;YW5=SE* MYNS6EPD>;0/AIX(%N 9;E[)I2GJ4(,6MD3.'6VZYF2>Q3]Q>"'6+6=UI^A$8 M^;G/SWE
&4SG6*-*IX#BZ 1D9NM.9?Y:2>OD#TA]:WK01"0F*HZT6QL)P#+1 MV4;3BN16A W$B&'F.8["D^,H.L$IG$C V'45'RSVD8K(PP%"T#^_8!>'/Y$9 M
JR.6$M%/$B0D&)IDI@D#X%J$%G!,!,#\^\RAW/,ZX\'/2-7&-[K+;FKL',E,<^]S/6H&H<'" MA@%HF>W?8*Z^M.U!)Y&@^[>U/ V5?O@Q8- 'O,G"_Y;L*
K*YR$U*M3_DB[ MZB%<[Q;/=)D*XREEJ2P!L#"7X!D*U(1&-MWMUF2Z2.5^@3=[H,>@,U6M@KN= M 6OD>DV2 E,OC%@1CF:^:EA?'5'0-3*V4?\
(I1>/D($8O,F3CB$I:>!:("I* MN;8 AS7G>-RMY#(L7]T4PNK@Q7$&QI=RFD1P$1V^3T=.5L)<)1_IQ@ZZH0*P
MX2KEP#7PIC9VJ=8D7K5WZI$5V1:CX&TIH2:,EZ@XRO):7"!!@5AHW 3) MNBI:;9R12PUJU8 0^68;5TTD#3;#2SE$5*SD!&:7D[.,(D4!,J? . ^=,
M$W\X_G*B&QW5%\D>K"F <=?+Y.SOS1:C/9AL(>@F"G2$39LNX&R6 H98. M.\ ,B]=:,QD45^9/SD2W&\!X[!@WX-CEP0/U@ 9M_+%Y2&TR:&-
]7:EE4FN= MW+YI*-KT4(H!(<(\!I)IWM8"HKYW@>@3EV;??IH.W-;Z%K,.3+/3=?+J7!4R93Q\FA-O']L(*.:V]MLQ/A M)"H@?
=^I3X7).@U+M@*N=2+05^]KG#"+8<)0.5*V:]?59*35>17ON3,EE0J! M"+Y!DD[-_S%BU[[&LKX6(TX>8?F#; [NWY>JX@N(W)T_ JP1?#.F+G#FJUB
MKM-[Q[TM=QNC2AB3Z+4J?.Y_:E>?.0DZ^M MB #HT:Q20,:!7APO3(;[5,F2@7BCWF+\!'O"9\87FMA:;T5>=S>YGM&>]J9N M*9N7:%@JUX(P:N7
(NL^,PJ()A>H0JJR#PPTA8Z)NBZ];5A KQ4QI5=;;8 / MG'!)PNIB8Q\;E>"7EN&&PDQIH!4XRLER"XBR>D4'?HTK"R*-W75,[!?G>)OK MEBHOG%
[EV3LV/Q=X7QKND,4C.,X;T-2G)-B3$\]E M;K''3R:>\6=;5Y@;N2 ')4?297%^^^72Z&JQ=,7"^(JN6A(.C[_#B\B4.^]
MO45>F7;6[+WACWK0+5_YYM<8X;5G"!(AM%Q2OOX;]6T_00I E,[EVFY'\-+0
M6P""XFHN7:GENT:P=NZRCF[7(G1M1"6>:%L1=X5R7M2ERYEL%>_TS9)JC<2@X6->.TV D.C--/&7:T)6H"44G#OHT6]TJ.>>?:E"KGI2 VJ+R:V<)+;7_?
2.!41MQ>5+3=AE_]-M!B*!?!9<)W8R7WDJAXWK!&G1)KI$](W M]=)M!_%1?*CZ.+K&TGWU?O]+Q03,R";Q]^TWB^GCWHJYLOMV/
M,=@^<@U!GJ8&:=#5 @L5#N.840@)U(OY#1;B*@S2Y.C5O:\W:GLPP%T%^^;43\%OE_-\%1Z MNL04$SML,&-4L6:3R5N(=^Y4
MSAI>^I/X14UQ+\X4_RLRA8 M+=SEONP(^F0Y=A\ZFTH ,?*[*RF?I]BI/&@U1PYB25FTVZ'J0D6,RV[! I'C
MR.V#%9R&D+'VETH[0!GH3C:$#434G!REB[55(3&QDN524VZZXGMH:/51](SE M((2$FR7LBT'$("(#'8>[,I(3.AKOG2^P,MFXZYX=R94,(?
Z8:9UO[]%HZ:ER M/Y."EY+]#?M.MZY"5B?0XQK&;.M+&*B4F'UX862PND 3D7F7I7 7>GNM/I J
MBDH/O)9+5924ZN"!0]S;6XQH=OVUCYXHZXTU9^L_,^]2B2N$2[&:I)[PY/@0 M/0?\.14?PJD55P0!:2AO !6!_U=&W+@EU_A*N'J>FV&+9
MJCECMHUDO06#I MCNXWG.2X5B[*]AOE_$KLACQN'+@.S4T.B__TGH01EGP8DW@-U@T="F?ASH" = M153>7%\-]58^3G_/RDW%5-
*3OD_ZZ([%Q8>2W-8E\L.R&LDI:LS=/3HBTH9? M0.&UBXY?705$M:])U]PW3CE2&G"CXWN^6X<6W"G8LT:QXU^66\/A\)ZBWQ^/
M8\.14\4YLP8%=J"S6:5T%YR[69DPOA!0GP,,72O_!-;U7.@U+TP9$A=U5:RG MTM?A9#\M*SV67 MX7@KL!D^'O6(4MOAO;._2^O>T]U=*G!
']3GY43'_S.?-]S7<'PWI]>1YJO[ MO+1NR^5MD?I!_5Y:[P_K]B+T@BSI,^_6MC9X7:3!&( MY@T\4?/&5W%>.FT"-
_@N#^&M.*WC3^\V\='Z$:=1K^*@H4C][4-XX5QKC\Q6 M?4B8KN M;9R\66/O0RX_]V>\@O?6^/6T(6>:&?3I#A?A&2R3B87"RSGP4HUG$$SJ$E;G
MA].+,S<.Y@ TX'75N/(DG4VV)ZGJ?=1<71U*H.6,,8'N4K]T@'GWHM"-UU2)F MO];\9\13D35NM;#(=H54? \7:478:B=_[V&M!@'^TJ%7 M5!.L+\>(?
D<8+[1JW*1;WU_%7FLSE*+LJ_O**6(^,>+:)+HW8S4FB7 ?X?>G M\(OJ?6 0N+X5PT\D8(D4S1#_+'ODG7$OOOT%WV+T="+O>G1T^ED[P!&UJ^_?+X6
M"PFF>*'HYK Y##TSS7$I^X# M+K#1YHK >_E_4$L#!!0 ( \9UD94]6!@@8 ( 1 9 >&PO=V]R M:W-H965TV%,*Q
MKY6J[7FO=*XY&0QL7HJ*V[YN1(V9J385=QB:V< V1O#"*U5JD,;QX:#BLNY= MG/EO-^;B3+=.R5K<&&;;JN+F_DHHO3CO);W5AX]R5CKZ,+@X:_A,W
KWN;DQ M& W65@I9B=I*73,CIN>]R^3D:DCR7N /*1:V\\XHDHG6=S1X6YSW8G)(*)$[ MLL#QF(MKH109@AM?EC9[ZR5)L?
N^LOZ+CQVQ3+@5UUK]*0M7GO?&/5:(*6^5 M^Z@7OXIE/"..REVME_2];!-GLJ,?RUCI=+97A027K\.1?ESAT%,;Q%H5TJ9!Z MO\-"WLO7W/&+,Z,7S)
TK-&+#]5KPSE9$RFWSF!60L]=W);Z=J5EKVI"U$\UA_ H[5;Z]DZS,S;R[;9Q(F>Z^=8']=3JPS2(Z_-X4=K XW6Z6" M.;$-
S\5Y#Q5AA9F+WL6KGY+#^'2'S\.US\-=UI]-S?.MO/IIG"9'IZOX_13[ M*)K6Y"4RF]T8/3.\8F]K]ENK[CWX$=,M$E]S4S ]984TJ"=M+..M*[61_XJ" M<6:]*?
-@JEF:>RGC&.ZIS-C)AQ$-(Q(7-!:^Z-XK@? M(_N50B%'3'S-56M1S#3)ZWLV,?I.&/00ENNJDI8ZAH7CAKE2L/=H#=\&V6>?
MD:N[)"*V*&5>PDG+:HU5&VFX;R4%_,2L0"'>[PIO:C000 \C&/QS'4*@ 0D MIFN*G6&'\0[4^ & MT5H[P+=S+?"CT":"F[8%R584&!( 6TNG4V#
(A2U5*&O@-!?5!'BG<7*X3%JP M9DF0%]!LI7? /Q%$^=H!;WA7 92\Z+I!HMUTG[ZPH-N&"F(OZ8_8Y(5%_4$5
M&ST&P!&,SU!@0(3(VAD@S5%73./3;QGP_3)-3OOL=6M6M>)*9#"RQF]W(5VP M6;G P&K'\LV!L@F) V\
<5[Z/):-.'WO2&I/^<#VSO1)5I[2VQ439^@3T;L$_ M1I.\BH_[64J=)RP4,KG;4HH7A(^<%M,ILA022%*X,4 J??%_* M:[AD.N,'_4=Y6M#5B
MX0^^^5WK"J?2DBY0T/Y=6^L+&UH-:HLV3;+84=->+7^DIDB-;X' ;V>O1;[\ MFH0T"0A"9ZH5[GR6[:/^:=.T$+
<')XC>X?"%*Z3R,.%VA;M3S3YY;J^X(NR) M]V\M[[$T&^%W?SQ,HVR<'JS>D^'1P3+LQ_XC-32=NP3((+9RQ8'8%*>JT'62 M:'24LG281&DRQC.-
CHYCG%Z(2]N1)SKI-/^$RW*H?Q,-_$^^XF6%=IL04JG'_:-1C)MSWP\#IQM^Q)|KAQNY? M2\%1[B2 ^:G&'K,&ULS5AM;^-$$/XKHX 02&[B
ME]A)2ENIO2OBD"C5%;@/B \;>Y*LSO::W773_GMF=NTD;=/0JM:6L\5J#::M*Z/L++-7Z=! -^@_OY7)E^EMM)%2R IK(U4-&A>G@_/H^&+,]
([@=XEKL_,,[,E_BKHO# M#L/T.8:X8XB=W5Z1L_*ML.+L1*LU:*8F:?S@'7'<9)RL.2DW5M-?27SV[(KR M_J[.5870H(9?
="%K2@[F$3F>#J@F#.I;')Q]\U64A=\?,':\,79\2/KK MDW-0W'YC#^J "V%D#C71R"V-ZFF,HY'&U44!5&1VA;!VE8#%D;A%384-=5O- MF6WQB-,
=0EC14T?ET-X*\N6V/X7;4 W:)3%VDI1EO=0L'+J#X=-].%@WN)% MQJZ1+O2S<;3"P$*5U 8-?"O9>M4:DF4"P+L<&^LD>$91J;:VYKMC^'6E$1]4
M%5Q17A]^X>+@2[+S=-56%!"K]#%<;8W\&N(H#<(TI:=HG 73.*2G))L%8 9OL5;4.7TH/CR&R^-\MXPMRLXV%[DH\[84 MUGE[Q.@C#&11,
([&D"5!Q+?MP$\=D(4522.(5)D&8AC(-) M',$T2,>S?4*P:DIU3VC OUII[SDTC%^B<6AN->DP%*I2D*'CA.R)9I!&)'V:
M_@>.]Y!GGR=CF$1!/$L@(J.C""9Q,*6H7QW*V'%7/Y2:8UM%0A MA(3W-[_1@S,'M1NTR,8CW^8.L%U[OEW=>(>>D&K2V1!I> M;6\G-
[9>M^F5NV[M72=FP4O%G#L52R.27)B52]R31\[3+C3<9CW98MLQVO=0LG1JGE]K/SZB&Y]I"G2HAL+ MNE$R(4-[Z!3"HH?
7OJ2NR6#.NH/#3DV9SMY\)C!D7P88LL\,ANS# @-E_5H MH#UAYTX2]L,.88)MT+S2:'2]R>?>43X).-FZ2>]*EF5'Y?OU(];MO 4+%+;5 M?
E!R>?"RQ%S=/J$EC3FZ-OWHA]_ ![T%P5-,Z9<#<$@SZA[I',2R]'Z)[:(@ M":2YFR5?.$&OT&>T'ULJH3\2AW/-+[&/>8R+C8 EZ7/CC%2%F["Q,'LCM$5F
MG\IM>E\+I(=RO/L.W62 1_=F&?3[@M?A.^!-!#-W4^%:M26MDVRAE4>;*!L> MZ[4I8O[W:$]A_TSAZ M9SQ>#'3F\!2"N:#AN.M/W2Q2=:'W^*X?
Q;_+SH-=WJ?LY2Y?-?D'XRR%.$C# MB'<4=$V"=J2^_.[GX5> M2E)?XH)8P^$D'8#V9V+^Q:K&G4/-E;6J\NL78KYS1LV34=^,BR\2XU^TP.CM)>]?N

M[,2N0]<.YMJ17_>]=IL+T]F[TU$^VF_]6UPYOXP/* MK.W-X%L[D#/ST]%Y?GQ11OVD\+XU=_Z!3#&2J;6_QYC+#ID.M.$B*"Q
MW)I+TW41"&Y\V&&.#D=&PX?R'OU%BAVQ3+4WE[;[J9V%Y>FH'M',S/6Z"S?V M[J79Q5-%O,9V/CWI;JM;RA$U:Q]LOS.&!WT[;%=]O^/A@4&=?
<:@V!D4R>_M M0S&W)IA;?S). M[HV; MG>7%UK+XC*6B5W8(2T]7P\S,/K4?PXN#*\7>E8OB2<")61T1SQ@565$^@<;.]G0)7QU*
/2&)5TF8HVC7\^G/NW_]A@!6_SR.-NS>CLJR]RD7WWA/?EP?OR*?0G$_/W+.GM$L';#GW7#@L*>MH92IX. MP9/>]R'9.04;=
(<>VQE^W0X4EG;M]3#SWQP#R!GS2;KI-0[]="=F+3[X ^GG MS9V^I2^)US4KA8@2SYG@'%+.,EFP@M>0%:^8JFKH.]-35;,\+RDO*JP9Y77)
MJD)0*3C+,D57JW;6VL[SRGMXF"UV;MK&]:,S2&9%8PB5"$K%A6Y_!8"0DX!,>R MO&8
MD(0_55;0F[!$DR!+!4)@*I.$/"I)"E8U73L[6Z.EO.Z,9S3@+T35^ 0UQ4&/ M0CZ85#&U/$H"X"#\)2[*;[V=M>N>[/UFJH.A\^_)V8WNPF9?A:D**@D7F2K
MO8 7HB8N4K:VCNU-4*;4[!O\4,62Y5F%7-J'_>53H$UT[7 ;T2+"V,73B]6K8->;MVS7_9 M=N^&-IXR": VA@?
^F4C!U;&7I$H!B5JPLA9)QAXKLYRN4/XK$\N2H](@N)<@ M#Y=R)#%7)-?I.)J,GD^H;*@9^C;^$B2 MPN-5\Z/Q'H,)NO49+KO#(\?C?/(<[D!0NU^T?
=$.>F@B(;'@5WJ#X2C0&[B[ MEX-QO:?;2,UTDZ@)&Z0SJG>VT6D.VD6X9X10D0?[UJ,N!^-TU\5&_+!N'>)"
M6>H$34X/BWA^XA1W$.I85#33&W_TV%_>^,%<@J,6:?KR:-7U$+8CRF'W,.= M;^>:/]6WT^$K[7"RI\
[,89H=R6I$;CMQ;5^"7:4I9VH#XDKB$D.J<5$!W^?6 MAOU+/. P]I[] 5!+ P04 " /&=9^'CRFQH' 1$@ &0 'AL+W=O
MN=*5KF6I]Q>C>-2_N%&;K>,7X\OS1FSD MK73?FJ7!T_@@I5"5K*W2-1FYOAA=Q>^N)[S>+_BKDGL[&!-KLM+Z.S]\+BY&
M$0.2I6ZM/X_[=NUDW1$^PV]"OJ@*_C:"C;7^=A!.J\9YYVDZU92\HRD!7W1M=M:^E07LCC=/P:J [2D MAW:=O"CP5C8AI5% 291,7I"7'E1-
O;ST!U1=B@2#_^^]7*.@.: M_.,IY5O9DZ=E<^B\LXW(Y<4(L6&EN9.CRU<_Q=/H_0O()P?DDY>D_UM.^L\D M43NQ\A/Y<$+>\U@B
$OA,.DTW=Q^LP$MVY\-#.@L[>!T0WIGZ-/M!&]H=>0OTCPF\ P M\9P'BR!+TS<_C+26W@",X8PFLR';13R8!BF\ ^MF",\G#MIX'KXB^2O M.X
]+F0B:E.H&H6FU<%ZM[*XO<_4LG@KL!^%IQ5(!>A-:Z$,W8ER)Q\?]U]0 M] 3U*?'!CH06,<$;3)5@ELSICT_"89Y&(7R/03H)4V_;>!ZFGL*3+(PR;\(G M-%
6='2("8 0-?>"EX^5K3*MP[NIE"=O\.I#9PDGS.F7RI:F.$+!WL^=0'!*0-:2F-;S_JO,]=+W#H)*V]$E7S
MGKZ(6G1)_N,@KK&R4L[)@Y(K+4S!#X4RZ!JT\:0)2+5VR7%TO_3#5LDU?;J7 M^Y-V?A0Y0-ZU>F-7+PIA7$F3JRY7-JJ1
M7";8$;V5*3<*A%&"I:X@R5II/4/8->)D:>N_-N\,B<7CEER0\5'FW@Z4QFT] M#W[S*O-H'K=+]@\MI&^>2L?6JH=X[QCHZ?
B7I6E!\M6!-93VI\PO#/>JY_F M23Q[;T\LM5=NVY_)T'G]4Z8)"6UAYZ@^N!$R>(=-K8K>"97>M?;OTU 'KX<[ M\)\H?D''YU&

/!M#%=V71_<.31#)3D $9R?:Y :)N/HL,&CA#WT3R4> M6%^$=.WS ?HNBQ=N+V5-T<_>_;A+_-R?YH39( T=A9V #W^H8"S_SQ5C^3\J M&53
M).5XQ&WR60R#@U^(^!^N:8\J8WBH*<@7)/FVA5+"2]S[LN2[E M.V,XJDM=;]YZYM,:1]<^"3;76KO^@0\X? 6Z_!=02P,$% M @ #QG6>/$Y[&F" 214 !D
!X;"]W;W)K&ULO5C;OW=(.4J%BVI_9A'^*((-"WTWVZP?/.^:^A4BJ*=6ULN)A4,3;/9[.0 M5ZJ6(7.-LGBSUU'9R>:&,ZRXF\\FP\(G].25[N
M3."_HDM[CX\G(F]#=!5_&!;4VJ;_Y;J/P^C V=$=!Q;]@07;G12QE:]DE)?G MWG7"TVY(HQ_L*I^&<=H2*!^BQUN-<_'RK7_Z13J]
MN./T3^*=L[$*XK4M5+%_?@9+MN8L!G->+.X5^$$UF3@^FHK%T>+D'GG'6_>. M6=
[Q@^Z)5SKDQH76*_'OJV6('@GQGT,N)XDGAR52D3P/C[*U]^0^Z0_"\==/B_>M%SHM1+B_5%:M=!2=#.+1_"0[1389 MPX5A"_'H^'BT@EH7L<*YRBO%
[RTTB3IAK0AK :2BJI?*;^&:HDA#H[C,S&8J MH+J1'ENC$X].GF6+?8UG3[.S6QJ#A+F-\MH5 =:3W&.2:V34MB1)Y(OT.M C
M#O8>XCBP#8H/O:7]MIBRQ$_9;]GPZT/&JG/E(^A*.*QZ4HW2M>)+"ZF%9K(( MO()4H]7CM+,D12CQGXB-*10>80*Y2[X= M /I_ W$/M;L0(:#!>MC4>
TNUV:38I-7\"*!0&=KO490L$G]2);U1I(I/5@R M]_C!9N^%/^/LM0@FXJ\\FX,]1LNE-@B@T&&DFM,C62QS!-CO!U1"50Q3UHMS M)!5&
[0E.6\:".%E6"OA(PR=#Q*LQ$-.[]M"O 5]6ANBE]"6O12ZJW^!])WV1 MT$UY"" :YRE)"KV";<@YA4!\1A@E>8.82G$C32M3.S/HIQ)[A"SQ+L1M6A_P
M+!.O95[!/VA@2Q*@4]$IH9),Q8A9I=CX.U3AP0&80[%#UH\A9,=D\04=C(^H M$ %7),P#,*KV'K+M5K#
M/MT8=;L0$W/6#B@&Y+,&&4K+]9/L((ANT6VBK(%Q'R^1WZ*/WE M1J%'I(JT MR#0D8QOZ\MG3_R03&+YV*KJ4%=:AEL T-
%TNOP!R2H^1;R/?.3.Q1EDOVU@Y MX,EA>/3+^C/2ZG#B37NQ>9LCGZ?!SV&PV;*;W!'*G2 M$IT,O4K)]=:*]WETM ?-=#&$ZU=I6V+_-/)TS!.*AX.!
M94-@DD.YZUR-X'W82*1/;^1M3\?#U99QO+0!'$\IFK/ ;9M*() A_2@RF--X M!VXDE HF2*3#R+!1G1 Y-]B]YH:
Z#]:G&9'PR@X3.@WJ8=9.QA6C.*;>2X6=8R2B_D0QP)U7W.C2>1"2V20/ MWS@DON78P_8]NMMK>=KVK/BK_/9-
7&-.K'%/:",UDB"N34Y)1X'PU.CA7^]K MLHS$O3%NB;B]TU;7;8WGR)#DZ6A)T5R)P5HZZ?V")KS_M MF?8*C9FG_;VI^OWKEZ_$FU87+
K!4MQ9R6CXG!2]I"'3\AA'$/64$G*,2KWU M2"1V=]J'-.)>W[?WE/A#N6N&"8S.'-!!]A<* 38\.!2BTF4%>&A<-VJ=QD]V79C)?X>F'EB-QCG'W-\/X<[N
MWQ"AR*>XHQ(+,C;U5^[>8!$V^V2?@$9[$H!JGR2Q< M,'6DZ75W%S2R8WGEP K? ;3S)#OT#64V^KR%>;SDCWB4@DBA]*5KN[K]3GB5
M/H_MMJ>/C.^D+W%90N:OW8Z0<+SA[OT@)CSQS(,K='5_+-2$LQ"&_!^ MY5P<'DC!]NOIY7\!4$L#!!0 ( \9UF); #G.0\ % I 9 >&PO M=V]R:W-
H965T.!;XS#G84/M6[Q9U@>QB887?)#=75X M_:RCIS%E3LZEJ'S7-3^?6SO>.]?.&]7:Y:NG!X M^K312W-NVH_-6N="F;Q;&]V_.3Y8UK/"_YMS3J.?BNR9.
[] M)_KC;?EL[X@4,I4I6I*@\<^%>6&JB@1!C=^3S+U^2WIP_#M+?\VVPY:YCN:% MKWZQ9;MZMO=X3Y5FH;NJ?
>_7/YADSP.25_@]\O_56M8^NK^GBBZVODX/0X/: M.OE77R8_C!YX?'3+ R?I@1/66S9B+5_J5I\^#7ZM JV&-/K!IO+34,XZ"LIY
M&W#7XKGV],/*J!>^;K3;*.U*=2[!47ZASNW2V84MM&O5K"A\YUKKENK,5[:P M)JKO\J^_/SULH0H)/"S2ML]EVY-
;MOU>O?.N747URI6FW'[^$";T=IQD.YZ? MW"GPW#0'ZM[11)T6*==876E(AXT2-PVJI6^,&IN MC%.PNM&!UOD*3$".;8&]8'[O;$BKL3-=^WAP?
J#.3=$%VY+?"9>O+HN5=DL& M:VTC.X>1$=8)X]%&[4JW"LHK1Y>J:I/5+M5\(^HNC3.!;^FB, UMK0<( M-<%":L/;0VE^XLUL=@9EM(-
_1C[%;2^Z'Y#GM_2 D*I#ON '=$*H?NYT@/W8 M]3W;K["(R$H='WW[S>.3H^^G/ZNX\EU5TB9$VO0H-ONM<**:]NNE.\"?. Z
MF#T*\F="2TXC$YD[R$CQY5A'DCL3N;?I]T^.(D5]8W10ANA O32%J><(Q[UC M3NA[!^JMXT6^L8[4!E)J[5 U2)<)W8KFSP+3RQ91UX:
('N[5D:]\E6N2'Q0P MH73Y&YB<[TWX<1L9%MY5S+0"*\0'D ]TX^8#0#%V>3W0;'&1RL5D&".U-"\.9Y!Y8J"LO1'+[9=!6/X 0>.4+60M43GG. MX4E\
M.TG)T?8*6AAF78GB044W)W;>I?4$1W/9H#0S(VPC@+2[#@'L08:4N+>!$S"6SAUI34"L7.1ZPJ[FW'ZF,JB+=',5^3J 6#1+$D] MA402=A9/:]Q>67
74T))B9B#?V"LE%TA1B$=&&)G",[0(292V1> BI08L*!^L6(C:5I MJ98XVI^JP-JDK0U'';DQ[R)NQYCMG:CURA8K,ILM2GL6G)T3"+Q )]RP9\BE M\'4-
CR.B]JI/X-IHY-URT2%[M()'WBB[@G*(:U)9!MJZ#.?N!CY-1]!;9"!3)Q5T?Q91*8;(1Q>V-O@33A@TJ?;3>"C[YJ MYNH;1S6 T$$ 4*;?B@M4Q+31"
(#%8XL%2">Q40*EKON,P7I#G%M9/;<5MQ\3 M++PPKDL2B;60EBE=@JDX+4L;B\K'+G %%)Q^00+OKJ4'ZMU@'XT>D(W%@X7P M'[J
U@<..VF&1$9^2GZ[+>OG2%3842;R12\0O=/SRO0M$E2VH>AJ(KZ"=I\5 M;<>I**Q=P1]_#.[$S*WV3,?(CQKM12WX.%4L= M2O'<>W#HM1DE>(??
A;AW%VS_@JW1DOSH+X2]B;FY#5&O^_CN?.BYQS],4J]G MY\\G8(G8(2BS\X\L8__HT411O3@YFIXG_GS?4^%W']#_%.KD\='?U;YZ6Q,U
M)@0AJK*.0YH??3G DH4>3S,[]2EDW(K"O0UA//QC54-#@6BT[I!UE!-B8ZGO?IWS#Q1=0P>N8S ".AI'G&F'3LDZ&32 E,P&L:ZD:;ZZ#\"F3= MY\: -
*%.'6I!L+G052>M"-?[A"+4$B81ODSH QI'K6<&YEU$^:@GRD=WLM7X MH.:]C9^$%3^Z-.A2$=M%@7]:*/E"$DIJ*Z5-WPVM+?(=
((("UG>'JW/FK/47L,@3/)8^1=4D;D"DDCK M+HS,;90EOV[6^H+1@C[[-W83T*AN2V>%N>38=>.3YS;LI26],*V-D MJO?DM0V&";BISR>>;
MA[C[ZN4YV>@TYIS*-'&3&8T;S%J'3P9-/ :$M:'9'?3D:4BA4I!&RQO>0!_. M?U'5?_.'#.7'DH?^^ ,R^N;M?4"V "O4R\%C**Z%#$S(/U*3'IFDD9;;TG[>
MG6\X*EC8!IOF.SYDM_6\"U&J'9C,1S[B(LC9@!UT0+XT>H.=)P-*;\TF!.CW MC@PH4+8".MF43N-=*%X,T[$IP"W(7T*:E9
>Q)9:]9;2+BHM.0#7*Q5/'0@&^U8!ATB:35+IJ2 MWKS0'9W4LOWP6D<[;HWDN7NCX$=C/O%";?'0",$+>$U0LW,MWP:6NXXM73 B:-$^P$S6D#%I
MJN8J.XS(GH5OJ<>E(!O+YC,'9S(E%=C?E32MUZ(UH?G_&J&GG!S QQC?DHI5 ML6/42O4;G80>J/*+S>#)<,!M3,=%7(F)?O3T8+9.=L1\Z$
MOBSGDY^12^7TPV1GTRN.UBPW6Q1X6Z4B2\2/,KS:8?Z]=G"!:H($"FF6O_T4 M9 2/R><*X6U:8>[UD$6NI\>>P+2E)T=3 K$V-'F _U?R5I <,9[FL0]UI^
4 M/R>AI'#L>H1+DL=L.$(I6$\RT,U43RI*^%??;YL".WI]>I]+.3 HV%1>II MQMN.$WWG5I.;^<\&CDAE0H,/[=P?O\+>, S6NX,)
Q8Z8GW50#I^D8OR^8E.$!J3-PC)Q59"[J%$Y85^E_+V8HXU\RKUCG<>G#[NSP,>WSFZOR#R M(M)N\U!! _RN(X"OD3,ZX03GH"U.YU&4D#T!
(N=RBR3M:'%#%IB^I$,9$IE> M!S3YP!Q2P9BQ[R[ M2+R['/$N13U=1CESD!#[KQ'H?6Q L*F.SCUURCZ,VY=&-_1V4@[X\MJK7S5SZ6[ M\91*Y@"'=
(IB+OE])!U?AG+X)B"]]U3\G15K/1Q@W5;\J 6H?6ROE\W)#G;/ M'&I#^DSM9O>\)+](8.D\Y>PMT/X+$1Z"TN11A(:]-!H.VY$!6$\':4.!3*_=
M.SH+@%]W&]%3._QL8?NH2%'4MJ3-,7Z0K"[FU^&X):R)OV?MJ@*0)^HM]=AT MT.,X.V@=(7%_SG-_WG@G"QZ.OG)#MBWY6SX>?5TK'[SU5_O/!6?
RE=RP7+XU M?*?#$HA!@5S@T:.#1P_VI)[D/UK?\#=SL*KU-?]$,PE*H 6X3]\.Y3]H@_XC MRM/_ U!+ P04 " /&=9$EE^F"P# #S!P &0 'AL+W=OA))E)'T
/G>F0 @>& M@V)O8DUMRY7DI.77LY(?<BA (E*R%SIO$HUYXJ);#$&N691WU_Z.6,%\YL8GGW2
MJ"K/F7RYA$QLIT[@M(QO?)UJP_!FDY*M80'Z>WDO\>1U7A*>0Z&X*(B$U=29 M!Q>7 Z-O%7YPV*H>30R2I1"/YG";3!W?) 09Q-IX8+AMX JRS#C"-
)X:GTX7 MTACVZ=;[9XL=L2R9@BN1_>2)3J?.V"$)KB%B5Z6]B^Q4:/)'Q%XM,V95L:]T( M(\:5TB)OC/&<\Z+>V7-3AY[!V#]B0!L#:O.N ]DLKYEFLXD46R*-
-GHSA(5J MK3$Y7IBF++1$*4<[/;MB*B6L2,A\PWC&EAE\P$Y_6+ ,R +B2G+-09&S!R-2 M[R>>QJ#&U(N; )=U
'HDP$=R)PJ=*G)3))"\MO+ZI5^"7_.ETA)OT>]# M1:AC# [',)-UH4H6P]3!T5$@-^#,WKT)AOZG$P@&'8+!*>^S!4YJ4F'#Q(J8 M?KIVM1
VV$<$9B'U@!Y"<#+&801UL-@$@W^"\5TP$@N<8:4A,0GJ%,A*9/@8 M\&)-SGB!'%$IM%'O+[#>I89\";+K,)GG0FK^!ZV_2*%4L]XHS7$FD=O=X!Z^
MFOF6C#Z.W&@<(O7NS9@&]-,K:B?=UWO EP>GNQ2*H[MAY+N^[W?2=F_YM-D' M?KWCE8<7'%/YB,_JJD)L)'"#D>]&$=USLI/LZSP(S3*%>5%W&
(S=((R.8.G+ MJ4L[NLWH&N*FKH&M:_A?=1V$(W>$O3FZK@-ZN*XM/VRR#^C1NHZ& M8VS=<,]%R_]7WE4T<(=TZ(:!?P1%7QZXD=_132Z'!M?
K/<0YR+7];LP 5(6N MW^2.V_UH_HAWZG7W^$=DVM>*)+!"DW]\U'D$%E_,?5!B](^ZTNA\9.P9(J_ M,DBC@/*5$+H]F #=/S_["U!+ P04 "
/&=9D5T6W[4# #," &0 M 'AL+W=O+-NR M:QNPFQ4ML !9G'4?AGV@I;/%11(UDK+C_?H=J9UM0"*2=[R']]SQ>)X= MA'Q2&:*&YR(OU=S)M*ZFGJ>2#
NF;D2%)6FV0A9,TU+N/%5)9*DU*G(O]/V1 M5S!>.HN9E=W+Q4S4.N5QA+@YS)W ZP0/?9=H(O,6L8CMT\GJ4E!=8*BY*D+B=.\M@NHK,?
KOA&\>#.IF#8;(1XLDLOJ9SQS<.88Z) M-@B,ACU^PCPW0.3&GRVFTQ]I#$_G'?IGRYVX;)C"3R+_E:/;)-CNK]S--TB-
GJ)2W@J@$,+P!.X$Z4.E/P8YEB^MK>(^=Z#\/.PU5X M%7"-U0T,?!="/XRNX UZQ@.+-_AWQK=<);DPI!7\MMPH+>F2_'Z.X>@:^F)-A9C6.8+8PE(IU
I8F</) MG&UXSC4GY]O4I< TG/ SMQX>,*FEY.4.5DQQ=8[=U?//LWO,$+8BIYHVR-K< MEK:P^5^H7-@"V:-
$J9Q)PR=%&IE61K.+^891\EDDAWA'2])*6I%QNK]])R/ M__ /?JZ%)N@UWY5\RQ-&5?SZ@V$W?"TU94=I MD)2?,PC!P/QUJX$[CJ/V:X/X?2Q&0SIL/+;2.
(S=23AY%8LH(GDPL?HP\-W( M'YY6WO2B/Z=A#-W)>'0ROF@&;A3X_?@_ G5I',6!_>_)_A?!/UX[LGR M3CI,@7)G^Z@BO^I2-\VFE_:M>METJ)?
M39^_8W+'2P4Y;LG4OQD/'9!-[VP6 M6E2V7VV$INYGIQG]W$!I-I!^*Z@^VH4YH/\!L_@;4$L#!!0 ( \9UE8 MBK(,&@8 %L8 9 >&PO=V]R:W-
H965TXYLC%TH M83KMRTX>&ENR=*[?^7103]92?=$I8X;6S2TT[8(3%+:)&9:[E^PRI_AB@ODIFV?\FZ6NMV2%1H M(_J,UB0 M2=^
;I30CRH]9Z4>_P=Z)N2=%";5Y*6(6=S>WP>;:\/]C>%G_D&!-VSUG Q< MA_BN'QR0-Z@#,;#R!K\D$!=<1YG4A6+DTWP!RP%=G_=%I50:[%>*%3?5*QJQ
MTPZ4E&;JCG5FSYYX(_?% 9>"VJ7@D/39#51P7&2,R(0 A &@@KR\CU(JEHR\ MAH(EW;=2ZQZ9:RTC3@V+
7TFW5U\#KE#%S5Y+PVY8!J^VN54U]%I1&U?( Z; M>ILRDE1:V48K!%@3L%(6BD02<",TJ(0W+3,>6_W:P*/,%#C)121SAH^L )01 M8Z5F0#QHX!
(\!@BC5( PF-YV>D=]5#LMP.FXY71:..EZ V<83'KP.G&"<(A3H3/QO=X!S UKS V/QMQE#M V!+AW'D5% M7F0V>A\@*PKV5X('K8<(FO1':
MFZ"]J;47TV;Q:BQJ4+) L.0E6)@%"W >H'T!QFR(CZQ!%M45RG\2@Y?",& ? M0Z[!W9\'WC$A@]XF[H>),Q(A$@.9@@2IWAV+?()+VP5 9:,BC6
M,G0VRD/OT0JJ$;.*X=^XX[<@_5PJBNA='Q M_$NY(A]I5MC1A\( X;OCU,H-,M$!4"<T!F, N*%CCL8DEMI:/9=-!L< M8+>TF. I[A^/X>E[3NA-
R%M.%SRKNHI?$RY@6U7 OJPA^BDIZ^K9D]#W_!>.YO"OD^VSU[4]/KJV/R0)I-G8%M%B9%\='Q1W=!UORUC;.EY) QYR" E+$E8>70?: MI07-J(A
"OY>L"V3W-J.^W@+%G@*[;03NSG3Q>(?U V,JXLH2)2LE[SC^:MME MD#TGV&N%;#W/95%U<=?;4Z4,9[]5).WU9>R)56//KJVS9Y6S-_;'[7OXUU"R
M3_(51EZ8\C1[0%S;"NR*C[8$VN=(\96ET$9_\XH+6(2I;'8ZMJ^!GYQXV"GX M!L%AL#HFW:L,&X>XU_"L*:YFR0W?;*IH.P,G7SAP>ZUO(V@-
QTTYS4+LVC+J MU4_U;4UT=*X-2PYM3P9SBUD;=]Q'I0YB.Q/E;;([$^IOI_1JS]QH5OSM32 M7FMK8 YPH+S[K6?KF_-
Y>6&\75Y>N[^C:HGW8AE+8*O[?#SL$%5>99<#(U?V M^G@AC9&Y4T9A9X;%\#W1 )55@-44/]_PNP_4$L#!!0 ( \9UES&^5J MD ( (0% 9

>&PO=V]R:W-H965T^*:T;B+(9C7; MX!+MC_I>4Q;T+ 6O4!JN)&AV M$FB^S )+S&X]R'E66"\.^RSV! :PE14#09^6$R@6/_/3AP1H5ZT_K?
M==U(VYFDG^V?F,O.6>_EW?MTQ_2&2P,"UP0-+T8##W3G^2ZQJFY]ME*67-N& M)3V3J%T!K:^5LOO$;= _O-E?4$L#!!0 ( \9UF0G%^3:@0 !\+ 9 M
>&PO=V]R:W-H965TP&&11YY=[]|\N8' M(;^H$D'3IYHW:N&46N\O75?E)=1,78@]-'BR%;)F&K=RYZJ]!%98IIJ[@>?%
M;LVJQEG.+>U6+N>BU;QJX%82U=8UD]_6P,5AX?C.D7!7[4IM".YROF<[N ?]
MR_Y6XLX=I!15#8VJ1$,D;!?.RK]"$,;77J8SJ#2,X_51^GMK.]JR80JN!/^U*G2Y<%*'%+!E M+==WXO 3]/;,C+Q<<&7_R:&
[F\0.R5NE1=TS(X*Z:KHO>^K],&)(O>\P!#U# M8'%WBBS*:Z;9&.W4^=S4J,RQNW@M=>X*#[PC.R"?1Z%*1FZ: XB6_ MBR
'I,$1Z3J8%'@/^PL2>I0$7A!-R L'RT,K+_QOEE]7*N="M1+([ZN-TA+S MYX]3;NBT1*>UF)JZ5'N6P\+!HE$@'\%9OGWCQ]Z["1NBP89H2OKR'FNT:!&T
MV)(/4BA%KIB4WZIF1U:U:!MM#WI#3X&?%\:_$,)9&=UY4==;-"U.SKUP!3! MWU9P+'O,HZHANA2M0F>K\TNR9IPU.1"FR37D4&]
DM"WL0W)#\2GR2RD?N@1 M+#TLK(; 4UYBA(#,?#KSX[$ 3 S=2^BSPTI(O8C&44PFW#P;W#S[?VY6-HE^
MQAZZQOY#/C/>@C*W7^75J2!,*O^70>B0-(C$=$+R." 1K235,QK69?D!)$S% MZ81O7\?K#DSW-Q@ZYZSRO*U;SC2,?
#)QM,J_MI5$2@&/^$KL<:4A+QO!Q:Y" M].F%AQ%-J1='U,],?IP%-/,SFB7Q.>YFU(\B&O@)KA.:I#,:9;/N5A@G-)KU MMR(?9838F%C3;K&
<6VDPY]BF3'$K\O9-&OC!.^+[-$LCAX-O*RW/PVHGW@O[9^HB'BHB/@?5\2-TE5M(_J^U:9?8DU( M7?W)[+-
[\X3S@X*3B3^IXW3BK_$%+@C*_1M_2L]LEAH^76+C.<#SA;X[&3& %N?&'0:; MU6ZHG41*MIV/V-A'T/NH*T<8_#E1F+\!D^9I-6!?5.1S-
$Z%H2OA,VDK%JTU MB>'"F".8,'@T(W&4TBB,S28>;Y+Q)L5-@CP1P3Z$H^!6HW*3;!F-L[A/Z'%> MGLHX=S2TU"!W=C3#?
F:Z6#>_#-1A^EMU0_S]6YT_,3DKFH4X;!%5N\BP8XJ MNW&LVVBQMR/01F@&PO=V]R:W-H965T,30
6XOZK2PQD*0M6J#%@KK;/@S[0$NT350259**D_WU>Y1L M.05<8QCVP18EW;U[=_>.XM5.FZ]V*Z6CQZ9N[?
5LZUQW.9_;AX&03IOA&IGBZOAV;U97.G>U:J5]X9LWS3"/-W* M6N^N9WQV>/!9;;;./Y@OKCJQD4OI?NON#>[F$TJE&ME:I5LRR#0^+;'G$TAO>/S
M]0']W9 [JW/9ZEL^HDFO1U^ZSWKV7^WP&@J6N[?!/N]$V#F=4 M]M;I9N\,!HUJQZMXW-?AF4,>_, AW#N$ ^\QT,#RC7!B<67TCHRW!II?#*D.
MWB"G6M^4I3-XJ^#G%G?2.+2.;D4MVE+2]3;$37\ 6I!GW3KMI;>MI6LOO>?@^%$,SS0O W/ BYE]YJB@%$8A/$9O&A*
M.QKPHO^0]I\W*^L,Y/+7J<1'W/@TKA^A2]N)4E[/,"-6F@X/!-.Z)T3U2<"3:BMY^ZU6'B7&GB)^%/DW\&*.;
M8LA##"HU1M,Z67DZ;BMIK6O,N&HW]!*E=5O=6WC8BTM"^U#:E31##]_(;KG>@8O7:[821%'.6 MQQE%.>-1C/:9P0SUF:\B/,D3_/6!(%Q!,6%3F]
MZTVKD*,EU#/@@.%U\L50(XP@C%,?$"$LUI.21D)"3IO[-# M22F,60)]AP&+HP0%JNL#)+[=7^48X$#!&T<%<5"(HRD1U6(BI'44ABP&5@1Y MX?
5=;XP?D,YK%D5!=VH_R]\U#]1X$/E+C&'\T#[ 0YNG5T:.(S"%1LR 8PXC M5F39%!I?Q5JLM!G++A]]"SPJ\@Y@'#">Y,^,?S#C!0OB@-#:F$_&V*H.'"=8
M]!'9)[@D"=1CU(/P1PT4P.,.N\'SW)(LI#3G].L@IQP)H&]9PA(>T9=A!Q G MY(R-+\E9DN589072Y?')^9P_.PLTTFR&$X^?AKYUX[%@>CH=JF[&L\31?
#R1 M?1)F@QS0GC5<@]<9)M.,IYSQQNEN.%FLM,,Y95AN<3"4QAO@_5IK=[CQ ::C MYN(?4$L#!!0 ( \9UG;FF;%Z0, !X) 9 >&PO=V]R:W-H965T
M;)+#.><,A\/1?*_T)[,#L.1+74FS"';6 M-M=A:(H=U-QJJS!F;!K67,A@.?=K3WHY5ZVM MA(0G34Q;UUQ_O85*[1=!%!P6/HCMSKJ%
<#EO^!968#\V3QIGX8!2BAJD$4H2 M#9M%JWT5I=XL@"T@)&]Y6]H/;_P)]/%Y@H2KC M?\F^VYLD 2E:8U7=.Z."6LCNGW_IS^'$(6/?
<8A[A]CK[HB\RGMN^7*NU9YH MMQO1W,"'ZKU1G) N*2NKT2K0SR[O86W)Z)FO*S#C>6@1TAG"HG>_[=SC[[CG MY%%)NS/D)UE"^=
(_1"F#GOB@YS:^"+B"YHI,&"4QBY,+>),AOHG'FUR*[UZ8 MHE*FU4#^O%D;J_$N_'4NV XK.8_EZN/:-+R 18 %8$!_AF#YYE4T9>\N*$T&
MI,!K"Z4$8\Y)OPA^7OKS#LA& M55B7CLJZ.] 7I_@'#+%H+@Y^"!$M9J($%D)"3N5:WALC3C:X(IM%"O0?L\
MWD/13Z(NJ>1791']-7GS*HNC^!V.TEE*&6/DHT0:;9&])&^)HR#"F);+ I4H M8\W@,XHH2Z;C$T!*)#YA!WLZF] \39Q]VA-&CL+3'$?_3SA*:)(BT6A*$\;&
M)X =89ZG-$T2_)_0*2+&;,*^(3RH^@&Z**=5*F-(HBFK&8 MI'06Q31/8O+@$HP,&C#YC=..+^G$1T:F+/%GW$%42F[?6L?EP5XC'$,%#@X3
M3",VHWF6D0N%D@Z%DOYPH3QRVVIA!<:.LP>GP%-=1Z,MS.#TDSS#2X-IU"7J,N9G16>KN;9P>$NOO M.
Z/T]F)*NMD(94L$%7=C7#+.NN&W<3JQK? =?* M8C_UPQU^P(!V&]"^45@]_<01#)]$RW\!4$L#!!0 ( \9UDY<1'-%@, M ,H& 9 >&PO=V]R:W-
H965T2F^U:/?N]&JA&BM*B7<:3%-57/_:H%"'I1=YQXW/Y;ZP;B-8 M+6J^QRW:+_6=)BL84+*R0FE*)4%COO36TG/%' MMO1"1P@%IM8A<'H]XBT*X8"
(QH\>TQM2NL#3]1']M[9VJF7'#=XJ\;7,;+'T MYAYDF/-&V,_J\#OV]4P<7JJ$:9]PZ'RGL0=I8ZRJ^F!B4)6R>_.??1]. N;A M"P&L#V M[RY1R_(]MWRUT.H
VGD3FENTI;;11*Z4[E*V5M-I27%VM2VXQD*) M#+5Y"Q]^-*7]!:-[OA-HQHO 4@KG&*0]W*:#8R_ 7<-')6UAX(/,,'L>'Q"U M@1\
[\MNPBX!;K*\@#GU@(4LNX,5#O7&+%[^$9U7Z\-]Z/RF+\&V],U;35_+] M7-D=:G(>U4W.C:EYBDN/1L.@?D1O]>95- W?7>"
<#)R32^BK+4UBU@@$E<.M MJFHE45KCK'6:-E4CN,4,_K(%ZO:<+M1-S2/"G\J8<]5)8'+<]F8:1'TV3?AW[\?5L?.Y[#4[TI4*];U74$$4JOY.:
M87<0ZG6G3T_NGYHF'M#9=@^'VM_@502P,$% @ #QG62\ ^WMD! V@H !D !X M;"]W;W)K&ULK5;;;MM&$/V5@5H4"4!+Y/(BR94$ M^%8T#W&-
V&T>BCZLR)%(A.0RNTO+_OO.+"E92F7%10L(U%YF9L_<#F:V4?J+ MR1$M/%5E;>:#W-KF?#0R:8Z5-$/58$TW*Z4K:6FKUR/3:)294ZK*D?#]9%3)
MHAXL9N[L3B]FJK5E4>.=!M-6E=3/EUBJS7P0#+8'GXIU;OE@M)@U[>\BA MO)96+F9:;4"S-%GCA7/5:1.XHN:DW%M-MP7IV<4MY?U#G:H*H4$-
O^FLJ"DY M<)]+C?#N02Y+-.]G(TMOL<8H[>U>=G;%*W:G\%'5-C=P4V>8'>J/".,J-@"
MO10G#=YC,X30]T#X(CIA+]PY'CI[X2OV;J2NBWIMX([<[KS]\V)IK*8Z^>N8 MOYVYZ+@Y[IUST\@4YP-J#H/Z$0>+GWX($O_G$V"C'=CHE/7%/?
5BUI8(:@67 MTA0IR#J#ZZ)L+6:PE\.[?^;P2E5-:R7WP#&W3CY\W*T7!%F/H"8$Q4L5J2T" MXQ!LD#ZI@T&RTL!*E40&!MX5-=A(>[\Q:J UY!]E
MYR47J2S3MG1E9.",F9!J( F*(@@";V _X0GQC'O8@)QO<6/NR"^&B&*2BAB M&'MQXD/DC44 $R^.IL>,8-64ZIFJ
;^VA7WFT&#M9+@BFU;3&X9"54H"&H6$ M)YA"')#U2?P_.+XM>?9Y',$X\,0TA(2@!P&,A3>AJ-^>RMAYW\&4FF',92>&
M(2S3"2<#,67+Q.6B8;)&$[02KRCE?C-M+*+S$4?F4,:,9R\ MLN4V6VE5[;,*:[]"14[U&.N8:+Y3G9M
M+FU'1WC@#2OOY9D]>ANU<:.R,ET5*C/0PR&])::2BHEUZ2$'F>8IFE':,H-< MNG*EGRW.LF]J_( 5_POWW?RK3O&B) ;AQ7[ '4C?T/.GP=$R&^W-
&T2O:S=5 M&>)#8NMN]-B=[@:WBVY>>1'OIKZ/4J\+>K[$%:GZPS%5ANXFJ6YC5>.FEZ6R M- NY94[#)VH6H/N5(@+I-_S ;IQ=_ U02P,$% @
#QG63X@AEH"!0 M0@L !D !X;"]W;W)K&ULK59K;]LV%/TK%]XZ MK !72]2#9)88R&OK,*0-XK0;-NP#;=.V4%GT2#J)^^MW2#^6%*FQK?L@\HKB
M/3SW*1[?6_?!SXT)]+!H.W_2FX>P/.KW_7AN%MJ_LDO3X'6SOE\Z MHR=):='V>9;5_85NNM[@.*U=N\&Q786VZ-^;>/Y(I M6C*R]D-\^6ERTLLB(=.:
<8@(&M.=.3=M&X% X\\M9F]_9%1\+._0?TBVPY:1 M]N;3#8MCZ-=+_96]4]&J]\L(NM,A@L
MFFXSZX>M'QXIR.PS"GRKP!/OS4&)Y84.>G#L[#VYN!MH44BF)FV0:[H8E&%P M^-I +PQNS)WI5L;3M[=ZU!K_\K@? !L_]L=;B+,-!/\,A*
(KVX6YI\MN8B9/ M]?N@L^?$=YS.^$' H5F^HB)CQ#*->'L K]C86":\X;"--G5W0.;@ZY +\'.9T MGCQL'/U^.O)I_8_G'+#!+Y_'CW5SY)=Z;$YZ* QOW)WI#;
[Y*J^S[P^P+_?L MRT/H@R']<+)]#=DI731>SV;.S'1*::QL;7N.]$'8YTG?SN$EVZ)2FVY&(68$
MI:]=*1WE1O/#3;H%E6YRYZFHS"W*Z^[B7]Y1+=S9\R3O* W(/!T)88W#L4C MZ=?
UO;ZCKZF0DI5U':4B9W510,I9)CCCA82LBHJI2F*_,PNJ),OSDG)>8$UE7; L4W2Y;":-;5'TXXUR0I M!0G!E )>"6R5@7X%4PNZ,-
,FF+:Q?;2D9N1L:":&:NCDDDK!1($CX":55S"# M8Q;T?OU@K*>B9$6.&"@FHXWQ_%)BSF!YL;7R;8=&8V=KXG"MJ'!^G;$2KI:Y
M8G7.28!/E7%Z&^:H)D2)PP2F,D&(HQ*DH"7IVMG)"K7G-5H-HPX_'27Q"=M4 M ?9I!@LD07#-:!=1*L#0S=N;TN:^(IPP#71O/@?
U8GXV2L):&20;6L62GK)&.-E5E.ETC_I8EI62#3 M:OA>P'GHWM&)N2I9CJ">MBW93684$<% M^W7,YRT8(KJPSL35#@7](NHCA 4-
L'NL_%K__H7@/S9NGVYE&XJRYLKCC[U?T%\71S M+_I[^^9V>:7=K.D\M68*U>R50(30EVF6Y)(QO@RR3.<J1M3P
MV+6]FCNUUIMSUU5%C1U7$['!GKY40G9B?:/IM3UW)DZ4&+%AU;?B.VO MN(O'$BQ$]^P_;'=S/0>*06G1[9R)0=?TXY,_[O+P$8=@YQ!8WN-
"EN7/7//% M3(HM2#.;T(QA0[7>1*[I35&66M+7AOST8EESB6>7%%<)5Z*C6BMNTW5RRU$!W!"_QC8;. MU887.'=() KE
SJ+'W_P$^^G(\RC/?/H&/IB29HLAQ9!5/!FY:X?C8V'N!]% M/\Q]7&9EERE>+H/C,J3,EFOZJ 7<+.\4@WQ\K"FA6L% 32!!#!*NEWD.O"]!
M&4@0&P.C8,L5T*\2+6T0"DZ:'G0M!D4SU>DYW-82\55'P6_$^_6(:0SS%[ZP MEJ3TIE\3$>Q1\M8NS4O24&.J:S8#^ 1ARGS/-T;,@F1*AN\'+(I]:X7,CV.X
MH5QP6=06H<0'VLDVME*"&;BBL*O&@V5%-V[^'!"T?N9=PHGA)\%] PH,?[4&!F+ MP_#TPTQ[M DP'#Y!E+(X]8R1L)"J0]F-
TI;:JPH8F&2PA&!Q'N!Q!\6")5- MRZ8PO;G4HKB'N[ZAAKPPYT"CGVPUE_3:#]T*R.8RJII5)%-\0-*:F=B#?AMH )\GVC$)639]'2JCG51 M-
C@#M['$!9GG/SIE!T!H23)0L4;"0^\'?"R_T+V;UB_5K,U/$!9#Y0AYGV M9VDPA5\.TC':\R;4SV2$T22T_>)/)Z&5911/O!@^DL+\?\YA_A\E,3^6Q7A*
M2:&-BQ))BGHS@5XZ\49U!9-DS"2EU.YP,7WR#\K-?7&3Z%"N[7U)4>:&7H^7 MBOWH_DIV,=Y$OD\?[W-?N5PWM+^W6)&K-TE))G*\(XTO6FSLO60E-
-URK%G3 MM1*EF4#?*R'T\XM98']17?P-4$L#!!0 ( \9UF[J0C"3P( /$$ 9 M >&PO=V]R:W-H965T MA;V5S3/3D10:5I9AIQ2WSTN09C>/)M%^XT'4#?
F-.,]:7L,:Z'N[LLZ*1Y92 M*- HC&86JGFTF%PO9]X_./P0L,.#-?.9;(QY],;7)6-$A&36 G0(E=/_G3T,=#@!I^@(@'0!IT-T'"BIO.?$\LV;' MK/=V;'X14@UH)TYH?
REKLNY4.!SEWQI@-T:U7#\SKDNV[B^'F8JM1:U%)0JN MB2V*PG2:A*[9RDA1"$#VEBTY"O2N*PL(FG@H]-D]MY;[8I^SLUL@+B2>9S$Y MM3YF7
S*EKVR] 5E']B=T=0@^Z1+*/_'QR[+,=5TG^HR/4FXAO:"39,W+$W2 M&4.H76_1"=[I6,)IX)V^P'NL-K\6&R3K6N[WL<1[OMEQ/C^&U]CR N91Z^MJ
MMQ#EKU]-KI*/)]3.1K6S4^SY?:%*TBHZH@4 M.#Y9")E0C9=RZ:I4 HTRIR1V _KNPEEW)F.LWMW2J'624/ET M#K'83AS?V=VX9\N5-C?2;QR2Y2()<
5$YQ(6$R<,_]T%@3& M(;/XD\%6[9T30^5!B*_FXBJ:.)Z)"&((M8&@>-C #.+8(&$<_Q:@3CFF<=P_ MWZ%_SL@CF0>J8";BOUBD5Q-GZ)
(%G0=ZWNQO82"T(G!"T6LLG^R+6P]AX1K MI452.&,$">/YD3X6B=AS0)QFAZ!P" X=^B\X= N';D8TCRRC=4$UG8ZEV!)I MK!'-
G&2YR;R1#>.FC',M\2E#/SW]8P5D)I*4\B="><43F>3F)6) Y6W*V8"'E MFIR%H5ASS?B2W(F8A0P4^8B./ 2N)3454<;GGJFOY.B62G-O \?DZ (T9;$Z
M1O,O\PMR].&8?"",DQL6Q\9K[&JD88)QPR+D\SSDX(601^1&<+U2Y!./(&KP MG[7[^T$+@(OY*Y,8[))X'K0BSB'MD*[W"PF\H-<44+O[!83H[F?
NW99PNF5- MNQE>[P6\6=8V(.OUR6OSC?PFA5*[@BIR#R&P#7V( 9]]QIJ1G7MC:5I'-N^< M4Y72$"8.OE04R TXTY]_\OO>KTUIL0162U*O3%
(O0^^^E*3GN?G[&FW(E89$ M_=/$O6>3NR6P&O>3DOM):X/<@33<\35MYNPR:PBZ:PA9-<01Q?LDS:V/FU*2 MCS/,QC%?C,W4ZPQ];__GC]W-
/O$FE\&H-*H1ZI>$^N_4\9_F\XMY$[/6 5]; M;$M@M=P,RMP,;#?ZP"9W2V U[L.2^_ '-?JPH6M[AZW]/T8U"J.2PNB=6OL, M/[?S%$)&8_U$+@$/JY!*(-?
7LR:*K7&\MNJ6P&HI\[U*U'BV>[Y M$3?%EJ= M_YZH\W]0WQ<#U7O:[QTT?K-5M[GS_:"B$;Q3[]^$OX-2@C=2:AWTU96VA%9/ M427U_*
[U3K>JX6RAU?E7*LYO%4HV.[WW79W>:/7".]ZO!)G?KLAP28H+3D[@ M,5Q1CF1P@;ZE,B*A,,4-DIM@%2)S&A":F MXQOYY@BCO88-1D%G<-
C7S\U.?'_/K!YA)<#\=@5V"QJ;4^'_4=Y!I[TC+JG)R]_9 43(NLZUA13(ED&^'EG?+[>>S M;-/5KL;*G&N*A+# EV]S@#+
(_/MX/Q"BS3;47T0&O5I=KH"&H$T!OA\ M(83>79@!RDWYZ7]02P,$% @ #QG60N<*7#*! _QD !D !X;"]W M;W)K&ULM5EA;YLX&/XK%C>=-JDMV
22]I)(7;KM M*FU2M:R[#Z?[X"9.@PHXPTZRW:_FU ,L?.FZ-)\2( \[\OSOC;/@V&XY<63 M6#
(FT<\LS<7(6TJYNO)],5NRC(H+OF*Y^F?!BXQ*M5L\^F)5,#HO@[+4)T$0 M^QE-,A7\LTR=E=@<0ZRVCQZSU+^7;D8>_YP-?D<2GU 7\\7-%' M-F7R?
G57J#V_SC)/,I:+A.>H8(N1=XVO)B'1 27B>*VHK&-="D/G#_IG=OY MR LT(Y:RF=0IJ/K9L E+4YU)\?A1)??J<^K YO9S]H]E\:J8!RK8A*=_)7.Y
M''D##\W9@JY3^95O_V1509'.-^.I*+_1ML(&'IJMA>19%:P89$F^^Z4_JT8T M G#O0 "I LA+ \(J("P+W3$KR[JADHZ'!=^B0J-5-KU1]J:,5M4DN1[&J2S4
MOXF*D^,)%4M$\SFZWM DI0\I.U=SXWQ*4X:F;+8N$IDP@<[15$V@^5H=Y0ND M@\[*;_3AQSK9*' N19GF-M\P(;-R_^T-DRJI>*?"
[ZJ!LW$GU5\W^_XD@-\IVQU@<+@#)& ]!SA$SC\ALU4."[#PW:XKSI7 MMX_4[2-EOO!@O@?9Z-/97AN%;N/?GU40NI4L$_^X"MZ=H><^@[Z,K\2*SMC(
M4]>I8,6&>>/??\-Q\(>K_!,E:S4CK)L10MG'UQDO9/(OFZ,)%])5ZBX^+N.U
MP&S&),8#'$9#?].LPL;AF,0A#FIUV#JQ>X1M'#C"_9IF'Z19R]F^.+FX]FVNQ,75QN$H.,QU4',=@%P; M4NEB-[#.V@OT9X^<#
<.D!6MQNZRY71[MHXL4&-55JTZ4K%4@#HSQ!:\NW=4I M3M2/4V5K-Z1Q)X#_IWQ7"9J3K7_9CP;AWIQTX'IAOZ\-VS4IL7%;#/I7!P&O M$D$:"4+:!
(T#8M@".XAXE0ED"$':#(T%8M@#7RKDV#8X]UC;.'"LC1UBV \[ M23FV#<_-UL:!;(T]8M@?CX@YMOW.&FP(TF9EW!##=OA-K;C4HF;%17* %QC? M6+
(<9?AP/6 VPQB M7)B IM9!T:M$T"4$0MH$C2L2V!4[*#JQ;<]B"$':#!M+4-@47ZKHQ/8M@[YU@[ M<.!8&W,DL#EV4G1B>Q]QLK5Q80"P-
49)8*,\HNC$X7NN^W,'#KI!)\8?">R/ M7WC.?J&,%D],HL7ZP-,4.$GGIPLGRM8NV9@LB5__:0OHXYT;P MOQ\7>.)8O.)^$$5D?Y[:P'X\B ;Q@7EJ7)G
R]P."F^O9:VK"8*T"1J7)+!+ M=E%XVP8MAA"D_5C-F&0(F^1+%3ZT_<\]V X@--BA<>SNM7(U]H\:BN )2RA8H)+OJJKF+WMF&W M(_FJ?

&#_P*7D6;FY9'3."@U0_R\XE\\[^AU _&ULK5;? M;]HP$/Y7K*R:.JDE(4GI8! )"-/ZT*DJZO8P[<$D![']V*GM0/O?SW9"%MH4
M55MY(/;EON]^^'R7\8Z+>YD!*/284R8G3J94,7)=F6208]GC!3#]9LU%CI7> MBHTK"P$XM:"6[B=-W]H); MLLF4$;C1N, ;6(*Z*VZ$WKD-
2TIR8))PA@2L)\ZT/UJ$1M\J_""PDZTU,I&L M.+\WFZMTXGC&(:"0*,. ]6,+IX+@Q?PJFT_VA7ZWH.2DJI>%Z#M0$T=9L
M9F&S;]$Z7X29.EDJH=\2C5/1',L,89:BZ183BE<4SG7QG2\Q!;2$I!1$$9#H M''W'0F!SJ.@T!J5UY2Y+%[TFV>"">R M@X,*FX,*C['K@U*@696^C G/
:T%SQ$^N-C27&S9G%G7054V!M:&&3/;R!^, MW6T[_97*L*72'_;\0Z7XI=)EV+L8MG^'B,5+1!CVPD:IRHG;:G8YB(V=,A(E MO&2JJNE&V@RRJ>W?
S^2S_FC>[Y#'>O!5<^HO?34UK['8$"8A;4VY?4N=2\6 MU22J-HH7MM6NN-*-VRXS/;Q!& 7]?LVYVF^,@>9S(/H#4$L#!!0 ( \ M9UGDA=,2V@< ']" 9
>&PO=V]R:W-H965TNNU^=L$MT4+");:=I/OCSPD4 MX]H\"'WLAQ7:YR_O^3V<3^P'IX]E]:.>*J7)SUE>U&>]J=;SDWZ_'D_53-;O
MRKDJS%_NRFHFM7E:W??K>:7DI!TTR_LTBD1_)K.B-SIM?W==C4[+A-9+^X]_>)+=C_5S2_ZH].YO%#
MNE!YWB@9/_Y=B?;6K]D,W'S\I/ZA#=X$_U"H@WNB-R[QN_R>/*]NH1\:+6I>SU6#CP2PKEC_ES]5$; R(DRT#Z&H MW7<
6PU@;:!+S]JP+J66H].J?"158VW4F@?MW+2C3319T:3Q1E?FKYD9IT5%56W)/WLLYJ\OI2:9GE]1LC_>WFDKQ^]8:\(EE!OD[+ M16V4Z].^-O$T7O7'*]_?
+WVG6WR_4?-WA$5_$!K1)##\ AY^J<9F>-P.9^[P MOIG%]532]5325HB]MT3M_, '*VUR]->^NM]4T$M9KWL G M]5R.U5G/O$-
K53VHWNCWWV(1_1D*%DG,"9VM0V>0.AQZ*/*EG&CEFI7F841% M/(@9/^T_; ;EV\6""A9':SO'WV3M;P+Z>U46ZI=Y&U4_S$)YM]A2?:!&U_0@
MB3GA\G6X'+DR.6;H2&).Z&(=NL"MS*4CN5W.)-%>A>5EG.N@>.+QK8I#$G$@'ZT@'R#4YP P=2F;)=0Q<[R-(XL($>CO^EH>O$2#8[NF!4O-
C70#AF+DHEP)8H6/ MI.:&;P$F!B%A]+74,@^#&/67Q0$=#.GP60V&#&D<)1'?4H46,6(&YF:#/,.9 M !&EWD Z:1S^$AJ;OB636(83CI?MU9ZNV$J8
C15&PA(P8O MY$[![F0K6*MSLHZ!&+%EC'B(7:L@M70.'TG-O16WS$)A9NE0G[5O$@8EL(C5IHH-,E7K;L'20;"E42RH4)I6=RP8JEV"IN?
ODEDL8S"7[+AO,QXS ;5[ BB7;-L>9 M11&V/XK\O2BUFI#K*ANKNCFP.6\/WLA5>^-7+Z?&O+O(QXDJ=#:6^=-QT>M/ MZD'E)'X3C
^55;#4W/FRK,*P686AL@J6FAO^QN$/S"K;-RM8@#2"-X !0^@& MD%DF82]C$H;*)%AJ;K"621C,)$ B=E,(:.(Z9!F$[<\@" O)WKM.L%N=LWH,
MB&$68A@VQ#!4B,%2<\.W$,-@B.E^MAQ F?"BXQN"BXXE&@8?\."7_Z@B>NGQ9X$/B["+_/# M=CU@-SLG_Q@PE5B82N!CK@-J'_7@"TO-
#7^C,0<^^#JP OSC+N\- )FXSEK> M2N"^FEUPF: >?F&IN<%:EDM@EMOWSC7Q.V.\7$ FKGN6DA+X< I_,>JP>P+[ MUCG1QP"NQ )7@MV9DZ
>G&&IN>%;>$M@>.N2=K_CQBMUR,1MYK-XQ&$\VK7L M<%08PE)S@[4PQ&$8VG?9X;L9"#1QW;,,Q/=GH!MSXPQLX19;.(PM0!Y\"@ELL0>LMG=2
M<8LK?']U; #FK/$A9G!'S(]9+2/FQ3 W:H<*/@4/"XI" S^$.J'?4DSDL-3=\ MBUP"/ID[L +\([E .U? "FCG$AN?G(*[G7=AHD ]9,-2$N2;;&WG$I:
Q/Z=S%W7GPY;&K 7G9-Z#&P2%IL$=@^T0#U&PU)S/TIH M:2R%::Q#VE._D[LM1/3YKO(%A_Y\3H?U!+ P04 " /&=9%:U. MPZ(% #%)0 &0
'AL+W=O/E!3)2E2F M2NGY)9%HW7-Y#WG$(XDG-T)^5DL C6Z3F*O3SE+K]&6WJZ(E)%0=BA2X^64N
M9$*U.96+KDHET%D6E,1=$@3];D(9[XQ.LK;WRT$]@>00R1MA#4_%O#&.+8(IE^?"E .V5.&[AY M?(]^D15OBKFF"L8B_IO-
]/*T<]Q!,YC35:P_B)L_H"CHR.)%(E;97W137!MT M4+126B1%L.E!PGC^G]X61&P$&)SF %($D(\$A$5 F!6:]PKR:T(U'9U(
M<8.DO=J@V8.,FRS:5,.X'<:IEN979N+TZ((RB3[1> 7H"JA:23!CI-%OZ"V5 MDEJ*T=X$-&6QVC>M'Z<3M/=B'[U
C*,K%L=F*-1)5YN>6+QN5&0]S[.2[V0= MHBO!]5*A5WP&LWI\UU10ED'NRS@G3L II(H1G.]6:Q3=<,RFMJ-1R5-1PY:_C+]
^]$90W]9]YE5'9=5';N5>ALM*5] IL,I<"8D>BNT4>S$ M+![FQME'W]!8\#5(S>PU$[C63>4ZT[0=9T]@-4:&)2/#W2IBZ),I3V UIG!0 MV8S
JR8*N..Z)L@#/;B3/K>H#>^$?TH28?"#DG#G:3O2OM#JK)"*%;);613Y M?;'E":W.5N44L=->M1=&#H?)@]4"DZ.'XMB&K\.5L<-/.+NGUHO>CXK#F:?U
M<'M"J[-2645\M&-Q>#6U@^T*K@D3OKFV6S(%=\G2E%=I[ VN($=DW&O'V1._N5^L9L@W?2BK? M2GH[UI-7/^L+K)^]WG1?E"%HDY@LT9I?
(9Q>V,:N0A1^YO+#HX"((' M*XX[_W/KJQPH<3M0WYKZX5<"[GZUGB7;,+RD,KQDL&-->36[OM#J;%5FE[C? MM/Z,IG+DHR?6\^@;?
CDL/+)8;#C[X]>';0O MM#I;E8,.W:]QZWI3Q;2:?>?&7(#5)-9[)#%WRN>65-GM
MI\4V['2X\0U_UQ_Q_7[%WX9M#BO;'+I?]]9%9']5]B#*YE1C];U']H\,'NO( MJ[WM;FR424 NLOU#"D5BQ76^9Z9L+?9[AO(3+=)LV\VUT%HDV>$2Z
RDO<#\/A=F.2M.;()RY];H/U!+ P04 M " /&=9*I,"9\# !A#@ &0 'AL+W=O;/%R#N<,AT/.9"O5-QTC&MBEB=!3)S8FNW)='<:8 M,MV3&0H:64J5,D--
M7)UII!%.2A-W,#S1F[*N'!FD[SO4&S29* M;D'9V<1F/W+?Y&A2PX7=QH51-,H)9V9S5'S#K"OA3FBCUK1%1@,3$7S$:,7% M"JZMI[GAJ.$]?&)*%=/?
S=$PGN@SZOVRF,.[-V?P!KB !YXDM$-ZXAHRT"[C MAGMC;@IC@I\8,X8'*4RLX7<1853'NR2L5!<Q^SM?_?V?_?4]C<&K0 MX=6H-
NC,WO[FC[P/32H[(JMI'I2:!VWLLWNI]3D(2DAR"8;MSL%(>$9* 6'" MM.9+CI'M0J8$19L&N4$%)D;"[ SX :1Y3#0YJ5AYG*]L\]5F]M[K#2?NIBJ^
MU;Q7BA^6XH>MXC^C2N%>,M%D?2OTI5O<$5E-Y:A4.>HJK$==:NZ(K*;YHM1\ MT;JS=\(@L1J@;$BYD%'*A Q52-GSK$EXP>;
[E5CU>EY_[%V.3N*U==U7JKHL M55VVJ]*;D>X] ;@+8R96"/1.V#(504AG4-&5J^%?.&ZWAD_24%L3AMP0 ;GA M<&M4;I,F?[3:\=)
Z(BLYK)QZ;)Q5\$_[E)S1V0US;YW?#5XK8%"^TY7/$N MI7(M3.-5[_V0G8-QT+LX"?>&:4/?KTRK6UAYU_B_=D"?[ %=;%EV$KJO"MOV
M15^ZAUVQU5T4'%T4=!6Z>Z:N='?$5M=]?(7YK0^>7PK>@F%4C4K/.PW=3M]5 M;N41GZ):Y;6-ILQ+)A;O^;*WK)^N\ZK!/4XOBJ\'IBB8-
22X)*C7NZ#7@2KJ MF:)A9):7!,_24(&1?\94 Z*R$VA*:4Y-.P"954Y^PJ02P,$% @ #QG M6=+)\D47 P .@H !D !X;"]W;W)K&ULK59M
M;]HP$/XKIZR:.FEM( E=88#4$K96:J>J[.7#M ]NY5Y^OOY+JJ\X0#=P7N= #+S-FWO-]G618,'TLYRCH9"I5P0PM MUL._V;M2P+Q2?PD>-*;WR#
M]>1.RJ]V<9D.O)8U"'-,C&5@]+?$$>:Y)2(SOE6<7JW2 C>_U^QOG._DRQW3 M.)+Y)YZ:;."=>I#BE"UR'S9^V3UNNF%.V3+-XGV7A/
M9%O)C.ID1HX]_'NC^7Q%9W!IL-!?FK(1[3,;^R2+]TDVWA/95C8Z=38Z.Z]6 MV:ESUZD5)G(F^ ^Z5K0Y?
7B!K%!3EDH%)TZ!G4:6PW84=D_Z_G(S_(^ECMIA M)^INB\6/Q;K1:6=;:-S ==H-VK54&0E_XS$L4,W<%*+I_B^$*7M/O5L/.F?N M?7^P?][NC=H-
^S$-1N4<\YN^G*JNF:*6I"'*:EJ';\BBU4YJ90+(^?N*;Z3 MAAYV]YG1<(?*"M#Y5$JS7E@%];@X_ 502P,$% @ #QG6=>J\1#3 P M@P\ !D
!X;"]W;W)K&ULS5?O;]LV$/U7"*T8 M$B"-9,D_,]M 8KEK@!;+ZG7[,/0#8YTMHA+IDI2=%?OC=Z04U;88-]TT;%]L M2;Y[1[YW>O2-=T)^5"F
)@]YQM7$2/7/F^6J:04W4I-L#QEY60.=5X*]>^ MVDB@B4W*,S\,@KZ?4\:]Z=@^NY/3L2ATQCC<2:**/*?RCQO(Q&[B=;S'!^_8
M.M7F@3\=;^@:%J#?;^XDWODU2L)RX(H)3B2L)MYUYVH^,O$VX%<&.[5W3->[JF" MF4F3*?I)=%1MX9%DH+?(J&5>0,UY^
MTX>*A[T$Q'$GA%5">)S0?2(AJA*BYU;H5@G=YU;H50EVZWZY=TM<3#6=CJ78 M$6FB$T(I0GY#4D:\;7 MY-IHR30#15Z2!39J4F1 Q(K4$8)
[^DHE!828U]C029;?K+BHR;DHSP"3(B\E9PG2HR MYPDDCOSX=/[H1+Z/PM3JA(_JW(0G 1>PN211<$'"(.PZUC-[?GKDVLX_JS[_ MV]4/R(CJ5HTL7O1-
K7I!?D0W)&>FP\ZQT3")W&K(U0>7_F6%KKN"\>0KA3T- M$P^;5X'<@C?]_KM./_C!17Z;8'&;8/.6P YDZM8R=4^A3TLY,BN'A*58<_89
MWV%F#H4O+B&L2RP/7,+D7!".AR.:BZ8/+@'+VGU;VYR!V^G+7F^!QZB!;( MI :431-XP'\+"KY&6;F8WCYEG:@;'%'FB@J'QYPYHKK!,=;
<$14&_<#-6K]F MK7^2M<8)\"?:0,6$1-*0+:XE'DA.XS^)_:TO?IM@<9M@\Y; #@0:U (-_G5_ M'K0I4YM@<9M@\Y; #F0:UC(-_T-_'C9??8<_-Z,
<_MP,^\D:+C9UI[H7& M"IC@E@S0!^/M*"/UX8PK4<_?T+U!+ P04 " /&=9\7,GR00$ "! M% &0 'AL+W=OEJ+$F+POMBC= ME>R!]J Z#)0QPE:F9MM-
Y>VK8*-A S=2&VD."3E9 QTSB4:UMM M); P \61[3K.T(X93ZSY-+MW*^=3D>J()W KB4KCF,F?[R$2^YE%K<<;=WR] MT>:&/9]NV1J6H+]N;R6.
[((EY#$DBHN$2%C-K"MZ>4TG!I!%?..P5Y5K8DJY M%^*'&=R$,\LQ&4$$@384#+]V< U19)@PC[]S4JOX30.L7C^R?\B*QV+NF8)K M$7WGH=
[,K+%%0EBQ--)W8O\1\H(&AB\0DB J#^$P W![@O!7@YP,L*/626E;5@FLVG4NR)--'(9BXR;(T5L,3,XU+ M+?$I1YR>+T#R'3-
2DIM$:9GB%&E%6!*2CQ"N>;(F5T9IKCDH\HXLT4=A&@$1 M*_*!<4F^L2C-1I]3K33B#*1D5>3U C3CD7J#Z*_+!7G]Z@UY17A"OFQ$JA"@
MIK;&2DP^=I!G_?Z0M?M$UDO87A#/>4M%9UMVP3P%ZJL),"H$&/WW=3=J^)5Z1Y9NAGBCL=]N MZ7&1V_@\EI;&TH%(M,3_>//D*@ADBM
H7\:\O<[.=$Z=U9[(:LI-"N4F9['U MI$\!>B*K"4"=LBMQ^MFQ+4%.N[EII6^B_Y.]#]MV(I)WCUOW M,T;OSNS4B>Z+K:YCV3K1_1.M-?
FJ2^VN@AE^T2[^Z>7V]UK=BB^XQ_[O1GE M^?0IRY==%.UNHZJ6_T/H%]D>W[7P32HA\!!L6+(&@F^>>R;#EA7P?./2G=_) M<]X36UW-
LN.C@_,8O]?VK2^VN@AE T<[VZ.7-3 Y1]7.8V_8,'TSBHX=;_"$ MZ\L6BW;W6&=S_0O;FN[T3I[OGMCJ8I8](1V?Q_2]-G=]L=5%*-L[VMD\G;#;
M3QIOP\ZQZYLAP_'QRZA=.1\RAW._,XFF522"%:*;YI),R)=$ MDN_EN>?N> >.#EQ\DQN,%7A(*9-C;Z/4]L;W9;S!*9+7?(N9_F7%18J4?A5K
M7VX%1DFFE%(_#(*>GR+"O,DH^S87DQ'?*4H8G@L@=VF*Q/ MK#?*?/ GHRU:XP567[=SH=_\TDI"4LPDX0P(O:I[M_!F%H9&(9/X@^"#K#T#
M$\J2\V_FY6,R]@*#"%,<*V,"Z7][/,.4&DL:QS^%4:_T:13KSX_6WV?!ZV"6 M2.(9IW^21&W&WL #"5ZA'57W_/ !%P%UC;V84YG]!8="-O! O).*IX6R1I 2
MEO]'#P41-87HG$)8*(1/58@*A2@+-$>6A76'%)J,!#\ 8:2U-?.0<9-IZV@( M,VE<**%_)5I/3>ZP('MDJ 0?F51BIU.)5L9B9L#6X-TT01+,$56.@Z
M2G84 [X"7U8KB97*9*1^RM5J7W\C:$EHKGIQAQ4B5%YJ(U\7=^#BS25X P@# MOV_X3FI%.?*5#LC \N,"_#0''YX!O\#;:Q %;T$8A!V+^LRM?
H=CK0XS]:BI M[FL:2R[#DLLPLQ>=L?>KX%*"VY3O#(6?N2JX,%&J#08SSB2G)$$*)V"**&(Q M!@N3.EOHN:^.W9?I[ANY13$>>
[I])19[[$U^_@GV@E]L1+1DK$%+5-(2N:S7 M2RPKD[=@H30%IM!,%;TG3!-!$ 5S+DG6VW^]>U#FI%CJ.GO'=$D*9+[_:/) M[?N+YET
QME5O!/">$19I=HX:L-2@Z!.25#G%>NFTV;=M&2L04NWI*7[U+IY M/$B^MUL[;O^G&:?5>68CJS5S#;IZ)5T]I_VYX"";;+9(G:K/+8J6C#6B[)=1
M]IV]4BN*LYT\[;<9;4O&&M$.RF@'SIPV3P9=\/,%1 "Z) M!G@85(M1X(3_6:.M,6^A&\Q-QID)X45A%0"Z[MQ8I!S)@;7%#
[[BU"FD2&JT^*+#&GX"+.=5[/$XNK:"C_^PLIT@3;+7O0.?>4&LM*ZC.B<=> MMW/2%J=2L-\/!V>P54L'[#YUP+C'_10ZY_VS2[XE:\VPJ^4!NK>'%B9-
X:%1 MVN&PWSM.G$7,T0'58@"=D[C%<5,X/9[=?2]::%P?5LA&ZEXV73)SP=#&P#!R+U/EYZ[YTVAW&M,;M@Y[@J+V#$POW8/9RY!/R&Q)DP"BE=: M)
[CNZZA$?J^8ORB^S:[FEEPIGF:/&XP2+(R _GW%N7I\,;=]Y>WNY =02P,$ M% @ #QG6;:$Z.6= @ [@8 !D
!X;"]W;W)K&ULK55=;YLP%/TK%JNF5MK*AX$D'4%J$TWKPZ2J:=>':0\.W 2K!C/; M">V_GVTHH@W>]K 7\,<]Q^=BI9)>=.H51]X;HR*Z D\IS7
M4.F9#1M=>UD3"@K,'FJMB[DP=E,.&[)BZY' < /WP$$'2#X5P#N -@:;9596TNB2)H(WB!AHC6;:=C<6+1V M0RNSBRLE]"S5.)5>5WNH%!
<4)/J,5OJ0Y#L&B&_0<.9T"8I0)L]TS/UJB4Y/ MSM )HA6Z*_A.DBJ7B:NT&L/I9MW*5^W*P3LKKZ ^1]C[A (O"$?@B^/P)60: M[ELX?@UW=0[Z1 1]
(@++A_^2B&>TI#)C7.X$H)^7:ZF$/FJ_QORUA.$XH;E^ M%[(F&><>]=WR,/;TEC3Y3"@0E;'0G6WAL MX:8N[-,@G/JSQ-T/+8Q$1=$LZJ-
>:0M[;>%1;0^Z"IB35@N>@1Q5UQ)$@W5Q M',=>\$;>85B(_0D.QO5%O;[HJ+ZOM*+Z^N5HR_GX-8@.UO7#R73JOY$W$H9G
M$_\=>7$O+SXJ[XXKPG3^^KL\IC ^V+@(S_!! D?"9A,/S]XH= ?5R+P$WXG8 MTDHB!AL-],XGVJ-HJVO;4;RV!6K-E2YWMEGH!PF$"=#S&\[52\?
4O/Z)2_\ M4$L#!!0 ( \9UFJALWU2 ( /$% 9 >&PO=V]R:W-H965T< M!*L&,]M ^^]W; @B4I+MHC?XZ[RO_=B<$]5"/JL40).7C.=JZJ1:%Q/754D*
M&54#44".*ULA,ZIQ*'>N*B30C15EW/4];^QFE.5.'-FYI8PC46K.!/;*/3J7/KD UL:94TSB2HB;21*.;Z=B[ ML6JD8;EYQ966N,I0I^-%7D&NA62@R
WY0:6DYE]Y1PT95Q=X>SC:DXN+Z[( M!6$YN6>_YX1'Y[+Q\#@G*AU8> M',I=A.[(_8[:1 M5N#$[]\-Q]ZG8Y!O9':
''3(@74/_O'8K^37=UPB"PV9^GT,.7A+Y#&PO=V]R M:W-H965T[[[[/]EW:*OUH*D0+3[609A)4
MUC8786CR"FMF3E6#DG:62M?,DJG+T#0:6>&3:A'&492$<-,RR%+ONJ-9JE96 M<(EW&LRJKIE^GJ%0[208!%O'/2\KZQQAEC:LQ#G:A^9.DQ7V*
6O41JN)&A< M3H+IX&*6N'@?\(5C:W;6X)0LE'ITQDTQ"2)'" 7FUB$P^JWQ$H5P0$3CQP8S MZ$NZQ-WU%OVCUTY:%LS@I1)?>6&K27
>0(%+MA+V7K6?<*-G[/!R)8S_0KN) MC0+(5\;J>I-,#&HNNS][VIS#3D(,/27S:Z6*E@L!3!9P(RV3)5\(A*DQ: V\A3D]@\V)%'K6$
M:ZV,@4NF]3.7)4QKM9+6;VQ1CJ_0,B[,&S@"+N%SI5:&D$T:6B+K2H;YAMBL M(Q:_0.P=W"II*P,?9('%
[_DAB>R5QENEL_@@X!R;4QA&)Q!'\0@>YE=P?/3F M .ZP/\&AQQW^ZP2_W2OZTEMIF2Z^[U/< 8WV [GVNS -RW$24'\9U&L,LM>O M!DGT_@#-44]S=
B]IWD""RRYE.X"Z>8:U%P5^\AV<(F'@^/<<]C?) 'G0]UB@1\RBMZ;+BO=(_BA;(T$_RRHB&,V@70_E(INS5<@7ZL9S\!4$L#!!0 ( M \9UDM0#;XIP0 06 9
>&PO=V]R:W-H965TWSN-3X^\6A#V2-?$B+ KS3)^-A:"K$ZL6T^6Y(4\V.Z M(IG\94Y9BH6\90N;KQC!49&4)C9R'-].<9Q9DU'Q[)I-1C0729R1:P9XGJ:8
M/9V2A&[&%K2>']S$BZ50#^S):(47Y):(^]4UDW=VC1+%*') M&?)40A'Q/28;OG4-5"D/E#ZJFXMH;#F*$4G(3"@(++_6Y(PDB4*2/'Y6H%8]
MIDK1''(GEV HL$)$YSA-Q0S=?25700.'-:,*+3["I M8AT+S'(N:%HE2P9IG)7?^%?5B*T$B:-/0%4"VD_P.A+<*L$M"BV9%66=8X$G
M(T8W@*EHB:8NBMX4V;*:.%/3>"N8_#66>6+RA=)H$R<)P%D$+C*!LT7\D! P MY9P(#H[
K7QQHEP^H7/PA5'.P1EF["G.%F":TCR302KUFWSC3N5D@>\XR0E7 MT6VT@W,B<)SP0XE[?WL.#CX=@D\@SL#=DN9DM4Q<)V_
'*0I^%S9DX_)S.9#HMT MUT#'K2?(+?#<#KS/<18+/!A2 I_T_7O!+";TB?;=TU5@YCDP\IS.9GF:)UC(Z9(DF8C_QTJP=%1+I,$6
MA2,4NE[@A7M<=8%N@.#0T9/U:[*^D>P=%3C1,?-;S1E SY,#[A'S6\0&'@P< MMZ.)PYK7\(4F_LQC)CL8D;7<:5;R2I#9,J,)7<1$JQ)&P+>^Z#V!

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
MS.IKCVPQHZ5(DYP\,L#++,/LY8ZD=#\WH/%ZX4NRV8KJ@KF8%7A#5D1\+1Z9 M/#-;E#C)2,X3F@-&UG/C9WB[1%Z54$?\GI ][QV#JI0G2K]5)Y_BN6%5C$A* M(E%!8/FR(TN2IA62Y/&] 37:SZP2^\>O?!_KXF4Q3YB3)4W_2&*QG1N! 6*R MQF4JOM#]KZ0IR*WP(IKR^C_8-[&6 :*2"YHUR9)!EN2'5_S<"-%+@,Z9!-0D MH/^:8#<)=EWH@5E=UCT6>#%C= ]8%2W1JH-:FSI;5I/DU3*N!)/O)C)/+):$ M";G8X ZG.(\(6-6]\TF0C(-KL))=$YKL"C#!4 YS'XY7N9 M%')1!7A_3R1.RC_(K*^K>_#^W0?P#DC@W[:TY#*6STPA^5:?:D8-M[L#-W2& MVXH4-|"VK@"RD*-(7XZGWY-(IL,ZW1ZFFU*E5BK42H5J//L,WK@ ?S[(\(-P M?ZE*/6 [:NSJ9KWE!8[(W)!W(R=L1XS%CS] S_I)5;@FL($,=BN#/8;>DZ%H M92"O,ER!#:-V,DGX@ MG,LM(RJS,L6"Q/).E])$"3[L);($G%$FDK_K"RKZ!WRWQ^L:NEX G2/^JCA9 MJ O5!;AM >[_43TG0D7:/2$#?
<]!Z(BS(LP+/<=34_9:RMXHY<|X+]=RFRY9 MDF\ZLC7U#$=;&5*Q'82^]532!#13P6P7|"7<,7Z<,FL &,@2M#,$D.T9P MTI:AO.6LH^8]C0I0<&Z_"%O*X;_L%](:;&D:@R0K&-V1BJJ2Y"C.I:ND"6Q0 M,K0Z*V!-V*X-N"8E=*$-I>BY(CA)RS:P_6[T8>@>]ZPBS//]WKX|I-TY%#CZ MS;]XJ+_)Y-]3F:2QW';5)+5Z$5UHPY([-P+M*9MVU.M<+(4FM*$4G<>!XR;G MS4U[ZEE\R_>.78(R+(3GFK9S-G#AMD!M)TS/=LY&CAN M:98TYX*5]2CB.LFOI4?82'G45$>A+EXO36C#PCM?!,,I6U>K6]*%-IP&='8) MC7J0-[=N SOH27T#33FP9V.$IP[6-CJPIS[3 XT[2=M4'CUN9CR?)$ ME(S4A-?)9T3=#N6Z8;R'EY+;=0X)N55#G7>*O6 M;KE5P)>54RY<_5Z!T(>)@YS3@^> MLO5&FP?N=+SE:YB#_K9J5'CG-E&660Y%F' @AX'[^C@O=?!/SKX5:(U6976/==|.E;R0)2QQFCFHJI-Y8W9 M9(49QKE6^#9#/SV=@=(XV.2."UZD0.;5W'G0D)?DBLQQUBQW HA;$LQZY&2O,M-ST2 MW=5$7@_1'+;7Q*>?B4>]P.(^&W:_AQ3=6>7NOW5WL39-@;RF0%X5S_\/!?KK M=E%JA3/Q;UN:==S 'M32+T![ )X7%@I1]WO1R./MBB[5D$0A9&=,FHHHV%*G(W8P;-B M78WV5LD5E$9S$-FLBRRU%S;J(GMQT)ZL72N6A'YL1XX;Y'@0>5XM)@5ZIXPR M5JO7AAAW/NX%81"V$"U6-/!#.V+2(";#B"BSIY*BVC]#7>"!*9#88/VD!=NU M8D$4^'981L^:1M^UE+)" Q946T6(=@F]H%-.BYD_"GH1+V27# <_3G5)0:+*5 MJFI-*+ "<#M"Q%E>K=C;,@49;7< JQDNKQLLQBR0:&9/A1[I);]J4J!0%%8
M#DZ"8["WXTM9I\86,S^)^F#/LL6&=>LT#7"/)/A"JEH$X,4(0D]U?4MKCVD' MV&*&:?7T 786+3:L6F?@ O<5M;9>9<45=K$USF,[-$AJT>ZW%*F1!C\BR MLV2Q]VG6BJ>G+>%@>;O"% :=IF"SPC[7T\+86;_8L(#=@\KVW)P:L#&8^N9F M 7YOO755*HR|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|NR/\=>P?-Q8/A[6|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|+O13.:N&7 M9(4S$9J*'*/PC9RUB2\1AP6B28'KF>ML_R;VNBGMATSWB ]JXH-.XO=< X9# M$SR(> RI(I1D( ,4<=%&ND1SO085I^?XKCLB'>PRP271 M,8J)11)N1>#]0,2*X!D*GD@F&:Z*EBR*$!].W:.;DL&XV:X>_Z!ODZ6;]QM MHSH&HY/$0$L:,AZ1D+XHE+M-)6V2RPD'#X2;LY/1&Q>-:|?@DBO&U@B O M[I17J!]_I]X_5-_)[XWJKVKU5S^AGN?I$K>SV>7E]8!;WVQU'K",)MLDA 4( M4^2<\3&%*5,OV EE&:4O[3RI7[_7J>"FT_%MXN%MY):XL*[E3B M3X2V+WY75[F=U" Q!96=0OVV[LQNBG[$WIF7;=U'*B,\X22!%;HZO1&F9UEV2N5 BZQH-I9" M8V(O'F/L+D$: _R^$M@T5 ,S0=VOSOX#4$L#!!0 ( |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|^82P@SN+9&C7<\3)TL:(:*^R>M5\(M[U@:I@U4U@W M+;"Y:_&NA3UH+Z.D[=]ANQ_K=;*B&BNL:>Z^:M9,:MV P.8.Q%N7V*#]AY*V M?W.:9[2#$=488ZV]LB-,:M#S56[J@U'FJLQNZQ\9#4E3\Q5_[OF;#-Z-XI);H>3BNE;2O2:O50C96F*M!8 M-1+?3&E=9!-C=??6Z=I,[9U-N[4.U#R?;:/6@T0S1H50M*\Z%H30GKXI>8B]_?V?.SFHFW:C IA+Q%GX,HD-J] M7]=F6.^W '0C BB-@M)|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|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

*MA3#G(SEJUW>K06Y&JK^.](NN!.^7DS.A7WX2>D\?[!C/@[K<6Z9GHM=?EXLT M*9-)7*?*
-0Q44.S1#K1ER>":T\Y76/ZR9:LV2C]6J#=;:CG+KB%73M56YOJ/< M/E0^K\KU=?GA=7&.T=:?<^^PYJJU,.[/1%]K/N=%7%8[Z@[%.^(#:A1MO^(?
ML6;]WB$E4"O?Y6*C'+$?AD>,J7?9;+N]8XH.?UOHJ6_4@=[ MU'_(>%:4,E\'BVTZ]R*(GXME4A8[AOA%B=6')^+13R4MYWJF*:0^9/LW/WU M+]I%
[^^[LH#$#!(S2ZPY#]!]1[AEG)6_'=7E S(*"$Q@\1,$K-(S"8QA\1<$O-(S">Q@,1" M$HL@K!4EYYLH.5<>D43+V:/,1386:7,@(L9)*D?
BS\,'8E^4]*FA0F(&B9DD M9I&836+.&CM?8?7YL*>[:N;T]#8IR,5Y).:36$!B(8E%$-9*BHM-4EPHD^+^
M*1()5'R=QOFL6L:R3(9Q6HA%.GR=P^R*"5Y:D20F$%B)HE9)&:3F$-B+HEY M).:36$!B(8E%$-9*D\M-FES24YA+,DI(S" QD\0L$K-)S"$QE\0\$O-)+""Q
MD,0B"&M%R=4F2JZ4!R;N?)S7*3)JSM,6HCX8^23FFZE-_JN4%'2IX8*B1DD
M9I*816(VB3DDYI*81V(^B04D%I)8=/5A0GJ^F9"VDN)ZDQ37_U=29.6T"HI% MG)@X;%1S4,U%-0_5?%0+4"U$
MM8C2VG'RI@U-.S).FF./3_4A2CS)X\54N+^+HX$+%85%.>*F-V=;5^:72M_V8- M>V>]_GE[+1_4HS@Y%$C-1#4+U6Q4U:U=1M MJ^\F-
MM3('666,9]/<,IXQ]R]6LJV7QGAJ"]K*AFH)])):M:!+;-_MF2CXW!0 MS44U#]5\5 M0+42UB-+:J;)M8M64C6UWP7*1S%6](^KZDS.#U Q4,U'-0C4;
MU1Q45U0S4:CF:Q\;0-|'4X N,42UB-+:4;)M=M74W:[UA9FBC%_J,(D7=3=:G-;7 M>9-
L=U:@W:JH9J":B6H6JMFHYJ":BVK>@;VWWQ.SU=VR=B8#VJ2*:B&J1936
MOK_8MJ555W=CMJ[1B#_%OU^>XZ==Z:%V3DT/5#-0S40U"]5L5'-0S44U#]5| M5 M0+42UB-+:>;+M:=4U^EJ-CC:NHIJ!:B;J6:AFHYJ#:BZJ>:CFHUJ
:B&J M19363A9]FRSJ'M=ZMI/+83:9)ZM3(]6D)\L7TW@N1OER(N3/8;HLDJ>D?/FD MF 2I%W)RV* -
L:AFHIJ%:C;J.:CFHIJ':OZ!K\BE>)%QOFM"%:#C"%$MHK1V ML&R;7_5#]VQ]BE5=:NKRDR,#[6Q%-1/5+%2S4U
-5"5(LHK9TLVZY87=U7^$N_TZ>V3\Z8C_>@O&A/K(T=;[ELO\5$QV2A MFHUJ#]JYJ.:AFH]J :J%J!916OO/<6[[6_OJ_M83SX"HM5.__ZAFH)J):A:J
MV:CFH)I[8']3G@%!1^*C6H!J(:I%E-;.D&U/;__8^[1NCBBR^22K9BY''5.H
MJ9,S!>UO1343U2Q4LU'-0347U3Q4\U$MZ'^\E>J@?;@;H@N,*&T='=UB*F5I MQ&5\=S.3^40^R#0MUG]2HOY3XV]>%;D[W0_O.YJGWVM?KV[9>YN
M%O%$AG$^2>:%2.6X(GMGE]5GE2>3Z>9)F2UN.]5:/69EF&ULO9I=<^(V%(;_BL;=:9.9%'\! M@1282;!WFDZSR82FO>CT0L$"/&M;7DG
;G]])=OX@Q@-;DJZ$VRC\TA^7TL^ M)V*RI^PSWQ BT-UX[1NI67BG] MK$[N@ZEAJ1&1B"R%0F#YL2-S$D6*),?QI8 :99\JL'Y\H'_;:E[>S"OF9$ZC M/\)
;*;&R$ !6>%M))[I_F=2W-! \98TXME?M"_:6@9:;KF@<1$L1Q"'2?Z) MOQ9"U (DISW *0*<

%G@V872/ MF&HM:>H@4S^+EGJ%B7I0%H+);T,9)V:+#69D0Z. ,/X#\K]L0_$-_8@^8<:P MLA!=>$3@,.*7|NHC"\)$/D[H,54N&ABP^7Z ,R$5U
M"PJA%*F(*]FP=CHQA;P'-1)S68SW+A^O ME-J5 CH' >|<+7!!TAYRK2OD6$Z_;3S_+=P[/]QM"??UX;]L(QENM_7>$,,M
MGR8WX_5/\)Y)NF7+C9RXZ(G1-<-QJ\5:B%H:;WB*EV1JR+6/$[8CQNS[[^RA M]5.;OI P#Q+F \$:3O1+)_H9W3WU8&Q?>1B$:K)2=IC7#T1L:
(#NDQWA@A#T MYZ\R"MT+$O._VGSJ0_H$"?,@83X0K.'3H/1IH)TQBWR)9.7$:5O3[K2,KD;D ML'$&4WG$;N;:=D]._UU=8<@N?
2!80^%AJ?"PH\+H0KZ"\G?399O:6EY7M7.8 M;=7D=GJC([$A>_2!8 VQKTNQK[5BW^X(D_DE2EFX)(BN#BG L?H!C2+,.$H) MRYNT&J'MJZL1.>RZYH-
M6SUK>&0%9)|^$*QAQ:BT8J2UXI-,TM^^C]MDUG*Z MR@P)\R!A/A"L8<:X-&/_J_C,:1/D# /$N8#P1H^V595#UG::?,;%3A".*;;
M1""\E0ZQ&^&Y:LF:O+:*U9:VK2PDBD6LWB ]/=_T(^AJ)"C- Z7Y!6U86W0' MEE6NN$V+:B6K#9 S%9!ZW_: ;]IV?L"=Y7V/TM>N:E];7_P^1L&9
M*:H>U/F5"4GS0&D^%*UI254LV\/W3U1#H:E.:!TGPH6M.MJMJV]>7V_Y&L M@A;AH#0/E.87M*.$|52V6I7AMKX./S-
;!2W"06E>06L(2_X>E;)35J/QD2%0O>:&F+5=W9BP=;;=SM%2+?;Y_F1YM=RRO\TVJH^NS^T;+]]XKS#Y M[P >,%N'"4<164FDU;N6R0?
+M];S$T'3;._XE0I!X^QP0[!\AZ@&|OL5I>)P MHCHH?^ P^P=02P,$% @ #QG6:;9]I2_!P ND4 !D !X;"]W;W)K
M&ULS9S;CT@I8@BRT/"DG929^^($6+!K6&*6('L=RU>':7%_^6 M:|XK\CE-LO)|M*ZJS>EX7"[6/(W*-_F&9^*;55ZD427>%C?C%;.S?%LE<<;?%:3QS?
KJOY@ M/#O;1#?\BEDX*OST04]#=FD=F@L_HCY7?G@-:D/ MY3K/_ZV?A,OSD5:/B"=\4=6(2/QWR^<)26J2&,>G%CK:QZP='[Z^IWO-P8N#
MN8Y*/L^3/^-EM3X?V2.RY*MHFU3O\[N MP=DUKQ%GI3-O^2NM=5&9+$MJSQM MG<4(TCC;_1]];D_$ P?!@1U8Z\#Z#L8C#GKKH
JU,%H'8ZB#V3J80QVLUL$: MZC!I'29#SY+=.MA#(TQ;AVDCA|W\-9/O1%4T.ROR.U+4UH)6OV@4U'B+.8^S M6NQ752&^C85?-;M:1P5?
Y\F2%^5/Q/VTC:LOY#6Y$HMJN4TXR5=DGJ>;/.-9 M5=;O+A:+;;I-HHHOR>_5FA?-]X)1+X!;3G[-RY*|='@5Q4EY(E ?KQSR\L4)
M>4'BC'Q8Y|LRRI;EV;@2HZ_',%ZT([W ?J/VG M^O^Q.&O[4\?N3]TE4P*O^.8-T;57A&G, ,8S5[O_LV4[H[:_6U4"'?ZJ+L[ M?/ ZX.X-'SSD[@\?/.0>?-
V9#Y]]()0]/T:TAN>_@@OS!9BGREY+?O=JY-: MZT^M%.&6I*I7C$GY*_W>9(0<0&_BXEW#RV W"@ =1;XJGY29:\/.1B%'R MXI:/9C_ ^0"WM9TB;F#
'$^9BPCQ,F()"S!A(1),4K^Q5[^AHL\N^4V<97%V M(Y*.),H6'-+N#F$UB#K_NIWI$XN9T^G9^/:A+ $[:VH9%I7M'(@G+*<3V;A72Y
MB7>7FVLN,F0N\M1%$I5EO(H749UU@ANR,LBQ5QQ,F(,)MY92MQ=IOJWSS$Z=8N]<%7DJ;HJZS30'U)V(3122 ML#+>L1+&A#F8,!<3YF'"?
$Q88!U(^+6A&7T%(X64%#S9*WCRW"OORUJC)Z]( MQBM(J9/#Y6D;MMX[N/FAV6O3UO7>_@A8&2)7[F^/@!FUQ/YC];;'0SM*=4/K MX7S
S##%)::W.0)'JML3LS^-AV93C5(-WAGM_?S8ROD1+W]/I"KV05B#3JAF M]0YV?F@'IC0.8 >E-"Y@9]A3D3;TY@*P@U(:'[*#4II@X/&&3X]/FI#I?D*F
MR@GYD%=1,JBJ $V6DGWLY1T3YF#"7$R8APGS,6$!)BQ$@DFBIEI75M. ^AYI M.PJD!8!*1U|*"\3+ ^^.M RI#S$MFW&^GLN;,CT M:>_ ^VP$-
#48/,B#0T+)LUM]V(<.IK;%^@N9#AI0RT]3Z>=#0089#D/+|L&Y^ MV#?*5UOPDPDK8 =EK) 9E+)"=F#."AB"22MD!V6MZA-Y]+)$HLG3WE6LJ;(D
M." -;@'2>;8T7>^7L.:MH?74XG4@(K1X78A(-=W4^[FU!\8&5J\/&4*K-QAZ MV.&00700)^/*FGK:+ND,<5S&' MVVA*^M$Y
2;-0:6YJ#0/E>:CT@)46HA%D_7=%:>I^5WDQJCE:U2:@TIS46D> M*LU'I06HM!"+)J^#KMA-U=7N8;DQ:@4;E>;0PWHLT\W^;HY:FT:E^:BT8,CI
M"+%"RIKKRM/TV?7I8SJ#ZBA'JQ*3YJ#27%2:ATKS46D!!28NJ6U*!JF)IQM(11 M?
P7!H&:4P72[=POMHH;U4&D^*BU@4,L/."4A5EA9>UW'C:D[;DA5,764H]6) MVGE#I;FH- ^5YJ/2@I8F_]D\9;1_7X85559PUU-CZE]\X-?%U &/%C-J^PR5
MYJ+2/%2:CTH+V.%O0/HU,:R LHZ[GAA3J\2>7Q-3@X_6*VJC#)7FHM(\5)J/ M2@L8T%$#+[[?HJG&NJ8:4S?
5!A3%)H>YH:51:AG]LAAJ*PR5YJ+2/%2:CTH+ MADY7B!5V)[SQ@^@D-V;*M\T3Y&XSJLJ3YN7 M:QXM>5$;B.]7>5[=OZD#[!_7,OL?4$L#!!0 (
|9UD2VQ/-ZP4 +HC M 9 >&PO=V]R:W-H965TQB;#J3="+>X[NE8YU MKX0FSX1^9UN,.7@I\I+=#K:<[VY&([;:X@*Q(=GA4GRS)K1 7#S2S8CM*$9I
M#2KRD6U9J A 63F83NJV!SJ=D(KG68D?*&!542#ZXP[GY/EV >O#5^RS9;+ MAM%TLD,;O,3\Z^ZJ!BJ=1RY)F!2Y91DI \?IV\!'>+* K ;7%7QE^9D>?
@0SE MD9#O\F&1W@XLZ1'.\8I+"B3^/>%[G.>22?CQ=T,Z:/N4P.//K^SS.G@1S"-B M^)[DW[*4;V\'XP%(\1I5.?]"GA/VU@"L*L9)T8'"%!T56
M[O^CEV8@C@""1P^P&X"M MPS *. MTK@!C"_M(6P 82V'_?S5DS]#'$TGE#P#*JT%F_Q0*ZA&BSG/2BGV):?BVTS@ M^/2S>)\6Y8H4&.PP!7_0-
"N%Z,%RBR@&'\!2O%UIE6- UN .L6P%4)F"6997 M'*?@"/W01=^38E=Q5(OZ[0QSE.7LG>#\NIR!MV_>@3=@!)BT9" KP=E;WP63_\$Z("#L_"H\N=
M=S3P^>7.Z^#QY<[KX,E_&_G%OX[]1 A.^_XY-9]S[OVK"DP1)_1&I^H]UM5C M91Z\83NTPK<#D>@8ID]X,/WU%^A;O^DD99)L9I(L,DDV-
TD6FR1+3)(M#)&= MB-9M1>OVL==)(ZN7?9UH]UB_QLI:ZVEJ0_RO,GHZ5B.73/HCSU_?&HVZYI] M@*X%;-(P^;Z8]LZ-
9MKS"S7=12VN&OFAZY*EG2M'#^T+"70A<;,MOS@T.?) M"CM"B]E&DY*SD68Y-DB6[T Q\J^M)8A:$']?+R6WGY%[[B0.RH0"H+/K$KJ>62'>I%\EKQ
MU66;3D&^9C7PK;&C:*C7FVLU9)(LZ@8 /3MP5!69[#,V299T W"",/!]148: M,]?R[5"OHZ#54=!;W\QP2<2VY6R%$YBL<$R2S4R212;)YB;)8I-
DB4FRA2&R M$]F.6]F.>Y>_;_4A"4X_()%&T08K"QT#%1-95FQ*Y2)8-X$5RE=57N]VF=CD M/M:;Y;?"9(]XIU/_N+-T^]"%KK(V]KIZK:Q-
DD4:_QVH^C\WV65LDBS1^&_; M@5K Z:+TCA+ B<+"5F%AK\)FKQD5MX4KO7 MG6M59)(LZKH?>+Y:N9OL,39)EG3===P-;+=*ZA1///9-
;H74XO+.N%E&QR\D/ M+)K^KC+^0Q9KN*QMY,'=KJ)"8TP4;SDJ?ZJKIO>3T!Q55_TN7BLLHVR1)@ ? MAHJRC'89&V5+- %X4%V?-$;!V#NCK:.#8?
@_I\"T.27^FSTKMT!I"3/$66' ME5*_#N[I@N,=^+"3;8V>XAMEBS0!V$.GLP@:/: WRI9H(O"&ZC*^T%I9YQ+N MX5 =]I^]SX[2Y86*<36*
<6U5,KW=7BT9DVR1)@)[V-E &NTS-LJ6:"+PAGY' M,ETK=^@'BF1&1[_C%YANZDL@#*Q(5?+]3XIM:WO1Y&-]O4)IOX,W,=2T)_)B
M2GUOX$"_O]7R"=%-)JJV'*]%5]8P$!F>[B^*[!\XV=6W"!X)YZ2H/VXQ2C&5 M!N+[-1$[U>9!=M!>UYG^ U!+ P04 " /&=9\,Z\|<" !@"0 &0 M
'AL+W=O$ \N,EM8\T?P7;:|>^QG2QJI38PU =>$MOQ.;GG^%[:HXU4 M#[I -/#(F=#CH#"FO Q#G17(B3Z7)0K[92D5)\9VU2K4I4*2>Q!G81Q%2<@)
M%4$Z\F.W*AW)RC J\%:!KC@GZM".K@KC!L)T5)(5SM'!)#CDE3,W,G- M>VST7#B^3#+MG[!IYD8!9)4VDC=@&P&GHGZ3Q\:'+4!O< 0-X#X;P']!M#W
M0NO(O*PI,20=*;D!Y69;-M?PWGBT54.%6\6Y4?8KM3B3WMA$F8E,$(7P&FZ(4L0Y#:=3-(0R_+ '/NF&?ZC8(7AH
MK6G]B5M_8L\W.,#G:.!&&MPKI1/K"O!2ER3#<6 K3*-:8Y"^?-%+HK?[A!V) M;$=FOY79]^S] S+](LZ$-JJR)6K@^T<[ 68&N?ZQ3WC_F,*/1+8C?-
*'W2N M[TPI7,N,N$QN]Q:[.8)&8QAZ,SB:0N:PI(]GKO0HKSAD1!>^8DYZ9U$40:FH MR&A)&!
N*V'VF59'DOA(W.ZZ3GNC<+WM1&>L_^C$1>O$Q9\R/3F:YIPXZRJ9T(M\X_=_?X1-2* M"@T,EQ83G0]MPJGZ/*|
[1I;^2%Q(8P]8WRSL%0B5FV"_+Z6M@Z;C3MGV4I7^ M!E!+ P04 " /&=9UEG_=! # 6"@ &0 'AL+W=OAF11$P6+@C3J] M6=?*.X$?
#-9Z8TZL)S=2WMK%>3KP FL0<$B,9: XK& "G%LB-.-WS>DU*BUP M<_[_M'YCK[<4 T3R:]9:K*!]]XC*2QHRZ7_GN M C>EA@[[2JZ)LM+
(9B)S($4H,A7E3*! MYX7,,ZJ ')$Y'LRTY$#D@ER[J$-Z-%J!PD.T):W)["[A90HI62B9DXG,B])0
M=QX0/66\1##9T'B)&BM%!U,PE'%]B"IU158/3)!OF2PU%:GN^P9=MH;[2>W> MN'(O?,&]B%Q(83(T3:!=+?CI;OS9#KR/H6[B'3[$>QSN))Q#
<4RBX!T)@S\1N ML6?R>GC4YL[_:9_]L_8GP8B:PQ<'D/0.!WR>IT+2%Z71;;/9<* K.'H4JC_V-ARX'M70=AB:)+(6I MRDZSVS0Q(_=V;^V/.
[U)IV5_BDU/U:,\TE<=TP552R8TX;! 5<'Q*9]JJBZD M6AA9N&?V1AI\M-TTP\8-E!7 _PLIS$?4$L#!!0 ( |9UGJ MO9*JT@@ .-- 9 >&PO=V]R:W-
H965T;F=W]@6Q%9LI!A=P$O?3K\". M90F9M=?';Q),_OJ!=/")_NC [4M9_5$OE&J"UV5>U'>C1=.L;L;C>KI0R[1^ M5ZY4H?_R5%;+M-$?J_FX7E4JG76-
EOD8AV$T7J99,9K<=OL^5I/;7+W0B-WG9\RN:+IMTQGMRNTKEZ4,WGU<=*?QKO*;-LJ8HZ M*XN@4D]WH_?H1C+6-
N@4OV7JI3[8#MJN/);E'^V'GV9WH'_](Y6K:=,B4OWK M6=VK&I)^CS^W$%'^V.V#0^WW^C?=YW7G7E,:W5?YO_,9LWB;L1'P4P|I>N\|
M^52^_*AV'>I.<%KF=?-EIPU$P7==-N=PUUF>PS(KM[_1U-Q_'#33'WP#O M&F"W 3W2@.P:D%./0'<-Z*E'8+L&7=?'V[YW_R?
2)IW<5N5+4+5J36LWNM'O M6NOQRHKV0GEH*OW73+=K)(_4LRK6J@Z^#1[T13A;YRHHGP*1U>E\7JEYVH53 M[]D)@Z^$:M(LK[_6+3X_B."K+
[X.O@BR(OAU4:[KM)C5M^-&GUB+'T]W)_%A M>Q+XR$F0X.>R:!9U((N9FGG:B^'VR4#[L1Z0_:C@MU'Y@ >!#VKU+B#A-P$._M,?
6\6OAWW_7TN"G1BWK__BBON52 M/[=-@3?U*IVJNY'.<;6JGM5H\N7?4!1^YQMR2)B A$D@F!4_LM]@5AVS[JVK?_-
IXG*&0TB9+;\?/A^/9U28P1#6V9Z,MPPL,XCFV=_M].@XQOC@L%9_V;Z_;+"_GXNL4;/@H4D;?W<'FY)[S4'"'"1,_L&L&$3[&$17 M2@@19'
@80(2)H%@5G#B?7#B"Q/"MCT[_*(S$O7R05_&.66Q(Q-]&8YX1'GD MY./3L-HB/SY@.^[RP>[*]>5GC3[NCG8[MQK#1(F(&$2"&8-?K(?_.1*B2"'! M#
XD3$#")!#,,"@X*S=0^O# 5[_"'W\HX)H@[J< CBW@2(R<5>&28A!P[.NG1 MH82BA/M3 3KP,FBPP^_S/"B;A:|\?1UL>^XU!TH3H#0)1;.C@$T4\)6RP@X,
M%2)(F@"E22B:'2+CZ-"@)SDE,Q#/=SGAV,T,?1GB+'%-@T<6$1J';F+HR_1$ MXD!F=]=X)#1LDCY6Y6P],8(ZS57]35"HQMOE0Q<(A=_M*T&
NCM0F@"E22B:'2+C\-"@1SDE041]&Z'G\&'L9@B/CG"2<#=%]'4X3IBV M)FZ2\ FC)
KID31AG!,ZQ3K]0VE+44\S54R]OF(8#Y0F0&D2BF:'R/@_-.A@3DD32=]AA#C&U$T3?5T4LY#W/$9?AY(H MYI2Z::(OQ"'BA!Y)$]C8*CQLJW[?
O*3/OKX.MSOWL@.E"5":A*+9$3_^#Z,K M908,;@)!:0*4))%H=HB,"<2##N:$S+ #''Y!">})QY/8#_JX*#[NJWS>56GJ["KH0!DH3H#0)1;,C8(P>IM=*
M#*#F#Y0F0&D2BF:'R)@_/+R_=T)B8+WO)^,(N3,&CPQAAI![[\&GXY1A=X'" MHZ,1"<,C"Y;8>"D\
[*7D*IME9:Y>Q^W6IMWR=AMT<0R4)D!I$HIFQ\/8/!Q? M*TF 6C]0F@"E22B:'2)C_?#PJMX)28)[UA,18^[2A4^'2(Q<7^'114E,XEZ6
M\.A"JJPZ)^/L2'BES$! K1\H M38#2)!3-#I&Q?F1XB>]_9X8=P/H_SMQRA'N?*L+.S4OA4>GD$;KW&GPRRLB1
MT@9B3!0YQ43]4DS+O)QOO)T%73$#I0E0FH2BV:$XJ(&\6A$D;!4D;!DD;!WD M-:/7%H*N0-8DP%.8^9:"Y]._Y?O60N/CJ,D0MC-
#WU=3!$+\9$$8[/131">ZL@$T_C(O0=BC!09 M-E+_4JN_5#Y-O7T%724#I0E0FH2BV4$PUHY MLD;E63F>Z:W'JFRRF7?
^,,PYJQ($I0E0FH2BV1$Q9H]>JVR2@II 4)H I4DH MFATB8P+II663U%/HR'BOH HCHW%,>L];:>:HK&4\0<[.$1T=P@N(C6>+@X;)A
M2_7;YE65_HZ"KI>!T@0H34+1[!-8BT>O52Q)09T?*$V-TB04S0Z1<7[TTF)) MVJ]9)))2@WN3!4]J8\-Y=28\,:5=!W4('KRYD_-CDP?@H.NRC?*

CGVC,5PN[,O M.= %,E":A*+9$3"^CEZK-I*"NCY0F@"E22B:'2+C^NBEM9'44Z*(<>^Y;(\J M<4P;%;S_(:C*
M39HWF[&8HPCMQIA$='HJ.KF\RX*3;LIKI9Q#Y) MI,4LF)9%4Z739G@00-?30&D"E":A:'9\C/ECURJF9*#F$)0F0&D2BF:'Z.!E M*)<64^X
A^]AB5'(W(S15]'><]O"H*8,;=$RB-#$2+N&PO=V]R:W-H965T M6:^TZ[M+EBLL.>SHN\1+FP+^6MU2T[$8E27,H6$H* M1&$QL2[=B\A5!
(7XEL*6[3TC&.:?^004O@KG'#&8D^YXF?#6QAA9*8(7&;\CVX]0!W0F]6*2 M,?4?;6NL8Z%XS3C):[*809X6U2=^K(W8(P@=/<&K"5Z7$#Q#\&N"?
^@(04T( M#AWAK":HT.TJ=F5CBG9(BK10DT^*/<56_B5%G*AS#D5;U/\X],[V$"Q M!H9.T%PLPF2= 2(+= LTAH*+I2);7PC'&6J@"TIR-%-S \K040@U5-
UGMFLCZZ(05?,105"20:?MC/ M'_7P;6%T8OF\W"N2VHO35;""U;B&":6*4,Z .LZ=LW[KGS7N>H2;'01%AD2*SE M?
=!X'RAU_QGO_]Y=Z,=G@4'7""+V4Y>5P&163(J%)L4B0V*MK)PU63GKW1'M M*LI5;,2[VGB$&<*HK"#'N@Q5XD,E+K_P-U/G-/#&]F;?>2UHT
:%ARA%6M"H M ;4<.&\<..]UX";^\(R10A=>+_.E"]"D6&A2+#(DUK)_T-@_,%T6!B:S8E(L M-"D6&1)K96789&7XFF5AJ-FGKM\I"UI09\>'AX B+:B+ MK)?
TTK5G4BPT*189$FLY{SI//_@=TS6A5C24&*-]H5&UR)1:.S=[AS'W-2M# MK=[9JYW*H 4YHTYI. @5Z5$#1_77K17VWFE5G R7ZI] H9BL"UZ=-IK>YBKB
M4AW ._U7[L7,U?2'\NI"G8Z?Y*M[CQM,EVG!4 8+,,91S.A"_>6AUE5 U."G5 M6?F><'%L58\KP E0"1#O%X3P74,.T%SH3/\ 4$L#!!0 ( \9UG=O^7* M5P(
!D' 9 >&PO=V]R:W-H965TV7-!L=)=D;JR$( 3 M*Z*YZWO>U*68,"<*[-A:1 $O54XB& 62):58G):0\RITALYY8$/23)D!-PH* MG,(6U-
=B+73/;5T20H%)PAD2L ^=^^%B.3?Q-N ;@4I>M)')9,?YB^D\)Z'C M&2#((5;& >O/ 1X@S4V1QOC5>#KMDD9XV3Z[/]G<=2X[+.&!Y[])HK+0F3LH
M@3TN<[7AU2=H\ID8OYCGTOZBJHX=31P4EU)QVH@U 26L_N)CLP\7@F&7P&\$ MON6N%[*4CUCA*!"\0L)$:S?3L*E:M88CS!S*5@D]2[1.11LX
"M!HG?H"Q8" MFSU";QY!89++MX&K]!HFTHT;OV7MYW?XO460/*WWM5L+:!_!ESZ MO89;* 9HY-TAW_/'/7ZC-N&1]1MW^*T((]2DUS+K%9I_QT(6.
(;0T==?@CB M$[U^-9QZ'WJPQBW6V+J/.K">",,L)BQ%F"5HC4_ZXBOTX[,.0*J/QYC7A\ M ^))2SSIW<@SHP)!Y1T2F*5PC;'?
9>2A!)JD#\^TY9GV'RP^=AULK_ ?MVG6 M8LUN<+"S&Q#/6^+Y?SG8?I?H/_@W8MR14&DMB4+%/.2J;IRM:-MW;^ORJV?
M\/K16&&1$B91#GLM]08S?=M$78CKCN*%+7X[KG0IMWW.NSAVS M0/L:1K\!4$L#!!0 ( \9UD?%B8;C@0 .P7 9 >&PO=V]R:W-H
M965T'JSGZXU0#^SY=(O79$G$E^T= MDW=VQY+E);EX3BO R&IF?837"?2508WX+2=[?G0-U%(>*/VJ;FZSF>6HB$A! M4J$HL/QZ) M2%
(I)QO%72VIU/I7A\?4S^_UXN5B'C G"UK\GF=B,[,F%LC( M"N*<4_WOY!V076 *2UX_0GV+=:Q0+KC@I:ML8R@S*OF&S^U0AP92!Z]@=L: MN$,#
[XP!:@W02SUX8'W4@]^;U OW6[67@L78X'G4T;W@"FT9%,7M?]UM=0K MKU2A+ 63O^;23LR7&\S(Y8V4.@,+6LKZX{C.X"58RJ+,=@4!=_7.PI(G=4W
M^Y@(G!?\@S3\LHS!^W\Q3TM;(PTF-7("/'14'3IEYD+=V3 ME*ZK_&\)NR,LIPK-!0=__"H]@%M!2OZGKEB:<#Q].*JA7O,M3LG,DAV3RYB( M-?
_Q!Q@X/^DR99(L-DF6&"+KY=3KDL]SOTH#)RI_7@LOP850.CW4?$1"H;AQ!_ $AT,1<[!9T\+ MO]/'"]7BMI)K)T N$SR0BJQR 5:,EO^JCDZ4QI-
_%.$E=&$T5$4#B\+('BB M0;F^"R<#572PR$=(KTK0J1(8J9!*[G'D?_U,D00GL7FA'P[ET* "Y**!*AX)0+T?8R1&.RK&4.YR\6E^ M2P1)161;SJ
,_FBSKE@6&V" M=.L?)7UM*S-)%ILD2PR1]3(SZ3(S>5NOIXG)G)HDBTV2)8;(>CF-NIQ&W_OU M%)VT 11"!PXZCP8E>\]@P\:G*
A=SQ^0)3H8@D=OL9X6T#GLW)U1->ZEOIBE MF[KG9.11#GU;.<()[49[E.JUU6F4+3;*EIABZR?E:)R";ZOMM/&8RJQ)MM@H
M6V**K9J9]Y!9]WLWG]9#KQ5,(G>P55GH8$& AKMC#<4Y;EP.(%]4-!!H3?L M/!H81%%TZ#SVT>EE2=BZ/C;FD#%8*6]>6&X(PP!9"_ MKR@5SS?*07?
/_\'4$L#!!0 ( \9UEK+0,\% , %8) 9 >&PO M=V]R:W-H965TB!UH:6T0D425I._[[DI2LVHYB!&TN$I=Y,^8 EV%WP_B#2!$E/.99 M(7I6*F5Y8]LB3C$GHL-
*+-3,@O&<2-7E2UN4'$EB0'EF>XYS8>>$%E;4-6,3 M'G792F:TP D'L<5N-2__?;,_9/1KO2,B<"ARS[01.9]JPK"Q)5NEL%U[O9_E MIS;7[J')Z*F)Y[I'/,,67Y?
>56-TH#5LM(8GM7[6,B$A$F%!*()2"%C,_Z/C^41K:V*XZ_E&VQBUF0=AQPJ-4 MV'N%(D>^-!5:0,Q6A:R.=#/;/ +ZIO8=C0_&PO=V]R:W-H965TU0-
3PE"9<#;V% MUMF%[ZMP@2E3+9$A-V]F0J9,FZF<-RJ3R*+<*$U\&@1=/V4Q]T:#_-E8C@9B MJ9.8XUB'GJ8IDYLK3,1ZZ!%O^^ ^GB^T?
>"/!AF;XP3U0S:69N977J(X1:YB MP4'B;.A=DHLK>F8-\A5?8URKG3'85*9"/-K)EVCH!181)AAJZX*9GQ5>8Y)8 M3P;'/Z53KXII#7?'6^^?|^1-
,E.F\%HDW^)(+X;>N0<1SM@RT?=B_1N6">4 M0Y&H_#^LR[6!!^%2:9&6Q@9!&O/BESV5A=@QH)T& UH:T!QW$2A'><,T&PVD M6(.TJXTW.\A3S:T-
N)C;79EH:=[&QDZ/)@LF\?3*Y!7!M4C-9BN6E^L4_F!2 M,ELS.+I!S>)$'<,GB#GX]*RSC4 MIBH3+
<)'>."Q5G!T/WE0Q_OR=KJSU+I0&0MQZ!GN*)0K]$8__T2ZP:\.L)T* M;"?WWG;NX?3E'EZ:#>1S-'32,-W [KHQV^2/+]=,1O#7[\8E?-
&8JK_W9=V;$[B=C,? > 3*[@2(3#?1] #2 MSX'8@W4U:G=Z+3KP5WOP]RK\/2?^;_D1A=$I6Z$T1VY94L"G#,,2^12A3G(? M,G<(6A0;>I
61.]"Q#:NXI]7X,^=GL3PZRHX3D\/1X)0;)^0&=+3V,:+W"#T)K M_/1=&0+_&27G<;I,]R;B#/;6=]KUE[0_F"[D$))-:LTF3M$<78:+&%=%'IK)
M.>H3VW"AF=O>$S-@-@T%"3;H?W47.3X:W)E@K.G'K[;MT4>]/%%S5\;)!:K(E;K6_3+!$;Q*)C]D8]
MA!B36HW)1\LQ.80>TUJ/Z0^CQ_2E'O=;I/_L;W]#T5J_M12LX;.]_?N6E*T>B-O4]3IHI+KHM+I^II=6=W6=Q4 MU0D !D !X;"]W;W)K
M&ULK59=;]HP%/TK5]DTM=)*0@*E8Q")KVV55@F5 M=7%N8?2"[&\)EMH/WWLYV0\9$BM/4EL9USSO6YOH[=VW#Q*!-$!4]9RF3?
M293*NZXKHP0S(AL\1Z:_++C(B-)=L71E+I#$EI2EKN]YUVY&*'/"GAV;BK#' M5RJE#*<"Y"K+B'@>8LHW?:?I; ?NZ3)19L ->SE9X@S50SX5NN=6*C'-
D$G* M&0A<])U!LSMI&[P%?*>XD3MM,$[FG#^:SFW<=SPS(4PQ4D:!Z-<:1YBF1DA/
MXW>IZ50A#7&WO57_9+UK+W,B<<33'S162=^Y<2#&!5FEZIYOOF#IQTXPX]FT M3]B46,^!;"45STJRGD%&6?$F3V4>=@A:IY[@EP3_D-!Z@1"4A.#
<!"*V2T#HW M0KLD6.MNX=TF;DP4"7N";T 8M%8S#9M]R];YHLS4R4P)_95JG@IG"1%X-=2I
MCF'$,UU^DM@5O(*9KLEXE2+P!4Q1V)IDT19\CU0&BG=G>

XML 82 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 83 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 85 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 384 304 1 false 101 0 false 10 false false R1.htm 0000001 - Document - Cover Sheet http://www.jazzpharma.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME Sheet http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME CONDENSED CONSOLIDATED STATEMENTS OF INCOME Statements 3 false false R4.htm 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 4 false false R5.htm 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) Sheet http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) Statements 5 false false R6.htm 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? EQUITY Sheet http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? EQUITY Statements 6 false false R7.htm 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 9952157 - Disclosure - The Company and Summary of Significant Accounting Policies Sheet http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPolicies The Company and Summary of Significant Accounting Policies Notes 8 false false R9.htm 9952158 - Disclosure - Cash and Available-for-Sale Securities Sheet http://www.jazzpharma.com/role/CashandAvailableforSaleSecurities Cash and Available-for-Sale Securities Notes 9 false false R10.htm 9952159 - Disclosure - Fair Value Measurement Sheet http://www.jazzpharma.com/role/FairValueMeasurement Fair Value Measurement Notes 10 false false R11.htm 9952160 - Disclosure - Derivative Instruments and Hedging Activities Sheet http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivities Derivative Instruments and Hedging Activities Notes 11 false false R12.htm 9952161 - Disclosure - Inventories Sheet http://www.jazzpharma.com/role/Inventories Inventories Notes 12 false false R13.htm 9952162 - Disclosure - Goodwill and Intangible Assets Sheet http://www.jazzpharma.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 13 false false R14.htm 9952163 - Disclosure - Certain Balance Sheet Items Sheet http://www.jazzpharma.com/role/CertainBalanceSheetItems Certain Balance Sheet Items Notes 14 false false R15.htm 9952164 - Disclosure - Debt Sheet http://www.jazzpharma.com/role/Debt Debt Notes 15 false false R16.htm 9952165 - Disclosure - Commitments and Contingencies Sheet http://www.jazzpharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 16 false false R17.htm 9952166 - Disclosure - Shareholders' Equity Sheet http://www.jazzpharma.com/role/ShareholdersEquity Shareholders' Equity Notes 17 false false R18.htm 9952167 - Disclosure - Net Income per Ordinary Share Sheet http://www.jazzpharma.com/role/NetIncomeperOrdinaryShare Net Income per Ordinary Share Notes 18 false false R19.htm 9952168 - Disclosure - Revenues Sheet http://www.jazzpharma.com/role/Revenues Revenues Notes 19 false false R20.htm 9952169 - Disclosure - Share-Based Compensation Sheet http://www.jazzpharma.com/role/ShareBasedCompensation Share-Based Compensation Notes 20 false false R21.htm 9952170 - Disclosure - Income Taxes Sheet http://www.jazzpharma.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 9954471 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies) Sheet http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesPolicies The Company and Summary of Significant Accounting Policies (Policies) Policies http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPolicies 22 false false R23.htm 9954472 - Disclosure - Cash and Available-for-Sale Securities (Tables) Sheet http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesTables Cash and Available-for-Sale Securities (Tables) Tables http://www.jazzpharma.com/role/CashandAvailableforSaleSecurities 23 false false R24.htm 9954473 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.jazzpharma.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.jazzpharma.com/role/FairValueMeasurement 24 false false R25.htm 9954474 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivities 25 false false R26.htm 9954475 - Disclosure - Inventories (Tables) Sheet http://www.jazzpharma.com/role/InventoriesTables Inventories (Tables) Tables http://www.jazzpharma.com/role/Inventories 26 false false R27.htm 9954476 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.jazzpharma.com/role/GoodwillandIntangibleAssets 27 false false R28.htm 9954477 - Disclosure - Certain Balance Sheet Items (Tables) Sheet http://www.jazzpharma.com/role/CertainBalanceSheetItemsTables Certain Balance Sheet Items (Tables) Tables http://www.jazzpharma.com/role/CertainBalanceSheetItems 28 false false R29.htm 9954478 - Disclosure - Debt (Tables) Sheet http://www.jazzpharma.com/role/DebtTables Debt (Tables) Tables http://www.jazzpharma.com/role/Debt 29 false false R30.htm 9954479 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.jazzpharma.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.jazzpharma.com/role/ShareholdersEquity 30 false false R31.htm 9954480 - Disclosure - Net Income per Ordinary Share (Tables) Sheet http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareTables Net Income per Ordinary Share (Tables) Tables http://www.jazzpharma.com/role/NetIncomeperOrdinaryShare 31 false false R32.htm 9954481 - Disclosure - Revenues (Tables) Sheet http://www.jazzpharma.com/role/RevenuesTables Revenues (Tables) Tables http://www.jazzpharma.com/role/Revenues 32 false false R33.htm 9954482 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.jazzpharma.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.jazzpharma.com/role/ShareBasedCompensation 33 false false R34.htm 9954483 - Disclosure - The Company and Summary of Significant Accounting Policies - Basis of Presentation (Narrative) (Details) Sheet http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesBasisofPresentationNarrativeDetails The Company and Summary of Significant Accounting Policies - Basis of Presentation (Narrative) (Details) Details 34 false false R35.htm 9954484 - Disclosure - The Company and Summary of Significant Accounting Policies - Concentrations of Risk (Narrative) (Details) Sheet http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails The Company and Summary of Significant Accounting Policies - Concentrations of Risk (Narrative) (Details) Details 35 false false R36.htm 9954485 - Disclosure - Cash and Available-for-Sale Securities - Schedule of Cash, Cash Equivalents and Investments (Details) Sheet http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails Cash and Available-for-Sale Securities - Schedule of Cash, Cash Equivalents and Investments (Details) Details 36 false false R37.htm 9954486 - Disclosure - Cash and Available-for-Sale Securities - Narrative (Details) Sheet http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesNarrativeDetails Cash and Available-for-Sale Securities - Narrative (Details) Details 37 false false R38.htm 9954487 - Disclosure - Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 38 false false R39.htm 9954488 - Disclosure - Fair Value Measurement - Narrative (Details) Sheet http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails Fair Value Measurement - Narrative (Details) Details 39 false false R40.htm 9954489 - Disclosure - Derivative Instruments and Hedging Activities -

*Narrative (Details) Sheet http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails Derivative Instruments and Hedging Activities - Narrative (Details) Details 40 false false R41.htm 9954490 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Foreign Exchange Gain (Loss) Associated with Foreign Exchange Contracts Not Designated as Hedging Instruments (Details) Sheet http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofForeignExchangeGainLossAssociatedwithForeignExchangeC Derivative Instruments and Hedging Activities - Schedule of Foreign Exchange Gain (Loss) Associated with Foreign Exchange Contracts Not Designated as Hedging Instruments (Details) Details 41 false false R42.htm 9954491 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Impact on Accumulated Other Comprehensive [Loss] and Earnings from Derivative Instruments that Qualified as Cash Flow Hedges (Details) Sheet http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofImpactonAccumulatedOtherComprehensiveLossandEarnings Derivative Instruments and Hedging Activities - Schedule of Impact on Accumulated Other Comprehensive [Loss] and Earnings from Derivative Instruments that Qualified as Cash Flow Hedges (Details) Details 42 false false R43.htm 9954492 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Fair Value of Outstanding Derivatives (Details) Sheet http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails Derivative Instruments and Hedging Activities - Schedule of Fair Value of Outstanding Derivatives (Details) Details 43 false false R44.htm 9954493 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Offsetting Assets and Offsetting Liabilities (Details) Sheet http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails Derivative Instruments and Hedging Activities - Schedule of Offsetting Assets and Offsetting Liabilities (Details) Details 44 false false R45.htm 9954494 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.jazzpharma.com/role/InventoriesScheduleofInventoriesDetails Inventories - Schedule of Inventories (Details) Details 45 false false R46.htm 9954495 - Disclosure - Inventories - Narrative (Details) Sheet http://www.jazzpharma.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Details 46 false false R47.htm 9954496 - Disclosure - Goodwill and Intangible Assets - Schedule of Gross Carrying Amount of Goodwill (Details) Sheet http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountofGoodwillDetails Goodwill and Intangible Assets - Schedule of Gross Carrying Amount of Goodwill (Details) Details 47 false false R48.htm 9954497 - Disclosure - Goodwill and Intangible Assets - Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets (Details) Sheet http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails Goodwill and Intangible Assets - Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets (Details) Details 48 false false R49.htm 9954498 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expenses (Details) Sheet http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expenses (Details) Details 49 false false R50.htm 9954499 - Disclosure - Certain Balance Sheet Items - Schedule of Property, Plant and Equipment (Details) Sheet http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails Certain Balance Sheet Items - Schedule of Property, Plant and Equipment (Details) Details 50 false false R51.htm 9954500 - Disclosure - Certain Balance Sheet Items - Schedule of Accrued Liabilities (Details) Sheet http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails Certain Balance Sheet Items - Schedule of Accrued Liabilities (Details) Details 51 false false R52.htm 9954501 - Disclosure - Debt - Schedule of Carrying Amount of Indebtedness (Details) Sheet http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails Debt - Schedule of Carrying Amount of Indebtedness (Details) Details 52 false false R53.htm 9954502 - Disclosure - Debt - Credit Agreement Narrative (Details) Sheet http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails Debt - Credit Agreement Narrative (Details) Details 53 false false R54.htm 9954503 - Disclosure - Debt - 2030 Notes Narrative (Details) Notes http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails Debt - 2030 Notes Narrative (Details) Details 54 false false R55.htm 9954504 - Disclosure - Debt - Exchangeable Senior Notes Narrative (Details) Notes http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails Debt - Exchangeable Senior Notes Narrative (Details) Details 55 false false R56.htm 9954505 - Disclosure - Debt - Schedule of Maturities of Long-Term Debt (Details) Sheet http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails Debt - Schedule of Maturities of Long-Term Debt (Details) Details 56 false false R57.htm 9954506 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.jazzpharma.com/role/CommitmentsandContingencies 57 false false R58.htm 9954507 - Disclosure - Shareholders' Equity - Narrative (Details) Sheet http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity - Narrative (Details) Details 58 false false R59.htm 9954508 - Disclosure - Shareholders' Equity - Schedule of Components of Accumulated Other Comprehensive Loss (Details) Sheet http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails Shareholders' Equity - Schedule of Components of Accumulated Other Comprehensive Loss (Details) Details 59 false false R60.htm 9954509 - Disclosure - Net Income per Ordinary Share - Schedule of Basic and Diluted Net Income Per Ordinary Share Computation (Details) Sheet http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails Net Income per Ordinary Share - Schedule of Basic and Diluted Net Income Per Ordinary Share Computation (Details) Details 60 false false R61.htm 9954510 - Disclosure - Net Income per Ordinary Share - Narrative (Details) Sheet http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareNarrativeDetails Net Income per Ordinary Share - Narrative (Details) Details 61 false false R62.htm 9954511 - Disclosure - Net Income per Ordinary Share - Schedule of Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income Per Share (Details) Sheet http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofWeightedAverageOrdinarySharesExcludedfromComputationofDilutedNetInc Net Income per Ordinary Share - Schedule of Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income Per Share (Details) Details 62 false false R63.htm 9954512 - Disclosure - Revenues - Schedule of Disaggregation of Revenue (Details) Sheet http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails Revenues - Schedule of Disaggregation of Revenue (Details) Details 63 false false R64.htm 9954513 - Disclosure - Revenues - Schedule of Percentage of Total Revenues from Customers (Details) Sheet http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails Revenues - Schedule of Percentage of Total Revenues from Customers (Details) Details 64 false false R65.htm 9954514 - Disclosure - Revenues - Narrative (Details) Sheet http://www.jazzpharma.com/role/RevenuesNarrativeDetails Revenues - Narrative (Details) Details 65 false false R66.htm 9954515 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details) Sheet http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details) Details 66 false false R67.htm 9954516 - Disclosure - Share-Based Compensation - Schedule of Restricted Stock Units Activity (Details) Sheet http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails Share-Based Compensation - Schedule of Restricted Stock Units Activity (Details) Details 67 false false R68.htm 9954517 - Disclosure - Share-Based Compensation - Narrative (Details) Sheet http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails Share-Based Compensation - Narrative (Details) Details 68 false false R69.htm 9954518 - Disclosure - Share-Based Compensation - Schedule of Performance-Based Restricted Stock Units Activity (Details) Sheet http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofPerformanceBasedRestrictedStockUnitsActivityDetails Share-Based Compensation - Schedule of Performance-Based Restricted Stock Units Activity (Details) Details 69 false false R70.htm 9954519 - Disclosure - Income Taxes (Details) Sheet http://www.jazzpharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.jazzpharma.com/role/IncomeTaxes 70 false false All Reports Book All Reports jazz-20240930.htm jazz-20240930.xsd jazz-20240930_cal.xml jazz-20240930_def.xml jazz-20240930_lab.xml jazz-20240930_pre.xml http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 88 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "jazz-20240930.htm": { "nsprefix": "jazz", "nsuri": "http://www.jazzpharma.com/20240930", "dts": { "inline": { "local": [ "jazz-20240930.htm" ] }, "schema": { "local": [ "jazz-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "jazz-20240930_cal.xml" ] }, "definitionLink": { "local": [ "jazz-20240930_def.xml" ] }, "labelLink": { "local": [ "jazz-20240930_lab.xml" ] }, "presentationLink": { "local": [ "jazz-20240930_pre.xml" ] } }, "keyStandard": 268, "keyCustom": 36, "axisStandard": 31, "axisCustom": 0, "memberStandard": 52, "memberCustom": 47, "hidden": { "total": 13, "http://fasb.org/us-gaap/2024": 7, "http://xbrl.sec.gov/dei/2024": 6 }, "contextCount": 384, "entityCount": 1, "segmentCount": 101, "elementCount": 558, "unitCount": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1001, "http://xbrl.sec.gov/dei/2024": 31, "http://fasb.org/srt/2024": 2 }, "report": { "R1": { "role": "http://www.jazzpharma.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault":*

*"false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R3": { "role": "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "jazz:CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R4": { "role": "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R5": { "role": "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-57", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-64", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R7": { "role": "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R8": { "role": "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPolicies", "longName": "9952157 - Disclosure - The Company and Summary of Significant Accounting Policies", "shortName": "The Company and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.jazzpharma.com/role/CashandAvailableforSaleSecurities", "longName": "9952158 - Disclosure - Cash and Available-for-Sale Securities", "shortName": "Cash and Available-for-Sale Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.jazzpharma.com/role/FairValueMeasurement", "longName": "9952159 - Disclosure - Fair Value Measurement", "shortName": "Fair Value Measurement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivities", "longName": "9952160 - Disclosure - Derivative Instruments and Hedging Activities", "shortName": "Derivative Instruments and Hedging Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.jazzpharma.com/role/Inventories", "longName": "9952161 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.jazzpharma.com/role/GoodwillandIntangibleAssets", "longName": "9952162 - Disclosure - Goodwill and Intangible Assets", "shortName": "Goodwill and Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.jazzpharma.com/role/CertainBalanceSheetItems", "longName": "9952163 - Disclosure - Certain Balance Sheet Items", "shortName": "Certain Balance Sheet Items", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef", "jazz-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.jazzpharma.com/role/Debt", "longName": "9952164 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ],*

"reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.jazzpharma.com/role/CommitmentsandContingencies", "longName": "9952165 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.jazzpharma.com/role/ShareholdersEquity", "longName": "9952166 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShare", "longName": "9952167 - Disclosure - Net Income per Ordinary Share", "shortName": "Net Income per Ordinary Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.jazzpharma.com/role/Revenues", "longName": "9952168 - Disclosure - Revenues", "shortName": "Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.jazzpharma.com/role/ShareBasedCompensation", "longName": "9952169 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.jazzpharma.com/role/IncomeTaxes", "longName": "9952170 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)", "shortName": "The Company and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesTables", "longName": "9954472 - Disclosure - Cash and Available-for-Sale Securities (Tables)", "shortName": "Cash and Available-for-Sale Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.jazzpharma.com/role/FairValueMeasurementTables", "longName": "9954473 - Disclosure - Fair Value Measurement (Tables)", "shortName": "Fair Value Measurement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesTables", "longName": "9954474 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.jazzpharma.com/role/InventoriesTables", "longName": "9954475 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsTables", "longName": "9954476 - Disclosure - Goodwill and Intangible Assets (Tables)", "shortName": "Goodwill and Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.jazzpharma.com/role/CertainBalanceSheetItemsTables", "longName": "9954477 - Disclosure - Certain Balance Sheet Items (Tables)", "shortName": "Certain Balance Sheet Items (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.jazzpharma.com/role/DebtTables", "longName": "9954478 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.jazzpharma.com/role/ShareholdersEquityTables", "longName": "9954479 - Disclosure - Shareholders' Equity (Tables)", "shortName": "Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false",

```
"lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareTables", "longName": "9954480 - Disclosure - Net Income per Ordinary Share (Tables)", "shortName": "Net Income per Ordinary Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.jazzpharma.com/role/RevenuesTables", "longName": "9954481 - Disclosure - Revenues (Tables)", "shortName": "Revenues (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.jazzpharma.com/role/ShareBasedCompensationTables", "longName": "9954482 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesBasisofPresentationNarrativeDetails", "longName": "9954483 - Disclosure - The Company and Summary of Significant Accounting Policies - Basis of Presentation (Narrative) (Details)", "shortName": "The Company and Summary of Significant Accounting Policies - Basis of Presentation (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails", "longName": "9954484 - Disclosure - The Company and Summary of Significant Accounting Policies - Concentrations of Risk (Narrative) (Details)", "shortName": "The Company and Summary of Significant Accounting Policies - Concentrations of Risk (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-102", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-102", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails", "longName": "9954485 - Disclosure - Cash and Available-for-Sale Securities - Schedule of Cash, Cash Equivalents and Investments (Details)", "shortName": "Cash and Available-for-Sale Securities - Schedule of Cash, Cash Equivalents and Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesNarrativeDetails", "longName": "9954486 - Disclosure - Cash and Available-for-Sale Securities - Narrative (Details)", "shortName": "Cash and Available-for-Sale Securities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:InvestmentIncomeInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:InvestmentIncomeInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "longName": "9954487 - Disclosure - Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-142", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R39": { "role": "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails", "longName": "9954488 - Disclosure - Fair Value Measurement - Narrative (Details)", "shortName": "Fair Value Measurement - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "longName": "9954489 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details)", "shortName": "Derivative Instruments and Hedging Activities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofForeignExchangeGainLossAssociatedwithForeignExchangeC "longName": "9954490 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Foreign Exchange Gain (Loss) Associated with Foreign Exchange Contracts Not Designated as Hedging Instruments (Details)", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Foreign Exchange Gain (Loss) Associated with Foreign Exchange Contracts Not Designated as Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-156", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-156", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofImpactonAccumulatedOtherComprehensiveLossandEarning "longName": "9954491 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Impact on Accumulated Other Comprehensive [Loss] and Earnings from Derivative Instruments that Qualified as Cash Flow Hedges (Details)", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Impact on Accumulated Other Comprehensive [Loss] and Earnings from Derivative Instruments that Qualified as Cash Flow Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
```

```
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-161", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R43": { "role": "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails", "longName": "9954492 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Fair Value of Outstanding Derivatives (Details)", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Fair Value of Outstanding Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails", "longName": "9954493 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Offsetting Assets and Offsetting Liabilities (Details)", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Offsetting Assets and Offsetting Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-175", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-175", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.jazzpharma.com/role/InventoriesScheduleofInventoriesDetails", "longName": "9954494 - Disclosure - Inventories - Schedule of Inventories (Details)", "shortName": "Inventories - Schedule of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.jazzpharma.com/role/InventoriesNarrativeDetails", "longName": "9954495 - Disclosure - Inventories - Narrative (Details)", "shortName": "Inventories - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-177", "name": "jazz:InventoryStepUpValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-177", "name": "jazz:InventoryStepUpValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountofGoodwillDetails", "longName": "9954496 - Disclosure - Goodwill and Intangible Assets - Schedule of Gross Carrying Amount of Goodwill (Details)", "shortName": "Goodwill and Intangible Assets - Schedule of Gross Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R48": { "role": "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails", "longName": "9954497 - Disclosure - Goodwill and Intangible Assets - Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets (Details)", "shortName": "Goodwill and Intangible Assets - Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails", "longName": "9954498 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expenses (Details)", "shortName": "Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleoffiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleoffiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails", "longName": "9954499 - Disclosure - Certain Balance Sheet Items - Schedule of Property, Plant and Equipment (Details)", "shortName": "Certain Balance Sheet Items - Schedule of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails", "longName": "9954500 - Disclosure - Certain Balance Sheet Items - Schedule of Accrued Liabilities (Details)", "shortName": "Certain Balance Sheet Items - Schedule of Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "jazz:AccruedRebatesAndOtherSalesDeductionsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "jazz:AccruedRebatesAndOtherSalesDeductionsCurrent", "unitRef", "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails", "longName": "9954501 - Disclosure - Debt - Schedule of Carrying Amount of Indebtedness (Details)", "shortName": "Debt - Schedule of Carrying Amount of Indebtedness (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R53": { "role":
```

"http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails", "longName": "9954502 - Disclosure - Debt - Credit Agreement Narrative (Details)", "shortName": "Debt - Credit Agreement Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-216", "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-216", "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails", "longName": "9954503 - Disclosure - Debt - 2030 Notes Narrative (Details)", "shortName": "Debt - 2030 Notes Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-147", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-231", "name": "us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "unitRef": "rate", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R55": { "role": "http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails", "longName": "9954504 - Disclosure - Debt - Exchangeable Senior Notes Narrative (Details)", "shortName": "Debt - Exchangeable Senior Notes Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RepaymentsOfConvertibleDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-233", "name": "us-gaap:InterestExpenseDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R56": { "role": "http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails", "longName": "9954505 - Disclosure - Debt - Schedule of Maturities of Long-Term Debt (Details)", "shortName": "Debt - Schedule of Maturities of Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails", "longName": "9954506 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-243", "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "unitRef": "litigationcase", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-243", "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "unitRef": "litigationcase", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails", "longName": "9954507 - Disclosure - Shareholders' Equity - Narrative (Details)", "shortName": "Shareholders' Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-263", "name": "us-gaap:StockRepurchasedDuringPeriodValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-263", "name": "us-gaap:StockRepurchasedDuringPeriodValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails", "longName": "9954508 - Disclosure - Shareholders' Equity - Schedule of Components of Accumulated Other Comprehensive Loss (Details)", "shortName": "Shareholders' Equity - Schedule of Components of Accumulated Other Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-46", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R60": { "role": "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails", "longName": "9954509 - Disclosure - Net Income per Ordinary Share - Schedule of Basic and Diluted Net Income Per Ordinary Share Computation (Details)", "shortName": "Net Income per Ordinary Share - Schedule of Basic and Diluted Net Income Per Ordinary Share Computation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:InterestOnConvertibleDebtNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R61": { "role": "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareNarrativeDetails", "longName": "9954510 - Disclosure - Net Income per Ordinary Share - Narrative (Details)", "shortName": "Net Income per Ordinary Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-272", "name": "jazz:DebtInstrumentIrrevocableElectionForSettlementMethodFixMaximumCashPer1000PrincipalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-272", "name": "jazz:DebtInstrumentIrrevocableElectionForSettlementMethodFixMaximumCashPer1000PrincipalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofWeightedAverageOrdinarySharesExcludedfromComputationofDilutedNetIn "longName": "9954511 - Disclosure - Net Income per Ordinary Share - Schedule of Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income Per Share (Details)", "shortName": "Net Income per Ordinary Share - Schedule of Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-274", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-274", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails", "longName": "9954512 - Disclosure - Revenues - Schedule of Disaggregation of Revenue (Details)", "shortName": "Revenues - Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-330", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } }, "R64": { "role": "http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails", "longName": "9954513 - Disclosure - Revenues - Schedule of Percentage of Total Revenues from Customers (Details)", "shortName": "Revenues - Schedule of Percentage of Total Revenues from Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-342", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1,

```
"baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-342", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.jazzpharma.com/role/RevenuesNarrativeDetails", "longName": "9954514 - Disclosure - Revenues - Narrative (Details)", "shortName": "Revenues - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-354", "name": "jazz:RevenuePerformanceObligationPaymentTerms", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-354", "name": "jazz:RevenuePerformanceObligationPaymentTerms", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails", "longName": "9954515 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)", "shortName": "Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "longName": "9954516 - Disclosure - Share-Based Compensation - Schedule of Restricted Stock Units Activity (Details)", "shortName": "Share-Based Compensation - Schedule of Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-368", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-368", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails", "longName": "9954517 - Disclosure - Share-Based Compensation - Narrative (Details)", "shortName": "Share-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-370", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-370", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofPerformanceBasedRestrictedStockUnitsActivityDetails", "longName": "9954518 - Disclosure - Share-Based Compensation - Schedule of Performance-Based Restricted Stock Units Activity (Details)", "shortName": "Share-Based Compensation - Schedule of Performance-Based Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-374", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-374", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.jazzpharma.com/role/IncomeTaxesDetails", "longName": "9954519 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-384", "name": "us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jazz-20240930.htm", "unique": true } } }, "tag": { "jazz_ASDSpecialtyHealthcareLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "ASDSpecialtyHealthcareLLCMember", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails", "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASD Specialty Healthcare LLC", "verboseLabel": "ASD", "label": "ASD Specialty Healthcare LLC [Member]", "documentation": "ASD Specialty Healthcare LLC" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r70", "r820" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r750" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of allowances", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r903" ] }, "jazz_AccruedClinicalTrialLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "AccruedClinicalTrialLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical trial accruals", "label": "Accrued Clinical Trial Liability, Current", "documentation": "Accrued Clinical Trial Liability, Current" } } }, "auth_ref": [] }, "jazz_AccruedCollaborationCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "AccruedCollaborationCostsCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued collaboration expenses", "label": "Accrued Collaboration Costs, Current", "documentation": "Accrued Collaboration Costs, Current" } } }, "auth_ref": [] }, "jazz_AccruedConstructionInProgressCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "AccruedConstructionInProgressCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel":
```

*"Accrued construction-in-progress", "label": "Accrued Construction-In-Progress, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for construction-in-progress. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee compensation and benefits", "label": "Accrued Employee Benefits, Current", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r73" ] }, "jazz_AccruedFacilitiesExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "AccruedFacilitiesExpensesCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued facilities expenses", "label": "Accrued Facilities Expenses, Current", "documentation": "Accrued Facilities Expenses, Current" } } }, "auth_ref": [] }, "jazz_AccruedInventoryRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "AccruedInventoryRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory-related accruals", "label": "Accrued Inventory Related Liabilities, Current", "documentation": "Accrued Inventory Related Liabilities, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r73" ] }, "us-gaap_AccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesMember", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Accrued Liabilities [Member]", "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered." } } }, "auth_ref": [ "r73" ] }, "us-gaap_AccruedMarketingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedMarketingCostsCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling and marketing accruals", "label": "Accrued Marketing Costs, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consulting and professional services", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r73" ] }, "jazz_AccruedRebatesAndOtherSalesDeductionsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "AccruedRebatesAndOtherSalesDeductionsCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rebates and other sales deductions", "label": "Accrued Rebates And Other Sales Deductions, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates and other sales deductions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued royalties", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r73", "r770" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Unrealized Gain From Hedging Activities", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r208", "r216", "r217", "r492", "r776", "r880" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r215", "r216", "r536", "r537", "r538", "r539", "r540", "r541" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r20", "r21", "r95", "r195", "r628", "r655", "r656" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r215", "r216", "r536", "r537", "r538", "r539", "r540", "r541" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Other Comprehensive Loss", "terseLabel": "Total Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and*

*circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r9", "r21", "r499", "r502", "r549", "r651", "r652", "r880", "r881", "r882", "r891", "r892", "r893", "r895" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Adjustments", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r2", "r9", "r21", "r93", "r94", "r216", "r217", "r537", "r538", "r539", "r540", "r541", "r880" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Weighted- Average\u00a0Useful Life (In years)", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r336", "r763" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r82" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r663", "r891", "r892", "r893", "r895", "r966", "r1033" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares withheld for payment of employee's withholding tax liability", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r40", "r41", "r425" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails": { "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total share-based compensation expense, pre-tax", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r455", "r460" ] }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total share-based compensation expense, net of tax", "label": "Share-Based Payment Arrangement, Expense, after Tax", "documentation": "Amount, after tax, of expense for award under share-based payment arrangement." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": [ "http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r99", "r383", "r886", "r988" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible asset amortization", "terseLabel": "Intangible asset amortization", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r6", "r333", "r341", "r785" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofWeightedAverageOrdinarySharesExcludedfromComputationofDilutedNetIn ], "lang": { "en-us": { "role": { "verboseLabel": "Ordinary shares (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r262" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofWeightedAverageOrdinarySharesExcludedfromComputationofDilutedNetIn ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r26" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofWeightedAverageOrdinarySharesExcludedfromComputationofDilutedNetIn ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [*

```
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofWeightedAverageOrdinarySharesExcludedfromComputationofDilutedNetIn
], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]",
"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do
so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r26" ] }, "us-gaap_Assets": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true }
}, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel":
"Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r133",
"r145", "r192", "r226", "r266", "r268", "r275", "r276", "r314", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r490", "r493",
"r530", "r624", "r695", "r780", "r781", "r820", "r852", "r951", "r952", "r990" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label":
"Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current
assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } }
}, "auth_ref": [ "r186", "r199", "r226", "r314", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r490", "r493", "r530", "r820",
"r951", "r952", "r990" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsCurrentAbstract", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": {
"role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang":
{ "en-us": { "role": { "totalLabel": "Totals", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for
present right to economic benefit." } } }, "auth_ref": [ "r510", "r511", "r808" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang":
{ "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] },
"jazz_AvadelPharmaceuticalsPlcLawsuitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname":
"AvadelPharmaceuticalsPlcLawsuitMember", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Avadel Pharmaceuticals plc Lawsuit", "label": "Avadel Pharmaceuticals plc Lawsuit [Member]", "documentation":
"Avadel Pharmaceuticals plc Lawsuit" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails": { "parentTag": "us-
gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
"documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security
measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r286" ] }, "us-
gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails": { "parentTag": "us-
gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": {
"role": { "negatedLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
"documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security
measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r287" ] }, "us-
gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": [
"http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": {
"role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of
investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } },
"auth_ref": [ "r283", "r322", "r623" ] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AvailableForSaleSecuritiesAbstract", "presentation": [
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang":
{ "en-us": { "role": { "terseLabel": "Available-for-sale securities:", "label": "Debt Securities, Available-for-Sale [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
"parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 },
"http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails": { "parentTag": "us-
gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails",
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang":
{ "en-us": { "role": { "verboseLabel": "Estimated Fair Value", "terseLabel": "Available-for-sale securities", "label": "Debt Securities, Available-for-
Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other
comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r284", "r322", "r510", "r618", "r808", "r812", "r905", "r970", "r971", "r972" ] },
"us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
"http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails",
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofPerformanceBasedRestrictedStockUnitsActivityDetails",
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails",
"http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label":
"Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r429", "r430",
"r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449",
"r450", "r451", "r452", "r453", "r454" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation":
"Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r348",
"r1000", "r1001" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BalanceSheetLocationDomain", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]",
"documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [
"r51", "r54", "r348", "r1000", "r1001" ] }, "us-gaap_BankTimeDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "BankTimeDepositsMember", "presentation": [
"http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails",
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang":
{ "en-us": { "role": { "terseLabel": "Time deposits", "label": "Bank Time Deposits [Member]", "documentation": "Certificates of deposit (CD) or
savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial
institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend
money to the institution for a certain amount of time and is paid a predetermined rate of interest." } } }, "auth_ref": [ "r140" ] }, "us-
gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

*"BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.jazzpharma.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r334", "r335", "r336", "r337", "r339", "r487", "r803", "r804" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.jazzpharma.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r42", "r43", "r334", "r335", "r336", "r337", "r339", "r487", "r803", "r804" ] }, "jazz_CapitalRedemptionReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "CapitalRedemptionReserve", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Capital redemption reserve", "label": "Capital Redemption Reserve", "documentation": "Capital redemption reserve created under Irish company law to preserve permanent capital in the company." } } }, "auth_ref": [] }, "jazz_CapitalRedemptionReserveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "CapitalRedemptionReserveMember", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Redemption Reserve", "label": "Capital Redemption Reserve [Member]", "documentation": "Capital Redemption Reserve [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r25", "r188", "r767" ] }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock", "presentation": [ "http://www.jazzpharma.com/role/CashandAvailableforSaleSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Available-for-Sale Securities", "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]", "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities." } } }, "auth_ref": [ "r904" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, at beginning of period", "periodEndLabel": "Cash and cash equivalents, at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r25", "r105", "r224" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r105" ] }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss, net of tax, to be reclassified to earnings over the next 12 months", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r63" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofImpactonAccumulatedOtherComprehensiveLossandEarning ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedges", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r49" ] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashMember", "presentation": [ "http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": [ "r188" ] }, "jazz_CertainBalanceSheetItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "CertainBalanceSheetItemsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Certain Balance Sheet Items [Abstract]", "label": "Certain Balance Sheet Items [Abstract]", "documentation": "Certain Balance Sheet Items [Abstract]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 9)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r79", "r136", "r626", "r682" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r115", "r350", "r351", "r751", "r939", "r944" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r840", "r841", "r842", "r844", "r845", "r846", "r849", "r891", "r892", "r895", "r966", "r1031", "r1033" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r10", "r81", "r683", "r701", "r1033", "r1034" ] }, "us-gaap_CommonStockValue": { "xbrltype":*

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0,
"order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": {
"terseLabel": "Ordinary shares", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable
common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note:
elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders'
equity." } } }, "auth_ref": [ "r81", "r627", "r820" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": null, "weight":
null, "order": null, "root": true } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": {
"totalLabel": "Total comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation":
"Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other
comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to
owners." } } }, "auth_ref": [ "r22", "r212", "r214", "r218", "r619", "r635", "r636" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in
the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails",
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation":
"The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r28", "r29", "r66", "r67", "r280", "r750" ] },
"us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConcentrationRiskByBenchmarkAxis", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails",
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation":
"Information by benchmark of concentration risk." } } }, "auth_ref": [ "r28", "r29", "r66", "r67", "r280", "r658", "r750" ] }, "us-
gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConcentrationRiskByTypeAxis", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails",
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of
concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref":
[ "r28", "r29", "r66", "r67", "r280", "r750", "r864" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Concentrations of Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy
for credit risk." } } }, "auth_ref": [ "r69", "r149" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails",
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent
financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one
or many axes to the table." } } }, "auth_ref": [ "r750" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails",
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-
us": { "role": { "netLabel": "Percentage of gross accounts receivable (as a percent)", "terseLabel": "Percentage of total revenues (as a percent)",
"label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount,
which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the
division." } } }, "auth_ref": [ "r28", "r29", "r66", "r67", "r280" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails",
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information
about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of
percentage of concentration risk." } } }, "auth_ref": [ "r27", "r28", "r29", "r30", "r66", "r132", "r750" ] }, "us-gaap_ConcentrationRiskTypeDomain":
{ "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails",
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity
that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net
assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r28", "r29", "r66", "r67", "r280", "r750" ] },
"us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConsolidationPolicyTextBlock", "presentation": [
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Basis of Presentation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the
principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion
or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example,
common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost
methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions,
noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r45",
"r777" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConstructionInProgressMember", "presentation": [
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Construction-in-progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a
structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } },
"auth_ref": [] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": [
"http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of exchangeable
senior notes", "label": "Convertible Debt, Fair Value Disclosures", "documentation": "Fair value portion of borrowing which can be exchanged for a
specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } },
"auth_ref": [ "r969", "r970", "r971", "r972", "r979" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": [
"http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails",
"http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails",
"http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails",
"http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails",
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt",
"verboseLabel": "Convertible Debt", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified
number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [
"r117", "r368", "r369", "r374", "r375", "r376", "r379", "r380", "r381", "r382", "r383", "r787", "r788", "r789", "r790", "r791" ] },
"jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname":
"CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight":

1.0, "order": 3.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of product sales (excluding amortization of acquired developed technologies)", "label": "Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment", "documentation": "Total costs related to goods produced and sold during the reporting period excluding amortization of acquired developed technologies and intangible asset impairment presented separately." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of product sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r100" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Country Region", "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [
"http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r358", "r949" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [
"http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r358", "r949", "r950" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails",
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r111", "r280" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails",
"http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails",
"http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails",
"http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails",
"http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails",
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r18", "r72", "r73", "r134", "r135", "r228", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r787", "r788", "r789", "r790", "r791", "r819", "r887", "r940", "r941", "r942", "r987", "r989" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [
"http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails",
"http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term debt outstanding", "totalLabel": "Total", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r18", "r135", "r385" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Debt instrument, convertible, conversion price (in dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r118", "r370" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, convertible, number of shares per principal amount basis (in shares)", "label": "Debt Instrument, Convertible, Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r36", "r76", "r121", "r122", "r370" ] }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "presentation": [
"http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, convertible, threshold consecutive trading days", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [
"http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [
"http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, convertible, threshold trading days", "label": "Debt Instrument, Convertible, Threshold Trading Days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "jazz_DebtInstrumentDecreaseInBasisSpreadOnVariableRate": { "xbrltype": "percentItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "DebtInstrumentDecreaseInBasisSpreadOnVariableRate", "presentation": [
"http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in basis spread on variable rate", "label": "Debt Instrument, Decrease In Basis Spread On Variable Rate", "documentation": "Debt Instrument, Decrease In Basis Spread On Variable Rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [
"http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails", "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r368", "r542", "r543", "r788", "r789", "r819" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails",
"http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest

rate (as a percent)", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r75", "r387", "r542", "r543", "r819" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [
"http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails", "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails",
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails",
"http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r75", "r369" ] },
"jazz_DebtInstrumentIrrevocableElectionForSettlementMethodFixMaximumCashPer1000PrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname":
"DebtInstrumentIrrevocableElectionForSettlementMethodFixMaximumCashPer1000PrincipalAmount", "crdr": "credit", "presentation": [
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Irrevocable election for settlement method fix, maximum cash per $1,000 principal amount", "label": "Debt Instrument, Irrevocable Election For Settlement Method Fix, Maximum Cash Per $1,000 Principal Amount", "documentation": "Debt Instrument, Irrevocable Election For Settlement Method Fix, Maximum Cash Per $1,000 Principal Amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [
"http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails", "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails",
"http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails",
"http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails",
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r228", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r787", "r788", "r789", "r790", "r791", "r819", "r887", "r940", "r941", "r942", "r987", "r989" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [
"http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails", "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails",
"http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails",
"http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails",
"http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails",
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r18", "r228", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r787", "r788", "r789", "r790", "r791", "r819", "r887", "r940", "r941", "r942", "r987", "r989" ] }, "jazz_DebtInstrumentQuarterlyAmortizationRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "DebtInstrumentQuarterlyAmortizationRatePercentage", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, quarterly amortization rate, percentage", "label": "Debt Instrument, Quarterly Amortization Rate, Percentage", "documentation": "Debt Instrument, Quarterly Amortization Rate, Percentage" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption price, percentage", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r141" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [
"http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails", "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails",
"http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails",
"http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails",
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r18", "r36", "r37", "r68", "r120", "r122", "r228", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r787", "r788", "r789", "r790", "r791", "r819", "r887", "r987", "r989" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term (in years)", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [
"http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } },
"auth_ref": [ "r954", "r986", "r987", "r989" ] }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNoncurrentNet", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } },
"presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel":
"Deferred financing costs", "label": "Debt Issuance Costs, Noncurrent, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } },
"auth_ref": [ "r986", "r987", "r989" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } },
"presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel":
"Deferred tax assets, net", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [
"r463", "r464" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel":
"Deferred tax benefit", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r6", "r152", "r889" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit",
"calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities, net", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r463", "r464", "r625" ] }, "jazz_DefitelioDefibrotideMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "DefitelioDefibrotideMember", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Defitelio/defibrotide", "label": "Defitelio/Defibrotide [Member]", "documentation": "Defitelio/Defibrotide [Member]" } } }, "auth_ref": [] },
"jazz_DenominatorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "DenominatorAbstract",
"presentation": [
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Denominator [Abstract]", "documentation": "Denominator [Abstract]" } } },
"auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation",
"crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-

gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r6", "r34" ] }, "us-gaap_DerivativeAssetFairValueAmountOffsetAgainstCollateralAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetFairValueAmountOffsetAgainstCollateralAbstract", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Amounts Not Offset in the Consolidated Balance Sheet", "label": "Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement", "crdr": "debit", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset derivatives", "label": "Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset." } } }, "auth_ref": [ "r200", "r741", "r742", "r775" ] }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetFairValueGrossLiability", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails": {
"parentTag": "us-gaap_DerivativeAssets", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts Offset in the Consolidated Balance Sheet", "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset", "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r13", "r17", "r128", "r129", "r741", "r742" ] }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": [ "r495" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails": {
"parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": 1.0, "order": 1.0 },
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
"parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails",
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange forward contracts", "totalLabel": "Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r201", "r204", "r510", "r511", "r521", "r529", "r665", "r666", "r667", "r668", "r669", "r671", "r672", "r673", "r674", "r675", "r689", "r690", "r734", "r737", "r740", "r741", "r743", "r744", "r775", "r808", "r812", "r842", "r970", "r971", "r972", "r1032" ] }, "us-gaap_DerivativeAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsAbstract", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets", "label": "Derivative Asset [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCollateralObligationToReturnCash", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails": {
"parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Collateral Received (Pledged)", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset", "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets." } } }, "auth_ref": [ "r15", "r60", "r202", "r774" ] }, "us-gaap_DerivativeCollateralObligationToReturnSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCollateralObligationToReturnSecurities", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails": {
"parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Derivative Financial Instruments", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Security Not Offset", "documentation": "Amount of obligation to return securities collateral under master netting arrangements that have not been offset against derivative assets." } } }, "auth_ref": [ "r15", "r202", "r774" ] }, "us-gaap_DerivativeCollateralRightToReclaimCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCollateralRightToReclaimCash", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails": {
"parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Collateral Received (Pledged)", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset", "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities." } } }, "auth_ref": [ "r15", "r60", "r202", "r774" ] }, "us-gaap_DerivativeCollateralRightToReclaimSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCollateralRightToReclaimSecurities", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails": {
"parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Financial Instruments", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset", "documentation": "Amount of right to receive securities collateral under master netting arrangements that have not been offset against derivative liabilities." } } }, "auth_ref": [ "r15", "r202", "r774" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails",
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails",
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofForeignExchangeGainLossAssociatedwithForeignExchangeC
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofImpactonAccumulatedOtherComprehensiveLossandEarning
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r673", "r675", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r696", "r697", "r698", "r699", "r709", "r710", "r711", "r712", "r715", "r716", "r717", "r718", "r734", "r735", "r740", "r743", "r840", "r842", "r973", "r974", "r975", "r976", "r977", "r978", "r980", "r981" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails": {
"parentTag": "us-gaap_DerivativeAssets", "weight": 1.0, "order": 1.0 },
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
"parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails",
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang":

{ "en-us": { "role": { "terseLabel": "Interest rate contracts", "verboseLabel": "Gross Amounts of Recognized Assets/ Liabilities", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r14", "r92", "r128", "r129", "r200", "r775" ] }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Amount", "label": "Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction", "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r15", "r59" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts of Recognized Assets/ Liabilities", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r14", "r92", "r128", "r129", "r200", "r775" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net Amount", "label": "Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction", "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r15", "r59" ] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": [ "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net asset (liability) fair value", "label": "Derivative, Fair Value, Net", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": [ "r529" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofForeignExchangeGainLossAssociatedwithForeignExchangeC ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized in foreign exchange loss", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r964" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails", "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofForeignExchangeGainLossAssociatedwithForeignExchangeC "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofImpactonAccumulatedOtherComprehensiveLossandEarning "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r52", "r55", "r56", "r130", "r673", "r675", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r696", "r697", "r698", "r699", "r709", "r710", "r711", "r712", "r715", "r716", "r717", "r718", "r734", "r735", "r740", "r743", "r775", "r840", "r842", "r973", "r974", "r975", "r976", "r977", "r978", "r980", "r981" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivities" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r127", "r497", "r504" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofImpactonAccumulatedOtherComprehensiveLossandEarning ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r11", "r52", "r55" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofImpactonAccumulatedOtherComprehensiveLossandEarning ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r11", "r52", "r55", "r56", "r61", "r62", "r496" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofImpactonAccumulatedOtherComprehensiveLossandEarning ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r496" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails", "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liability", "negatedTotalLabel": "Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r201", "r204", "r510", "r511", "r521", "r529", "r665", "r666", "r667", "r668", "r671", "r672", "r673", "r674", "r675", "r696", "r698", "r699", "r735", "r736", "r737", "r740", "r741", "r743", "r744", "r775", "r970", "r971", "r972", "r1032" ] }, "us-gaap_DerivativeLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesAbstract", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liabilities", "label": "Derivative Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"DerivativeLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instrument liabilities", "label": "Derivative Liability, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r201" ] }, "us-gaap_DerivativeLiabilityFairValueAmountOffsetAgainstCollateralAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityFairValueAmountOffsetAgainstCollateralAbstract", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Amounts Not Offset in the Consolidated Balance Sheet", "label": "Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityFairValueGrossAsset", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Amounts Offset in the Consolidated Balance Sheet", "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset", "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r13", "r17", "r128", "r129", "r741", "r742", "r774" ] }, "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement", "crdr": "credit", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Liability derivatives", "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset." } } }, "auth_ref": [ "r200", "r741", "r742", "r775" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r495" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails",
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofForeignExchangeGainLossAssociatedwithForeignExchangeC
], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r504" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails",
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r962", "r963" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails",
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofForeignExchangeGainLossAssociatedwithForeignExchangeC
], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r11", "r46", "r47", "r48", "r50", "r53", "r55", "r57", "r58", "r62", "r504" ] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesFairValueLineItems", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails",
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails",
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Designated as Hedging Instruments", "label": "Designated as Hedging Instrument [Member]",
"documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } },
"auth_ref": [ "r11" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DevelopedTechnologyRightsMember", "presentation": [
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Acquired developed technologies", "label": "Developed Technology Rights [Member]", "documentation":
"Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r124", "r924", "r925", "r926", "r927", "r929", "r931", "r934", "r935" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisaggregationOfRevenueLineItems", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r412", "r793", "r794", "r795", "r796", "r797", "r798", "r799" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisaggregationOfRevenueTable", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation":
"Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r412", "r793", "r794", "r795", "r796", "r797", "r798", "r799" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.jazzpharma.com/role/RevenuesTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r956" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.jazzpharma.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label":
"Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } },
"auth_ref": [ "r423", "r428", "r456", "r457", "r459", "r806" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": {
"xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": {
"xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [

```
"http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r856" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r857" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r219", "r234", "r235", "r236", "r237", "r238", "r239", "r245", "r247", "r259", "r260", "r261", "r265", "r485", "r489", "r507", "r508", "r620", "r637", "r778" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r219", "r234", "r235", "r236", "r237", "r238", "r239", "r247", "r259", "r260", "r261", "r265", "r485", "r489", "r507", "r508", "r620", "r637", "r778" ] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": [
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income per ordinary share:", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income per Ordinary Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r244", "r262", "r263", "r264" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r535" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost related to unvested RSU's, PRSUs, ESPP and share options", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r458" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average period expected to be recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r458" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails": { "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax benefit from share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r455" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [ "http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
```

```
"localname": "EntityAddressCountry", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] },
"dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressPostalZipCode", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] },
"dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCentralIndexKey", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r854" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype":
"sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [
"http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": {
"xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails",
"http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label":
"Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } }
}, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityEmergingGrowthCompany", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel":
"Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r854" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": {
"role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": {
"role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } },
"auth_ref": [ "r854" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.jazzpharma.com/role/Cover" ],
"lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] },
"dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityInteractiveDataCurrent", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r858" ] }, "dei_EntityRegistrantName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } },
"auth_ref": [ "r854" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityShellCompany", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r854" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": {
"role": { "terseLabel": "Smaller Reporting Company", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r854" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": {
"en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } },
"auth_ref": [ "r854" ] }, "jazz_EpidiolexEpidyolexMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930",
"localname": "EpidiolexEpidyolexMember", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Epidiolex/Epidyolex", "label": "Epidiolex/Epidyolex [Member]", "documentation": "Epidiolex/Epidyolex" } } }, "auth_ref": [] },
"jazz_EpidiolexPatentLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname":
"EpidiolexPatentLitigationMember", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Epidiolex Patent Litigation", "label": "Epidiolex Patent Litigation [Member]", "documentation": "Epidiolex Patent Litigation" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EquityComponentDomain", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
"http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [
"r10", "r184", "r215", "r216", "r217", "r229", "r230", "r231", "r233", "r238", "r240", "r242", "r267", "r315", "r316", "r346", "r402", "r475", "r476",
"r482", "r483", "r484", "r486", "r488", "r489", "r498", "r499", "r500", "r501", "r502", "r503", "r506", "r536", "r537", "r538", "r539", "r540", "r541",
"r544", "r545", "r549", "r633", "r651", "r652", "r653", "r663", "r722" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [
"http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities without readily determinable fair value", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r312" ] }, "us-
gaap_EquityUnitPurchaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquityUnitPurchaseAgreementsMember", "presentation": [
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofWeightedAverageOrdinarySharesExcludedfromComputationofDilutedNetIn
], "lang": { "en-us": { "role": { "terseLabel": "Employee equity incentive and purchase plans", "label": "Equity Unit Purchase Agreements [Member]", "documentation": "Contracts and securities that allow the holder to buy equity units from the entity." } } }, "auth_ref": [ "r26" ] },
"jazz_EuroDeferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname":
"EuroDeferredSharesMember", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": {
"terseLabel": "Non-voting Euro Deferred", "label": "Euro Deferred Shares [Member]", "documentation": "Euro Deferred Shares [Member]" } } },
"auth_ref": [] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember",
"presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Europe", "label": "Europe [Member]", "documentation": "Continent of Europe." } } }, "auth_ref": [ "r873", "r874", "r875", "r876",
"r1035", "r1036", "r1037", "r1038" ] }, "jazz_ExchangeableSeniorNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.jazzpharma.com/20240930", "localname": "ExchangeableSeniorNotesDue2024Member", "presentation": [
"http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails",
"http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails",
"http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails",
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exchangeable
```

*Senior Notes Due 2024", "terseLabel": "2024 Notes", "label": "Exchangeable Senior Notes Due 2024 [Member]", "documentation": "Exchangeable Senior Notes Due 2024 [Member]" } } }, "auth_ref": [] }, "jazz_ExchangeableSeniorNotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "ExchangeableSeniorNotesDue2026Member", "presentation": [ "http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails", "http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails", "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails", "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exchangeable Senior Notes Due 2026", "terseLabel": "2026 Notes", "label": "Exchangeable Senior Notes Due 2026 [Member]", "documentation": "Exchangeable Senior Notes Due 2026 [Member]" } } }, "auth_ref": [] }, "jazz_ExchangeableSeniorNotesDue2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "ExchangeableSeniorNotesDue2030Member", "presentation": [ "http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails", "http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails", "http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails", "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchangeable Senior Notes Due 2030", "verboseLabel": "2030 Notes", "label": "Exchangeable Senior Notes Due 2030 [Member]", "documentation": "Exchangeable Senior Notes Due 2030" } } }, "auth_ref": [] }, "jazz_ExpressScriptsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "ExpressScriptsMember", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails", "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ESSDS", "label": "Express Scripts [Member]", "documentation": "Express Scripts 1 [Member]" } } }, "auth_ref": [] }, "jazz_FDARecognitionOfOrphanDrugExclusivityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "FDARecognitionOfOrphanDrugExclusivityPeriod", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FDA recognition of orphan drug exclusivity, period", "label": "FDA Recognition Of Orphan Drug Exclusivity, Period", "documentation": "FDA Recognition Of Orphan Drug Exclusivity, Period" } } }, "auth_ref": [] }, "jazz_FDAStayOfApprovalPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "FDAStayOfApprovalPeriod", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FDA stay of approval period", "label": "FDA Stay Of Approval Period", "documentation": "FDA Stay Of Approval Period" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r510", "r511", "r521", "r808" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r510", "r511", "r521", "r808" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r64", "r65" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails", "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r376", "r415", "r416", "r417", "r418", "r419", "r420", "r509", "r511", "r512", "r513", "r514", "r520", "r521", "r523", "r553", "r554", "r555", "r788", "r789", "r800", "r801", "r802", "r808", "r812" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r510", "r511", "r512", "r514", "r808", "r971", "r982" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurement" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r516", "r518", "r519", "r520", "r523", "r524", "r525", "r526", "r527", "r616", "r808", "r813" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets\u00a0for Identical Assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r376", "r415", "r420", "r511", "r521", "r553", "r800", "r801", "r802", "r808" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails", "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r376", "r415", "r420", "r511", "r512", "r521", "r554", "r788", "r789", "r800", "r801", "r802", "r808" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation":*

```
"Measurement frequency." } } }, "auth_ref": [ "r510", "r511", "r512", "r514", "r808", "r971", "r982" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails", "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r376", "r415", "r416", "r417", "r418", "r419", "r420", "r509", "r511", "r512", "r513", "r514", "r520", "r521", "r523", "r553", "r554", "r555", "r788", "r789", "r800", "r801", "r802", "r808", "r812" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r808", "r968", "r969", "r970", "r971", "r972", "r982" ] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument." } } }, "auth_ref": [ "r51", "r53", "r61" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails", "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r317", "r318", "r319", "r320", "r321", "r323", "r324", "r325", "r384", "r400", "r504", "r528", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r634", "r783", "r808", "r810", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r821", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r906", "r907", "r908", "r909", "r967", "r970", "r971", "r972", "r979", "r982" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Totals", "label": "Financial Liabilities Fair Value Disclosure", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": [ "r968", "r969", "r979" ] },
"jazz_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.jazzpharma.com/20240930", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit",
"calculation": { "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails": {
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
"crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails": {
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ],
"lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
"documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r190", "r329", "r340", "r785" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r342", "r763", "r785" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "2024 (remainder)", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
"documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1039" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r342", "r763", "r785" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r342", "r763", "r785" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r342", "r763", "r785" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
```

"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r332", "r334", "r335", "r336", "r339", "r340", "r343", "r344", "r584", "r585", "r763" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r329", "r340", "r585", "r785" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r332", "r340", "r343", "r344", "r345", "r584", "r763", "r785" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r332", "r334", "r335", "r336", "r339", "r340", "r343", "r344", "r763" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAmortizationExpensesDetails", "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r584", "r931" ] }, "jazz_FiveCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "FiveCustomersMember", "presentation": [ "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Five Customers", "label": "Five Customers [Member]", "documentation": "Five Customers" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCountryMember", "presentation": [ "http://www.jazzpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Tax Authority", "label": "Foreign Tax Jurisdiction [Member]", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": [ "r466", "r467" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange loss", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r531", "r532", "r533", "r534", "r719" ] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails", "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofForeignExchangeGainLossAssociatedwithForeignExchangeC "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange forward contracts", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r689", "r693", "r698", "r711", "r717", "r738", "r739", "r740", "r842" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "jazz_GWPharmaceuticalsPlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "GWPharmaceuticalsPlcMember", "presentation": [ "http://www.jazzpharma.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GW Pharmaceuticals plc", "label": "GW Pharmaceuticals plc [Member]", "documentation": "GW Pharmaceuticals plc" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill, beginning of period", "periodEndLabel": "Goodwill, end of period", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r189", "r330", "r617", "r781", "r784", "r809", "r820", "r913", "r920" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.jazzpharma.com/role/GoodwillandIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r911", "r923" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r331" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails", "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofForeignExchangeGainLossAssociatedwithForeignExchangeC "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r11", "r496" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [

"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails",
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails",
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofForeignExchangeGainLossAssociatedwithForeignExchangeC
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r11" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofImpactonAccumulatedOtherComprehensiveLossandEarning
], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r11" ] }, "jazz_HighSodiumAGOxybateProductRoyaltyRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "HighSodiumAGOxybateProductRoyaltyRevenueMember", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "High-sodium oxybate AG royalty revenue", "label": "High Sodium AG Oxybate Product Royalty Revenue [Member]", "documentation": "High Sodium AG Oxybate Product Royalty Revenue" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Income before income tax benefit and equity in loss (gain) of investees", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r144", "r638", "r779", "r897", "r899", "r900", "r901", "r902" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity in loss (gain) of investees", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r6", "r96", "r138", "r266", "r272", "r276", "r313", "r631" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r347", "r348", "r349", "r515", "r517", "r522", "r648", "r650", "r706", "r763", "r811", "r1002" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r348", "r349", "r515", "r517", "r522", "r648", "r650", "r706", "r763", "r811", "r1002" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.jazzpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r223", "r466", "r467", "r471", "r474", "r807", "r961" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [
"http://www.jazzpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r223", "r466", "r467", "r471", "r474", "r807", "r961" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://www.jazzpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority, Name [Axis]", "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r471", "r961" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [
"http://www.jazzpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority, Name [Domain]", "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [ "r471", "r961" ] }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyLineItems", "presentation": [ "http://www.jazzpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Line Items]", "label": "Income Tax Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyTable", "presentation": [ "http://www.jazzpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Table]", "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r959" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.jazzpharma.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r227", "r462", "r466", "r468", "r469", "r470", "r472", "r473", "r477", "r479", "r480", "r481", "r662", "r807" ] }, "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationEstimateOfPossibleLoss", "crdr": "debit", "presentation": [ "http://www.jazzpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proposed additional tax including interest and penalties", "label": "Income Tax Examination, Estimate of Possible Loss", "documentation": "Estimated amount of loss resulting from an adverse tax position." } } }, "auth_ref": [ "r960" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
"http://www.jazzpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax benefit", "negatedLabel": "Income tax benefit", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r146", "r153", "r241", "r242", "r266", "r273", "r276", "r465", "r466", "r478", "r639", "r807" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r5" ] },

```
"us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Income
taxes payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount
due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given
jurisdiction." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel":
"Accrued liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period
in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r5" ] }, "us-
gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel":
"Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in
obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r582", "r885" ] },
"us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInInventories", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel":
"Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the
aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } }
}, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel":
"Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] },
"jazz_IncreaseDecreaseInOperatingLeaseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname":
"IncreaseDecreaseInOperatingLeaseAssets", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 21.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel":
"Operating lease assets", "label": "Increase (Decrease) In Operating Lease Assets", "documentation": "Increase (Decrease) In Operating Lease
Assets" } } }, "auth_ref": [] }, "jazz_IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.jazzpharma.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel":
"Operating lease liabilities, less current portion", "label": "Increase (Decrease) In Operating Lease Liabilities, Noncurrent", "documentation":
"Increase (Decrease) In Operating Lease Liabilities, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr":
"credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel":
"Other non-current assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in
noncurrent assets classified as other." } } }, "auth_ref": [ "r885" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit",
"calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other
non-current liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in
noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel":
"Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of
increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r5" ] }, "us-
gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": {
"terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-
gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "calculation": {
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails": {
"parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of exchangeable senior notes (in shares)", "label": "Incremental Common Shares
Attributable to Dilutive Effect of Conversion of Debt Securities", "documentation": "Additional shares included in the calculation of diluted EPS as
a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": [ "r255", "r256", "r261" ] },
"us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": {
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails": {
"parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of employee equity incentive and purchase plans (in shares)", "label": "Incremental
Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the
calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } }
}, "auth_ref": [ "r248", "r249", "r250", "r261", "r427" ] }, "jazz_InfringedPatentsSuitNumberOfPatents": { "xbrltype": "integerItemType", "nsuri":
"http://www.jazzpharma.com/20240930", "localname": "InfringedPatentsSuitNumberOfPatents", "presentation": [
"http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Infringed patents suit,
number of patents", "label": "Infringed Patents Suit, Number Of Patents", "documentation": "Infringed Patents Suit, Number Of Patents" } } },
"auth_ref": [] }, "jazz_InfringedPatentsSuitOtherPartyCounterclaimNumberOfPatentsRequestedToBeDelisted": { "xbrltype": "integerItemType",
"nsuri": "http://www.jazzpharma.com/20240930", "localname":
"InfringedPatentsSuitOtherPartyCounterclaimNumberOfPatentsRequestedToBeDelisted", "presentation": [
"http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Infringed patents suit, other
party counterclaim, number of patents requested to be delisted", "label": "Infringed Patents Suit, Other Party Counterclaim, Number Of Patents
Requested To Be Delisted", "documentation": "Infringed Patents Suit, Other Party Counterclaim, Number Of Patents Requested To Be Delisted" } }
}, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } },
"presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel":
```

"Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r332", "r931", "r933" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, debt", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r99", "r381", "r388", "r790", "r791" ] }, "jazz_InterestExpenseDebtContractualCouponRate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "InterestExpenseDebtContractualCouponRate", "crdr": "debit", "presentation": [ "http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual coupon rate interest expense", "label": "Interest Expense, Debt, Contractual Coupon Rate", "documentation": "Interest Expense, Debt, Contractual Coupon Rate" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r780", "r884", "r899" ] }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestOnConvertibleDebtNetOfTax", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of interest on assumed conversions of Exchangeable Senior Notes, net of tax", "label": "Interest on Convertible Debt, Net of Tax", "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash." } } }, "auth_ref": [ "r246", "r252", "r261" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r73" ] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateContractMember", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails", "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofImpactonAccumulatedOtherComprehensiveLossandEarning", "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate contracts", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r764", "r775", "r800", "r808" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails", "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r764", "r847", "r848" ] }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryCurrentTable", "presentation": [ "http://www.jazzpharma.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Current [Table]", "label": "Inventory, Current [Table]", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.jazzpharma.com/role/Inventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r326" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jazzpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r113", "r771" ] }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLineItems", "presentation": [ "http://www.jazzpharma.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Line Items]", "label": "Inventory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.jazzpharma.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.jazzpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r196", "r768", "r820" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r113", "r773" ] }, "jazz_InventoryStepUpValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "InventoryStepUpValue", "crdr": "debit", "presentation": [ "http://www.jazzpharma.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, step-up value", "label": "Inventory, Step-Up Value", "documentation": "Inventory, Step-Up Value" } } }, "auth_ref": [] }, "jazz_InventoryStepUpValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "InventoryStepUpValueAdjustment", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition accounting inventory fair value step-up adjustment", "label": "Inventory Step-Up Value Adjustment", "documentation": "The noncash expense recognized in the current period from the amortization of acquired inventory written up to fair value in purchase accounting" } } }, "auth_ref": [] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/InventoriesScheduleofInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/InventoriesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r113", "r772" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income from available-for-sale securities", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r266", "r271", "r276", "r780", "r883" ] }, "us-

gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Investments", "terseLabel": "Investments", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r621", "r622", "r837", "r839" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "jazz_JazzInvestmentsILimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "JazzInvestmentsILimitedMember", "presentation": [ "http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jazz Investments I Limited", "label": "Jazz Investments I Limited [Member]", "documentation": "Jazz Investments I Limited [Member]" } } }, "auth_ref": [] }, "jazz_JazzSecuritiesDesignatedActivityCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "JazzSecuritiesDesignatedActivityCompanyMember", "presentation": [ "http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails", "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jazz Securities Designated Activity Company", "label": "Jazz Securities Designated Activity Company [Member]", "documentation": "Jazz Securities Designated Activity Company" } } }, "auth_ref": [] }, "jazz_July2024ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "July2024ShareRepurchaseProgramMember", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Repurchase Program", "label": "July 2024 Share Repurchase Program [Member]", "documentation": "July 2024 Share Repurchase Program" } } }, "auth_ref": [] }, "us-gaap_LandAndBuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandAndBuildingMember", "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land and buildings", "label": "Land and Building [Member]", "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r114", "r548" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails", "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r86", "r137", "r630", "r820", "r888", "r910", "r983" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r74", "r187", "r226", "r314", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r491", "r493", "r494", "r530", "r820", "r951", "r990", "r991" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, commitment fee percentage (as a percentage)", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityExpirationPeriod", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility expiration period", "label": "Line of Credit Facility, Expiration Period", "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r71", "r77" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r71", "r77", "r358" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LinesOfCreditFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of lines of credit", "label": "Lines of Credit, Fair Value Disclosure", "documentation": "Fair value portion of contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time." } } }, "auth_ref": [ "r969", "r979" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]", "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim." } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]", "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium

(discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r18", "r135", "r375", "r386", "r788", "r789", "r819", "r998" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "verboseLabel": "Less current portion", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r193" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r228", "r379" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r228", "r379" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r228", "r379" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r8", "r228", "r379" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (remainder)", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r890" ] }, "jazz_LongTermDebtMaturityAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "LongTermDebtMaturityAfterYearFour", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.jazzpharma.com/role/DebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, After Year Four", "documentation": "Long-Term Debt, Maturity, After Year Four" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 },
"http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, less current portion", "verboseLabel": "Total long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r194" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.jazzpharma.com/role/Debt" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r116" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails",
"http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails",
"http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails",
"http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails",
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails",
"http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails",
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r18", "r940", "r941", "r942" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.jazzpharma.com/role/Debt2030NotesNarrativeDetails",
"http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails",
"http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails",
"http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails",
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails",
"http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails",
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r18", "r35", "r940", "r941", "r942" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r352", "r353", "r354", "r357", "r461", "r786", "r945", "r946" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r352", "r353", "r354", "r357", "r461", "r786", "r945", "r946" ] }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNewClaimsFiledNumber", "presentation": [
"http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of lawsuits filed", "label": "Loss Contingency, New Claims Filed, Number", "documentation": "The total number of new claims filed pertaining to a loss contingency during the period." } } }, "auth_ref": [ "r945", "r946" ] }, "jazz_LupinLawsuitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "LupinLawsuitMember", "presentation": [

```
"http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lupin Lawsuit", "label": "Lupin Lawsuit [Member]", "documentation": "Lupin Lawsuit" } } }, "auth_ref": [] }, "us-gaap_LuxembourgInlandRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LuxembourgInlandRevenueMember", "presentation": [ "http://www.jazzpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Luxembourg Inland Revenue", "label": "Luxembourg Inland Revenue [Member]", "documentation": "Designated tax department of the government of Luxembourg." } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing equipment and machinery", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails", "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r280", "r795", "r831", "r835", "r956", "r999", "r1003", "r1004", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030" ] }, "jazz_ManufacturingContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "ManufacturingContractsMember", "presentation": [ "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing contracts", "label": "Manufacturing Contracts [Member]", "documentation": "Manufacturing Contracts [Member]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails", "http://www.jazzpharma.com/role/RevenuesNarrativeDetails", "http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r155", "r157", "r159", "r160", "r162", "r182", "r183", "r353", "r354", "r355", "r356", "r421", "r461", "r514", "r581", "r647", "r649", "r657", "r674", "r675", "r727", "r729", "r731", "r732", "r745", "r761", "r762", "r782", "r792", "r805", "r812", "r813", "r817", "r818", "r832", "r953", "r992", "r993", "r994", "r995", "r996", "r997" ] }, "jazz_McKessonCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "McKessonCorporationMember", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails", "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "McKesson", "label": "McKesson Corporation [Member]", "documentation": "McKesson Corporation [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails", "http://www.jazzpharma.com/role/RevenuesNarrativeDetails", "http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r155", "r157", "r159", "r160", "r162", "r182", "r183", "r353", "r354", "r355", "r356", "r421", "r461", "r514", "r581", "r647", "r649", "r657", "r674", "r675", "r727", "r729", "r731", "r732", "r745", "r761", "r762", "r782", "r792", "r805", "r812", "r813", "r817", "r832", "r953", "r992", "r993", "r994", "r995", "r996", "r997" ] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of ownership (as a percent)", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails", "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r957" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails", "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r280", "r795", "r831", "r835", "r956", "r999", "r1003", "r1004", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r222" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r222" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r105", "r106", "r107" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 }, "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 },
```

"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income", "netLabel": "Net (loss) income", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r97", "r107", "r139", "r185", "r210", "r213", "r217", "r226", "r232", "r234", "r235", "r236", "r237", "r238", "r241", "r242", "r257", "r314", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r485", "r489", "r508", "r530", "r632", "r703", "r720", "r721", "r850", "r951" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income for dilutive net income per ordinary share", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r220", "r246", "r251", "r252", "r253", "r254", "r258", "r261" ] }, "jazz_NetIncomeLossPerOrdinaryShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "NetIncomeLossPerOrdinaryShareAbstract", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Net income per ordinary share:", "label": "Net Income Loss Per Ordinary Share [Abstract]", "documentation": "Net Income Loss Per Ordinary Share" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption of New Accounting Standards and Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "jazz_NoncashInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "NoncashInterestExpense", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Noncash Interest Expense", "documentation": "Noncash Interest Expense" } } }, "auth_ref": [] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails", "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofForeignExchangeGainLossAssociatedwithForeignExchangeC "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesConcentrationsofRiskNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Not Designated as Hedging Instruments", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r11" ] }, "jazz_NonvotingEuroDeferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "NonvotingEuroDeferredShares", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-voting euro deferred shares", "label": "Nonvoting Euro Deferred Shares", "documentation": "Shares issued to satisfy statutory minimum of Euro-denominated share capital required for a public limited company incorporated in Ireland." } } }, "auth_ref": [] }, "us-gaap_NotesPayableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of secured debt", "label": "Notes Payable, Fair Value Disclosure", "documentation": "Fair value portion of notes payable." } } }, "auth_ref": [ "r18", "r72", "r73", "r969", "r979" ] }, "jazz_November2016ShareRepurchaseProgramAndJuly2024ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "November2016ShareRepurchaseProgramAndJuly2024ShareRepurchaseProgramMember", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase Programs", "label": "November 2016 Share Repurchase Program And July 2024 Share Repurchase Program [Member]", "documentation": "November 2016 Share Repurchase Program And July 2024 Share Repurchase Program" } } }, "auth_ref": [] }, "jazz_November2016ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "November2016ShareRepurchaseProgramMember", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Old Repurchase Program", "label": "November 2016 Share Repurchase Program [Member]", "documentation": "November 2016 Share Repurchase Program [Member]" } } }, "auth_ref": [] }, "jazz_NumberOfDaysProvidedToDelistPatent": { "xbrltype": "durationItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "NumberOfDaysProvidedToDelistPatent", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of days provided to delist patent", "label": "Number Of Days Provided To Delist Patent", "documentation": "Number Of Days Provided To Delist Patent" } } }, "auth_ref": [] }, "jazz_NumberOfLawsuitsOngoing": { "xbrltype": "integerItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "NumberOfLawsuitsOngoing", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of lawsuits ongoing", "label": "Number Of Lawsuits Ongoing", "documentation": "Number Of Lawsuits Ongoing" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesBasisofPresentationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating business segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r781", "r898" ] }, "jazz_NumberOfPatentsParagraphIVCertificationNoticeFiled": { "xbrltype": "integerItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "NumberOfPatentsParagraphIVCertificationNoticeFiled", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patents, paragraph IV certification notice filed", "label": "Number Of Patents, Paragraph IV Certification Notice Filed", "documentation": "Number Of Patents, Paragraph IV Certification Notice Filed" } } }, "auth_ref": [] }, "jazz_NumeratorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "NumeratorAbstract", "presentation": [ "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Numerator [Abstract]", "documentation": "Numerator [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income before reclassifications", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent." } } }, "auth_ref": [ "r16", "r21" ] }, "us-gaap_OffsettingAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OffsettingAssetsLineItems", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offsetting Assets [Line Items]", "label": "Offsetting Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OffsettingAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OffsettingAssetsTable", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offsetting Assets [Table]", "label": "Offsetting Assets [Table]", "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements." } } }, "auth_ref": [ "r90",

```
"r91" ] }, "us-gaap_OffsettingAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OffsettingAssetsTableTextBlock", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "lang":
{ "en-us": { "role": { "terseLabel": "Schedule of Offsetting Assets", "label": "Offsetting Assets [Table Text Block]", "documentation": "Tabular
disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements." } } }, "auth_ref": { "r90",
"r203" ] }, "us-gaap_OffsettingLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OffsettingLiabilitiesLineItems", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang":
{ "en-us": { "role": { "terseLabel": "Offsetting Liabilities [Line Items]", "label": "Offsetting Liabilities [Line Items]", "documentation": "Line items
represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members
defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OffsettingLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OffsettingLiabilitiesTable", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang":
{ "en-us": { "role": { "terseLabel": "Offsetting Liabilities [Table]", "label": "Offsetting Liabilities [Table]", "documentation": "Disclosure of
information about derivative and financial liabilities that are subject to offsetting, including enforceable master netting arrangements." } } },
"auth_ref": [ "r90", "r91" ] }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OffsettingLiabilitiesTableTextBlock", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of
Offsetting Liabilities", "label": "Offsetting Liabilities [Table Text Block]", "documentation": "Tabular disclosure of derivative and other financial
liabilities that are subject to offsetting, including master netting arrangements." } } }, "auth_ref": [ "r90", "r203" ] },
"jazz_OperatingAndFinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930",
"localname": "OperatingAndFinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-
gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Current portion of lease liabilities", "label": "Operating And Finance Lease, Liability, Current", "documentation": "Operating And Finance Lease,
Liability, Current" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Operating
expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0,
"order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": {
"role": { "totalLabel": "Income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting
operating expenses from operating revenues." } } }, "auth_ref": [ "r144", "r779", "r897", "r899", "r900", "r901", "r902" ] }, "us-
gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-
us": { "role": { "terseLabel": "Operating lease liabilities, less current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation":
"Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r547" ] },
"us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } },
"presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel":
"Operating lease assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under
operating lease." } } }, "auth_ref": [ "r546" ] }, "jazz_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.jazzpharma.com/20240930", "localname": "OrdinarySharesMember", "presentation": [
"http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Options", "label":
"Ordinary Shares [Member]", "documentation": "Ordinary Shares [Member]" } } }, "auth_ref": [] }, "us-
gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "The
Company and Summary of Significant Accounting Policies", "label": "Organization, Consolidation, Basis of Presentation, Business Description and
Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity
which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications,
new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r108", "r109", "r110", "r125" ] }, "us-
gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-
gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due
within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r73" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order":
5.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": {
"terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } },
"auth_ref": [ "r198", "r820" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } },
"presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel":
"Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } },
"auth_ref": [ "r191" ] }, "us-
gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit",
"calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag":
"us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": {
"verboseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and
Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain
(loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment
in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } },
"auth_ref": [ "r4", "r9", "r126" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "crdr": "debit", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" ], "lang": { "en-us":
{ "role": { "terseLabel": "Income tax (benefit) expense effect on cash flow hedging activities", "label": "Other Comprehensive Income (Loss), Cash
Flow Hedge, Gain (Loss), after Reclassification, Tax", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from
derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r207" ] },
"us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr":
"credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofImpactonAccumulatedOtherComprehensiveLossandEarning
], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on cash flow hedging activities, net of income tax (benefit) expense of $(1,727),
```

$1,176, $522 and $3,063 respectively", "verboseLabel": "Gain (loss) recognized in accumulated other comprehensive loss, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r205", "r206" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "crdr": "debit", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Tax expense effect on cash flow hedging activities reclassified", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r207" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofImpactonAccumulatedOtherComprehensiveLossandEarning ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on cash flow hedging activities reclassified from accumulated other comprehensive loss to interest expense, net of income tax expense of $445, $428, $1,342 and $684 respectively", "negatedLabel": "Gain reclassified from accumulated other comprehensive loss to interest expense, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r206", "r209" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "netLabel": "Other comprehensive (loss) income", "terseLabel": "Other comprehensive income (loss), net", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r4", "r9", "r126", "r211", "r214", "r238" ] }, "jazz_OtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "OtherCountriesMember", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All other", "label": "Other Countries [Member]", "documentation": "Other Countries [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsMember", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": [ "r51", "r61" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r78" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other non-cash transactions", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r107" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueofOutstandingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "jazz_OtherProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "OtherProductsMember", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Products [Member]", "documentation": "Other Products [Member]" } } }, "auth_ref": [] }, "jazz_OtherRoyaltyAndContractRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "OtherRoyaltyAndContractRevenuesMember", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other royalty and contract revenues", "label": "Other Royalty And Contract Revenues [Member]", "documentation": "Other Royalty And Contract Revenues" } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": [ "http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": [ "http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share repurchases", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r103" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of employee withholding taxes related to share-based awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r221" ] }, "jazz_PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquired in-process research and development", "label": "Payments To Acquire In Process Research And Development Other Than Through Business Combination", "documentation": "Payments To Acquire In Process Research And Development Other Than Through Business Combination" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel":

```
"Acquisition of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r101" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r102" ] },
"jazz_PerformanceBasedRestrictedStockUnitsRSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "PerformanceBasedRestrictedStockUnitsRSUsMember", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
"http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails",
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofPerformanceBasedRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance-Based Restricted Stock Units (PRSUs)", "label": "Performance-Based Restricted Stock Units (RSUs) [Member]", "documentation": "Performance-Based Restricted Stock Units (RSUs)" } } }, "auth_ref": [] },
"jazz_PlaintiffNumberOfDaysRequestedForFDAToTakeAction": { "xbrltype": "durationItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "PlaintiffNumberOfDaysRequestedForFDAToTakeAction", "presentation": [
"http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of days requested for FDA to take action", "label": "Plaintiff, Number Of Days Requested For FDA To Take Action", "documentation": "Plaintiff, Number Of Days Requested For FDA To Take Action" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r197", "r327", "r328", "r769" ] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrimeRateMember", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prime Rate", "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "srt_ProFormaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProFormaMember", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pro Forma", "label": "Pro Forma [Member]", "documentation": "Information reported based on historical fact adjusted for potential activity. Includes, but is not limited to, information expected to be reported in future period for effect on historical fact. Excludes forecast information." } } }, "auth_ref": [ "r181", "r243", "r859", "r860" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of exchangeable senior notes, due 2030", "label": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from employee equity incentive and purchase plans", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r3", "r12" ] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturity of investments", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r23" ] }, "jazz_ProductAndServicesProductSalesNetOfDeductionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "ProductAndServicesProductSalesNetOfDeductionsMember", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
"http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Product sales, net", "terseLabel": "Product sales, net", "label": "Product And Services, Product Sales Net Of Deductions [Member]", "documentation": "Product And Services, Product Sales Net Of Deductions [Member]" } } }, "auth_ref": [] },
"jazz_ProductAndServicesRoyaltiesAndContractRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "ProductAndServicesRoyaltiesAndContractRevenueMember", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "verboseLabel": "Royalties and contract revenues", "label": "Product And Services, Royalties And Contract Revenue [Member]", "documentation": "Product And Services, Royalties And Contract Revenue [Member]" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
"http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails",
"http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r164", "r165", "r166", "r167", "r168", "r169", "r180", "r277", "r583", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r765", "r793", "r830", "r832", "r833", "r836", "r838", "r877", "r947", "r948", "r956", "r999", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
"http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails",
"http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r164", "r165", "r166", "r167", "r168", "r169", "r180", "r277", "r583", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r765", "r793", "r830", "r832", "r833", "r836", "r838", "r877", "r947", "r948", "r956", "r999", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated depreciation and amortization", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease." } } }, "auth_ref": [ "r862", "r865", "r938" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 },
```

```
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r865", "r936" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, gross", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r861", "r879", "r937" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r7", "r548" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r548" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r114", "r548" ] },
"jazz_ProvisionForLossesOnAccountsReceivableAndInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "ProvisionForLossesOnAccountsReceivableAndInventory", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for losses on accounts receivable and inventory", "label": "Provision For Losses On Accounts Receivable And Inventory", "documentation": "Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction off the carrying amount of inventory, generally attributable to obsolescence or market conditions." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails", "http://www.jazzpharma.com/role/RevenuesNarrativeDetails", "http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r155", "r157", "r159", "r160", "r162", "r182", "r183", "r353", "r354", "r355", "r356", "r414", "r421", "r451", "r452", "r453", "r461", "r514", "r556", "r565", "r581", "r647", "r649", "r657", "r674", "r675", "r727", "r729", "r731", "r732", "r745", "r761", "r762", "r782", "r792", "r805", "r812", "r813", "r817", "r818", "r832", "r842", "r943", "r953", "r971", "r993", "r994", "r995", "r996", "r997" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails", "http://www.jazzpharma.com/role/RevenuesNarrativeDetails", "http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r155", "r157", "r159", "r160", "r162", "r182", "r183", "r353", "r354", "r355", "r356", "r414", "r421", "r451", "r452", "r453", "r461", "r514", "r556", "r565", "r581", "r647", "r649", "r657", "r674", "r675", "r727", "r729", "r731", "r732", "r745", "r761", "r762", "r782", "r792", "r805", "r812", "r813", "r817", "r818", "r832", "r842", "r943", "r953", "r971", "r993", "r994", "r995", "r996", "r997" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": [
"http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "presentation": [
"http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive loss", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r16", "r21" ] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://www.jazzpharma.com/role/DebtExchangeableSeniorNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of exchangeable senior notes, due 2024", "terseLabel": "Repayments of convertible debt", "label": "Repayments of Convertible Debt", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r104" ] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of long-term debt", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r104" ] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 },
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired in-process research and development", "verboseLabel": "Acquired in-process research and development", "label": "Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff", "documentation": "Amount of writeoff for
```

*research and development asset acquired in transaction other than business combination or from joint venture formation or both." } } },
"auth_ref": [ "r338", "r763", "r958" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
"crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-
gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Research
and development", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "Amount of expense for
research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and
development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset
acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r958" ]
}, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial
statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-
gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedStockUnitsRSUMember", "presentation": [ "http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails",
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is
convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } },
"auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0,
"order": 6.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": {
"terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed
earnings (deficit)." } } }, "auth_ref": [ "r83", "r123", "r629", "r654", "r656", "r661", "r684", "r820" ] }, "us-gaap_RetainedEarningsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": {
"terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } },
"auth_ref": [ "r184", "r229", "r230", "r231", "r233", "r238", "r240", "r242", "r315", "r316", "r346", "r475", "r476", "r482", "r483", "r484", "r486",
"r488", "r489", "r498", "r500", "r501", "r503", "r506", "r544", "r545", "r651", "r653", "r663", "r1033" ] }, "us-
gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]",
"label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
"http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total
revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from
customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from
customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction,
including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r142", "r143", "r266", "r269", "r270", "r274", "r276", "r277",
"r278", "r280", "r411", "r412", "r583" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofPercentageofTotalRevenuesfromCustomersDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Total Revenues", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from
satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of
risk calculation." } } }, "auth_ref": [ "r280", "r863" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [
"http://www.jazzpharma.com/role/Revenues" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue from Contract with
Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to
transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer,
judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with
customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r154", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r413"
] }, "jazz_RevenuePerformanceObligationPaymentTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.jazzpharma.com/20240930",
"localname": "RevenuePerformanceObligationPaymentTerms", "presentation": [ "http://www.jazzpharma.com/role/RevenuesNarrativeDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Payment terms, range", "label": "Revenue, Performance Obligation, Payment Terms", "documentation":
"Revenue, Performance Obligation, Payment Terms" } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:",
"label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [
"http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility",
"label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following
repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] },
"jazz_RoyaltyRateForFutureSalePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname":
"RoyaltyRateForFutureSalePercentage", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Royalty rate for future sale (as a percent)", "label": "Royalty Rate For Future Sale, Percentage", "documentation":
"Royalty Rate For Future Sale, Percentage" } } }, "auth_ref": [] }, "jazz_RylazeEnrylazeMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.jazzpharma.com/20240930", "localname": "RylazeEnrylazeMember", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Rylaze/Enrylaze", "label": "Rylaze/Enrylaze [Member]", "documentation": "Rylaze/Enrylaze" } } }, "auth_ref": [] },
"jazz_SalesReturnReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname":
"SalesReturnReserveCurrent", "crdr": "credit", "calculation": {
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails": { "parentTag": "us-
gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 12.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Sales return reserve", "label": "Sales Return Reserve, Current", "documentation": "Carrying value as of the balance sheet date of obligations
incurred through that date and payable for sales returns reserve. Used to reflect the current portion of the liabilities (due within one year or within
the normal operating cycle if longer)." } } }, "auth_ref": [] }, "jazz_SativexMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.jazzpharma.com/20240930", "localname": "SativexMember", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sativex",
"label": "Sativex [Member]", "documentation": "Sativex" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang":
{ "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing
information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r181", "r243",
"r422", "r859", "r894" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities",
"label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } },
"auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [
"http://www.jazzpharma.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Accumulated
Other Comprehensive Loss", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation":
"Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r21", "r984", "r985" ] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",*

"presentation": [
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofWeightedAverageOrdinarySharesExcludedfromComputationofDilutedNetIn
], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
"label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could
potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r26" ] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"presentation": [ "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of
Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income Per Share", "label": "Schedule of Antidilutive Securities
Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those
issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included
in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by
antidilutive securities." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [
"http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r286", "r287",
"r288", "r289", "r290", "r291", "r292", "r293" ] }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": [
"http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash, Cash
Equivalents and Investments", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "documentation": "Tabular disclosure of the
components of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [
"http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of
Impact on Accumulated Other Comprehensive [Loss] and Earnings from Derivative Instruments that Qualified as Cash Flow Hedges", "label":
"Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular
disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other
comprehensive income (AOCI) and reclassified into earnings." } } }, "auth_ref": [ "r131" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [
"http://www.jazzpharma.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Amount of Indebtedness", "label":
"Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements,
including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt
arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity,
if longer." } } }, "auth_ref": [ "r18", "r36", "r37", "r68", "r120", "r122", "r788", "r790", "r890", "r987" ] }, "us-
gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
"presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel":
"Schedule of Foreign Exchange Gain (Loss) Associated with Foreign Exchange Contracts Not Designated as Hedging Instruments", "label":
"Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative
instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss)
on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r52", "r55", "r496"
] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
"presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel":
"Schedule of Fair Value of Outstanding Derivatives", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value
[Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative
instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r53" ] },
"us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted
Net Income Per Ordinary Share Computation", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation":
"Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of
the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r896" ] }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
"presentation": [ "http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment
Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under
share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount
capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r39" ] }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://www.jazzpharma.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based
Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation":
"Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or
comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } },
"auth_ref": [ "r39" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [
"http://www.jazzpharma.com/role/FairValueMeasurementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities
Measured at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text
Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified
in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value
measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall,
segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level
2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r968", "r969" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]",
"documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [
"r332", "r340", "r343", "r344", "r345", "r584", "r763", "r785" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"presentation": [ "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of
Gross Carrying Amounts and Net Book Values of Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
"documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either
major class or business segment." } } }, "auth_ref": [ "r785", "r930" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gross Carrying
Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment
and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r784", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920",
"r921", "r922" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.jazzpharma.com/role/InventoriesTables" ],
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation":
"Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to

```
be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r19", "r87", "r88", "r89" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.jazzpharma.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Long-Term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [
"http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r7", "r548" ] }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "presentation": [
"http://www.jazzpharma.com/role/RevenuesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Percentage of Total Revenues from Customers", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails",
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofPerformanceBasedRestrictedStockUnitsActivityDetails",
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r424", "r426", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [
"http://www.jazzpharma.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Units Activity and Performance-Based Restricted Stock Units Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Subsidiary or Equity Method Investee [Table]", "label": "Subsidiary or Equity Method Investee, Sale of Stock [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [
"http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Future Amortization Expenses", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r785", "r932" ] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": [
"http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": [ "r965" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r853" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [
"http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r855" ] },
"srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r156", "r158", "r161", "r163", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r278", "r279", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r667", "r670", "r672", "r728", "r730", "r733", "r746", "r749", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r766", "r794", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r834", "r842", "r956", "r999", "r1003", "r1004", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r98" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "jazz_SeniorNotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "SeniorNotesDue2029Member", "presentation": [ "http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails",
"http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Notes", "label": "Senior Notes Due 2029 [Member]", "documentation": "Senior Notes Due 2029" } } }, "auth_ref": [] }, "jazz_SeniorSecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "SeniorSecuredDebtMember", "presentation": [ "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Secured Debt", "label": "Senior Secured Debt [Member]", "documentation": "Senior Secured Debt" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": {
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] },
"jazz_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementTargetPercentageOfAwardsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname":
```

```
"ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementTargetPercentageOfAwardsGranted", "presentation": [
"http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Achievement target, percentage of awards granted", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Achievement Target, Percentage Of Awards Granted", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Achievement Target, Percentage Of Awards Granted" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"presentation": [ "http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r806" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofPerformanceBasedRestrictedStockUnitsActivityDetails",
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "RSUs granted (in shares)", "verboseLabel": "PRSUs granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r443" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGra
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDa
"presentation": [ "http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofPerformanceBasedRestrictedStockUnitsActivityDetails",
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r443" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails",
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofPerformanceBasedRestrictedStockUnitsActivityDetails",
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [
"r424", "r426", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445",
"r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454" ] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
"http://www.jazzpharma.com/role/ShareBasedCompensationNarrativeDetails",
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofPerformanceBasedRestrictedStockUnitsActivityDetails",
"http://www.jazzpharma.com/role/ShareBasedCompensationScheduleofRestrictedStockUnitsActivityDetails",
"http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label":
"Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r429", "r430", "r431", "r432",
"r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451",
"r452", "r453", "r454" ] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ShareRepurchaseProgramAxis", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [ "r955" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": [
"http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": [ "r955" ] },
"jazz_SignificantRisksAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.jazzpharma.com/20240930",
"localname": "SignificantRisksAndUncertaintiesPolicyTextBlock", "presentation": [
"http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Significant Risks and Uncertainties", "label": "Significant Risks And Uncertainties [Policy Text Block]", "documentation": "Describes risks and uncertainties related to the pharmaceutical industry." } } }, "auth_ref": [] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
"presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItemsScheduleofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Computer software", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-
gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementEquityComponentsAxis", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
"http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." }
} }, "auth_ref": [ "r10", "r81", "r84", "r85", "r184", "r215", "r216", "r217", "r229", "r230", "r231", "r233", "r238", "r240", "r242", "r267", "r315",
"r316", "r346", "r402", "r475", "r476", "r482", "r483", "r484", "r486", "r488", "r489", "r498", "r499", "r500", "r501", "r502", "r503", "r506", "r536",
"r537", "r538", "r539", "r540", "r541", "r544", "r545", "r549", "r633", "r651", "r652", "r653", "r663", "r722" ] }, "srt_StatementGeographicalAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r156", "r158", "r161",
"r163", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r278", "r279", "r586", "r587", "r588", "r589", "r590", "r591",
"r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610",
"r611", "r612", "r613", "r614", "r615", "r667", "r670", "r672", "r728", "r730", "r733", "r746", "r749", "r752", "r753", "r754", "r755", "r756", "r757",
"r758", "r759", "r760", "r766", "r794", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r834", "r842", "r956", "r999", "r1003",
"r1004", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020",
"r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030" ] }, "us-gaap_StatementLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
"http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": {
"terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [ "r229", "r230", "r231", "r267", "r545", "r583", "r659", "r664", "r676", "r677", "r678", "r679", "r680", "r681", "r683", "r686", "r687",
"r688", "r689", "r690", "r691", "r692", "r693", "r694", "r696", "r697", "r698", "r699", "r700", "r702", "r704", "r705", "r707", "r708", "r709", "r710",
"r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r722", "r843" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel":
"Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label":
"Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us":
{ "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } },
"auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
```

"localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofOffsettingAssetsandOffsettingLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r181", "r243", "r422", "r859", "r860", "r894" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r229", "r230", "r231", "r267", "r281", "r545", "r583", "r659", "r664", "r676", "r677", "r678", "r679", "r680", "r681", "r683", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r696", "r697", "r698", "r699", "r700", "r702", "r704", "r705", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r722", "r843" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares under employee stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r10", "r80", "r81", "r123" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of ordinary shares in conjunction with vesting of restricted stock units and performance-based restricted stock units (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r10", "r80", "r81", "r123" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares in conjunction with exercise of share options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r10", "r80", "r81", "r123", "r437" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares under employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r10", "r80", "r81", "r123" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of ordinary shares in conjunction with exercise of share options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r10", "r81", "r84", "r85", "r123" ] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total amount authorized for repurchase of shares under share repurchase program", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r955" ] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining amount authorized for repurchase of shares", "label": "Share Repurchase Program, Remaining Authorized, Amount", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares repurchased (in shares)", "label": "Stock Repurchased and Retired During Period, Shares", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r10", "r80", "r81", "r123" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares repurchased", "label": "Stock Repurchased and Retired During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": [ "r10", "r80", "r81", "r123" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares repurchased (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r10", "r80", "r81", "r123", "r660", "r722", "r747" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares repurchased", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r10", "r80", "r81", "r123", "r663", "r722", "r747", "r851" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.jazzpharma.com/role/ShareholdersEquityScheduleofComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r81", "r84", "r85", "r112", "r685", "r701", "r723", "r724", "r820", "r852", "r888", "r910", "r983", "r1033" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r119", "r225", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r401", "r402", "r505", "r725", "r726", "r748" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeLineItems", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary or Equity Method Investee [Line Items]", "label": "Subsidiary or Equity Method Investee [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "jazz_SummaryOfDeferredRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "SummaryOfDeferredRevenueLineItems", "presentation": [ "http://www.jazzpharma.com/role/RevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing and Payment [Line Items]",

"label": "Summary Of Deferred Revenue [Line Items]", "documentation": "[Line Items] for Summary Of Deferred Revenue [Table]" } } }, "auth_ref": [] }, "jazz_SummaryOfDeferredRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "SummaryOfDeferredRevenueTable", "presentation": [ "http://www.jazzpharma.com/role/RevenuesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Deferred Revenue [Table]", "label": "Summary Of Deferred Revenue [Table]", "documentation": "Summary Of Deferred Revenue [Table]" } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.jazzpharma.com/role/CertainBalanceSheetItems" ], "lang": { "en-us": { "role": { "terseLabel": "Certain Balance Sheet Items", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r878" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r72", "r73" ] }, "jazz_TeamstersAndGEHALawsuitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "TeamstersAndGEHALawsuitsMember", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Teamsters and GEHA Lawsuits", "label": "Teamsters And GEHA Lawsuits [Member]", "documentation": "Teamsters And GEHA Lawsuits [Member]" } } }, "auth_ref": [] }, "jazz_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "TermLoanMember", "presentation": [ "http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails", "http://www.jazzpharma.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Term Loan [Member]", "documentation": "Term Loan [Member]" } } }, "auth_ref": [] }, "jazz_TevaLawsuitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "TevaLawsuitMember", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Teva Lawsuit", "label": "Teva Lawsuit [Member]", "documentation": "Teva Lawsuit" } } }, "auth_ref": [] }, "jazz_TotalNeuroscienceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "TotalNeuroscienceMember", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Neuroscience", "label": "Total Neuroscience [Member]", "documentation": "Total Neuroscience" } } }, "auth_ref": [] }, "jazz_TotalOncologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "TotalOncologyMember", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Oncology", "label": "Total Oncology [Member]", "documentation": "Total Oncology" } } }, "auth_ref": [] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksMember", "presentation": [ "http://www.jazzpharma.com/role/GoodwillandIntangibleAssetsScheduleofGrossCarryingAmountsandNetBookValuesofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [ "r44", "r785", "r924", "r925", "r926", "r927", "r928", "r929", "r931", "r933", "r934", "r935" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.jazzpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "jazz_TrancheB1DollarTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "TrancheB1DollarTermLoanMember", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche B 1 Dollar Term Loan", "label": "Tranche B 1 Dollar Term Loan [Member]", "documentation": "Tranche B 1 Dollar Term Loan" } } }, "auth_ref": [] }, "jazz_TrancheB2DollarTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "TrancheB2DollarTermLoanMember", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche B 2 Dollar Term Loan", "label": "Tranche B 2 Dollar Term Loan [Member]", "documentation": "Tranche B 2 Dollar Term Loan" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.jazzpharma.com/role/CashandAvailableforSaleSecuritiesScheduleofCashCashEquivalentsandInvestmentsDetails", "http://www.jazzpharma.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r384", "r400", "r504", "r528", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r634", "r808", "r810", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r821", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r906", "r907", "r908", "r909", "r967", "r970", "r971", "r972", "r979", "r982" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.jazzpharma.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average price of shares repurchased (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r38" ] }, "jazz_TwoThousandTwentyOneCreditAgreementDollarTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "TwoThousandTwentyOneCreditAgreementDollarTermLoanMember", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails", "http://www.jazzpharma.com/role/FairValueMeasurementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021 Credit Agreement, Dollar Term Loan", "label": "Two Thousand Twenty One Credit Agreement, Dollar Term Loan [Member]", "documentation": "Two Thousand Twenty One Credit Agreement, Dollar Term Loan" } } }, "auth_ref": [] }, "jazz_TwoThousandTwentyOneCreditAgreementEuroTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "TwoThousandTwentyOneCreditAgreementEuroTermLoanMember", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021 Credit Agreement, Euro Term Loan", "label": "Two Thousand Twenty One Credit Agreement, Euro Term Loan [Member]", "documentation": "Two Thousand Twenty One Credit Agreement, Euro Term Loan" } } }, "auth_ref": [] }, "jazz_TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMember", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021 Credit Agreement, Revolving Credit Facility", "label": "Two Thousand Twenty One Credit Agreement, Revolving Credit Facility [Member]", "documentation": "Two Thousand Twenty One Credit Agreement, Revolving Credit Facility" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "calculation": { "http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jazzpharma.com/role/DebtScheduleofCarryingAmountofIndebtednessDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unamortized - debt issuance costs", "label": "Unamortized Debt Issuance Expense", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.jazzpharma.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r31", "r32", "r33", "r147", "r148", "r150", "r151" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.jazzpharma.com/role/DebtCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": {

"terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "jazz_VyxeosMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "VyxeosMember", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vyxeos", "label": "Vyxeos [Member]", "documentation": "Vyxeos [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average ordinary shares used in per share calculations - diluted (in shares)", "totalLabel": "Weighted-average ordinary shares used in per share calculations - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r246", "r261" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jazzpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.jazzpharma.com/role/NetIncomeperOrdinaryShareScheduleofBasicandDilutedNetIncomePerOrdinaryShareComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average ordinary shares used in per share calculations - basic (in shares)", "verboseLabel": "Weighted-average ordinary shares used in per share calculations - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r245", "r261" ] }, "jazz_XyremMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "XyremMember", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Xyrem", "label": "Xyrem [Member]", "documentation": "Xyrem [Member]" } } }, "auth_ref": [] }, "jazz_XywavMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "XywavMember", "presentation": [ "http://www.jazzpharma.com/role/CommitmentsandContingenciesDetails", "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Xywav", "label": "Xywav [Member]", "documentation": "Xywav" } } }, "auth_ref": [] }, "jazz_ZepzelcaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jazzpharma.com/20240930", "localname": "ZepzelcaMember", "presentation": [ "http://www.jazzpharma.com/role/RevenuesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Zepzelca", "label": "Zepzelca [Member]", "documentation": "Zepzelca" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-13" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-8" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",

"Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-4" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r131": { "role":

"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-4" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r234": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB",

```
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r327": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05",
"Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r328": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r329": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r330": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r331": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r332": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r333": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
```

"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470",

"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r528": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r529": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r530": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r531": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r532": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r533": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r534": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r535": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r536": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r537": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r538": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r539": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r540": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r541": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r542": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r543": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r544": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r545": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35",
"Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r546": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r547": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r548": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r549": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" },
"r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
}, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
}, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" },
"r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
}, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
}, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
}, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" },
"r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" },
"r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" },
"r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" },
"r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" },
"r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" },
"r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" },
"r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r564": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r565": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r566": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r567": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r568": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r569": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r570": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r571": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r572": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r573": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r574": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r575": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r576": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r577": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section":
```

"50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)

(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",

"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-

S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715",

"SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",

"Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r859": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r860": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Subparagraph": "(ii)", "Footnote": "2", "Publisher": "SEC" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "1", "Publisher": "SEC" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification",

*"Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification",*

{"Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-2B" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 89 0001232524-24-000086-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001232524-24-000086-xbrl.zip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|&]" [FI(1^N<:!>=TZ#]BKSZDKWB>@UUK M\$]L_|*Y O[JQW3V_\&(?*5_B9_>T*JU&?&+>L$-'1YYKU_AU-K_,K=_00;2 M&7T%0<%%Z.''_\;3^<.IIFUK5(<9IM'<915G*2&OJ-0-O7-JL%Y#Y-&_U,?T M*:.ZAY[GH-?:NO'1U'.]WIR_?J;*3L_IH'LJ=?>X$\AF2R]J M\I<^&O@!16R'!;0V6<#\13[>=A6-O4%@-O<.P3N3+P""AG$8"]26]78='9=: M$8(}.F,_H6NYQ]Y%2+V,.S;7C&2_8N8@8J]#'5%TAW_$>)@&E_[PM;@R_2WC"'T^JU:3JG'MA+I23=-T MYK.;3Z?-__#"_A(\Q)097!PO<1N8>W4:? S7]GSUAX7DKG\9A,W?K}$?O/.^5J-'LL4D\/9,Z/+Z'?PZ] MRD0T(EN^=N'I[(_G.(S&5"\L>>RFI'GUB(^O9__>JF-\QQAO@8H,Z]/9A[G( M.!.#Y>N8T!]S/8TPT_V631:.Z5"D>]).%VLDE-M M_FFN1S+E?<=5O\OBG:4/?AYSAN)\]Y^@9"7*V6>;/&ZFVC(:4+]M_G?,/#UTR?DC#_D#O/=4VG M_Y]_[_FSIVEZ+X8Z=1;FO/YD_OO\)1]?K7LY&0P!R)"%_TFV,EVKFT]$F'^R MSY)CU,[GT7=QY]Z@1PY3/[]!-ZL_BV5]Z**#.+*8> M\SEFO].'Q=G3/W] <^M(G^CS-;0O]81]>?UB V-:(F9LC9A:'F V([2)C)=CH M%B"VBXQMBEB!,N9(C]AM-$4!R\C0O[%$/(O0;_$]#E-<23NF:P"99(9,WW1(

*M5V'(RK%D^M[#S0I#5HXITT6(HT4P$")$W2)HW;W'Z)+(A7"1[WQ3YFF[KOMG*

*MRK:\H_$D"NFO<:,7YL/HW\=1V$LB]X_B%==^TD.Z<+'KAC3GMJ2;DNB<[341 M[/&-FCW$/GNBNW 1:!ZZGZ&)GZ#@%GMX/&$QYRV.J3'?*

*@[G>$_6%BR9S:IJ. MY_%: 13<(-^[^&> R$)_0{C0,"_]73<=IP$KG.7U%FPJSQ_F0S"A!?=A2[^@F+L43\R(;Y+S2I7*S]"/XEO*

*M>S_6Z730;#F91/9(NQ3_2P3@9 W7#^>LB8"2K,'JH1-9;VB^DSPQ?=B*K2"QD#]Z J0="L-"]@W@0Z<="B,\Q.:,T=PHL)F?K.%V&>Y.D727-7(NS]TI*

*MD/J6]!%Q">Y.D?27/; MV]TI$@M9 ]Y2W)TB"2]"TZ8]+4WV+&67I22P1-B.%8$.LL>'Y>]CE 2_BT0QDHR1Z]"I%V* ,X64/@$M(.19U)TZ7<8\2+]9Q*

*M0E+V]5L__N,U3WV-"/;OPNZC.T+A':_LJOXUG#6QG/XAKT[RJGG.*;O0$R/ MOW[[511ZL_PNI?NQLX%=C?0-6&CX\TPOZ"KH1YD>*

*MC7V>IC5H"Q=UQR0Y_8Y^C\A9&B?4().7'NQ7R@Q/?R*Z;,H=.G<" >9,=B7 MZ?/MG4^#9F]=&+S'67S!H3L:(_+'@A<3I=2>WF(74P$9!&)=*

*5E47D'7A$LL MO,N;W42J2\9QSR7^) 'FK#IS"I>!>9?J=:"2=? MT]"3B.;"9:[%T2=F5*XC!BP01EL(%S" M"($>NTML$1VTT)>=,4X;- F"&*

*S&##%EZ,*"2<&:1KIU9Z8T#,* 2)X58U*9_0EM%X" ML88,*?7C04.&-#+H\%+,>Z63RD>GPPME#1GRNL>#AK#9S',\2-Z&/K,VKME&*

*M&VNXU\.A'Y&K*,'Q>8HI;:RB1/,R"N]H?#5FTUC2A3 *[S%)?#H%-D >DRUL MQG(KN$T-X'X7;D@$@JHIB_=D2/9)RGN@]]*

*{GO::PV<7M5$T#X'X7;F$SABOA M7H#8V15B#_NGE_@.!5U.@A?O^B?]I\N>;^9S$_]^=@OT'^M'T.L1GE.Y^TKDCF 5 LYU$0(-*G M8%U&J+*

*^[N\PP(:OV@)W$>[J:58Z(;I_EP>4HF1*$;*\H*%+9T)A\\EP*_>^ MLM9-@;/61X_Y6T_,+L,3$SC/#0SRYDZC31G$+))!A,V, X.*

*($_>$CBUNXD8;E&DO=,,XE^0'UY&X7S)0+T' M-#E4$/)B4R>>C7V>9E&3^((\"%+JX-\(XN8S<)=.X3D:8G*6$L.1_'&.)FGE; MDN=9@?,.R7E%9O@M2.*

*>*/TB+[\5]ND@'PS\=DC])GEZ>9]!@236M>.Z),7> MI8\&?L"KB*31=K:PN6O@/C&YKTC=9T-.7W;NXY:76GTW,[Y2ZD#8& N+%\7*

*M2KZ[<)1QA\R>G^2;$K./;DA$F6J, MY)%HX7+T(E"X4!X6-A?])8W]$,=QQ_TS]6/_67/P8J]??KT9(4IH%Z>)[Z(@*

*MO@E<>=A:V(2L8$0OE-.%S4I^]4_P9?4._!HX$~-/SNDGN5\OTR_HJ\C!]$$>WWLCL(HB.ZFM_I=:!]I8A$*35K"9O5$1V]/.JPE;*)+(D"*

*MU&\M87, ^N0#AAN8["M,AA-0'=() MO2X-[B?L&5^FBXW2OB-WY(>83%\.E,?:"!OE"PY"D0;'$398SP7")48Q'D6! M=S&>D.@^:X,MC20XP@;H@H-*

*0J"0(&Y3G P&%'AWS)?7IPR6ZQ<,1-A 7EOR% MB8?*_"$;CYC_.TH7L&V=1+)-5$##8;EPJ20]5$V/ \%R0T&&>E M+2[,,[P(Z5?O"*

*(XE$@QA@VW142A4%JH10[,&]VF"B7SQLU.-^/FP !0H 896 MC=CY:TI"/TFYA?[J/[*?I+$%AE:-T/G@&!0J!\)&SG#-Q3[@%C92APN4]@&W ML)D!N+-*

*H'W +FW4XX'T-XD%1$KVM-^O^GY{Q3&6%JG@#_TZJ0A[[4 M[H@TAGP)N>-FFGTI#_DR=7V"0CJC+WJE'4E>Y5Y0S*G+EY^;@VQ4'62[,)"%*

*MS=!5D=C"YLJDEZB-W_AO1'RV6\,ZR+TI'\PN)+Z^QR1DI[R_^B%=.[N-@353 MCX9D8SSY=OON"'7C+E;CZ=A*G%XV'*&T)'LS]7E/DDS%7NE_E*

*/[UA$4/"?.;Q MZ*==F7+M%%@#M5M68O'<3^V['_KC=%Q1=I^Y@)9,KBR&EST6&&#*V$N&X3QB(6QTMZOA'L.((QB"..FJ3*P M@&^%3M@]*

*(!"ZHQ:Z2ELZ"?<"0>@.(71'9WXDW( $22A+$BIM$R3<#05)J%1J MVI1OMW6_9[ ]I)]>XCL4=#DY7KSWG_0?G@#B%Y2]N"'23?Q[.I2UFT'A@9AM*

*M[\='W^1'Y_#-E U3OKW1HV@0( 1O"+>ERMR5ZX<0DWCD3][HC0N*2)RP!\47 ME_[87W^[HD F0K[=RZ.4PAP>,'%2*-*

*]FVE%T['G%&^;FO&$6R1OR[>T<'V^4 MI3?DVX(X/MXP-[]"I5"](5^F_/AXHYSK=0Q3OMSQ432$?,1,K;J^T6'U-T-W MXPWYLJE'R1ME^!N-.J4Y]\D;)*

*<4IC6IE&:O)&R7Y$PWALHS &Z+$*0WA\J(L M WWI)_X=8C=_G*'X=0],-(XI9'$G]'I?NM!.P-IKWL%O%&0_D3VG?8*&L+E M_,0B^UN]9=2?5[E&;*

*[T2"^P&KB&1%[J)M>DA\F][[Y\ MU?],']#]_D&W-@?=*BJ(;\H5Q!]0"KGO:Q@;FO>70W<#1*[ O8_OT2$L#PT MS<(LCUQ!^EY)_#8@-S=/))]%&1ZY*

*O+NQ/?*,"/-W3%8?(\KJ+HR!6W'Q"= M/=4;-^4*PLL3!]W8L,KBS=#=Q$&N\+LL=+(Z!W,3=-X,W0D=2[C ?;XEV'E MQ'MS+=LU\?P0D6EOA-,?2KP1'_*

*GW>))2MP1900:T]P1-'YY&",-IHSFRP?N M6T<6ECRPA$L>"(;S573/OVAHNB4[UL+E)03#^M R+4)!FR5';ZA"(7[SL@6 M=]VS)5R.:7M(6'?X.. Q=L?*

*[/95N R0 %B49/E:PJ5U!,"B)*/4$BZ?(P 6)=F+EG 9G;58 M%S12I]6<.D6 ; HRUX(EPL1 (NR[(5P:0H!L"C+7@B705B#Q5/9/?MARGZH*

*MJ/$0+M(7#9BR+(EL$7D9$E.*69$M/"]#8LJP,8YLL7H/L21D10V+(UNT?A@T M2K(FCFSQ^L%DHPP3XL@6L1],-DJQ&[+%*

*[/TH0<$53DD4NSX.W7576_G>.@G./ C]L. 1 E]5T7MB&PA? G0 ME&539(OBRY&:4NR+;+%\.5)3AJW198OH_SU]Q%$USVV:NFR1_$'.*,F>Z+)% M*

*(>2C#(LB"Y,_'XHR2C%9L@6O?-]K.O0C8+H;EI1TR%;"']{3,JR(++%\0>6 MDU(,B6P!_('EI!1[(EOD?IV,,)E]7M501+:0_9"8E&1/#-EB]0/+21GVQ) M*

*M9#^PG)1A3PS9(O=O_MVH%WE^.N[\F=T.011K#*0*AH= M&;)E$HI4Q9*L5 29EI*%.6RK!++H"YAZ<^_;]@=D/29.2[*,B@ MBDR4X9Y:*

*<@6LI4,;U_UXF(!%[,L)KN3Y}:/__@R77+[W6PZ"X/W M.(LO.'1'8T3^>#V56:HUNTPHR[[^ZB>C^0RK:7<;0B8X@%,%YM2R_! A\S_*

*MJ0)S:EE^F9"),>!4@3FU+#]5R(SA2D[}[OXW9=0H/(O(),HP!78])F=5R'PJ ML*OH[%J6QRIDMAG8571V+ZILN(Y>KL==ZJX>#P_O?L$A)BCHA%*

*['&U.!B;G.N\?=QPE];%6K.)O" M)>@EQ*XL+U^X;+6$V)6E,X5+W4J(74D^GR5<'C,7=K1"[" R*D^MA M#P55C/'Z&?Q+>]'Q6U/L)F*(1"IR3;8PN;@Q*

*G9(LCRULOD$H=$JR M.[:PN84WZ/ Z@QM,AA$9H]#%7U",O150[7P,[-CVC6UA\Q6B<4&5]ZYM87,@*

*M>^0"23U26]A\B,!8E>62"IL;$1BKLG2@L'D2@;$JRW>%G,D*=/R08D#'+@K' M_)/M"'"Y+&J1DX=@3^5NRY3FZXTD033'F]):'S+*

*(E+%Z1^7JRP5E2@8@M2_[A M0#PM@@_4DB4;<% !$ (982/T;!>OCQX[:3**")W::XB^1@3[=V'6.7/=G3N(@Q0Z%7E9KN/_N,IP3%=F(OC[-<11AZ?O.??*

*MS_3 M?SC?^$.SZ6JVYV(T-!H(#9Q6R]"M@>M8)K*!_F<%[_DZ<3 /*/V,_K(\H M9J/D5&]-DD\/OI>,3G5-^_]K?%S[Y/1O&O_?IR%=87V(QGXP/?*

*U'GX(>*U?X0;F_J"OW#S5& M85R/*4V&V<+#8_PMG$^2_/F0SMNES C_$3RLPV+1_7%WTN^=*K]_I=WNOYRS@ M,'O=LQ^W%_V+;D_I7)TKW?*

*\Y^].Y^J6KG%U__W[1ZUU<7Y6X!&.C)?S:Z7V[ MN/JE?WVE*N*H34;SLIICQ&YHUR71)-3ASY_V2H2- CP?/P@(I3?ZW0U M*

*9K$^'3^PR?/CRDX3U]YV]A+\O^WC& M[4WSI*7IC.$3*E:)-W_Q3!9.Z!H_+O[=.9TXVO*/M!.=__TC?QZ9?S@CFCE) M:OP[="&,1#_7S-J;M7O&1+*

*[T4#M'> M<$AC*8?\G[_IEO9)>%G\>GW[7?E,56P8A5?IF#[$56::^!8/F6W6:TJ(F-WU ML']Z'KDILQO,5:EQ)3RD-]JZ5O\75]3/3VDKFTA#$Z1A+]*P;YY?*

*SDP?OB/R MAW(=XI\VQ/[@2#O.2:MIYD6Z<6(WK7>!WIAGS!.MT=B$9U8QR)P!C,DC8X&7 MTA/@X2()HLGFFJ5#?!0H/T+?C3RL?.]M:B,7-*

*&#F2^76*O]*J3.)23"]Q9.( M)#6%I[D2ZND])J=#_Q%[]82D3XK'8%K6L1O6I[>ZYXG]$J\,.A;E:G R/A%%*

*M(9PJRB0E<8K"1$DBI8==%A1FQD8WE8@H>O.#]Y,2#95DA-GG*8T>?#J=[J,[ M8GN^2L=-V,>Z8S9>T>E]N_I"&7WRA?SY1*0LK%!IM8&\+RW;#*

*MO]I-81'77'.C1O}3']!$C]K6ZAZ;U*4:DCL,Y1YK4N<63A(=:&2:FIBHL%,IM M'6=:C=]*3QMXCV60/B*@Y4'+;^$[$OHZGW<:6:GFARB(G_1\8Z;G&Y76\\]D*

*M 47_C])/GLDTT_1#$HV5C#"[_\MH7=2S=DD'E$'BLV@\]F.6B%2^^E1=4RFC M=NPTAQ'M\BPB^W+VW;D$-*

*UEV5F=W4VI:H7%B&2'S/SN__;7RXLSY?+B._$G5U_O^E<_:>\|'^SI7SH/B*J)!B 3%,0?,=/ MJU.5@V(E9HVOAC[UHOQ0\9-8H6J%^5A/P9V*

*:14Y'8_62=,T"_$\&LZ)8=E[ M\CPR3CV$Q5RKKW*Z'IE>8IIJ3TV) ^;FLV:[-&76$7GDA=$;N*?;N$)F0Z'YV*

*M>?.SFV_5VA<$LSV78AT2V0G<1X\7LRVW[*S;:RM@U]I.JZYKIM&P%\S HH=2 M((]F0GIP'F=*+/=;<))\)IQE*OHY"?YG=:\ M3Q/';GS^P_E_1Y^EQX*

*M6M0%]H?)2/D:1!%1E5\12W=$T9.[KV[N6%6'/,:\L9_?&:]*.') ^VO:[7V>3]@RU$6TCK;OR:S,8M6:&9\V->>#9"NK[1 VT[@ M)HH3%/SF3S)C.'N/09>J-*

*91N\U=;/O;2=+V^.35F"-Q2'SAZ)K19:YM-\^W: M\SR6D9A@](JLC5I;W^&9["AY<#.*PC=AED[C+,MLU.U6GC!+E%ADQH@J#3?<*

*M(&7F3/G+GR@L2Z4JE-.5! =XPE:MA'S9+T!S/_Y6\O0[4^Q,B%T ML#]!@8(?L9NR!F9T)+4W.-YTMPIV*O>X,_^:_<1D!YHM$6L9%F-(>'4J*

*MSO@P>$K"==SD5!Y>HL&JK=EY>N.DU3**B7L-^JCW9R5'3+&> M2[-DL9\$/&6#D3M2W #%L3Q1PJ9K)(BK]MYT/(B"#[%$<="&*[R:Y=TXB'B>*

*MMJ?1S\/(IW]YH7_R1,!-G>)9FI[JAL#+AM/+!%5:U\3NF1$ MIDH\HFX"=3#":$S_$"CW*$BQ\G?MA*Y"0]L)V8@MDCI'2?.9@&;R^41P.\N0 M*

*Q'S,>X\C&M'[*$S*G!=L6?G+%E1=$;??'07MQ%Z+%,$E8&4\4=84H:=I4%U:N8Y^"8 ML_9BL^.#_E/FS8UOK S]@"I<% 2S;5CF!_Z9^DP+4^=O@&<#Z(-*

*WW)-5//HI MM6]LZ(1@%W-KIQL*+S&)E0_T>90/E#BEMB >16SO9;[GF8QO\G85#^CU5-D\ MLR_/%O)3%D9],%ZL=D!9B@X:_$[7PK[$Q]-*

*OLJG,'L;V[&,^$SY3%">*HRD> MFL8G*W<^<^8@SE)"Z%NR>@"F4A*4I/$3]SNU]GJP_),EEVVU%EP"L>F>U*P(_MK>QML<5_KR*QJ-*

*3(MRDNH2YA0D7E:>PG"15#'%"Y(E'(]%(P53"U45/E@IDK MY/(4Q#E*4+;;_D;+/#_C9>QYF]*1#:W)=,@MODN#+%O>J_?WK4VR^3SI!QS_ M5)CTOZ*

*'(\=,&3Q5>6H@_2#]DDB_'RM('>A:L()DA&X]/%.I\8#XY M#P_]D-=+Q4QIL'RH0=>Y8HK\8_W3?-C: :LG.!_((I9X!63G8_TPTR]T1"N M;I0J}.TXG 91}-*

*W=6UC1=/W]*M&-'W5B-YJ%/,G03FR[F/1>P>MK';"> M5I+8\;G.X%@ MS GS"Z?+64:6]0)B%G&F;)]LFZO458Q,R?"=C 2KU5J:2/&'RS*H/&]*[7T8*

*M\;1G&F?)#+K6[%SODE-@$>'O"J;LY0\^?35]K1+2M44L/W'OQ]Q_"%'(KG-G M\0XK^&.#69E>0E%J49N;>2-&>OX(&*

*<12DR>)7UG5>ROX=D6?)NX2"8B[GR@0HO3SEFQ\;>3^C]=#(!._D?'(N7 MHRXODS_/VY=*C=P>*N.#C>UO8WWO#FF$IL,SZ]=N$CVW?*

*="SM@]/YP& ^\@TN M:D72T, ^(F!4CU=X0UJA1\7%]ZNW'/]E-1G#Z0.!W7RZ+.T)Q18O;BF-IH-M>D8BW.TY^E;)[96S!:F*

*MW3RQC/WE7\FYAUELUD&*$\,WU^BN+X&W=FOZ=2X6ZM-0,=/]\R> ^"'=ZQ-OQM %%,:.#UUR!9;'.! AP20A;K"T;2W*QW0OZ$S=\O!3B"PK8#5!*

*M;X1Q$C^96LX.LB[UJ7FJU*MXBE]Y\>LY=E_V@\T2@ZND%C2P"'/)!S=HX$HC M[*S4P,_^%$LORJNR'+;OQ^X;DGH)*

*<@/P9+_[]&N8&PZIUW/EAU+/7W)9^!{Q M0W_=K F^S$NI@$OHO'4)P0&LE'O0 >PP@BS6NJ-'$!6^T+PB%WE>(_E5;IL MO9D[*/<:/EQ&,>L9)?$2Y*

*:@0AXM6P[U:.5U"CDW5<,I9$N1WRGD@(!36%V7 MH0E.8941;F[H%/(2W5$4T%?$LU[$2O?/U$ ^F5:/%2@@H$M6FHKR!90$2O(EB*_%>2 @!6LKHYL*

*M@16L,L(-UL$HH7_*(F6%.83RW$K#[[POX'!"87\G% PXH2"^C.B:66M_1R&Z MXZKOZ;JN(HZ(10;KB=O2.1BCZE&4(35 M@7AG1;C85:(0#0?-*

*^L1H5F&:\VX5S^TJKOO?NK=;MZJ ,A30C0+T\5)9LVKM M2WR'@LS6\BO*P-A6"-PF9&C*4X$=T($2B$G#J+59LD7YBMPD(J#^*H0K]#_8*

*M[0,I>4]*;"HE/*L@31F-\OV4) UEIX5Q;^X,YOE9'[$O'7OS%T$95DA-FBN M.38MC;*<-[L-(TJ$E4_=;A2\6JQ72V@8+3",$FC$EEYK=Q]'L"'\K\J8=I<*

*M07<(W0O=8(>PC7A!_CX@?I3%EV,DT^ZO*[O7S,+MRC/[,XC_^.[\" M*6:7 /([Q:*4*(/93:CL=W8ET8^3W@G[PD?ZFHA?5<9O]R,TCF0W#[!!R@2*

*M#QU&01 ],%0_HG^^DNY&2$R1BY.N0C$>[G]RSH;D"K)9<>L7[W=?-DR649 M Q3CC/&IFV>7>VN9JOS/] '= ^GRDT[Y0.?*

*E^NE85<;HCK(T_W$2)2C.?F12 M$$<>_5F)'J<#E.#X)RI,*%#X)5=TR8SZ!(^!^MM0_S5I%RC;G?B>'P7X$;B[*

*M'6^'(1IP$BXE[11(NRUIF2E[MH[,#G93$DVRDM\W)I#?O^=[^-E4LMMRGWC[ M)U6YG0;H+PQ(;(,$HJ\EZ,X/Z:P43*AKX2/%'9$I?2PE^-A7/A#])8X'[-*

*Q* M\E.=3!]"2O)N2(#H);$_&W2&0N0A+@D9]U-,?L.3OW#@(L!D&TR"E% >YQ=W M^XS#S_'03^C\(B#G-*

*N1DUR@/2)0PSLW<%*!I@32EQ/SW]!%'TD9\>2^=+Y24 M'SR4AA%)![[K9\#S^A*_M_>A&0QG??=0UC?Z'AHL/'C5XC-AN%++\'&%WN+/?Y_[V#*

*(EA&G,@SI@[*27RR MD-A]-^N[44KX]5V^GU9GB-MZB;/N@6_VON87H>_EZOI>J@*FNMMUY1O*BUE;HGYFNZ-UMA5Z:IEO5&/=*

*M,@^P=;;BGO@$CY7GHTV'G*G5[0QS1/-8,18WK-J2TRL99B\-B.25XGM7,9H MY5,.#>L_.[_]MQ\ZU#).NO^Z%<=2Y[RLWEV?*

*N;N0),_.SZZKQ[U>N>*_2G MWO7EQ7FG3W_YTKFD^J*K]+YUN_V>*OX<,$JI+7+LW4^=5!,^.$[]-G2XA0),8G\Y_^#0OA_1#/A'^I4^SI\^\K27!!7]?*

*M]O',BW"'<$UNSF2,QJRB:O7CF8YS0A7U<_+O5.FDU]*4?:2?+_[[J43]-@BPC MUZ-6_[UIFL5-*

*JO'NH_;>^#%CB)4E/X5R>&N#4]POVK2R3J=5$Z/1Z+PW) M:@Y8N=B9@F,*D:Y5X>TVE?G$-^2;M93<]OOY)I<;[R'_WWMXBU6J?I820AE0*

*M07&,D_AT*]C?K#DW,OOZ?D'"JK#_VEF8+BZ.K)4[WPE@/^_4_\>!:]"@QFB M>1:O*7F+5LM8^M]W6N++I?%"2*'6]ME_9*=COA+$-W&4-*

*/236Y;]2&.OQO8; MV.SY']PZY6@/N_X8!?'/-?8;RYFRD?4[A":GC$,ZH2!7,98O'EL&X;M;:A&GI+U MA/=F_46O3Z:ETJ;LR_SM,N \#L8E; M"HRS1J/NP#A-*

*JC<-D1CGF.*)CLLK.&,%8!=30S@(L*J$.&%;:8B=X4&AB[=3 MJ)LZ47++Q1J%.J?O[1-YKW R"\;S"HI5:]N&J5JF(XA[461*!SAIC88MDI-L MRDE:4[6=AB"*

*<=&R.:IA$K&@>'-5='%5&Q"D5@KSAG./8JK:[!097-3>,DMV,D-OY$ V- MAFW-IJJ,.VM1\$8%9*$U6K00%M(I"[6::L.V!&&A8W)#K[/Z_%?[PN"/;JM2*

*M.34[G(A;"H-1:YO-AFKH.V^P@5[\P^_NT]36YHDOND^&TP6TH8R MEY71'9%U?3]*4%"$KE]77%5U*5Z7[=U%@-D&FFHZFMI@Q8B%^$.,X22!LWVT*

*M#+$OH4?5*3?[(PC2JV_^*]Y9<^BH:]M46;!YA9/N MXZS7]R]1Y#WX09!3*)KLRA5;[!LMRV(OP'^[T%K,(KG*78/B-K06J6KSA!7 MU\ZQ_]U6^VZ+;<;*

*[+!12VL4$;&!CRH@WZS1H-OR#3^D9C=-53?!(ST0[.=X MB F[AS-!C^"3%]$UYQ2]"-UHC/OH\D M6AP? M-6OMAFVK+7/GC!XGCFUZC!KE!?*

*>T77&D$'=7:O.=B#.OHG!6-K*%4%A9 M14.%.D8 ,^55K84QDUUK6VK#+]I2 ;S6C>J#*:'K4"-<>(WPLR3D%0.V,]54 M#5,7Q,\ ?[6<*N'M.8CM2-*

*EJ8_>]3?!4\U3?+M>>6Q?4;53[*]_JLW77QTE ML%&1<4ZIMJAQ/4,UFDW5UHO*&&\,CJ#]W4"XCD^X-BJHSBM<["'"C3B-=4S6;*

*M135GV:MP[2%Z$:V_\>5%Y\O%Y47_HMM3.E?G2N];Y[,[[?KRO'O;XY=PV)^4 M[K]^7/3_LTLSW! M!$:%CF.#1%15(C;L';>;1+#:$R]=%]CIW,%",&)>/M-*

*R M2V%H,"/14IO";$O!'N=AU6HQ;-2LM6W'5!U=E/-&QQ1'S(-"=JTP8XAHJ 11 M>%=/,!E3^ =0I[>UGKVD=.Q3,IY3*FXI&E;M;>H"-0>'_5C6@-*

*MU6E6;+M3"M6:U56RNF>\,DT#[L:FVK3/R+A;",=:'U-AL$7Q,\!=/: V+8!_ M'-:D4-6$X1_9>\P)/\%<9E"F)GB[YE$6=]B.JS'9.L]_UYC89@4KJF8XU%H5*

*M=4:_'9X!44%%1\MUZ^*%G;E.YY?XF99J.45UYBJM)YZ$QD6V@H++5XDB50EP M'#^9F%E"'"0*>(M)'6]<[VP8[.**U6&MDN*J@BER4(XFT/1>9O&6-*

*9JM.2Y2] MGNH?07K3(N^%SUZ@JCV.3&NN[GES/VJZO;PT:FU;5W6XS:"2W)2K@UX!W-1D M%V^IAC#%6)5W;%_U+'FE=*

*{=M7'(QB4O(M;\9Z)M=B.LHZMV2Y1\+#BV-M978OV8V9[%J[U;!56Q.EH5CU_=N%(_8%9:4K+A>;G+-_*0M;NQTM=JY+4QT;*
M3MM7D8\V.6U?"!\YK'*ZH=I-4?BH\O[K630>^PF[4B'F-ZDPX.G$<>A2()4/-M5U&"%>>GXLY^Y=5?C[%_&OK!S[6$I/@MX[V8?"?TSEY.?PS:WGE
M;>=UZT_KKKQ[T!LA@D=1X&$2ST^LLAN!DNEVAQ8W,0IE?/]8MK&D*-F[)G3*-MB$R5F'$?
G#'9V@MERBP*>TGD_O%O%#!E]]8M:+&=*4%B+0C<#^A8;L :ICBL M<4QG0:B+7[^/^)833DE$49RE07?0AL<12ZW0AK^CO_XZI53-B-JE-)UGK;AW
M$R]A?=:2690\/\3;!U"+6_!(4R >.2;O\ Q-?%9%2[!\XPD'G_*$R3TOM$S]N,G$MXGG53MHNZ&1K\19$XY#W%F(-#;)$XY)C<6?
A6BJUWWC)MU7+@MH\]YR8'CQ67UQ)E?A:U$?" =C<83@D"8 MSI_^M*3/R9S.?$_T["65L^J32TKJ*YQ<#_OH,:<4.1H[HF^JIK-XSFMAAP[\
M6JDX;$$CE\-A.BMM,E2](0""'9-??(L31/_H*1B1D$X>$JA;N\-S4G9GE'PA M,>=XZ+M^WJ(4QZBU'=-2#;.H@X[@#(O$3VN+YR:1*UFZI5G/GC:O#N,+"
MUQ4(/T'YR\2RGA#QRD*;7;*'W6Z7D%OYK#%F/-B>$;S+"9U7V338U8*ZK:N:-MM7-W"$EN,P'>*\3P[\%4XKH+>> "2#9*]SRY4A4BV-M7>3M8D)(-O=
(/B:L$27]K^??MS_3?^:3'B-RYX?\U8UE=XS-.*3]>4#8LV8+-M?^)K&R[U@")E<+=LA!7DLBTY%$Y926T8)+3F=T17C%! M$M9T/1GA&#-)\W
88WYDBW,=W]X;\FO$?1:L)_0/_(S0R4]"S*;1,++|^"2* M^<;O*<$!2OQ[_.G!]Y+17/)??'$F#]KS5]"-3B)-5G]%%&J;KZGQ\E\V6Z9+
M_*9=#7;T#1F@OR2"2D'0Y'{6Y*M),QPN#?"9-)E6BVD>&1%F6_ZV'B)J#?I,<3*184?DF"1_HC;R^!_CTVSR?A,VI)3T^)G^?;+
MMPOW-'*^_6?GM]^4FV^=V^^=L^Z/_L59Y[*GW%R>Y5:2AY[XV?75>?>JUSU7-MZ$^]Z\N+\TZ?_M+KT_]\[U[U>\KU5^7BZNSZ>U?
XM7RX"*G^C5+Z#"]6%?SH-M8FK6)YAD4;2"QOS^])_$7\B/$*6>3TW&XEP+GI&SD5I^XYZ]8[J;7-2Y4_1L
MCK@31J<:H$F,3^<_?)HGZOV0OY%_Z=/L63,;QA3PVPP-RG[^%DWGVB9?IXE-MB&9OGGU\0C_ZN/CWAG/B&.;2C[03?>G?5SU*UTZ:3C/7HU;_O6DN?
PE,:H^3-MLC3CW4>M23_FS#+N)TAL;10C+@^UGM;D;+*FY=#Z@),#5U@_/F[VY92$J.*_J7/)0Y&E9_D8[+D2<0&VQ#
M,QI%+7A=;X0J$UM:*N)9)@GQSD1:2UY9$7JW1Y<=@Y M@Y9J5NC0+7%+EM>Z)1I)*3:3E-UFCLWNS.4%3++;AS9&?P\LN.4+SNL"VE3-
2RX'*^*#*9KY7.8-M66N;IFHW@,,JR6%Z^1S6J+7U5D-M&7-14B59S"B?Q5C+44.UK)W;C@K81T1W-M1/8NL^-]-SF3KT\]'.6Q6'UM@Y']RQ-[HZ9JS8;J6
4?9!'V!!JPYX;LN;9?-MR?[9TZZU'9NUB=*-.8$Y7S)G^;S98ADNIZ6IMEW4OB-P9T6XL_0]<5US&'NV-M#$,UY+#LE:L>[]"6\&/$W:@#
{1USO=1;%_(3PY&7=E_(!SQ47-M.YY&I_H7/U3)!B+WS}1GU_9X5/4%T83=8X[=44CG>^?C>/6]C]-V<%68F-U%-M0(&X'L[*[WH,A6?
C\0*'CV%G!1#YG/I}.?FGC="[",ZV%&WOF#_3DUR>)@GJ-MX_SWJNJZQEHCZ*JEBW*Q*O2P/$10*"8SZNR67QH^5JEJ-YAQ71-H)B\;M;-I
MVRJE'O!B%7EQ1<@G)C.R_5^CI9HFU.:4<(LT#N@?[U3E#H>8]=MA)3K(&_NA
M'R>$M\.!^IRM=TUFU/TEHRV5FLXKRG:SV#NWQ#28Q#15VX:2B4IRU;H>M?OA-M*M:X5J-Z6_9*0"N$I&K2F&];&]7MZBO650W9&
KH=AJS?;"GOB*;<8V:-1C-M[YS:$;#@1G2GD=TQBH@[XL[B+(G*7'](G.Y07Y.1E-K(^3-!9]+Q'*#-0K*+-MD,9O+HYC%LSEEIT6U6^K1*:!V0_AU=N",-
}:]S:^95'=*)X-;,>XZ@BD\,R=-*)%HXV[I(57GG,-MM/+Z:4U,P'9.V-6VLRV6W(&SJ=7:MM-0[=TOK-M"YJO#LL2
MGNL*REB+ZYA>A&XTQLJ01..Y>QJ%^VE55WG)6>.6/C4VR6A^&<7YA:=!AMEOCF1;!=LU:6[>!UG:*JI4%ML>[?;/=19K7-M46Q8H
M.^"ZS;S3(MC.SLHFM-TKNO;.=D=678L)CI-Y[G3I]8D5+S;ZL)L_&M,%T)_>-M"LV0>HON"(5W6-EH+'!DA;;[<1=GE#U+"<&A.^T3.L/L^;\@
M/V0AUQ=.A03S;MR+-F%0-Z[MHF6A9DQ{]MG4*\S%/CF5+3N,I9I+[AD-[I*<-MNP1@+G95F]IJ-7-5CKDV=1!WM'SL(C9K<<_[X.P#]:K[J5O:-
ZR62.&9F']9J-J1[\,$#$0,5%%;(\29FFUMFDY]J:!$0,).UH)6U,$-MM9N(Z53$#$VU[)WS$H<0,8B](6E1"N'F'\^EN$E5=K'YV0V^_T*T3"H\7I2R-MNT_?
RM:V3X?923.[(\JD*1-,%$H=/T1DJL0C1/#IRKWZ72MBX/N'__XQE:%\-M0;'O[K+14S6W?MD2Y??<;S#1,07U?J;7>.O
=Q$)Z>kC=G,UI8/W*LWZC&-9GMQB<+#D5*PO#'L-Z[^3&=V>\QNU=O/$'\YO%L#YKX',R>^X?NCGF1OW<#](@>SOD?M])8U11L/,3H()BGR_,F?'8
M,L&W6*#3V,/E)VM-$7_7#\3J^,0J7PCUCEBQ"N23)8V10:Q-K(Y/K(J2*G;S-MQHFUA\MK0*I$X"V0JCV&?N^(E5-K-TZLG?
OT'42LBMS#T@4/#7_EOV"OCNB4-MT!U^LSD;*VF,/7;2FFW<\C\I=-IN&F0-F92Z,EBV"_9$MGS]L+91,1))6D;2-MO"<'YA!U,H2NTO$-D^LAE[CX.DWB!
(6,1+/$2[Z*,5NKM2U=;>SN1^9&4X(C-ME$?/FFLJ[O?+FCIE37/IW2_-FL":97*F03G34-V[J&0V<&:5.'--A?=^6=/D-M2K.YC[:K(KC:[^S"5-
_5]J;OXVPDC*\CIPR!98@>O?1NYXW/0M\%(Z-O??CT1?&WDU^:-VQ>P4,L#>P=U%106'<;5'E;;M-??&"-M1N!NX.ZR(HO"V-
NFRMM06TMN89.2O7GP\3%!})GTOYY_W_Y,_YG/>HS(G1_R-M=S=>\Y&+V6T#,Y9I?QX0]]S9RM]YBE/V4^!K\#59OG9-36PP3=P?806Y;C2F
M[YY2I:*$44*?SH)P.AF?SNR.H$"9()*P1L/)",>8:6>/M8]F9B[D1^,1U;/*-MD$;UH>O3X533)ICW%SQ928'9-!I&EKZ81++'/5.HIP2SPO\>?'GPO&-LMFR^R-
/S2;KF9[+D9#HX'0P&FU#-T:-MN(YE(LL9#O[7,&KS+XV>3G1/J-VK#PA&?]31D"[P%-4/:!HS=?]2GU)E^H;N
M;TFVDC##X=X(DREV:H"C[+Z;4VHR,6&CZ)R0,'-11H3Y(W];#Q%U&/K,O#*1-M8??Y,$GX_!&UE\$OHRZQEW+W/SN__;,-3-R3$._3>0SD+*/
MGY7WB98I\-F6PNS-LX]/Z$<&X9ZU.J_-M-\WE+X%)[7%2EF:\^Z@U&U8Y6W+L)_G0VBCWL#QD?UJ3L\F;,NU8SJH65*:6-M^?
$$8^4[']>*E2YU63SN_-3PA#KB-TP44U,W:#CR;BI+4M)*T@68:6=F*JBL7-P"ERT:YJ^[#'>C-M?1V)#YGD7K^D^UF';IAO%]

*:YA_"!&K?*?HZV2$B<+*,-@>X3#V[_&\<_0'-M=M?S3]-MNDK?/Z9NT5\C0G\-%3RCQYN(\-^2A/B#E.],
M]Z,;1!^3Y#8U1JUM.+IJ[MX%0YSNGQ5GSAVO1EJQ(;'8;&K2L-[6:%@/E[%+-MP*$%QJIBLV6#:L^&KAJZ*#=-N-V\>,LH3FSF;M7;+4)UF48?
NX6(UN%A-KE$'-MS4R*#F=?;_.!I]:/-0LZ4S#CY!@.LF_L*?<(3^^LE/"GZ-?Z%K8G_LL%,5M]@-4!S[0PH-FPM5I[EUID7]3-4V-M%H.AGU3E[T7NF*SS8
A?7P/JA&HMV34&AEW,16UKX_C/*WJ-MSA+5D_<$LV0G["7DP%(M0<%\QS:;U*;I%'1\'1A/*.83F_<,YHLT[:)NX0#>-M$XKWBO:M"F8^L]9VBDC=%
<1\!ZW$%BU8Y7<6-M=@Q+=\2P,+/8RAAUL7X:-EHE9[FB]7MA+,>*]E6CM1B"-LM)SG)B%[.RDFFKI3:75'KDWE$&/A61-M3P\4B>V#.5GAM-
E2[29H4N#0W2.W?;!HL]9V-%77Q>?0RO=PZD<)"O)XUQN>-MAUY^Q\,N(EB9T_R[D:9"6FE-"+)$(&-<%*,-L(!X4H@W!%=-MZ@Q/@:;?-4ZKU%/B:
%>RPCWAY5.[6<@]X4VXQSN"9=1:1WC]>(]NK#NM^O+-M\^YM[_\C?*)_4GI_NO'1?_PJ^O0K>++_%GK!7^S&'O^':S'O%M]XZ-M,?
5\MTJO>I1UHFO%W5N=[TFKYM0\<9HMF).4V.7GS/W/R3XQ6N]?@W[X.;&[-MV:V&8),Z,*&$3+AM3BN]\3Y^LYSGFX#'T'F7I#>3(=%#]O-SG7]U+B27]
(+Y-M:T+GBLA4Z8UH/+SZ(AMS87E+3W'(2H6K**S?1PG++#713$BGG>(@)P5X!%XOG-M8WKQ2'.&)GZ"-AYFW6(/CRF=)Q*_/121J^7A4[\+^P$$Y#O%?
EN<8+H'S/;=1$)Z62@?<_E=J)6WUM;*CZ.PET3N'YD"N$Z3.$$A-MHTK>8GE=J[4M0S6*/NT"U[D+P7G5N\U]1XE;=C1EC;AQ01M%.5+G'FTR^1(
MIW)T)"($FGQC36X?4),;O*FIMG/#$DFX$!0Y*/)\TK:9(C=K;7"&0(:.589:-M1<@0NY'$7KR[$(0(A.@HA,C)+T0YG;TFN[;/Q@)R!G(F]YSEZNUD-M:!OV=BI
XJQ:N]4P5+VQRQ6M(&H@:L*L.Y>DK>G-5(" V53-[)9J+6F:5DV#-M)FHU-D@_2/]KZ5]S=5@!PM]B_JQM6]JSY-IT-<4?>B'-*!AUF,8B-M\/M)FJ
MO8CCE!=+1$,EFA>D9SM&BA\R7?M[&F9:^,%/1@I^Q,3ULWN(^3-EXE7)]RM]
M)+MN?"^;;8:Q@95B4&#O/"64%#=T5I&7;;SQ#Z\S*G=GY/>6&2JGUM[90,%]-M]8A4!AV1,@"5YY1<)F&3=.NN)D$7R21-A5&P:BRLJG"W
>YGVSJ/8YYYPLZ-MG-Y)B.^R1I/Q:EZ\1&6(_2?D+-M%XV346M;K:+*-$3:Z:\D1VWG$0,Z@-Z@-^@-.H-.H-/H-#J-CORU\-U>^,:
MJ!);F=>88,+K,>FWZP/$+O4H,--1O9S[BDS'FBMJ]Y+I,&OMULX=&P3<7*HD-M0U5FZP_0-70-'4-'T-%T-!U-!]-1'QT9$QW-0=)=$A6P)%%S#R),<*!QXX*
M*Q,T97>-LF0&'D^":(KQ/V9#HH"M2DG0HQ+X:._';WO*0]L-EF0MH-/H-#J-M#]-#Z-Z!^V4MN:86;W5O6C/GK\]=D!^QH1[KA]8?M+[!8K
M',;|=NV\O5X,UAW440UGL<-S=R,U8#)0-8"._.C(F-R0EFOR&8XUA]$..:3B:-MXA@..+$&HV!462?6MJOL*E/G<@TX]\UR7^C-XZK(JLQF#*-#Z-Z@-Z@-^@
M.@*URWH1CO:C#J4$>R(*;I#O781G:.(G*.,"^V.!M-'J+_TS]V$]P#Y-[W\59-M=?8E@86S+-M-ZE1&-6CRD]-
;E<+6J9RODY&F/"D*,$CJBO}>ZP$47QD;;DJLY4+Z-Z@-Z@-M-^@-.H-.H%-A=/(54ED;WE7,_>&SE^[P14B]8WQ)?6+>4J2/'F\BPE[821+B-M#]
($#0++HJ2,H-M6*,(;!^%D7:CH#+;2X-.H-/H-#J-#J-#Z-Z@-Z@(T'L:6\8>]++HY#G8S!M)
MFEJMK3=42V_M$$D*R#\RYE2.A*|WS:GLQM>Z.'Q=]:H5>RD'?$$!;]>.$N4[-M(NY(,755,32CL4OARB-B'B;U))]<,K+'4>![*'EN*A"*2M_]ZZ_W"R[-H/(Y"
MWEX]ZR!WG29Q@D)&E=RB8O"B2BALQ>PT=2)@8S'!4$I9+-MP-:TC"E-KAPJ5U9#U+NN$(0@]"_R3T:[IX["[T#8UYK99CJ0UKY]8;-M>Q=
[:,H!HV#489IRE#]!&-6C9!D%P@2C8!0($XR"46*-F&"43#],,)4A2/S-M%W&<\HKP:*A$A,X:D:F2%/^7@^3(DF[-,C-M.W.?L];0;&Z0V6-
08.\\)90469O=K.Z0?WB=4;D{([^W++FGU]J+>V1PQ$Q(-M!H(#@(-.H-/H-#J-CA".R[+]R(7N?QMY+?Q&@(V=%J/6;H+7(@GW@&P#.M-4
MH%IDATS[=&=7YH)L9S6\HR>-E0M.HM77#**BD2Z1ZS4KR465:(@,Z-M@-Z@-^@-.E*@I/Z-9K:.A75N058#!0-H",_.C*FB*3EFD.E
MB(HS&Y9@9@,JB18JB>YQG-"EL>%T2$)\-|'>+,7$&-PJBO:66KI]HC@:X!IJTP"@8)=.!0_G*S;(,%$\!CG#@L<2N,D'3,0X3E@J?WUVP+Y&A#MN7U",O;-
H/,%AC-A[<^_,MVIM0VTU[-V;-M>0./@08=.1'1Z0-O/)R(*;I#O781G-M:.(G*,"^V.!M,'J+_TS]V$]P#Y-[W\7968E;[$9W(7*/YV4-V1M:K5VTU+M-MW2]8
VX$70'H5-8=D>+ORG/-GO*=8E@873-+#-MJK?/U.R$5"P2GRP[MYI,/HQ:6U<;S47Q@,UFT?BJ,MN9@-Z@-^@-.H-.H-/H-M-#H51B=?,5&KB$!@NSC9I'&
12,!HV*1@(R9I"/A]DW:H.V)VQL"&4/P2,G\Z4]O0QON#Y^]=(!,1]L).DA!_D"9H$.!^=(,(-M#I/JW=4.GJCX'_0'.#YMY4R#;3
MW$:MW02G!T3GN$3"*$)T3&IX[,6R-Y-=D)TJRXZ97W9R>G2-6MM4;=M1=;T!-MX@7B);MXY:JS:S0VK+,K0-":M7:KU5(-8Y?
N_R!A0C';44I8+@';I"6;G)E-M4;FR=56WB^H?)[1PB;K7"$(/0O\D]&MZ'!<@]#;W6BU#;3J.\&(/=^W-*!AU-MF+MVRI\@C()1LHPZ@D-4%W&
<\DJA:*A0"^^'B$R5;"=5\4/FN?R>AIE/\^-G-M(P4_8N+Z,1_/ARG1A'VZ72>,J^/-M%=H)4F(')<=0$-[H-#J-#J-#Z
B$3JY$U2;=7!>]%M[0JUM%;6I+E+%3"49JC+-*-$=0-?0-70-'4-'T-%T-!WQT1$1]@:NV2?7'$&A-M6!8T\Z5%"-<>JTA7)F@ZQF'"LA=X/-FB*<;_F-V)
K8P)4&/2N"C@1_XR?2X-M2L0JLQL#Z-Z@-Z@-^@-.H#.0<_?KRG-ZGB_IW"'7+#X%@Z30-FIM7;6TQ?Y,4E^N74D>-PT-Z$"55K6X-M)I?
=6%>F=4B[80IC-Z"6"T;!**CERI7QK-^8!J1+?%:!QU6259G=&$-'T-%T-M-!U-!]!=-0Z1OHB&NU''4H)]D04W"#?NPC/T,1/4,!JL<;8/06_YGZL9_@
M'B;WOHNS\NY;[$9W(7*/WB4.V1MU-J6INJV-57>\IW-MBF%AFH)9F..I7R-XDA)WQ'-^KG*TU1L(.YRMNWVF9B>D8I'X9-E1N]SR8;%-M
W.)>,,!FLVA\59GM3$'T-%T-!U-!]!=-"="J.3KPC5*2(0V"Y.MFDSI)0OQ!FJ!!@/O1#2(X3'*.4ZM;;0::LO4!-G]!FX[%ET@8]Y%
M6JXI,NUR8!W5TD3344=0H4-QW"'7_(FU^$O9*!U-!]!=-=0-?0-70-'4#G-M8*<3UY2WT*CD.=3,'4?J-([4FZK67.Q_(S_OR)A-.0J>7I=-V8VG#=%XNE*U
M*O92]+^@@%\KAA*EAR<)'@]P44Q-50S-:.Q2KC*(B(=)/5O;J4FI[7I(,#*-M?$FS-4DT.678Q%'@>T\?5DB,EI^":NKO2])9-!Y'(2*RXXZ7:=)G*"0426W
M8)G\5&"C81:4)*FL1-5*:?Q<+S,W[YL8XH+EIUMH-E:X>^!BL#5B;/5F;-0*]F;6Q-M:NW=@RT04Q!3$-,58KK)J9^U8FI3@V1#\-9R"G*Z+SEMY)?
3G%YQJ]8VU99I-MJY;3-E$&4091WM-)VV;SK2S'=/[TIST(M<,RJZ9J.O8.)VM!FD&:CTF:D$6=2,>%-PHF*(5S!8!>D[]HK-TN&[KJF8M>@DR
M:AA>%O&1GX.A__7\^_9G^L]\TF-$[OR0O]IZ+3\NIH0G,Y9H?QX0]JS9P@M^-M"J.]/S2;KF9[+D9#HX'0P&FU#-T:N(YE(LL9#O[7H#'9OA8P8\B&
<6(WZ5,F-M4,IHS[(LOSD#5GK^'"!A2_-%G]E553+$SL=&V=W!EL-M3M9K:KS\=T3FDYF@.UP?$(S^]*,AG>LI"A[0-&:,]1($BL-;$KY=_ZY0G_J75]>G'?
Z])=>G_[G>_>]WU-NORH]NK#MN^O+\^YMC]<)-MVY^4[K]^7/3_(_5Z/ER$2C**4OH,+_Y)_.G^"%']^0GV5L]U-Q'@)O)9KW.3-M3)
<0H$F,3^<_?)H[NG[()*_]&GV])DQ8.KOC3GF[\L^GFE&IW7BV!93CK.2-MQ=F+9WKSA"[LXY*_VR=.L[`T(^U$7_Z5%8^R3G33SO6DU7]OFJU"YM0\
<0SE-MG\"<1,>N=6(V3<'F9)^8NB/8G'3MQ-8MP29U8$()CK)81RN]}3Y-9I7H;X(+_MHS%);@N3(='#V{(Y(0O25QV-6A80/ZW/V61-
F0$6J8D'KUL>D>\6)XC^,:-=%Y&0SKQH&HGDK%0)NWY$U8&2-M(8C5U:OAWYF;$U%S46>6;,,6IMRU0-MO5'0T7\A2FS>Z76Q7]83+:FS>:5*
[N7+*7'+*MTVN1=UW5$1QRS@_+-D(@2:-M?&--WCJ@)F\4=/I7$BX$10Z*/)^T;;;
(FT49^E@)JVVUVJ+5AVZIN0.0.G9IBATS9_IZ&F1^\).1@A\Q7[[=9FW038U!@[SPEE!0W=%:1E^V]\0^O,RIW9^3WEADJG4:"K.):B8G4
M=:22+%29JVX!'4-'T-%T-!TIT,D572]T3MS(_-DW"E*\PFW)&7SS*Z!4PP"W-M1A+V-N$'=(ZO$6&UN2:7R=BD/^=>388IF,F-?"R,@E%EY6.W.\$F33[V'L>|
M?08=3HW;5[R,O>/M&;#^L\(.)=X>1Z^#4B0^PG-M*7_AHGUJU-K-EB@WVA[XV(U\'-7WKP,Z@-Z@-^@-.H-.H-/H-#K'6GX+7+,-W
MKJEZG5D6,O.,P8;D+/)X$T13C?\R&1-%;E9*@1R7PT<-/-MWO9KJWS.O3([-8-.H-/H-#J-#J-#Z!ST%/*:ZJV.]WL:)\]P%BV\Q[PG=C_KH
M\==G!^QK1+CC]@7%V&,=HG$8\ZNESJ,NZ+#=XZT+?XS]2/_03W,+GW-M79Q5I-YB-[H+^5/X28K<;K9=:S$*N!%T!:-C/SHR)FFDY9H]Y6C$-ML#
MP2P,'N#43"JK&-YVY6OE:F<^56Y/"GZ=$VNXH?T]]47,5=R)Z$R^T^-M#J-#Z-Z@-Z@-^@-.A5&)U=B8_J"/'F\BPM{3-M21+B#)($#0+!_00%O
M(8T2Y3LB[D@Q=54Q-,/\F%1>3-5IV05E$C?#K:1,^QZ93K1TY>:7.>=;NYR"MLP,K9&R93M'5!ULQXW*EW],?-?:&[0W)L*V6::VZJUFSO?B@&B
M(Q07@>BL$QV]"-&QJ>&Q@9-=D)VCDATCO^SD].A:M;:I-G5=M4T0+Q-OZ<4K-M5QAUQ38O7O+//_P-M.J-R=T9^;YG79]3:1DN0(CLH.8:"<$'T-%T-!U
1R!T&V\.ZP-M*[R6G(DLD[HTJJ:9X-7(P5T@^X.G"2K%M?DLAAK#D?NWV(TQ+(8E3ILEC^%

*M1!>&B8+'DR':8DPG1B%6)BEQ1RC&"I6C[>Z56T(DR65I#WFC[HSJ?-#-C.8W ME.3Q,KE!UMJMHO8*12H$J"0;5:._'J #Z Z@*
Z@(P4ZATH>K71=5XU,99+,@ Z@ ^@ .H .H /H M'+1QW9K:DX[W>QHGS 6+;W& $NSUHSYZ_/79 ?L:$>ZX?4$Q]M@4]LCB,$7MO
M[KU$A_4$UUN+.Q^YV]H!CX$& '3D1T?&](:T7)//;JRI/CF@W3 U8>S&$92? M<,SJ P8:7>(S:L=515*9!#*@ ^@ .H .H /H #H"'?IYX4#WHPZE!'LB"FZ0
M[UV$9VCB)RC@OMC@K?]\B_|?>^_:I#:2+8K^%04S^YSN'"%4U>B-[@@AF2N7._G?V(G M="+Z2(,79T!Y1NI7.O"?/?84E@)>6E)N
IIUFAM>50;/>Y[E'.=#7#)H]#\@BSA5KF8J(VK8E%O=47'-MM3/\'T'=XG3$Z1PA!:/3KL,6V]54/VM3Y1Q]6=>\[*6ZW1P(-MVF[],G_0@+]J196M'*O5511-
UMM60\+O MNNA1>E*O Z6W>E+UP6F\W#:2_7B)50/<11&Q$.H5*87K&?79.VN-]\2N7,[D:O[@$C7-'_EWP]S M<*4/K%F$5J1:,:$R1E_8I(T&X8?
_Q$XT*R(?+-:]!LH1K+LLXX%[30* MC03M;*,=HSKM5-3HS%97DXU.6U84(9H$>9T]>54KY%UI*K2IB\)^A&:UNAW3
ME#OJJA0K7\PH**Q1R':5%%:)P+;T6JV!KCI 5XHB=W3[&L174V.-@N@%T<^)
MODS'@/V(WF9:JVK(IM5\K75+.+81]"NN$E>=Q5574/=Q'X8Q2V[P1Q(P)<PRR9_BK^%UE8U4C9NM=-_KD%)X M%$4=9-
F/#QS*'Q+P#PL$E=%N=8V]HV4-3'6[2 P22:SB=,3IB-,11R-.IQ&: M2X%Q;9?I/;FJMK#^>VNTEFJVMZ& 2B,;BBJTFO/ +D'[XG1$\:E"5PD0AU
M,=WWQ.F(TQ&G(TY'G(XX'7$ZXG3$Z33_=)ID>PNL.2367$#F63*$'+T68^H. MT:\K30P"<2]PMQAO?>'9DZ$7&9+M9?U!^_TO_$3NA$!)$&+|\Z
\HS4KW3@ M/WOL*:R6HK*6;,:ZABDK=E-&K@IL%+Q"G,[I3^<,[7E4&SWN>Y1SG0UPR:/0_((G*"HNJ@(A+H( FL5J:* %C3 M$.=B0BSB=,3IB-
,1IR-.1YR..!UQ.A=\.M42XY0Z-/W=#&&[U;5T6;.4RS($ MSM%3=!W(7JHITV&0W6PW!]FO('WG(1K3@"7N!'1,O=!YH9+KAU?6!.9BG,_B M=,3IB-
,1IR-.1YR..!UQ.A=\.M6L=[7D*$VF#]_EU>%[#[1C^@ET8M:J[XG\ M^.('^,)>% 5./XY(WZ5/_A<24''^J;.THK:YB=F3#,O>?NRE03C $D:/3.*S9 MT_/2$$:E-
HA174$B#ARAY+ #O:X$'!$Q$:#(0UN^-[>: #]H1_W72JE M6THNB/SI&SR;T'>=X?S'"R*CXF(G6]M,27?^9.)[+#>,5S0]Q%$8$0^A4IFP MC%;75&5;-
VHJ_JOO;$_DO#\Q\C;-0?KWTR% Z8-O%E$7Z7M;*)K1,O9GHT'X MX3^Q$\V*2-4$4A546CV4)<3-9G&S17&S=Q8K:XNP^X%'@M(Z3-@:1-F;J" MK=
(&2^*%4BC(5)#IHKX*>]Y$SIV# MBV:UU>UT=%FU.T(PGSS(OO$JP6 $@ZF=P93I.[D?@]%0}]<[MJQ=B!G/,B-^ M8U4P_0>>G^
_Z3+GI"@F?'8Z\V%PEH0 'R08(3W7_T WQ6LG'QE%]?4AO% M*>UM)*#/ +!K3W)@9<\!<:4I"=C$Z6A,0XJ4 M.*0>GW?D,13%<5;2R/&(-W#@\C""+U@?
Y=NU $F6H:NWE@%+G?HA:Y3\)L#A M6,X+??OJ#*-QRAER-R;$T\YN(7U81!RMOZ4IT+86H9'_+ZX6&8\STHQ!VQH. M*!FI.B%]N]-1%;_L$V-F/:H_V\-
S)?DIG0$F!*GNE-/Z#D^PT9P0;?$/>5 MS$*D^CP2 @:F<$>@+!-K+51&HX-!A9,"L&$_8*VTWP#7I% =Q8K:XNP^X%'@MI

^EG0{\M.BTR2/)O)1Y,!*_EYIDE6{O=!0 MW%B6T>_G>_^1CE($FK@Z_3ZG9NUTTTK0:\!_,6 MB3!\)=.#X9AR)!RS6UVCW;Y=UXL^ 5.BB<_3S6;
{X<+*YM9,%BV#%"M;,MNM MKE:P(2D{\@U,NZBPPD1{[HG%AV/$@+DWRL\JP!(DX$[' ,B)=3#Q2((..;VF M3{SO&<|,LMUXHA\R6.ZY
}6"60N4247O2K@F.>G_FXX!*WP$'0F.5E/3>S1 MD0O&Y#6=>1[!/#6>-QY(#,AY:";GTV0NUJ3-*VB)&!1F/S-="HW!1-(6/9%[ MH5"X18B#3#.]XPM\IC=
{#,[E]FEA;>'67$=7P#3FX;IEC)W>^]+>P65C.*" M,Y>PG[K>41,@+H:7%^_).X^SD(V,KO1)6CDS]TDG^JZ?KW69X_'*.\=^.$7+ M#
<%W%X>1\&P&%O*QC08QY_PM9B'+!)8UJ$"X9"4=_DZ)V&J1>/ 2#K^1-N M%W/W+$^Y313V>4.8K+,J3VR;D%EJK\-E+
{#)E'$EA4$1UG$\IX82/Y)IFL7A M+0RY96[=)'2"#@XLO1TQ;VF2XP"1+[3Q#QCYUUXUCG16ZCR_';>(>O.$I&3 M%-
ID";/#A6!V@B3HD*>9JZ,82UE@;XN@XTTVU]?7L&X&_BL/A+!".6&Z^D3E7"M6>/[/JF11\Y)%W>H]^0(\&2M8GZDRER0H M E)1HH
*H:Q(DQ_"73VS3L@%P,Z'WC_\8(DDTB-K<@[_SBGT?9XD'X%K. .D MR'MO<#MO14%&(\!9:EABSLWC(S;)XPB^)YRT>N$$1HU>'4Z]Q_KU[A?T
655L]R\7W:L?PS^#^"#CQVLYHX,5G,6SS]JKJ;M M& 5N7]]A^W-VL)&_U,L-S'JW;,2ZEKT'-RAJ5;5VC.2QU+ ZN8I5+{S-7;E* M3=OIU+L=,.
<5;1^F4=.V[']W!6:V4O64E@MUUYL"^IF,S_B3YA*RUV5&X%-_M_'>0\HRN59#_[F)&(074ZRD5CVC^L===U"@LO]PS&P8M=5 ZIFFB&N8N)IF. MV?
M0IX4>,_?'TB0:@8Q3PZ,.(NI.-\"@.*[H6G|<&$P&?%85KU M#3]Q-1P;FD=CU_> 8N_1+/.X80!7XW5HB"2=Y=(7EPFD%2*1OB'@VOA@UU>*
MQ+%3Y[G_^ 7K*Y3+ M"$JJ%"+6Z13_VBY5&NO>BL]BT=E+=0I>@MY!C5++DAJJT9)T03[>!@&6Y MKA-IN=96ZM^8?
52:&/8;VZ5KIQ_;I58=VU4P_[3G#1_'?A ]T6!RGX7V5DO. M3'O54V?;JZD&\XG?O1?BN*@!W !ZW3P25]4X[QRW=?)6^5T]8O/4V*4/HPK[
MPX6M;M(JF#AF%4P<6R>_.$ *P'0NH\'NR@5^TX89P]3'EK4,_(7Q13^&50S# M7]\O7;+'\<*(W.Q)[( M;GJ;/"M)8,2,O:51NNR$^<|9,M]MFR?
TX7#=;/AO\O,M_/3;ZO>:<:L85N%/-M[5NE\/MUCP+]IZWIE1ZU_GM#*WY)U459MZJFB35M/SS_']7JRP^]*/O6L-2& MK:ESJRN;G\2&6R_[M^>7+
{KMN,&A#^C@XB M!KYO7E)%P;'Y.P90!3CK N9 M+VJNW%>QR9#E$NMU#*WD8+A8DLV.JM!OR4O1-W'B+|6.L[U#',:O\@S7&&& M@@SK)L/!()
[$+&F3*;>97HL6PCN*6>Q/Y,1I0:WW^JO5=ES(!LZ=')03NR^M5MI=<5AH0$@NV+ M8/4[YC]U<6]!<->$<#N[G&R!<
+A#N!,Z;2%Z+QJO#]{ZF"CM+JJP*KKQ;JU M!G )W,$&#>TEX<[%YRG]D6\WR?I,[F3M%FS[(G%?/:VUV\&.'K)BM67#4&MR M%#7 T2I0K#84]]W>
[>AU>R8%PET%PNUJ[W8,@7 "X0YA[YI">%XY:AW&XK4$ M7ETY7NT6],W4%TJH"6TN/ZZ+?:Y73-QMVTMBZ4F+! T ,_1C;+B0+OAJ,T'J M\]#E<
WMQ+X"N]5595/IR(IFU.1,J^<3^3(%90N*+UIE%ZJE\9NUQTQ%GO0 MZ%[0 ,;'H?E?/F:T(NA=T+^B^:71?EP/35H5&+RA<4/CI*2P@2F1;0 )6!7D+
M\A;D?5+RWB.%S=;K3F$[+0EOB0BD'85AFW0]Q8NKFG,5.]#?6.OGS5WJUXPX M3FA.5UFK[[>L0@[N><-F%CHO-&L1_5^+?<,3!&YGMY
^X&HQ.:LDNB*[OHRBZZLHLN7T=)^#YQ\]9MM+JZ M9LF6NCK O('JP&HH-Q!D*,BP;C*L/[/RO-KT";(49'E.9+ESX],ER%*0I2#+ M4^4E=H2R*LA/D-
])D@9M07N"]@3M[9K1MTFO--KU%=*)KNRB*_L1R4$_]?O2 M;"L@E=0F-7*L(15=(%AM"%:W8\YHUS <#4Y
M4XRV+D3G52/6(=P$1MMH=;5&==866'54K-J]I,UH8]_,1G&DB\]3$EW9*^&^ M<6)KUVIU+:,C&QVS(7T<:W"S"@2K#<'JMW8;USA4(-Q9(-
S.UFY],\@$PET"MPM5E[2IM(3]O&K$.8NTJBL"JJ\;JW<'%2O$A#.8NTJBL"JJ\;JW<'%2FL4U3AP35[CL M-E,U94VYC-Y0.;AP!.4+2F\;I=?NKE']&Z$GZ%[0O:#
I(/]KEXSI;Y)AH+N M!=T+NJ^)[FMS7II"HQ<4+BC\]!1^&"\RF^MIM 5Y"_(6Y'U*\MXC>4WIU)V\ MUH!^[-O:=Z_M2 =P=T"F_KZ)\#9STZD1CR0>
<<3SB2D 7Z6+AH<^P,5@8K(+@4@)*_MI0DU=' L1)'N4_!R*$FCP)!L1@?IE832 MWRM%%!?K1XWU',B>+2)=TYSCF!G'P;FKYNTJNY$ ."XNA#4S+
#UL2!:#3*[ M_J8,G\Z@IF(BB'Z[+EZ?@*Z9")10^BF/E),W(I8'OZ5T3H'U#*5', HU8;V8. M2JTM;P]]6]5EX"S(+G%R@SN3\0G-A'$UG-5KHV95 ?
W!OE4W4W.UU1GUK4YM M=77]=K7U@[2!8(Y-%SOBIK:(FXU$R]NE;1*U:&)=UM]V\WP%]1GPE 0V7I!FR8
M20%,].7=GX7V_P1\8>2[KO^*&=GR0)R6>P'KA(;$LI;'ZY2]0U!.E;B9\LRDH MUC[HQYM5/^0S8#& 68%@QT*,D7X@2G%FX0ANS>=8Y#\KBPP)-
"7(^D5N#'8 M$OR8)/ABA/CVPO -Y0&PK>3@0'^'DV,/93>!'4*?_8 9&W'(=HYPR&X?.S0@ MP6 \DWYAS-,/ ^ZO'3##V\0]6DAQRG0#4
M+_;E/7.SPB;XU4RI91]_^43!=).47\6$CJHT# M@CFLO8I\ $61_NA#T\ M076)PJZ;QHO05H\%[3JGE%[.R;&*!CZA9F4"$">;LF. K@[I!0-JSED(!G2N M)
[<+ J]@ABIKYBTRGO"F#&+NU;IU&W_8J>#S3!97*SDV>:-B<1>$(A=?8MO; MY"[?C2.6ZO)!AF5?-B[.0&0MD2 M4WP_[T+ L\^K:
+6)7MZ!>XHZI8HVV;<*<%,.ZUN1];,U%E+PLG%G2]1B7]:C8_.^CMS6C O$'R$& MZ\7%+=&.O7%1;1@N7GSAV[QO<$ BNJ=)>R6^'VU+-"4C@GD/PX?
1$F54$?":-M<'A?-CYM";*4PZ=5O-&!EVH7B#+"E5TO^FV)M^R*?L.%HI] &47;$OVH6P+6 M5Y,E*F1^%0Z2% 6GTJ8&E;KJ\E69V^/6P-
12DC(>M&S=!RB1O3L-L]+S[,MRSJ"56[#L+:-SC64493<_ 5Q GU;/1/S>A4,;JA,_G;I);'EC]NA18""T*Z+
MT+95,M5%:$8;4Y0[LF99UT!F=:J(@F0%R>9)=EMU56TDBP%+N:-V9%NUKX%H
M!:$)0LL3VK:2L]H(3:V[K%>064,03I#9=C+;5C17&YEI.)\2))IR%=),J*"" M9 ]%LMO*$6LC68RMRZK2EO5V7:E*AR/:"TIB*AYO[MP1: #GH1_C
ME,:%,SA5Z^;3+^TH7:%/OTVQM(CBTK\[UBJNN^:H$T=*?4[FD\S&_QYU> MJ;S2 0J}$(5+H7Y0("K2**T>J:'>4"D42( MO!,UG-R"<&:3$.[BTTJ-M-
85._D<%I)\;S.6HXZ07-!?&%;(XZ/CD>|@4/< M'%O86O>Q6;>I;]I$C6?;T"B-H&1!R35U^MB)DDLXLCOUIA*<,3$?,[XD&(-@ M##7U$SD48[ %8Q#$+
{CYN#U+ZM?7K?KFX@A*%I0L*+ED6Y0#B65+:75UN6WO M[<([?V(6^KI@#$UD#%L*; [%&-3+8 PL)O!;A#.CX=^A\])--_0YGL#Q#;K_M@"_3Y4]
(\.QX;!UF2EB..Z1>]$;5;RV#59)?&6541)E>*/DCZ9%.(SKITX"? M@=:6^0>UK>JRY,>!1-(!V3=PW#:4 E,IT&_@] GXBZ M,XG^)R:N%/G)'2/
P.3J6TGZ8_5U[!$32A WAU(Q.9R1Y M/OSM!'00P=EDE\I%#X+S]8/ !QHDN,X^W #O#M:\X79.^8R8SH%X'H PAO.(
M9@IU/"0WXYD<<"_^1IOO&]TG"R:/0S1-'"*;&.S55@F!QO&@-$DG.>]XDOA M_!<6$7+:]E\]:0 O<.:;)_R.=[U2U\5_:847T>8/ %.@=YI^
Z/Z.A+!DN"F/;C+^50)DN.V!"S\ZP>>\NH 37AS"I)EX&-RL!@[ M-"#!8#P[0R1Z&B/E,/+Q@,L%*@1TGJ?1]^4>AQBS@B^0YIW$0;A)A @U2/? M1QJ#?
[4S!,EVH<0PYCT=Y'|7LM\UCFAS\4(FB++X4,<#VHHFL,=P64K@'01$XT6W@"(J8?PZ7 E+#AAC63OI[P!;S.\?!?_*5?.7+>)];Q5QGZS$@E-/7S$Q?
PVZ7M^L&@\'A MN[@3/(Y*V],;LCT=M[>NEWRR/1F.-YQ2)DK=&3"WIU7D2I4()X2+!ZAVSOD6 MEWKP]\O8#J-BSO9DO+B?XY.2BTPYRC-
UQ@\2>#)!OT3.N&Z$K.-Q'KU X E1 MZ2HCYK=,=X%KW@3496C]]M491N/4>,C=F&C3[>P6T@?=.8[6WY+3G <4Q<.) M>
(>B+@$H]_QO.W3E#S3FSX0!?<;,H+%OB'N*YF%J-CG&21PQR48+F]_!29' MHX-MDG/J(69.,_WH/C2 *^"_9'&K$4:!TCK?W-&FC%H6\,!)2-5)Z1O=T!C
M,/L#V]2(:8_Z_[9 "C)L!P9]AVS"PS(9TBTZR25\3^E8U6[4UJ5(-RZ]@!,P M(VB8-WI2R;^6UP++@X>N6OL+]?
[WGS^N9N;UHWLOC((815O:C^@KO/\QPD5\ MH0'2-=#-G(L"Q.=LU&AUU5N VPHC_;^Y=LM.& P7QT=F"(Q.&H)@A/V:;_@"'7AQ@N\-
R4+"NT,!$"KRNVZPA;A M'%!UFZ%FTXN?8]!J%$-.GL#,.]]U4[!*WSVT04G(H/4AOX9'O@;V+H#^27BG MH1ST.#IMIF%;15PE.0+F:H/-
>!SDR5G8J3M'>DQ^+V:?B4-R95OJYGT\@8Z] M0%,@\ 9OAG'P"MHM+"S;@-+JAF"'7>CZ&J"SMC'!T5Z6?=I,?=>:"A;][&)U E MPH?
1'7.FU+$/#87V.MMG$P-<(BI*P/#AQ!6B>Z+SAPT?3-Z7/#OBZK MQ(.YZ [M!_YW](ADKA]?JUB^916_KK_Z >_=5==) BB[8HKCOW+;CIZ,W6F
M3NJW6^A\?0U&1NMASQO^DPX!9L\]/&IV^-_!5!TB!.U/A1X<1#?>J3RE:6O G<^5Z#!3$=6=RXFAF5[KQ M(.)08E& %4BYM?$%OKP)\-=&=2G[C$&^
%8^JRN$ 8]T-GZ,!:*>] M261!;(QB:\#W*7$7RF#&'>A+ ^UST;J/NP?S;<11&<#ES\LT%4!]C$Z_P'>H5 M?Z+[W ,!G? P=A:H5*8^'&?!W!G]'#M#BH>
(VDK@Q\[<[8M#9K[F//BHKKAN MZC3/.;V=/"' P<<10.PG9?$ [H'G:V%>R&D<(%HD4OT5V*O/@C!QN!@N8.$? M6&3,73MXA&S#Z?UGZ
:&0V&>)#Q6?Q6'5SIK#!QU0$-), )`T\1IQ45,30:MH^Y$0W@*1W77F3@1UQ>3\\9O2Q+/9D)*1BI?GE,SA-.%5H!9$)^"9QBP,(O
MI,*080)H3JXS7\@"6BRB6B@]PY*2;(L?AIQ"^#UC]O" M6 MV>H:BE(QZK"B"Y77^!X'@&]QNS#E/]>-_0X4_0EH^=YCYBI^]S":I_^ \R,^3W/,2-
RT1M##ZQK"'&L<,4/B&/)0*7IEGR M'XO(.IMG6D7")W_A3/)7#/GX ,XH'0MMX@XLQX(Q7G8Y<(%QHBKGV?DO#O)N M/P8X#,-?
WY04[SCD@CMWTD@/2Y!";PR9AO1-^N%MFGSH>_O\[*:WR;.2\|#& M0Y9+F/&(^<]9J 3]PA@N22]HDSN_[3BEXA%'7)1JK[Q45OJ\SE@HH0N:_;>-?
95C^U$W>$$V5T'V?U2C>Y6YH.@BP8^'9X M,6%'DPW=7B' 7P7M"=H[1]JK1GJE^\+71'%VN]6U9;VSFI,E))Z@NO.ENHH2
M;Z6;_K$DGJVTNAW95E>KQ)LE\"ZD"OS)E\A@[%"LR82A)TPFG3@_6!C;]7F^ M$4NXP18^:I)LL'Z9A9982?MF 6**,T_AX#?
Y2S6PX2N92N0YH$E,#T@8!ZV,L#6L,#% M;G=6+?W_DJ6I&_,,_?E6I'"*A:_R*D7F4=2L)W?ACH3CCZ[_RO*@POLDZG[O
MJ0:#>!*S9*P'+,6X\R>PJC'U0L;F@#%ZE$BLPEPU@\'6SS:#P9E,X7 8VF4@ M2*I-!WD@\-0&EKQ) H^A(,LE79.HQBHZL.T&3W@DH30 T*,@>.4-
)=L#R,1UB8U(5YC:Q[@28+G$%R0RV938O1*]U-L?5SSYOH)&+ M4C61S""2&40RPY:=I[J+A,]+R& 006>1P2"0J0'(M(7#[C]&ZE*O.M+LWX;F
M>Y0QT6162X?>!O)#I(((#_UVKYBY,HUEC8=^DV=DP;&2.O#?4H:LF*OEKPTRY\O0OFF"4 \1P#:W#$FT0ZFC:E*YQQH]$A3 MC4]OCP=UD:A
MF$HM;_I]D=Y0[28#DXZ6DC@W_%LK)IPSFRW$>?4SC[9^P+GFHES==L;M.*?B*-
ZVV0"'SY^E9.)$TLYW$PM3MJQ\F^(2(>N MG@Y=+:=Y,:-Y3>RFD&B?_'J:M">;[0:N:SV=9:W?;M:E%3 MFO>,)[X89=*/@LFS8_E
M10IA0=?/K+]7FCQ;.646LVPQ&X$50\R;CB7]2?&\V"J287%\W-]\5RS)>NPF M#*14A[/YOI8/1HR=61X[HRT!2(R=N8;Q.TF7Z3J[,:
[IPIA0Q+SM^THE@]D^ MWTJ&K&LB4]EP>N$$.U/_I,MC[AA?S=HYYSL@GTD-@6W?6FVK<@F!=JM;]63K MJ^:M5C$Q?
FTZNWIK:-4*&S;EV&].C*^TJ.[!Q8YFHOI M\)@@7S+5=?^#;AXPTE;5DJ;,87&0'ES;\!T8[,%%2C$(>FR\8IE4YRH!Z2KW M;Y\
]ONN3C]BR(P4(CX$GQ7ZW]SGM86O#Y5*%)SLY-<_Q_CK[^%E-QI'[A1+O MN1%?!W,YAP#Z _?P+,RMK9K%< 7).!>;;V.4,;S$9.[<.OT]\,.0?76?SC7Y
M[$>/_#\(CA3Z3*-T3O6" #W;R&2+@@H&=Z[4DD]S!FEM@EB;M+=]MQ%*Z,6=-Q%(Q/,>2O*W.NL&%QR:F"RFDNRHMN=1H$J$!7Z6F_''K@#:A-%=;
M%RVK$YR[X%SIK-LLP6EA,T+_;(K@K--C)++!/,4LWEST-JF'W]8[ZJB)WE+UK^@I.F8E"L90^'J.@\
M.>>XX=$:PZL:@&+HQYA;U+3(I];E79".5YPB\"F;O2Z\5?5[JQHMVHX0]F\( M-ZK]_IKX G=F-
G\]7YW!_ITXY$FWWQL.@A@HPUW/+*ML]T(5WPM5;Q5S9?K+ M.@4W%;:S125W_O6^.0'"TNK6T/BFIMK"(QB2@FJ;M+=*5&.U3T0U>?.031>Y
M^4D#OXB:U!903D=5U+<-H:A:0Z37I56)A9N:,/3%"S4,=M-5U:,48BHJ4@3:]H(DWLZA2A
M$NX5(7AR@J=T)/QDEI51FV4E=)]&HF#IF._!76)F]VMV5L^2PUH$)# M@PB"&0AF<,"LMM,R@PYK;VOOK0 U@AE<1R7DZ1=X?
=NX@!:X+O9T>QY+KQ1H MDGD6_=$(*S"62S+XA/N<,R7MC8F-.-->TN^P3EW@#*H5C"@^0V:4L/.>Q1EF@ M\#^^DBE[<-Z_V0M#?
^#P3H#D.:!)Q\RD]R9K\(D-.6%1D.6NA3N^/)<"N>:%2CVZ@H4>W4%!2T(LPZ$(8/QU,?V MD X@!._P*OD5\(IU+9ROF]VWT'Z9X==HJU\4UL3$*!YQ&
^27]\APZ>5YH=+ MI+]R=R(?-S2WY(>U]E<&R(8U5C1,I6IC14VYM6RULE:#]JUN57O2IF:(J31[ M%&L2:Z#J30?LK9DSA10WJ6*!QSXS[Z\
(UES[2GO(W^55GG>)RO.( M*H\ ^1X@_PP0SB%W 49+7T!WQ'4/3WP4BG&!\%]$^<]@<>Z$]L5<7;-+":^00:IJ=6>0"KIK%/H)NCL
W865A9LNA)L@LLLCLFJ#I,M3 M668I/_1AERP._1_I5$<>&S\,/-*5J9"'.T@=[1]YD4+ A0$Y*"-GX#^T)55 M1<,TA88I:$_07@TN%>
[MY+&AWC/!NI^,4"L+0ZO5-65#/PN5]!KJO;8Y=3L+ M3MVB&MX=2GG+]GJ]'O4=2O4L)+\UKI425&:O*R(JKW(VIXW8A:/4@3!J3>%*
M@9=\HR*EM9O61DM@U*F85"XUIRI'TA3!D .%84$XI2[HTTM5 MQ)K$FD3ITVE3EP=)Y9/"*I\T4?DD*L_.$-:B\DE4/HG*)U'Y)"J?C@QL4?DD
M*I^,#5)1^;0N2*X9HO))I.GLX^@VCU_YI)EU3HN? M=&U_G5-DIYXW1Z^I^$G713[XN6'4H9C4'L5/NB$XTMG@S\'MN[]*GW2SWN%@-M
K4N#+6JN@WJBTP)C#IOC*JM]FDSPG6:AG!KALGEYT*5^V93S13?4C_X;6D\ M%=Z#D%&FC%H6\,!)2-5)Z1O=P!&9G]@FQHQ[5'_WP;8I=E-A\;\E6PP-
K#._MN*TX3NW>PREL?C![JX0#UP_CH&"4F5XPRDPO&&66/@Q3I7<;^]7;Z="O\CMX M'(SL,':!*.9[N8N# #ZM&&P)W#+,(\<''U:+6MJE6+9N>VHU>K
5OW*$6[-Z%,+"QCRX2K03573'5Z4>G M.K 54,V;,,% M@VT_Q-=:7#LNRO1C306UT=S )+.S(:7+S%\='Q MG'!,A]*S[P_+L+A26[Y I"_+^U*_H[PW
_I<9]$;LF=SMXAOV*L/(4Z+3"]J M,ANM$:._P"C-EBVE(AL]&$9=BJKXY$?$!5UQ[DE?!\B%)E@:0&SHQ^B=3I=X M+>9D?
7"X'(905L1\KE]];5BMK@&4KU75H^L[J,.JX8*^'!W5)7!WH;\.T)=M MR6VF6(9S/G3M M5E^#8P!.%U>)FZVX],Z!EVZV6UU-[=RN:]V>++%V6 AI.Z0 3D-
P9_N6RKFR1 MS[(1IG$P&).02F0PP*0DS$M(#VXFC8@32"^X.D!_.KV)IQ)F@.Q_)X/_Q$X M3R.A-"5!A$CCQP'_/G08E."KW_^\7#OU^8/>L)7#+I*L
M@(1;Y6Y.2+Z=W4+Z0-UQM/Z6E?#MB>A-T9< E/OO.,C$]#.]Z0>4?++\A(UCL M&^*^DEF(?"?/5("C+,%P>?MK-SD:'6R3G+L!/OL!._,W8/O0
*^"_9'&K$4: M!TC!?]N>1 8*($M;0@R_0^>G;>9H=&U_G5-DIYXW1Z^I^$G713[XN6'4H9C4'L5/NB$XTMG@S\'MN[]*GW2SWN%@-M K4N#+6JN@WJBTP)C#IOC*JM]FDSPG6:AG!KALGEYT*5^V93S13?4C_X;6D\ M%=Z#D%&FC%H6\,!)2-5)Z1O=P!&9G]@FQHQ[5'_WP;8I=E-A\;\E6PP-
K#._MN*TX3NW>PREL?C![JX0#UP_CH&"4F5XPRDPO&&66/@Q3I7<;^]7;Z="O\CMX M'(SL,':!*.9[N8N# #ZM&&P)W#+,(\<''U:+6MJE6+9N>VHU>K
5OW*$6[-Z%,+"QCRX2K03573'5Z4>G M.K 54,V;,,% M@VT_Q-=:7#LNRO1C306UT=S )+.S(:7+S%\='Q MG'!,A]*S[P_+L+A26[Y I"_+^U*_H[PW
_I<9]$;LF=SMXAOV*L/(4Z+3"]J M,ANM$:._P"C-EBVE(AL]&$9=BJKXY$?$!5UQ[DE?!\B%)E@:0&SHQ^B=3I=X M+>9D?
7"X'(905L1\KE]];5BMK@&4KU75H^L[J,.JX8*^'!W5)7!WH;\.T)=M MR6VF6(9S/G3M M5E^#8P!.%U>)FZVX],Z!EVZV6UU-[=RN:]V>++%V6 AI.Z0 3D-
P9_N6RKFR1 MS[(1IG$P&).02F0PP*0DS$M(#VXFC8@32"^X.D!_.KV)IQ)F@.Q_)X/_Q$X M3R.A-"5!A$CCQP'_/G08E."KW_^\7#OU^8/>L)7#+I*L
M@(1;Y6Y.2+Z=W4+Z0-UQM/Z6E?#MB>A-T9< E/OO.,C$]#.]Z0>4?++\A(UCL M&^*^DEF(?"?/5("C+,%P>?MK-SD:'6R3G+L!/OL!._,W8/O0
*^"_9'&K$4: M!TC!?]N>1 8*($M;0@R_0^>G;>9H=&U_G5-DIYXW1Z^I^$G713[XN6'4H9C4'L5/NB$XTMG@S\'MN[]*GW2SWN%@-M K4N#+6JN@WJBTP)C#IOC*JM]FDSPG6:AG!KALGEYT*5^V93S13?4C_X;6D\ M%=Z#D%&FC%H6\,!)2-5)Z1O=P!&9G]@FQHQ[5'_WP;8I=E-A\;\E6PP-
K#._MN*TX3NW>PREL?C![JX0#UP_CH&"4F5XPRDPO&&66/@Q3I7<;^]7;Z="O\CMX M'(SL,':!*.9[N8N# #ZM&&P)W#+,(\<''U:+6MJE6+9N>VHU>K
5OW*$6[-Z%,+"QCRX2K03573'5Z4>G M.K 54,V;,,% M@VT_Q-=:7#LNRO1C306UT=S )+.S(:7+S%\='Q MG'!,A]*S[P_+L+A26[Y I"_+^U*_H[PW
_I<9]$;LF=SMXAOV*L/(4Z+3"]J M,ANM$:._P"C-EBVE(AL]&$9=BJKXY$?$!5UQ[DE?!\B%)E@:0&SHQ^B=3I=X M+>9D?
7"X'(905L1\KE]];5BMK@&4KU75H^L[J,.JX8*^'!W5)7!WH;\.T)=M MR6VF6(9S/G3M M5E^#8P!.%U>)FZVX],Z!EVZV6UU-[=RN:]V>++%V6 AI.Z0 3D-
P9_N6RKFR1 MS[(1IG$P&).02F0PP*0DS$M(#VXFC8@32"^X.D!_.KV)IQ)F@.Q_)X/_Q$X M3R.A-"5!A$CCQP'_/G08E."KW_^\7#OU^8/>L)7#+I*L
M@(1;Y6Y.2+Z=W4+Z0-UQM/Z6E?#MB>A-T9< E/OO.,C$]#.]Z0>4?++\A(UCL M&^*^DEF(?"?/5("C+,%P>?MK-SD:'6R3G+L!/OL!._,W8/O0

*U37(3[6-QJW)JCC"[5KAU,0U&9UJ3K+CP&DS"=>; M;'6<4L%BA:M8G\E,6>4*R"WVR%5<|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{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

M1]_&ANXH<_2L"@:DP=PI!R0" ]X-%Q3"A%U54N<"[%:_-"/(!%4I^>+]UV_?7SWN_8K M35OI]-MMP 1WBJ8C,
<1#H&.B7Y'>L$Q%VU@'(LPJ5W]HVRNQ'&>0*TC)P8P MVD#+XP ]5V[]"HNRDU5;R-YS,2;D3*?)[.>LU$^6'<,L'IK $O%FV]X[!DL?F:;_9PBJH),
MLJ%]@NE?IP MUC"L+MG\+?#B0VD=*UGE]<=?^09R1G'^\Q6&\9YUF$-:Q'JI27Q>=)!IX9GE M?*:WRA@\)%7<_5Y??O+XB)T[Z]'WW3"GJ.]
("><56*_D.GQDL_?_=0'-9I6FO MK;PO4;26X?D'S_8U;M_$1_0BGO.-XA<'3"ZD/91V\]M/]-(;.IC';N18\N?*=$Q M/J2=QV>3A2D.QY-WX1G*
%B(5%MV"4MD0[K[G(MT]'L$VOUL!M9CT7W7T>6M M<.>IA9KL'0N>'$MR7.E.W1IN42_QL^-Y+/0C1TSL@:;#DW8Z M-
P/N'P:P,,I'Y9+V/[693QC$*Z313RI2]O.^8Z/tHD?V#L22;ZW]G=E'5EWE#IK1JC!BZK/3*5OLEC+0 M@&"*%M[@6H-K.^#:1S8)8C-
8%/,1#5UFRKQ3K#WR<_JMM$&[ET.[*ZZWG@_MN_+EQIE1#_RZ$5$>,1'5A/^85+:%"BPY"[%$,"V&D(]'JE>2P^>RS.-3T$R$
MFBW1WZC8BU2=LH'D__,?8'$-?Y;:D5!@L531@SV#CBVV"@_2UAD%/_*9W%K(_MV#=9K1J90A-VO#]BCP?,<4DV;1VS%+&\$/+HF'2??!#[CH45
.C_6CR;3RIT-MIYBI3RC"K^#(<,PBOS'(C?L1S$E/DC>4M_7,;3FR\?KI,)]-$&'^B,T'3'(4_MT5R%?GQ*N_\>8EZ\[XF2(KE(-
AM!H<0>IPQNEFBP364N(%\>![UL0\\>D5ZS_MY43"*RPS!L9"_8S7*018[90EG\H3G1?G4](CN_E13U*<*M86XRQDD6)PZZ@U-MR?7D_P*NFC'*@+24?
E3PFC,FR,OF4\=S9"4_3O+NQOVNXS8)KLEK5"^'8/<-MIH'N$@-BPHPSX=5K%HED$=XW!__4JWCA73R'I\// M$F5&NOAY8=AP@1=T7[N8B=Z$41MFN[&-J))
$4[>TD"6<[W*)+%"+,3-UF2_M-M;<1DG3UWP'0#,2MAZ_B:175UIS0@V:R=V6FAYIU!-D@)YMQ#S-WT?6'*"B
MTI(UF]M:K:BHI-.5#%XP=.$6QH!24ENNPKR![ZJ*%"/K_$Q<_3+"I'_<,LE]_M#=6-;TPVN4X:4A5L_U$_M.=DI3
MJF+VQ9^Q&3["HY17VB#H,K>_ZN)78BP$V42/4[RJ4J'7>CPN?B#H&N:9V.=IDZT'GMYZ3K17FF=:]9G>@I>._N"ZW#_M%#N:)[@E#U]*T#R*BB6]
(UA53Q-P%]YL!)'DG;VD_4=5IVLK;3AI\BZ>>EE'_M;WZVV*_9@=R-0L?&W4V5E |>4*5.Y! B5*5_6WS)8'O1W/(>?_M\7T0@^1)R?
C1VFW3<6-,@1DO1^4M/U)_3!5@\;+"-,G?-F? !<%88MJQ*%;V-MHS_A"2))GON?#173M2_T8>EI[$IHJ(<',_C!#]*1;7_34SD_"=_$@!^GUU(L M-
="T3QC!!;LY#!W^(^PR+'FP]QR\GMDSI5\! S(HYWPNLGTV;N M>0Z^R"3D90O5U=1;?L>9R9&\KZ#@$_)$%9V*Q==B.AR.P..I(=Q=Q.L/@>ZF
M\#]'XI?;]IIY#_SG&22IR,D5K0^YV",>QS>2F%C'-%)_C6?!X]]:FE)<#,C;_MKFZAS]&BV#]_5]$ZGP:.2T9A<\81WL$E\7;Y-U/QT:9]\XV+]RD(@V+C?&3!
MP+#Y/D-5O\M!]BI&_4HZ!0AS5R=Q8IFY']?3.2L$]X:;,K_X-(_I0\/@$]B_M66@B'E'1CZL)II<(+>XL_>T.YUY*PJ'XCFO"#QY)V4DFMQ+6/I-P2NZ#JZGB
M4+)/OH:(3SDZ>1&G.5/Y&MN'/_EK^)WJ2!F",_@_U\CLRQ5*[,$U8O1NT?>8'WX MO%A-3H_JUY#;_-H%#;-IE,V/QVS.B]6H\7"]<$]_4%$1(^,]^"5SO*\(/#",
MX81400?;XLB/(V=0MPE8UHN56\SW+';IX=G0^O)M)YXE7BP;$-[UY\028>F'_MP)S1Q4]D0;F,@Y)GS+24BDJE#C-
%T;KP5Y;4!)U1P$[T;HHIF3^W1DHA68A[S*@XA#X.]I1_]@XC?M!DQ#BT)-,P"':)H!M_"_M](/PT9D3V_"8=(E(:*5"-3.7.%1E6RN^IT]?DPPU*:6E/-
D^V[4I9T<=4WC<_MDXWDT9WPE!I3%BH3]I)%F4=6Y68'/XTH'RSRE M.?_GK=S"IW^_4S?PA8Y,W8W]8;V*[RA2;Y &*6S/A37"5&US+&XUJJ!@T1B
MYCZ:.,HF11ZB*MP3>D6&[4MA37@N.=P$=H$)F%(H*Y)!ZG8@1::+]>5T5N-%5(;JKFVQF52K@L=,OIW*F"DE'/95&.
M<)=4!>YP=Q@>1,J=YJ6'F86ZLI\M2R_WAN=$=V,ASDD/(TF?,^B_>06312A M0O E,3.F0!UC]N$C/I4:9VT4301R@IQ%?9).I"J4"N@!/:5C45VO0(J$<\QI
M,!\XI28Y,Z"' )MWG;^2+])EI/$[;M'%N"8H&N)U]DJN?$*T:Z6O^5U%P4_MQV]'J11YC,OK:Y(S%5IAA3%0DJ#+3.5?DR:[/$W6:-)DZ[&7ETZ3[9>FR0XV
M&*?R4C@JN%=FEJ+*W3#VI2C:<]'R+F!$@PHC+3#$NK:VN2:.1?:&IMGPIQ:2 M.C,C)>?37=YVCB=E8/8QV7B(<[)6ALL2GBD--
S./";P@WQ,7#==2$C@V;7;7 M:@74K[B1I#GI<^!$ $_-GSN>[)',73/$)YY2#2[3$CK-=R^Y5'&!-5"=2OI#MW"XZX8@FI%G!D:V^)
(_BCQC@/76XU*3[$]%/"O2A(E$AMRS M.$0<)H8")!K'U\2/OS!=\K%O7SDV9<%*+EBU!/B\SF(2G>IDG@
M8"OF!U3RXJAV5U1+8**K2@&B;8JSN/%%JU3LFW1.8Y9;Z]_"%S>_;(_6/,[XD MY!:!,;1U)KR*HU3YPW$?'TAX70_*A/Z,!]8&H\T).,8G8,84V7'C:7E"U|^
MY*L7'(*N.6&\62LQ7Y(,LC!;%J3]_4@89EQ]BA?.\2CV_;_]H[4(:,G985X MV7!D2)$V68@Z*UU$SE"Z,]=5CA\]_C(]/(KB+UDSQG/I,C*NW1UH[/O<$>.>
ML,>;M#L*+]8QA/('5CUAMKR(#=)8EI! EKP(CCSS<5]\$U>B1T]M?:.,_+;\4# M:/DNFX<+'7Y4]2O8@L-K[!Y]I7<1ED2*O#MQ=#/I :,DY2O'4M_[J=!2FK&;
M"_E&:N>#5ILH2[,9FA.8;4!@A:W"7C$Z"H"GV?74X"X4%9,_")3$@O>LOZG,_M@!=8SE_"JK.
<;2$^AQ_&Z,Y/W/@2)WP%B*BBI(#73(KCX88*9YV8&"]+Y_A:_M43>?,%@10Y!!-@%#)?:,I'*)}AE8&60R*-X3S%(-%2#1-U,B.@K/_E76/VC
M'WRD<]_!L6_!TH:#@O*4A'TNC33N,[BXZK;ZA;C/WVOKMA Y2]'(T^;$3,YU M-9ZP0^IV(Q)+16(^KQS[2(2F8TL\9^3]X06R<]>T."/!($?2QQIG(.0&IR!"
M>K89-%"OEO99+3PQJ9+^HE:266-R/V61O4M_);\G-=P+];52NZ+Y*]P-Z $ \I(9 M]20AF+.-+4V@8*ZL@#J1K<,^+C*<@V^FM,51E//8+
N@$157Q77QNZR33O'B M]T6UQH]WJ0E)V>0ETA+3353[1ON%^I,;\+?\-(/,(+[R/H=$7+F-5@$A4]-(
M(73U1+)W@L!MT#U=4+7+HSES/XS$?':Y%QIZZ47R].K<8!>C MRL$I:# ;1$KXROKGQ:V L>KX<>@N+E5@YD>:8R5.3:B[5G1:E3!6Z14#ZRR9 M!!?
H293%A8OQ**RO2SM19EDFT[.X/Q-^Z/6'/E\>@<7U.O9?S3C"38>=_D M3(6LA_D520R,+,ID.E?(LM-"1>WE-KPO)2+JE;2Q(B'-057X+/"FDLM;NOW
ME**D4;TE^TMRB',X<4[AG4S&H=')I&7E[(5\IN'"]]=-E#>_JVUK%MZ!HC"; M.*:N68^8BLE]EP!BI:::^XTXGBHYE#2D0NW"A!?&'<M5J,-*._-QE>3<#-I
M$771V&MUT4O:82B3\Q0^7B7(\\%C/?'$BVY:2E/^"+YGYZ6>V#?-NY0=6S1M$RN6"PT\1^=B1/)>_'YW-.WAC'V^_]\MD|*? #*)7UC,
DTRAZG!6BZSF+*)%".O,3\T3'6C,2PQ_R543"@U*#6]%ELR,+&4'2/%V:MX)/ MBZG)M;S4XS<:'^H-8,ISLH&RL@UR&D"5[]#;8% U!E6ET:
&H&HZ2YF8XG_. MJ0'\L97FFRB-0 ONA/IF_M?BV7R2=;DU;PFZ]""?,E4UL@%%:5EE,K>,SX 3 M$V73*LM0"'H*E5!B"ZB&7]Y?ZR*Z)2OPL.^L\-(2&
(5SI_@J1R8I+C6OZ'5"_MYE(JSZ:UF^/CUFZ.+]Y@Z96=[-(.3I4VB[6@\DIHM![.M?"&+:DIN_E/I:2NV<*& BPI^QZ-&G2CTJN!3WJ2O?<54ZR7]Y?F2>V"/F
-A@_MN.&Q L934OT9$*"'%.?YTJ4G[(9_M8;?GA2Q&3XL@U4K4R4(6HJ*!R&F7OQFI.RVYW93$^NT7[IHZ7DY32YPOFO8[
MRS2LK\B95:I>.81$)EQ$F73\P2J&5UH'F^O_F9^MYX32)<@+1;]S=D>UUDG>_M@&II4O/Y%29VOY.Y"& L@%.+F^FU6.
<6QWB6,#2PI&>PTF,"\&$;=*UVP9:F M'Z6=UYT9;U<_:(;B 2!"H/M/CFK83;THC/"'Z,AX\(#8[%7G,?+G^Q_$#Q]XLM^3$RV6G#%!,'G*SL45MGCVM
48@&'AN !U_@H-WZ$I M+U%XL\QH+'<$#[E:W!B%RW;0:[3Z2]V^(SGV\2LLZ5BWSUD2L_6-NBXU5=B5_MH[V;*NP?]PI[4%]%=QQ6-
$+]KU*D=+RMCV<;Y5U[5DKN%;>9&]5ZQMN?V9& M170J_-=+.\'L2T'G"GG"@ZLU\E0;)WMN>7]!4S'5]F^-%1O$O+C.W,KW!\FV
M"D|=75B>ZX,4,V5CK4I;)AVRA+&)HDW3K;!IXO#RP33G;W[UP_=42ZJ6^WCUM"3,%:>%9G$CP^2+-+B';+\6CPL6L30G95G(F1M=_MS]M"'DGH4$??
LY^81K!DFB@LJV4;A"]G!?V&%2QC!4OT%*P#D2PA*48Y)>6E M6Z&\))I+FQ=>KL0 RPU?R&%[F_B!?/X3ZGB-<^2ZE>$'>54]%" MI\;502^!4R\?
\Z(7[QCR>N%!@<,>L%=!2"\4]R(HG638J[^OL%=_N[ 70BYA M:"+VQ5U0C794X?YN],9E>B,GQ5.. ^)R"/%O55)!W&$%-(>FR27W2Q:P)+,X6
MJ<)+-7UN8B^/5D62GBLU+O'!4@>M8)I)=J M0?0H(NQB\&&WN%)-1\X>J. ^P:M-E';XQ>9"V4994[XYFTVQ_X@7E=:>A%C;_MA0+8Y*MX/CP5N Z?
1WG\1SL ;@'_R" M7O\)Y.0OP&LKUN2T]RMO__&S=F\&?NZG\$,[1CJ&/?X:V?#,_S /&)-\VVW@ M/"$*BS7HI6\=?_[H@Y3FOY$O^WSW1?O5G&#@VJ?
U;I^B%BW*>S? UQ7;O\;_ ML5GV6;X7Z@T;8OY#^:/:*[\6F>-1S@%W"HOB2#-,.K 9[9]3%"0?_J2 JJ- M,3H_OI8S3!HH7^'2Z[LGTE>\LDS/,R?
TYVO>MTCVA^"&ANQ*G;@,G%#P0-X0 M-V"\=QX.MR(#BFQR_GK:><8+$];C:4N/R8^C.$@$3*K%CP!,P5V2^_BV\9.D M>]O08Y(U%[?WER0;6.(SX:
(B^>4/-YKF]/AQ$P-M"I'V$P)=[16L9K$OYRJ$-M%1PN"X0I5[XADF,I.\AQ[FIO'.>-R; E7HN]@7*,OZ+.;:D#N]B"&S@Z?9.P MJ>+<@9?
RUPWVY:\;;.>OJIQA6?)+P#Y!OOT1=9;.OXFNA#W%#+F1E$T9*7%1+WRR$;*BK,\STDAE=]O8DE$]5GU+]7[ K M;B?
A4\$ZH+%G@22OG(1"3",=W0M0_Q,(@E)!L2,#]138SWB&'8J $N5\,-X= M6"85Y'P*^49D_14#L)1N80K?X9>A#O52$YB*"9"E0QPD1Z*B4='UF1I+BV+0
MA?I9=MA6.E8'WEI+D7C'YE'%I(S>X2>YU*7/@2>U-MO-F;=.YH*AS*%<%>4^%0C[V\=(7#L+3"870B%0XITW3RBF!+!T:ITCN6A&K1&
M"@+'Z)^@)BE*-TD%R!0Z+TE6RNDEY3;4,4(WJNM)]#;JI42K@?G>;1P;>\CM-MIK[=RZA@WVG?2R)^91O87P!0):U\ O<6GH[*'?^($<%5+EI155[L9-
T5PZ=Y M7B*8Z7B'V*%0#$P&+LOXOR@8D8V146*I^$C8T7Q@HF@GE'#<1 IF%E'P1L6-MWSR.":QT'[1?V;-(KF3",RQT(^!;&9\[GZHDO6J HCR2Z-
'E,1!.");,V(W MVF0PC&]9<4"%#_A4-FF3#Y]2V#T'FPF$DC#[!$+)#9=*&/T.H Y-'9LW*C]-M5%LU;G)M7%L_H7D=I*5!=L&]&OD:*!+%9
MY#\P$A3PLPVP#1?='==PE5IA&F[HI/ LL>C3T8F;H)AHK,<9T]H(PI,_=D<1 MD2A8)R3A6SHI-$DRV#K;8,G2G#-=>^:,75/@$/_W;W?
7\DM*Z"K)97L%IW?E M9!V9H21>)/.TUL=(NMPG;Z=OXHT^AL^OW/3]JKAQ=444+Q8457] MII$-S)UD8"JO]\)41 #)/,""/G!V%*=P>@&-
OO7CR/)G9%**:<7F"7'XG3.;F]P19,.2KC^?B76?X&[XX)U%NI5D_&D:!?>E M62OGG\X#WV+,IDFXM)O,"F50.4$B^*3*<,3MK.?
D^$YM&B2"F&FE$*)!BUC%IG/&R+,V!"9I0V1 MR15V_Z#GJ!4>HL DY Y2X%=+1]F?ON70I7,OQRW^.3[.YY?"HJXH7!&S)3 M;O$##ST'P77[-
/)4UT>;:8'5YL'K4A/$KP_A]|E;8!Z+*4O -K5B"MINJ\/[N>=%27:/(K0|&-6KRBVP0UT.L4I"M5 5P;YMW80K5# M'!#F2X;I@)-U#&FW,UF)XQ>RQ95!]V29G+]0OLT9
)IYB90.+I1U0:!-\61 M5Q69GR6]!F#U-"^O9/&T74_:B\=,6K;)V(%8%G6FM&:TH^:?%N;-5O7,LS!P MX+K";R+>DV:V:D;BDBH",]U*=N-
86P[7;M](!R@[1'0O=6\!0!!$5$"&+++(* MSH4\'7) WL0>,&? 4@E6Y*R1@B#U]#]O&.M%=[.)NU 0 1N.6,X1C496K-ER
M.35LMO4ROP.6,9LXIC(]K*"NJ6WI4R^O.G@]4W]E^LFTF0OBZ]=X%BS^TI]-C [X29\;1 M(_<8Q$FAZ@U/9N;[L4A,,M16&5A\8";;R;G -
%YOE"LWU8*M.EC?%DR<$B%[1284]{N5_QX M9G[#]%'X[Q_=5HH(%N/#U5(Z<(=:8E'T/ IAC7L_"#T"F$KK!XCJV6:;04 M'^F&OR:
[50:\IS'Y%S(0)D/6IO+!T.<'G9]_'DE.\"; CD_C.5D8BY26 3 M%'X%-@-8 $[X2.XXK+O0YCZ@!?>?P/4A4)\OBQ%7 M"O8D>\)
,^6O4#P:BV/!N,2=\$?,R,P';Z0?4\T-H.">&"<94/*E=HNUF38N M1,AIAM_$;SGAPD-/IH68QQT"L'7"]G+"G);A8(BIQM'ZU%U8!(G3#"8.;#E8 MZ(!QZ!3!
A6=M,&)2*_ N%D!2Z9(D"'+[[(1,-' &0+U /L\ M!]S M#:8MPS2N^!&+_BBR$L' #?PP3%P<5;B'GG#@P3%WOB9=%L13R/"]O7M&.U6=
M$%PJ)0BL==NJ%=\45"R_O4%34%&/O;QT0<72THDC86/.NLW/N)#C+#+&W!+!
MEIIJ^!1GA:EB+$;YJEHG,;S+%0R+3"N1$PUF+7?,A6IP]$:.X0#)NLFT!F'0
M@=WAQGP>!8XTI/Y$FC]/7PMJ,]MKRZ*7$%0;NOS^7^QHD3D3)2NG==1UQ^+F M1E^:F+\^]YEGIBGZO[7N6MHU")#
8VDL\68*YB@CY\IO=]JFGY[,9AJ;U M&&,W@9 L'L:'U]B^%<_R5?H2)M>*8IJOO@M;:0/AX;>;0^T5R+I\7/2,UHU M:WG@^Q<32$+[Y\(.T'D21XN
&G=18T3?\RTP*>$+BM7>_^V%8[6(V8PAF)2;X#]K,#\)#&%:J$%J]K?[F[O;W0*XXMI/>+!Q$1-_MCIX_0_'T=T:JCK"QBRT+^-

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

*GF&TTU-MI%T/0A73_S.Y]2\F[7(+<)\4T5%&AG)_3F_!,\$#T1JSHI^%PQ#^$!\5^0-]. M.]2MGO%U\3R(QR%<$'I'FBF5*QD0X=+?VLU"($\5]BIH+TH-.[O6Z<%M$[ZQ M7CDDJU""S%!?S+LPBL12-K6"0T@=> M=@7^6^A=@5!!\W>B&)4R_&A341CTPXA0#@NGA)7C0 D&1!)IE010-")'>8N8 MBRWHEO*5@>41=R F[Y$:HFJ, ^%YR^,0#QHSUG=&Q2G#)A?WBXKT#,]-M9$$9P'FXAS1*FP,O2I6F0R,C:W>(R MMJY7IA3VK"K"]2#/I%X&H&G* 9 MKX@CYZ!9!E<4?H&[-">F #>B7W6ZYFHP MB1$X*!FYES?(LC%'VM'M*4\,A *O5S,Z&MU0="(&0[$)\(<9%^X 1V+JF 1G MXC @:B !)*+C35ADD88&G>\S[96@L?XLAF/%Y37@![U]}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

*U=!RE6F/[P\X:D80@O%]O,) MT?)X0B-&ILU(V[=#' @>I]]R3RH#8^XR7+9?R0IN4(4._0[!1A-$]"3A><> M1;2RF)=;MTV!"PK2]C':_NYO/G-=B_.Y RA*Q'W:W_[?V=YFG '#-U)R [[ MS&] )@T^T+\M&12Z MTH& 6FD=5MU[=:-ED(DV(JLL^]X.$WI-F:\$9@&RZ MAFQC_Z)RO\(:"#Z*F;'*0VF^ RX7>'TZAD/I[,H1(<9AA6,&>3"+U 5#YADZ MC[T\K;(RM%\Y([*+;,FHM\4TG7_E9BM14,2#2=E^#IV^B5A3E"@)%_AIET;Z M4/FNXR^TI4$/8^G;/B5!%$IWW*6&1]Y+LD[2$ $N.B9EFS#[-4=-HV+:#TFV M*/6%A0H=N4$4I$X;+.+N=D^V9;ENR6+;_1Z7'8WX+LU[=&/!C *4_ZB HXBC MX)P.O9P$C&-WHMO61&ILFNY N 2#G/L-YQEW9T/"]U>;RY=5GB0#^EL0C0F MZQGH7KP^;2B;$5A8#G'K7KDYH 4V#^]4AC#K? (_OB7#&S*&'YFL,@HP3/FXN M9'1;&EFS?G@:?$%_'/KWGWP24;^O7^2ZR9(]<=SO#,UL,I$.!#:U6L15*%IH MY91X%KM.\+5CC>0 @&6E >GFF M1\M6#@=CF?A!(4>'T9LI^Q;0/U$1@^\=,9JV3+DGG::2WOG/%UC${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|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|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|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|(\#+ %M6CNS>8^8.S'L@20_8)M]%:.Q$( 0)>>T45]]SMP-XSSXHFAM;V(/9Q"C^EX= M;NDJ@E*2A9B+ !X2?@8Y 9H6Y*[_S6_/]? MAQK,G,3UM,H21G!',Z(T9C7ZF MT4L8R^D]7N^Y8K@8. T!SG,"|*T])L*=$7-!J:#.8YM]%D.8J M]7D*)T5C\OR1L1.'//B\]J?Z{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|(\#+ %M6CNS>8^8.S'L@20_8)M]%:.Q$( 0)>>T45]]SMP-XSSXHFAM;V(/9Q"C^EX= M;NDJ@E*2A9B+ !X2?@8Y 9H6Y*[_S6_/]? MAQK,G,3UM,H21G!',Z(T9C7ZF MT4L8R^D]7N^Y8K@8. T!SG,"|*T])L*=$7-!J:#.8YM]%D.8J M]7D*)T5C\OR1L1.'//B\]J?Z{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|(\#+ %M6CNS>8^8.S'L@20_8)M]%:.Q$( 0)>>T45]]SMP-XSSXHFAM;V(/9Q"C^EX= M;NDJ@E*2A9B+ !X2?@8Y 9H6Y*[_S6_/]? MAQK,G,3UM,H21G!',Z(T9C7ZF MT4L8R^D]7N^Y8K@8. T!SG,"|*T])L*=$7-!J:#.8YM]%D.8J M]7D*)T5C\OR1L1.'//B\]J?Z{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|(\#+ %M6CNS>8^8.S'L@20_8)M]%:.Q$( 0)>>T45]]SMP-XSSXHFAM;V(/9Q"C^EX= M;NDJ@E*2A9B+ !X2?@8Y 9H6Y*[_S6_/]? MAQK,G,3UM,H21G!',Z(T9C7ZF MT4L8R^D]7N^Y8K@8. T!SG,"|*T])L*=$7-!J:#.8YM]%D.8J M]7D*)T5C\OR1L1.'//B\]J?Z{66GWKS&Z$_MK2%M? #Z+XCX M_23[]!4-+^4C &L.HZ[,OQQ5R<;1^M61,&:\Q-B_SE/U?2! (?* M',V5S%(/L]>1> ]E"K0EI,BKB(_+\/!SF$ZU,N"]JK;95OA+T2808%V14V)&D68+BX M_96;'(UN;9,B]0C_2H'4P'*A@ MU-D+@O[1X6&GO=\?'.UW@_VC4? __#G[XY3/45G"2%S0AF-- /PM^]5_AO[^@2R>Z;@28U%U>P)I5KZ8?WK42CX4400.Y>A%DN MHH'9DQ$KF/MRX4_[(>D4!A%&H548ZE4*R+59. Q)+ET\PZG<0I?[A21-\[A_H^!^%F?*GSTQ7GOIYVZKOWFNAR1J9PZKWX\)HVJ(9DDA(X MQ+2;8BBBECR!(Y8MJN.W;[USX],3;4;*-L(IX CKBHB&8!O&L+;"(7U-@E?T MK=V-/!MDVQ-P@(D0AGL4"60#CV_(TTQG1-&QVR#F!V3Z_XU>E2)3;#5.3_M*"E2,GVU92LLA=%&1O(P82<8R2%"FT? &/<\]6*2QQPE Z))^0F:[7K$?F=UV?1E\Y?@JR'4C" M$@D,O2(/.?3 .CDLA;BHWNGSH4D,694THT'S^^[IKO5[)#.";%[$83YGFAH5 M>4$VO_87Z#= (CZ,#P\2,]^9$(V/ZLHARC]CX%Y73#O^E9E]5-_CN6\6ZPH5U MM:)Q+6=4?:_IM4!PZS)U!0ANNNI;$0=KNQZO]BBN4@.D->%]D^721EU7&#U5 MV>T]A8?]CBM$!AXV56-Q:4[#BX>D;CL,E+-C%]RJX*N.(&:+R% K0(_>/<7 M-3>,CMEMFFFG*ZQ7VNQXLNQ!U>3RYC?-^?S2S+00E8\.BC0%UY1GA? N41D\8 M,TLYK_RL18,92T2$RY,PO9%^(_YK0<'X\+I&8X"DK*H'>]*J8N!KA>+< 3?$ M40F_B ;(2V]_4LZ*I$E6R49?*!*C@EA52C: #Q-M .76LE["09@RE_66RA.M*WV3S*]2#*6QY5DC-6QQ8T52&8?FV&Z:1]9 M+54>%FVI:C]PA3[X=Q%F6O49# (@C<8@EC(EN\R0EVSZ@XWP61#1^EJO93C'C M0Q1GBCU.JW^FPUX/F])E>Z<&(MQJV@ W$U^VMSI#:C )XK$<.K,E6$L>/'!D MYPN- >@&=:BP';@^86YP1D2\:'O34X>'NP4_L/.DGI_FS6YD5+&Q=3AT6Y; M8D#W*0,(YK2*C006"$53-9B5!QD+9FS6YD15*R\.4D*HFF6TPY36&6,BC!G@^2"B-|(\#+ %M6CNS>8^8.S'L@20_8)M]%:.Q$( 0)>>T45]]SMP-XSSXHFAM;V(/9Q"C^EX= M;NDJ@E*2A9B+ !X2?@8Y 9H6Y*[_S6_/]? MAQK,G,3UM,H21G!',Z(T9C7ZF MT4L8R^D]7N^Y8K@8. T!SG,"|*T])L*=$7-!J:#.8YM]%D.8J M]7D*)T5C\OR1L1.'//B\]J?Z{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|(\#+ %M6CNS>8^8.S'L@20_8)M]%:.Q$( 0)>>T45]]SMP-XSSXHFAM;V(/9Q"C^EX= M;NDJ@E*2A9B+ !X2?@8Y 9H6Y*[_S6_/]? MAQK,G,3UM,H21G!',Z(T9C7ZF MT4L8R^D]7N^Y8K@8. T!SG,"|*T])L*=$7-!J:#.8YM]%D.8J M]7D*)T5C\OR1L1.'//B\]J?Z{66GWKS&Z$_MK2%M? #Z+XCX M_23[]!4-+^4C &L.HZ[,OQQ5R<;1^M61,&:\Q-B_SE/U?2! (?* M',V5S%(/L]>1> ]E"K0EI,BKB(_+\/!SF$ZU,N"]JK;95OA+T2808%V14V)&D68+BX M_96;'(UN;9,B]0C_2H'4P'*A@ MU-D+@O[1X6&GO=\?'.UW@_VC4? __#G[XY3/45G"2%S0AF-- /PM^]5_AO[^@2R>Z;@28U%U>P)I5KZ8?WK42CX4400.Y>A%DN MHH'9DQ$KF/MRX4_[(>D4!A%&H548ZE4*R+59. Q)+ET\PZG<0I?[A21-\[A_H^!^%F?*GSTQ7GOIYVZKOWFNAR1J9PZKWX\)HVJ(9DDA(X MQ+2;8BBBECR!(Y8MJN.W;[USX],3;4;*-L(IX CKBHB&8!O&L+;"(7U-@E?T MK=V-/!MDVQ-P@(D0A

*M|O3G]2];RM*LLX1OB!.0HF"6]9_-A^?#,)M%P?SG,..:M\DO/]5C:PP*7PF*-_M,Z!#?BZ]#;LM\3CH$FMZ9OWS+OWT;/G[O=[N8>>H]?*
6;KOV^U5#M=N[^^WK M#;7Z^UZW?I)F4;>Y],[>I4-=4<#OTN(#1TN/U507$*?@W5RZ/US@-@?U)?W8 M)?%.K+036&G_W4^?_6(M-
8^,M#4*_#Q$T+R'-+H&9+Z%>IS2%]=H:+79\(-I MNTYMJ'4V_)B UOW6_9 X=(0TS<3TX.O4/MB'9_%#6LCW;#EXH.IGK7&_C>[ MOE"[=>AW]SO?
5"#K?AM-?GMUN(:(MYV(]UI^]WO#HF -$6\4+A\M$76].WMM\Z;:J+;2AV]GLDW9]> M?!N*G4Z[XW_I]#QX!]F[,%)9GL0VF^M&@G-[]VES
M=9O.\^UO9OPPT=/S:?P&.9N)G.;L;#1Z>G[OOL[.%6+3Y-#%)'=6X_(Q/O7@ M+75);GUDUGFGY>\=--V#-Q4[77^O:_?5%_W! MV^;<7OF[-
N[">IMPTW<&#T&:?S?;1D7_4OHW^;+}>'TF0'79MS\NC/2:>[Y^^U-MOBT-K#DGS3EYZ.=D?ZJ[*[-45#LH: M@/VY]V-W;Z$TRFU635PL:K#J%H(N:
[!4K?".*CERU6K4$3 -^FB-7'B%'S04[.[@/$F_,&0@U2%1@*!*CQY.Z:,W<1[$XQ"ZQG&&$W\|
M)6HV77RVCW"=_02\G\#=S_WW5:FVB2!JI\6;1AR#.>KMQ%DDBPV&?Q92UBOC MWLV7;:PIDGKC(JG=*CB:(JF/M$C]!C+G8Y1-
)QYSR[69K[DJ8D4['],$Y9V\ M597SMD]P&%@3OT2Y,M[=*D6'K9TW'S_]-9C.GK_T;1&E&^KSCBHM_9)(RX'Z M&,QU43%Y -]VK33(,ASS] YBQ%YYG-
F[)D-$A!Z^<.B]R"(H]"OCYY7C F MV2=:#][YI(877,%> .&-HZ2/ZGF 46;6]OBXH2T$2;R4A&#@G85ID3%(-M_O[I^-0G\IB$_3'"02@*\,-2EU2*XF,GIH+_>
{6%Q&ZW81L12.O B@7=V3VL M4AM(Z,=N9[=[B1E#E4I;="&9B^DW"7T(_(%$3-'$L.A\)M^]QO-OZ?FLTI%S<6{!E=.4^#]!8^X39DXY.Z[?B,: NC[E
M.A!YQ>T_TUPF1?%&86.,BA E2".&!BD1*-V9>&]#8F1#E$WDKF3!#*<<$DL] M$#X@KO1*S(@-4Q-.+J23"6$PV\(><%*!4>PS9;82H0-
+F"VZ")R&@XX!AVJ= M.2NW8VFM6*0)]:YQPN6SZ1T<9.*3*D?OX"B4*I]<-=:M\DI#\,F.YQX)9#HD M>&"B(F;36='/B,BYV*S(\4 ZZ-]E"(V*>&!\(,:(=)T?
2SND+\Z#M&Q7E7$= MV*'*Z"E^(\AH\N%8BI)G>5J{A;IUK:'>".O['%QXOTJ-WNVCT0_"GK&/G/:A M:PUSVY\?VTOA#I'?W<6OJWT);B+ BQ(.0#@Y.&/L?
N8JSMUS%V?6:EVV8L49[2N>>(J$$ M/,,WUM+'P/. MBPC\H&15XIPMNU?AW6EX(2U]4/3UPBQ2M 3&5C"0[M7T8P7^W\%I_@N7:EP>
M)QS^SP]7.QG;[R!.ORB=&M6,*UZV.[VKYP'/Y'FZ+9E'3#=1"$E M]4&](D)[M.Q(9BIU6J<<'1TLF-/RARY*?Q-O$O99Z8_MQN',PCQOU)^IRQ:H
M>VTCEJ>D%GW!CB!Y1"T7KQ^JG4B=Z?-E"#J;*!*)W.P\)T:RA<'0TQ#[_"X& M)+0=J:DAP*LWB <,GP)21-=0/8 BM&L/N.4FEC(O.6BW
MGE_]B(KK555M4=]S=3-L[%)#WGO"ECMWO*P"X4^X&!=9 M7L:M-; \F1]![RYL+V=E6!@QP'78S)Z%/6M.P@*VC\+_4*;Q!,R\D!1>]*.M% EQ
JW_A[NP56>M$(T0BISE]45FM1)(_!FGNO?&]-_2K MUY9QP\S[1T'?D_T_)UU!I&"0V"QEX@#35*%BIR-^"B MP(HZG=;S3V'V!0H-'N"OVL\-YHYCM
U9V)+7;NW\W=H;2)Y%5KU4_U=!4M9U> M7[Y6QO & U<3A0). V4C_R(Y UZC+%%/<6S(1I-P68]1CL9%44D6W!
M!U7!=!F,YJLUCU)K*W40TNZ&6@D15ZNLL2]H=+\SVC)+@F4N6V6SEVJE8+7_ M6) 62;:^FEC'-
[%&_>CG!4<$K7QA[^>ZN5NL=.?)9$KZ;D7ULQ*TJO\)@+ N MW0=.^Y8):RSMSD/:!VN_6MICWT4LM@/LE1(5QD_HN#D,H"O+O4-YMH7VY(<%
M=64:<)OB,Z5S4L]3;OZ7+B@C>.R* )G*,,.B8SS)8G\ /JITRKQF1N;'56S&5:U=9Y_8,CL1H3[.V,8V3U6R!!=O M'7 @3)X;6,W8:.L$!,<_@E6I%)+
KXY9E3=EK]I2,H@SC'D]G%SIL'1"*C+& M"HGB:Q-AV45LGB&Z.K<3B0)(? Q$DS[!:K):@\-7=3"9,T
MA)9RDRE=>I^Y!L0RF&FANTQZZ[M<++#39/069%FA:J1O"4KB2H1->,4EPUH_=61"8O0+-?=;!FHI? &O3O(JPDU6+&=)7^ 5AY-
(W?:RBR1"$I!GS(FS$^!9"/4 M+'%@_44#UAK#; +M9I(FQ7CBH0(O#<[>TEE!HF. /\GL/\,,(E!20UA:-V3) M41F.6Y56[UMRCJ",OZC?+$DXN8,OF\,\,-
XY$HY(B S'!JEL(6*C=" M AY86A--Y4!7$VX->)-T(@1')6*6FVE<6 MX@M^SMAM=APC@L$Q&)>_T2S!@,D%]*WS7$]]=2^[5=BX7I6S@RGNT(EPL4YG
MOWI.78?>(BL1:^!-2A3O1<$YLQ8H:**3%&1(4% 7]E3[=Q@5O$OIX)=GR-A+F MO160,#[9M]14!WBL!HQ$23KZ.P%;T4,Y4S/:
M_HYTKO;!3^A',@P"CG4@VM+)E(_6]%-'?#X4ND M=99HUZ7,K(S4)68N(L4L>5[V.K]DDR9XH\FF^M0LYZV6U!YF_[^]+VUN&\NR
M_"N(G,P9J8.BN6BUHR="ENTL97E16LY;^LL$2(_BTB# PB*)^>OG;F\#0(JT M-M)F1U2G3(+'PUON?
L]1E=@@.E!9X8C!HH.UUX,^Q)/4D$I(!W2650VT_2#U M %VB5GMK1W2XTLU1PX-0[U&)FO(N@9G&'3GOH3*7@:H97_AL5\R4XIHU'TL=_MIG?-;2?
SKMQ(8_/;OB%G:%/K?5GQZ7-OI(G/9/)8IJ"F7\S_0 O$+%0M-;E* M(-I5)OQO50VBW+>&DI?JS2D=[^18.?V:6V&5TPD"'R2[<:H;>'\;G.H4$UP!
MD.\WNRVV"6;LJ9;3U"KQK0W;Y+#5P%NB<>+H:ZAT4CWC)2(_0:N6G).J$N0B M++S]7&,#"XMHQF,DJ$_@?+-3 Q\75(",12]\!WE(L
7Q86B8T&U>GX@>/W MP2OY7]DJNP;-Y2.+^W-]"&Z0'=3PA;C8E.M'MWUTD++I/KW-(;_%R^6% &[*Q&@#I24@FY0DP6.16:,_&V:MI-C.MCF MF-
9C+$^<8UJC6.,Y6Y>>,2P'*;;*8)4.R"B.85O.AB^FC#$9%"2,*'SU:=7\ M!YG-P3V[4,W<(I(RX7]),;8B$U+/-2LL;!G*T]\@R]]"#G3F.1<9B""BF3$#
M40V[GO>'%]K-ERC'%#X#-<-5$Q0;(3/56;*$PFI6'3B BAEI M/'ONZJ+T(Y=WDN*\C*?\FAA). C*:\A M0+,9UXW-Y@@6KRS$J9)Z29B_Q0^#%8I]%7W-
RRD;64'(J2ISSY#MUL_F'4=0 MJ1_!,;$&EUZG>RC[EAQWL2,"JF5&[Q->F+Q@-0#M \T[ ]BE8 U#^EKUCA]] MX\DNI]0[52W"7_ET?P(#]FG8W!J57H7D-
E$:>]%;XG>2Q:TO@\]$P@*_,47K MRZ"_<9$N;JH"78"TX"# S]V#6B6R*RZ[!7WWZ_EG,[8.V[S7P^U;601;!+@3 MB^/KG+3[/11&_"#9VK:4"5:
<"9B(3'D57)@D.6#0-DEXE1*Z5> &[:CH(7-C MR2.1&A'Y%&BI+F>6J:M<4S]\)=>DJ4&G*MI5Q$(>6^GT>'-4DT*=RU'WOUM;3\RZ MJ?6HH1 7+
[:USO,$1LZ"R@.'B$X,#V&5A4< CD-GX5>;@OZ\'7_4M..M_=Y? M<0J:#_Z]W[]WW#X^<=[_%#W&RC#,S >\KX>8WXICBA=4VK^LS<'"FTQPG>R:5.G\
M$85AFCP#,*U0Y.R0]Y^6,*P@WWVY;(4 3_7GN>A%]+:;MI'KY4?[Q25%A1 M0]]#/WHE]Q)W%?VS*CL'3CE_+:
[;R4G[]'.$WIMP@\B#Q;%KP_2\]'^"!MZ MO]OX5:.?=_/F\6W7[[8/#WD]WFQ_Y0;__<(/:7WBK._A45]1->1P(YN,EB0F;_MH)?U.YTL\TXMZIU_--;?
42U\H'5REM4*]34[_A0YY5_F/6T$-U7 ,=> M[\5&3?A0+]S(1_6=3EI_E2.P^111'T.I0)20-CO '+%'VPF3)A1X^$8<^A^= MK6#CR0A.3HY;_=[QO<@(-
IV38(N)-WT3@U=X>+B.F_AA;;PUT'.E0&)S 'NQ M#FG@MMU]U+6>&U9J5NHU9)S-V\"?+$[( [-F788\,&,@5Q$C>HKVOKSX_3)MN1P[F
MKE5"L=+)_)Z8[7O'K:.3?1F;'XC;_@',EN]\=79Z'1"H^W,%Z],MS?>BC-]* M3=G(%.HQI"ZRS:!@X'X5%U7A^U3.A]W]A<=\]YQ7/)N":![VM8KZ'8M;T1=$*
M9W%)%V7+'?G#=;NMX]!!)G)';CE6M^?DR69F_V"_U>O<+R*T[ARK:X61 M_DGE%!Z96F QD]JN+L-<]?K8EH$+FPU?/=Z#(&#%S(4]7(%?\)IF\ M>71*
[Q8EJ#9/#2^?A:LHY5Z_ YRV\E8//Y:P.+5D.'9#['<.JJTI4<*836;; MB*F$"IM(9<- &A\1ZT+!?E4:V^WR1-NEN]^M$]_!=JGV*N5;A?
^HBV*A@2)KU&&5G(XZ[^QS&DZF M<3H+0P5E@50P"37[$CZ?;IZ*_44=0S\D8L/A%K%A/<;RE(@-CVN3+N3*0U*7 MS;,XOQ" N=.89X- V3BCW!W_;?
PW=;8YXK&U66P>C!SG(;AQ]GYGX"0!4Z-7 MKT*[(98HD4P3>V;]^8BFP",0D[F*]T!M_X8 @]"RY#GU>Q-[%B);94@&R$@3
M81Q2^S7!DD6W0@)>%$PU(=_5U$ZIBG@:4,*X_]Y"L2;@+/D!+CI23#$6$N-5 M2.B;0(L4-D +MJ4N1\"67/EH'N&?]7@U-$8!)H@C[((%?V. Q,0:(9;K'%X(
M\$2MNQ[?DD">5+D2XC.!SR0><$2O%#*VOAK<*N-\6%*OBHGL%^K\4."ES'52 M .>D3.@AFL(<<1)"POJ#$9G>.O[4;_Y??WGG%K/-N?>>(?
08).8&EA)-[IM$ MB(R8"990&]J_9:\O#@FB60/!VEWX#G0$\AEZ\ZD,&WKV-T] +M=BW^A!T[)Q M#WHB (":GU:DI.71.V1D?H7P@(1CM[= .JX@$^?2
VC]R@<.;B;[93UGW"P MHM',6>MNM#U[

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

*:@B*"H(IX1F7;<I_H,9;^_Q"O"B)61 M&P@Z@G>||W.H G&?4!X,_2Q#E ZT#_S$;@@V20#P23"(J=%NM>]'1!/D7\AK&YP= MN]N#LSY*Z(>WBH\AQ=H>8EP,K.]-%%;^URCO%FSGT){4]9]4*MKYYO)T=[?O M[W4/=D*A]ST(Y%\BC&SLI%W+B<9&&$7$P&01U)N@ C,K^,XPW:\5(!+7'9EI M;MUW=G ]"&@D,,[W$A-%IJFIWO/OY*U<3UZ(%0_I>PW!HG'*WZHY2*271)W7 M9SV@/._>J:9[XH1^2[P))(X9IS<<||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|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`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{QY'- QX_AS85J=-_MB+,G3@CR8LN 8X+$$!M[[$#4AH->_W[4_^7SS?@?3Y@.*<*UX)_O WY#X6]/VNNO96J1?;U7LP;Y1"FH$9+C&>N*^8(Z M*^J8(W\^IW(EK\&?.MR'"LSQ.H;JMW\G>B=L;L BJSBD^PC78OL&ESO<-6SA M^I++!!]"0C4$))0$1$6B:DB&UTD4E8CG+O4G4%PD:815O,T6(S;79B!F^_MY%X15/6BM!A>[&*(,A5X:ZE-$-M$N60CN$9X75,N? Z6VSSXQBC'"CJPX1*G< M6E0N=U%!,43)(3%!-4*AQR1?@@U+=N.XGE0E%A?2]",SI]"1= SXJF3K*2Y2 MA]?KUBY>&]DD)ERUJU \V C=6B9CC M*GM*=CU)?FWL$\MI):BI))&&X]!IA$;3W,7TLMQ+;,.FB_B:Q* Z[&,5>HTCO M47O|)@7>@H7>L[.WB37U_H5>\B+ZJU8[L( MT!X%- P@<=X5U%_/[EDJI%G\]!I,C^WD+?D7T:Y,B484XH!;8),HD)(T;15ZL MS?J1O @M. ^96+K9=_7-JQY/*<@#YGKM?OFER%3) FUV)\LA!V;5M$_*@5;5/ M+VWQ&&]<,7V;"0M)\?\X4UT"35#[PIJ(&QRC*)U:SZ%M38=$&:EP.JQUU1+EM-V+37,_-:FX0 MQ0&G$VZKD(6$)O76O,*A]QA2"9VU&OY+9\3SFJ'-GD1E*X/,?9KOS""N3F&0Q MPR(&DU_O+@4"R*[?U]22)m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

*=T9/%5[54<,|·MC]I,V"0%($.G4\FF(=PA1>G|*RU9FS>)|\M[ZOH_M%-G6H|/B#@B/" >;HTSB·M6^[0>(0U%AZU(Q+5U'W7@V8AR\^/#U6DQ3]1,, (OWJG4UC2O\^/'.RWV+V4&U:M!.EQ,P+@;9;<"99·M:, Q05(@NV>N)[D!TYN1)XPOGT&Q&QZ57SUY?A11IDV/|%_YT*?'1CE1VHE2 M'[T7L#IFQSIP!U8T]?*T&*=7-=,Q/@X >4T.IC66 (P<(Z#ZINU]'^7:W$BO·M;^K;?\R8D/C8(R3S*?;;&WN\'I+@U:*9*",;&?[ICWQV!GT\>W;=TL>",)?!) M\·EQ1&"[>@1/F!T<0$%\,.Y_W·IG*7 CKN]+T6.6DQ*.E*ID- B=N.I=^*N& M16V7-8A#Y^RJD .OHWI15]-@@,, M5PU#G9)I$-<'M=SST>X/4OB+]T9 R3TV;Q!/"0F>S(4#J.H5'GM$X8V33$>[·M=,'5"M!D\P6*AB;+Y))E>IG-4%47[Z0P?"V4>\N\H=5C·M^!FTNI_8?,)DW/O F<#YO43IXV+ZP=5V!2-@>K*)? !FG;TTQ!S9*PCW8D5M·M/"K0"3:ST=MPU5$"0G'(@JID<%AQ_<;·T.H8?_H;[&MRY'XY.F[MX8·M)XQ65J859'IRW_]>X·3%F1:P,=G?Y5>@:/[M)*.'CI? *1U7)5PK,EV^'WW6·MC0(EI53"]>A=X·7(8XO/"_6J7@[@QZ3·;MRPL+·M5'ESMU3RJKH'0\F2NR#R6DCL')D[=,*[<]U[9C"·1*L[P2VK"K],U_<15=6P MP&@A&<5*;/#OC3,$HZBZ!0,_1S^4[O8W>1XY3@N<#Z#JELV?%J62/I\?Q:<^,)K# MH.Z.#,D7GFYNGDI;B1E<9!0;+9C!8:F]^LC@OS,#U@Z#03?? (RU;%2#Z9/PW·M1%TX72$7(E"6[U4.0R7·RGB9I^>S=]O]6I>#17@K[^:KUOYN;GBKD)VY@)P=·M·.99I9[UHV?27<&3^(1 4SX^++.^ &^60T=MO,N:T^ G1)?D1H(JNEQ·M]A97B6·$6*G?0,#]XL0K·FT*>26<*0A8%7'X,_QG\TL4FWN4HRW1\#=R\CTK M*:02CG_X[4YM9AH,9!LP· [ZSC7PO\S@JX5);;:Q4(>V0/-G72[_HHYO@0\^·M+I/65W!K9F2Y/)4·[!KWD·D·UBF[6RE8\,,";GPWIF·Y3/X#%NO7PI>9N!XD·MLZ+PAU? CW+,)]"JX5E7E";5OM=G>[&JJ1^6$5'7S./2B:P/,T >-):RCHKK7·MJF (·,Q5=5U!=<^@04=[.3I_·MH.Z9>C$U5MTMF.=%)%0\"%VQ\BZK^[Q5? ZRJU%,L@!5V·M.Y>YXJY?4R/,S^B.R()NYS!6U>4"RU<\E_!D:^$T8968!!:P_9XMA;W$:.QZ·M'J*M690=+K<:X9&0C3/V_K14;22? J0HUO,C$]CY^93!5P2\LSFQ^D6&S5:M^·M:G"T@$_FT/F5PM03#+V'83FS;]M#TC,&8!&\+5@Z·K_X5,(:RU[%EUUH[>;U·MPX(1*"2I1'?_;_' I!!686K07W"3·M"YL]WD$7YW@#6+!,"VRM:]FJX·OOJP>ZS/=CBZ02"77C6%@<9V8067<$"'7/K·MHX%#*WR4,Y05X'WJV4CX!$;1*9· [.JC*OGH^=YABZSLT96KCN.::&%@7V!Y]L'E JS/=(@N8BKA·M8·@#P$2GDBYF·[_B$4!U, XEW0H8TM@UMW.PWT?4]\8W>#]JA3/-:R&#WRC! M6GF!)4D1UDJLPNYL=931LN(9N6YO:'NO,Q9C^H5UC/RCLZ4%??_\!I·&'ET-·MK?:F819])5RY9X:8!F_;#JVA7,RHTY/^5+VRYJH#!GKWBLOX M_BY'B18M&(,:5,#PHNV"$O3?NY_9OBDN?W:43EN);=*M6"ISV]W3U\]\>[;P·MI3&C+E,[#'0.*[R_^_8*3]"E$^3[_H0*]C·7/B04_SI>ZD$[%/1]·0)_CAO+ M0FI?DDT2?N^W)GK,$7-\;45O?2KI][<_7@>^D9(MA8$&]6VFYAS7>#;2\P*^·M3\R;"?.:/WZBCWSNS_&7VV%P.VVU6G>@T. +:@>_3U.P\V4*BM;XL/K_VZ9·M+X5K< 8*-166+/)*M·7?5Y)I>I\MDDH8O2[SX!\K_*·@62A!7PEW1NJ&*HT/·M.T25,%RE]M QU"4/!5K!+FDEG+A?V? 0KZSM2_9OO13IM%:88_\,67YEMT'S[·M=ZDJ·4"/62#"YGBQ!)}(X7%3·T,>1R5<^G7UR(1F%;--4PFS@T)D<-6+;@V6·M1EH))S[RZ6PD3. [/.Q^&CRL\PAO:&16DBMP45%9*)5Q7H(3V)>\S*H*HGKDZ·MCJIBN>2%_$K05L*·D3^?PYP3;]X*KM0)@SU&RS(G·OE,3^'8Z;V=K;!\ZD_8·MS? Y+D2Q#*]Q18MVR'L88O_XWA!0IX@"%[3ZRX@.]?9$R_·MR;.C);X9O2_]\2%.X'$)*W7_9-=#]G·M9Y"R#:%NTG·GHM,C·R-# Y,S!?8V%L+GAM;-U]67- ;,;+F>_|*3\WKH(Q]Z>CN&UZ[·M'6%;#MO5=>=>)D0·2-F]1I(:D['+_^DD<4OM&D3C4D:..K98FB>+Y$?DAD)H#, MQ_W7GX>3)|]POAC/IG__1?S*? WF'TS3+X^F7O_·RV^2?S/_R7__XRU_^]K\8·M·7+3E+QXHF&.2\>B1,<,&.YX*@5] M^C?]2_@K<1UF8=)YSG0HB? FB@;DLO;128G2V^]#)>/K'7^N7" M\0N)·%]V/·M?_·EZW)Y]->G3[]___[KGW$^^74V_)4GKS[E_7;_[SR_N^J>[<((3SM·M?GOZUL7XNC?2QXJG__WNI:? T%0^!C:>+)4Q3?#MV]>/OO\ZN7S9V^?O7_QZM._·M7KWZ_(DDZ3YY^>,(__[+8GQX·,&3U![.L?S]E_JYK*J+1:X7+PXGL]I@HQ$-'*YY)DRE=? 66P8<@>FH/1B!)A2X.&)5J@6)·MU:FXP")V>EY_^M,ZE$]QLERPUP)8C>7VTKR·Q==GTUS_>?7_CFG*·M3NA#%\^6+V ^_T'FX=\P,<:1SE8) ,>\UHKI)!.+Q086,IH8/77HRFV>KI#LXJ1;O^/IXOCPL/M,·E[B·MXI30{)C ?,2$!BQ·|C\L3F3UZ(PI8QKV+·M)&DI+&8GF4Q2Y,PS=UZWG@NWX· F$'/+1D:.9!IQXLWT&SU[·O]!0$8]Q&*$·MCRQ+3(2 !Q8!%7,H=·B0@HVM|>'YYV^B<_7H=+[U"#?3|8G]=W'O)GZ#\CU·MGU^4+!D4A=QV%ITF'%P!IJ 2"R5CH)C+$L0F5MFG'%,HR·H5E)@1C%=-E%&+40/=GW]^$WT;!^=GK<=WW;>7"?*·MB"=+:XE(].Q?6D=2M@(876NU$JG:#·MW]#? 6L+TRYA"^I5\%,V]^C--CFN;_I^S62X^GDQ(9HKV-·AB]B"F1B2'0W+-·M+·9EC·PJHVKNB-V-:W@AV$[L:*Z*9B0Y?3I:$94,G"$MQ$PG]"RFW/F@3EMA M50RN,1'NH^S]AET[*7NK(6VFT)=8D'RL_&::9H?X&?X\91SA4<@%.B:D)Y:Y·M2+%^,,,!$U-$F633PUA[MS6B&%X/MI/1&P]Z)OV*R M*H%)5R0C=UPPK[1BSD:),X6,-J:>V' C]$U(X1X?*=HHH8_TVQF:4;0*C#&T·MZ!A.(1F4PH*$P$KPU@*0*#:VEX$[·[0!_SCX<#N@]U.[Y^6L_3'U]F$AG!1 M@Y[ECU'FWBN/F41QQ+!0!_M'$LZ1]E=X$]WWE.IBL+G3>?9X>%LVGWN:B\3·M8W1>&455B631M·(RX,FP['1H"1]'6^]OWP)PY"R·SQ]_ M.KGK(4/*B#32;M·Q:,/E%W·T7L+D(V8\/*HC\1$7,/^&(Y4·K?5L?9$,&LX·MH\C)L$3AM5/.@S1R(Q7?](0A)2=:ZK?)B+:,;+\AY7$'·Y·.,R7->HSMG7T9! M6@A")R94]B0I2%IYK6:NJ)!+LDGDUMN"=Z,·4G*BL6UOK)*6!X5.\JZ=0T6·MCN:X%;>+\3=8GX%\RDM>(L+F?TR3N/EJ&·Q,64*SBQ%[SIR MPB4\L$QQ6DR%%VNP,8GN1C6DO$ECWC1623.JO!U#'$_(+N+BV31?(]1S5G,E·M.3-&U$,T,3*/3K.(*+BV+F5HG42_"U- #F4_V:)5WRIODF2DZ,.U)]\QPU3A·MPH2D@NY3R@'NBC?EQ>7)L*,_"IV%_-OWR&>>'+S$NSR4P;$X89$"F2_4"=.·L MH"&;G4ED$[3CS3>ZKTMII/Q/YQ#A9!R,DHQ5#2%YV#(T/M·M,O-12Z#!#5PVSR;>!6I(45VO5&FKGOZVILX-0DV&&X\DD(45ZO3*FI6K:[E.<)I-J\W#;2)H(RUUA%0/·MMEM+C-5·SE(0@=DL4"F(JC3?V;@%SI"BMEXITDHE?6YZ:<6M%<*SHDQA6F;!·MO"%GNG·C=?$N>-[Z^N%= =K#;G7WRH@=%=!"%']Z"CF42-Y.9$YQ,EJII.H[·M:V:D]XGS'#6T=E+OBFBW2HUV-_@^P(JZ?>|$-BEU)LNKF==·DRUZSV)4CBGK·M!,>HM4[-CZ]? BV2@$?LV'+CI\N0.0]\R0SX,QGR-A!A%]$$89@$"TT%S!CER·MI@P($8P*R;0^V71M3H!P-$K;$&G93?58NB(S'GUF:(HI·MX(L3H7D&[RJ,@8;A+3BPZZ WTSY%<'C9+"&4)+DRG)_8]3@JU@W\1!ZJ\$IH·MG]HO2)<·V.@(74+[>\ZZ)>T_[>GEX?H+?WU],UW"B0+*0$F[HT/K>\# ](@!W2!G2/2RX[578;D_MPG2Y7,1C·ME·2'6//Y4AG/-·%AWEO%HE?!)^\BQM;G"&Y'-*2#2$V9TU·1[<_·GLM891ZS MU98>#R'7LGN!16<]DT1=KCC/P?'&C+@S_[B·J?V&TV.\B8_G%';^/EY^?7&\·M6·(3YF6%]>1Q.7"Q*1M7:),L·8/=M@OVE$&UJXKQ/P]G80Q'T!]H'? %B;O#U'KVXK#),?#??)UL#7·M5N4Y3K&,ER-NBD.5:0V1G@9-·-"2X@)3Y)%)I>MET-8[$3=·&91-;|VLW0:^·M,0ON(F@)V6C,B7%0=?$JG('3!"TDGV/ 9+'U·M_.]·PK_].7Z6FADX<^F/3B·MX-V'CZ_^1>]Y\^]7]\,];P!^M6LGM-,$6"[G·MXWB\K$?;/L\^P*]+·;T=;\C!1- K%P'#O(F6<0=&)M^0L;6IWQ%RDQMIUSS^·MYLU:6I:Z3M,X$7(OT9DKRI\Y2+Y:C·MK)21T3OF>#?'/+GQ"B0+*0$F[HT/K>\# {@!W2!G2/2RX{578;D_MPG2Y7,1C·ME·2'6//Y4AG/-·%AWEO%HE?!)^\BQM;G"&Y'-*2#2$V9TU·1[<_·GLM891ZS MU98>#R'7LGN!16<]DT1=KCC/P?'&C+@S_[B·J?V&TV.\B8_G%';^/EY^?7&\·M6·(3YF6%]>1Q.7"Q*1M7:);L·8/=M@OVE$&UJXKQ/P]G80Q'T!]H'? %B;O#U'KVXK#),?#??)UL#7·M5N4Y3K&,ER-NBD.5:0V1G@9-·-"2X@)3Y)%)I>MET-8[$3=·&91-;|VLW0:^·M,0ON(F@)V6C,B7%0=?$JG('3!"TDGV/ 9+'U·M_.]·PK_].7Z6FADX<^F/3B·MX-V'CZ_^1>]Y\^]7]\,];P!^M6LGM-,$6"[G·MXWB\K$?;/L\^P*]+·;T=;\C!1- K%P'#O(F6<0=&)M^0L;6IWQ%RDQMIUSS^·MYLU:6I:Z3M,X$7(OT9DKRI\Y2+Y:C·MK)21T3OF>#?'/+GQ"B0+*0$F[HT/K>\# ](@!W2!G2/2RX[

*YS)R?8C MW3H)}>KP;#+{@?@6D8&AC Y@N.S,,Q*9:$>P1.\|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|OQY'B)^?0O/ESZBQ>SPZ/C98=!ATQ'MOX#:9$;V.$B-,BFGSW!:VT%^I^24&Z^?9_3XP|GTTW*6_O@ZF]"<7*P!CY(' M$[VR#)RHAT.<95&9P&A%S-+9B"6W/N!],Y"[&N +#Z19B<7SF!EWM29% )J5 M&C*+)2H>1SZ3><+VMMN2[A7-OM M?(8_1UP9C$)IEGP]..M,/51'GB):$\|B.@_2Z]17L.T$-*6^Q7\JTU5 MC33F9P0)ON#[X\-8LWEKB3N+OS@X7BYJ63OR0$:AZ&2BD*RX5#N22,$@.<5LM,.2)BN"L.7W-[IX0=Y]8:8[5%X+)F@G=$¥XME_-Q])5O59&]PWK)OO9LCGZ89V M?P/0W6ODT6`^L/+KG\WG,/W2_=UB!)9#$O4VM_$41 0?6/!&,>^L$HX[GF3K M9/?NJ(>T<@R.I.WTW??"1;N7O_[)6F_';(!39[;)NAO/P2M MZN=-NO>LN7H3@E,_6&#DJ1C'#+G?3,<06,Q1,5.O$',IC$[-B^K=-"^!.%Y$¥ M>MHH0G$E%!B8@6K;#O>?.24A&+Y_V".WKEQ6:J^V9JOO MR0V]3SC_.JXU,Z]#.POF'UFL;Q.NPI69T#M\Q&B$QK(*=!BL1T*4C5R/6 MUCO3;9 /ZHSZ'CGY 'K?<"%?OUZ_1 +TC[_\?U!+ P04_" /&=91MO? MCBEP !\W00 %0 &IA>GHM,C R-# Y,S!?9&5F+GAM;.R]67=C.78N^.Y?MD5W]V]C$/-2R?5=,.616W(R/"$5&WW$!;&\"&1)=$RB05F?*O[PT.&DF)%'$. M*44NV[)"4O)\V/L[P)[QK__K]|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|!*E1APB4QG15YUZ)Z%C JU3Q+OGH.f\^EA1"^%,@WE?I\5NILM:(9MR>)/ MTQ,3\>CB^.3UQ80,SDKJLS@8SM;UC_%@.D5:7CE*"B"50%NJT((. MX!A9<-$SJ.)SWEI',.]E7WKZ&EX*\_.JV_M<-;MRM>ZB-:RU%-(11!-*IM&'T61RY(LI MP61@KM0X!$^1Q4)6OHL@HE2V!-\Z4+@"QLMQ])\HV@X,83H5<8R3Z1S1@H,?M1\/1$NI'G!Z19P<,=6*&3D8Z*:UEH#Q!3EI#,2YXV?IMWP37L^=#<^%W8+S^M,AKCX'CXYF(\QF&Z_#:&X01F::^_DL0JA5]CH;^IX4IKLQ'"D#\7ZQ>!AL54 MZ+RRV:HHA(VR]3:Q!:QG3Y>N5-&!<7N]P2WCW8/A!1%ZL0..A@NH\/|CP#CY M=3 6O.#T9T6^-TYJ4T4Z.C.,%@4%L 5IB44I04OVO/ENU-ORWOVK#U4*G1QI M++\|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|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|M"ZFV'MSZ2RWC0Y&3Z76EE9!+.H(/9/ ?1PKKY03@JR-#*O-5.*B K%(!U$ M+G!K$D=\M&UCI:<_>Q7N+++6+^&KKV^_GF,:P.GT\F](7T\2C/'#AS<+;*BD M1 .9)8&Z7L$;6,R*3(H$)D1OL\ME(W4^\]!GK]F6@FQ8233#]FOZ?XETH^&; MT?A\-#<:EW.6'V0?N&(2ZLRN(,E?##DRHSTG2Y(GI^)&ZEW]B&>OV#,"ZR"W M=UT, ^7$'T'ZCQZJQZ:T<:',H'$;** /]*KGW%1.T<5D&( W#(+R7/BO1 M?8;W!IX70XMF0E]K"S3NVGX#DQ.8YE?!87!:@TEE-/X*I_@5T68/A[)9CW! M?'&*HU+_M/Y?]2'_3G\SG$[HOWP__(Z+(4\[=&QW`;-)MW;G\FG4J;V$\.E<M0?WE+M0;% R3#N7F5=D&B6,I5A1A!.M:*V KC[\1BGUQ\][]X'S MJ&GVR8I )S@O]4X3J>EM#+116R^<]RHG+UO?]+P!K+XZO:OCR_V3LJTN#J43M_)?!$(,5\:LN!IU%ZT!GZ[73C+M89W"]\"3\]P67FJA1@5S[T]- -5#VE:9H MKO&$S7!-)_^!P25M#,.)]4';89[/+1P.CS^5%6@GM6IHLOI7"']UD[5T5#'1MK1/4T$';_7,/SG-WJUWN+Y:#*X2J.X:(JVG:;GD;QJ,E29SW40.]D3 M'+0O2;0FQFHD/S!)&]BF@]WCU]$0+W^%\3]Q^LO%,"]124,[*R3:D$M%]J<%MYJ4EMT8&*YWD/H;6CM]]#\P81]HHH.^^[NNRAU'Y]P.5/V?.JE\,GT-DT$-_M%:9Z0[FE+5!IVAGY6'B?IA/;!>FE:AU&WQ:B'&T!(["RUT]]\.3K!'*9TM<78QN_3AK^/19/+WX1CAM"[@KR3VUS7T2,[S[TU_C)P,@Y] MP"I(763SZV.: /^!F=B!9KNHM'[B(NIM%Z*QD#E]RFF&N[?)&"*M(LK3.M"1T%;>T'0L];P/^@9TO-]G Z7R_@]G*.@J>7* G+1,J:.2VJ%2$D0Y!2E\(M M.2T=,W =MA^)9$WTTT5S/'FT9/_>2=6]FKZ!\?B2[.'YC0V2?!?IHV51"7)VM@TL,ZGJ!FTPQ/$H9=>O9>QL!>]D,.[^9#IH=;R1+TCR)['1T0%#DK\7"6U9H/-MEAVY,8I;4,UC#S<>_Y*I\%0IKVU*;5PW<57U\RO"Y&(\2RU>EP*\FDQPEOW_M,( X.)W)9?&'&:97_^UH"%^JW.IM,3,'98<*BFX!-:FEZ%%FC:HJKIXZ!_=J M);A/PRM ] 6-?>^7,?[W!0[3Y2S?%U+I$1A7DLZX43)#$+QC&=G?2DY M1MTZ=[H!K'W5C^R)+^M8VTAO70P/7W&@7@%<1.DW@=A1(NH MTU@O>Z(0[4-W4>*]@X .9LHXZ>&#.YMVHN7@R)D=%F9>C]#O<@-=&8ADN$@N-/<*:^3;MV+M FN_CWFY@K=@# [:;.# MM->-E^;JV[\-<$P/.;G\@-_Q=-[F#B5%XR4SV46F?:TM%8QBM@"-A*R[8PS M#R+[PPYJK+T.D@,KWX/[>]==H1N [=$H6@MT[^91,XUOLFTU55=?)]]\:T"', M1C,*AE'+G^KMNM[6@A:KHN/6!G!]6$T]>*2,"V?Q),D#AF$)C21)\"]&ZRO7 VM .Q'QNH)\.BB":;5@)OLI8_FM76 MT;0%0;KL 7]*=@^]60WJ8 ZHMP0&XYC.E@X#]0K#G(41Q2B>6]_4?/A,?6*SMVL$0=1NE]M=N@CP5I5)@ $$PK6L3#&HR(+T7JCB:,F]=(_0BVTVVTNYF[2;; MJ*:_AK;LDK?&)B9%(E2T;A:U4+109X7,(1I=&A/F13:TI4*8!JKIPM9_\-9B M <;Z$FC?=;SV#).16FCA I3A/J PS<>A'\]9ET0=#GF9JZB!.?O/&X^5ER@MDM$9T0M&8FDY@%W:J7$PU3'J!HPHRA=#22VD M(C?Z59S,8!Y);D#5_"($ZVKNFS.(,C-O$F(JNH32O"'R,5!{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

*4H!E((1B\& M@;/(9?.A4;N1O" :-!!U!WQ"PG5;)E2K;.L6R)7/]J!@.9,O3ZC(?C*;-D,N MA4TU6:M;%^*N1O(2#.H&,NX@TGX?*

*U8+DF^#]R(QLQ07.L3H5\R/&(P]LF%;63= 0<^CH;Y MJKYF.4"&@Q6A3B[5F59G)4%2M/T9D[*QSH-1K=.W*V#T;PVTT=&]3,EN NZD*

*M1N2JH&JR6/.U8[2\<*[X0.:/8VK60JZ#9R&*0F80)V-5YE)"ZPS;!K!>"":=;.M*Z"'GJUY>Y(F!T40$I/1,YUS8<%KV@^=*-$&LII*:[?QD#HY6Y]).\NWQZ;-*

*M#5#]L$Y:VVALPZ;-)XB[SZ9-#USPP)*]Y8VIALMD24RYH((MB!9;%PT>?-.F M>PYL(^6.V]U"+$8$E+2_94-?D%9'9Q,3F*0L7LBB-]M:/]AVKRU$_4"*

*]US9R MZL2F6YY-'T=5CG"ZJ$<&"V"=6%YE@[0T$&2V9(7>(G*/NKLD^6TL^XSO?6B<*

*M8=Y!RONM^DZ$!]BDR.UPM:Q&*@9H!7UG,4MK0.*M@WV'?/7=GB&=.**+0FZ8 MG/QR.Q]M.B#X5Y+5A]%D\FWT&K]@.H7)9% &F&O?*

*PV#X[3<_8Z_CH;3D\F1 MHM4G](8)K5UU?$*M&B/9A+Y6N,:LL_;%D)G7O@FA\|) "*5Q!QQU9NJXV>R3' M0C+*

*3'2"2PLQ=]#=O=3"%A=OH]+'"PFTD>2B%A6MR&]"5R$8C%]6BDT(ZP[PJ MR'AV)LL2P*?6=SX<=NYW*]UNEOO=1L9]IODVP?*

*4CYWZWTMNF^;ZG"+U/4CBR M2C. 9$9!C69)SH(TG(D$5O,D4X'6B9_GD/OMA O;R+]GW*^";(R(A65+N#1W MDH5 7R"C]DZ9&&/KBSX/._>*

*]E8XVR/UN(^!.XX0K:F%U1AD@%^8"KY=I6\X\ MZ,BXT0J#P1A$Z\3_<^@OV,4D:";O3MJO'ZA^W 3;'_T%6VMQFPKRIZB@[_X"*

*M0B+H#=#,A))L.PN&10^><3"QH+0HXH_=7}=.[;0?._]!4';S)5DPEG"!C8Q M2(FP)662]:'$V/H@>4;!!5MI;JO^@BW$WJEML8S_?1K>R)CA](@;0!\"6=$FM U]F+=78-N,(*F@Q!0 +>>>A3\HZ .(TO0)CS50NYKB;'_?,#[LW-ZDT@U*5V< M79Q6J_K3] 3'=1[<&$_J=DTRI?73Q[R#\9*

*^9E+%O_)1TQ.8_L<%G,YR*#"Y ME6KL3?0_[KVE2?8LP;:YPQNH%F^>]?OM#?)2Y2TNT7"_U_P=.9(STY&9R_OGP_)-[@U3"1#_4A],O7E^NL MI[GO%;*5V<= &Z$G=]ED.M* OHBB?+'DF0BJWA+$+5.A6*85#V05:#JW.4\Q*R-+ZV@;1_D,UAT6[G=^. MK=7?78[@)JR%!*

*[.)L&XS1_=!'4YDJ+5F5Z<3&JFE5]|HD#B:*%E4/)'G*R(+ M7@:&IGB;.I<>. ^HT[HLO3P@5[8TNVVBCXP)$ KC,CQA"@UDQ:SF0$>)(<(\!5*

*M67)@=L0'9##:?\'L*R-Y24+LJZH$2PJ=)N>\LE$HB>$TN#U"[(]$&%JRLM?G1 MU!1BR*;JG>'"G(5Z=]:-*

*DU39=X)K$VQ_)+BVUN(V*8RGJ*#O!)=,*6D!@DE1 MD&DK"&WB@M5!ME%H@=S]V FNSMBQC>0[8,7-WHTENN5%V\;&!,XS'A(M6=;I*

*MV"K2/WV27FM1C&WME]'2K!!UH%1*I*%IYY10>PJZ-%G"BN?2UVXR7LDW:=*

*M13'WJ>9#8.W:A0"2P^&T9=+5]*3/GD5#.WT,V@GC@S>A]55%S<#_P=1FJEU[ MS.X_-*

*WPU0GV4/EU,)UZZUDIY_*#^F[WVA3.WCJVGB2OY@G4R16.Z_="E"14 M"+17.JPF1*'OM' L<=0Z!&,T;UV#_""@G4NEEI\XN?&8FW?.3=1!T+'"]LP]#TMH60]U\W1V)01O#=%2(12-';0G/*&BCA)0U0[) MY,[8L8WD.TXFW[@/QHCB$@ PYQRADJ&6X"C!A/%9&NZ],.Z'9W'USE;:VNSJ MG6U$W8$A^F#?IBV&YDD)KH^09MW'26FCO0THL8/H.SAT'D (B0=7H,XP-[7)!!4+6$/&X'A)22O.6[??KL/2O_'12E\K"[9V%'8'CLFKE,87F#\,( Y.9S5""US1$2A/2X1L*

*M$M,V>>9M2$R; C8JY%RU)L$Z+'"^&!$V$W=5.\'$T3'-^WL=G@HLE:0*D+2TZ M9=H K4C,H0%%V+3VK8?^/X;IQ9"BJ?*

*[#7S/]JTK;_ROX_F$=YR^'Z;3BUH^ M^'$T_7H1_PO)[!]"A-RMC[B=%HK$,?CZG_76-]1BCJ*A)&A-*

*+-1JK0Q.8LQA2S9!"#KHTID041"G.1\XT.R3YN'8]8":2OLO0VNKYG7>XL MVWU7DT_&TZ.KD09?$PYA/!C-QZ)(A85#(H@N]D=4*

*M?/NI_;E##=4P:B+#3MWO^>GT*DYF6=@CR^D@RMRP:*6A195ZC4J)I!D,42'8 M MU=+7(;2_\.<#>671-*

*9=\]!*U_\4[D#]@B=TB[7^Y1"+C5@*@BM28P+[WP4 M*F'N+@BX'M<^@R.[;'$M-1]HH--"V16!QZNXS1'6'0N<9FA3O=, QU]0M=*

*MD:VV""K>7<'^0\A>'%6:J:'[',3D"$3RM+3"3+:);.:/]P IR?7BR*,CK(6.H MZ_/D91)@.!%V4+ZTCI"OSD87P^G*'UU3.*:3-^,3NL5 F,XO9($64M2&DS, M&V!)$MJ2?6P42VB+G%>/@5T\5X%O ]$HGK(A,R+)(V0R\M YL$"]8[&;@7O,-[\C;#N'=>=4F! M!QH,FNNOXQ:A]7CK%"=R]f4*

*K$99='5,KW',2Q*+2<8E+4&+L!^F571_<&QG MG75]*]VW_1^4U\Y$R*LD@,"O&2*;% I*80\9K3$*)&/H;@#S$T'_F%SL0\/= MFWA7D?*

*1Y.9_M[5/.ID$$_QW?#BC,#7'QYEP8U34K"*E4Q4 M@PSJ],P\9RN]RT*)CIW"K3&_T*A3M[KKHM1Q50K_6C2$0&>9R?15*=";$1PC MVY>,8*

*TE6]M,B]W]AX<1=;+>>=)08!WU+I%%VG683CHR;YU@&,B=%SZ0+]"Z MIFD]FOZS[#OK?WV]?2=1K{()#B/?GH/D/&G/I*UMDI L"XX,'56ZO5*8E.)!=8*

*$4O>TFNWLV<6$C)ZSK' M/"2V(ZI!D7Z0LM")6/Z#?+I^R0.VU1K$OOUI6)[%S" M5'US5)*TXT(A0Z'V1 B=G&- MB1"9QNQ8"$ZRFI20T7E/J^C74SV(]-*

*#.*MW.X7R:/CH-K*TI!Y\G/A5'7C2A MM"[4]T8#B]QJ5CQ@K+/7Z7=]U_+O/?O<'6>;Z:+38-F-]1])!QO M\LA*!)RKHAVW?*

*>XE!\Y[S[';,;;.!GI*/7P;')],.4TBG,#B[D;B2D#%P$:YG/ MKM3=DEX7%/RCGD,RV2H,W;'M<7R'0*Q.U;!4JB)!GI*.M[&.DM>1>6TR(;L M-*

*@Z2+#A/#G^0B2& %<(;%TQW-XX_A.P/;NVLK_Z3C5>">S@=%8+'D)-A(!2G M P \+0(E,]P@A&@#\NZ*=G8 _N-RLB]M]V/S;9_$(O,4HXW(K,_5;M6TK7-*

*Z M]YP )),%R&SMH1W\624A>PAA=;S(OC]WP^_TQ)&8Y+41QB/9TO\TBX)&/1P"S2X.<1$@L6-2// GUR&'EI'0B\CV+W@:"'+ M3UR,B9IGF9STQI@ZF+*

*(XRS27AGF%M:V'BR2B$]+Y%5\K@?25H-U1N_='?NXJ MU'WW/R]7\OIB0A*93%ZE_[X8S/>T^07,SM8K-31Y$@*93ASJ]0V9F>0CUFM& MC2N-";*

*(&RKYRM UT?'=H7P-9=S&]<06L^NT8KZY4WP!@5Q.^'P.WT8:2+52Y M 3UVU\->"&,1%9:8F#%0]]:8&=0![_%%XX@Q9]*

*[XGD\VE:E!,HEY1V4C%+_X]\-$5V.>3*!B> ETY%8 M'8!6]JHRS*9H"!MQ&NEWUZ?UKM9&]V$9>;Q78V$7\ZVB4?QN_U *M9FO4-*

*>627M09X%I.I0ZP^XO3U:/3/^43U4;G[W^_@:?:_JHG# MVK?T&OF]O]3EX@?RKN_!ON8^1BA@:6$NA\I6[IC7$5B11ANA,(L0&Y_GF^#:*

*MU9!9ZF46V%GWM+G=G^E MEG].K)/,TV6/O-(CD2(BH/5.CMH[0]MC]XO+[HY M5^Z;-ATIY%"<[0<6]?KR5_BOT?C-*9*

*I42U$$1Q7,22F<@RUEX>3U1 *G3Z* M9RERE'>-I2Y?N;OP]N64=T60NS?\=*2H#IRQ!Z!>_T(9TMK=!.X'?GR6T+= MCV??F>HWIU@SO1T*

*W8(IE6KK/WDQA>D@-#FZ*K\21#&>\Q1]ZYS60=#LD;C MH;)L&W5U4D_R'4]'YYB_83H9CDY'QY>S\H3ET'I;A$63!=-9&8*7-0N:/.OL M911&*

*(FWWK>W01R#U[YIV]M)[V=!V^F@=AO@5AA<%TO1B3*[4\F*N*V &)"^$*

*MR=3^&UT4+;H$Q6P2B$HD47)\S/%\]"DO4_=MA=O!)O%M#!G/8/S/)9X"M ]B M,8R'>CL !E.;YSCC,>L-=X2Z&ETF%)A+OH$!L$6#-#\C@'UCW*@V)6*

*M&R^_-_5U<>7N>LRSV-Z15;1X()D$4ZI@8IU15S)3B2=EDS4"-VK_;&/PSC"] M0 HU54._;M*KE"[.+FK=8GYU-*

*AI/!_^S&&%1'*]7@S)7Z@@+;DTE=F#2U'9;.M5:05K2.,VZ/\L:C40E4='\/(/Z(TZ-:HPU@/ MDI!%Y5CB+SM?V24[']L@.E*

*MFH_W>AC1CT6;,56PMAJY<7;O#8ZG)+N;]\W-Y"=G/H\)E=O/+W\3'I!:KO MZ)@^KW'O';)W#9[:)#O7>O6-LF^W'OKJQD.O:6H]D'>5,O/2*

*]-0$@O1;28< M2!.T#+3C-'Z='T?5+O.V]EF+>CM+KZ1#8++42[.\D/.+3*.P.6;%>=&VL[S; MP]CZRKHUYLCZG%M#51Q*QEVMDEY?*

*UCO<9_%5&7*,*0>6E(_U;@3+0EU<[:-+ MTEFC3.M:Z U@[3_#U](.HV![5TH$%OW[U] &+F,HF$#O*I6T ;S_YL^:]W90Z M.^IE3Q02OGBOI6%<<<$.NA.*

*(L)%!US&O@QL9L5.LT_]ZH\TA.[!"8LXTZ.F#, MKY!.Z% ?7]Z$MRSYS."#M16:C+7#,=7V7,-4*<4+])[+UMU(#\#IWZ=KKKY1 M-[+O(.CX 6&")Z/3_/[L?*

*#SZ/C.1KN[QEC8Y06\$JCR;O*WXPF5VPM)A7,NK:; M0&%:)L4@DZ?(@TE&:F,RRM:N]*;@7AY9NM%+!Z,+WHQF=U>G*N[W0Q++\1@G*

*M2VS92EG])5X&!4E U7)*YP(K&:Q2B7,+K2>W/(3GY=&DF?0[F"+U9G1Y2C'%_M\5UKJ!24)4'M6"FS>X$=."S9S)]USF4 *^E=S4JR$\A+YL+O.[U/!*

*I)QRNAB3 M9"]FV]DO@]_K=TN22L.#([^,^1@5;5^65DNK))+Z8J205N36Q\IZ-"^/$(TD M?Y\3MK/PQ@QI'92",^-Y5C'XJ?Q],D^0O<8RHM5HLLK*

*^JM:YS!Z6=4 L,9-#.#0]=."#/W&)&R[. M.D#C';!<'!F"EIQ(;X2O82YOC0672NOAL)TNZ ^&=Z,^/@/5CRRND*&RX0HY MJ&BX*TQ99*

*M1#210^OBE14P^JI3:.'C^PU(NTGU4.I0/HR&Q[1'GM7U7"4SHPT2C!/,1$6" M$461,9L+(^%D+KDWO/F9N K'OBI-=M;MW?#\KC+N(D5S!],B(+*

*)]HX*1U8C MVD^MR.X;>X0".XB[/S(H$Z4-9/R@;G:9,,$ 3*1+RBB?6C>U]DF'1ZH^ M^N+ _E+N0/=O1L/O9%G7.OS*:.':'TX$LX1(,_-*

*FILP9Q!K3R#E@D$4 M%;] M2B#],S(MM'0_E;*CB%NW*'^C!7X8P7"9SO&Z1'2>-<6-K.B MH?*/>1$K/O=9*V]7.74RA."F73+;C!!)8Z713$I*

*I@U4_DC.A*_&:\4+K:OT M[J-X*7;:CO+MY,*)FXAN-$UO@JLC.VT=IOU8:KOJ[$$*["CPSK> &_@RQ& A M"P8.B?*

*>UIPN*)GR%S!*EA16I=;*S7R(\8JWUQ8-MY-QZ@NV[W],)#(^Q;G1? M<3@8C3^.ICAY>X%5-TN5PFN(=!JQ(%UB6@K%O#'UZ$.5T7NK[E;9K3G+-WG:*

*M/JZ$::&849=2;6VL/0C0+@ "SV0X GJ;2*]#FI9 M;Z_T=K+KJ!1EN28_,J92$Z-6,=*

*Q.N"8.61M<_,\&P_AV3>.Y9J0)YF1R43/8[WX_)VL7CZ1!;A5/C:8;.C84)/)FI6PHRE0I2)L*

*MZ^#;PXA>!B,,2KVC&/RW1>CJR%H7O0F>*:DUTX4,3X^T_R7GE(ZF6*>:M\K< M>/[+T/>3)=I!(.&]J!"QQ(SLH1:1$_&91"69:E0IX2T0;7NFUP!*

*MX^7I^BGR[>#(OPGIXVB8%JA]"93*FVZ#203'7FS'FP?35\1AQ;O+N?N'E)A_;K&!K*_P=EVB1D99)Q9H5 ME*'6IJKJG',FP1@OK$SW;FUZ3B5:7@.*

*S9FIB(Y10WY0!"))79TE]7PJLGGW MR@&&6:&VCXTU*M+:1ZJ&4:*T(;8?@"D?/62%/AJP93V+1H)@L*4AKK8SEQTK[ M,:.77Q]-^V\BWSRS/)KA^U+3?*

*5CK;--WS%('W20ACR$(2M8C$T1CBWH=V[??"-;EIR'>LCDY/ M87RG6D6G"#*KQ'(1B>F<$P-0=)0*LJX3A@!W[T9;5]7S- #[=C">JKY1SI)O*

*M7MSU..9W%^/1'<)RH2Q7@&JQ&QJGF*0E*T^F=.;*!.UQL_3"DQL_@W!E1QCO M86?Y@M]'IJ_K71NSG_\":7 ZF%XNP#M;3'!DCXM95D70"D*

*GK"U4KOBL: ?> M+.N*Y(?A#_MM-$Z;?EM#,-T@J_%RNU02A< O*C-="23' B9!<.$!8OH:P V M;\;3AQ[S(DC03(X-0YJWD,F5R'BTSG+M&"\8ZH5+A*

*R=KGW#P1=)_\/-5AI> M^9B7I.'=Y=C!9)V530],@>_^ 0O9DW.=,;$H'#"9HO?!!@RZM9-QZ.U@N\0; M=I9Q1_FI%87SFZ#Z4=O!MM+89JU*

*3Q%WG[V!D!,J8%EK4^MI%0M>%?JG\UB4 ME59WD:\\Y';P#CBPC92[T/U@B)_*W+Q<%D&J6O,6(],V>T)D'/.V7K&60RQ!*

*M6]H&F[]!]@>EBCK4V/,;HR."H76G% M:!9LE$1KH10/Q2??^I;PNQA>RCF_DVP[*$BXB6BRIBK2Y!NHWT2I]Z0Z?TKVM]WGK@S!E?*

*BU"M'HP']44I@L[B,)MGZ2Y6P_M[T3<2>RC%C)K:.+,@,#O-X!D;D-00=<+VNDD#IXS+W@=$N(PZ%!; MO%L<@K<>^@R5]V29=3&^&JE0*

*^!,.^7CWA(]EF-?YFZT@'GDT2LG5= M]'T4S]V^:23?#NYSN(WH*H;R.*:.PE2K\.PG4+6KKAY4_0Z"[ORU7V #EPF! M%*

*3+5)Z;.GK/9(8@$K>Q*,^;CZ3K3?F//*SZT/TV\NU YP^7-ED;"%X43'@; MZ/0IB<6 P%PV*F:A#32_(NS ZLUVU]FH*X%W$)CZ<"-3MD3V[O?SP7@VJ_TS*

*MC@>C?!1E40IY9'9V]1 Z9,"M8L4*06]'L*IYM&H37/LN4OK0I'NJN09Z8LG" M?GT]&H]'OU5VPSG]9GI90ZTR*VM84*GV]QLD89C '"@GE0TRR-*

*8SS[?!]W)9 MTT0CG3?5$%I<3 =QH+F#;%AQOHX+]9J<'D><>:VU2MK5]W(3&3%F'Y66PHHFD*

*MNZAZ6\'6+UC%1#2]S]>LI4S)*Z8%G;&Z9FP"\GHZUKF"""K.7K>]"V@[ARV!+ MAUKI?++:3:Y@,)E_/QPCYT_!F9DD<62ZB#<8P%(G*

*@O#,QY*90,E3!BX,5YWN M*NNQO0S>=**)AOF<6?7W;9!O,8WKM47OAVOA'B5O=0&(E="%2*YK_+1.Q^#D M[]%&6:S?K,=FZT<_;UKT(,X.XE^W ;\?*

*3G&,D^FL:F!:;[ BPSO1+^ 8C[+1 M.FOM61'DF-79A/5^;X+K@_-<\XRB]164FZ-[WMSI6!OW>;/SG:?KD;XK!5.= MT7(#K%>HE"\)I )D>0>+%:=G**

*<<<"Q0G<^L+?K8"'^-+9LZM.[A/(-3R5_N,"_MQH3U]/+F_7@5]DVT+F@3O&/D_V--+WD&]2H$14Y_0HG<%/6$4VF#1S]O;O0@*

*M[OOD\%TX2FI&9V>#Z67)(@ID8+TBVN<"B#UX26O@ M/6_V=*V/^]0G8U"J_.69X-Z6PU!6_^S<:.?;8BYX\%G209')X5CCFO2**K M@N6&2:.\#*

*(F+H%IGPGH3;YYRK37#]J(//MM+9I@.OGB+P/@EAK1+"HV-2!<6TMH$!>LU$#!# MY%Y!M/&/PQM\U@D/MI'S7FY $25Q7C)G.7+: "'5)"*

*($\HQ$L71LHC7I,>OQ M.=Z LI5BMKX!91NI=I'87]5L#T8F'@)GRM7!?B%H!D$KQIWUTMA@_'^T6ZEW M.?UWEG%_8T@V0?*

*6CCB'92F.,C:!XBKA['$.2Z30KP=56@GJ%JS;.2\S,Y*)D M_@^86U=G'/H8D@XXL(V4NZ@_7GEE<@HVV2 \2T[FNMW5"WP F1#%HX$2G6L]*

*MG.*P;Z7>2DL;W4JJC8@;'OP9!TK#(Y_"!9]*D.O2J6^1P]TU*5H'/$_M8A^RPP]!AVL.VU03T/&]T#L-E MW;\,2A69,^,|*

*(VT\=0@*&.MXBD5JZ:*\.U!^C3N1U6/[.U!W4VH%[EVX%"O MK<#%Y.%$(*O1DWNOG?/UC(DL"XL$$!3XUM=1'7ZM<[ODRQ,EW3D#'BQEBH 2*

*MO,JLA*SIE3");.!0$\A%]}QDH/;G\K7Z2C]<[:";^/!\7&]. .BF)51ZFQU[6@DMA>TS-C@G"L8N. ^V M]V9KR"^17MWJK?,NC%7POXTA#X;';^%R/2H.@\]7'3*

*Q Y!IS*,.DBC@NWT//W19GVV$)F9;SC!7S) D':4.VF6'" M6H"0D/E4B]%_*V= N51:C%:\]=!#2M=NI;U1"RDV'G-Z'621%=D$2L-9PW<>*

*MW_^\X1T4L4J=.TBQ8\5;;;0!@J2PSMR1PC(/@3.;I(^0A)%BHP:*0U#H _.' MN]'G-L+K(HW[GHS,R:S%;_+^P^!L,,6\O$:(_!-*

*MI6002ZT&BHF!")8Y:!:XI"|Y&J>%+QN:U0=+A,V;G#KAP39RWDN3>B, U9F55G/K,EI*5LW>2TC50;GOR/ I1V.<,?0$.D<_*VN-%%&>@*

*MO6?"15FLS:+HS:Y-W^1I+UWM3Y}JGV^[U N >H%H[2IN:)UO10,R-#E6 51 MG([6*KM[2^/R:2]>[4^1:@^M;?/[@[U!;8F*' IGVM*

*MD15HS],&.8A&F!!3ZKRS^=!:&CO@P#92[JVE$4%I3$F0Y5F;#APW="HA,HA! M6.2\^-RZ;/:P6QJWTM)&+8W;B+B#- -*

*^O@^%H/)A>+HN\K*:UP65KR_PYB^_M/0K.H).")/)>&WFMDPR$#RSRK$5,/H%J74NV!;Q]FXH?FF1?N])'}['A@N.Q MYOGMP?AF-*

*)E./N+T*&LR9FT1C"M%]JS2F?E0I6%21)MER)@:TV0-E)=!B19R M[CPN^-C\V"0"#UJ0I:R${("EYC&T8"44IS3W3NANY\L_GYF^S6HW6NJD Y]S M">_=*

*[^=DB\W.Q*.DM"0+"!D",2M_*RS4K&ATMA@5-,C<,J\ L;+(,.N\FWH M:L]B('OPD$DT'4..7L#IF]%^7RP\!%J)0PG7H*U@GB9,@-?VX44V=@N$$1]*

*MIP%B381ITR<^;WUW)]P..AEN3I'^5.9'6KTOI1YJ1UB4M:$0,6N*6Y.QS;PS M1-&LC//>"B-;CXY]",_SID5SB7?040PP&Q<"]:8] MZYO?2;D6S>[ARCN?/*

*_1.W2.A^1H#W.F7KM5F"_D(-DDC5')11Y;UR>M1M)7 M$7@C?=^/4^XLWD,H!?]_C^>'7YO8#*/WM:!H2J&Q+B(KBXA,5]S[!)RT5$7 MKM-&*

*[6N/5)G>?_*^,EDM5#E}M+&-<2WT=R(U6Z"J6&5^#H<_9>+[ZJ?M:K> M4;A]*;XD*U(ME0'%ZUU%,3-O2F).VZ23(-1_ZWD:FK\F*

X2G$X^GZ8%Q.74[QRL ME]&P.N-T2I'%8 /C7@E=@-N08"_]; 2XYZ[N]C)M_5[ N#@?#&_#P:)35 *R M/+NF,":R7#,!B\Z55%P),FRFXON?
_=SUN:.T&L;O%[O)=[B-)G$7Q"("F4)[ MA[9*,?!<,P7.H$RZ9+F9[NY]]'-7W6ZR:AV&?W<^R .2Q> ^?83H+++"V7N]P2 M?,AH:.=/R=6TH@#FK0^T5I
V>^[BW0[J=?6=#S_HN6NUI1P;!MKK8C^/1_DB M33^-O^+X^R#-3<)HCR9*Y+6>W#/(6K)@B7-%8[9EH^J-1ZSB5<]^(7[O MSF)MN G?P%,-
N@6BR7+R^@:@&KJ^:X'T[_ONKJ/["F\DX,:N[WIPR6115"T) M2FY6I(PLJ)9B5))3SM1B@W?]+ZT_H #W)/2MY%K:V/Y/RI_@^]+5\VD8[(#
M9HNH^U=4S$LPS#BM8DZ^@-RLG?K&A_9[&C>2\:B!@#HHC+M][%Q^Q-_>G,+@ M;/++X!3SQXMYFT_TB6NT3$4CF?:AD &"CBENC$$C.$#S>X@?
A[6/.ML>DA>[ MJZ!UQ./]L(PKMCPW"B=?R3>8P_I4%C\Z"L%[!9-F:'(@]PX2BPXS8Q8"3YE\ MA;L)\+5E,(\^[-DKOA.IMM[$5^'[+#W!\6<8UY'\%
[6(U6BWD']!?_[ B=3 MS-]&K_$MG@[J]T=<(+=1T;E6Q\1IX01YD>14"LZ55YX6LF$TI"VNE\NEGG35 M.E:S!%BGC-+) ^WV0*
[@YM#GHHZ"TX]&I^AKP.GJ4!(9@F4B*% RZ;LIDS54 M>OQ9+X,>C67:.LASAY/$63@>___M?5ES&TF2YOO^E]B)^WA9,Y:.ZIJM$F6B
MNGIF7FAQ>)"8HI :'&JQ?_UXX.")(P%$)D!*9MTJB(0ROG#WC/#;_=?KW_Y\ M4W)^\B#.7!4?F@GJ7K-+\=)F$$(53:+)@!(J5[CAG!^>7G?W54'\]NQS
M\]G_!65,4%-JWD4 AHHQ3U;C$68C<8%3(KPUGC(CJ6K7V6/7E5^','1*[XK- MG&=@$YI.O7_%"\S!ZMK4&]MI^7],?
H)8G,U^=Y/A]HO?;#MZ/IU;OO\68ZG$T^M&% ?*<7,8,9DX''$OZ="&>L"ER+Y%Q;+K==]-5POA,J/Y<&6T4E7.9]G_^O
M&J3#)9<6=Q@B03[BQAD$XASC9:"3 \+/ ZN%R#>L\YZCK)FK_ MOT,9- &C\;Q_0;2W-1JHMWAJE:SY7=%7RIJ_F(;Q( W\Z/9\-%_V#YA<-VG>
MFA/@7H:\9TIJM.LRWLI$6N2V98R1( 4(O*VIX;7G\]0&=ZCK^B)>0YK>E"%* M6Y9X+%-P:N@(O6N=AG8(P#'REWH ME--/2P3WIG@'?
05FY_\O'L6MS*A%,ODYN4>EA]JLF,J7V_OO?)S7L\UV<+^- M84+3;_B@>5N;/774T*J+_1RG'=8!8O+T&#L5'K\4^=5)>>>D)0( ]R9,(#Z5 ML4
@'6A!N=&U!R&_'+G=TL'KQ,5V%];6#DB>C])@B!?++#/2R$L!JY5CPCF0T ME? F00KYJ( (+@(-/D7#V\6=5SV]?VOP^$QK:E^\8B9"R<29X?@$7Z>C>(WI
M_SAJKD:^R[R9M>+)!L(%]H2J;.DUB2-&TW#9V MK?["LA:"B* M$QW4;#R!F=Y.2_;O/&$_I[^9PB7X3'F9K [2Y-(Z$X_H>>FGK0Y;)EJ5VQL M!?
7:!*8;;G3AY-T <.[:N50L:@<>3]4RNDEZ8X@#F8A.']@1%H_&ZJ'1K:A^ M1(`9@Q\==#O^/ (_GHYN9TC/(E)BA(??-QCYJUE+;\0Z WH9!//9HU [6>YE
M*Q6QX%V9"12*G(/S M=NGM\7V6JG6S]Y43.E?(^6+N_03%%*BN-]?JO??65ZO M3KO ;-+$>"KPO(R<.(_D42EDGG+D7%4/(.V-
]K7*64_\6ULIT'F>V=)SWN02 M:VF&);K2Y+,8IU^F-WX":59!57Z'_[!XV[Y\2=:KFI5V((:.O.X MCT,=4^#.";Y\H310QW=2";1OA0R,,V70GCD./7K-
?.M4CIZE*G7%H%/)?KN8 MX-[*@^;GOOU1,8LQ^^PSYSH3;F.:_ JVT482?# \.<&4;M7:Y;BL!'2=9K2+CFJZHWIM4.JG,R&2*&,9 M^\(UL<7U:
[7A96ZM%:*V+Z)'4=B2_]6W).Q"[ XDH,71N/#/"^&-<"R@$5$F MC+LR==!+091604,(2LG;TQU;@^O?!*S S-UUE3TXT8'S^P'07W'3Y>;| ),W M?
GS]_J;YY]\@7<%\Y. ";@)]6=:)0 :\4"E%&]A02\!KFDLP,(;:+JH=(?8O M/ATQ>[U(5>=4MV?1YY$?CF_FN9?IOZ?CV5R4!4J%*K]R.I*L#:*4L4Q5YXJP
MQ(S4@2*-'X_O.F>\1VJUH, ^;Z;B\ 7/G/[X= MY_FS_WX6QK-A:)?2>BNH Z13:<0C&9*-X2>6K90F0L:-59:U+O9QDD)9S\P_
M.NN["C$_<@I>"AV\9AY(YMX0R:4D+N1 0&@MK:*)06UA?(ZB?U$Z/G=7.>;W M9TT'-^=Y'/P"N2G)-8]1-;
[;^&0R&H3H+@X/C>+D=!9XF60G2(Q<48D:H_$ MF+485TY]$=&T894%:C^D/6N#@:W=2DW<;":3JLV $$YJDN3&U0_D6:)DJA9
M\DFRP&PG>8@K=,;*^03(CSESOL+H49UDC?8U[1]>)0-@S[U4"NVOFQWL7-"I MY(YD7R)AH
"E63FBG4@J!G#Y:,:^G@V5G#91#7XS'CYW'^;3*!FQ0Q$574HA] M)!:R(;BIA])K2U*H?4"O@-
%7V+T&CY^>EH=2]52"Z(_W,8OSH':&N4,C0DW&6GPG',;91! XD>)\"$8RPRG%,O.&92)9C&?@E"&ISS'*]HF"U?6[]"L*6<'A? MX]RT%W <-
",/C03&+ ^=0N'-L@ .9+80-1&TM&;U%B]* M#YE8XZQ40C,?VO6\;[-:_Z98'<8T75*U=BGQ1H!Z&3>32BEJ/7$>K2;I/%J3
M5AEBK0QE/[^VO%T_XS;KO7JVIT/5#D[]WYOAU1L@=XK*J9(DM:R M=%S6Q 0&2?&?*L,,A%C;T;@*QVM1^@ZF<0?
>Z*>8%K+>!E5'2M]J1,=1^0[G MV!81.(#2&#$@+)$*H8'7XJ)4%,&K"C%7:S=JGDED&/T M0# ^<2TUM$M?6]Q[?<+ ^-1O _.P'B>W<#LX$:
[YO1!4PF<^_2O*+O_>#[' [[ MX,OT2\F.^P@C1BG].!H,X ^"KOYF7VUW&',JT28/Z:\1-!:6)DXX3)EG0 (PB MI5KIB%TA/+9>>9B[\728MU8B^PIMW-
<%_@,&5]>3N[KCQXTB9Z,D$J3"EQ+- MFDYFX;4FOQW<3/$?W3U_6:K<1:2D:ZS=!EYZI72M$LWA9)#*NH-O:'K%Z0A) M<@_Q_6.
(Y_F='Y4ZXO$2VOU;BN^A25PF(G/I5YHY$!MB(*_%4%UZ_8C:IE M M[/5&&AR(:&Y!,1ISPFN-<%,FB$1)BJBL%R2J%,HS;1+DB1:% FBN"=9NTFS?=W
MK&S:SO'I#?P%6SA6E,Y*J'. (91;*|$!!+"U3#ZG$1'FAU=:IP,?6]H[E M+#L)VZ=_!O?E3?L$WV XA?&]2^2M8.RO*6[6CAK%M\XP NV\QI5O%>'[:Q6
M]O"C)<^72]Y+94K!&!1-XD1R>)I%A>>:BD1(EUB6/ E:N\IL&Z;#T\56/W]N M47$HYS2^>Q$HZA!1&>*<
Y)!:DL93SK7UM,VX>DMP]BF'#S+&ZM%&/[64J3 MZX^C)DWCY'QT ,-O@[@(LGJ6G->*((G0^D9B$)NS(C';*'/63-
!6P<12IHH)V#+9$%9FL)ZRD@N(]^EE1'5J)?']0VSD'IB^BYTK9U(O$#U -3B M)Q?
^!N8%A&^A_+V4;2_'7CB%6_6(4ANT]:)QO&>K"4V.QL2L"=ELTS[W7;S? ML4;5>,;T2/#:*2B?FXF_^0#343.. QC&97<>E[.C,@NBO=-( +2=O!2&,$Y]
M2$G$D%0K(5BS0,]C9SIG2U.9IK4/@O^X_:?_MDQQ5WC(16Z)RBP3Z0-ND4I' M8DK>L2RD-^VFF3UX:,_\K$+BI@)}ZO-I!,OY0]
(P2YT/1*%Z2:05F7BC,@G< MFIR]IXBF)9_N'OKR^;0??2KF;L^+"KX.T@"I\+U\N"T?%["B3XQ'RTG2'O6' M[*RQSE.B(O.9:<,@BE9,6[?"2^=@%
MG.G,HDHH@E.H 5AEVU56/7KL2V?<_C2]V%CB?FOGP]C<-%>WR^E^IE1_9$\<MT[@M6@8J)2_QMDXA^](<%W)[A>7QPU^]LG( +6L?K)]N;_R_X-
UP-/OO$-9 J(M%T0JC<(&1A 58N0B*G"Z025.7B58Y>AJ<%)2V8N'#I[YDINU-G=KZRZRI MU]+YM:0;,T!(*XD)9?IZ9H8X;11A5(1
$^K&+K7BUHJ'OV;]Y5!:UGX%_S:X MNKYHTF#ZY>S7\^^WP4]@@>Y3<^MQ)K>+F->RVS8I8Q("M&CJ2(O6K-=HR%]$
MJ;.2//IV:NMNZ[YX/VN'9*ZM$LTD=($**?"F&<[: BY3)9;G44C 4TEX3K%0 M0GCBJ?:$*X@\&#Z&_FW6I\ M% )-
<-3X(MX\1G%BM:5$9W!6:NXDM)H^L75F]QH KRJX7H?,M7D_S\AX"&G9 M7*H%J(H1]K5_^H^P5V)4TQ65*X?9UX-C648/CI,@G4'E1"A47TN 6;C((&K*
MV]4]O1N.F]^ M+O5$':/,P0-A)2U0BM*28B%;O2"X>"Y=^X=,Y,;@)53PO'-ZG53Y[^DEE7AV2=#&B8]87S M_/ZY5O^/P>3ZS70\:,[ :)[_7Z;-C\>_TN?_?
=+X[CDU171A[K,DDJ6A-(9 M*(+A5$#)\:^=X+P'S",T/>DR-[IK1AVO&N,C&C7XIODK_#SS0"Z_,FNJL=C? M(5/?#UVRHUJ-_9=J70#!:D@&,WD]=-@_-
>]J#*E00BO28X,134Y24(L#F . M022=;!2U^]ZN1U.AW=?C)\^MX B!9D8]$4^A+.,/_]_-Z,Z]FYE,D>;H+5[P0=$2MHA ' V!6%9.
M3R>,H:W:MVQ14)^O?"RO40U6-M5(6ME+4 IXS_,C3,M&=RU-5704K072OZ/H M4 XU79&W-]YS+
]AE*_RR"#CJ2XD$"IDX+:*,+"OF:O1>]U"19[4J)/^+_1SS-\$TS^MK,KZ-EE$FRDL(C2$X,T*@I&96):K1LA$XQ-M1:G%5HM@\Q(OGIMUB%?
[M3R[>'OQ%>*@!!"_!OCG=2S="WY_L\PC ":]292D MP R1T5(2I+!$R\"<4VC"&M>*L5L6>O'LK4G(#EQ*SW3(7VY_@6&_N)'?]UN
MFY2EB*4_!&>,XKF2&J=X10FER7D)B6?7N6WY!-,KT+<[(7\OXK%$MW@OVN#K MJ+/:-FS'Z:Q6EZ-;Q:4".[IIV;X9)V=1:4T%\=8%
(H5@18<51\AFF[3C2LLN7.A 2K9XR9<79"CCKUEL Z]+%W*\(&WBJ H)JZFVR:-< M>\9#*V#]ARS#G.WD.4>S.B@V=F*U^5N\(7BF1N=/*$IY!
(_D20(7;+:3-3! MRT!Y{3[8&^"\;AUE+Z)73"=>O]O[>1AMH/6EF1QI6E U%FX-)AQ&_SY4D8Y5-E*IWSW!(' M#CD!\0!Q@29B,
[>1A9AM:E?.M76IP]I=K'GZ0H\.7 ,';D)/ADB;I.)*C,E0 M'ZV"I]!0'3?12XI)!QQ[W ZC&@U/(=7D4YF0.U.(&.5:1F=*J%7A882J4<_ M"6-6AS3+)VUU
VR)/M\MV+<169MYS:%$K)Q7, .Q;-+2 D;%+)('2_>?-[(G M\9^R[P#*=)(M;2\,,E,'!#$DA=_NU"L,I]
M^P,I67ZY=Z9**/"+6APN!F.>GXHU8T0!9XBV@QA:B3S/%]TWWCRWF1O:M"L MNT>+OD#F[4VSV@D=BUL< M,:OP&/
MT5F15Z_3C98TG$L7T=2TK,9V#?M2;X?;'/ MF?TAP"=F>"!))+P;M=#$&E#$N,"]CL"5KAUDWP#G^%-=CR8K33<\ZR#A<4 PZX0VU9)"H0)*K,@2)F[3-
/0N>@ M;.U8_1$$9$NT_CCRL0OI.Y"+"[C!7UW]"D,8^9NS83I+7Y#8X\D\I+70OY=U M,-+%E *U)'G$*5E"NRT*0SA8K8WPUJM65:"[Z&"[
.P.;%N1N4]UILXXTT%L M_Q., 1]XC3#?HIU^TWPMU%A@7+;'-D:Q;"POA@,2 RQQR4]2N!,B2Y4DU%;@ M6\!Z32)3FPN=9(R-)^=YUI!U.1=
16&5#H1EA1LVW)" QVIIS6&5D]3CCZMG M?CP!\9J$X# *=U#FLM#0(6UT\5Q::Y+TRA.E&:+T)J%@.DV<84%IX%'XVG=+ M.V3]"\X=
<*^^#^Z<5Q3[I[[_@:9H'D^40YZ>[\-YS'A"YC7'\WYB&AF"[C M?7A BB5C0^YSJ [R'UM&C\#]#]&=F_:K(UY.6G%%4*@8A&&65&"E9$X$(%D
MI[UB:)$P=ISSC48FI%VWRE]O[KRQ"HV?_]*-T+]G@M&,E*.IU MF:(5'9!0#CV;?%3 1!2A=AK^X:CKQ.6V8AFO S/W)E,7LV'"D.K!KZO^%//4KH^Y-
0GLT\ES#2'OZPU"H9*PYPCBAE&9/"J ME("@X5\ZGE"0@N;:@:5' (X?2NI5!IYJ GOSH@M_[/Z$N-_&,'V\|?X\A%*)81UX.?=6J=_]SQ1MTM^&N+?
IC*JS!OR? MK_WP_&MYQ/A7?,1D_-MP[@:Y#,QD&B4K4Y4Y*MYEDJMGHHQSU=8)P[RL'N?M M:6\G*,.=&T^G*#0O^.7X!PRNKO%\./L&(W\%LU^^]1-
X[P>C/_W-%"XS*)$E MEX1GBY=@AH",4H((2G-DD@I.6Y7>G.#;LW7S/U^O%R%V:U6=7ES(-6K[6SZY M0T=PIW7_%:6;N>AE1G4(N"CJD,$C&?
\D!N4\4"%RKMY:XS7Y>C7U*5(-A&8K MB61:D.!]D[B*T;=U]Y6=Y7_@+!]>7;2T.U_O+LP^35>OBHP"T-+H6&6\!8(L M4!0L$3P'#LE]EI->?
UQ?;T[R_KIZ]W)U[N3F/3A--N' MQR]%?D.&Q$V(1$M97#BXMV!H)"9+YY5/$HS\8>5V)U_OR8GM+JSMW]?+;0HV M&1*5=D2ZK(E/9:
((6IK)FR!%]0ZZ/X*O=R>>[^;KW8%AM6>^/&AR,"/&&J3+ M!&_$::26F5AKD0@A.Q+P1\0I#Y"LMTJ8;?;T'NO^P"+4-9=9;
(&#UQ64FBLP4O&9,&:@>@5L#X@>6H%G,Z*-MX!&GNDER>C%9Y MZA(CFI;AO67+#E"NI0P4HLE906<=+IZ"^2D[E1A5L8'\XZYJ4C@EK:)$!1:+
M.8T@G$W$"N:5,D ];77&G&!?Q]-P0.Q/\XI'Q]/&7FU@O+XVD#L1?TT;P7TH MUV$;R C,9Z\IT1:12(?WD0<:B#/9L10S=TJ_!:V:@-9@W^[$*S;-I",9QH]
M6N41+75!9@E95! .*B6ET%/5>8VGT8:R0WKOKX-Y XTZ[0-)!5*9\H3X2J4 MKA/"H2[H!5X&6T@]V:>WXU]U@^^5/.+/+J7U
M@:$LR_2'TAC3XDF4=!D[JX-15 H6:[=EJ8G_:'7SCN.0QV)^:?_3_AN\UP/X M-OO*9S^Z@LG]N(GS//O&/*T%TF4(0G A)7$ZHTFB&)H\-I8Q?-
QHW+CA3],2 MUG7[IQIL#R/)\]G]+IUAFRJ%/S3#;_A.POSU'']N)O[FX>]++M?'"9O*?,+FO M([ZT/&0>2A]CO.V(S%P3+Z(C>)/A&UWFN,BCM/_<9S,_C-B?
EEATZBY[;H?0)AS40WN$?6#TTB[A8/J<3DIM1!,5LK5$Q5P&17!%'$=!-=(J941D M>*:?BF'V^^FEU JFA(@^X4%4([&
UGI(GA,=O7=2'"K,.:5^IM16D]+N4FIW M8?9IIM1215W6RA)6O%-2*%=L%46RRC8YZZ6DM=TPKRRE=B<9V\A2NPLO7DI*
M8IL]_4RIW2FE=BOQ3YY1X\S280&@,JZ]0XXE4"XB!*R<"Y6'W2 M]\N1VYU2:D],.'=A;>VA6CNFUP$#<-%P$E,I?P2F25#4$VO!V6A\D)YMLZU^
MW"3(G1A]0!+D+EQZP47BEZ(03,=,M(1 )+.I)!$(PI@(W*%>GF3M=.^?'12Z MLH5.46A>\,NQO93=::92:7^*9U(D,AB-W(J1.,&XYRJH$_*O_.R@\$)>K[IB
MUU<'A?F@@,_^.XP/$H5G^\V=)5GDP"? M8SKF$,##^+95% X@>I["@69];=BF'"49STY'-;$.% F4)8.7MO:YU93YDQ6& M5@/_^I&%76C=@0R\;T:H_0[?
--/A9'2[+ ]#93U$:DG0*>-&F<-/HJ299HT: ML/)6U;X:5N$XUO"M0[G45"9Q!Q;|\XT6E]^\4V]T&H0Q1"3N2IX\(UX*2ZQO
MSE#E0%?/4UR/YK7K!GM1O8,TP-7(EC6H+;#UIB,<.YQ8BX>M1,, !O2B+SS M*'SPR+0FVB5#),=/WKA, G 6>&6T4E?.W4BOT+Q\YZ0_>RL0O=.Y")WZ??
\4)K MIJ.KWX8W?I@^P3<83I>56\YK'2)CA"<7$5P9/JND(T: SH&)R'VK\M =A&(C MH%/0*/;E7=,5X;M4+Q;3S!;S]2ZEY)8F!!,C<")#-
,0[1@F@!DVYLE:8VO*P M!LH1):$[=]4!U.Y6"/R7P7_^W6X\&7SQ$SC/'YOQ>( *U>_XWTNOLZ>E?7[0 M-!"I9D-"?
2(>U6LIO8BR^ARB]NA>J:C4Y$GME,%1L& 0!?O0D %0 &IA>GHM,C R-# Y,S!?;&%B+GAM;-2] M>W/D.)
(G^/]^"EROV5Z5F=#%!TB"O3MSIGS5Y%I695JF:F;6RL["\)0X%8I0 MDQ&J5'_Z_B(8+P8 A2?=;6E5*(A+O_&.YT./SQO_Z?[X]+\"S*JEBO_N4O
MX5^#OP"Q8FM>K,[_Y2^ M__W7V _^"__S[_^M__VO_XO"/_SS==/X-V:;1_%:@/> MEH)L! =_%IL'L'D0X#_6Y1_%,P%?EF0CU^4CA/]:W_9V_?12%OHN
MZ_Y:_BUE.4=YB"%.10)1$&601B*#"4F"+&!2"LQN[O]& DPCB1,893B_*)<, M8HD(S'B$HS2*!,W2>M%EL?KC;_H_E%0"'*%65?WKQ_SE8;-
Y^MM//_WYYY]_M_4[+Y5_7Y?
U/41#$/W57_Z6]_/O)]7_&]=5AGN<_U7_=75H5YRY4RX8__>GL2__*4]'I^6HOOLH13R_+++LCQ857.9;R[#5'/YWR\1^VD$^Y[X MW9SRZH&Y6MQ???
$XA.FOWMB]4Q9"3,]PC\QHEILOU/L5G^N[NR,UFO7I.?;U MM5AOR'*&K\6>3(_EI?[@D_JI):,7&C"F-9W6=/=8%=\W8L5%8RT/E@8%_Y>_
MJ)\6VPK>$_*T>*<>\[.RV<_B[7JWG*B),NO^LUVM_XJV)(4C]\$VY;%IA#5 M@M_@I8))*+.00!3+!%*6YY"E-$I0PJ,DKO^$"OXV[>.M9J^:_&_6""R
MN:#9I:C6VY(U[T3%D/8'&A[_=<|*^%"LU'NM(SOP4;WBRMHUJ/[73WLA/*.Z M?%6LEJXP?2H(+9;%YN4&?-O2_Q\L S9K\ NI%&M 6>F-OZAI9YT'+_
GY=;\;G*2NQN8CYFAWPN]1>Q[H\!F_-1H&WU_!*H5#LEF/_U8V#TTQ^Q>P+KDHE8M^1O 3G;KE_[6M-K4RUHLK(8NE M4%^TC\JW?Q2?
UI7Z_"VI'KZ4Z^=*6;\W+[]5@G],+(G2:=^G/;B[4M\V;_?%5 M/*D']D JH;3TOB2/7X5^%HYMYN'=5G\0_#]-;>/Z^UJ$RI2-$!QDC*8"1Y# M)
,!29HCB#*.8L%).?,QE%R9V5BE=RQ $A-#Y =*T"N2^4?=?R M035 U%K MV7D\(YZ"F5\S&#[;6QD #!?8$01QC&!D5XB
M/&#'WH.'%1UWCL^D4+\OQ8=U^8TLQ3M!-_MMZ2UCV\>MWKORGTOEP?RV*@59 M:CZT/_-&**47=^3](D BE2Q,8,*H\C"2 $&:B
QREB0LY7&6R731#T5>WW_X MX,M(9:^&8@..S2=TOK9H7GB:=T_F$\:339C7Q=TLZC[L5WT@1?GO M9+D5GXJ5^+@1C]6"$"+3+&
(PH9A"1((<$GV2'8=YC#$F4IE,MV._"_]1F.Q=0 M*J>I@YH\^%TS &H.#'=I9MC9'@:,.1,0U^N\ QHB@_8"0WJ/TYVB]4EA^0.S+

*MQ!\,U22?)8ZM*/___[O6T5MJ>-`MRO^3;EMFSM1/GY<*?)M>$@;`MJ#OQ??-&B?;'(I;"Q_%1V\4\5;M'@@-(<8!A)&2B=I!YS%%DM7L_K#CHL6>YAQS_3SWDK,B;6>.S(_%O]?\`,T0J#GR:*/\`MP>-K>SF>H7FWF=X/-EN^EO9SFYR42S>KI]%N3N.RE&6RR03$$O&E_WD$:0R_MH!C)&F4I4&4&)F_DY4GMF(U+9.CH2OR#YN:45)96@Q3@8P-P47FS^AS)=A?`M[]?//ZF[&E56/^PU^`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`^+JJ]S_;=LN.!H(1B,&4YDD>N<>ZNYH$HTTQT&0.L1H:N*N-M7J0PL<.9ZD/RIHVEFQB[#.6R1O-AI9UR.Y._-P0-,U7^PQO;RJBR-Z=.7U?8LR..@MFF7;YS%/%WEN[,TUR\<>V+S:5?QETD1,*+W-MMB3.(8I8-O-44!W_2](\BW+.K%J0G:$QL>'H!HTH%D\%06*U8\D677VHJ2JJC#\6JO>I'VU>VZ4,P?9%/-*WM-MZYUN>FV?=<_B'JI]/D#-B,^WOJ7HWGP!4[HS>PB6<)SZ#;8+N-FA5YL'4>K@-M0BD>Q*I2?LJ^%;.N1OFP7/_Y;X+?BY{)L=(?WDJEZW5KY*HJ9,&Z6,4BSTB4-MDXS!!*<((LE32$*L-@1Q0B@.I!"A5=,4;YQ-GLRUB[+^T(99?^PBJ4#493E@-MW58F2L4S>%!,'W86R#_1-P+LL[*"9:Q.?52TA-I>-MJM?"(I.<9AG-82Q)-E6Z-S9E$)*LR"-998*+.VZ^YF0=3C(1K.N'4G=UKVE-M:5VH=QT\,T/H#1#7K[C*F==\;X#Z.MU@%Q*^8PE]E?6=YWDW"5^QB"<*?_94"KG=#VG;ILI'5\&K+I=-;Q{]-%^J-M""KHOFN@S^A\SJ%\)?$O5@)?_$&A_,1]78MMX*_57_78QON-MRH(L=W.^WF[+4A>/)IG,$Z&4EBFW&")*&*0)2F"(HBA(41JED5$W"V.*$ZMQ-M1QML-'%_-$=D:1A5,(?-X/#%-QAVFMU2!SL\:OKJ.6\M"[Z1L3C)\8V0VQ'/-M>*3L3G]LI!X\%C);.+[S(ANY#@Z2K&X<,2OE8U4I,N^VY2X]MTXVZ_4@JB^KMLWA_%9O/\L.ZE*+8;-4U"Y0P%B8X@40BM9,080A)&D76J__:KIK..?60[>N$Vl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c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{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`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{4DY#F2;">OIDS\]2&4.*(:(>O'ZK'XX2KBL4>;5JL779N#4?'F[;&JQNP'U=27_QE%T#2K'G>U+EC-MXW.KY\#%_!M=ZC.;@M'+.=8Q.=8J2A^*@@MEK5E[88L9%(]%L:H.FDHA8CJ-M;HA9JL>%2@/*([W*X1^R5*$]NPEBY8[@E;UN1=A"CF#*$59B&-@8P11'-N8-M4QY-]4J0841$E"-NTR3&#T2NW6+(=$"9V64OXMM9WN[+T:,YP?B.JX+YJE:\-M2&?>(L5KXI[4)EZ]P=&XK39]$[O<;HKGGNOX_CM;;KG@'Q3C^IAYNVF'^QQ/-MF6Z&1RTB7465D!1F>8HARM6FDQ"E]'&6\)PF(8\%M9S[X8.OR7.X/Q\Y?,[>MG)_'8&A#YH;6TM[TV.MM7$"'(-#:!'HLUGWE3D;7=X/-/)HHG[CY,F=>>>)K7-M]/F$\<1,>EWJ1[T_W50\%GMR%=U>[!O#^-MRH]O<-O%!?9A>[<>O4]W-M@0O=0SL(/[-MF]G(B?&SLX$:>5R:0![_&4-$L-8LP;HS=8\I\/LD]31'H.*K):.#!_-V#72'-MZ*2QX(BE'"U7*7BQ^-4*88=C%?VCYY(4)I0J,(*E=.^79QDD&FB3H:#JV%#R+CJ$Y&2FSI;VP%=?>$-S(XTO3SY&85Y4'A*S1-MU:%KO;D17Y7"EP7;"*[_H(S!X0>]*QF!"/'6'5WD4MSF[@-.#Z<0CWK(#F$HW[T8?].R;U#.V!FLY'M.#EM;U%>]@._$:'14>=E?Q"-MRC^$;@E6-\?>G04$(F;;=HTS@D&A-M+QP3#-_CIMJ[\U51/A=,G*]#^W7=9+_QNN2LJD_-^G_7-/RZWOP?L?DJV/I^-M5?Q#!$4F;)ZP.((9Q9%$;8]@'AV=O!L=>Z^(/,&[-AMBG9O:CNI>Q"-%[$!>Q;]GUE,CJ8GJSL=-MG[..[,GA/K;WTQ-T]..K2NQ>/+=4.9N$;19!@)7K1P.(,D(A2C(),6,"$I80M]8,D3%IE!)ZE.G4LL:$&2$W[;Y:NWEE8#'\VL<),.G)A&4*&!A+E'(N+2-1K]#-M8AU8W$,R(HBX\/,!KN(9V=VKW[5K8WL,<^>[.INV5E-Z;$PQ],SY.\./4[^-MM_I/[W#UXZ?BL5#.4]=$#P9*3(#/N6S)(-M:F*CJFD?Y-Q\!"UYBPX8PU@-*Y5?!.S4[++P+GU-AE&PZ.WA#0VW?AUC4+'KMPF$DZ&!GC>$5YNN6823)00<,LSOI31[_\H-@\/ZZ6>M:QK-MQ-YN$1@Q\K-^49V^U"9/Z]G+"B>O"1G-F:UJL:"=>R%C5[/S?A]WCR(M4J]7B@>U9/$L/J[8^F%6E?5KV+S62HVFHHQ]7DI%/5WHOEW%XKA,HA9%B.H-MS*&NXZ(9Q!3GD(4LR,N9'"*-NM+Y8VEB+[!FL#YLV'$(BII%\,-2,?FC983+-MPS,PLWKS(FMG_QI0#Y@#'UM0-7_W@#%HGX!:0,Y163-'SJ>#"$'AF8UB?X-M/#:.'E=V&9QST%BIZ[BVW3RL2QWV;\Z?PD4HXT!D&8=A1*0^D@U&'@'IE!X-$-M.8DQRK+(%7#@N:$AJXMX*QL;(C7D\.WK=$TSIY4+S?G*3V+GBZTHW0&?)A-ML5<1D-X'G6=:,JZ-/1/^SC=1!XUT\>,THP3?JQ$/YSW8W>KF[NUFP3RKJB8-M\A6VI=B7V>-ISS-5&TE]4F#R^0DE.4P%Y1QEN4\2*P=(@-M0&9>CB^Q[?1\1Q7LR4Y44F0BH"<70)#4K,Z%B=#';H/1/8Y!H)X%%-53JT-M6&:@Y!('B(1IE:-3X-6GUA=:VI-DI,.TARA8!A\-M<0?-,J:R$VN"V987I/-5!#E:?=[8QGG13D(6%RZS=[']5VY9O65.KUV3E5&VM-MF$19&J0T@QG&-BH?6KT.PSR"29S$01KR).&AJ5-]D>S9?]JIX?>_U^L4C$YBU=_RYSHUM33T5-M>93%E,,,)[':[481)#*1:O/+8YR*+"&!6P+R,:6)E;/=]80=,SZ/<'&[#7H-M16I*S>A0UFW#Q@1ORZO"^DZ*/:'S.DFME\2]F)1Z\0;72>]TLV\5<=SXLND:M3:-4#YDED*&JWK$)3B#-DQ1F&8E"E(2)1*G=M/>K-"=6:J/.MRX-N4W@---^MSR#9V0&C!K>^&VU;2.QM(/QUBC,/A3>&X'0PO/FM;J9"+26*^U4W=U#]JL_M-MVU<:3L(P85B]Y+,-0225C-M<1GM7]?+9;ON@B<\R$D<]GI/&<MVG\"K9T&=$O)08?>Y2QUL$.DYGW#&@A]\H8UN<=U-ML_U4"E8TB:@4ARD7C$(2D;/?'-M/01,-\)N-U$_:6WKF3>JI4*>[T3/7N"I-63P3W7QVIYF?-MY?[#7\5FD46(R"0D,-BI4B7,-DB3*(."A6H[&DF11Y:ML]\3M?DJ.O7\UME,-M=4$T^*%KC?_R(Y#ZC?$\.%'1%453=?2)C*V2=F1NP/[562=^^M194P&]:.?)5M@C/KMRD-IUO2:@U@'@

6M^SOVZ(4_)UX%LOUD^!W@CVLULOU_M_0RR9A#0+*VB$0G[%;@!']H&O2=T+H"TDK!N"='"5(8
M3Q:=YT$/FYU_NL=G&Q903^ZS!%WY3\T]V'$/^NSKZSH!P$X"L!E=%P*K-@=-O^[7:UZU2]O[?NFN^NNE4LIZ\#S8_M/-1=
(;2$ZK>F]2APUNEZ^6+_Y6C.4HL="HH/4:E_U6V5>")ZR[!\^:NG7GQS_M/<+!=GZ3,S%?1\"Y\#QH*C@;40=WHQU*\G:]5!^MRUW/^?U@()YG.,LRF-_I
MA8AFN1X?GD$92,&2!.$,F?=4O49M;J^^'8K#^O259=!-SDP;2)BA9O#N]8F% MY1:@A>& M.E\(_^6, L?.N)L*.VB? .!K?-*X8 MH:UW:!9E+WN'>
747XNE0M'RIYAVHO92&JV:A:;]GV(+4 M C\#U\D[*G;&0P/2)B)H!NJ]M8Z%+H'-L@+% A\+;\H[3FXNU76\/#E45O(. M>E5F*\WG6EE)=N!?V=TYLMO@?
ZS+/SZNU$Z7B;9AZE=1B?)95 O!\E@7GD&1 MY0*B@_>0X#"'B*&81!G2AT1.30#20011 ;(JNOH62J3GQ?M: )-U#8# M\QPNF*
(XD8A"$>@&5U&@<.%IJL")PCP)F8BIM"LZ&HV,4YW1%-B86<#1\MH> M/1T*.D$;BT&)O&69GJ,Q+)X^K_W6
M;Q6@+P<7[MK#-1UAQA7^C'V*9O;F59Z-G8TZ?2QO3!_+&X?',J(:R!.$W@N! MQO+U2C5 GN"\7/[CBX!CAF%
[0QJA6!4;\:EX%L?'HM5_B.+^00_45F\+ESH',F&#Z_9 >_]@'V9$C"+\XR)@',]U? (H-TIAP,*@V<=-NO-=^+A M(.7!N8?+_6X^Z5?
QO%X^*U_KK3+]Q>8#876/G3:$A;2Q91'&.*$(TB:N-T#E*;W*ML:8.&..BHV_F-PX"9.8;>8+"SFA<1F" (;"2B M)[]MF-:LCIF1V,>>E]E-
;OK]JB\)=7#EW+]7'#!W]PHTWY=[QRE%D"I7*Y(\C7ANE4IFS6\+$EF!'&9 =:3LC MX("JF668%BL]07/.2?6"@3/:,%FM%\E
M,]8*EDO)L7:+N'82D:)L(F!$25@G\O^J9&UR~75W4)+1&*=YKG9!D=H/)4)W M!8@)))D(>2;2+ @LAP!=H3BQT>GH UDSH%_F=;VB;=N0:[B9&1.O:-
@9D*91 M2%5M->&N8&9/VWMW54-!O?4%N49OYH8@AN!*?=@(QO='_'R64AD6[>A\:IL- M*T_G4[$2'S?BL5KDA FB-D P#S&&B&$"*8E#R
.*$)=K@=TT?U Q8NA=7P#,S ?X@L=/_,6A8]J^9D)YT_PJQ617?3/!CK3>\RT?W ML%Z:UIW"OWI8+[GZK!*L[AAZ5Q)=]_R.O%3A@B MIC[&#"B[^!X]@-
_V =[Q!7],@98S\&X(X)%MRQS F:2/F0T?K]C8S &NX4YG M+@NZEL"P4!*O!/-OQ]7;6%S4WQS1[Z+Z@MY:=K%IVD:@.B; #QT; M/^I:F1:OF@?
PY0I>#G4RUD)[JY_&X M?7RS+LOUG_KPESRIOVQ>%[':5F1(ZC*S7/TGC"BD>9RHUVRJ5"D6E)#(Y@UK M0WQBI;JWTVL)6)-_(%MN;L!CPP^@'4.
M1S9O8&M@##9[!4\%GYT"=\@=96[< M@)85L.,%O+V&G/6[V 4"3RIC*]*SOHU=0#E^'3NMX5S7RH0>W:TSRKX6U1}? M1*D_(/EN]@^QK"? * B?
Q6JKF\Q.!:"9 M2?8%BYT)/J *_-DZ-[8E[+5^]JT_LIH+Y.:NYKVJM!GBFJOW^,^I&FKM.;] MW[?%DP[&M/F=$0J4B20,8\(HWRR04OEF2:@.9:@V-B2C&;.:
(7&!SL2ZW5$% MHB-K/XWI'#JFVCM:9EO%;<7=49RDZGU0*H_3E_T_,Z+>BG@Q/<+[O^UL6JIJVM(^CK9<'K=MQOR+). ^/CV( ;R M.RPP-
CV$&OFMLCU@VGVA/EW]0HT8%?Q&&._3@?LT7FD@\!RO6Y>\\/G>Q0Y'D M-[$JUN6OZXVHWFV%PB=O7[DTT0/D8@ZSA.ED?
1TGRG19I!0HD7D0)2PTKHB\ M1&5B@U\@6VFW0CW;_IJN6!T6^+/8/ #1\J6OKR#\ZX9A\(.ZO+G1 M,FKB\%C,?)%IP;8TD0;-?@9[_=R
EED]'+QAMWY"ODJ8QX/F]J6//0/S]O1Q M!NBD>8_[2CXR C_M$E@I#[G,,NU:Y02]_1)5FTPL(6N[0L] MH6YZN%UU+]]MR_=1]?3F1)&9Q!C/)M4Z6FT5_
M+@G1*TM M8]O';3VR\IUX*@4KFD:9*]Z?^,?(A&"6Z_)7F2$9YCJO/V XCR#,$\E#$D(<\SF7#!,Z.^;<<+ M3ZP9-26+X\>^R,.*.480.[6HB;B87SP4+1_
M_7SGH&>X/#CZ//=WMU?;44?K7[=ZS<_R7;'L;I?Q!G) M DPQQ!$F$,54PERJ7T.415&>~<F,>RXA$8F>\)[F>&S>@9=":?Y^4(A"?W
MS):ZK#Z<(S3'CI[K,JXS7NIRZE[:7^M=!(AR)@,)>2X3]>8(ITASI+QJB21 M-&18,KOY++<)3?R*:,GN.I.M6^=>!,C,W$2<7 MR,P\OF18V-
/1)%>N=]/5@4DG_>A)>S+53"7BVG9*"KUFOT_@I0+QJ. LSB% M810AB!!.(PH6[H3/C WLQ0S(VEG M5 9G+]W41]>L]DIZG-Z '9/:/6G8!)I/?V;
((VB>+)8/CF8U;AXA/+:.#/I=V M;&2Q7MTKF_&HLWGNU!*WWXMJP5G&TTQMA;E(E0VD00XQ#U)($H1$F(>)(%;9 M<>>(3&S4-$FH:=9#<6^
)@M^UX0ML^+. F1FL,:*;6>!,HGO["2V;QPQ()*O M!A'G2,S;"&) R).&#T/7.L2?#[/]JEV=WI"JJ+XJ]=_XY]6_D[+0?0^^DHU8 M!(21*,TX3,
(DT#WT0)I'.*0RB@3L5$!)C?R$ZMQQX$.B5#-_ZA]L!Z M!9Y;-D"I^+ ($=M#;!-5GQ0X.T-PTGYR!^+'%:CY 0U#X/,*="R!KU.#:!&-_MGQ1,MYC]!*#.!?
J=,1D\K!?=;Y# V>)#XX6W%<946ZE.WlJ8Z?/_#LD) M&@]D2EJ7*G,@:S/)(P9D%,*98RS)A-2/N4Q.11ZJ?2NXDVMV3_QW_'49C! MS[K?
A&TQ^QF$8I80)*6$F,0Y1#H5@88D@HD(!4T$)BFGBV90YK<-*0W;%HW# MZ9B<,5IOQ'VQJ]<=TZ8:?30\$RH0'D*18X5/#D.(UQ%9;
[B8N>'C)+5[]S;KWX#;S:8LZ'93OP4V:_"%E$/I M_&[U:F=E\EF/=DA@_GJSLP*>K2<[?Z5+73Y9BNJKV&S+E4YK+Y_%VV88Q2+-_ME']_"8-12
1$01HH&Q75<4+.6(RPB(Q.BH?)3.Q/UW1!61,&94/9IE+](CH& M+K(7F>W4L1&WH0E:HC>@)>M%;IL2?1_RNWFO;TE9OFC+^TR66P%(W5U%-TJI
M+;%ZMPNQ ;J'2ET239?%?7OB7#336+@>#++#>WC^H?TE[!4Z4;=MJ [DN0=7[ M11'^R%*5X*"99J6R[*'__]JP_!M4V"BQ?P&#;BXZ6T#"C:"6A5]G-
9CA%/V<6 MG:T$Z+)_4*@@:O<=!MMOZNZW=4GC;C.%==?!9B31&\8!RI;17*I-HR8!KK M6G<9Q7E*1&!UC'F)T.1*=M#/"W2$G0+Y%Z$RVT7X
,#2>5$O^:9#1GTX6,_S M4V^[+^NJ'B*_0^-FU_7,=[3_FLR>]AH7R2!(& LS),$BB1A$.$\AA@A!G&L_I"'D<34JBG/)4(3:W1+%O3H M6LYDN(J4F4+[D-
],H9U$MU;::W)Y4MJ+9&95VFO"'BOMU>O'#9K=#5UI3^S? MB)60Q68A<)Q%)&(PPKI39X(P)%Q&D"8IRS#%*)26K68&Z4U^*-<.F=V0[X V M)-T&S%
["RTR#/:)@I\@[ /83DW;-*7YHJ5].HW*>+GM%3L^S92]1>Y7)LE=$ MOS17]MIMCD<\[$'P[5)\EMTPZSOQ??-&\?W'(@QR(?.<*;],IP\& 89YCG(8
MX"S*23 P"#6QP5?2TW?Y)2 MW*YX]V.OP4T]K;HK!F X1R06D%,IG',D$:$&%.>V CL M.NU7+1>6BFX,H*':3P&+!1%HZ=;1[]TO_395-1L35!18"^_+-
AC3G==2V,)Q M8C>L%_ TJ$<GG";9;U92&018%?!L*Y2YPDL)8D9UZ9] P<0/N&S:.1E@'C%BZ"69@&OH(WB&R=! Z=`[NH7/(
M0QWG>G8CZ"]Y5Q]@;JW>A==OBP0#>,| MBI03$# =,] 3V /=C1H1%NHA[ (9;1XN$9C8'+2CB%N:-Z"E;CM@^0B4867W
M(;J=6MM*Z3!X^;PH(P8P'RTX\R#F\^*<#F2^<)UK_^BG9GY ]5F]M_^S*#>Z MIDYG@2\"HH?\!0@RK+0+"?
4>)E&@7LLID0F*>,1ROIN79=,^^B))HZ_CT=0L ME^[1+0,Z,"6^LP<]6J&.2E7-,);5GBER W@@SG 79=I6^C&@210%BC,$8A1@B
M*C"DB1XW4P=4,AY++*S1'E#NR5XD&Y.\JO:8Y) M[!VKZE>Q^2SOR/SWPU)Q:-DN833X61+%3"8P9%SW M)(S4.XPK TPR(5)&:*3>8^:#O>>
WG7V]SG@&\1;_.<%GD8TB?)8P4TI@^ JE M)V"NONXPYYGZ>D6I2(BT>=7-^:VW?QU>_=:?@)7M@,VQ3\#LU3DCKG:OUP;2 M
\ZZ_($?/C60ZO&GZM6K.+P!+8^35Q)YPLO3&WLI-[.^U3U!=_SF][6LFW>P M2YE03H>NJ1
K]O)I/S,KH"@/TPR&.DHAXCB!>1ZGR@IRQE/$0QY8)2$.4IO8 MQNV3=W0#L$^N8[.& 3,S6MY@L#-)O?2E'N&))FD9R>C)C S3FM5(&(E]; +.
M;G)LDD:*\M]U&=@O@E3;LLXPK[!JB;UZ&%#[*#]\?!!&+(>1[GV&6%H79$L8 M1R$.42J9;1&$3J[*[;#HNZCO=M*7BAJZWJIE4G,W M2+TJ])DFJ=?
O<:U7Z#?%Z847FQ\KM;7X4A9,A(L\)D%$<@:9R$.(4!"2B,! M&1%AGBL+(5,KA]^8\L26H>]G5/3Z.?5"_MTOFAGPI+FINZWS!7)RFK?FMTR M]&
<.NID5F01*.Y-RTA7K;1_%/1^@9F2JJ;P&HD\RIW>(]BM.[C6 8WB6K\D" MKJF0U>;SK+L+M)YS)%-$:9I"20F&*)8)Q'$40YYQFF9I+&AL%58]H3"Q'='T
MM#?QO5*[YEFV:'ABVN8['H)CI_RA1[?2\D[+IIS+!N*I+HGC+83Q>?^;,Q0OB MG>8K7KK03=[^*5;KLMB\?
%RIK[90:_^Y4E_QA^+IBRAU8B2Y%V]>VO!ZD,6< M12* "WZ?@ /Y *$/TZUW^U M?)G;(&NFSA/A9:?HW[:T*GA!RI<;L&, [#FX\7[^X""V)Z-@0WE6<^$
R;$A M<5G"OJ7/EW+]0;=@ZF9)$AF&FC#*CY.(#L-WLGB>5#W>?Y'=.LY6G"V3CWG!>EWZ;EPA6.H M;;4IZIE=Q;/XIH-X=7>S!]_9S+\:F#N'UV 1[/D'"*-
!/%_18 MU>_XCEG]YFK&?HTXX//V! V#@Z_P7"P#B7.^$OOXHF?\?.4B?:$U:]S2,Y@G M.4[?
Z[M/0:EKIS@L$DSC),PBF.,@@8@FNI:;2\A8&A/!4208MLEO["\^<;)B MTZC;F/Y0'XS,^4JE9VI.1QJXG>.R3'W'N>7[):>?6[)L5#GYI6<7.,_CU@/
MX_ZP7/^I^RV)GTFQTA^^$7)=BJ^"'+4E5%;)H>J;=D>\+Q"F6"%.(2:!V#DB/ M+!$.#L$H#T08Y#DGOI(K[5B;V+O1J3>B[1PDI-3M<=7KDNFA\%+Q"!
I:EF&$ M*0O9O&7+'9,#8TNG?F!F-N)U'H.=A3%(R]2L LTKJ)F] 9K=W5]IS3,X9OI& MIU7-DZ;I!N4,&9N6C/W3)&^Z 6J3Q^E(P;[@!%W;+
[P9&/>E'MOP07U6+1*9 MA7G(,YA3F4/$@@#FN4AA\&0H3S&GRM$QK3J]2&7]4]R6;C<[L1E+ 6K2Y06G MES$:-G/>)+
<\=#T2^HN)T%;EJ%>%OWC\9N,7LFGW M//UZKR]E6;B6+%$UE^7.D1CQ_4-V$1*$^("^4=I4QM39!27DA80"'"/ N8H$&2 MAK8S&:VYF%B=U=
<%NV]E6'5;K#NI+ZLS>D$OQ+P\IM6>H2 M\YJKA;(_J< 9@7&:*C\"2P9I72<7Q%($<8*I=4G(2):F=CJZT&>W89-_/#XM MUR]"M//0=*F<8D1?4\](40L]Z
D*3V]=]LXE]_/';&M'/3PL,\LW]R.P,X,] MWD##7!-_KDX]Y7;/Z?WN.=57PIHT'(_^FQ[K7;Q!*&_DIBQ#,U=-_^,)P#/% M-;Y6]C>TH^UMAX,XY;E$, R2#*
(HQKK F$*U&4N8'I83Q*/'=LS2#O#2X ZG M;H #@)D9-#\PV!DJA_$=WKL$7I=[PA$>K]$C\+K )F,\O'0(5(^\V(A/Z@7$
M/RI;[K7^;2W524VU>VC+M_]1TVK]2FF_:F[/]>+*.0A3BF&,2.ZCPX1,$]" M:E4^[^$)%0D5HV$G;B8?IN76A;A.6%I9ALF1\C.;#3LP)H?L&<(U!S=U)T#
MV4;]J<];NP54?'DLXQL#BZ^Z/B<>YBWT&P/32>7?]J,4<\Y..Y:GN<<@V"YKS M. BYA!F-*-2U_I#DE$.,, ^B**-A8!05/K_\U+E"W[ZJO_MFF=US*+^9S7"7
MRLX8-'3 [QTEGVDR9T7PE>QRN/B*2MG!3M)/#E_U@+-_G7C!RK\(W$-IW%?X0R=>IPC< X6(5OLF][N>R MNB'Y(LXY)6E(8$Y8!%$B8HA9D,!
(LB"E,I,H-#(-QPO/=?JJ;=D?M];BFY^P MV@KD>*@Z*(O3*6J?\5$'I_5"LY^5]MD_=SQZ\'?'$]%B)3[+INW :\+T!/ 7 M'9HK-O7Y]Q#
[JI4%S7B4IYS!/$H91"*5D-"80(RS@(H\H.KU:G4..DY[8G7?2 MG-3-9YOV"[)E1E>C=^P *417L*;+V0XJV-0'E@<*-K@;GIE.@Z;E26D+9-O'
MXL_.R+TG0+'2*VOS

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{1C>QH8.9$1_4+NB_ MXB-T*8K("9>J=.*#U"GVZMX/$5(Q4 \(!Z*QSZ*Z 16ZIYZH#?GD ML:4/[ OA J.;R0D-#LS 6.HVVNGQ&1BX2K8L))_' 8(WC0!(*I[A O):=M( M $XZ'"KK5GZHJ1Z>&P?WLR$,A2$S7BX4[=E59&<9PKQC"N$F3)_ MRZE"E&B.ZUH7:0H;,NE(-[*UV-)-'BWA*VLD>M0;\4-1U?W)#@ZT)U8;@_W M!@ZNDAVD/G=(?3Z/E(>'_I([F$OB1G5B'P0$Q:'3 ;O=(Y'O_U&/_ZGF@O5A M.F&B*#)IMS-TB3"7 O&TM.UG,OOS5(K4*;HY\NS(5F @!DA->R'[N%9?*!%, M75G?VE<%RVHZS/YK&]N*6Z3+7CO.ZEZQVXI(XHQN_ MJ,_+^7<3P>S[*?TWE N69[DJ4:EQCK#$M6U)KU"A%,Z8\1IXX=3*,0@WD>W( MB8&.&Y>.M]AYQ".OP<''S4ENC';YCZ-|\36D88_CH,>=@YD,//CCX2$? #! MIT,Z877IH,AQ(C 5S$@G/*#C(]T>ZA>7?E)_[K1W;Y8+\U?1U;VUS=Z? NS^W MB7\E2\M448FR3-<(5W6-B'"D2JS#!/"I"Y F^M0!J(?M2T?AX0^PUJR,X;@ MZ]J\(l;(K]S^B[*N_>[O]YF'A;7@U^ 6W\8$% [;TO,!RGY>K;L2#63SZ_T9) ME/0%(U#T"R8_:1CL"\[+>-C[.9[;[\O%G9VL:\/PK7*HHBA91BBJ2!Z*(IY2AC374E)>"5F[;\//Z4>VA1U# M-C1Z[%BZ,G_IF4H^_#T1NVPEBY:O1%O&(-7H<-0=-MWB8@F,A3H8;W3R>8#Q M\RZ,>QPE'4O);_%AA-3Z1X73;`^,L JS BGUO4,8+^>&/G;"^WUOF_;)__\?X M.:TC<^#?//_-_KELWMI$]C;5D5-2D;P@J)):(BR)<60K5J*T4H+J5-8U!Z62 M VA'-N@=)ZAE)=GRTA>#)? PY:=E)6GZ\LDLA.+LY=I'0@YGPH,"!O4 /" )Y MAA#*DW]+`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|/3($Y]F+F-BA6O: M,D*"""H0_X"9=N8-EY M%LL%FU_V(F)MR7/RXKP'*FT$@AS;7P!)3-4ZS0G)3%V)'5JD7".4&2K,1!+ M6$O-=^/H!3C0G1[D7VW;JZ2C>37XY)?L.%R7*$@.R8OR+S2EL=Q84_O69RX M_E(U[0H=:G$ERHR899Y5667"EU(@GC*.F*1I25++%LYKZJ6=`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{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{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||>SI?(EK\7-MD9@(;)A%C(GS%).5(C5COH23UQ^H 8,LP%BE"]LVMY;V6HCF2]L?$T@,,@)L6$A0_G^CA4 G_.C*NPH|&<'8Q>0%@\,P[Z9/Y?!@Y^->Y7MLD6HY:)OI1D>(8 E#(^4GST,@QC,,,)D'S6/CH^:SDC"9-LSE:$:)(]*%JIOQ$DZT_9\."?N0;^&LS<$/IS>MFJA M9:597>2(9?9P.L;L #!U/W.MV73$KF#N4L<^H7ZE/C#N_#B?4(?]JO6M88N5-IIF'MXEQAA+=*-_FRW80LS8 M?&?7R>:GK8[_JL]PU'E!B4XQJGA&$2YYCGAAO($JS95DQJAD&G2V'9*YR)9G M0WAOY]8O?S3H.W$S3*^%-,R$>8(,-E@QT ADVH*R-JD1C'J2W.9A89GKGS? M<6&F6F9L%VU;(VYXLS9_;R)#[26%)5__=OWE_=]N/KY[_^7K?_TO),_]_Y&\ M_]|_?/CV?X#)]:ZXNAF^&&C!C-H.!QN?K!W%@PH;*BW?E>RTB?I_,_Y2 MJ'W^V^Q:LV;:"UNM&?EZN5G0)CJP9O2UHHG-4% M*DN<(9SE)-)"4L12K@I=*L!9+4!V:.,^G(ML1ZP4O;C(5),:-<&_=K69+<3\ MJ>VY,AL&K5D-,F$TF_N,CG1&VLVVQ,$/O+EM:_9'C4[7%PE Q]MI-QS,M[E MP:/B#BI^L'H\9\(35^M!3FLY0,_P7/'5^N56MM=]6X#^>,F3[>]1&9GSB*1 M9C7'0DH3XS&!4N.T2%X4I"1.B91G*<7>|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|BD!,)VT;!K19<4]+M:WR_E;@?Z-$WS&MNVV[GC/C0E19X]L_D4|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|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`3M:BKD7YGZS_5IOIO_Q8)6 MS[/'863Y.5L+FM2HMNV!Q;U*6@)&*$IR4#'VB>,)I+@ CWN;NJF8DF]\(-ZGA MNRK_VQJ=KXO9L\V[$U(BF15YJ8% N4TT8 Q0D2E0E!DO3=0.N'"SV& -_0RT@=EF0T3L-'9*_EAMP0[N/6T/KU-J'37< M.OFA@:5X-_H]JQX^+E8_=H<( K%#6.7_)V">IL"P!ZE MSY8#]ET36@S3='[\H)H_/RVOA5@-_*[F7(353*E.2ZPRD&A* 35@,6(8$@%04 M$A_^SF(OK4R#L2Y67IL.OPL?MO[\Y<,_]=F^[ AZ+,# M00$5-NX:1RNY<8" MOUNMUZL?YH?WI,G\V^9EAFB:%JS(0(%T86)LK_')2@%$7D!4$]I@Z92Z'P8_MLK?8 B>\0TY$"^V:N>S%JIL#&8\K/U=BY:CCAEJ2I!/E*MGQMY4F>7^)OX"\ MYQ :HN5">X%/G:!=0LQOSG3070)31)WIV=7'U?JKZKKI&?35XZ-M7VAG XHT MY[#D!.2,(H")+@'5.0*%0&5.,"M+6,R6ZKX>.^N1Z'$1VD9I)+B$B1 TFX M-&Z";V"6,M"V'T[+0D#)"]>.WL/$&#E ,=^K,GPPD@>;C@']Z!QY!B:OQBNU M,IG(Q((G-?HX Y;\M1]A!I.'$&\VILF?J+Y)3@%W"W-*%FPW\:[ITI5I*6$J M)4@SB9LB)98Q#E(E2"&X0KGVVA<]@3'V=]AX4/)Y4;]H/V\GTUDY]H8K5F$M MS4XQYN95!O+@N1'ZFH*[(*

MZZ7\IM;?YT)5VXG%YG==S-R&T>W9;;-PA%\1]^===)4"??B&[!M_9;' <3[""&,#)I?EZ@%28Q-MR$DGSM5N[GC[^^T:NEM9!
[21",'2X^QA9$[#3B/&X=;OA&( ,;UG%B'WG>X4 M8X#6!^<;0^X3TM&G/@B^T9_9C^IYOJENEO>K^?)^QJDNN4*V8T]! ";Y E0* M#AA!69EQ5*J2NC?
P.0TR-&?X<7"Z$;3VU8?5(YLO9U#E>9$Q'IR; WKC MQ^$97&R?1"=N8N6U#\+*<-4,6-@3Y2K92=E^Q#ZL5[!\O*+I*?!L.^ANGM2Z
M7G)$[+@W(N&17.H8$D[JC4>D^+4C'Q,JL(/%YD&MKX58/RNYE_/V_GEM>Y#-_M6$%8KM(4D)PC@,N\ $0*.5
IT@RJDO+4:2/'#6YDSUR#>W:JZ*?'S6G&4]K/ M_]6X20N<',2CMM@1^U0XZ1BK3T4_V+1]*IP4/^I3X795X*"&NN3T1-KJS*Z\ M-"XR8[^Z!)B;Z(S!
@,D29I/&( Q0N:19K9L)9G&G')%Q2]V@RPL4+ HY.:@_0',Z\'|_-5.V) MHDHYI9H6("/(O'\U*@#C90$@+ LJ2Z$+IIT/4IP@IW@')^M&B,$'WFXD.IRV
M1*FAT< M[OA=&9[D?JO6\Y7\;2D_F%723%(A9'6W<\ (OOWI[$F-MZ(C(?D:Z!;]*
MMFS4^%=U|Z^53CH9XG:B=E0X8@OJ2XB3]YYVI.!4TVG72P=L!7XQBK#JH4G* M[R8/AB+/&3.&3W$A 4XSXP*PG2N2<0$+KC31*F"8[%E
I^_]X/FQ312Y7"U! M?1IC@IAEQ43__KTG<1I[@\$\|#%APM)C;<10M[/FIWF';@GVJQ=P1/(DS_69@ MG[HG]P%[+PC86O@7\Y]=+_H/JIK?+ZV-7)LO]_?
YYL6.=63+KCM:*:!$@C! M* ZE1+GA1%CESRM+PAQ[Y-6]EV9^NL),FZ<1)6GD\UM1^Y#IL M/8Q&F9]'\& K9"O"CS;/+8G1Z
O;FHCOI?;/H@#BH'>KPN^.TVU9!&EZL'41 M=H< %WS]G4VCUN'U@ZT?^EVI^G\I)=F!_I1|\H O_B[^'!55:V6[U?K
MIU63+-5^4X56)+7+2TX*:ELKULZ?_5TKNBB!@?N MY_*G Z=!/#\]+>KN$FSQCIG'*-2W!Z4V>X-W=UW#(**,$Y@#F:H<8&&",H*A
M!IAE.M>4X,ROF8L/^,CNZ;U:;]A\F;1B)+4->O2=Y^!#]-LFV%@T^7FW-M?2E>T;0GR$C=Y${HB#6PP0=ZVDD- .0E'D>I4W9WS64@_!SL]';N/8A
MOM=(E_^Z[C;^O5\]-\>?]QOC2_F[/%MH'5>_94GR%]GB]5 M_6J=I3!/!2U3D+," JQR 7@N%1"*Y9PP3;E(O4:S#!1H[./U;,,JU:M7:"=C M?
>C<2+G7=]V3,_G#2MJ$)9ZN9/"C:(732X"0L9DWN.(3?[=_W:@YM]E%;SJ]@
MU@4J",A)6IC7;\8!RY0"M%\%)H@=6*^_KI]7:1CL>!QIAE#1<\HQ.I. ^^1R-&\DLGT*_)IV6RH[86ZK#<>"?7Z(1Z MG!Z-3FS8R=)
(!/L=/0WBIO=8*NS.TQU9#=+\X#AKV)U"FW&MS3MD,_^^?_?M M=FHNI$*XP""EJK"#"A#@K*"@P!KSHL@)T4Y#%9W01O;E.^Q]-^[;CJN/+;>8
M+1H'?FYX3_T.]V64[652)I3;%"5Y_%-)R^4/*?6J5K)LY\--\'_]&F_M822C6-J**(&8>;6R4@/*A+% 3C0K\XPC[92WUH.QE0%N88/M[S4Y[N8W0.5 MZW/6-
LCXSN@SR/9>WW-RTSNCU"G+._?1(6<%]\>GM7I0QJ*_JZ98ZO.]JFP_ MM(^+U8]_5O)>_8W-E_:77Y58L*J:Z[FH%U_U;-\[]G.68EE F@I0%@H#G$MJ
M(F"I !=%F4'&"TA^:"EC# &=OOB#2Q^M%-M-E K(ECP8X>S:DC65$+9T9;T5 M4ZB;53)?&F54M4E44\QVE2R;HN)Y4VBX M83^[?I*__;8YU?
FOXB8_*K#*.Z,=^>M_70*^^2-\$\Q7X*T>I_IV52/:,AQ MVP'Q72FOE>C7ML.I%36I9;U*ZN?9_>MKD:\25D^=O^MY.(&G=1&)C']\%T.N M-
S@/C$CGZ0/$F !^[_S*Q(V?S1OHOKZ9051WY@9MFW2&"L0R^[!&)3*N&$G M(.% T*(HJ,BS5'&7;+L/9.1P>P=KK=.WD7PO._V>+9;.?
D[*6UUG!^,B3Y^>O M,-?O^0GSMYV/Z+WU).,NHEQGN4Z?'9C[V*027"_WNY7^KIA-LY0W9G5M=Z]- M_&@^\&6U7'=_?
<>]>75GCS1G4*%,8LU!;E,%=D1U#GBN)$@UHYPQ31$D04F0 M0R6;,!MR*TP=W^Z+D_Q1RQ*:[CCXZ:C%1&_"N9^[B41W>(9C+&IBISH.EnMM
M+;BZJMQ_>7/Y%(ICMX_1M^ZIVZS9O0."3-#"E)TN!PN M:" E(2 (B4% M09 6]OO]#O7$'JEDKQUV=;SS(;W$=8M#1E3-
S_+W"'7/8C6E;*T;=7@GD(E[& M1!?ZU(F8(=2;LY.#&QAJW >*YF2M&2I$0"CI!Q/8(*0(A$ M0-&4Y8B)$]=.U:.7@$;V,0WTMDA@"YXTZ+Z3+L^0=?
G@,18%?@XC5/N <9?] MJ@V8>'GFQA,/O>Q7[WCNY87/AX4/7Y7MIZ#D;VR]-/?LZG-R2"13/ =EKNW4 M!H$
H8+;#LI89!GD"'OM=9R&&=E0.]"D0_5[\Y^AQNT%/UQA/[,\TG6$&HA^ MG2*]C\^ 3/K:[5?T]=OUPJ<#P_I';^3_4>^'WNBVEG%Y_WY5;;J9IC+-N()
MH4(##"4#G(@,$ @)A[G(,/*::=8'-G; O@=M(TMII[7.J^JY+OP55@+/>+V/ M.,?@/!(=GI'X*R::N;4=$^]IF?"/N1U4C!5@]T%-&TT[*T4.KM<$]HHQ0;>
M)MZ^?MX\K-;F# &'"EC# &=OOB#2Q^M%-M-E K(ECP8X>S:DC65

^[=2$@CF#E>T(_3 MI(_F>@/0>7T_LG35¥¥TGO6+@&30KF94;=^&\U*#*RZYAW-=O"?:$B'XA4T&P MV^>4'\#EOCO(/IVFO=J$\2+GH$KS>$)*\749X3%JYLP'BW)^G'FWI:JKVTK M],NMU<-!/3;VC85MX{1OAT0$0DO+.F 4P2Q\5N 2BQ"3UX($K>6.<^N?7Z??
M1X/*N*C(T@8NE"VCL5>;0'7=^./J)>\QP,H $G02C.P$?GP4EIHN$Z<5:[.4CK3VG6D M#PAHY('C^ C-X6QM !.WM?=I\;R#NG$E@:D;GR_X,WMU<_|
[G]W-HK-NV?'] MML?Q\\B-/IK+M#[J,97$ZNP@$E6ZRC \=#RCVT"$5"X(H4SME+,N]M&OMOMVI=L,A+
M6S9@2240LKQC(GO1S171>X=NS.-4X6W3&_=:M^?P8^\@F9Q&8BTHW:=EXLE1 MS:47X-#Q08_'EKQ\9]$$)1XWD41TG;V??-AKX&/W*8X5'TT.8W
#$'F<6_Q^_M_/1\LMD-'HWF9;C-TA,AN2#!DTTNC#$+KJ=1*#4!.XX$3G6;LVP)XF-O*X< MB(BGW?4Z$T\#Z%/M[/GC:92)(GXF)!(((J-
03NLR6A0161FZ95S[%VC&,Y^CI M%U>= F'[X\QQ4CD885>+N@<\2]-YI8OP,:\&#CDAK+1 &5[@"[7O4=4#"2I1 M$22WFE>_"!]3T:]O>DI,'2F!MI#T?
C:[3O'-]10/Q+)$9WE.%G_Y:?%D,7O[ M(TW#$$W*_7':H=7HP2B9RR007^(X&21/(EO##=&U R#[4]FO279R)'8GP09N MU2T[_$\WNDZ;-QA3H"PH#\
(S4Z;&0'!1:[ )SZ&U*:,;JF3%[$]GORU0#'"*TD MOR8>%IX]A&\OKT:3F[3/O]C2RGMA.,IH68"((D!YP(.0I6/"_M&A5H[,*2_TGM]Y6K
;A6E67C6G7K+@2B(A"QT,R]ZG M#O)5#R"TWY>T!N!:48[M@G5Y)A\%.1=QU47A+;(WI^\&G]G(!7;X9(Z4!:=
M/3RF%+/QG#'@B5B\:W'$J:MI=B.¥W5$<#(.¥(OVD8#/?]F'"#BVR+,Y-O[L?? MA_.+PF+D 6YO\^O"
(,L4LQ,"O"U%6XOFSUH8"$9KYFC*VM6N\#^"W'[G@YP2 MQJ>2:3M=5M9V_&VR)3EML6'_>,.?$K)^-IRGKVGZ?1C2\L1_26%R/EY\RN(&
M&VCMLS0T@\KH!0BM#(J#*\"#6LE "SB[7-CBZWE._@T]Z.@_]HZ,)K;_@]9=T MM;+%XMD8-S4ODY:?WGN#B&S/R@IP&;DNDK^W3[H06SN:?
+4PCT"TG6>VAXV9\\BF*R#@5RBVT*:8NZG!-S+F)E.+%7/[3R@*?Z_Q O9 MX8SO'3//IRY$IBE J03!(U?EY GA@.+)@=#G&&LMGEX?$+)O\2+5C6Q')D'
M\'8_O?OPZ>\=#2.Z^_23=8#3[T/DW*N;W]#-.>3]>C9H?GY^%^?#[ M<#Y,]QR@WN%6F05MO .;RSBOTLJ7Y:1]XK)*)TU9:GV-=G0;*NNI?VL(:\/ZQO
MS8-8> EDC\.PE!YLZ=MD7VY&;9FQ7*.)8"-R4T:P7$C(1D>.:374U6[@V\4^_M^LT:/C&*>P=""X?
ALD1U_KD0<6F5BK[3^="/TMELEN:S@6/2):\C>%/Z6,2, MISD)/-\F)L2C8494;_?P+$4]E[3VCIC'$*XGO@; N.5!'ITN;UC48#BQ()ST MX-"/ R99
M>SX/+',B*C3 %9$"1(X2O' 9>#3!""9C4(\Z]&TII'Y^G7YK())K!56V)-*#1 MWB1<.0R7!P.)HVB52"B]$$ H-%BL,QZXM(Y*GS*QM2_3]?7[K7-H!F5'BZ9O
MG?4168=\PLL^H0SG;W\4U9L&CJ.MBQX76$5="4TB+RAS8*0)TFE/^&,/9(NN MVOSY_98=-(.>6A+H&T0+/LU0>N\FT*]-
/LT/@MA2OWO8W7DK@F_NQNH5>I7'*PS(WFN-!9P*RC;@A9PAZ_30 28$'PWC2 MKO;;RPLD]5M]T!R$;PJP :6],&YWAE'9TJU9E*+QV6L+TKE4"H(">)
<"*)&9 MR&A=:U&[!GPK,?UF_#>'P3I';R=`]6F>R!WG5D4.=VR3G*C -8?(;)F#XQ0X M)Q6$H),37@85:Z-R=^IZ3NAO#J<=R;4!M?
ET9T]M^8$23,;$+03C\3 FR\%D M+X!F187TP;EA-Z1 CI66W8$NUMO$8_LP#F:A#(!N+ WTX!96 MR.K%TI)LA2_Q?94X
MM"=RZVM=3Z>WL2H*LK'3+2'Q!D%(,(%3Y,&;A,U*F461.W(IE4?=GJ-= R='XX688 !U48+Z3S:!!G5N*"Y)Q$4^) HZG?.;#R) M#_N(KM8Z.YT.
<<<(J&70W<73T]UY,H:EX)(%;H0I?2 $.)XH1&L\&J])*=)] M;_FMY+76E>FT$#Q27$TB\?5DO.!8:3?U^GHVQPU.;X_:S2#YX%0.'K)%%2^" MDV
4FK8Q),.5C)$^GMS9 1J?);&UOD@G0F0I]L?6=#MV=HP,>5"!96PC,EYTQ !9#9Q>R34SOE43=GM<$N+V8PU>$CEVK=Z# D M$BTY@QR$ J$-
!Y=*!IV.+F2JHR2URZ;VH:^Y!D;],,&'2JP!..Y>4C9@+GDJ MM0&:+2M5_GC. KK\T5B5&#$NJ/ZJE?L--Y^^O+0+H1T.QPD>M2[A6%YZ9MO>
MS;T1Z(@)*%U+2H/H -X3 A$/H6&>LZPZZ$^T)Y6-S$(J41%]+7$UH!]7/(.SF6B&NE[XVN_S]'39(E]-2Q. M.A),.V\B3[:$O$25/K\IC?
#G9^-8VNTL$GD'S'+',)6@&4-G*U*\/5(6D*RU-MT6@3 Z_=UW)WZIHLDC\9#NL(K?]GWPT'#+-<6TFRV.;E\AWSR 9HUA'LO09+B MJJE@P9?
AGT1FJ;+P@807FRAU15R3%F1MU#8AV88T;MEVBK-W*(^O;I1^=?/K MZ7!^@_M_/1F-4EB,>RJ- ^[O%I>-4C9R4)*CO20UVDM9&D!A.!Z3T-145[W[
MD]EO>L2I=7#'8FS #MV=HP,>5"!96PC,EYTQ !9#9Q>R34SOE43=GM<$N+V8PU>$CEVK=Z# D M$BTY@QR$ J$-
C!&URO"-L0R^45Q\%LS^5 MC0OQ(Y&?7DM<#>C']2O@]00/V'1>^OR\27X^()8YG3F:W"+)8G>C4D/',S'R.6QA!6!H AO]*GO.RJ_-L8I?8>?S!&[I5L
MW\VM?Q;C%_'71M>E__+Z1-%!=Z<; M:C(&< J4]PN-!L()EW2U\B^1!2EO*"-]"2I.>?E?8K"&.)C)V;Z,6>\^KDW@^O$P"J&(")$E,858D"G3
M$/#:";YV"OFAM#;IM7>F-4\AT*:@BUNZ'X&$-O[]<(8!DS)HZB3PZ-#-##2# M=T2#HR&ZF$-DG8%T.U5-.NM=P[&2D-H)%\]F/D,.?V6-_1X,1\CEG:
MCL#!TX*%Q)GX!-A:'WH#,81 8S9 MF"CC08G:0ZYWIZ[?FH<3P[ CH340HWR;AG':'_5K G9V4AF'2P,5QG,90PA!""042+7JG-# P,GF0
MF5*FG!7$-74F^C6ZVX3X7D(U!/W<^,:-X]?KRTLWO9GDK\/S M\3 /0TFM7#8%*+/#)Z-A*[;@XWM-I+QD&4JS68>H>5AC0^7>8.R)PKS6WF
MX+DJ3[2H!CU1#BPAQA#M%(^U2WZV4W-T!J;IN1NO9@&]GHQG^/%Q\TK;-Y3!JU&)#3HMA&*10%[DDUE)P.;@D',>
M_RIZS5SM:9:=:JCG05)U,/FDGVLS$*CF*]8?@8M7"BJDL^]N."KM!O)D6G(J M%V^'R_#8 6KVY0^M-?!V/^HKJ="UQ-(2OUUE_<]O[H>]@Z\U5EO"-5
7(XBD M)?C20EBQY)F6G#A2N]?^[M1U8($N,AXFT_FW-+U<(^3^U)! @R%@ P1 MH9A-"8@(T>I@A=6U0\$'D-EW+]=.\+6#
[5E5?.TJO7=N.%V.TOHUN=GU=&'9 M'Z+G-GY.)=7V.HV5M-G=0F^&LS";E+76?!MFM&',@#'4E05;5$JSC#C)G)-D0 MI-
>UW<3GZ#E68VWZ['MP2Q%RU *WJ 4>IF@BV%*[Y45TQB$'4JS]*O\L0?UJ MH6JX>*QWZ@FA70WS!IWF[Z]D +X?(\NN%VH4+96_I7C^\/7Q
+6S^X=7TD4' M[J;2@MJX^MF&U>_Q=(=3';4SI=#'ZNQ!9*O_""7PCT ]4R$$47_NR\'D'C\% M9^^EU_P9;J.//($-
>+^+7.;D1F\ARJ1\),YG5CMC\QAZ^U6.I\+DTS$Y)Y)P MNZIUO1/^ LPRR32237%]H4_0[']X@HQ5(FZB5,DD5ZS?#WTY/ M_SYB#4P\
[7Y520+M*I"_3B;Q[^%HY,I0R(;A0HT.W!*A5+>5;R":,;$H8[P+7/GJ3^![$7BL4MIIL?M#0EGB.G$)
M3%,!PED.)\+%E+'}1X<2VH_#>Q'8;^*JSML/59'7V.DWG;CA^Y4:E M+.WK14KS]_-T>5@8?]MGU8K>[T3KD3IMT0-EVTKW-
CGW2FF>2_/(JH/B,>*IS,9M:MV%O4JRES%EIL_!9LE! M>L=4E)G*6/VY?!\"CTXAV&6QM>=G9AA5.8)2HD0VM$=W0!((W ?/16*65L]: MW8O"?
I55=]AZDCO0G=S:56Z+ O52KXX++3,R#M%I&SZEDBI[B;Y*&FQ1'?U@ MF8^3^9K+3B/S 4UE3C1>9!)O16>R!9(4C50EIW/M(0;/4W2TRI7QTS?!7/#
M,C?%-*BMGG8FKE_-5!$S3[RM3L33KA;Z&SQ_E::? MIG$X=M.;Q, M#!QU:&PKCM==B#SGVB=S&RU'"%SH_^MRU]]TL?(S)@:91XRUKT850,H&+-&4J
MI""I]@S+K<3T]VZJX.!)P7$5QK>K6+ZD[VE\?9BC=O=O*ZF-S;14TA*K#U]U M*7PRY&PM48,RZS2#I(("88N3GUP"IC6EDG-"JW?IVY&TXYO$/+O,/;*-
TT)K M1L!+6E)&C 1+\9T(*5V|<^6)FF'NEA; MVJU5H+-6Y#GLBEVTIKI;-5&[!25D-I\MR/&%&G-N>5G?@,X(1::0 ZJ/ M>XGCE61X!{J6L+,)25)23""B1 M
VA&32J/P(35#K<=27+/T?'3X?-))N0)1=VNSER;%WQ8,N3]/Z^6#+F%HFK) MD*O/WQ#19,80;LK0[K"H2O"\U,,',-8%'TG0HKH#] PY%4:'/O[H>_CZQ#--
MCD"(@90R"0)&E9(L$Z0.WFL2.ACBO96>OI,AZV!BPRC0.A)H5X$6.DL2"TQF_,C1EXK@BN?83?'<-&1Y4X"\^_:^,&E: MPK'H%QE5>]UJD<$)$2
[K0.QB@52VU)]CIYVVR'L@8BG;W:5!-! Y[O?2K/> MM[/Y\!*-O=G Z,"(L1%BDN7] *U)@^8C^$S1]35)6U_;;G](0;\#$#H"S!%, M;@
B']/O:WR93L;X95ADY2WU^"_?;)+8RLCKG? /]#6_S,F5FN@QZ MX 9?(PW#Q58'(L5L7';@D^4EIQ@U-45US0WC>,GC,:&U4S">(:??KJK=&5-5 MV-
^N9_AB;Z5OY:?=](=:???IND1MVLGI>T4I%Y-W3D-.FH(@I23<$0_,N<< M34:,VD;LZ7!%0T7*5Z/TK*\YHYMAXI8[A5T8C1;RBB@@@M!@7;3
+7YM M C?V\=5X?';5T53W'1CK!'U/4K!.*]QV=>:FIDV']EG/JW#)E,=*L-G6PJI M$!GZD,66]QKO8&'!>.L@,\ZCUT(043MXWV6KJ?LS<;?
*LO84S\.'H?/#T>+\ MK1@?)XV_E#,Y13MET9WRT?%PAOGL=_#*$S(GL8S&A4@099#92N=IJCU.M^H&
M&FYEM0_NMBN^4PNY71VX<[.HPQ7CODNY,Y_F%VE:WDBGZ2*-9PM>E8?PPJ)'5U;D M06FN/4B9+%Y9,H C*"-&!356C/UPT=3PV"F*+7IC, MA@4?
=Z;?_?:S$%X(CH(@A( 0FH!#:8 RA&5FLA.D]N"XREOHJZ6[ ^-P>APT M< P^Y8S.2XF5+[V8Q_Z)4(8+*B"X\@ <@P13AM1GP8D+1EHG:S^0/D]1OX]6
M?8&THI2:PMR:P_QH2SHYF[*Q8 TS(^0UQ3$VP 25BA(IT&GN#'A;R>KW7:M_
M]-615[N!C+6VKH>'*IY^2/VFLQT_7VUK,TJEUD%D@RY0B=M3[L%D+H%]*E(B MGA%1V_;OL/7L_=5_M\CKZ^GT-B"^WK!+X>XX!>991G#S#):[B
RP,2N>G#*U MIP3L2EO_CTTUL++=**LHF7;5SC/-7@]?0R]_:/>M:CM44_LU%:6!,]>RA$R# MQ^O/$[#6)
<@IB$"5S5;43H\Y:>/U(IV']1L5V"2;0!>WWMR6LX'L[3!]1 -Q_UM?9/67E" M,@5/F05!*%J&Z'J#DC%K$3(+JKLK2= M'M8GEWF[IN2V+L='9&X^_XD=-
P;OP(+OLPH$QO MK930FN:76'>2]N""?IY,K7.+\FV2@4.B[3_;X665UWT XFD.12 JFH!1%0!N.8 M 1G1X@B(7?K7\8O4]5R*_!JA/]8*5661T-
7ZZ=\%L+T.L7M84"!BE(IXB"A M=0#"X!X]HI@]*IPUU"%-:N>,[$Y=/]9>]XCK2#[M7G*+-MI'I)+YRCFUV^CI
MMAE]#%Y(AK+TG].6<27V)0D!1[.67'NM7>V81C?-Z->?8/U\[6UC/5=<2&$\ M1>_#E4DM91QU!*5[,=/42>(-ZRX9=AM5?2=6'8V*Y\["*PBBJ;OK5S=?
U3\\ MR@_.:\3]4D#8Q&4H)%=R224(H2/#B#[$L\)*58XLEUE\;Q&XU]IRUU"+L.A-3N M+?:T=_?A=]K6S^JLSWB']JT+G:.)1V#9E"&*TGN'HX]N#?&031
B12Y8K&YC M=MMM?-U^.R#SSAJC.'4!O$(#4FAAP>5$(40F5"0LY1VJNZV=JZE=]"J3@!X;*4-=2\X.WGK4L!BX M4Y[:VF,EN^I@?
G\N]H0JJ+"V3B^&8ZN\;P\,@4]89,D@=._?1F1A->]59P M$\V%91)ZS-T5 .]%;J/=S_?!T'9EUIW0FO(1SL;S82Q;0A5]7R_]H\>
\LPSJ0)R7986I,AUJ['%Q((2FBK#>/6I(-5WT:^?T3&B M>Q%UNS?V;?/]PR_H1Y]0>2A A]?OKFW=$7=H^\4(F7 !0I
(UFL)#OW[^M>@]XGEBRI5ZJFZ=& M'!GDV_9YG4ZZZ/)QZ[AY LKJZ$AYRW2)XQ]"@U':H@WFG=)99QIJ.XC]SKM8
M<\H0,Y.;A.;K]/NP/"IODMS9:/&1JWLC3,['PW\B46DZG"PI7;-DJ21*;@,N MJ-(;#WTW(TP&O%=88)XZFKM[8ZN\F3_TC(Q],/V,S]XC/)JR+^XY_5 6R.UA
M0'$LPL%GX_CH)[^-ARB394W=S6-;*S"M.2T5EC:!((R"S?B5M(X;]$$#"QL IZYSP);VN5$,+:\$D0T%J2[DQJ6075-[F5F*;'3RQ#Q;>-'BO
MPOL_*:WXH'TT'OO2-[HGM;@3*?WIQ?TYU;UBI%1P.ST!ZG@9.53=M$S($(02 M/B&4J?_C*.8GG?@F*#"*O9AQK7Y2E9E7B
M/BAXL7W_DQOP*W:U(,D;.;LQW VR%EDRBV%0!5:O%SC-DP,B[ "=%I+(S&JW MAWB.GGYA5$/>CQ\":C&_*2#=!J*_X;],
[ETP_$@AI+/211P7A(\I40F)627 MHC98QQ.1L?:HP^?HZ3O1NY;4M\+I2!$T *=WDVE"F^+MCW#AQN<)O_W=3>.O MJ9BA R=%]Y:/("&X94**\\Z"1,=
<,T-34K0RG)ZCIQ4X'2OU24OO[FJU"'T8"E]PGX,@,$,8[*%,*("F3@R.>$UG;"MQ,2=\U !U! MJ +;&P#/JA_;FS3#X[ 42E'5*F6IRXPI;LL,,Z(-
F!P9*!=I2"IDH6OW8=E, M2;_@Z< NJL#P)F&S.E%!1AJ##:"BDV5NN05/3 +'"0F.*NM!I8>Y;,3T>W75 MD/.+T#F Z0V Y^-D'%=
[2+=W;O1),8.GB2GI08A@P&LN +U4(8/@-+#:5O0& M,EJ#S"'R?1S=/)+9#>#ES1W]9[,5C^Z]B]66RCP\$Y6 Y#B>]\PUJN1L0?,8
MJ:+$)UG[PMJ!K'YOKT[P5%L8#>#KR2W_ZJ;8B MJK8EV5)L(Q%ED55*\9'!; MO.IQ&T)3H6P'D[^WD=-OLZ0.K*%;K&\116M^AM*99\+0"PCH8@B9 N
.(D1C MN<2 -+KZ;,!GR&DLUGBHR%^,61_& Q:@M,H^?;*EE7[%]YMG83THHY!-2N") MDPP=V&R83 +/H;G=;P,,D[G_;]B*;&M-51'"@17D>
(HP%XK1ZX9U]22,/O MY?2M=*\J6;V)>-#!J643,H]^ZZ(O,;%*<$%KZZIMM+0&IV,D/NF_3W":#;= M#QX6]"Q.F# ^XKTM01MDA*"+5OQATX&'OSX-
>#@=_>@V;QROT-9 M*EYG%1C;,RP^NLM%%/Z>U/;P.C$!G0TOE0 9;JA.+ R*.*;/'60AH0@1U4RSR M!71L): ?25)#HI/:
[,T1(XM>F._*N^$M/VZC6TQPQ3(%E43I BT)^.!P$U0$ M*2,E1#W*'-K2;7?#A_-3Y%NEO^O1^XL4=B?]HJO4M_[.O:[Y>I3)#=<7[S
MMX1_7@3DXX@J,/(!MS5)Q:VA^$X+;IG#XQ67C*!P$Z\>/76@[,F@N>< M2Q%0\J+SX-H=-3NA1]5&SRG#:HL?9R4S;C1V67QP0?":9(R31!I M>1P1.2-
G" 6C1;8I4<6K!]*VT=)8Q.-_66]-,3Z"\4T!Z&D_K Z(I/HC> MX@:T!,K+PT7("JS6!K2/1!@;D_/ULR5>HJJQ5+_;H*HBC((A]3U-_;2K2^YS MFI8?N/-
$!TX[$GF((,N 2[RE%3C')"1+C6$F4:[:!1FU9E!US:&*$YKOEO&W,X;F-_>$WA4L6DT4ZD$.G#H-_M GT&\-0)($E[%[,@Z%14UAR[4W?\I>SG:Y]Z*
[9W2[$M[=]H@]{6[0R2%07! M!)Y",E0;PV,PK'.S^:!W(ZG]]7I-UQ5/ V;@N^'8C4N,-LLHB?UOB5H'_#<#HV]2-
M9[F\!HWCLCW7<'R^F,WZ>'>SDG4UV_Q7]P"15-FAV9,@BQS0P\)6K(\4]'?2 M"]N\#[6S_&O2WR]@P!]THAT&T!VL8EN"R*81!NY-("G+$+I&
HV*P[1);PV M=!:I>H^=^]7[155_"'CLU!PFC@:.],[__%M>)G>I*O);'CWU*6]S$(19(9) MZ(B5=FHF4@<*KQ#BA,F'U@:59DKZ#:PT [_*8FH
;+].QNGF5S?]1Y]_NQ[' MVUTPB3>_"Q0281PM%>7 ,*7P*ZN89L1X6]MWV$Q)OP&79L!604P-@&UM!L4C M^_C>5DZM/]SV7]UT:ER8'0@DB2%-
H,P:$)8#F:1KLK0'#96&29KAZ'W MI;'GP7+=P>5Q#G&7LCLS]?XZG M_A\#;G6TC'#@"?C%&9I*XT7&;^*T@-V-\'Z5:C,H[D#*[.O=K9LN-MTR+O-
RTB9]$*!CZ6=@.94=PO]\A[I345GJ(MU BT'Q#>$KRC;/K0/E_(1[%IG MA9!.P'V_Y8<,&%B#1S90!8S',F'&%]_=,DB,,9$S45EUC=]MM/5;'MD?1*O(
MJHUD"C>[0&?UT0/MV?RUFTYOT'E=I(P,F)>9&:__UT=^"2$UPZ)9XLT)*V@Y"5!U%HX3I3CU<,5 M:\OWFY!Z.B
=RO%VV\N_F(E2HW'_HN<*I_F),W>]\B"H,1:1'"BB5@*PD0* M+G@'-$;%J)",IMHWQ>FR:.Y76DX^O^W!.7"6><6^3!R9*TELHQB<:G*5@@_H>_MA)8R=
[;KA[3\8?)E]D'*=C5VA"#:U6EWN;J_)E>&/96-WB?4G/TG^.7J.S@>[_>RE(,XV"N+3^(IY^_L? M)^CKK\MB^4KAC?<^L](:.P803.LR1EQ!0&M&DZS0
:O=X[4:\3YG\-3"VY-D MLUZ$VT"$\|FCKV[6M,Z[:ZOZS0-.XL$*1ML"IPB)P7#VXIC_YF R1]97*_MWHO:66<[D-4(S@\+F&VPK22]E@"Y:4-W"7D8&E?
20X@DX4G7!GPIFQ762$$E M=Z({0&XG]Q% UH+"-]A5DDNC4)O=G=C;1DW,Z\AEF;(B2E&M*-/1F05*M"'"; M&Q%$[;]*7>AJ!&RUP+
#V(Z23$MH>W5S]^7?AFF*1%WOWH;]Y^[:6#%M"YOH>[]_U;FV?M&< ME4)R)=_3"@Y&E3P\Q;TF2EFG3W'Y;B6P$-
MU3S1A%.T)K3#K21+P&I"P.BH4D3;F.C:/<&?(;>1R[87ID'-64%J[LN"9>M',\K$:L> J2*D!L%6MTW"E>XHK M8_NLU""BP@/,>

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})DVR0HBJS<[V86N?I,_'0.NNF": MOR?AAXZK2@ MW. AD8M^1'@=*&' "&D]95(X5[\C\4,.^HWDG Q$!S"\ BLQ/>NA;DVM*A)HH(O2FD/T'*^DU3(!0D#) M,AZ,$E."E@YTF1WDB.6KS>E7?EM9"#]:6DEBAK'T]YJW@]KA'2KV7?A<2WWI.'LK\!#-T%V!]GV,!R MK6CDMO093<6@P!TQSU"/%\Y9DT/LK$'_\Z3U]^-.@+,N1%3M;CU)E7N-9AT[ M?6Z'->R1!\O2\5I'2_*_3R?456@_+!Q45O9E? YO2H&+NC1/EIHEBBN<\0+ VEO'E&8QC&G3.U@=MHLN=*?9_MF>*QO1!R5/'8/N)J"8L;JDF8H1G_E\!S6:I4- <3$@6\0 QSRO)8/:!V;'U/ M(\5C>X%@C_J>?232 +C*.]BC'"^6-5-)E1FD9;BZSQP\P1U0X{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|*O32J:/#B7SCA3PI7T'%'CJ2KQ2O)L9 ,,!.=X-)" MS /4P?V+)/SM@YSG$O[VT4,'=LLC+W"@E)-^V1)?GLI=[- H$L1S97!I#,**@A3-I-01K.1 *K>9*I M0.NWI1?UIKV7GG=]T]Y'Z!V YZ%G5@79&!$+RY;XT-Q)%@+] AFU=\K&&%M/ MD'PY;]I[Z7>'-^U]A-T!7I[,D-4998!GBQ\5Y=3<^+K_CO+:#G.-WG"ZJ%DAB])EW M,)_29Q9580\NM?P.R_]U >>K]Q=8W'JF.?$KP>GY&N_%8&0==O!Z !:=YXDS MZX!,W& ($"QC)29:\R$1NL\'6<8@N7@]N++T]V5Y?;BCXC.O+Q|S'=:7=\A69A\#';,>Q&DRV61 OXBB?+%TM(.@ Z@^PL77O0^)HZ"R)BB=R[T5DP)>6F W1\)# !\5':F6#O!UTVPDAK0&8;(HQZR8M1R8]LXQVI +6F$VU@P_S>C%W:8*:0K<#X0%9(NTB.5W %TIX>]UZ*M3#U8Y/$:RVQ^H\QC+?A7A4CZ"G^= M\52"#3K5%"EB.@O/O"*!N]J+QHGBVN=1-V:AE].V'A-:#GYH1W[*W-!+.FZAY?X2'-<*G M^*V^&W:V.GW5F'Y6/EXL%TOZUZM4V^V'3EUZMBLY(U;/'22Q#IYPDW31U;Z4 M7]&KYSC4$G5/H$]%B!JT"#JT(# +6C@!((- N'28;CIL.S:$!\/SH[,MQT=&!@_!8 MCTDG$76R3-6).!J"(@]=8;:AL =YQ9;)_F^]&*YO?2\;{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}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~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

M6]!BS0LN[U'1%U@.T>U=N!PGZ Z@\N\PG]2#]C,LU[M':L-CC(ZNSUKV5XQF MP49)6T@HQ4/QR4-CH-REH2?
OZ/A;Z"@)=X:0S9;1$50J6C$Z6VG+H+',1V^9 M"F"E5P$3;YV/_D&8V%;YU76;61%1VDD';>@>6/D[$A:/W Z! &SX=71 GYT8POM
Y.A]K:UC./>2+2CT72'A'$=IL:H.4:\ M(Z)C,5^>?:XU/NO*5>!<:&&8U9HS#28RB(E^D;I8]TN0;B=,T%=OX(%^=XV% M6POV%(D[W%@Y7(8]*'Z+UV2%-
='7U&8B.Y//YYVC&!G&A)(A;?"=,FUV4?V8 ME\81RKJK[@,D-[+" YA,)S\N?FP(-Q]BUW0P>3!T@24H+%H5ZG0KJ:0P6=Q] M0CQ(Y.
<6'5GIAZALUD)^8RL>_KI!>.8V!!4TLZ'ZVI%SY@6OA5P.@PZU;KS% M,7]KT7$N^V:*/UA^'5A^MQ\--PY7":! ,,[I\-,^DJ53XS:V]J?@V20A6^=5
MW]>BIY>6XT.51TJY.YQL;&)PF2B5@6LJ@W522F-E0SF2&(Q&TLRO/FC<,>H&-< M#_-8W3X)E0.$W0%8GDY)L#80.U$P4:?SZE@2BN:N6Q4S,(;P-
;GR_$Y(R>" MSR'ZG@TE_ Z0]%@1C*%2L$ M'>#!JN9!KEWHZBE-]T //&8UT0;G2)LXPB\GLWGLS_K 0P_Z6^6ES4:++.R MM;M^JD7B!DEX)C
'RDEE@PRR=<_O?>CK*3EE.,0UT4X'R+LM+^(.-ZTM'&CN M(!M6G*_M2KTFS],%QFNUJ:U5Q*;],:)Z':>GIH;D-HI(O0/T/+0S/F,U.FE+ MW-
\;64N9DE=.,"S(_=7W,"LBKX5B[5BK,OODHAOTH[.F58+BS]Y&&.L#?;8F] MAL5D\85H@?QQ>O/139Q9+J(-QC 4B9@#X9F/)3.!DJ<,7!BN!CW-']>MI]C4
M$*=;(ZV,G3!^FZFWF.9U\O#OTT?9,TO>Z@(0Z^8IM*%T#=K7U@S<>T4'>K%^ MMS*6O9?
NR8I\&#(G$'UWQ]AV+OHJ"6196S614Y.L@W522F-E0SF2&(Q&TLRO/FC<,>H&-< M#_-8W3X)E0.$W0%8GDY)L#80.U$P4:?SZE@2BN:N6Q4S,(;P-

B$*$LDP7X_HA6!3+39V*)T+1<+(NM X2VD@^_MK;ON"=\3(&$X_OT&__*)$?IXL1N>CU@HK+'<<^TIF#!KZ55S-_M;F>KCR.>M>[SM2Z^_\[N/]>[9RO/H?+M,FB6$^9LNEARQH/;7+U6$K)3#+3C## M+5G1.K5L)OQ9GZ@.P>SN$]53FK^#N'PC^=VEWV"9LMQ[T-QR4 %UO4_IP%?B M)49*LMSZW/2! +V$P:_M3,EY03FNZQ1T_SS:H'6DLK];D[J.L8YIP7T$K![[RJEMW`;GPKK?OWG;W>S M(5.RH=X]M:S.6Q/"0R!KH:2DQ+1AD6%KP#XKT.1N=7*\?'ZWN_M4NY]VDO>>%X[?=`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|K0GN7P$F.6EMBR/;R;4UY8<_@Z/B0_/APS?<ERW* M(W';;!@85R16OCA;)!;.V^QYBEEXO19 M12RY=2S$YMK+KAC4F09!.2>N2;LUX1_0H#*I368B M@=^A,L-H7R(KE)!=4M%05H+OQ:%S? C2R!QO^8/UU$(\V.(/F/J+*20,)65L# MK00LKV"CIP)YF7/SV27FV,O5;0/Q8(4]=>#U]X,2C= MKMJR@95WG%W0)1(Z>#SL=:_]\\7\MNQ_VKB"ZXMZY_NO?Z\-'S\O5O^F MU?WM|TLG0A:A3BJJ\7R^VOZOMX2@!SD$#%.1!9RM(;Z:'O.R EM";"R\7.@F4(BA-(M[A@E+/*EUHT[7TK;L^1:RHBI.*W;J4 B04@HP$1$KZ1D:K\R][>VYQ$Q.U[; M\Q#S=Q!S/>R&9)KY;+0#7HO62FI?DRL-66>7O$.E6.OZTQ?9]CP(!,^V/0^Q M2 =P&J7/0B ARS8 BZ%L;&8]H$X$GJ{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r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|!L'K*=9=+D M'+X;-LO\R<#_!BZTQJH7UDDP:V^L6]"^.?HI;*>Z('*E1B0'"X/5.P+RC9 M0W"A(#@N./C/_'Z>$>C/1L'\$/U-E883D-?_WP#^=;3CO09E!(550!MONGG[ MGBH"-EKJL-B(34E>,Q>(%#*P@4!^PW'L_+CJFQ#7[IGBD<>&1"LS='2TR+/W MHK.ES.@"B('9=B(A<6 CKBD!$*Q2F$Q;WS8>[+THLO'\=FCOP2ERB[S1@=LI M9#L)YR>MPCKQ)*LJHG1$^*Z7,FK]B6 ;1,DE;4V,T+KM# Q)GH2T M].XIA$^VE"?25Y1]V$BVQB3 /-DN;-*R=C2>?SE%N:BUG(U5%52'3J"'17W:1"=S0^/4NC]PQ:S_CA;?]<-'N?U!+ M P04 "/&=9_'2JF=L' "S)P $P &IA>GIQ,S(P,C1E>#,Q,BYH M=&W=6EUOV[@2?;^_@C?!['.: [=B.TR2.&Z#;ID6%]W=HMA]7% B83>A1"U) MV7%__3U#RE^QSU7#%BQ!6>LE)ALXN'M#_9"D>(62=0: @"B 5K"<"[8DW*7LTR;J9NC MU,JQB M")-E"H]'[F6(W WC5@:,(.8JT9)BR22B8SEB>|W3L]DM&*WJF( M3_%14:E:1I"2?D;>!LK6!,@Q$\[R/:$A0S@\%WBXH/;\/TD&( MQM[ E+_<(YCV!^2'=])A.X)PA:SV=2RU*.&FO':[=Z',ETC@HADIYE)36R@ M04V4"[0'*5D&/534+PESE72MU#P K4FF2["T&D*F1@7RA"W.:"7"GMC5B5-" M<:MH BJF_)&2M)4.TK#86FZD+,#21HG81!VPZ%3A3I3I;7FQ.V85C!BF<[1 M(Q8'JS4-_DHD"8)^T5^*G>EVWX&<[ V0+SJOSC9QO#-C;U=.I,X=@$Z5)2&86S%'$_"M>(+=KI]1AM\V+*VM +R J;@LUD17*M.0 M.^Z:"56UK8!I%RJ2-#56! -"C3J6)0H-#6BC15:T9D@$]7>$+]:6JD#?SP:MZ=X >,'$UQ.NZT!7%%Z99:@2U02!<5NJO45!L0/QOL2M!6 +#]".ETL,Q-3 M^X86Y!FC.8F*FCSMW91NH64K]!Y\E93039K6EF*_DCVW."V,\WA/YZ/0Y5(H^CL>\K"C![ID #%( M[)YT8SCV3#*<&]"10EDO['H9K7'1B&[L(ZCF/7&MND7&#R_IL+)0WDOYA;20&-04U"X4[ M*CH!G<+ CCL?_5%+/%Z'\NU8P/RRX MND5#<0\<.I1D&_V2?&88PNY!;@&<<<$K>(*P5T[ J M)T9/).7BDH^;PW[;,+0L*FUF$JW3W$1.YFOX!=Z>I%#Y9Q+7-Q'>@Q_&G_X+ MY\43$W-(O2,?-KQ-:X)U*FT;IFI>,3F<_W&)%MI/ANJ.HP8.ETVNA+CO2F" M&R>4JU'D-1_1P*+S' [!W^(VDL_F[<3/DWN6A1^"_2PX\V,G;.X@V M1!=V:Q4\1T?1;.ZR+T0M.OP[++KSKUT4"B'8]"_RT/6=3&LZ&&)_8+?$?K.H M"*GV"<76VUS)C+U?Y-9?XY:*^CT4Q"__KJV"$,OCD!VVY)[U*V:5<>&#ZC!^ M-)C(C4MGRV %[>777B"B-5^L\M7[JDUQ_'2W'&XK/<_4$L#!!0 ( \M9UEW8LVK: 8 ,L: 3 ;F%Z>G$S,C R-&5X,S(Q+FAT;>U9ZV_;-A#_ MOK^"<[#62Q'DIWXV0"9TP(MAC9-TO5C08E41%06-9**X_SUNR,EQX^X<;<$ M*;KY@V&+Y#U^[^#=:9R:.78\3CEEQ[^,?_4\&,E%KD5^0SMX_HK\;QJUT06]40_F$O9CW:#:(PZ?;\7L1[O'\416&?1;UNGWT)&G 4MKLSVLPS_JHQ M%;F7CF4FU7#/MY\1KG@)G8IL/GQY*:9U\(JR)&U\D.2CJIA1$23,DS:L0U M'R%47L>>ON;*B)AF%6(1U1P)-(Z;P?X&XD\-9'==_"_$(.]*I4L*?(TD)N5$ M\;]*H;@-2,T-2:0R*1$Y.2\S3H(.]8)N,]HG,K':+WA<*@!']]$Z<.2/@LZA MC[0F*2W VDK.4JBF->6GMJ4E11IF( M22:FEG4LIP7-YRLJ3MRS5>W.4I&)@OS1)N]DFFN9MY:8_@DLR9GB6C"'$'_<[ MN=Z(G.:QH-FR7,BJXM$BG,8I2;GBT9S$Z'4)FL2DU+1JRT9<6[ND0I.ON9QE MG%WQ%WN'_=%F]#^R+ZY'TH8KVIAV%MHE$UG?+L!P<%%X&4^0H@TXFYY$CO-MO:!?/"UNO5^5H/TD.6DG[JO !!;8QO'EG;>@1P:]D28?2ZH@JK(Y,><%Q#F1-M.7DCU90$OO<1(]_Z30%"2$9<#%]PB,-IQ)4S5L=OV?O8.MDL%>"$!OUKXEPP MIAAY!!Y08\!#@0#%1+%T\2Q'S)GE!&'EQ+F+G*3,0$@,L@S=>B9,NIZL-+KVM6J@W*>0IM?;TL,D6V6LU"QT.1AAS/X4#AC^D XHB:!>1#M&\+]}$LW >=D(NA(4"3 LK>#Q9Y$B@$S.R=;#,H["HSYQX2 M7-DRUVOYL[VKS1M;J[RM)=,S.< IH.22.WDOKVW(DIX+UB=/]X-'3O?6?|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end XML 90 jazz-20240930_htm.xml IDEA: XBRL DOCUMENT 0001232524 2024-01-01 2024-09-30 0001232524 2024-10-31 0001232524 2024-09-30 0001232524 2023-12-31 0001232524 jazz:ProductAndServicesProductSalesNetOfDeductionsMember 2024-07-01 2024-09-30 0001232524 jazz:ProductAndServicesProductSalesNetOfDeductionsMember 2023-07-01 2023-09-30 0001232524 jazz:ProductAndServicesProductSalesNetOfDeductionsMember 2024-01-01 2024-09-30 0001232524 jazz:ProductAndServicesProductSalesNetOfDeductionsMember 2023-01-01 2023-09-30 0001232524 jazz:ProductAndServicesRoyaltiesAndContractRevenueMember 2024-07-01 2024-09-30 0001232524 jazz:ProductAndServicesRoyaltiesAndContractRevenueMember 2023-07-01 2023-09-30 0001232524 jazz:ProductAndServicesRoyaltiesAndContractRevenueMember 2024-01-01 2024-09-30 0001232524 jazz:ProductAndServicesRoyaltiesAndContractRevenueMember 2023-01-01 2023-09-30 0001232524 2024-07-01 2024-09-30 0001232524 2023-07-01 2023-09-30 0001232524 2023-01-01 2023-09-30 0001232524 us-gaap:CommonStockMember 2023-12-31 0001232524 jazz:EuroDeferredSharesMember 2023-12-31 0001232524 jazz:CapitalRedemptionReserveMember 2023-12-31 0001232524 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001232524 us-gaap:RetainedEarningsMember 2023-12-31 0001232524 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001232524 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001232524 2024-01-01 2024-03-31 0001232524 jazz:PerformanceBasedRestrictedStockUnitsRSUsMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001232524 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001232524 us-gaap:CommonStockMember 2024-03-31 0001232524 jazz:EuroDeferredSharesMember 2024-03-31 0001232524 jazz:CapitalRedemptionReserveMember 2024-03-31 0001232524 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001232524 us-gaap:RetainedEarningsMember 2024-03-31 0001232524 2024-

*03-31 0001232524 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001232524 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001232524 2024-04-01 2024-06-30 0001232524 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001232524 us-gaap:CommonStockMember 2024-06-30 0001232524 jazz:EuroDeferredSharesMember 2024-06-30 0001232524 jazz:CapitalRedemptionReserveMember 2024-06-30 0001232524 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001232524 us-gaap:RetainedEarningsMember 2024-06-30 0001232524 2024-06-30 0001232524 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001232524 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001232524 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001232524 us-gaap:CommonStockMember 2024-09-30 0001232524 jazz:EuroDeferredSharesMember 2024-09-30 0001232524 jazz:CapitalRedemptionReserveMember 2024-09-30 0001232524 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001232524 us-gaap:RetainedEarningsMember 2024-09-30 0001232524 us-gaap:CommonStockMember 2022-12-31 0001232524 jazz:EuroDeferredSharesMember 2022-12-31 0001232524 jazz:CapitalRedemptionReserveMember 2022-12-31 0001232524 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001232524 us-gaap:RetainedEarningsMember 2022-12-31 0001232524 2022-12-31 0001232524 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001232524 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001232524 2023-01-01 2023-03-31 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001232524 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001232524 us-gaap:CommonStockMember 2023-03-31 0001232524 jazz:EuroDeferredSharesMember 2023-03-31 0001232524 jazz:CapitalRedemptionReserveMember 2023-03-31 0001232524 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001232524 us-gaap:RetainedEarningsMember 2023-03-31 0001232524 2023-03-31 0001232524 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001232524 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001232524 2023-04-01 2023-06-30 0001232524 jazz:CapitalRedemptionReserveMember 2023-04-01 2023-06-30 0001232524 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001232524 us-gaap:CommonStockMember 2023-06-30 0001232524 jazz:EuroDeferredSharesMember 2023-06-30 0001232524 jazz:CapitalRedemptionReserveMember 2023-06-30 0001232524 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001232524 us-gaap:RetainedEarningsMember 2023-06-30 0001232524 2023-06-30 0001232524 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001232524 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001232524 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001232524 us-gaap:CommonStockMember 2023-09-30 0001232524 jazz:EuroDeferredSharesMember 2023-09-30 0001232524 jazz:CapitalRedemptionReserveMember 2023-09-30 0001232524 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001232524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001232524 us-gaap:RetainedEarningsMember 2023-09-30 0001232524 2023-09-30 0001232524 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-09-30 0001232524 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001232524 jazz:FiveCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001232524 jazz:ExpressScriptsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001232524 jazz:ASDSpecialtyHealthcareLLCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001232524 jazz:McKessonCorporationMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001232524 jazz:FiveCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001232524 jazz:ExpressScriptsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001232524 jazz:ASDSpecialtyHealthcareLLCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001232524 jazz:McKessonCorporationMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001232524 us-gaap:CashMember 2024-09-30 0001232524 us-gaap:BankTimeDepositsMember 2024-09-30 0001232524 us-gaap:MoneyMarketFundsMember 2024-09-30 0001232524 us-gaap:CashMember 2023-12-31 0001232524 us-gaap:BankTimeDepositsMember 2023-12-31 0001232524 us-gaap:MoneyMarketFundsMember 2023-12-31 0001232524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001232524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001232524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001232524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001232524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001232524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001232524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2024-09-30 0001232524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2024-09-30 0001232524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2024-09-30 0001232524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2023-12-31 0001232524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2023-12-31 0001232524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2023-12-31 0001232524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2024-09-30 0001232524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2024-09-30 0001232524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2024-09-30 0001232524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2023-12-31 0001232524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2023-12-31 0001232524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2023-12-31 0001232524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateContractMember 2024-09-30 0001232524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateContractMember 2024-09-30 0001232524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateContractMember 2024-09-30 0001232524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateContractMember 2023-12-31 0001232524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateContractMember 2023-12-31 0001232524 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateContractMember 2023-12-31 0001232524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001232524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001232524 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001232524 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001232524 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001232524 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001232524 jazz:ExchangeableSeniorNotesDue2026Member us-gaap:ConvertibleDebtMember 2024-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2030Member us-gaap:ConvertibleDebtMember 2024-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2026Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2024-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2030Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2024-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2024-09-30 0001232524 jazz:SeniorNotesDue2029Member jazz:SeniorSecuredDebtMember jazz:JazzSecuritiesDesignatedActivityCompanyMember 2024-09-30 0001232524 jazz:TwoThousandTwentyOneCreditAgreementDollarTermLoanMember jazz:TermLoanMember 2024-01-01 2024-09-30 0001232524 jazz:SeniorNotesDue2029Member us-gaap:FairValueInputsLevel2Member jazz:SeniorSecuredDebtMember jazz:JazzSecuritiesDesignatedActivityCompanyMember 2024-09-30 0001232524 jazz:TwoThousandTwentyOneCreditAgreementDollarTermLoanMember us-gaap:FairValueInputsLevel2Member jazz:TermLoanMember 2024-09-30 0001232524 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-12-31 0001232524 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-07-01 2024-09-30 0001232524 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-07-01 2023-09-30 0001232524 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-01-01 2024-09-30 0001232524 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-01-01 2023-09-30 0001232524 jazz:TermLoanMember 2024-09-30 0001232524 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2024-07-01 2024-09-30 0001232524 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2023-07-01 2023-09-30 0001232524 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2024-01-01 2024-09-30 0001232524 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2023-01-01 2023-09-30 0001232524 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001232524 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001232524 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-09-30 0001232524 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-12-31 0001232524 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001232524 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001232524 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30*

0001232524 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001232524 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-09-30 0001232524 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-12-31 0001232524 srt:ProFormaMember 2024-09-30 0001232524 srt:ProFormaMember 2023-12-31 0001232524 jazz:GWPharmaceuticalsPlcMember 2024-09-30 0001232524 jazz:GWPharmaceuticalsPlcMember 2023-12-31 0001232524 us-gaap:DevelopedTechnologyRightsMember 2024-01-01 2024-09-30 0001232524 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0001232524 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001232524 jazz:ManufacturingContractsMember 2024-09-30 0001232524 jazz:ManufacturingContractsMember 2023-12-31 0001232524 us-gaap:TrademarksMember 2024-09-30 0001232524 us-gaap:TrademarksMember 2023-12-31 0001232524 jazz:ManufacturingContractsMember 2024-01-01 2024-09-30 0001232524 us-gaap:TrademarksMember 2024-01-01 2024-09-30 0001232524 us-gaap:MachineryAndEquipmentMember 2024-09-30 0001232524 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001232524 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001232524 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001232524 us-gaap:LandAndBuildingMember 2024-09-30 0001232524 us-gaap:LandAndBuildingMember 2023-12-31 0001232524 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-09-30 0001232524 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0001232524 us-gaap:ConstructionInProgressMember 2024-09-30 0001232524 us-gaap:ConstructionInProgressMember 2023-12-31 0001232524 us-gaap:ComputerEquipmentMember 2024-09-30 0001232524 us-gaap:ComputerEquipmentMember 2023-12-31 0001232524 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001232524 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001232524 jazz:ExchangeableSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2023-12-31 0001232524 jazz:ExchangeableSeniorNotesDue2026Member us-gaap:ConvertibleDebtMember 2023-12-31 0001232524 jazz:ExchangeableSeniorNotesDue2030Member us-gaap:ConvertibleDebtMember 2023-12-31 0001232524 jazz:SeniorNotesDue2029Member us-gaap:ConvertibleDebtMember 2024-09-30 0001232524 jazz:SeniorNotesDue2029Member us-gaap:ConvertibleDebtMember 2023-12-31 0001232524 jazz:TermLoanMember 2023-12-31 0001232524 jazz:TwoThousandTwentyOneCreditAgreementDollarTermLoanMember us-gaap:LineOfCreditMember 2021-05-05 2021-05-05 0001232524 jazz:TwoThousandTwentyOneCreditAgreementDollarTermLoanMember us-gaap:LineOfCreditMember 2021-05-05 0001232524 jazz:TwoThousandTwentyOneCreditAgreementEuroTermLoanMember us-gaap:LineOfCreditMember 2021-05-05 2021-05-05 0001232524 jazz:TwoThousandTwentyOneCreditAgreementEuroTermLoanMember us-gaap:LineOfCreditMember 2021-05-05 0001232524 jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-05-05 2021-05-05 0001232524 jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-05-05 0001232524 jazz:TrancheB1DollarTermLoanMember us-gaap:LineOfCreditMember 2024-01-31 0001232524 jazz:TrancheB2DollarTermLoanMember us-gaap:LineOfCreditMember 2024-07-31 0001232524 us-gaap:LineOfCreditMember 2024-07-31 0001232524 jazz:TrancheB2DollarTermLoanMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-07-01 2024-07-31 0001232524 jazz:TrancheB2DollarTermLoanMember us-gaap:LineOfCreditMember us-gaap:PrimeRateMember 2024-07-01 2024-07-31 0001232524 jazz:TrancheB2DollarTermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-07-01 2024-07-31 0001232524 srt:MinimumMember jazz:TrancheB2DollarTermLoanMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-07-01 2024-07-31 0001232524 jazz:TrancheB2DollarTermLoanMember us-gaap:LineOfCreditMember 2024-09-30 0001232524 jazz:TwoThousandTwentyOneCreditAgreementDollarTermLoanMember us-gaap:LineOfCreditMember 2024-09-30 0001232524 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-07-01 2024-07-31 0001232524 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-07-01 2024-07-31 0001232524 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:PrimeRateMember 2024-07-01 2024-07-31 0001232524 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:PrimeRateMember 2024-07-01 2024-07-31 0001232524 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-07-01 2024-07-31 0001232524 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-07-01 2024-07-31 0001232524 us-gaap:RevolvingCreditFacilityMember jazz:TwoThousandTwentyOneCreditAgreementRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2030Member us-gaap:ConvertibleDebtMember jazz:JazzSecuritiesDesignatedActivityCompanyMember 2024-09-01 2024-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2030Member us-gaap:ConvertibleDebtMember 2024-09-01 2024-09-30 0001232524 jazz:JazzInvestmentsILimitedMember 2024-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2030Member us-gaap:ConvertibleDebtMember 2024-07-01 2024-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2026Member us-gaap:ConvertibleDebtMember 2023-07-01 2023-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2026Member us-gaap:ConvertibleDebtMember 2024-07-01 2024-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2026Member us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2026Member us-gaap:ConvertibleDebtMember 2024-01-01 2024-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2024-08-15 2024-08-15 0001232524 jazz:ExchangeableSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2024-07-01 2024-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2023-07-01 2023-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2024-01-01 2024-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0001232524 jazz:TeamstersAndGEHALawsuitsMember 2020-06-18 2020-06-23 0001232524 jazz:AvadelPharmaceuticalsPlcLawsuitMember 2021-05-13 0001232524 jazz:AvadelPharmaceuticalsPlcLawsuitMember 2023-02-24 2023-02-24 0001232524 jazz:AvadelPharmaceuticalsPlcLawsuitMember 2022-06-07 0001232524 jazz:AvadelPharmaceuticalsPlcLawsuitMember 2024-08-27 2024-08-27 0001232524 jazz:AvadelPharmaceuticalsPlcLawsuitMember 2022-07-21 2022-07-21 0001232524 jazz:LupinLawsuitMember 2021-06-30 0001232524 jazz:LupinLawsuitMember 2021-07-31 0001232524 jazz:LupinLawsuitMember 2021-07-01 2021-07-31 0001232524 jazz:LupinLawsuitMember jazz:XywavMember 2021-06-01 2021-06-30 0001232524 jazz:LupinLawsuitMember 2022-06-22 2022-06-22 0001232524 jazz:TevaLawsuitMember 2023-03-31 0001232524 jazz:TevaLawsuitMember 2023-03-01 2023-03-31 0001232524 jazz:EpidiolexPatentLitigationMember 2023-03-01 2023-03-31 0001232524 jazz:EpidiolexPatentLitigationMember 2024-09-30 0001232524 jazz:EpidiolexPatentLitigationMember 2023-12-15 2023-12-15 0001232524 jazz:EpidiolexPatentLitigationMember 2024-07-03 2024-07-03 0001232524 jazz:July2024ShareRepurchaseProgramMember jazz:OrdinarySharesMember 2024-07-31 0001232524 jazz:November2016ShareRepurchaseProgramMember jazz:OrdinarySharesMember 2024-07-31 0001232524 jazz:July2024ShareRepurchaseProgramMember jazz:OrdinarySharesMember 2024-07-01 2024-09-30 0001232524 jazz:November2016ShareRepurchaseProgramAndJuly2024ShareRepurchaseProgramMember jazz:OrdinarySharesMember 2024-01-01 2024-09-30 0001232524 jazz:November2016ShareRepurchaseProgramMember jazz:OrdinarySharesMember 2023-01-01 2023-09-30 0001232524 jazz:July2024ShareRepurchaseProgramMember jazz:OrdinarySharesMember 2024-09-30 0001232524 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0001232524 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0001232524 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-09-30 0001232524 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-09-30 0001232524 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-09-30 0001232524 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0001232524 jazz:ExchangeableSeniorNotesDue2024Member us-gaap:ConvertibleDebtMember 2024-08-31 0001232524 jazz:ExchangeableSeniorNotesDue2026Member us-gaap:ConvertibleDebtMember 2024-07-31 0001232524 us-gaap:EquityUnitPurchaseAgreementsMember 2024-07-01 2024-09-30 0001232524 us-gaap:EquityUnitPurchaseAgreementsMember 2023-07-01 2023-09-30 0001232524 us-gaap:EquityUnitPurchaseAgreementsMember 2024-01-01 2024-09-30 0001232524 us-gaap:EquityUnitPurchaseAgreementsMember 2023-01-01 2023-09-30 0001232524 jazz:XywavMember 2024-07-01 2024-09-30 0001232524 jazz:XywavMember 2023-07-01 2023-09-30 0001232524 jazz:XywavMember 2024-01-01 2024-09-30 0001232524 jazz:XywavMember 2023-01-01 2023-09-30 0001232524 jazz:XyremMember 2024-07-01 2024-09-30 0001232524 jazz:XyremMember 2023-07-01 2023-09-30 0001232524 jazz:XyremMember 2024-01-01 2024-09-30 0001232524 jazz:XyremMember 2023-01-01 2023-09-30 0001232524 jazz:EpidiolexEpidyolexMember 2024-07-01 2024-09-30 0001232524 jazz:EpidiolexEpidyolexMember 2023-07-01 2023-09-30 0001232524 jazz:EpidiolexEpidyolexMember 2024-01-01 2024-09-30 0001232524 jazz:EpidiolexEpidyolexMember 2023-01-01 2023-09-30 0001232524 jazz:SativexMember 2024-07-01 2024-09-30 0001232524 jazz:SativexMember 2023-07-01 2023-09-30 0001232524 jazz:SativexMember 2024-01-01 2024-09-30 0001232524 jazz:SativexMember 2023-01-01 2023-09-30 0001232524 jazz:TotalNeuroscienceMember 2024-07-01 2024-09-30 0001232524 jazz:TotalNeuroscienceMember 2023-07-01 2023-09-30 0001232524 jazz:TotalNeuroscienceMember 2024-01-01 2024-09-30 0001232524 jazz:TotalNeuroscienceMember 2023-01-01 2023-09-30 0001232524 jazz:RylazeEnrylazeMember 2024-07-01 2024-09-30 0001232524 jazz:RylazeEnrylazeMember 2023-07-01 2023-09-30 0001232524 jazz:RylazeEnrylazeMember 2024-01-01 2024-09-30 0001232524 jazz:RylazeEnrylazeMember 2023-01-01 2023-09-30 0001232524 jazz:ZepzelcaMember 2024-07-01 2024-09-30 0001232524 jazz:ZepzelcaMember 2023-07-01 2023-09-30 0001232524 jazz:ZepzelcaMember 2024-01-01 2024-09-30 0001232524 jazz:ZepzelcaMember 2023-01-01 2023-09-30 0001232524 jazz:DefitelioDefibrotideMember 2024-07-01 2024-09-30 0001232524 jazz:DefitelioDefibrotideMember 2023-07-01 2023-09-30 0001232524 jazz:DefitelioDefibrotideMember 2024-01-01 2024-09-30 0001232524 jazz:DefitelioDefibrotideMember 2023-01-01 2023-09-30 0001232524 jazz:VyxeosMember 2024-07-01 2024-09-30 0001232524 jazz:VyxeosMember 2023-07-01 2023-09-30 0001232524 jazz:VyxeosMember 2024-01-01 2024-09-30 0001232524 jazz:VyxeosMember 2023-01-01 2023-09-30 0001232524 jazz:TotalOncologyMember 2024-07-01 2024-09-30 0001232524 jazz:TotalOncologyMember 2023-07-01 2023-09-30 0001232524 jazz:TotalOncologyMember 2024-01-01 2024-09-30 0001232524 jazz:TotalOncologyMember 2023-01-01 2023-09-30 0001232524 jazz:OtherProductsMember 2024-07-01 2024-09-30 0001232524 jazz:OtherProductsMember 2023-07-01 2023-09-30 0001232524 jazz:OtherProductsMember 2024-01-01 2024-09-30 0001232524

jazz:OtherProductsMember 2023-01-01 2023-09-30 0001232524 jazz:HighSodiumAGOxybateProductRoyaltyRevenueMember 2024-07-01 2024-09-30 0001232524 jazz:HighSodiumAGOxybateProductRoyaltyRevenueMember 2023-07-01 2023-09-30 0001232524 jazz:HighSodiumAGOxybateProductRoyaltyRevenueMember 2024-01-01 2024-09-30 0001232524 jazz:HighSodiumAGOxybateProductRoyaltyRevenueMember 2023-01-01 2023-09-30 0001232524 jazz:OtherRoyaltyAndContractRevenuesMember 2024-07-01 2024-09-30 0001232524 jazz:OtherRoyaltyAndContractRevenuesMember 2023-07-01 2023-09-30 0001232524 jazz:OtherRoyaltyAndContractRevenuesMember 2024-01-01 2024-09-30 0001232524 jazz:OtherRoyaltyAndContractRevenuesMember 2023-01-01 2023-09-30 0001232524 country:US 2024-07-01 2024-09-30 0001232524 country:US 2023-07-01 2023-09-30 0001232524 country:US 2024-01-01 2024-09-30 0001232524 country:US 2023-01-01 2023-09-30 0001232524 srt:EuropeMember 2024-07-01 2024-09-30 0001232524 srt:EuropeMember 2023-07-01 2023-09-30 0001232524 srt:EuropeMember 2024-01-01 2024-09-30 0001232524 srt:EuropeMember 2023-01-01 2023-09-30 0001232524 jazz:OtherCountriesMember 2024-07-01 2024-09-30 0001232524 jazz:OtherCountriesMember 2023-07-01 2023-09-30 0001232524 jazz:OtherCountriesMember 2024-01-01 2024-09-30 0001232524 jazz:OtherCountriesMember 2023-01-01 2023-09-30 0001232524 jazz:ExpressScriptsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001232524 jazz:ExpressScriptsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001232524 jazz:ExpressScriptsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001232524 jazz:ExpressScriptsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001232524 jazz:McKessonCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001232524 jazz:McKessonCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001232524 jazz:McKessonCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001232524 jazz:McKessonCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001232524 jazz:ASDSpecialtyHealthcareLLCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001232524 jazz:ASDSpecialtyHealthcareLLCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001232524 jazz:ASDSpecialtyHealthcareLLCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001232524 jazz:ASDSpecialtyHealthcareLLCMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001232524 srt:MinimumMember 2024-01-01 2024-09-30 0001232524 srt:MaximumMember 2024-01-01 2024-09-30 0001232524 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0001232524 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001232524 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0001232524 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001232524 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001232524 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001232524 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001232524 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001232524 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001232524 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001232524 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001232524 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001232524 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001232524 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001232524 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001232524 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001232524 srt:MinimumMember jazz:PerformanceBasedRestrictedStockUnitsRSUsMember 2024-01-01 2024-09-30 0001232524 srt:MaximumMember jazz:PerformanceBasedRestrictedStockUnitsRSUsMember 2024-01-01 2024-09-30 0001232524 jazz:PerformanceBasedRestrictedStockUnitsRSUsMember 2024-07-01 2024-09-30 0001232524 jazz:PerformanceBasedRestrictedStockUnitsRSUsMember 2023-07-01 2023-09-30 0001232524 jazz:PerformanceBasedRestrictedStockUnitsRSUsMember 2024-01-01 2024-09-30 0001232524 jazz:PerformanceBasedRestrictedStockUnitsRSUsMember 2023-01-01 2023-09-30 0001232524 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001232524 jazz:PerformanceBasedRestrictedStockUnitsRSUsMember 2024-09-30 0001232524 us-gaap:EmployeeStockMember 2024-09-30 0001232524 us-gaap:EmployeeStockOptionMember 2024-09-30 0001232524 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001232524 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001232524 us-gaap:ForeignCountryMember us-gaap:LuxembourgInlandRevenueMember 2024-01-01 2024-09-30 shares iso4217:USD iso4217:USD shares jazz:segment pure utr:Rate iso4217:EUR jazz:customer jazz:litigationCase jazz:patent Jazz Pharmaceuticals plc false 2024 Q3 0001232524 --12-31 http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent P0Y P0Y 0.0065339 10-Q true 2024-09-30 false 001-33500 L2 98-1032470 Fifth Floor, Waterloo Exchange, Waterloo Road Dublin 4 IE D04 E5W7 353 1 634-7800 Ordinary shares, nominal value $0.0001 per share JAZZ NASDAQ Yes Yes Large Accelerated Filer false false false 60454592 2218135000 1506310000 400000000 120000000 723639000 705794000 539302000 597039000 155132000 185476000 354215000 320809000 4390423000 3435428000 176422000 169646000 77164000 65340000 5144217000 5418039000 1804646000 1753130000 583218000 477834000 4395000 6478000 75231000 67464000 12255716000 11393359000 85425000 102750000 858578000 793914000 31000000 604954000 54974000 35074000 1029977000 1536692000 6080802000 5107988000 71115000 59225000 791784000 847706000 110971000 104751000 6000 6000 55000 55000 473000 473000 3837698000 3699954000 -603397000 -842147000 936232000 878656000 4171067000 3736997000 12255716000 11393359000 989707000 938398000 2795953000 2769604000 65262000 33742000 184824000 52665000 1054969000 972140000 2980777000 2822269000 111611000 102153000 317000000 328334000 325772000 308310000 1016007000 947071000 199919000 234402000 643500000 633050000 157457000 154883000 468410000 456731000 0 0 10000000 1000000 794759000 799748000 2454917000 2366186000 260210000 172392000 525860000 456083000 -58702000 -71497000 -186841000 -219114000 -701000 -1377000 -1887000 -566000 200807000 99518000 337132000 236403000 -14533000 -47176000 -33517000 -86823000 -285000 126000 -1644000 -2548000 215055000 146820000 369005000 320678000 3.50 2.33 5.93 5.05 3.42 2.14 5.63 4.67 61414000 63114000 62275000 63532000 63174000 71293000 67511000 72866000 215055000 146820000 369005000 320678000 291367000 -170826000 241218000 82952000 -1727000 1176000 522000 3063000 -5197000 3539000 1572000 9218000 445000 428000 1342000 684000 1340000 1289000 4040000 2060000 284830000 -168576000 238750000 90110000 499885000 -21756000 607755000 410788000 62255000 6000 4000000 55000 473000 3699954000 -842147000 878656000 3736997000 7000 494000 494000 686000 80000 49296000 49296000 63131000 63131000 -40247000 -40247000 -14618000 -14618000 63028000 6000 4000000 55000 473000 3714283000 -882394000 864038000 3696461000 4000 54000 54000 122000 10886000 10886000 49000 2847000 2847000 56738000 56738000 1458000 161428000 161428000 -5833000 -5833000 168568000 168568000 61745000 6000 4000000 55000 473000 3779114000 -888227000 871178000 3762599000 1000 17000 17000 69000 1605000 1605000 60172000 60172000 1372000 150001000 150001000 284830000 284830000 215055000 215055000 60443000 6000 4000000 55000 473000 3837698000 -603397000 936232000 4171067000 63214000 6000 4000000 55000 472000 3477124000 -1125509000 733586000 3085734000 188000 21228000 21228000 585000 43266000 43266000 56646000 56646000 145279000 145279000 69420000 69420000 63987000 6000 4000000 55000 472000 3511732000 -980230000 803006000 3335041000 28000 2003000 2003000 81000 8863000 8863000 58000 4188000 4188000 61705000 61705000 756000 -1000 95595000 95594000 113407000 113407000 104438000 104438000 63398000 6000 4000000 55000 473000 3580115000 -866823000 811849000 3525675000 50000 5512000 5512000 59000 1884000 1884000 56197000 56197000 562000 74371000 74371000 -168576000 -168576000 146820000 146820000 62945000 6000 4000000 55000 473000 3639940000 -1035399000 884298000 3489373000 369005000 320678000 468410000 456731000 177855000 173900000 9722000 11994000 23240000 22764000 18877000 16255000 15866000 7732000 10000000 1000000 -205972000 -224317000 -19615000 -54262000 21979000 -23581000 26877000 12016000 -708000 37327000 -10697000 -14423000 9544000 20881000 -16938000 17705000 56428000 -76261000 20098000 61159000 0 -459000 -9701000 -13855000 320000 20500000 997328000 924668000 835125000 270000000 24783000 13860000 10000000 1000000 555000000 20000000 -314908000 -264860000 980767000 0 11451000 37606000 23250000 23250000 53748000 49338000 311429000 169966000 575000000 0 28791000 -204948000 614000 -652000 711825000 454208000 1506310000 881482000 2218135000 1335690000 The Company and Summary of Significant Accounting Policies Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases - often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Our lead marketed products, listed below, are approved in countries around the world to improve patient care. Neuroscience •Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product approved by the U.S. Food and Drug Administration, or FDA, in July 2020, and launched in the U.S. in November 2020 for the treatment of cataplexy or excessive daytime sleepiness, or EDS, in patients seven years of age and older with narcolepsy, and also approved by FDA in August 2021 for the treatment of idiopathic hypersomnia, or IH, in adults and launched in the U.S. in November 2021. Xywav contains 92% less sodium than Xyrem®. Xywav is also approved in Canada for the treatment of cataplexy in patients

*with narcolepsy. •Epidiolex® (cannabidiol) oral solution, a product approved by FDA and launched in the U.S. in 2018 by GW Pharmaceuticals plc, or GW, and currently indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, or LGS, Dravet syndrome, or DS, or tuberous sclerosis complex, or TSC, in patients one year of age or older; in the EU and Great Britain (where it is marketed as Epidyolex®) and other markets, it is approved for adjunctive treatment of seizures associated with LGS or DS, in conjunction with clobazam (EU and Great Britain only), in patients 2 years of age and older and for adjunctive treatment of seizures associated with TSC in patients 2 years of age and older. Oncology •Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn), a product approved by FDA in June 2021 and launched in the U.S. in July 2021 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who have developed hypersensitivity to E. coli-derived asparaginase. In September 2023, the European Commission granted marketing authorization under the trade name Enrylaze. This therapy is also approved in Great Britain, Canada and Switzerland. •Zepzelca® (lurbinectedin), a product approved by FDA in June 2020 under FDA's accelerated approval pathway and launched in the U.S. in July 2020 for the treatment of adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based chemotherapy; in Canada, Zepzelca received conditional approval in September 2021 for the treatment of adults with Stage III or metastatic SCLC, who have progressed on or after platinum-containing therapy. Throughout this Quarterly Report on Form 10-Q, unless otherwise indicated or the context otherwise requires, all references to "Jazz Pharmaceuticals," "the registrant," "the Company," "we," "us," and "our" refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries. Throughout this Quarterly Report on Form 10-Q, all references to "ordinary shares" refer to Jazz Pharmaceuticals plc's ordinary shares. Basis of Presentation These unaudited condensed consolidated financial statements have been prepared following the requirements of the U.S. Securities and Exchange Commission for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or U.S. GAAP, can be condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our annual audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three and nine months ended September 30, 2024, are not necessarily indicative of the results to be expected for the year ending December 31, 2024, for any other interim period or for any future period. Our significant accounting policies have not changed substantially from those previously described in our Annual Report on Form 10-K for the year ended December 31, 2023. These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our subsidiaries, and intercompany transactions and balances have been eliminated. Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker, or CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the identification, development and commercialization of meaningful pharmaceutical products that address unmet medical needs. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Adoption of New Accounting Standards In November 2023, the Financial Accounting Standards Board, or FASB, issued ASU 2023-07, "Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures", which requires enhanced disclosures about significant segment expenses. The amendments are effective retrospectively to all prior periods presented in the financial statements, for fiscal years beginning after December 15, 2023. The new guidance is not expected to have a material impact on our financial statement disclosures. Significant Risks and Uncertainties We expect that our business will continue to meaningfully depend on oxybate revenues; however, there is no guarantee that oxybate revenues will remain at current levels. In this regard, our ability to maintain oxybate revenues and realize the anticipated benefits from our investment in Xywav are subject to a number of risks and uncertainties including, without limitation, those related to the commercialization of Xywav for the treatment of IH in adults and adoption in that indication; competition from the introduction of two authorized generic, or AG, versions of high-sodium oxybate and a branded fixed-dose, high-sodium oxybate, Avadel's Lumryz, for treatment of cataplexy and/or EDS in narcolepsy in the U.S. market, as well as potential future competition from additional AG versions of high-sodium oxybate and from generic versions of high-sodium oxybate and from other competitors; increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party payors, including our ability to maintain adequate coverage and reimbursement for Xywav; increased rebates required to maintain access to our products; challenges to our intellectual property around Xywav and/or Xyrem, including from pending antitrust and intellectual property litigation; and continued acceptance of Xywav and Xyrem by physicians and patients. A significant decline in oxybate revenues could cause us to reduce our operating expenses or seek to raise additional funds and would have a material adverse effect on our business, financial condition, results of operations and growth prospects, including on our ability to acquire, in-license or develop new products to grow our business. In addition to risks related specifically to Xywav and Xyrem, we are subject to other challenges and risks related to successfully commercializing a portfolio of oncology products and other neuroscience products, and other risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: ongoing clinical research activity and related outcomes; obtaining regulatory approval of our late-stage product candidates, such as zanidatamab; effectively commercializing our approved products such as Epidiolex, Rylaze and Zepzelca; obtaining and maintaining adequate coverage and reimbursement for our products; contracting and rebates to pharmacy benefit managers and similar organizations that reduce our net revenue; increasing scrutiny of pharmaceutical product pricing and resulting changes in healthcare laws and policy; market acceptance; regulatory concerns with controlled substances generally and the potential for abuse; future legislation; action by the U.S. Federal Government authorizing the sale, distribution, use, and insurance reimbursement of non-FDA approved cannabinoid products; delays or problems in the supply of our products; loss of single source suppliers or failure to comply with manufacturing regulations; delays or problems with third parties that are part of our manufacturing and supply chain; identifying, acquiring or in-licensing additional products or product candidates; our ability to realize the anticipated benefits of acquired or in-licensed products or product candidates, such as Epidiolex and zanidatamab, at the expected levels, with the expected costs and within the expected timeframe; pharmaceutical product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements; and possible restrictions on our ability and flexibility to pursue*

*certain future opportunities as a result of our substantial outstanding debt obligations. Concentrations of Risk Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet. We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of September 30, 2024, we had foreign exchange forward contracts with notional amounts totaling $292.7 million. As of September 30, 2024, the outstanding foreign exchange forward contracts had a net asset fair value of $8.4 million. As of September 30, 2024, we had interest rate swap contracts with notional amounts totaling $500.0 million with a liability fair value of $3.0 million. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant. We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and, as of September 30, 2024 and December 31, 2023, allowances on receivables were not material. As of September 30, 2024, five customers accounted for 81% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliates, or ESSDS, which accounted for 41% of gross accounts receivable, ASD Specialty Healthcare LLC, or ASD, which accounted for 14% of gross accounts receivable and McKesson Corporation and affiliates, or McKesson, which accounted for 14% of gross accounts receivable. As of December 31, 2023, five customers accounted for 79% of gross accounts receivable, including ESSDS, which accounted for 41% of gross accounts receivable, ASD, which accounted for 13% of gross accounts receivable and McKesson, which accounted for 11% of gross accounts receivable. We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to our oxybate products, the API is manufactured for us by a single source supplier and the finished products are manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based supplier. Recent Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740) - Improvements to Income Tax Disclosures”, which requires enhanced tax disclosures providing greater disaggregation of information in the Company's effective tax rate reconciliation and disaggregates income taxes paid by jurisdiction. The amendments are effective on a prospective basis, with the option to apply it retrospectively, for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of adopting this new accounting guidance. Basis of Presentation These unaudited condensed consolidated financial statements have been prepared following the requirements of the U.S. Securities and Exchange Commission for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or U.S. GAAP, can be condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our annual audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three and nine months ended September 30, 2024, are not necessarily indicative of the results to be expected for the year ending December 31, 2024, for any other interim period or for any future period. Our significant accounting policies have not changed substantially from those previously described in our Annual Report on Form 10-K for the year ended December 31, 2023. These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our subsidiaries, and intercompany transactions and balances have been eliminated. Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker, or CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the identification, development and commercialization of meaningful pharmaceutical products that address unmet medical needs. 1 Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Adoption of New Accounting Standards In November 2023, the Financial Accounting Standards Board, or FASB, issued ASU 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures”, which requires enhanced disclosures about significant segment expenses. The amendments are effective retrospectively to all prior periods presented in the financial statements, for fiscal years beginning after December 15, 2023. The new guidance is not expected to have a material impact on our financial statement disclosures. Recent Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740) – Improvements to Income Tax Disclosures”, which requires enhanced tax disclosures providing greater disaggregation of information in the Company's effective tax rate reconciliation and disaggregates income taxes paid by jurisdiction. The amendments are effective on a prospective basis, with the option to apply it retrospectively, for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of adopting this new accounting guidance. Significant Risks and Uncertainties We expect that our business will continue to meaningfully depend on oxybate revenues; however, there is no guarantee that oxybate revenues will remain at current levels. In this regard, our ability to maintain oxybate revenues and realize the anticipated benefits from our investment in Xywav are subject to a number of risks and uncertainties including, without limitation, those related to the commercialization of Xywav for the treatment of IH in adults and adoption in that indication; competition from the introduction of two authorized generic, or AG, versions of high-sodium oxybate and a branded fixed-dose, high-sodium oxybate, Avadel’s Lumryz, for treatment of cataplexy and/or EDS in narcolepsy in the U.S. market, as well as potential future competition from additional AG versions of high-sodium oxybate and from generic versions of high-sodium oxybate and from other competitors; increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party payors, including our ability to maintain adequate coverage and reimbursement for Xywav; increased rebates required to maintain access to our products; challenges to our intellectual property around Xywav and/or Xyrem, including from pending antitrust and intellectual property litigation; and continued acceptance of Xywav and Xyrem by physicians and patients. A significant decline in oxybate revenues could cause us to reduce our operating expenses or seek to raise additional funds and would have a material adverse effect on our business, financial condition, results of operations and growth prospects, including on our ability to acquire, in-license or develop new products to grow our business. <div style="margin-top:6pt;text-*

indent:24.75pt">In addition to risks related specifically to Xywav and Xyrem, we are subject to other challenges and risks related to successfully commercializing a portfolio of oncology products and other neuroscience products, and other risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: ongoing clinical research activity and related outcomes; obtaining regulatory approval of our late-stage product candidates, such as zanidatamab; effectively commercializing our approved products such as Epidiolex, Rylaze and Zepzelca; obtaining and maintaining adequate coverage and reimbursement for our products; contracting and rebates to pharmacy benefit managers and similar organizations that reduce our net revenue; increasing scrutiny of pharmaceutical product pricing and resulting changes in healthcare laws and policy; market acceptance; regulatory concerns with controlled substances generally and the potential for abuse; future legislation; action by the U.S. Federal Government authorizing the sale, distribution, use, and insurance reimbursement of non-FDA approved cannabinoid products; delays or problems in the supply of our products; loss of single source suppliers or failure to comply with manufacturing regulations; delays or problems with third parties that are part of our manufacturing and supply chain; identifying, acquiring or in-licensing additional products or product candidates; our ability to realize the anticipated benefits of acquired or in-licensed products or product candidates, such as Epidiolex and zanidatamab, at the expected levels, with the expected costs and within the expected timeframe; pharmaceutical product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements; and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt obligations. Concentrations of Risk Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet. We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant.We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to our oxybate products, the API is manufactured for us by a single source supplier and the finished products are manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based supplier. 292700000 8400000 500000000 -3000000.0 0.81 0.41 0.14 0.14 0.79 0.41 0.13 0.11 Cash and Available-for-Sale Securities Cash, cash equivalents and investments consisted of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized<br/>Cost</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross<br/>Unrealized<br/>Gains</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross<br/>Unrealized<br/>Losses</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated<br/>Fair Value</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash and<br/>Cash<br/>Equivalents</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Investments</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Cash</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,583 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">797,583 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times

New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Time deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">650,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">650,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">250,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">400,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top">Money market funds</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,170,552 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,170,552 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,170,552 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Totals</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618,135 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618,135 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,218,135 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">400,000 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized<br/>Cost</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-

height:100%">Gross<br/>Unrealized<br/>Gains</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross<br/>Unrealized<br/>Losses</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated<br/>Fair Value</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash and <br/>Cash<br/>Equivalents</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Investments</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Cash</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,724 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">437,724 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Totals</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,626,310 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,626,310 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506,310 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">120,000 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Cash equivalents and investments are considered available-for-sale securities. We use the specific-identification method for calculating realized gains and losses on securities sold and include them in interest expense, net in the condensed consolidated statements of income. Our investment balances represent time deposits with original maturities of greater than three months and less than one year.  Interest income from available-for-sale securities was $26.0 million and $74.6 million in the three and nine months ended September 30, 2024, respectively, and$19.2 million and $44.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the three and nine months ended September 30, 2023, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and investments consisted of the following (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">797,583 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,583 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">Time deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">650,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">650,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">250,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">400,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Money market funds</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,170,552 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,170,552 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Totals</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618,135 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618,135 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,218,135 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">400,000 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized<br/>Cost</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross<br/>Unrealized<br/>Gains</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross<br/>Unrealized<br/>Losses</td><td

colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated<br/>Fair Value</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash and <br/>Cash<br/>Equivalents</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Investments</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Cash</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,724 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">437,724 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Totals</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,626,310 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid

#000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626,310 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,506,310 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 797583000 0 0 797583000 797583000 0 650000000 0 0 650000000 250000000 400000000 1170552000 0 0 1170552000 1170552000 0 2618135000 0 0 2618135000 2218135000 400000000 437724000 0 0 437724000 437724000 0 420000000 0 0 420000000 300000000 120000000 768586000 0 0 768586000 768586000 0 1626310000 0 0 1626310000 1506310000 120000000 26000000.0 74600000 19200000 44400000 Fair Value Measurement <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our available-for-sale securities and derivative contracts as of September 30, 2024 and December 31, 2023, that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,170,552 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,170,552 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">768,586 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-

color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">768,586 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Time deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">650,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">650,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">420,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">420,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Foreign exchange forward contracts</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,364 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,364 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,035 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,035 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Interest rate contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,784 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,784 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Totals</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170,552 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">658,377 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,828,929 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">768,586 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-

color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">441,819 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,976 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3,410 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Totals</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-

bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,976 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,091 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,091 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of September 30, 2024, our available-for-sale securities included money market funds and time deposits and their carrying values were approximately equal to their fair values. Money market funds were measured using quoted prices in active markets, which represent Level 1 inputs and time deposits were measured at fair value using Level 2 inputs. Level 2 inputs are obtained from various third party data providers and represent quoted prices for similar assets in active markets, or these inputs were derived from observable market data, or if not directly observable, were derived from or corroborated by other observable market data. Our derivative assets and liabilities include interest rate and foreign exchange derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterparties' credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the fair value hierarchy. There were no transfers between the different levels of the fair value hierarchy in 2024 or 2023. As of September 30, 2024 and December 31, 2023, the carrying amount of investments measured using the measurement alternative for equity investments without a readily determinable fair value was $4.3 million and $4.7 million, respectively. The carrying amount, which is recorded within other non-current assets, is based on the latest observable transaction price. As of September 30, 2024, the estimated fair values of the 2.000% exchangeable senior notes due 2026, or 2026 Notes, and the 3.125% exchangeable senior notes due 2030, or 2030 Notes, were approximately $1.0 billion and $1.0 billion, respectively. The 2030 Notes together with the 2026 Notes and the 1.50% exchangeable senior notes due 2024, or 2024 Notes, that were repaid upon maturity on August 15, 2024, are collectively known as the Exchangeable Senior Notes. As of September 30, 2024, the estimated fair values of the 4.375% senior secured notes, due 2029, or the Secured Notes, and the seven-year U.S. dollar term loan B facility were approximately $1.4 billion and $2.7 billion, respectively. The fair values of each of these debt facilities was estimated using quoted market prices obtained from brokers (Level 2). The following table summarizes, by major security type, our available-for-sale securities and derivative contracts as of September 30, 2024 and December 31, 2023, that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total<br/>Estimated<br/>Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Quoted<br/>Prices in<br/>Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total<br/>Estimated<br/>Fair Value</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Assets:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Available-for-sale securities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3"

*style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Money market funds</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">768,586 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">768,586 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Time deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">650,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">650,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">420,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">420,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Foreign exchange forward contracts</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,364 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,364 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Interest rate contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,784 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,784 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Totals</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-*

color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,170,552 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,828,929 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768,586 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">441,819 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities: </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,976 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3,410 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3,410 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Foreign exchange forward contracts</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-

align:right;vertical-align:bottom">681 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">681 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Totals</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,976 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,091 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,091 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1170552000 0 1170552000 768586000 0 768586000 0 650000000 0 650000000 0 420000000 420000000 0 8364000 8364000 0 18035000 18035000 0 13000 13000 0 3784000 3784000 1170552000 658377000 1828929000 768586000 441819000 1210405000 0 2976000 2976000 0 3410000 3410000 0 0 0 0 681000 681000 0 2976000 2976000 0 4091000 4091000 4300000 4700000 0.02000 0.03125 1000000000 1000000000 0.0150 0.04375 P7Y 1400000000 2700000000 Derivative Instruments and Hedging Activities We are exposed to certain risks arising from operating internationally, including fluctuations in foreign exchange rates primarily related to the translation of sterling and euro denominated net monetary liabilities, including intercompany balances, held by subsidiaries with a U.S. dollar functional currency and fluctuations in interest rates on our outstanding term loan borrowings. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. We enter into foreign exchange forward contracts, with durations of up to 12 months, designed to limit the exposure to fluctuations in foreign exchange rates related to the translation of certain non-U.S. dollar denominated liabilities, including intercompany balances. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of September 30, 2024 and December 31, 2023, the notional amount of foreign exchange contracts where hedge accounting is not applied was $292.7 million and $511.7 million, respectively.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign exchange loss in our condensed consolidated statements of income included the following gains (losses) associated with foreign exchange contracts not designated as hedging instruments (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Exchange Forward Contracts:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in foreign exchange loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">14,396 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(13,549)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8,921)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> To achieve a desired mix of floating and fixed interest rates on our variable rate debt, we entered into interest rate swap agreements in April 2023, which are effective until April 2026. These agreements hedge contractual term loan interest rates. As of September 30, 2024, the interest rate swap agreements had a notional amount of $500.0 million. As a result of these agreements, the interest rate on a portion of our term loan borrowings is fixed at 3.9086%, plus the borrowing spread, until April 30, 2026.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact on accumulated other comprehensive loss and earnings from derivative instruments that qualified as cash flow hedges for the three and nine months ended September 30, 2024 was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate Contracts:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in accumulated other comprehensive loss, net of tax</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(5,197)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,572 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9,218 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gain reclassified from accumulated other comprehensive loss to interest expense, net of tax</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,340)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,289)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,040)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,060)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Assuming no change in the U.S dollar Secured Overnight Financing Rate, or Term SOFR, based interest rates from market rates as of September 30, 2024, $0.5 million of loss, net of tax, recognized in accumulated other comprehensive loss will be reclassified to earnings over the next 12 months. The cash flow effects of our derivative contracts for the nine months ended September 30, 2024 and 2023 are included within net cash provided by operating activities in the condensed consolidated statements of cash flows. The following tables summarize the fair value of outstanding derivatives (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Classification</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,<br/>2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3"

style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,<br/>2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Derivatives designated as hedging instruments:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Interest rate contracts</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other current assets</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3,784 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Derivatives not designated as hedging instruments:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Foreign exchange forward contracts</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other current assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,364 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,035 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total fair value of derivative asset instruments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,377 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">21,819 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives designated as hedging instruments:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued liabilities</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other non-current liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,404 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,410 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Derivatives not designated as hedging instruments:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Foreign exchange forward contracts</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">681 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of derivative liability instruments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,091 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Although we do not offset derivative assets and liabilities within our condensed consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following table summarizes the potential effect on our condensed consolidated balance sheets of offsetting our interest rate and foreign exchange forward contracts subject to such provisions (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts of Recognized Assets/ Liabilities</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts Offset in the Consolidated Balance Sheet</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts Not Offset in the Consolidated Balance Sheet</td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Description</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative Financial Instruments</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash Collateral Received (Pledged)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Amount</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative assets</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,830)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,547 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,976)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,976)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,830 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,146)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts of Recognized Assets/ Liabilities</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts Offset in the Consolidated Balance Sheet</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts Not Offset in the Consolidated Balance Sheet</td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Description</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative Financial Instruments</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash Collateral Received (Pledged)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Amount</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative assets</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,091)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">17,728 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,091)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,091)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,091 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 292700000 511700000 The foreign exchange loss in our condensed consolidated statements of income included the following gains (losses)

associated with foreign exchange contracts not designated as hedging instruments (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign Exchange Forward Contracts:</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Gain (loss) recognized in foreign exchange loss</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,396 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(13,549)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,485 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8,921)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 14396000 -13549000 9485000 -8921000 500000000.0 0.039086 The impact on accumulated other comprehensive loss and earnings from derivative instruments that qualified as cash flow hedges for the three and nine months ended September 30, 2024 was as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Interest Rate Contracts:</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gain (loss) recognized in accumulated other comprehensive loss, net of tax</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,539 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9,218 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gain reclassified from accumulated other comprehensive loss to interest expense, net of tax

</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,340)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,289)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,040)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,060)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -5197000 3539000 1572000 9218000 1340000 1289000 4040000 2060000 -500000 The following tables summarize the fair value of outstanding derivatives (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Classification</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,<br/>2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,<br/>2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Derivatives designated as hedging instruments:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Interest rate contracts</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other current assets</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3,784 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Derivatives not designated as hedging instruments:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Foreign exchange forward contracts</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other current assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,364 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,035 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total fair value of derivative asset instruments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,377 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">21,819 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives designated as hedging instruments:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued liabilities</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other non-current liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,404 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,410 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Derivatives not designated as hedging instruments:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Foreign exchange forward contracts</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">681 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total fair value of derivative liability instruments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,091 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 13000 3784000 8364000 18035000 8377000 21819000 572000 0 2404000 3410000 0 681000 2976000 4091000 The following table summarizes the potential effect on our condensed consolidated balance sheets of offsetting our interest rate and foreign exchange forward contracts subject to such provisions (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts of Recognized Assets/ Liabilities</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts Offset in the Consolidated Balance Sheet</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts Not Offset in the Consolidated Balance Sheet</td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Description</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative Financial Instruments</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash Collateral Received (Pledged)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Amount</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative assets</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,830)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-

align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,547 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,976)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,976)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,830 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,146)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts of Recognized Assets/ Liabilities</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts Offset in the Consolidated Balance Sheet</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts Not Offset in the Consolidated Balance Sheet</td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Description</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative Financial Instruments</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash Collateral Received (Pledged)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Amount</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative assets</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(4,091)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">17,728 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative liabilities

</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,091)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,091)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,091 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table summarizes the potential effect on our condensed consolidated balance sheets of offsetting our interest rate and foreign exchange forward contracts subject to such provisions (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts of Recognized Assets/ Liabilities</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts Offset in the Consolidated Balance Sheet</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts Not Offset in the Consolidated Balance Sheet</td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Description</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative Financial Instruments</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash Collateral Received (Pledged)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Amount</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative assets</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,830)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,547 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,976)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,976)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,830 </td><td style="background-color:#ffffff;padding:2px 1pt 2px

0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,146)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts of Recognized Assets/ Liabilities</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts Offset in the Consolidated Balance Sheet</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amounts Not Offset in the Consolidated Balance Sheet</td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Description</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative Financial Instruments</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash Collateral Received (Pledged)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Amount</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative assets</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(4,091)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">17,728 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,091)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,091)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,091 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 8377000 0 8377000 1830000 0 6547000 2976000 0 2976000 1830000 0 1146000 21819000 0 21819000 4091000 0 17728000 4091000 0 4091000 4091000 0 0 Inventories Inventories consisted of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td

style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,<br/>2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,<br/>2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Raw materials</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">25,595 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Work in process</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">366,602 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">431,732 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Finished goods</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">147,881 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">139,712 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Total inventories</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,302 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">597,039 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of September 30, 2024 and December 31, 2023, inventories included $243.4 million and $328.0 million, respectively, related to the purchase accounting inventory fair value step-up on inventory acquired as part of our acquisition of GW.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24,819 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,602 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,732 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">539,302 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">597,039 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 24819000 25595000 366602000 431732000 147881000 139712000 539302000 597039000 243400000 328000000 Goodwill and Intangible Assets The gross carrying amount of goodwill was as follows (in thousands): <table style="border-collapse:collapse;display:inline-

table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2023</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,804,646 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <br/> <br/> The gross carrying amounts and net book values of our intangible assets were as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Remaining<br/>Weighted-<br/>Average Useful<br/>Life<br/>(In years)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross<br/>Carrying<br/>Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated<br/>Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Book<br/>Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross<br/>Carrying<br/>Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated<br/>Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Book<br/>Value</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Acquired developed technologies</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">8.0</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,064,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,919,976)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,144,217 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,785,495 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,367,456)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,418,039 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">Manufacturing contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,984 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11,984)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,828 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11,828)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Trademarks</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">—</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,889 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,889)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,886 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,886)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

not be impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year Ending December 31,</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated Amortization Expense</td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">2024 (remainder)</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,109 </span></td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,436 </span></td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,104 </span></td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389,696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,144,217 </td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The gross carrying amount of goodwill was as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2023</td><td style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ceceff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753,130 </span></td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,804,646 </td><td style="background-color:#ceceff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1753130000 51516000 1804646000 The gross carrying amounts and net book values of our intangible assets were as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Remaining<br/>Weighted-<br/>Average Useful<br/>Life<br/>(In years)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross<br/>Carrying<br/>Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated<br/>Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross<br/>Carrying<br/>Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated<br/>Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Book<br/>Value</td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:top">Acquired developed technologies</td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">8.0</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,064,193 </span></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,919,976)</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,144,217 </span></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,785,495 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,367,456)</span></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,418,039 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Manufacturing contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">— </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,984 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11,984)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,828 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11,828)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:top">Trademarks</td><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:center;vertical-align:bottom">— </td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,889 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,889)</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,886 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,886)</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

1pt;text-align:left;vertical-align:top">Total finite-lived intangible assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,079,066 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(2,934,849)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,144,217 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,800,209 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,382,170)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,418,039 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> P8Y 8064193000 2919976000 5144217000 7785495000 2367456000 5418039000 11984000 11984000 0 11828000 11828000 0 2889000 2889000 0 2886000 2886000 0 8079066000 2934849000 5144217000 7800209000 2382170000 5418039000 Based on finite-lived intangible assets recorded as of September 30, 2024, and assuming the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses were estimated as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year Ending December 31,</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated Amortization Expense</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2024 (remainder)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,109 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389,696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,144,217 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 162109000 648436000 648436000 648436000 647104000 2389696000 5144217000 Certain Balance Sheet Items Property, plant and equipment consisted of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,<br/>2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,<br/>2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">Manufacturing equipment and machinery</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,560 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">82,897 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Leasehold improvements</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71,950 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,722 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Land and buildings</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70,762 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70,912 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Computer software</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41,847 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,134 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Construction-in-progress</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,645 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,661 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Computer equipment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,530 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,398 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Furniture and fixtures</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,942 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,273 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Subtotal</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">333,236 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">302,997 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Less accumulated depreciation and amortization</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(156,814)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(133,351)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Property, plant and equipment, net</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,422 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">169,646 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Accrued liabilities consisted of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,<br/>2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,<br/>2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Rebates and other sales deductions</td><td style="background-color:#cceeff;border-top:1pt

solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,134 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">325,711 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Employee compensation and benefits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,497 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">121,209 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Accrued royalties</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,923 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,706 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Clinical trial accruals</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37,620 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">44,757 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Consulting and professional services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32,844 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,538 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Sales return reserve</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,545 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,435 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Selling and marketing accruals</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,539 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,743 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Accrued interest</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,445 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36,443 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Current portion of lease liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,103 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,447 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Inventory-related accruals</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,015 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,977 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Accrued collaboration expenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,805 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,158 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Accrued construction-in-progress</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,040 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,141 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued facilities expenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,439 </td><td

<table><tr><td></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,455 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Derivative instrument liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">572 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">681 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84,057 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75,513 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total accrued liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858,578 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">793,914 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Property, plant and equipment consisted of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,<br/>2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,<br/>2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Manufacturing equipment and machinery</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,560 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">82,897 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Leasehold improvements</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71,950 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,722 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Land and buildings</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70,762 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70,912 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Computer software</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41,847 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,134 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Construction-in-progress</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,645 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,661 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Computer equipment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,530 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,398 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Furniture and fixtures</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,942 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-

color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,273 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Subtotal</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">333,236 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">302,997 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Less accumulated depreciation and amortization</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(156,814)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(133,351)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Property, plant and equipment, net</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,422 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">169,646 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 91560000 82897000 71950000 67722000 70762000 70912000 41847000 38134000 30645000 18661000 17530000 15398000 8942000 9273000 333236000 302997000 156814000 133351000 176422000 169646000 Accrued liabilities consisted of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,<br/>2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,<br/>2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Rebates and other sales deductions</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,134 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">325,711 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Employee compensation and benefits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,497 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">121,209 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Accrued royalties</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,923 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,706 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Clinical trial accruals</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37,620 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">44,757 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Consulting and professional services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32,844 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,538 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Sales return reserve</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,545 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,435 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Selling and marketing accruals</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,539 </td><td

style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,743 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Accrued interest</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,445 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36,443 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Current portion of lease liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,103 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,447 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Inventory-related accruals</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,015 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,977 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Accrued collaboration expenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,805 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,158 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Accrued construction-in-progress</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,040 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,141 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued facilities expenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,439 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,455 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Derivative instrument liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">572 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">681 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84,057 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75,513 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total accrued liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858,578 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">793,914 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 405134000 325711000 125497000 121209000 40923000 30706000 37620000 44757000 32844000 19538000 24545000 20435000 24539000 14743000 22445000 36443000 19103000 19447000 14015000 13977000 12805000 10158000 9040000 5141000 5439000 55455000 572000 681000 84057000 75513000 858578000 793914000 Debt The following table summarizes the carrying amount of our indebtedness (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, <br/>2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, <br/>2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2024 Notes</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-

color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">575,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unamortized - debt issuance costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,046)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2024 Notes, net</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">573,954 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026 Notes </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unamortized - debt issuance costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,456)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,400)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026 Notes, net</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">995,544 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">993,600 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2030 Notes</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unamortized - debt issuance costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19,081)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2030 Notes, net</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">980,919 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Secured Notes </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,482,824 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,480,214 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Term Loan </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,652,515 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,665,174 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"

style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total debt</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,111,802 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,712,942 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less current portion</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">604,954 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total long-term debt</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,080,802 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,107,988 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Credit Agreement On May 5, 2021, the Company, Jazz Financing Lux S.à.r.l., or Jazz Lux, and certain of our other subsidiaries, as borrowers, or, collectively with the Company and Jazz Lux, the "Borrowers", entered into the Credit Agreement by and among the Borrowers, the lenders and issuing banks from time to time party thereto, Bank of America, N.A., as administrative agent and U.S. Bank Trust Company, National Association, as collateral trustee, or the Credit Agreement. The Credit Agreement initially provided for (i) a seven-year $3.1 billion term loan B facility, or the Dollar Term Loan, which was drawn by Jazz Lux on the closing date thereof in U.S. dollars (ii) a seven-year €625.0 million term loan B facility, or the Euro Term Loan, which was drawn by Jazz Lux on the closing date thereof in Euros and (iii) a five-year $500.0 million revolving credit facility, or the Revolving Credit Facility. In January 2024, Jazz Lux entered into an amendment, or the Repricing Amendment No.1, to the Credit Agreement. Upon entry into the Repricing Amendment No.1, certain existing lenders converted a portion of the outstanding Dollar Term Loan into a new tranche of U.S. dollar term loans, or the Tranche B-1 Dollar Term Loans, and Jazz Lux borrowed $201.9 million aggregate principal amount of additional Tranche B-1 Dollar Term Loans, the proceeds of which were used to repay the portion of the outstanding Dollar Term Loan that was not converted. In July 2024, Jazz Lux entered into an amendment, or the Repricing Amendment No. 2, to the Credit Agreement, or the Amended Credit Agreement. Upon entry into the Amended Credit Agreement, certain existing lenders converted a portion of the outstanding Tranche B-1 Dollar Term Loans into a new tranche of U.S. dollar term loans, or the Tranche B-2 Dollar Term Loans, and Jazz Lux borrowed $289.6 million aggregate principal amount of additional Tranche B-2 Dollar Term Loans, the proceeds of which were used to repay the portion of the outstanding Tranche B-1 Dollar Term Loans that were not converted. The Tranche B-2 Dollar Term Loans are a separate class of term loans under the Amended Credit Agreement with the same material terms (including with respect to maturity, prepayment, security, covenants and events of default) as the previously outstanding Tranche B-1 Dollar Term Loans and the initial Dollar Term Loan incurred on May 5, 2021, with the interest rate amended as described below and the credit spread adjustment removed. The principal amount of Tranche B-1 Dollar Term Loans outstanding immediately prior to the Repricing Amendment No. 2 and the outstanding principal amount of Tranche B-2 Dollar Term Loans immediately following the Repricing Amendment No.2, each totaled $2.7 billion. The Tranche B-2 Dollar Term Loans bear interest at a rate equal to either (a) Term SOFR, or (b) the prime lending rate, in each case, plus an applicable margin. The applicable margin for the Tranche B-2 Dollar Term Loans is 2.25% (in the case of Term SOFR borrowings) and 1.25% (in the case of borrowings at the prime lending rate), a decrease of 75 basis points from the applicable margin on the Tranche B-1 Dollar Term Loans. The Tranche B-2 Dollar Term Loans are subject to a Term SOFR floor of 0.50%. As of September 30, 2024, the interest rate and effective interest rate on the Tranche B-2 Dollar Term Loans were 7.10% and 8.27%, respectively. The Tranche B-2 Dollar Term Loans will amortize in quarterly installments equal to 0.286294791% of the initial aggregate principal amount thereof, with the remaining balance payable on May 5, 2028. The applicable margin for the Revolving Credit Facility ranges from 3.25% to 2.75% (in the case of Term SOFR borrowings) and 2.25% to 1.75% (in the case of borrowings at the prime lending rate), depending on our first lien secured net leverage ratio level, any loans under the Revolving Credit Facility are not subject to a Term SOFR floor. The Revolving Credit Facility has a commitment fee payable on the undrawn amount ranging from 0.50% to 0.40% per annum based upon our first lien secured net leverage ratio. As of September 30, 2024, we had an undrawn Revolving Credit Facility totaling $500.0 million. 2030 Notes In September 2024, Jazz Investments I Limited, or Jazz Investments, our wholly owned subsidiary, completed a private placement of $1.0 billion principal amount of the 2030 Notes. Interest on the 2030 Notes is payable semi-annually in cash in arrears on March 15 and September 15 of each year, beginning on March 15, 2025, at a rate of 3.125% per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2030 Notes. The 2030 Notes mature on September 15, 2030, unless earlier exchanged, redeemed or repurchased. The holders of the 2030 Notes have the ability to require us to repurchase all or a portion of their 2030 Notes for cash at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date in the event we undergo a fundamental change (as defined in the indenture related to the 2030 Notes), such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from any of The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or The Nasdaq Capital Market (or any of their respective successors). Additionally, the terms and covenants in the indenture related to the 2030 Notes include certain events of default after which the 2030 Notes may be due and payable immediately. Prior to September 15, 2030, we may redeem the 2030 Notes, in whole but not in part, in connection with certain tax-related events. We also may redeem the 2030 Notes on or after September 20, 2027 and prior to June 15, 2030, in whole or in part (subject to the partial redemption limitation described in the indenture related to the 2030 Notes), if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. The 2030 Notes are exchangeable at an initial exchange rate of 6.5339 ordinary shares per $1,000 principal amount

*of 2030 Notes, which is equivalent to an initial exchange price of approximately $153.05 per ordinary share. Upon exchange of the 2030 Notes, we will pay cash up to the aggregate principal amount of the 2030 Notes to be exchanged and pay or deliver, as the case may be, cash, ordinary shares or a combination of cash and ordinary shares, at our election, in respect of the remainder, if any, of our exchange obligation in excess of the aggregate principal amount of the 2030 Notes being exchanged. The exchange rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes (as defined in the indenture related to the 2030 Notes) that occur prior to the maturity date or upon our issuance of a notice of redemption, we will, in certain circumstances, increase the exchange rate for a holder who elects to exchange its 2030 Notes in connection with that make-whole fundamental change or exchange its 2030 Notes called (or deemed called) for redemption during the related redemption period. Prior to June 15, 2030, the 2030 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Exchangeable Senior Notes The Exchangeable Senior Notes were issued by Jazz Investments, or the Issuer, a 100%-owned finance subsidiary of Jazz Pharmaceuticals plc. The Exchangeable Senior Notes are senior unsecured obligations of the Issuer and are fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc. No subsidiary of Jazz Pharmaceuticals plc guaranteed the Exchangeable Senior Notes. Subject to certain local law restrictions on payment of dividends, among other things, and potential negative tax consequences, we are not aware of any significant restrictions on the ability of Jazz Pharmaceuticals plc to obtain funds from the Issuer or Jazz Pharmaceuticals plc's other subsidiaries by dividend or loan, or any legal or economic restrictions on the ability of the Issuer or Jazz Pharmaceuticals plc's other subsidiaries to transfer funds to Jazz Pharmaceuticals plc in the form of cash dividends, loans or advances. There is no assurance that in the future such restrictions will not be adopted. The 2030 Notes are accounted for as a single liability measured at its amortized cost. The total liability is reflected net of issuance costs of $19.2 million which will be amortized over the term of the 2030 Notes. The effective interest rate of the 2030 Notes is 3.46%. During the three months ended September 30, 2024 we recognized interest expense of $2.3 million, of which $2.2 million related to the contractual coupon rate and $0.1 million related to the amortization of debt issuance costs. The total liability of the 2026 Notes is reflected net of issuance costs of $15.3 million which will be amortized over the term of the 2026 Notes. The effective interest rate of the 2026 Notes is 2.26%. During the three months ended September 30, 2024 and 2023, we recognized interest expense of $5.7 million, of which $5.0 million related to the contractual coupon rate and $0.7 million related to the amortization of debt issuance costs, respectively. During the nine months ended September 30, 2024 and 2023, we recognized interest expense of $16.8 million, of which $15.0 million related to the contractual coupon rate and $1.8 million related to the amortization of debt issuance costs, respectively. On August 15, 2024, the maturity date for the 2024 Notes, we repaid the $575.0 million aggregate principal amount, plus accrued and unpaid interest thereon. During the three months ended September 30, 2024, we recognized interest expense of $1.3 million, of which $1.0 million related to the contractual coupon rate and $0.3 million related to the amortization of debt issuance costs. During the three months ended September 30, 2023, we recognized interest expense of $2.5 million, of which $2.1 million related to the contractual coupon rate and $0.4 million related to the amortization of debt issuance costs. During the nine months ended September 30, 2024, we recognized interest expense of $6.4 million, of which $5.3 million related to the contractual coupon rate and $1.1 million related to the amortization of debt issuance costs. During the nine months ended September 30, 2023, we recognized interest expense of $7.6 million, of which $6.4 million related to the contractual coupon rate and $1.2 million related to the amortization of debt issuance costs, respectively.</span></div><div style="margin-top:14pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maturities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities with respect to our long-term debt principal balances outstanding as of September 30, 2024 were as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Scheduled Long-Term Debt Maturities</span></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remainder)</span></td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,750 </td><td style="background-color:#ceceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:top">2026</td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,031,000 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:top">2028</td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,598,500 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,500,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,199,250 </td><td style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table summarizes the carrying amount of our indebtedness (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,<br/>2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,<br/>2023</td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-*

size:10pt;font-weight:400;line-height:100%">2024 Notes</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">575,000 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unamortized - debt issuance costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,046)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">2024 Notes, net</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">573,954 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026 Notes </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000,000 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000,000 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unamortized - debt issuance costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,456)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,400)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026 Notes, net</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">995,544 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">993,600 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">2030 Notes</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000,000 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unamortized - debt issuance costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19,081)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">2030 Notes, net</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">980,919 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Secured Notes </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,482,824 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,480,214 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Term Loan </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,652,515 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px

1pt;text-align:right;vertical-align:bottom">2,665,174 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total debt</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,111,802 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,712,942 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less current portion</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">604,954 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total long-term debt</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,080,802 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,107,988 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 0 575000000 0 1046000 0 573954000 1000000000 1000000000 4456000 6400000 995544000 993600000 1000000000 0 19081000 0 980919000 0 1482824000 1480214000 2652515000 2665174000 6111802000 5712942000 31000000 604954000 6080802000 5107988000 P7Y 3100000000 P7Y 625000000.0 P5Y 500000000 201900000 289600000 2700000000 0.0225 0.0125 0.0075 0.0050 0.0710 0.0827 0.00286294791 0.0325 0.0275 0.0225 0.0175 0.0050 0.0040 500000000 1000000000.0 0.03125 1 1.30 20 30 1 153.05 1 19200000 0.0346 2300000 2200000 100000 15300000 0.0226 5700000 5700000 5000000 5000000 700000 700000 16800000 16800000 15000000 15000000 1800000 1800000 575000000 1300000 1000000 300000 2500000 2100000 400000 6400000 5300000 1100000 7600000 6400000 1200000 Scheduled maturities with respect to our long-term debt principal balances outstanding as of September 30, 2024 were as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year Ending December 31,</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Scheduled Long-Term Debt Maturities</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">2024 (remainder)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,199,250 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 7750000 31000000 1031000000 31000000 2598500000 2500000000 6199250000 Commitments and Contingencies Indemnification In the normal course of business, we enter into agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. Our exposure under these agreements is unknown because it involves future claims that may be made but have not yet been made against us. To date, we have not paid any claims or been required to defend any action related to these indemnification obligations. We have agreed to indemnify our executive officers, directors and certain other employees for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the

*insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we did not recognize any liabilities relating to these obligations as of September 30, 2024 and December 31, 2023. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations. Legal Proceedings We are involved in legal proceedings, including the following matters: Xyrem Antitrust Litigation From June 2020 to May 2022, a number of lawsuits were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the patent litigation settlement agreements we entered with generic drug manufacturers who had filed Abbreviated New Drug Applications, or ANDA, violate state and federal antitrust and consumer protection laws, as follows: On June 17, 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by Blue Cross and Blue Shield Association, or BCBS, against Jazz Pharmaceuticals plc, Jazz Pharmaceuticals, Inc., and Jazz Pharmaceuticals Ireland Limited, or, collectively, the Company Defendants (hereinafter referred to as the BCBS Lawsuit). The BCBS Lawsuit also names Roxane Laboratories, Inc., Hikma Pharmaceuticals USA Inc., Eurohealth (USA), Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., and Lupin Inc., or, collectively, the BCBS Defendants. On June 18 and June 23, 2020, respectively, two additional class action lawsuits were filed against the Company Defendants and the BCBS Defendants: one by the New York State Teamsters Council Health and Hospital Fund in the United States District Court for the Northern District of California, and another by the Government Employees Health Association Inc. in the United States District Court for the Northern District of Illinois (hereinafter referred to as the GEHA Lawsuit). On June 18, 2020, a class action lawsuit was filed in the United States District Court for the Northern District of California by the City of Providence, Rhode Island, on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc, and Roxane Laboratories, Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals USA Inc., and Hikma Pharmaceuticals plc, or, collectively, the City of Providence Defendants. On June 30, 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by UFCW Local 1500 Welfare Fund on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals Ireland Ltd., Jazz Pharmaceuticals, Inc., Roxane Laboratories, Inc., Hikma Pharmaceuticals plc, Eurohealth (USA), Inc. and West-Ward Pharmaceuticals Corp., or collectively the UFCW Defendants (hereinafter referred to as the UFCW Lawsuit). On July 13, 2020, the plaintiffs in the BCBS Lawsuit and the GEHA Lawsuit dismissed their complaints in the United States District Court for the Northern District of Illinois and refiled their respective lawsuits in the United States District Court for the Northern District of California. On July 14, 2020, the plaintiffs in the UFCW Lawsuit dismissed their complaint in the United States District Court for the Northern District of Illinois and on July 15, 2020, refiled their lawsuit in the United States District Court for the Northern District of California. On July 31, 2020, a class action lawsuit was filed in the United States District Court for the Southern District of New York by the A.F. of L.-A.G.C. Building Trades Welfare Plan on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc (hereinafter referred to as the AFL Plan Lawsuit). The AFL Plan Lawsuit also names Roxane Laboratories Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc. On August 14, 2020, an additional class action lawsuit was filed in the United States District Court for the Southern District of New York by the Self-Insured Schools of California on behalf of itself and all others similarly situated, against the Company Defendants, as well as Hikma Pharmaceuticals plc, Eurohealth (USA) Inc., Hikma Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Roxane Laboratories, Inc., Amneal Pharmaceuticals LLC, Endo International, plc, Endo Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., Lupin Inc., Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Holdings USA, Inc., Sun Pharmaceutical Industries, Inc., Ranbaxy Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Watson Laboratories, Inc., Wockhardt Ltd., Morton Grove Pharmaceuticals, Inc., Wockhardt USA LLC, Mallinckrodt plc, and Mallinckrodt LLC (hereinafter referred to as the Self-Insured Schools Lawsuit). On September 16, 2020, an additional class action lawsuit was filed in the United States District Court for the Northern District of California, by Ruth Hollman on behalf of herself and all others similarly situated, against the same defendants named in the Self-Insured Schools Lawsuit. In December 2020, the above cases were centralized and transferred to the United States District Court for the Northern District of California, where the multidistrict litigation will proceed for the purpose of discovery and pre-trial proceedings. On March 18, 2021, United Healthcare Services, Inc. filed a lawsuit in the United States District Court for the District of Minnesota against the Company Defendants, Hikma Pharmaceuticals plc, Roxane Laboratories, Inc., Hikma Pharmaceuticals USA Inc., Eurohealth (USA) Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., and Lupin Pharmaceuticals, Inc., raising similar allegations, or the UHS Lawsuit. On March 24, 2021, the U.S. Judicial Panel on Multidistrict Litigation conditionally transferred the UHS Lawsuit to the United States District Court for the Northern District of California, where it was consolidated for discovery and pre-trial proceedings with the other cases. On August 13, 2021, the United States District Court for the Northern District of California granted in part and denied in part the Company Defendants' motion to dismiss the complaints in the cases referenced above. On October 8, 2021, Humana Inc. filed a lawsuit in the United States District Court for the Northern District of California against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On October 8, 2021, Molina Healthcare Inc. filed a lawsuit in the United States District Court for the Northern District of California against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On February 17, 2022, Health Care Service Corporation filed a lawsuit in the United States District Court for the Northern District of California against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On April 19, 2023, the Court held a hearing on class certification in the consolidated multi-district litigation referenced above. On May 12, 2023, the Court granted the plaintiffs' motion and preliminarily certified classes of Xyrem purchasers seeking monetary and injunctive relief. The Court excluded Xywav purchasers from the classes.  On April 26, 2024, we, Hikma, and the plaintiffs filed motions for summary judgment. The Court held oral argument on these motions on July 19, 2024. On August 26, 2024, the Court issued a decision granting in part and denying in part the parties' motions for summary judgment. On June 13, 2024, we filed a motion to decertify the class.   <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-*

*weight:400;line-height:120%">On June 28, 2024, the plaintiffs filed a motion to amend the definition of the certified class. The Court held oral argument on these motions on August 22, 2024. On October 18, 2024, the Court issued a decision denying our motion to decertify the class and granting the plaintiffs' motion to amend the class definition. On November 1, 2024, we filed a petition with the United States Court of Appeals for the Ninth Circuit seeking leave to appeal the Court's decision amending the class definition. The Ninth Circuit has not yet ruled on the petition. Trial in this matter has been rescheduled for May 19, 2025. On January 13, 2023, Amneal Pharmaceuticals LLC, Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, notified the Court that they had reached a settlement-in-principle with the class action plaintiffs. On April 19, 2023, the Court held a hearing on a motion for preliminary approval of this proposed settlement. On May 12, 2023, the Court granted the motion for preliminary approval of the proposed settlement. On January 11, 2024, the Court held a hearing on the motion for final approval of the proposed settlement. The Court deferred ruling and scheduled a further hearing for final approval of the proposed settlement on April 17, 2024. During February and March 2024, the parties notified the Court of settlements between certain non-class action plaintiffs and each of Amneal and Lupin, and the Court dismissed those plaintiffs' claims against the applicable parties. On April 17, 2024, the Court issued an order granting the motion for final approval of the settlement between the class action plaintiffs, Amneal, and Lupin. On December 11, 2023, Blue Cross and Blue Shield of Florida, Inc. and Health Options, Inc. filed a lawsuit in the United States District Court for the Middle District of Florida against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., and Eurohealth (USA), Inc., raising similar allegations. On January 23, 2024, the Blue Cross Florida case was transferred to the United States District Court for the Northern District of California and consolidated with the above referenced multidistrict litigation for pretrial purposes. On May 9, 2022, Aetna Inc., or Aetna, filed a lawsuit in the Superior Court of California for the County of Alameda against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On December 27, 2022, the Court granted in part and denied in part our motion to dismiss Aetna's complaint.  As a result of that ruling, the generic defendants have been dismissed from the case, and certain of Aetna's claims against Jazz have been dismissed.  On January 27, 2023, Aetna filed an amended complaint against Jazz. On March 22, 2023, we filed motions to dismiss and to strike portions of the amended complaint. On June 26, 2023, the Court granted our motions, and granted Aetna leave to further amend its complaint. On November 17, 2023, Aetna filed its second amended complaint. On February 2, 2024, we filed our answer to the second amended complaint and Hikma filed a motion to quash service. The Court scheduled a hearing on Hikma's motion for December 4, 2024. The Court has not set a further schedule in this case. The plaintiffs in certain of these lawsuits are seeking to represent a class of direct purchasers of Xyrem, and the plaintiffs in the remaining lawsuits are seeking to represent a class of indirect purchasers of Xyrem. Each of the lawsuits generally alleges violations of U.S. federal and state antitrust, consumer protection, and unfair competition laws in connection with the Company Defendants' conduct related to Xyrem, including actions leading up to, and entering into, patent litigation settlement agreements with each of the other named defendants. Each of the lawsuits seeks monetary damages, exemplary damages, equitable relief against the alleged unlawful conduct, including disgorgement of profits and restitution, and injunctive relief. It is possible that additional lawsuits will be filed against the Company Defendants making similar or related allegations. If the plaintiffs were to be successful in their claims, they may be entitled to injunctive relief or we may be required to pay significant monetary damages, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Patent Infringement Litigation Avadel Litigation On May 13, 2021, we filed a patent infringement suit against Avadel Pharmaceuticals plc, or Avadel, and several of its corporate affiliates in the United States District Court for the District of Delaware. The suit alleges that Avadel's Lumryz will infringe five of our patents related to controlled release formulations of oxybate and the safe and effective distribution of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe these patents, and an award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product will not infringe our patents. Avadel filed a motion for partial judgment on the pleadings on its counterclaim that one of our patents should be delisted from FDA's Orange Book, or the Orange Book. On November 18, 2022, the Court issued an order that we delist the patent from the Orange Book. On November 22, 2022, we filed a notice of appeal to the United States Court of Appeals for the Federal Circuit. The Federal Circuit temporarily stayed the District Court's delisting order. On February 24, 2023, the Federal Circuit affirmed the District Court's delisting order, lifted the temporary stay, and gave Jazz 14 days to request that FDA delist the patent from the Orange Book. Jazz complied with the Federal Circuit's order and requested delisting on February 28, 2023. On March 3, 2023, we and Avadel stipulated to the dismissal without prejudice of the claims and counterclaims related to infringement and validity of the delisted patent in both this suit and a later-filed suit described below related to the same patent. On August 4, 2021, we filed an additional patent infringement suit against Avadel in the United States District*

*Court for the District of Delaware. The second suit alleges that Avadel's Lumryz will infringe a newly-issued patent related to sustained-release formulations of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe this patent, and an award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product will not infringe our patents. On November 10, 2021, we filed an additional patent infringement suit against Avadel in the United States District Court for the District of Delaware. The third suit alleges that Avadel's Lumryz will infringe a newly-issued patent related to sustained-release formulations of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe this patent, and an award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product will not infringe our patents. On April 14, 2022, Avadel sued us in the United States District Court for the District of Delaware. Avadel's suit alleges that we misappropriated trade secrets related to Avadel's once-nightly sodium oxybate development program and breached certain contracts between the parties. Avadel seeks monetary damages, an injunction preventing us from using Avadel's confidential information, and an order directing the United States Patent and Trademark Office to modify the inventorship of one of our oxybate patents. On July 8, 2022, we filed a motion for judgment on the pleadings, which the Court denied on July 18, 2023. The denial is not a ruling that Jazz misappropriated Avadel's trade secrets or breached any contract. The case will go forward in discovery and the Court instructed the parties to submit a proposed scheduling order. On June 7, 2022, we received notice from Avadel that it had filed a "paragraph IV certification" regarding one patent listed in the Orange Book for Xyrem. A paragraph IV certification is a certification by a generic applicant that alleges that patents covering the branded product are invalid, unenforceable, and/or will not be infringed by the manufacture, use or sale of the generic product. On July 15, 2022, we filed an additional lawsuit against Avadel asserting infringement of that patent. The suit alleges that the filing of Avadel's application for approval of FT218 is an act of infringement, and that Avadel's product would infringe the patent if launched. The suit seeks an injunction to prevent Avadel from launching a product that would infringe the patent, and an award of damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patent is invalid, that its product would not infringe, and that by listing the patent in the Orange Book, we engaged in unlawful monopolization in violation of the Sherman Act. On December 9, 2022, we filed a motion to dismiss Avadel's counterclaims. On June 29, 2023, we filed a motion seeking leave to supplement our motion to dismiss, as well as a motion to stay discovery pending resolution of the motion to dismiss. As noted above, on March 3, 2023, we and Avadel stipulated to the dismissal without prejudice of the claims and counterclaims related to infringement and validity of the delisted patent. On November 1, 2023, the Court held a claim construction hearing relating to disputed terms in the asserted patents.  On December 15, 2023, the Court issued a written opinion and order resolving the parties' remaining claim construction disputes. On November 20, 2023, we and Avadel each filed motions for summary judgment. On February 14, 2024, the Court issued a written opinion and order denying both parties' motions for summary judgment. Trial regarding our patent infringement claims against Avadel began on February 26, 2024, and concluded on March 4, 2024, with the jury finding both of our asserted patents valid, and awarding us damages for infringement for Avadel's past sales of Lumryz. On April 12, 2024, we filed a motion for a permanent injunction and ongoing royalties. On August 27, 2024, the Court granted our motion for an injunction in part, and requested additional briefing about ongoing royalties. The issued injunction prevents Avadel from seeking FDA approval or marketing Lumryz for the treatment of idiopathic hypersomnia or other indications not already a part of Lumryz's product labeling as of March 4, 2024, and enjoins Avadel from infringing in any way Claim 24 of our '782 patent by making, using or selling Lumryz through and including the February 2036 expiration date of the '782 patent, subject to certain exclusions including, among other things (i) for the treatment of narcolepsy, (ii) for the treatment of patients who have been prescribed Lumryz as of the effective date of the injunction conditioned on the payment of an amount to be determined and (iii) in clinical trials and studies ongoing as of the effective date of the injunction. The Court also granted our motion for an ongoing royalty for any future sale of Lumryz to patients with narcolepsy at a rate to be determined based upon further briefing by the parties on the appropriate ongoing rate above 3.5%. Avadel is appealing this injunction to the United States Court of Appeals for the Federal Circuit. The Federal Circuit has said the appeal will be placed on its February 2025 oral argument calendar.  Avadel filed a motion with the district court for a stay of the injunction pending appeal, which the district court denied. Avadel also filed a motion to stay the injunction pending appeal with the Federal Circuit, which the Federal Circuit granted to the limited extent that the injunction enjoins initiating new clinical trials or studies and denied in all other respects. The Court scheduled a trial regarding Avadel's counterclaims for unlawful monopolization for November 3, 2025 and a trial regarding Avadel's trade secret misappropriation claims for December 15, 2025. On March 13, 2024 and March 19, 2024, we filed motions to stay Avadel's unlawful monopolization counterclaim and trade secret claims, respectively, pending resolution of post-trial motions and potential appeals in the patent infringement suit. On May 24, 2024, the Court denied the motion to stay the unlawful monopolization counterclaim and the previously-filed motion to dismiss the same. On June 7, 2024, we filed a motion for reargument or, in the alternative, to certify the decision for interlocutory appeal. That motion remains pending and no hearing date has been set. The Court stayed Avadel's trade secret misappropriation claims pending appeal of the injunction in the related patent matter. We filed a further motion to stay the unlawful monopolization counterclaims, which remains pending. On July 21, 2022, Avadel filed a lawsuit against FDA in the United States District Court for the District of Columbia, challenging FDA's determination that Avadel was required to file a paragraph IV certification regarding one of our Orange Book listed patents. Avadel filed a motion for preliminary injunction or, in the alternative, summary judgment, seeking relief including a declaration that FDA's decision requiring patent certification was unlawful, an order*

*setting aside that decision, an injunction prohibiting FDA from requiring such certification as a precondition to approval of its application for FT218, and an order requiring FDA to take final action on Avadel's application for approval of FT218 within 14 days of the Court's ruling. On July 27, 2022, we filed a motion to intervene in that case, which the Court granted. The Court held a hearing on the parties' respective motions for summary judgment on October 7, 2022. On November 3, 2022, the Court granted our and FDA's motions for summary judgment and denied Avadel's motion. Xywav Patent Litigation In June 2021, we received notice from Lupin Inc., or Lupin, that it has filed with FDA an ANDA, for a generic version of Xywav. The notice from Lupin included a paragraph IV certification with respect to ten of our patents listed in FDA's Orange Book for Xywav on the date of our receipt of the notice. The asserted patents relate generally to the composition and method of use of Xywav, and methods of treatment when Xywav is administered concomitantly with certain other medications. In July 2021, we filed a patent infringement suit against Lupin in the United States District Court for the District of New Jersey. The complaint alleges that by filing its ANDA, Lupin has infringed ten of our Orange Book listed patents. We are seeking a permanent injunction to prevent Lupin from introducing a generic version of Xywav that would infringe our patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on Lupin's ANDA. In June 2021, FDA recognized seven years of Orphan Drug Exclusivity for Xywav through July 21, 2027. On October 4, 2021, Lupin filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product, if approved, will not infringe our patents. In April 2022, we received notice from Lupin that it had filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Xywav. On May 11, 2022, we filed an additional lawsuit against Lupin in the United States District Court for the District of New Jersey alleging that by filing its ANDA, Lupin infringed the newly-issued patent related to a method of treatment when Xywav is administered concomitantly with certain other medications. The suit seeks a permanent injunction to prevent Lupin from introducing a generic version of Xywav that would infringe our patent. On June 22, 2022, the Court consolidated the two lawsuits we filed against Lupin. In November 2022, we received notice from Lupin that it had filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Xywav. On January 19, 2023, we filed an additional lawsuit against Lupin in the United States District Court for the District of New Jersey alleging that by filing its ANDA, Lupin infringed the newly-issued patent referenced in its November 2022 paragraph IV certification, as well as another patent that issued in January 2023. The suit seeks a permanent injunction to prevent Lupin from introducing a generic version of Xywav that would infringe the two patents in suit. On February 15, 2023, the Court consolidated the new lawsuit with the two suits we previously filed against Lupin. No trial date has been set in the consolidated case against Lupin. In February 2023, we received notice from Teva Pharmaceuticals, Inc., or Teva, that it had filed with FDA an ANDA for a generic version of Xywav. The notice from Teva included a paragraph IV certification with respect to thirteen of our patents listed in FDA's Orange Book for Xywav on the date of the receipt of the notice. The asserted patents relate generally to the composition and method of use of Xywav, and methods of treatment when Xywav is administered concomitantly with certain other medications. In March 2023, we filed a patent infringement suit against Teva in the United States District Court for the District of New Jersey. The complaint alleges that by filing its ANDA, Teva has infringed thirteen of our Orange Book listed patents. We are seeking a permanent injunction to prevent Teva from introducing a generic version of Xywav that would infringe our patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on Teva's ANDA. On May 23, 2023, Teva filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product, if approved, will not infringe our patents. On December 15, 2023, based on a stipulation between all parties, the Court consolidated the Lupin lawsuits and the Teva lawsuit for all purposes. No trial date has been set in the consolidated case. In July 2024, we received notices from Lupin and Teva that they had each filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Xywav. On August 27, 2024, we filed an additional lawsuit in the United States District Court for the District of New Jersey against each of Lupin and Teva, alleging that, by filing its ANDA, each party infringed the newly-issued patent related to a method of treatment using Xywav. The suits seek orders that the effective date of FDA approval of each defendant's application shall be a date no earlier than the expiration of the newly-issued patent. Epidiolex Patent Litigation In November and December 2022, we received notices from: Teva Pharmaceuticals, Inc.; Padagis US LLC; Apotex Inc.; API Pharma Tech LLC and InvaGen Pharmaceuticals, Inc.; Lupin Limited; Taro Pharmaceutical Industries Ltd.; Zenara Pharma Private Limited and Biophore Pharma, Inc.; MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc.; Alkem Laboratories Ltd.; and Ascent Pharmaceuticals, Inc. (hereinafter referred to as the "Epidiolex ANDA Filers"), that they have each filed with FDA an ANDA for a generic version of Epidiolex (cannabidiol) oral solution. As of the date of this filing, we are not aware of other ANDA filers. The notices from the Epidiolex ANDA Filers each included a "paragraph IV certification" with respect to certain of our patents listed in FDA's Orange Book for Epidiolex on the date of the receipt of the notice. The listed patents relate generally to the composition and method of use of Epidiolex, and methods of treatment using Epidiolex. A paragraph IV certification is a certification by a generic applicant that alleges that patents covering the branded product are invalid, unenforceable, and/or will not be infringed by the manufacture, use or sale of the generic product. On January 3, 2023, we filed a patent infringement suit against the Epidiolex ANDA Filers in the United States District Court for the District of New Jersey. The complaint alleges that by filing their ANDAs, the Epidiolex ANDA Filers have infringed certain of our Orange Book listed patents, and seeks an order that the effective date of FDA approval of the ANDAs shall be a date no earlier than the expiration of the last to expire of the asserted patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on the Epidiolex ANDA Filers' ANDAs. <span style="color:#000000;font-family:'Times New Roman',sans-*

*serif;font-size:10pt;font-weight:400;line-height:120%">From March 2023 through May 2023, we received the Epidiolex ANDA Filers' answers to the complaint. The answers include defenses and counterclaims asserting that the Epidiolex ANDA Filers' products, if launched, would not infringe our patents, that our patents are invalid and, in one instance, counterclaims related to allegations of inequitable conduct and improper listing of patents in the Orange Book. On May 25, 2023, we filed a motion to dismiss certain of the counterclaims. On January 11, 2024, the Court issued an order granting in part and denying in part our motion to dismiss. On September 20, 2024, the Court held a claim construction hearing relating to disputed terms in the asserted patents. The Court has not yet issued a decision on the claim construction disputes.   The Court in the Epidiolex Patent Litigation scheduled trial for September 2025. In June and July 2023, we received notice from certain of the Epidiolex ANDA Filers that they had each filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Epidiolex. On July  21,  2023, we filed an additional lawsuit against all of the Epidiolex ANDA Filers in the United States District Court for the District of New Jersey alleging that, by filing its ANDA, each Epidiolex ANDA Filer infringed the newly-issued patent related to a method of treatment using Epidiolex. The suit seeks an order that the effective date of FDA approval of each Epidiolex ANDA Filer's application shall be a date no earlier than the expiration of the newly-issued patent. On October 24, 2023, we entered into a settlement agreement with Padagis US LLC, or Padagis, that resolved our patent litigation with Padagis related to Epidiolex. Under the settlement agreement, we granted Padagis a license to manufacture, market, and sell its generic version of Epidiolex on a date that depends on the occurrence of certain other events. The specific terms of the Padagis settlement agreement are confidential. On November 20, 2023, we entered into a settlement agreement with Teva Pharmaceuticals, Inc., or Teva, that resolved our patent litigation with Teva related to Epidiolex. Under the settlement agreement, we granted Teva a license to manufacture, market and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the Teva settlement agreement are confidential. On December 4, 2023, we entered into a settlement agreement with Alkem Laboratories Ltd., or Alkem, that resolved our patent litigation with Alkem related to Epidiolex. Under the settlement agreement, we granted Alkem a license to manufacture, market, and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the Alkem settlement are confidential. On June 7, 2024, we entered into a settlement agreement with MSN Laboratories Private, Ltd. and MSN Pharmaceuticals, Inc., or together MSN, that resolved our patent litigation with MSN related to Epidiolex. Under the settlement agreement, we granted MSN a license to manufacture, market, and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the MSN settlement are confidential. On September 4, 2024, we entered into a settlement agreement with Lupin, Ltd., that resolved our patent litigation with Lupin related to Epidiolex. Under the settlement agreement, we granted Lupin a license to manufacture, market, and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the Lupin settlement are confidential. On November 1, 2024, we entered into a settlement agreement with InvaGen Pharmaceuticals, Inc., Cipla Ltd., Cipla USA, Inc., and API Pharma Tech LLC (collectively "InvaGen") that resolved our patent litigation with InvaGen related to Epidiolex. Under the settlement agreement, we granted InvaGen a license to manufacture, market, and sell its generic version of Epidiolex on a date which remains confidential. The specific terms of the InvaGen settlement are confidential. The settlements with Padagis, Teva, Alkem, MSN, Lupin and InvaGen do not resolve the litigation against the other four Epidiolex ANDA Filers, which is ongoing. We cannot predict the specific timing or outcome of events in these matters with respect to the remaining defendants or the impact of developments involving any specific parties or patents on other ongoing proceedings with any specific Epidiolex ANDA Filer. In September and October 2023, we received notice from certain of the Epidiolex ANDA Filers that they had each filed a paragraph IV certification regarding one or more newly-issued patents listed in the Orange Book for Epidiolex. On December 15, 2023, we filed an additional lawsuit against seven of the original Epidiolex ANDA Filers with whom we have not previously settled. We filed this lawsuit in the United States District Court for the District of New Jersey alleging that, by filing its ANDA, each Epidiolex ANDA Filer infringed the newly-issued patents related to methods of treatment using Epidiolex. The suit seeks an order that the effective date of FDA approval of each Epidiolex ANDA Filer's application shall be a date no earlier than the expiration of the newly-issued patents. In March and April 2024, we received notice from certain of the Epidiolex ANDA Filers that they had each filed a paragraph IV certification regarding one or more newly-issued patents listed in the Orange Book for Epidiolex. On July 3, 2024, we filed an additional lawsuit against six of the original Epidiolex ANDA Filers with whom we had not previously settled. We filed this lawsuit in the United States District Court for the District of New Jersey alleging that, by filing its ANDA, each Epidiolex ANDA Filer infringed the newly-issued patents related to methods of treatment using Epidiolex. The suit seeks an order that the effective date of FDA approval of each Epidiolex ANDA Filer's application shall be a date no earlier than the expiration of the newly-issued patents. Epidiolex also has orphan drug exclusivity, or ODE, for the treatment of seizures associated with LGS or DS in patients 2 years of age and older through September  28,  2025, and for the treatment of seizures associated with LGS or DS in patients between 1 and 2 years of age and for the treatment of seizures associated with TSC through July  31,  2027. The Company vigorously enforces its intellectual property rights but cannot predict the outcome of these matters. Zepzelca Patent Litigation In July and August 2024, we received notices from Sandoz Inc., InvaGen Pharmaceuticals, Inc., CIPLA USA, Inc. CIPLA (EU) Limited, CIPLA Limited, Zydus Lifesciences Global FZE, Zydus Pharmaceuticals (USA) Inc., Zydus Lifesciences Limited, RK Pharma, Inc., Apicore US LLC, Archis Pharma LLC, Vgyaan Pharmaceuticals LLC, MSN Pharmaceuticals Inc., and MSN Laboratories PVT. LTD. (hereinafter referred to as the "Zepzelca ANDA Filers"), that they have each filed with FDA an ANDA for a generic version of Zepzelca (lurbinectedin). As of the date of this filing, we are not aware of other ANDA filers. The notices from the Zepzelca ANDA Filers each included a paragraph IV certification with respect to a patent listed in the Orange Book for Zepzelca on the date of the receipt of the notice. The listed patent relates to the drug substance, drug product and approved use of Zepzelca. Jazz is the exclusive licensee to this Zepzelca patent pursuant to an agreement with Pharma Mar, S.A, or PharmaMar. A paragraph IV certification is a certification by a generic applicant that alleges that the patent covering the branded product is invalid, unenforceable, and/or will not be infringed by the manufacture, use or sale of the generic product. On September 11, 2024, we and PharmaMar filed a patent infringement suit against the Zepzelca ANDA Filers in the United States District Court for the District of New Jersey. The complaint alleges that by filing their ANDAs, the Zepzelca ANDA Filers have infringed the Orange Book listed patent for Zepzelca, and seeks an order that the effective date of FDA approval of the ANDAs shall be a date no earlier than the expiration of the asserted patent. On September 12, 2024, we and*

*PharmaMar filed a patent infringement suit against RK Pharma, Inc., Apicore US LLC, Archis Pharma LLC, Vgyaan Pharmaceuticals LLC (collectively "RK Pharma"), in the United States District Court for the District of Delaware. The complaint alleges that by filing its ANDA, RK Pharma has infringed the Orange Book listed patent for Zepzelca, and seeks an order that the effective date of FDA approval of RK Pharma's ANDA shall be no earlier than the expiration of the asserted patent. MSP Litigation On April 3, 2023, MSP Recovery Claims, Series LLC, or MSP, filed a class action lawsuit on behalf itself and others similarly situated against Jazz Pharmaceuticals plc, Jazz Pharmaceuticals, Inc., and Jazz Pharmaceuticals Ireland Limited, (collectively, the Company Defendants), Express Scripts, Inc., Express Scripts Holding Company, Express Scripts Specialty Distribution Services, Inc., Curascript, Inc. d/b/a Curascript, S.D., Priority Healthcare Distribution, Inc. d/b/a Curascript SD and Curascript Specialty Distribution SD, Caring Voice Coalition, and Adira Foundation (collectively with the Company Defendants, referred to as the Defendants) in the United States District Court for the Northern District of California. The MSP complaint alleges that the Defendants conspired to increase the price and quantity dispensed of Xyrem and Prialt, in violation of the Racketeer Influenced and Corrupt Organizations Act and several state laws. The allegations relate generally to the conduct at issue in the investigation conducted by the United States Department of Justice from 2016-2019, involving the Company's contributions to certain charitable foundations. MSP seeks monetary damages, restitution, disgorgement, and a declaration that the conduct alleged is unlawful. On July 25, 2023, we and certain other defendants filed motions to dismiss MSP's complaint, which the Court granted on December 12, 2023. On January 5, 2024, the MSP filed an amended complaint. On February 20, 2024, we filed a motion to dismiss MSP's amended complaint. The Court scheduled a hearing on the motion for June 13, 2024. On June 21, 2024, the Court cancelled the hearing. On July 22, 2024, the Court granted the motion. The Court set a deadline of August 12, 2024, to file a second amended complaint. On August 12, 2024, MSP voluntarily dismissed its complaint. FDA Litigation On June 22, 2023, we filed a complaint in the United States District Court for the District of Columbia seeking a declaration that FDA's approval on May 1, 2023, of the New Drug Application, or NDA, for Avadel's Lumryz was unlawful. In the complaint, we alleged that FDA acted outside its authority under the Orphan Drug Act, when, despite ODE protecting Jazz's low-sodium oxybate product Xywav, FDA approved the Lumryz NDA and granted Lumryz ODE based on FDA's finding that Lumryz makes a major contribution to patient care and is therefore clinically superior to Xywav and Xyrem. Jazz further alleged that, in doing so, FDA failed to follow its own regulations, failed to follow established agency policy without providing a reasoned explanation for the departure, reversed prior decisions by its own staff and experts without a reasoned explanation, and disregarded the relevant scientific literature and data. The complaint, filed pursuant to the Administrative Procedure Act, asked the Court to vacate and set aside FDA's approval of the Lumryz NDA and sought a declaration that FDA's approval of the Lumryz NDA was arbitrary, capricious, an abuse of discretion and otherwise not in accordance with law and that approval of the Lumryz NDA was in excess of FDA's statutory authority and was made without observance of procedure required by law. On September 15, 2023, we filed a motion for summary judgment. On October 20, 2023, Avadel and FDA filed cross motions for summary judgment. Oral argument on these motions was held on May 10, 2024 and on October 30, 2024, the District Court issued an order denying Jazz's motion for summary judgment and granting Avadel's and the FDA's cross-motions for summary judgment. Jazz respectfully disagrees with the Court's decision and is evaluating potential options for appeal. Qui tam matter In July 2022, we received a subpoena from the U.S. Attorney's Office, or USAO, for the District of Massachusetts requesting documents related to Xyrem and U.S. Patent No. 8,772,306 ("Method of Administration of Gamma Hydroxybutyrate with Monocarboxylate Transporters"), product labeling changes for Xyrem, communications with FDA and the USPTO, pricing of Xyrem, and other related documents. On July 18, 2024, the United States District Court for the District of Massachusetts unsealed a qui tam whistleblower lawsuit underlying the USAO's subpoena, captioned 1:21-cv-10891-PBS and originally filed under seal on May 27, 2021. The public docket in this matter indicates that on May 24 and June 7, 2024, respectively, the United States and a number of states named in the whistleblower complaint declined to intervene in this matter. As such, private whistleblower litigation will proceed in the United States District Court for the District of Massachusetts. The Court set a deadline of September 1, 2024, for the plaintiff to file an amended complaint, and December 1, 2024, for Jazz to file a motion to dismiss the amended complaint. The plaintiff filed the amended complaint on September 1, 2024. From time to time, we are involved in legal proceedings arising in the ordinary course of business. We believe there is no other litigation pending that could have, individually or in the aggregate, a material adverse effect on our results of operations or financial condition. 2 5 1 P14D 1 0.035 P14D 10 10 P30M P7Y 2 2 13 P30M P30M 4 7 6 Shareholders' Equity Share Repurchase Program In July 2024, our board of directors authorized a share repurchase program to repurchase ordinary shares having an aggregate purchase price of $500.0 million, exclusive of any brokerage commissions, or the New Repurchase Program. Under the New Repurchase Program, which has no expiration date, we may repurchase ordinary shares from time to time by any methods and/or structures permitted by applicable law. The timing and amount of repurchases will depend on a variety of factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under the Amended Credit Agreement and the indenture for our Secured Notes, corporate and regulatory requirements and market conditions. The New Repurchase Program may be modified, suspended or discontinued at any time without our prior notice. The New Repurchase Program replaces and supersedes the share repurchase program authorized by our board of directors in November 2016, which, as of the date of it being superseded by the New Repurchase Program, had authorized the repurchase of ordinary shares having an aggregate purchase price of up to $1.5 billion, exclusive of any brokerage commissions, or the Old Repurchase Program, and, together with the New Repurchase Program, the "repurchase programs". During the three months ended September 30, 2024, we spent a total of $150.0 million to repurchase 1.4 million of our ordinary shares, all under the New Repurchase Program, at a purchase price, including commissions, of $109.32 per share. The repurchases during the three months ended September 30, 2024, were effected in privately negotiated transactions with or through one of the*

*initial purchasers of the 2030 Notes concurrently with the pricing of the offering of the 2030 Notes. During the nine months ended September 30, 2024, we spent a total of $311.4 million to purchase 2.8 million of our ordinary shares under the repurchase programs at an average total purchase price, including commissions, of $110.06 per share. During the nine months ended September 30, 2023, we spent a total of $170.0 million to purchase 1.3 million of our ordinary shares under the Old Repurchase Program at an average total purchase price, including commissions, of $128.89 per share. All ordinary shares repurchased were cancelled. As of September 30, 2024, the remaining amount authorized for repurchases under the New Repurchase Program was $350.0 million, exclusive of any brokerage commissions.</span></div><div style="margin-top:14pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive loss as of September 30, 2024 and December 31, 2023 were as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Unrealized<br/>Gain From <br/>Hedging Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">235 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(842,382)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(842,147)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Other comprehensive income before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,572 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">241,218 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">242,790 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Amounts reclassified from accumulated other comprehensive loss</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,040)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,040)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Other comprehensive income (loss), net</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,468)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">241,218 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">238,750 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Balance at September 30, 2024</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,233)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(601,164)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(603,397)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> During the nine months ended*

*September 30, 2024, other comprehensive income (loss) primarily reflects foreign currency translation adjustments, primarily due to the strengthening of the sterling against the U.S. dollar. 500000000 1500000000 150000000 1400000 109.32 311400000 2800000 110.06 170000000 1300000 128.89 350000000 The components of accumulated other comprehensive loss as of September 30, 2024 and December 31, 2023 were as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net Unrealized<br/>Gain From <br/>Hedging Activities</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign<br/>Currency<br/>Translation<br/>Adjustments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total<br/>Accumulated<br/>Other<br/>Comprehensive<br/>Loss</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Balance at December 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(842,147)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Other comprehensive income before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,572 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">241,218 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">242,790 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Amounts reclassified from accumulated other comprehensive loss</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,040)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,040)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Other comprehensive income (loss), net</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,468)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">241,218 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">238,750 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Balance at September 30, 2024</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,233)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(601,164)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(603,397)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 235000 -842382000 -842147000 1572000 241218000 242790000 4040000 0 4040000 -2468000 241218000 238750000 -2233000 -601164000 -603397000 Net Income per Ordinary Share Basic net income per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net income per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding. Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-*

align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Numerator:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Net income</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">146,820 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">320,678 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Effect of interest on assumed conversions of Exchangeable Senior Notes, net of tax</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,028 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,912 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,761 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,951 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Net income for dilutive net income per ordinary share</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,083 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">152,732 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,766 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">340,629 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Denominator:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">Weighted-average ordinary shares used in per share calculations - basic</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61,414 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,114 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,275 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,532 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Dilutive effect of Exchangeable Senior Notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,325 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,560 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,721 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,549 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Dilutive effect of employee equity incentive and purchase plans</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">435 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">619 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">515 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">785 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top">Weighted-average ordinary shares used in per share calculations - diluted</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,174 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71,293 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,511 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72,866 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Net income per ordinary share:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Basic</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2.33 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">5.05 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Diluted</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.14 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">4.67 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Potentially dilutive ordinary shares from our employee equity incentive and purchase plans are determined by applying the treasury stock method to the assumed vesting of outstanding restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs, the assumed exercise of share options and the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP. Potentially dilutive ordinary shares from the Exchangeable Senior Notes are determined by applying the if-converted method to the assumed issuance of ordinary shares upon exchange of the Exchangeable Senior Notes. In August 2023, we made an irrevocable election to fix the settlement method for exchanges of the 2024 Notes to a combination of cash and ordinary shares of the Company with a specified cash amount per $1,000 principal amount of the 2024 Notes of $1,000. As a result, the assumed issuance of ordinary shares upon exchange of the 2024 Notes has only been included in the calculation of diluted net income per ordinary share in the three and nine months ended September 30, 2023 up to the date the irrevocable election was made. In July 2024, we made an irrevocable election to fix the settlement method for exchanges of the 2026 Notes to a combination of cash and ordinary shares of the Company with a specified cash amount per $1,000 principal amount of the 2026 Notes of $1,000. As a result, the assumed issuance of ordinary shares upon exchange of the 2026 Notes has only been included in the calculation of diluted net income per ordinary share in the three and nine months ended September 30, 2024, up to the date the irrevocable election was made. For the 2030 Notes, we are required to settle the principal amount in cash and have the option to settle the conversion feature for the amount above the conversion price, or the conversion spread, in cash, ordinary shares or a combination of cash and ordinary shares. The conversion spread will have a dilutive impact on diluted net income per ordinary share when the average market price of our ordinary shares for a given period exceeds the conversion price of the 2030 Notes. For the three and nine months ended September 30, 2024, the 2030 Notes have been excluded from the computation of diluted net income per ordinary share, as the effect would be anti-dilutive since the conversion price of the 2030 Notes exceeded the average market price of our ordinary shares for the three and nine months ended September 30, 2024. The following table represents the weighted-average ordinary shares that were excluded from the calculation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Employee equity incentive and purchase plans</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,465 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,501 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,701 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,091 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td

style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Numerator:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Net income</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">146,820 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">320,678 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Effect of interest on assumed conversions of Exchangeable Senior Notes, net of tax</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,028 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,912 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,761 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,951 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Net income for dilutive net income per ordinary share</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,083 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">152,732 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,766 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">340,629 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Denominator:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Weighted-average ordinary shares used in per share calculations - basic</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times

*New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,414 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,114 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,275 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,532 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Dilutive effect of Exchangeable Senior Notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,325 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,560 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,721 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,549 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Dilutive effect of employee equity incentive and purchase plans</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">435 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">619 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">515 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">785 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top">Weighted-average ordinary shares used in per share calculations – diluted</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,174 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71,293 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,511 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72,866 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Net income per ordinary share:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Basic</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2.33 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">5.05 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"*

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Diluted</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.14 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">4.67 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 215055000 146820000 369005000 320678000 1028000 5912000 10761000 19951000 216083000 152732000 379766000 340629000 61414000 63114000 62275000 63532000 1325000 7560000 4721000 8549000 435000 619000 515000 785000 63174000 71293000 67511000 72866000 3.50 2.33 5.93 5.05 3.42 2.14 5.63 4.67 1000 1000 The following table represents the weighted-average ordinary shares that were excluded from the calculation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Employee equity incentive and purchase plans</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,465 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,501 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,701 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,091 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 4465000 2501000 4701000 3091000 Revenues The following table presents a summary of total revenues (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top">Xywav</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,466 </span></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">331,633 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072,238 </span></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">935,958 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Xyrem</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,114 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,110 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">184,526 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">463,009 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top">Epidiolex/Epidyolex</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">251,558 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">213,711 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">697,376 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">604,846 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Sativex</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,586 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,627 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,704 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,531 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Total Neuroscience</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">702,724 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">675,081 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,967,844 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,018,344 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Rylaze/Enrylaze</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98,780 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt">

</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104,859 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">309,359 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">292,479 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Zepzelca</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,843 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77,994 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">241,990 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">215,523 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Defitelio/defibrotide </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,818 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47,730 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">158,915 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132,917 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Vyxeos</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,313 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,827 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">109,348 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100,583 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total Oncology</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">284,754 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">260,410 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">819,612 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">741,502 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,229 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,907 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,497 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,758 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Product sales, net</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">989,707 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">938,398 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"

style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,795,953 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,769,604 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">High-sodium oxybate AG royalty revenue</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,157 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,921 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162,268 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36,531 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other royalty and contract revenues</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,105 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,821 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,556 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,134 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total revenues</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054,969 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">972,140 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,822,269 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <br/> The following table presents a summary of total revenues attributed to geographic sources (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">United States</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">953,669 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">884,579 </td><td style="background-color:#cceeff;border-

top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,686,486 </span></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,579,401 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Europe</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77,318 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68,971 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">230,821 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">194,198 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top">All other</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,982 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,590 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,470 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,670 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Total revenues</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054,969 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">972,140 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980,777 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,822,269 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top">ESSDS</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">49 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">McKesson</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">ASD</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Financing and payment Our payment terms vary by the type and location of our customer but payment is generally required in a term ranging from 30 to 65 days. The following table presents a summary of total revenues (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Xywav</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,466 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">331,633 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072,238 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">935,958 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Xyrem</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,114 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-

color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,110 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">184,526 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">463,009 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Epidiolex/Epidyolex</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">251,558 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">213,711 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">697,376 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">604,846 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Sativex</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,586 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,627 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,704 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,531 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Total Neuroscience</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">702,724 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">675,081 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,967,844 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,018,344 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Rylaze/Enrylaze</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98,780 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104,859 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">309,359 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">292,479 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Zepzelca</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,843 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77,994 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">241,990 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">215,523 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Defitelio/defibrotide </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,818 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-

color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47,730 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">158,915 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132,917 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Vyxeos</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,313 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,827 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">109,348 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100,583 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total Oncology</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">284,754 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">260,410 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">819,612 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">741,502 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,229 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,907 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,497 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,758 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Product sales, net</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">989,707 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">938,398 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,795,953 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,769,604 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">High-sodium oxybate AG royalty revenue</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,157 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,921 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162,268 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36,531 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other royalty and contract revenues</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,105 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,821 </td><td style="background-color:#ffffff;padding:2px 1pt 2px

0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,556 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,134 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total revenues</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054,969 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">972,140 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,822,269 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <br/> The following table presents a summary of total revenues attributed to geographic sources (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">United States</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953,669 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">884,579 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,686,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,579,401 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Europe</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77,318 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68,971 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">230,821 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">194,198 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">All other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,982 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,590 </td><td style="background-color:#cceeff;padding:2px

1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,470 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,670 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Total revenues</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054,969 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">972,140 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980,777 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,822,269 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 388466000 331633000 1072238000 935958000 58114000 125110000 184526000 463009000 251558000 213711000 697376000 604846000 4586000 4627000 13704000 14531000 702724000 675081000 1967844000 2018344000 98780000 104859000 309359000 292479000 85843000 77994000 241990000 215523000 65818000 47730000 158915000 132917000 34313000 29827000 109348000 100583000 284754000 260410000 819612000 741502000 2229000 2907000 8497000 9758000 989707000 938398000 2795953000 2769604000 58157000 28921000 162268000 36531000 7105000 4821000 22556000 16134000 1054969000 972140000 2980777000 2822269000 953669000 884579000 2686486000 2579401000 77318000 68971000 230821000 194198000 23982000 18590000 63470000 48670000 1054969000 972140000 2980777000 2822269000 The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">ES&DS</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">McKesson</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">ASD</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-

align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 0.42 0.47 0.42 0.49 0.13 0.12 0.12 0.11 0.10 0.09 0.09 0.07 P30D P65D Share-Based Compensation Share-based compensation expense related to RSUs, PRSUs, grants under our ESPP and share options was as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Selling, general and administrative</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">35,268 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">113,155 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,927 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,635 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,030 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49,346 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Cost of product sales</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,732 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,212 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,374 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,399 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Total share-based compensation expense, pre-tax</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,760 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56,115 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"

style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">177,855 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">173,900 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Income tax benefit from share-based compensation expense</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,190)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,792)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25,218) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(29,533)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total share-based compensation expense, net of tax</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,570 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">46,323 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,637 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">144,367 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Restricted Stock Units The table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">RSUs granted (in thousands)</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">91 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,112 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,728 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Grant date fair value</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">134.33 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-

color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">145.05 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The fair value of RSUs is determined on the date of grant based on the market price of our ordinary shares on that date. The fair value of RSUs is expensed ratably over the vesting period, generally over four years. Performance-Based Restricted Stock Units The Compensation & Management Development Committee of our board of directors and, in the case of our Chief Executive Officer, the independent members of our board of directors, approved awards of PRSUs to certain employees of the Company, subject to vesting on the achievement of certain commercial and pipeline performance criteria to be assessed over a performance period from the date of the grant to December 31, 2024, December 31, 2025 and December 31, 2026, respectively. The number of shares that will be awarded is determined based on the Company’s achievement with respect to the performance criteria. For PRSUs granted prior to 2024, the amount of shares awarded will be subject to adjustment based on the application of a relative total shareholder return, or TSR, modifier. For PRSUs granted in 2024, the relative TSR represents one of the performance metrics. In both cases, the number of shares that may be earned ranges between 0% and 200% of the target number of PRSUs granted. The table below shows the number of PRSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of PRSUs granted: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">PRSUs granted (in thousands)</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">371 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">270 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Grant date fair value</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">142.65 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">157.01 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> For the PRSUs granted that are subject to a market condition, the grant date fair value for such PRSUs was based on a Monte Carlo simulation model. For PRSUs granted without a market condition, the fair value is determined based on the market price of our ordinary shares on the date of grant. The Company evaluated the performance targets in the context of its current long-range financial plan and its product candidate development pipeline and recognized expense based on the probable number of awards that will ultimately vest. As of September 30, 2024, compensation cost not yet recognized related to unvested RSUs, PRSUs, ESPP and share options was $347.2 million, $37.3 million, $9.2 million and $0.1 million, respectively, which is expected to be recognized over a weighted-average period of 2.6 years, 1.4 years, 1.1 years and 0.3 years, respectively. Share-based compensation expense related to RSUs, PRSUs, grants under our ESPP and share options was as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td

style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Selling, general and administrative</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">35,268 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">113,155 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,927 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,635 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,030 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49,346 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Cost of product sales</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,732 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,212 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,374 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,399 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Total share-based compensation expense, pre-tax</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,760 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56,115 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">177,855 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">173,900 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Income tax benefit from share-based compensation expense</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,190)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,792)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25,218)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(29,533)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total share-based compensation expense, net of tax</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px

0;text-align:right;vertical-align:bottom">47,570 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"> </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,323 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"> </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">152,637 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"> </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,367 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 37101000 35268000 112451000 113155000 18927000 16635000 55030000 49346000 3732000 4212000 10374000 11399000 59760000 56115000 177855000 173900000 12190000 9792000 25218000 29533000 47570000 46323000 152637000 144367000 <div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted (in thousands)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"> </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">110.55 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">118.31 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">145.05 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The table below shows the number of PRSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of PRSUs granted: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-

*align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">PRSUs granted (in thousands)</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">371 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">270 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Grant date fair value</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">142.65 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">157.01 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 102000 91000 2112000 1728000 110.55 134.33 118.31 145.05 P4Y 0 2 58000 13000 371000 270000 107.07 142.65 130.58 157.01 347200000 37300000 9200000 100000 P2Y7M6D P1Y4M24D P1Y1M6D P0Y3M18D Income Taxes Our income tax benefit was $14.5 million and $33.5 million for the three and nine months ended September 30, 2024, respectively, compared to $47.2 million and $86.8 million for the same periods in 2023, relating to tax arising on income or losses in Ireland, the U.K., the U.S. and certain other foreign jurisdictions and tax deficiencies from share based compensation, offset by deductions on subsidiary equity, foreign derived intangible income benefits and tax credits. The decrease in the income tax benefit for the three and nine months ended September 30, 2024 compared to the same periods in 2023 resulted primarily from changes in the mix of pre-tax income and losses across tax jurisdictions. Our net deferred tax liability is primarily related to acquired intangible assets, and is net of deferred tax assets related to U.S. federal and state tax credits, U.S. federal and state and foreign net operating loss carryforwards and other temporary differences. We maintain a valuation allowance against certain deferred tax assets. Each reporting period, we evaluate the need for a valuation allowance on our deferred tax assets by jurisdiction and adjust our estimates as more information becomes available. We are required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. As a result, we have recorded an unrecognized tax benefit for certain tax benefits which we judge may not be sustained upon examination. We file income tax returns in multiple tax jurisdictions, the most significant of which are Ireland, the U.K. and the U.S. (both at the federal level and in various state jurisdictions). For Ireland, we are no longer subject to income tax examinations by taxing authorities for the years prior to 2019. For the U.K., we are no longer subject to income tax examinations by taxing authorities for the years prior to 2016. The U.S. jurisdictions generally have statute of limitations three to four years from the later of the return due date or the date when the return was filed. However, in the U.S. (at the federal level and in most states), carryforwards that were generated in 2019 and earlier may still be adjusted upon examination by the taxing authorities. One of our subsidiaries is currently under examination by the Luxembourg taxing authorities for the years ended December 31, 2017, 2018 and 2019. In October 2022 and in January 2023, we received tax assessment notices from the Luxembourg taxing authorities for all years under examination relating to certain transfer pricing and other adjustments. The notices propose additional Luxembourg income tax of approximately $25.0 million, translated at the foreign exchange rate as September 30, 2024. We disagree with the proposed assessments and are contesting them vigorously. The Government of Ireland, the jurisdiction in which Jazz Pharmaceuticals Plc is incorporated, transposed the Global Minimum Tax Pillar Two rules into domestic legislation as part of the Finance (No. 2) Act 2023 (the "Finance Act"). The Finance Act closely follows the EU Minimum Tax Directive and certain OECD Guidance released to date. The Company is within the scope of these rules, which took effect from January 1, 2024. Under the new legislation, we are liable to pay a top-up tax for the difference between the Pillar Two effective tax rate per jurisdiction and the 15% minimum rate. The rules on how to calculate the 15% effective tax rate are detailed and highly complex and specific adjustments envisaged in the Pillar Two legislation can give rise to different effective tax rates compared to those calculated for accounting purposes. We will account for it as a current tax when it is incurred. We expect to be subject to the top-up tax in relation to our operations in Ireland, where the trading statutory tax rate is 12.5%, though the impact in 2024 is not significant. The proportion of our profit before tax which is subject to the top-up tax and our exposure to Pillar Two income taxes in future years will depend on factors such as future revenues, costs and foreign currency exchange rates. We will continue to monitor changes in law and guidance in relation to Pillar Two. -14500000 -33500000 -47200000 -86800000 25000000*